<?xml version="1.0" encoding="UTF-8"?>
<rdf:RDF
 xmlns:xsd="http://www.w3.org/2001/XMLSchema#"
 xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
 xmlns:owl="http://www.w3.org/2002/07/owl#"
 xmlns:bp="http://www.biopax.org/release/biopax-level3.owl#"
 xml:base="http://www.reactome.org/biopax/91/1643685#">
<owl:Ontology rdf:about="">
 <owl:imports rdf:resource="http://www.biopax.org/release/biopax-level3.owl#" />
</owl:Ontology>

<bp:PathwayStep rdf:ID="PathwayStep2281">
 <bp:stepProcess rdf:resource="#Pathway531" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2282">
 <bp:stepProcess rdf:resource="#Catalysis619" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1707" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2283">
 <bp:stepProcess rdf:resource="#Pathway532" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2284">
 <bp:stepProcess rdf:resource="#Catalysis620" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1708" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2280">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1706" />
 <bp:stepProcess rdf:resource="#Catalysis618" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2289">
 <bp:stepProcess rdf:resource="#Catalysis623" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1711" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2285">
 <bp:stepProcess rdf:resource="#Pathway533" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2286">
 <bp:stepProcess rdf:resource="#Catalysis621" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1709" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2287">
 <bp:stepProcess rdf:resource="#Catalysis622" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1710" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2288">
 <bp:stepProcess rdf:resource="#Pathway534" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2292">
 <bp:stepProcess rdf:resource="#Pathway536" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2293">
 <bp:stepProcess rdf:resource="#Catalysis625" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1713" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2294">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1714" />
 <bp:stepProcess rdf:resource="#Catalysis626" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2295">
 <bp:stepProcess rdf:resource="#Pathway537" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2290">
 <bp:stepProcess rdf:resource="#Pathway535" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2291">
 <bp:stepProcess rdf:resource="#Catalysis624" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1712" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2296">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1715" />
 <bp:stepProcess rdf:resource="#Catalysis627" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2297">
 <bp:stepProcess rdf:resource="#Pathway538" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2298">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1716" />
 <bp:stepProcess rdf:resource="#Catalysis628" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2299">
 <bp:stepProcess rdf:resource="#Pathway539" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2260">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1695" />
 <bp:stepProcess rdf:resource="#Catalysis607" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2261">
 <bp:stepProcess rdf:resource="#Pathway522" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2262">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1696" />
 <bp:stepProcess rdf:resource="#Catalysis608" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2267">
 <bp:stepProcess rdf:resource="#Pathway525" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2268">
 <bp:stepProcess rdf:resource="#Catalysis611" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1699" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2269">
 <bp:stepProcess rdf:resource="#Pathway526" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2263">
 <bp:stepProcess rdf:resource="#Pathway523" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2264">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1697" />
 <bp:stepProcess rdf:resource="#Catalysis609" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2265">
 <bp:stepProcess rdf:resource="#Pathway524" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2266">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1698" />
 <bp:stepProcess rdf:resource="#Catalysis610" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2270">
 <bp:stepProcess rdf:resource="#Catalysis612" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1700" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2271">
 <bp:stepProcess rdf:resource="#Catalysis613" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1701" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2272">
 <bp:stepProcess rdf:resource="#Catalysis614" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1702" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2273">
 <bp:stepProcess rdf:resource="#Pathway527" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2278">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1705" />
 <bp:stepProcess rdf:resource="#Catalysis617" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2279">
 <bp:stepProcess rdf:resource="#Pathway530" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2274">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1703" />
 <bp:stepProcess rdf:resource="#Catalysis615" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2275">
 <bp:stepProcess rdf:resource="#Pathway528" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2276">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1704" />
 <bp:stepProcess rdf:resource="#Catalysis616" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2277">
 <bp:stepProcess rdf:resource="#Pathway529" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2240">
 <bp:stepProcess rdf:resource="#Pathway512" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep618">
 <bp:stepProcess rdf:resource="#BiochemicalReaction470" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep619">
 <bp:stepProcess rdf:resource="#BiochemicalReaction471" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep616">
 <bp:stepProcess rdf:resource="#Pathway134" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep617">
 <bp:stepProcess rdf:resource="#Pathway135" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2249">
 <bp:stepProcess rdf:resource="#Pathway516" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep610">
 <bp:stepProcess rdf:resource="#BiochemicalReaction465" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2245">
 <bp:stepProcess rdf:resource="#Pathway515" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep611">
 <bp:stepProcess rdf:resource="#BiochemicalReaction466" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2246">
 <bp:stepProcess rdf:resource="#Catalysis600" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1687" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2247">
 <bp:stepProcess rdf:resource="#Catalysis601" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1688" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2248">
 <bp:stepProcess rdf:resource="#Catalysis602" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1689" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep614">
 <bp:stepProcess rdf:resource="#BiochemicalReaction469" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2241">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1685" />
 <bp:stepProcess rdf:resource="#Catalysis598" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep615">
 <bp:stepProcess rdf:resource="#Pathway133" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2242">
 <bp:stepProcess rdf:resource="#Pathway513" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep612">
 <bp:stepProcess rdf:resource="#BiochemicalReaction467" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2243">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1686" />
 <bp:stepProcess rdf:resource="#Catalysis599" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep613">
 <bp:stepProcess rdf:resource="#BiochemicalReaction468" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2244">
 <bp:stepProcess rdf:resource="#Pathway514" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2250">
 <bp:stepProcess rdf:resource="#Catalysis603" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1690" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2251">
 <bp:stepProcess rdf:resource="#Pathway517" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep607">
 <bp:stepProcess rdf:resource="#BiochemicalReaction462" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep608">
 <bp:stepProcess rdf:resource="#BiochemicalReaction463" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep605">
 <bp:stepProcess rdf:resource="#BiochemicalReaction461" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep606">
 <bp:stepProcess rdf:resource="#Pathway132" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep609">
 <bp:stepProcess rdf:resource="#BiochemicalReaction464" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2256">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1693" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep600">
 <bp:stepProcess rdf:resource="#BiochemicalReaction457" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2257">
 <bp:stepProcess rdf:resource="#Pathway520" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2258">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1694" />
 <bp:stepProcess rdf:resource="#Catalysis606" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2259">
 <bp:stepProcess rdf:resource="#Pathway521" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep603">
 <bp:stepProcess rdf:resource="#BiochemicalReaction459" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2252">
 <bp:stepProcess rdf:resource="#Catalysis604" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1691" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep604">
 <bp:stepProcess rdf:resource="#BiochemicalReaction460" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2253">
 <bp:stepProcess rdf:resource="#Pathway518" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep601">
 <bp:stepProcess rdf:resource="#BiochemicalReaction458" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2254">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1692" />
 <bp:stepProcess rdf:resource="#Catalysis605" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep602">
 <bp:stepProcess rdf:resource="#Pathway131" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2255">
 <bp:stepProcess rdf:resource="#Pathway519" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2227">
 <bp:stepProcess rdf:resource="#Pathway506" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2228">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1678" />
 <bp:stepProcess rdf:resource="#Catalysis591" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2229">
 <bp:stepProcess rdf:resource="#Pathway507" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2223">
 <bp:stepProcess rdf:resource="#Pathway504" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2224">
 <bp:stepProcess rdf:resource="#Catalysis589" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1676" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2225">
 <bp:stepProcess rdf:resource="#Pathway505" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2226">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1677" />
 <bp:stepProcess rdf:resource="#Catalysis590" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2220">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1674" />
 <bp:stepProcess rdf:resource="#Catalysis587" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2221">
 <bp:stepProcess rdf:resource="#Pathway503" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2222">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1675" />
 <bp:stepProcess rdf:resource="#Catalysis588" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2238">
 <bp:stepProcess rdf:resource="#Pathway511" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2239">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1684" />
 <bp:stepProcess rdf:resource="#Catalysis597" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2234">
 <bp:stepProcess rdf:resource="#Pathway509" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2235">
 <bp:stepProcess rdf:resource="#Catalysis595" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1682" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2236">
 <bp:stepProcess rdf:resource="#Pathway510" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2237">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1683" />
 <bp:stepProcess rdf:resource="#Catalysis596" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2230">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1679" />
 <bp:stepProcess rdf:resource="#Catalysis592" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2231">
 <bp:stepProcess rdf:resource="#Pathway508" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2232">
 <bp:stepProcess rdf:resource="#Catalysis593" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1680" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2233">
 <bp:stepProcess rdf:resource="#Catalysis594" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1681" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep661">
 <bp:stepProcess rdf:resource="#BiochemicalReaction509" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep662">
 <bp:stepProcess rdf:resource="#BiochemicalReaction510" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep660">
 <bp:stepProcess rdf:resource="#BiochemicalReaction508" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1110">
 <bp:evidence rdf:resource="#Evidence1344" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Trans-autophosphorylation of EGFRvIII mutant dimers</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1102">
 <bp:evidence rdf:resource="#Evidence1336" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Phosphorylation of SHC1 by p-5Y-EGFRvIII</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1103">
 <bp:evidence rdf:resource="#Evidence1337" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Binding of GRB2:GAB1 complex to p-EGFRvIII mutant</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1100">
 <bp:evidence rdf:resource="#Evidence1334" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Phosphorylated SHC1 in complex with p-5Y-EGFRvIII recruits GRB2:SOS1 complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1101">
 <bp:evidence rdf:resource="#Evidence1335" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Ligand-independent dimerization of EGFRvIII mutant</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1106">
 <bp:evidence rdf:resource="#Evidence1340" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Phosphorylation of PLC-gamma 1 by p-EGFRvIII mutant</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1107">
 <bp:evidence rdf:resource="#Evidence1341" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">PLC-gamma 1 binds to p-EGFRvIII mutant</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1104">
 <bp:evidence rdf:resource="#Evidence1338" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Binding of PI3K to complex of GRB2:GAB1 and p-EGFRvIII</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1105">
 <bp:evidence rdf:resource="#Evidence1339" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">EGFRvIII does not bind CBL</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep654">
 <bp:stepProcess rdf:resource="#Catalysis136" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction503" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep655">
 <bp:stepProcess rdf:resource="#Catalysis137" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction504" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep652">
 <bp:stepProcess rdf:resource="#BiochemicalReaction501" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1108">
 <bp:evidence rdf:resource="#Evidence1342" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SOS-mediated nucleotide exchange of RAS (mediated by GRB2:SOS1 in complex with p-EGFRvIII)</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep653">
 <bp:stepProcess rdf:resource="#BiochemicalReaction502" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1109">
 <bp:evidence rdf:resource="#Evidence1343" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">HSP90 is inactivated by binding to benzaquinoid ansamycins</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep658">
 <bp:stepProcess rdf:resource="#Pathway139" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep659">
 <bp:stepProcess rdf:resource="#BiochemicalReaction507" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep656">
 <bp:stepProcess rdf:resource="#Catalysis138" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction505" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep657">
 <bp:stepProcess rdf:resource="#Catalysis139" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction506" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep650">
 <bp:stepProcess rdf:resource="#BiochemicalReaction499" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep651">
 <bp:stepProcess rdf:resource="#BiochemicalReaction500" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1120">
 <bp:evidence rdf:resource="#Evidence1356" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Binding of CBL to ligand-responsive p-6Y-EGFR mutants</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1121">
 <bp:evidence rdf:resource="#Evidence1357" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Non-covalent tyrosine kinase inhibitors bind and inactivate sensitive ligand-responsive EGFR cancer mutants</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1113">
 <bp:evidence rdf:resource="#Evidence1347" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Conversion of PIP2 to PIP3 by PI3K bound to phosphorylated EGFRvIII</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1114">
 <bp:evidence rdf:resource="#Evidence1350" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Binding of ligand-responsive EGFR mutants to chaperoning proteins HSP90 and CDC37</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep649">
 <bp:stepProcess rdf:resource="#Catalysis135" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction498" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1111">
 <bp:evidence rdf:resource="#Evidence1345" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Binding of GRB2:SOS1 complex to phosphorylated EGFRvIII</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1112">
 <bp:evidence rdf:resource="#Evidence1346" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Dissociation of phosphorylated PLC-gamma 1 from p-EGFRvIII mutant</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1117">
 <bp:evidence rdf:resource="#Evidence1353" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Conversion of PIP2 to PIP3 by PI3K bound to ligand-responsive p-6Y-EGFR mutants</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1118">
 <bp:evidence rdf:resource="#Evidence1354" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SOS-mediated nucleotide exchange of RAS (mediated by GRB2:SOS1 in complex with ligand-responsive p-6Y-EGFR mutants)</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1115">
 <bp:evidence rdf:resource="#Evidence1351" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Binding of SHC1 to p-6Y-EGFR mutants</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1116">
 <bp:evidence rdf:resource="#Evidence1352" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Binding of GRB2:SOS1 complex to phosphorylated ligand-responsive EGFR mutants</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep643">
 <bp:stepProcess rdf:resource="#BiochemicalReaction492" />
 <bp:stepProcess rdf:resource="#Catalysis132" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep644">
 <bp:stepProcess rdf:resource="#BiochemicalReaction493" />
 <bp:stepProcess rdf:resource="#Catalysis133" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep641">
 <bp:stepProcess rdf:resource="#BiochemicalReaction490" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1119">
 <bp:evidence rdf:resource="#Evidence1355" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Binding of PI3K to complex of GRB2:GAB1 and ligand-responsive p-6Y-EGFR mutants</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep642">
 <bp:stepProcess rdf:resource="#Catalysis131" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction491" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep647">
 <bp:stepProcess rdf:resource="#BiochemicalReaction496" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep648">
 <bp:stepProcess rdf:resource="#BiochemicalReaction497" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep645">
 <bp:stepProcess rdf:resource="#BiochemicalReaction494" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep646">
 <bp:stepProcess rdf:resource="#Catalysis134" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction495" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep640">
 <bp:stepProcess rdf:resource="#BiochemicalReaction489" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1131">
 <bp:evidence rdf:resource="#Evidence1367" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SOS-mediated nucleotide exchange of RAS (mediated by GRB2:SOS1 in complex with phosphorylated SHC1 and ligand-responsive p-6Y-EGFR mutants)</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1132">
 <bp:evidence rdf:resource="#Evidence1368" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Phosphorylation of PLCG1 by ligand-responsive p-6Y-EGFR mutants</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1130">
 <bp:evidence rdf:resource="#Evidence1366" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">EGF-induced dimerization of ligand-responsive EGFR mutants</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1124">
 <bp:evidence rdf:resource="#Evidence1360" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Phosphorylation of SHC1 by ligand-responsive p-6Y-EGFR mutants</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1125">
 <bp:evidence rdf:resource="#Evidence1361" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Binding of GRB2:GAB1 complex to ligand-responsive p-6Y-EGFR mutants</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep638">
 <bp:stepProcess rdf:resource="#Catalysis129" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction487" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1122">
 <bp:evidence rdf:resource="#Evidence1358" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Dissociation of phosphorylated PLCG1 from ligand-responsive p-6Y-EGFR mutants</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep639">
 <bp:stepProcess rdf:resource="#BiochemicalReaction488" />
 <bp:stepProcess rdf:resource="#Catalysis130" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1123">
 <bp:evidence rdf:resource="#Evidence1359" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Covalent tyrosine kinase inhibitors bind and inactivate EGFR kinase domain mutant dimers resistant to non-covalent tyrosine kinase inhibitors</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1128">
 <bp:evidence rdf:resource="#Evidence1364" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Binding of EGF to ligand-responsive EGFR mutants</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1129">
 <bp:evidence rdf:resource="#Evidence1365" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Inefficient ubiquitination of ligand-responsive p-6Y-EGFR mutants by p-Y371-CBL</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1126">
 <bp:evidence rdf:resource="#Evidence1362" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">PLCG1 binds to ligand-responsive p-6Y-EGFR mutants</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1127">
 <bp:evidence rdf:resource="#Evidence1363" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Spontaneous dimerization of ligand-responsive EGFR mutants</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep632">
 <bp:stepProcess rdf:resource="#Catalysis126" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction482" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep633">
 <bp:stepProcess rdf:resource="#Catalysis127" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction483" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep630">
 <bp:stepProcess rdf:resource="#Pathway137" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep631">
 <bp:stepProcess rdf:resource="#Catalysis125" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction481" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep636">
 <bp:stepProcess rdf:resource="#Pathway138" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep637">
 <bp:stepProcess rdf:resource="#BiochemicalReaction486" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep634">
 <bp:stepProcess rdf:resource="#Catalysis128" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction484" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep635">
 <bp:stepProcess rdf:resource="#BiochemicalReaction485" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1142">
 <bp:evidence rdf:resource="#Evidence1383" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NICD1 PEST domain mutants translocate from cytosol to nucleus</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1143">
 <bp:evidence rdf:resource="#Evidence1384" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NEXT1 PEST domain mutants are cleaved to produce NICD1 PEST domain mutants</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1140">
 <bp:evidence rdf:resource="#Evidence1379" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NOTCH1 HD domain mutants bind JAG1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1141">
 <bp:evidence rdf:resource="#Evidence1380" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NOTCH1 HD domain mutants bind DLL4</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep629">
 <bp:stepProcess rdf:resource="#Pathway136" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1135">
 <bp:evidence rdf:resource="#Evidence1371" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Trans-autophosphorylation of activated ligand-responsive EGFR mutant dimers</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1136">
 <bp:evidence rdf:resource="#Evidence1375" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NOTCH1 HD domain mutants bind DLL1</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep627">
 <bp:stepProcess rdf:resource="#BiochemicalReaction479" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1133">
 <bp:evidence rdf:resource="#Evidence1369" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Phosphorylation of CBL by ligand-responsive p-6Y-EGFR mutants</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep628">
 <bp:stepProcess rdf:resource="#BiochemicalReaction480" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1134">
 <bp:evidence rdf:resource="#Evidence1370" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Phosphorylated SHC1 in complex with ligand-responsive p-6Y-EGFR mutants recruits GRB2:SOS1 complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1139">
 <bp:evidence rdf:resource="#Evidence1378" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NOTCH1 HD domain mutants bind JAG2</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1137">
 <bp:evidence rdf:resource="#Evidence1376" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NOTCH1 HD domain mutants are cleaved to produce NEXT1 irrespective of ligand binding</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1138">
 <bp:evidence rdf:resource="#Evidence1377" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Ubiquitination of DLL/JAG ligands upon binding to NOTCH1 HD domain mutants</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep621">
 <bp:stepProcess rdf:resource="#BiochemicalReaction473" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep622">
 <bp:stepProcess rdf:resource="#BiochemicalReaction474" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep620">
 <bp:stepProcess rdf:resource="#Catalysis123" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction472" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep625">
 <bp:stepProcess rdf:resource="#BiochemicalReaction477" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep626">
 <bp:stepProcess rdf:resource="#BiochemicalReaction478" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep623">
 <bp:stepProcess rdf:resource="#BiochemicalReaction475" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep624">
 <bp:stepProcess rdf:resource="#Catalysis124" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction476" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1150">
 <bp:evidence rdf:resource="#Evidence1391" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NOTCH1 PEST domain mutants stimulate HES1 transcription</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1153">
 <bp:evidence rdf:resource="#Evidence1394" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Ubiquitination of DLL/JAG ligands upon binding to NOTCH1 HD+PEST domain mutants</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1154">
 <bp:evidence rdf:resource="#Evidence1395" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NOTCH1 PEST domain mutants bind HES1 promoter</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1151">
 <bp:evidence rdf:resource="#Evidence1392" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NOTCH1 PEST domain mutants bind promoters of HEY genes</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1152">
 <bp:evidence rdf:resource="#Evidence1393" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NOTCH1 HD+PEST domain mutants are cleaved by ADAM10/17 irrespective of ligand binding</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1146">
 <bp:evidence rdf:resource="#Evidence1387" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NOTCH1 HD+PEST domain mutants bind JAG2</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1147">
 <bp:evidence rdf:resource="#Evidence1388" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NICD1 PEST domain mutants displace co-repressor complex from RBPJ (CSL)</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1144">
 <bp:evidence rdf:resource="#Evidence1385" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NOTCH1 PEST domain mutants coactivator complex binds CDK8:CCNC</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1145">
 <bp:evidence rdf:resource="#Evidence1386" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NOTCH1 PEST domain mutants stimulate MYC transcription</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1148">
 <bp:evidence rdf:resource="#Evidence1389" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NOTCH1 PEST domain mutants stimulate HEY transcription</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1149">
 <bp:evidence rdf:resource="#Evidence1390" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NOTCH1 PEST domain mutants bind HES5 promoter</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep698">
 <bp:stepProcess rdf:resource="#BiochemicalReaction541" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep699">
 <bp:stepProcess rdf:resource="#BiochemicalReaction542" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep696">
 <bp:stepProcess rdf:resource="#BiochemicalReaction539" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep697">
 <bp:stepProcess rdf:resource="#BiochemicalReaction540" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep690">
 <bp:stepProcess rdf:resource="#BiochemicalReaction534" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep691">
 <bp:stepProcess rdf:resource="#BiochemicalReaction535" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep694">
 <bp:stepProcess rdf:resource="#Catalysis145" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction537" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep695">
 <bp:stepProcess rdf:resource="#BiochemicalReaction538" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep692">
 <bp:stepProcess rdf:resource="#Pathway144" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep693">
 <bp:stepProcess rdf:resource="#Catalysis144" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction536" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1160">
 <bp:evidence rdf:resource="#Evidence1401" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">p-NICD1 PEST domain mutants do not bind FBXW7</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1161">
 <bp:evidence rdf:resource="#Evidence1402" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NICD1 PEST domain mutants in complex with RBPJ (CSL) bind MAML</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1164">
 <bp:evidence rdf:resource="#Evidence1409" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NOTCH1 PEST domain mutants bind DLL1 </bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1165">
 <bp:evidence rdf:resource="#Evidence1410" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ADAM10/17 cleaves ligand-bound NOTCH1 PEST domain mutants to produce NEXT1 PEST domain mutants</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1162">
 <bp:evidence rdf:resource="#Evidence1403" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NOTCH1 HD+PEST domain mutants bind DLL1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1163">
 <bp:evidence rdf:resource="#Evidence1406" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FBXW7 WD mutants do not bind NICD1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1157">
 <bp:evidence rdf:resource="#Evidence1398" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NOTCH1 PEST domain mutants bind MYC promoter</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1158">
 <bp:evidence rdf:resource="#Evidence1399" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NOTCH1 PEST domain mutants stimulate HES5 transcription</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1155">
 <bp:evidence rdf:resource="#Evidence1396" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NOTCH1 HD+PEST domain mutants bind JAG1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1156">
 <bp:evidence rdf:resource="#Evidence1397" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">CDK8 phosphorylates NICD1 PEST domain mutants </bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1159">
 <bp:evidence rdf:resource="#Evidence1400" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NOTCH1 HD+PEST domain mutants bind DLL4</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep687">
 <bp:stepProcess rdf:resource="#BiochemicalReaction531" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep688">
 <bp:stepProcess rdf:resource="#BiochemicalReaction532" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep685">
 <bp:stepProcess rdf:resource="#BiochemicalReaction529" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep686">
 <bp:stepProcess rdf:resource="#BiochemicalReaction530" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep689">
 <bp:stepProcess rdf:resource="#BiochemicalReaction533" />
 <bp:stepProcess rdf:resource="#Catalysis143" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep680">
 <bp:stepProcess rdf:resource="#BiochemicalReaction525" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep683">
 <bp:stepProcess rdf:resource="#BiochemicalReaction527" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep684">
 <bp:stepProcess rdf:resource="#Catalysis142" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction528" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep681">
 <bp:stepProcess rdf:resource="#BiochemicalReaction526" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep682">
 <bp:stepProcess rdf:resource="#Pathway143" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1171">
 <bp:evidence rdf:resource="#Evidence1418" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NOTCH1 t(7;9)(NOTCH1:M1580_K2555) does not bind JAG1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1172">
 <bp:evidence rdf:resource="#Evidence1419" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NOTCH1 t(7;9)(NOTCH1:M1580_K2555) does not bind DLL1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1170">
 <bp:evidence rdf:resource="#Evidence1417" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NOTCH1 t(7;9)(NOTCH1:M1580_K2555) is cleaved to produce NEXT1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1175">
 <bp:evidence rdf:resource="#Evidence1424" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">PDGFR mutants bind type II TKIs</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1176">
 <bp:evidence rdf:resource="#Evidence1425" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">PDGFR mutants bind type I TKIs</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1173">
 <bp:evidence rdf:resource="#Evidence1420" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NOTCH1 t(7;9)(NOTCH1:M1580_K2555) does not bind JAG2</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1174">
 <bp:evidence rdf:resource="#Evidence1421" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NOTCH1 t(7;9)(NOTCH1:M1580_K2555) does not bind DLL4</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1168">
 <bp:evidence rdf:resource="#Evidence1413" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Ubiquitination of DLL/JAG ligands upon binding to NOTCH1 PEST domain mutants</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1169">
 <bp:evidence rdf:resource="#Evidence1414" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NOTCH1 PEST domain mutants bind DLL4</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1166">
 <bp:evidence rdf:resource="#Evidence1411" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NOTCH1 PEST domain mutants bind JAG1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1167">
 <bp:evidence rdf:resource="#Evidence1412" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NOTCH1 PEST domain mutants bind JAG2</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep676">
 <bp:stepProcess rdf:resource="#BiochemicalReaction521" />
 <bp:stepProcess rdf:resource="#Catalysis140" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep677">
 <bp:stepProcess rdf:resource="#BiochemicalReaction522" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep674">
 <bp:stepProcess rdf:resource="#Pathway142" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep675">
 <bp:stepProcess rdf:resource="#BiochemicalReaction520" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep678">
 <bp:stepProcess rdf:resource="#BiochemicalReaction523" />
 <bp:stepProcess rdf:resource="#Catalysis141" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep679">
 <bp:stepProcess rdf:resource="#BiochemicalReaction524" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep672">
 <bp:stepProcess rdf:resource="#BiochemicalReaction518" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep673">
 <bp:stepProcess rdf:resource="#BiochemicalReaction519" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep670">
 <bp:stepProcess rdf:resource="#BiochemicalReaction516" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep671">
 <bp:stepProcess rdf:resource="#BiochemicalReaction517" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1182">
 <bp:evidence rdf:resource="#Evidence1437" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Autophosphorylation of membrane-tethered fusions of PDGFRA or PDGFRB</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1183">
 <bp:evidence rdf:resource="#Evidence1439" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Autophosphorylation of PDGFRA extracellular domain dimers</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1180">
 <bp:evidence rdf:resource="#Evidence1434" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Regorafenib-resistant PDGFR mutants don&apos;t bind regorafenib</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1181">
 <bp:evidence rdf:resource="#Evidence1436" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Ligand-independent dimerization of membrane-tethered fusions of PDGFRA or PDGFRB</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1186">
 <bp:evidence rdf:resource="#Evidence1442" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">STAT binds to p-11Y PDGFRA extracellular domain dimers </bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1187">
 <bp:evidence rdf:resource="#Evidence1443" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">PI3K catalyses the phosphorylation of PIP2 to PIP3 downstream of PDGFRA extracellular domain dimers</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1184">
 <bp:evidence rdf:resource="#Evidence1440" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">GRB2:SOS1 complex binds to PDGFRA extracellular domain dimers</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1185">
 <bp:evidence rdf:resource="#Evidence1441" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Ligand-independent dimerization of PDGFRA extracellular domain mutants</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1179">
 <bp:evidence rdf:resource="#Evidence1432" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">D842V PDGFRA doesn&apos;t bind sunitinib</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1177">
 <bp:evidence rdf:resource="#Evidence1428" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Imatinib-resistant PDGFR mutants don&apos;t bind imatinib</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1178">
 <bp:evidence rdf:resource="#Evidence1430" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Sorafenib-resistant PDGFR mutants don&apos;t bind sorefenib</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep665">
 <bp:stepProcess rdf:resource="#BiochemicalReaction513" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep666">
 <bp:stepProcess rdf:resource="#BiochemicalReaction514" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep663">
 <bp:stepProcess rdf:resource="#BiochemicalReaction511" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep664">
 <bp:stepProcess rdf:resource="#BiochemicalReaction512" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep669">
 <bp:stepProcess rdf:resource="#BiochemicalReaction515" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep667">
 <bp:stepProcess rdf:resource="#Pathway140" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep668">
 <bp:stepProcess rdf:resource="#Pathway141" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1072">
 <bp:evidence rdf:resource="#Evidence1292" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">STAT3-, DNMT1 and NPM1-ALK-dependent ZAP70 gene silencing</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1073">
 <bp:evidence rdf:resource="#Evidence1293" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NPM1-ALK-stimulated PRF1 gene expression</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1070">
 <bp:evidence rdf:resource="#Evidence1290" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">STAT3, DNMT1 and HDAC1 bind PTPN6 gene</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1071">
 <bp:evidence rdf:resource="#Evidence1291" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Crizotinib-driven IL10RA gene expression in NPM1-ALK</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1076">
 <bp:evidence rdf:resource="#Evidence1296" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NPM1-ALK- and STAT3-dependent TWIST gene expression</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1077">
 <bp:evidence rdf:resource="#Evidence1297" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">p-Y705, S727 STAT3 dimer binds ICOS promoter</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1074">
 <bp:evidence rdf:resource="#Evidence1294" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">AcK685-pY705,S727 STAT3 dimer binds DNMT1 promoter</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1075">
 <bp:evidence rdf:resource="#Evidence1295" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MAPK1 phsophorylates ZC3HCF1 in a NPM-ALK-dependent manner</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1069">
 <bp:evidence rdf:resource="#Evidence1289" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MECP2 binds the STAT5A gene</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis414">
 <bp:controlled rdf:resource="#BiochemicalReaction1414" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis413">
 <bp:controlled rdf:resource="#BiochemicalReaction1397" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1067">
 <bp:evidence rdf:resource="#Evidence1287" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">p-Y705,S727 STAT3 dimer binds NOTCH gene</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis416">
 <bp:controlled rdf:resource="#BiochemicalReaction1417" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1068">
 <bp:evidence rdf:resource="#Evidence1288" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NPM1-ALK- and p-STAT3-dependent NOTCH gene expression</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis415">
 <bp:controlled rdf:resource="#BiochemicalReaction1415" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis410">
 <bp:controlled rdf:resource="#BiochemicalReaction1381" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis412">
 <bp:controlled rdf:resource="#BiochemicalReaction1393" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis411">
 <bp:controlled rdf:resource="#BiochemicalReaction1385" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis418">
 <bp:controlled rdf:resource="#BiochemicalReaction1425" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis417">
 <bp:controlled rdf:resource="#BiochemicalReaction1419" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis419">
 <bp:controlled rdf:resource="#BiochemicalReaction1428" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1080">
 <bp:evidence rdf:resource="#Evidence1300" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">pY-STAT3 binds the IRF4 promoter downstream of NPM1-ALK</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1083">
 <bp:evidence rdf:resource="#Evidence1303" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ALK mutants phosphorylate SHC1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1084">
 <bp:evidence rdf:resource="#Evidence1304" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NPM1-ALK-dependent TYK2 phosphorylation</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1081">
 <bp:evidence rdf:resource="#Evidence1301" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NPM1-ALK-dependent CEBPB gene expression</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1082">
 <bp:evidence rdf:resource="#Evidence1302" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NPM1-ALK- and p-STAT3-dependent IRF4 gene expression</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1087">
 <bp:evidence rdf:resource="#Evidence1310" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">crizotinib-resistant ALK mutants don&apos;t bind crizotinib</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1088">
 <bp:evidence rdf:resource="#Evidence1312" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">lorlatinib-resistant ALK mutants don&apos;t bind lorlatinib</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1085">
 <bp:evidence rdf:resource="#Evidence1305" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NPM1-ALK- and TYK2-dependent MCL1 gene expression</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1086">
 <bp:evidence rdf:resource="#Evidence1308" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ceritinib-resistant ALK mutants don&apos;t bind ceritinib</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis425">
 <bp:controlled rdf:resource="#BiochemicalReaction1448" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis424">
 <bp:controlled rdf:resource="#BiochemicalReaction1446" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1078">
 <bp:evidence rdf:resource="#Evidence1298" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NPM1-ALK-dependent JUNB translation</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis427">
 <bp:controlled rdf:resource="#BiochemicalReaction1455" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1079">
 <bp:evidence rdf:resource="#Evidence1299" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NPM1-ALK- and STAT3-dependent ICOS gene expression</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis426">
 <bp:controlled rdf:resource="#BiochemicalReaction1453" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis421">
 <bp:controlled rdf:resource="#BiochemicalReaction1441" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis420">
 <bp:controlled rdf:resource="#BiochemicalReaction1429" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis423">
 <bp:controlled rdf:resource="#BiochemicalReaction1445" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis422">
 <bp:controlled rdf:resource="#BiochemicalReaction1444" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis429">
 <bp:controlled rdf:resource="#BiochemicalReaction1464" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis428">
 <bp:controlled rdf:resource="#BiochemicalReaction1457" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1090">
 <bp:evidence rdf:resource="#Evidence1316" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">brigatinib-resistant ALK mutants don&apos;t bind brigatinib</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1091">
 <bp:evidence rdf:resource="#Evidence1318" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NVP-TAE684-resistant ALK mutants don&apos;t bind NVP-TAE684</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1094">
 <bp:evidence rdf:resource="#Evidence1326" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Covalent tyrosine kinase inhibitors bind and inhibit wild-type EGF:EGFR dimers</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1095">
 <bp:evidence rdf:resource="#Evidence1327" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Inactivation of over-expressed wild type EGFR by Cetuximab recombinant antibody</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1092">
 <bp:evidence rdf:resource="#Evidence1320" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">alectinib resistant ALK mutants don&apos;t bind alectinib</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis430">
 <bp:controlled rdf:resource="#BiochemicalReaction1467" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1093">
 <bp:evidence rdf:resource="#Evidence1322" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ALK mutants bind type I TKIs</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1098">
 <bp:evidence rdf:resource="#Evidence1332" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">EGFRvIII cancer variant does not bind EGF ligand</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1099">
 <bp:evidence rdf:resource="#Evidence1333" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Binding of SHC1 to p-5Y-EGFRvIII</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1096">
 <bp:evidence rdf:resource="#Evidence1330" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SOS-mediated nucleotide exchange of RAS (mediated by GRB2:SOS1 in complex with phosphorylated SHC1 and p-EGFRvIII)</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1097">
 <bp:evidence rdf:resource="#Evidence1331" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">EGFRvIII mutant binds chaperone proteins HSP90 and CDC37</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis436">
 <bp:controlled rdf:resource="#BiochemicalReaction1482" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis435">
 <bp:controlled rdf:resource="#BiochemicalReaction1481" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1089">
 <bp:evidence rdf:resource="#Evidence1314" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ASP-3026- resistant ALK mutants don&apos;t bind ASP-3026</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis438">
 <bp:controlled rdf:resource="#BiochemicalReaction1486" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis437">
 <bp:controlled rdf:resource="#BiochemicalReaction1483" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis432">
 <bp:controlled rdf:resource="#BiochemicalReaction1472" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis431">
 <bp:controlled rdf:resource="#BiochemicalReaction1471" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis434">
 <bp:controlled rdf:resource="#BiochemicalReaction1477" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis433">
 <bp:controlled rdf:resource="#BiochemicalReaction1473" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep599">
 <bp:stepProcess rdf:resource="#BiochemicalReaction456" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep597">
 <bp:stepProcess rdf:resource="#BiochemicalReaction454" />
 <bp:stepProcess rdf:resource="#Catalysis122" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep598">
 <bp:stepProcess rdf:resource="#BiochemicalReaction455" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis439">
 <bp:controlled rdf:resource="#BiochemicalReaction1489" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep591">
 <bp:stepProcess rdf:resource="#Catalysis121" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction449" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep592">
 <bp:stepProcess rdf:resource="#BiochemicalReaction450" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep590">
 <bp:stepProcess rdf:resource="#Pathway129" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep595">
 <bp:stepProcess rdf:resource="#Pathway130" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep596">
 <bp:stepProcess rdf:resource="#BiochemicalReaction453" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep593">
 <bp:stepProcess rdf:resource="#BiochemicalReaction451" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep594">
 <bp:stepProcess rdf:resource="#BiochemicalReaction452" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis441">
 <bp:controlled rdf:resource="#BiochemicalReaction1493" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis440">
 <bp:controlled rdf:resource="#BiochemicalReaction1491" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis447">
 <bp:controlled rdf:resource="#BiochemicalReaction1508" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis446">
 <bp:controlled rdf:resource="#BiochemicalReaction1505" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis449">
 <bp:controlled rdf:resource="#BiochemicalReaction1511" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis448">
 <bp:controlled rdf:resource="#BiochemicalReaction1509" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis443">
 <bp:controlled rdf:resource="#BiochemicalReaction1501" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis442">
 <bp:controlled rdf:resource="#BiochemicalReaction1494" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis445">
 <bp:controlled rdf:resource="#BiochemicalReaction1503" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis444">
 <bp:controlled rdf:resource="#BiochemicalReaction1502" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep588">
 <bp:stepProcess rdf:resource="#Pathway128" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep589">
 <bp:stepProcess rdf:resource="#BiochemicalReaction448" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep586">
 <bp:stepProcess rdf:resource="#BiochemicalReaction446" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep587">
 <bp:stepProcess rdf:resource="#BiochemicalReaction447" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence1">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence6">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence7">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence8">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence9">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence3">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence4">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence5">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis403">
 <bp:controlled rdf:resource="#BiochemicalReaction1337" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis402">
 <bp:controlled rdf:resource="#BiochemicalReaction1335" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis405">
 <bp:controlled rdf:resource="#BiochemicalReaction1365" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis404">
 <bp:controlled rdf:resource="#BiochemicalReaction1338" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis401">
 <bp:controlled rdf:resource="#BiochemicalReaction1334" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis400">
 <bp:controlled rdf:resource="#BiochemicalReaction1333" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis407">
 <bp:controlled rdf:resource="#BiochemicalReaction1369" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis406">
 <bp:controlled rdf:resource="#BiochemicalReaction1367" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis409">
 <bp:controlled rdf:resource="#BiochemicalReaction1378" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis408">
 <bp:controlled rdf:resource="#BiochemicalReaction1375" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis494">
 <bp:controlled rdf:resource="#BiochemicalReaction1576" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis493">
 <bp:controlled rdf:resource="#BiochemicalReaction1575" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis496">
 <bp:controlled rdf:resource="#BiochemicalReaction1578" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis495">
 <bp:controlled rdf:resource="#BiochemicalReaction1577" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis490">
 <bp:controlled rdf:resource="#BiochemicalReaction1572" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis492">
 <bp:controlled rdf:resource="#BiochemicalReaction1574" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis491">
 <bp:controlled rdf:resource="#BiochemicalReaction1573" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis498">
 <bp:controlled rdf:resource="#BiochemicalReaction1580" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep2326">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1730" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis497">
 <bp:controlled rdf:resource="#BiochemicalReaction1579" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep2327">
 <bp:stepProcess rdf:resource="#Pathway553" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2328">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1731" />
 <bp:stepProcess rdf:resource="#Catalysis638" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis499">
 <bp:controlled rdf:resource="#BiochemicalReaction1581" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep2329">
 <bp:stepProcess rdf:resource="#Pathway554" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2322">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1728" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2323">
 <bp:stepProcess rdf:resource="#Pathway551" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2324">
 <bp:stepProcess rdf:resource="#Catalysis637" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1729" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2325">
 <bp:stepProcess rdf:resource="#Pathway552" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2320">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1727" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2321">
 <bp:stepProcess rdf:resource="#Pathway550" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1006">
 <bp:stepProcess rdf:resource="#BiochemicalReaction812" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2337">
 <bp:stepProcess rdf:resource="#Pathway558" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1007">
 <bp:stepProcess rdf:resource="#BiochemicalReaction813" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2338">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1736" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1008">
 <bp:stepProcess rdf:resource="#Catalysis223" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction814" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2339">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1737" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1009">
 <bp:stepProcess rdf:resource="#BiochemicalReaction815" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1002">
 <bp:stepProcess rdf:resource="#Catalysis222" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction808" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2333">
 <bp:stepProcess rdf:resource="#Pathway556" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1003">
 <bp:stepProcess rdf:resource="#BiochemicalReaction809" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2334">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1734" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1004">
 <bp:stepProcess rdf:resource="#BiochemicalReaction810" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2335">
 <bp:stepProcess rdf:resource="#Pathway557" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1005">
 <bp:stepProcess rdf:resource="#BiochemicalReaction811" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2336">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1735" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2330">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1732" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1000">
 <bp:stepProcess rdf:resource="#BiochemicalReaction806" />
 <bp:stepProcess rdf:resource="#Catalysis221" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2331">
 <bp:stepProcess rdf:resource="#Pathway555" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1001">
 <bp:stepProcess rdf:resource="#BiochemicalReaction807" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2332">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1733" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2308">
 <bp:stepProcess rdf:resource="#Catalysis633" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1721" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2309">
 <bp:stepProcess rdf:resource="#Pathway544" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2304">
 <bp:stepProcess rdf:resource="#Catalysis631" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1719" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2305">
 <bp:stepProcess rdf:resource="#Pathway542" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2306">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1720" />
 <bp:stepProcess rdf:resource="#Catalysis632" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2307">
 <bp:stepProcess rdf:resource="#Pathway543" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2300">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1717" />
 <bp:stepProcess rdf:resource="#Catalysis629" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2301">
 <bp:stepProcess rdf:resource="#Pathway540" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2302">
 <bp:stepProcess rdf:resource="#Catalysis630" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1718" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2303">
 <bp:stepProcess rdf:resource="#Pathway541" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2319">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1726" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2315">
 <bp:stepProcess rdf:resource="#Pathway547" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2316">
 <bp:stepProcess rdf:resource="#Pathway548" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2317">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1725" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2318">
 <bp:stepProcess rdf:resource="#Pathway549" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2311">
 <bp:stepProcess rdf:resource="#Pathway545" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2312">
 <bp:stepProcess rdf:resource="#Catalysis635" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1723" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2313">
 <bp:stepProcess rdf:resource="#Catalysis636" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1724" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2314">
 <bp:stepProcess rdf:resource="#Pathway546" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2310">
 <bp:stepProcess rdf:resource="#Catalysis634" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1722" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis450">
 <bp:controlled rdf:resource="#BiochemicalReaction1513" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis452">
 <bp:controlled rdf:resource="#BiochemicalReaction1517" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis451">
 <bp:controlled rdf:resource="#BiochemicalReaction1515" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis458">
 <bp:controlled rdf:resource="#BiochemicalReaction1528" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis457">
 <bp:controlled rdf:resource="#BiochemicalReaction1526" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis459">
 <bp:controlled rdf:resource="#BiochemicalReaction1531" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis454">
 <bp:controlled rdf:resource="#BiochemicalReaction1521" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis453">
 <bp:controlled rdf:resource="#BiochemicalReaction1519" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis456">
 <bp:controlled rdf:resource="#BiochemicalReaction1523" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis455">
 <bp:controlled rdf:resource="#BiochemicalReaction1522" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis461">
 <bp:controlled rdf:resource="#BiochemicalReaction1535" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis460">
 <bp:controlled rdf:resource="#BiochemicalReaction1532" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis463">
 <bp:controlled rdf:resource="#BiochemicalReaction1543" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis462">
 <bp:controlled rdf:resource="#BiochemicalReaction1541" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis469">
 <bp:controlled rdf:resource="#BiochemicalReaction1551" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis468">
 <bp:controlled rdf:resource="#BiochemicalReaction1550" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis465">
 <bp:controlled rdf:resource="#BiochemicalReaction1547" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis464">
 <bp:controlled rdf:resource="#BiochemicalReaction1546" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis467">
 <bp:controlled rdf:resource="#BiochemicalReaction1549" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis466">
 <bp:controlled rdf:resource="#BiochemicalReaction1548" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis472">
 <bp:controlled rdf:resource="#BiochemicalReaction1554" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis471">
 <bp:controlled rdf:resource="#BiochemicalReaction1553" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis474">
 <bp:controlled rdf:resource="#BiochemicalReaction1556" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis473">
 <bp:controlled rdf:resource="#BiochemicalReaction1555" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis470">
 <bp:controlled rdf:resource="#BiochemicalReaction1552" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis479">
 <bp:controlled rdf:resource="#BiochemicalReaction1561" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis476">
 <bp:controlled rdf:resource="#BiochemicalReaction1558" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis475">
 <bp:controlled rdf:resource="#BiochemicalReaction1557" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis478">
 <bp:controlled rdf:resource="#BiochemicalReaction1560" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis477">
 <bp:controlled rdf:resource="#BiochemicalReaction1559" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis483">
 <bp:controlled rdf:resource="#BiochemicalReaction1565" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis482">
 <bp:controlled rdf:resource="#BiochemicalReaction1564" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis485">
 <bp:controlled rdf:resource="#BiochemicalReaction1567" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis484">
 <bp:controlled rdf:resource="#BiochemicalReaction1566" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis481">
 <bp:controlled rdf:resource="#BiochemicalReaction1563" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis480">
 <bp:controlled rdf:resource="#BiochemicalReaction1562" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis487">
 <bp:controlled rdf:resource="#BiochemicalReaction1569" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis486">
 <bp:controlled rdf:resource="#BiochemicalReaction1568" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis489">
 <bp:controlled rdf:resource="#BiochemicalReaction1571" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis488">
 <bp:controlled rdf:resource="#BiochemicalReaction1570" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep1071">
 <bp:stepProcess rdf:resource="#Pathway182" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1072">
 <bp:stepProcess rdf:resource="#Pathway183" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1073">
 <bp:stepProcess rdf:resource="#BiochemicalReaction872" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1074">
 <bp:stepProcess rdf:resource="#BiochemicalReaction873" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1070">
 <bp:stepProcess rdf:resource="#Pathway181" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1079">
 <bp:stepProcess rdf:resource="#Pathway184" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1075">
 <bp:stepProcess rdf:resource="#BiochemicalReaction874" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1076">
 <bp:stepProcess rdf:resource="#BiochemicalReaction875" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1077">
 <bp:stepProcess rdf:resource="#BiochemicalReaction876" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1078">
 <bp:stepProcess rdf:resource="#BiochemicalReaction877" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1082">
 <bp:stepProcess rdf:resource="#BiochemicalReaction880" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1083">
 <bp:stepProcess rdf:resource="#Pathway185" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1084">
 <bp:stepProcess rdf:resource="#Pathway186" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1085">
 <bp:stepProcess rdf:resource="#BiochemicalReaction881" />
 <bp:stepProcess rdf:resource="#Catalysis230" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1080">
 <bp:stepProcess rdf:resource="#Catalysis228" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction878" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1081">
 <bp:stepProcess rdf:resource="#Catalysis229" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction879" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1086">
 <bp:stepProcess rdf:resource="#Pathway187" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1087">
 <bp:stepProcess rdf:resource="#Pathway188" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1088">
 <bp:stepProcess rdf:resource="#BiochemicalReaction882" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1089">
 <bp:stepProcess rdf:resource="#BiochemicalReaction883" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2380">
 <bp:stepProcess rdf:resource="#Pathway578" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1050">
 <bp:stepProcess rdf:resource="#BiochemicalReaction852" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2381">
 <bp:stepProcess rdf:resource="#Pathway579" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1051">
 <bp:stepProcess rdf:resource="#BiochemicalReaction853" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2382">
 <bp:stepProcess rdf:resource="#Pathway580" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1052">
 <bp:stepProcess rdf:resource="#BiochemicalReaction854" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2383">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1759" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1057">
 <bp:stepProcess rdf:resource="#BiochemicalReaction859" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2388">
 <bp:stepProcess rdf:resource="#Pathway584" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1058">
 <bp:stepProcess rdf:resource="#BiochemicalReaction860" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2389">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1761" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1059">
 <bp:stepProcess rdf:resource="#BiochemicalReaction861" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1053">
 <bp:stepProcess rdf:resource="#BiochemicalReaction855" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2384">
 <bp:stepProcess rdf:resource="#Pathway581" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1054">
 <bp:stepProcess rdf:resource="#BiochemicalReaction856" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2385">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1760" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1055">
 <bp:stepProcess rdf:resource="#BiochemicalReaction857" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2386">
 <bp:stepProcess rdf:resource="#Pathway582" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1056">
 <bp:stepProcess rdf:resource="#BiochemicalReaction858" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2387">
 <bp:stepProcess rdf:resource="#Pathway583" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1060">
 <bp:stepProcess rdf:resource="#BiochemicalReaction862" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2391">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1762" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1061">
 <bp:stepProcess rdf:resource="#BiochemicalReaction863" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2392">
 <bp:stepProcess rdf:resource="#Pathway586" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1062">
 <bp:stepProcess rdf:resource="#BiochemicalReaction864" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2393">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1763" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1063">
 <bp:stepProcess rdf:resource="#BiochemicalReaction865" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2394">
 <bp:stepProcess rdf:resource="#Pathway587" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2390">
 <bp:stepProcess rdf:resource="#Pathway585" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1068">
 <bp:stepProcess rdf:resource="#BiochemicalReaction870" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2399">
 <bp:stepProcess rdf:resource="#Catalysis651" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1765" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1069">
 <bp:stepProcess rdf:resource="#BiochemicalReaction871" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1064">
 <bp:stepProcess rdf:resource="#BiochemicalReaction866" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2395">
 <bp:stepProcess rdf:resource="#Pathway588" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1065">
 <bp:stepProcess rdf:resource="#BiochemicalReaction867" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2396">
 <bp:stepProcess rdf:resource="#Pathway589" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1066">
 <bp:stepProcess rdf:resource="#BiochemicalReaction868" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2397">
 <bp:stepProcess rdf:resource="#Pathway590" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1067">
 <bp:stepProcess rdf:resource="#BiochemicalReaction869" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2398">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1764" />
 <bp:stepProcess rdf:resource="#Catalysis650" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2360">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1749" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1030">
 <bp:stepProcess rdf:resource="#BiochemicalReaction833" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2361">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1750" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1039">
 <bp:stepProcess rdf:resource="#BiochemicalReaction841" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1035">
 <bp:stepProcess rdf:resource="#BiochemicalReaction837" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2366">
 <bp:stepProcess rdf:resource="#Pathway570" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1036">
 <bp:stepProcess rdf:resource="#BiochemicalReaction838" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2367">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1753" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1037">
 <bp:stepProcess rdf:resource="#BiochemicalReaction839" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2368">
 <bp:stepProcess rdf:resource="#Pathway571" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1038">
 <bp:stepProcess rdf:resource="#BiochemicalReaction840" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2369">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1754" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1031">
 <bp:stepProcess rdf:resource="#BiochemicalReaction834" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2362">
 <bp:stepProcess rdf:resource="#Pathway568" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1032">
 <bp:stepProcess rdf:resource="#BiochemicalReaction835" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2363">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1751" />
 <bp:stepProcess rdf:resource="#Catalysis647" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1033">
 <bp:stepProcess rdf:resource="#Pathway180" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2364">
 <bp:stepProcess rdf:resource="#Pathway569" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1034">
 <bp:stepProcess rdf:resource="#BiochemicalReaction836" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2365">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1752" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2370">
 <bp:stepProcess rdf:resource="#Pathway572" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1040">
 <bp:stepProcess rdf:resource="#BiochemicalReaction842" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2371">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1755" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1041">
 <bp:stepProcess rdf:resource="#BiochemicalReaction843" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2372">
 <bp:stepProcess rdf:resource="#Pathway573" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1046">
 <bp:stepProcess rdf:resource="#BiochemicalReaction848" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2377">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1758" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1047">
 <bp:stepProcess rdf:resource="#BiochemicalReaction849" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2378">
 <bp:stepProcess rdf:resource="#Pathway576" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1048">
 <bp:stepProcess rdf:resource="#BiochemicalReaction850" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2379">
 <bp:stepProcess rdf:resource="#Pathway577" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1049">
 <bp:stepProcess rdf:resource="#BiochemicalReaction851" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1042">
 <bp:stepProcess rdf:resource="#BiochemicalReaction844" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2373">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1756" />
 <bp:stepProcess rdf:resource="#Catalysis648" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1043">
 <bp:stepProcess rdf:resource="#BiochemicalReaction845" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2374">
 <bp:stepProcess rdf:resource="#Pathway574" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1044">
 <bp:stepProcess rdf:resource="#BiochemicalReaction846" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2375">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1757" />
 <bp:stepProcess rdf:resource="#Catalysis649" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1045">
 <bp:stepProcess rdf:resource="#BiochemicalReaction847" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2376">
 <bp:stepProcess rdf:resource="#Pathway575" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1017">
 <bp:stepProcess rdf:resource="#BiochemicalReaction822" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2348">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1742" />
 <bp:stepProcess rdf:resource="#Catalysis642" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1018">
 <bp:stepProcess rdf:resource="#BiochemicalReaction823" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2349">
 <bp:stepProcess rdf:resource="#Catalysis643" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1743" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1019">
 <bp:stepProcess rdf:resource="#BiochemicalReaction824" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1013">
 <bp:stepProcess rdf:resource="#BiochemicalReaction819" />
 <bp:stepProcess rdf:resource="#Catalysis225" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2344">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1739" />
 <bp:stepProcess rdf:resource="#Catalysis639" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1014">
 <bp:stepProcess rdf:resource="#BiochemicalReaction820" />
 <bp:stepProcess rdf:resource="#Catalysis226" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2345">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1740" />
 <bp:stepProcess rdf:resource="#Catalysis640" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1015">
 <bp:stepProcess rdf:resource="#BiochemicalReaction821" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2346">
 <bp:stepProcess rdf:resource="#Pathway562" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1016">
 <bp:stepProcess rdf:resource="#Pathway177" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2347">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1741" />
 <bp:stepProcess rdf:resource="#Catalysis641" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2340">
 <bp:stepProcess rdf:resource="#Pathway559" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1010">
 <bp:stepProcess rdf:resource="#Catalysis224" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction816" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2341">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1738" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1011">
 <bp:stepProcess rdf:resource="#BiochemicalReaction817" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2342">
 <bp:stepProcess rdf:resource="#Pathway560" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1012">
 <bp:stepProcess rdf:resource="#BiochemicalReaction818" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2343">
 <bp:stepProcess rdf:resource="#Pathway561" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2350">
 <bp:stepProcess rdf:resource="#Catalysis644" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1744" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1028">
 <bp:stepProcess rdf:resource="#Pathway179" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2359">
 <bp:stepProcess rdf:resource="#Catalysis646" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1748" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1029">
 <bp:stepProcess rdf:resource="#BiochemicalReaction832" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1024">
 <bp:stepProcess rdf:resource="#BiochemicalReaction828" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2355">
 <bp:stepProcess rdf:resource="#Catalysis645" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1745" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1025">
 <bp:stepProcess rdf:resource="#BiochemicalReaction829" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2356">
 <bp:stepProcess rdf:resource="#Pathway567" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1026">
 <bp:stepProcess rdf:resource="#BiochemicalReaction830" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2357">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1746" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1027">
 <bp:stepProcess rdf:resource="#BiochemicalReaction831" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2358">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1747" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1020">
 <bp:stepProcess rdf:resource="#BiochemicalReaction825" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2351">
 <bp:stepProcess rdf:resource="#Pathway563" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1021">
 <bp:stepProcess rdf:resource="#BiochemicalReaction826" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2352">
 <bp:stepProcess rdf:resource="#Pathway564" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1022">
 <bp:stepProcess rdf:resource="#Pathway178" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2353">
 <bp:stepProcess rdf:resource="#Pathway565" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1023">
 <bp:stepProcess rdf:resource="#Catalysis227" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction827" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2354">
 <bp:stepProcess rdf:resource="#Pathway566" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep540">
 <bp:stepProcess rdf:resource="#BiochemicalReaction410" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep541">
 <bp:stepProcess rdf:resource="#Catalysis105" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction411" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep539">
 <bp:stepProcess rdf:resource="#BiochemicalReaction409" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep533">
 <bp:stepProcess rdf:resource="#Pathway116" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep534">
 <bp:stepProcess rdf:resource="#BiochemicalReaction405" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep531">
 <bp:stepProcess rdf:resource="#Catalysis104" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction404" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep532">
 <bp:stepProcess rdf:resource="#BiochemicalReaction363" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep537">
 <bp:stepProcess rdf:resource="#BiochemicalReaction407" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep538">
 <bp:stepProcess rdf:resource="#BiochemicalReaction408" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep535">
 <bp:stepProcess rdf:resource="#BiochemicalReaction406" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep536">
 <bp:stepProcess rdf:resource="#Pathway117" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep530">
 <bp:stepProcess rdf:resource="#BiochemicalReaction403" />
 <bp:stepProcess rdf:resource="#Catalysis103" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1000">
 <bp:evidence rdf:resource="#Evidence1212" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">pagA(197-794):ANTRX1 oligomer transports cya and lef (target cell endosome to cytosol)</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep528">
 <bp:stepProcess rdf:resource="#BiochemicalReaction401" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep529">
 <bp:stepProcess rdf:resource="#BiochemicalReaction402" />
 <bp:stepProcess rdf:resource="#Catalysis102" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep522">
 <bp:stepProcess rdf:resource="#Pathway113" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep523">
 <bp:stepProcess rdf:resource="#Pathway114" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep520">
 <bp:stepProcess rdf:resource="#BiochemicalReaction396" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep521">
 <bp:stepProcess rdf:resource="#BiochemicalReaction397" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep526">
 <bp:stepProcess rdf:resource="#BiochemicalReaction400" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep527">
 <bp:stepProcess rdf:resource="#Pathway115" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep524">
 <bp:stepProcess rdf:resource="#BiochemicalReaction398" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep525">
 <bp:stepProcess rdf:resource="#BiochemicalReaction399" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1010">
 <bp:evidence rdf:resource="#Evidence1225" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">CBLL1 ubiqutinates the InlA-bound CDH1 complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1011">
 <bp:evidence rdf:resource="#Evidence1226" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SRC autophosphorylation is positively regulated by InlA-bound CDH1</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep519">
 <bp:stepProcess rdf:resource="#Pathway112" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1003">
 <bp:evidence rdf:resource="#Evidence1215" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">pagA binds ANTXR1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1004">
 <bp:evidence rdf:resource="#Evidence1216" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">cya and lef bind to pagA(197-794):ANTXR1 oligomer</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep517">
 <bp:stepProcess rdf:resource="#BiochemicalReaction394" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1001">
 <bp:evidence rdf:resource="#Evidence1213" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">pagA binds ANTXR2</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep518">
 <bp:stepProcess rdf:resource="#BiochemicalReaction395" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1002">
 <bp:evidence rdf:resource="#Evidence1214" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Anthrax lef cleaves target cell MAP2K3 (MEK3)</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1007">
 <bp:evidence rdf:resource="#Evidence1219" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Anthrax lef cleaves target cell MAP2K6 (MEK6)</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1008">
 <bp:evidence rdf:resource="#Evidence1220" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Endocytosis of cya:lef:(pagA(197-794):ANTXR2 oligomer) (plasma membrane to endosome membrane)</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1005">
 <bp:evidence rdf:resource="#Evidence1217" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Anthrax lef cleaves target cell MAP2K1 (MEK1)</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1006">
 <bp:evidence rdf:resource="#Evidence1218" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">cya and lef bind to pagA(197-794):ANTXR2 oligomer</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep511">
 <bp:stepProcess rdf:resource="#BiochemicalReaction389" />
 <bp:stepProcess rdf:resource="#Catalysis99" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep512">
 <bp:stepProcess rdf:resource="#Catalysis100" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction390" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1009">
 <bp:evidence rdf:resource="#Evidence1222" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">GUCY2C trimer binds sta1</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep510">
 <bp:stepProcess rdf:resource="#BiochemicalReaction388" />
 <bp:stepProcess rdf:resource="#Catalysis98" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep515">
 <bp:stepProcess rdf:resource="#Pathway111" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep516">
 <bp:stepProcess rdf:resource="#BiochemicalReaction393" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep513">
 <bp:stepProcess rdf:resource="#BiochemicalReaction391" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep514">
 <bp:stepProcess rdf:resource="#Catalysis101" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction392" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1021">
 <bp:evidence rdf:resource="#Evidence1237" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">InlB-activated MET phosphorylates CBL</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1022">
 <bp:evidence rdf:resource="#Evidence1238" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">InlB:MET dimer trans-autophophorylates</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1020">
 <bp:evidence rdf:resource="#Evidence1236" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">EPS15 and HGS bind CBL-monoubiquitinated MET engaged with Listeria InlB</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep508">
 <bp:stepProcess rdf:resource="#BiochemicalReaction386" />
 <bp:stepProcess rdf:resource="#Catalysis96" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1014">
 <bp:evidence rdf:resource="#Evidence1229" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SRC phosphorylates InlA-bound CDH1 and CTNNB1</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep509">
 <bp:stepProcess rdf:resource="#BiochemicalReaction387" />
 <bp:stepProcess rdf:resource="#Catalysis97" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1015">
 <bp:evidence rdf:resource="#Evidence1231" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">InlB binds MET</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep506">
 <bp:stepProcess rdf:resource="#BiochemicalReaction384" />
 <bp:stepProcess rdf:resource="#Catalysis95" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1012">
 <bp:evidence rdf:resource="#Evidence1227" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">CBLL1 binds SRC-phosphorylated CDH1 complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep507">
 <bp:stepProcess rdf:resource="#BiochemicalReaction385" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1013">
 <bp:evidence rdf:resource="#Evidence1228" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">InlA binds CDH1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1018">
 <bp:evidence rdf:resource="#Evidence1234" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">CBL monoubiquitinates InlB-bound MET</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1019">
 <bp:evidence rdf:resource="#Evidence1235" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">InlB promotes MET dimerization</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1016">
 <bp:evidence rdf:resource="#Evidence1232" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">CBL recruits CIN85:endophilin complex to InlB-bound MET</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1017">
 <bp:evidence rdf:resource="#Evidence1233" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">CBL binds InlB-activated MET</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep500">
 <bp:stepProcess rdf:resource="#BiochemicalReaction380" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep501">
 <bp:stepProcess rdf:resource="#BiochemicalReaction381" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep504">
 <bp:stepProcess rdf:resource="#BiochemicalReaction383" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep505">
 <bp:stepProcess rdf:resource="#Pathway110" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep502">
 <bp:stepProcess rdf:resource="#Pathway109" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep503">
 <bp:stepProcess rdf:resource="#BiochemicalReaction382" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep580">
 <bp:stepProcess rdf:resource="#Catalysis119" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction441" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep581">
 <bp:stepProcess rdf:resource="#BiochemicalReaction442" />
 <bp:stepProcess rdf:resource="#Catalysis120" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep584">
 <bp:stepProcess rdf:resource="#Pathway127" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep585">
 <bp:stepProcess rdf:resource="#BiochemicalReaction445" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep582">
 <bp:stepProcess rdf:resource="#BiochemicalReaction443" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep583">
 <bp:stepProcess rdf:resource="#BiochemicalReaction444" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1032">
 <bp:evidence rdf:resource="#Evidence1251" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NPM1-ALK- and PI3K-dependent MDM2 phosphorylation</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1033">
 <bp:evidence rdf:resource="#Evidence1252" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ALK mutants bind SHC</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1030">
 <bp:evidence rdf:resource="#Evidence1249" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Ligand-independent dimerization of ALK fusions</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1031">
 <bp:evidence rdf:resource="#Evidence1250" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ALK mutants bind PI3KCA</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction5">
 <bp:evidence rdf:resource="#Evidence11" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SERPING1 variant does not bind kallikrein</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1025">
 <bp:evidence rdf:resource="#Evidence1244" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ALK mutants phosphorylate STAT3</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction4">
 <bp:evidence rdf:resource="#Evidence10" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SERPING1 variant is not secreted</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1026">
 <bp:evidence rdf:resource="#Evidence1245" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ALK fusions phosphorylate PLCG1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction7">
 <bp:evidence rdf:resource="#Evidence15" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">GGCX does not gamma-carboxylate 3D-F9(29-461) (pro-factor IX)</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1023">
 <bp:evidence rdf:resource="#Evidence1242" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">PI3K synthesizes PIP3 downstream of ALK mutants</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction6">
 <bp:evidence rdf:resource="#Evidence12" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SERPING1 variant does not bind factor XIIa</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1024">
 <bp:evidence rdf:resource="#Evidence1243" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Autophosphorylation of ALK fusions</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1">
 <bp:evidence rdf:resource="#Evidence5" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Hyperactivation of factor X by FVIIIa:FIXa R384L</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1029">
 <bp:evidence rdf:resource="#Evidence1248" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ALK fusions phosphorylate IRS1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction3">
 <bp:evidence rdf:resource="#Evidence8" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Cleavage of factor XII variant by activated thrombin</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1027">
 <bp:evidence rdf:resource="#Evidence1246" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ALK fusions phosphorylate FRS</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction2">
 <bp:evidence rdf:resource="#Evidence7" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Cleavage of FXII variant by KLKB1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1028">
 <bp:evidence rdf:resource="#Evidence1247" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ALK fusions bind FRS</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep577">
 <bp:stepProcess rdf:resource="#Catalysis118" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction438" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep578">
 <bp:stepProcess rdf:resource="#BiochemicalReaction439" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep575">
 <bp:stepProcess rdf:resource="#BiochemicalReaction436" />
 <bp:stepProcess rdf:resource="#Catalysis116" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep576">
 <bp:stepProcess rdf:resource="#Catalysis117" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction437" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction9">
 <bp:evidence rdf:resource="#Evidence19" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FIXa variant:FVIIIa does not convert FX to the active FXa</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction8">
 <bp:evidence rdf:resource="#Evidence17" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FIX(29-461) variant is not activated (factor XIa catalyst)</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep579">
 <bp:stepProcess rdf:resource="#BiochemicalReaction440" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep570">
 <bp:stepProcess rdf:resource="#Catalysis113" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction432" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep573">
 <bp:stepProcess rdf:resource="#Pathway126" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep574">
 <bp:stepProcess rdf:resource="#BiochemicalReaction435" />
 <bp:stepProcess rdf:resource="#Catalysis115" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep571">
 <bp:stepProcess rdf:resource="#BiochemicalReaction433" />
 <bp:stepProcess rdf:resource="#Catalysis114" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep572">
 <bp:stepProcess rdf:resource="#BiochemicalReaction434" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1040">
 <bp:evidence rdf:resource="#Evidence1259" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NPM1-ALK-dependent MAPK8,9 phosphorylation</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1043">
 <bp:evidence rdf:resource="#Evidence1262" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">p-T,Y MAPK8,9 bind TP53</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1044">
 <bp:evidence rdf:resource="#Evidence1263" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">JNK-dependent inhibition of TP53 ubiquitination</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1041">
 <bp:evidence rdf:resource="#Evidence1260" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ALK fusion proteins bind PLCG1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1042">
 <bp:evidence rdf:resource="#Evidence1261" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">p-T,Y MAPK8,9 translocate to the nucleus</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1036">
 <bp:evidence rdf:resource="#Evidence1255" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NPM1-ALK- and JUN-dependent CDKN1A gene repression</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1037">
 <bp:evidence rdf:resource="#Evidence1256" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Autophosphorylation of point mutants of ALK</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1034">
 <bp:evidence rdf:resource="#Evidence1253" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Ligand-independent dimerization of point mutants of ALK</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1035">
 <bp:evidence rdf:resource="#Evidence1254" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ALK fusion proteins bind IRS</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1038">
 <bp:evidence rdf:resource="#Evidence1257" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NPM1-ALK- and JNK-dependent JUN phosphorylation</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1039">
 <bp:evidence rdf:resource="#Evidence1258" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TYK2-dependent STAT1 and STAT3 phosphorylation</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep566">
 <bp:stepProcess rdf:resource="#Pathway123" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep567">
 <bp:stepProcess rdf:resource="#Pathway124" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep564">
 <bp:stepProcess rdf:resource="#BiochemicalReaction429" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep565">
 <bp:stepProcess rdf:resource="#BiochemicalReaction430" />
 <bp:stepProcess rdf:resource="#Catalysis111" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep568">
 <bp:stepProcess rdf:resource="#Pathway125" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep569">
 <bp:stepProcess rdf:resource="#BiochemicalReaction431" />
 <bp:stepProcess rdf:resource="#Catalysis112" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1093">
 <bp:stepProcess rdf:resource="#BiochemicalReaction886" />
 <bp:stepProcess rdf:resource="#Catalysis231" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1094">
 <bp:stepProcess rdf:resource="#Pathway190" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1095">
 <bp:stepProcess rdf:resource="#BiochemicalReaction887" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1096">
 <bp:stepProcess rdf:resource="#BiochemicalReaction888" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep562">
 <bp:stepProcess rdf:resource="#BiochemicalReaction427" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep563">
 <bp:stepProcess rdf:resource="#BiochemicalReaction428" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1090">
 <bp:stepProcess rdf:resource="#BiochemicalReaction884" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep560">
 <bp:stepProcess rdf:resource="#BiochemicalReaction425" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1091">
 <bp:stepProcess rdf:resource="#Pathway189" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep561">
 <bp:stepProcess rdf:resource="#BiochemicalReaction426" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1092">
 <bp:stepProcess rdf:resource="#BiochemicalReaction885" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1050">
 <bp:evidence rdf:resource="#Evidence1269" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MYH9- and RNF213-ALK fusions are phosphorylated</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1051">
 <bp:evidence rdf:resource="#Evidence1271" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NPM1-ALK and FOXM1-dependent CCNB1 gene expression</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1054">
 <bp:evidence rdf:resource="#Evidence1274" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">JUNB- and NPM1-ALK-mediated GZMB gene expression</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1055">
 <bp:evidence rdf:resource="#Evidence1275" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NPM1-ALK-dependent JUNB gene transcription</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1052">
 <bp:evidence rdf:resource="#Evidence1272" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NPM1-ALK binds NPM1 and FOXM1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1053">
 <bp:evidence rdf:resource="#Evidence1273" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NPM1-ALK translocates to the nucleus</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1047">
 <bp:evidence rdf:resource="#Evidence1266" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">pY-STAT3 dimer translocates to the nucleus downstream of ALK mutants</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1048">
 <bp:evidence rdf:resource="#Evidence1267" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ALK mutants bind PI3KR1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1045">
 <bp:evidence rdf:resource="#Evidence1264" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ALK fusions bind GRB2</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1046">
 <bp:evidence rdf:resource="#Evidence1265" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ALK mutants:p-3Y SHC binds GRB2</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1049">
 <bp:evidence rdf:resource="#Evidence1268" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ALK mutants bind STAT3</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep555">
 <bp:stepProcess rdf:resource="#BiochemicalReaction420" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep556">
 <bp:stepProcess rdf:resource="#BiochemicalReaction421" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep553">
 <bp:stepProcess rdf:resource="#BiochemicalReaction419" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep554">
 <bp:stepProcess rdf:resource="#Pathway122" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep559">
 <bp:stepProcess rdf:resource="#BiochemicalReaction424" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1097">
 <bp:stepProcess rdf:resource="#BiochemicalReaction889" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1098">
 <bp:stepProcess rdf:resource="#BiochemicalReaction890" />
 <bp:stepProcess rdf:resource="#Catalysis232" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep557">
 <bp:stepProcess rdf:resource="#BiochemicalReaction422" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1099">
 <bp:stepProcess rdf:resource="#BiochemicalReaction891" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep558">
 <bp:stepProcess rdf:resource="#BiochemicalReaction423" />
 <bp:stepProcess rdf:resource="#Catalysis110" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep551">
 <bp:stepProcess rdf:resource="#Catalysis108" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction417" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep552">
 <bp:stepProcess rdf:resource="#BiochemicalReaction418" />
 <bp:stepProcess rdf:resource="#Catalysis109" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep550">
 <bp:stepProcess rdf:resource="#Catalysis107" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction416" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1061">
 <bp:evidence rdf:resource="#Evidence1281" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">JUNB dimer binds GZMB promoter</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1062">
 <bp:evidence rdf:resource="#Evidence1282" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ALK-, STAT3- and MECP2-dependent STAT5A gene repression</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1060">
 <bp:evidence rdf:resource="#Evidence1280" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">STAT3-dependent DNMT1 gene expression</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1065">
 <bp:evidence rdf:resource="#Evidence1285" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">AcK685 pY705,S727 STAT3 binds the MIR21 gene</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1066">
 <bp:evidence rdf:resource="#Evidence1286" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NPM1-ALK-dependent repression of pRB phosphorylation</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1063">
 <bp:evidence rdf:resource="#Evidence1283" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">miR-21 RISC binds DNMT1 mRNA</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1064">
 <bp:evidence rdf:resource="#Evidence1284" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Translation of DNMT1 mRNA is repressed by miR-21</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1058">
 <bp:evidence rdf:resource="#Evidence1278" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">STAT3-dependent MIR-21 gene expression</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1059">
 <bp:evidence rdf:resource="#Evidence1279" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">DNMT1-dependent PTPN6 gene silencing</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1056">
 <bp:evidence rdf:resource="#Evidence1276" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NPM1-ALK fusion dimer binds SKP1:CUL1:RBX1:ZC3HC1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1057">
 <bp:evidence rdf:resource="#Evidence1277" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NPM1-ALK-dependent BCL2A1 gene expression</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep544">
 <bp:stepProcess rdf:resource="#BiochemicalReaction413" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep545">
 <bp:stepProcess rdf:resource="#Pathway119" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep542">
 <bp:stepProcess rdf:resource="#Pathway118" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep543">
 <bp:stepProcess rdf:resource="#Catalysis106" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction412" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep548">
 <bp:stepProcess rdf:resource="#BiochemicalReaction415" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep549">
 <bp:stepProcess rdf:resource="#Pathway121" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep546">
 <bp:stepProcess rdf:resource="#BiochemicalReaction414" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep547">
 <bp:stepProcess rdf:resource="#Pathway120" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence928">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence927">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence929">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence924">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence923">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence926">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence925">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence931">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence930">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep498">
 <bp:stepProcess rdf:resource="#Pathway108" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence933">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep499">
 <bp:stepProcess rdf:resource="#BiochemicalReaction379" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence932">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep492">
 <bp:stepProcess rdf:resource="#Pathway107" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence939">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep493">
 <bp:stepProcess rdf:resource="#BiochemicalReaction374" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence938">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep490">
 <bp:stepProcess rdf:resource="#BiochemicalReaction372" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep491">
 <bp:stepProcess rdf:resource="#BiochemicalReaction373" />
 <bp:stepProcess rdf:resource="#Catalysis93" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep496">
 <bp:stepProcess rdf:resource="#BiochemicalReaction377" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence935">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep497">
 <bp:stepProcess rdf:resource="#BiochemicalReaction378" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence934">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep494">
 <bp:stepProcess rdf:resource="#BiochemicalReaction375" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence937">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep495">
 <bp:stepProcess rdf:resource="#BiochemicalReaction376" />
 <bp:stepProcess rdf:resource="#Catalysis94" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence936">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis304">
 <bp:controlled rdf:resource="#BiochemicalReaction1025" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis303">
 <bp:controlled rdf:resource="#BiochemicalReaction1024" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis306">
 <bp:controlled rdf:resource="#BiochemicalReaction1027" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis305">
 <bp:controlled rdf:resource="#BiochemicalReaction1026" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis300">
 <bp:controlled rdf:resource="#BiochemicalReaction1021" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis302">
 <bp:controlled rdf:resource="#BiochemicalReaction1023" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis301">
 <bp:controlled rdf:resource="#BiochemicalReaction1022" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep489">
 <bp:stepProcess rdf:resource="#BiochemicalReaction371" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence942">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence941">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep487">
 <bp:stepProcess rdf:resource="#BiochemicalReaction369" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence944">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep488">
 <bp:stepProcess rdf:resource="#BiochemicalReaction370" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence943">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis308">
 <bp:controlled rdf:resource="#BiochemicalReaction1037" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis307">
 <bp:controlled rdf:resource="#BiochemicalReaction1029" />
</bp:Catalysis>

<bp:Evidence rdf:ID="Evidence940">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis309">
 <bp:controlled rdf:resource="#BiochemicalReaction1075" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep481">
 <bp:stepProcess rdf:resource="#BiochemicalReaction366" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep482">
 <bp:stepProcess rdf:resource="#BiochemicalReaction367" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence949">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep480">
 <bp:stepProcess rdf:resource="#BiochemicalReaction365" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep485">
 <bp:stepProcess rdf:resource="#BiochemicalReaction368" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence946">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep486">
 <bp:stepProcess rdf:resource="#Pathway106" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence945">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep483">
 <bp:stepProcess rdf:resource="#Pathway94" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence948">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep484">
 <bp:stepProcess rdf:resource="#Pathway105" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence947">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis315">
 <bp:controlled rdf:resource="#BiochemicalReaction1110" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis314">
 <bp:controlled rdf:resource="#BiochemicalReaction1108" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis317">
 <bp:controlled rdf:resource="#BiochemicalReaction1117" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis316">
 <bp:controlled rdf:resource="#BiochemicalReaction1113" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis311">
 <bp:controlled rdf:resource="#BiochemicalReaction1096" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis310">
 <bp:controlled rdf:resource="#BiochemicalReaction1083" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis313">
 <bp:controlled rdf:resource="#BiochemicalReaction1106" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis312">
 <bp:controlled rdf:resource="#BiochemicalReaction1102" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep478">
 <bp:stepProcess rdf:resource="#Pathway104" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence953">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep479">
 <bp:stepProcess rdf:resource="#BiochemicalReaction364" />
 <bp:stepProcess rdf:resource="#Catalysis92" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence952">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep476">
 <bp:stepProcess rdf:resource="#Pathway102" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence955">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep477">
 <bp:stepProcess rdf:resource="#Pathway103" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence954">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis319">
 <bp:controlled rdf:resource="#BiochemicalReaction1124" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis318">
 <bp:controlled rdf:resource="#BiochemicalReaction1118" />
</bp:Catalysis>

<bp:Evidence rdf:ID="Evidence951">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence950">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence96">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep470">
 <bp:stepProcess rdf:resource="#Pathway100" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence95">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep471">
 <bp:stepProcess rdf:resource="#BiochemicalReaction360" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence94">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence93">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence92">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep474">
 <bp:stepProcess rdf:resource="#BiochemicalReaction362" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence957">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence91">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep475">
 <bp:stepProcess rdf:resource="#BiochemicalReaction363" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence956">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence90">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep472">
 <bp:stepProcess rdf:resource="#BiochemicalReaction361" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence959">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep473">
 <bp:stepProcess rdf:resource="#Pathway101" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence958">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis320">
 <bp:controlled rdf:resource="#BiochemicalReaction1129" />
</bp:Catalysis>

<bp:Evidence rdf:ID="Evidence99">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence98">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence97">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis326">
 <bp:controlled rdf:resource="#BiochemicalReaction1138" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis325">
 <bp:controlled rdf:resource="#BiochemicalReaction1137" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis328">
 <bp:controlled rdf:resource="#BiochemicalReaction1152" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis327">
 <bp:controlled rdf:resource="#BiochemicalReaction1143" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis322">
 <bp:controlled rdf:resource="#BiochemicalReaction1132" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis321">
 <bp:controlled rdf:resource="#BiochemicalReaction1131" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis324">
 <bp:controlled rdf:resource="#BiochemicalReaction1135" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis323">
 <bp:controlled rdf:resource="#BiochemicalReaction1133" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep467">
 <bp:stepProcess rdf:resource="#Pathway99" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence964">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep468">
 <bp:stepProcess rdf:resource="#BiochemicalReaction358" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence963">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep465">
 <bp:stepProcess rdf:resource="#BiochemicalReaction357" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence966">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep466">
 <bp:stepProcess rdf:resource="#Pathway98" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence965">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence960">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis329">
 <bp:controlled rdf:resource="#BiochemicalReaction1153" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep469">
 <bp:stepProcess rdf:resource="#BiochemicalReaction359" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence962">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence961">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence85">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence84">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence83">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence82">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence81">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence968">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence80">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence967">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence969">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence89">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence88">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence87">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence86">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence975">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence974">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence977">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence976">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence971">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence970">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence973">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence972">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence74">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence73">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence72">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence71">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence70">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence979">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence978">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence79">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence78">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence77">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence76">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence75">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence980">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence986">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence985">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence988">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence987">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence982">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence981">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence984">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence983">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence63">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence62">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence61">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence60">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence989">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence69">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence68">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence67">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence66">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence65">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence64">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence991">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence990">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence997">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence996">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence999">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence998">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence993">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence992">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence995">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence994">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence52">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence51">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence50">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence59">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence58">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence57">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence56">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence55">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence54">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence53">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence41">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence40">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence49">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis373">
 <bp:controlled rdf:resource="#BiochemicalReaction1266" />
</bp:Catalysis>

<bp:Evidence rdf:ID="Evidence48">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis372">
 <bp:controlled rdf:resource="#BiochemicalReaction1265" />
</bp:Catalysis>

<bp:Evidence rdf:ID="Evidence47">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis375">
 <bp:controlled rdf:resource="#BiochemicalReaction1268" />
</bp:Catalysis>

<bp:Evidence rdf:ID="Evidence46">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis374">
 <bp:controlled rdf:resource="#BiochemicalReaction1267" />
</bp:Catalysis>

<bp:Evidence rdf:ID="Evidence45">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence44">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence43">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis371">
 <bp:controlled rdf:resource="#BiochemicalReaction1264" />
</bp:Catalysis>

<bp:Evidence rdf:ID="Evidence42">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis370">
 <bp:controlled rdf:resource="#BiochemicalReaction1262" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep1116">
 <bp:stepProcess rdf:resource="#Catalysis237" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction904" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis377">
 <bp:controlled rdf:resource="#BiochemicalReaction1271" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep2447">
 <bp:stepProcess rdf:resource="#Pathway601" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1117">
 <bp:stepProcess rdf:resource="#BiochemicalReaction884" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis376">
 <bp:controlled rdf:resource="#BiochemicalReaction1269" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep2448">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1800" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1118">
 <bp:stepProcess rdf:resource="#Pathway194" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis379">
 <bp:controlled rdf:resource="#BiochemicalReaction1274" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep2449">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1801" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence39">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep1119">
 <bp:stepProcess rdf:resource="#BiochemicalReaction905" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis378">
 <bp:controlled rdf:resource="#BiochemicalReaction1273" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep1112">
 <bp:stepProcess rdf:resource="#Catalysis234" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction900" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2443">
 <bp:stepProcess rdf:resource="#Pathway599" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1113">
 <bp:stepProcess rdf:resource="#BiochemicalReaction901" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2444">
 <bp:stepProcess rdf:resource="#Pathway600" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1114">
 <bp:stepProcess rdf:resource="#Catalysis235" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction902" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2445">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1798" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1115">
 <bp:stepProcess rdf:resource="#Catalysis236" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction903" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2446">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1799" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2440">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1797" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1110">
 <bp:stepProcess rdf:resource="#BiochemicalReaction898" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2441">
 <bp:stepProcess rdf:resource="#Pathway597" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1111">
 <bp:stepProcess rdf:resource="#BiochemicalReaction899" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2442">
 <bp:stepProcess rdf:resource="#Pathway598" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence30">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence38">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis384">
 <bp:controlled rdf:resource="#BiochemicalReaction1282" />
</bp:Catalysis>

<bp:Evidence rdf:ID="Evidence37">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis383">
 <bp:controlled rdf:resource="#BiochemicalReaction1279" />
</bp:Catalysis>

<bp:Evidence rdf:ID="Evidence36">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis386">
 <bp:controlled rdf:resource="#BiochemicalReaction1288" />
</bp:Catalysis>

<bp:Evidence rdf:ID="Evidence35">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis385">
 <bp:controlled rdf:resource="#BiochemicalReaction1287" />
</bp:Catalysis>

<bp:Evidence rdf:ID="Evidence34">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis380">
 <bp:controlled rdf:resource="#BiochemicalReaction1276" />
</bp:Catalysis>

<bp:Evidence rdf:ID="Evidence33">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence32">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis382">
 <bp:controlled rdf:resource="#BiochemicalReaction1278" />
</bp:Catalysis>

<bp:Evidence rdf:ID="Evidence31">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis381">
 <bp:controlled rdf:resource="#BiochemicalReaction1277" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep1127">
 <bp:stepProcess rdf:resource="#Pathway197" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis388">
 <bp:controlled rdf:resource="#BiochemicalReaction1302" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep2458">
 <bp:stepProcess rdf:resource="#Pathway603" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1128">
 <bp:stepProcess rdf:resource="#Catalysis238" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction911" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis387">
 <bp:controlled rdf:resource="#BiochemicalReaction1290" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep2459">
 <bp:stepProcess rdf:resource="#Pathway604" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence29">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep1129">
 <bp:stepProcess rdf:resource="#Catalysis239" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction912" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence28">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis389">
 <bp:controlled rdf:resource="#BiochemicalReaction1308" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep1123">
 <bp:stepProcess rdf:resource="#BiochemicalReaction909" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2454">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1805" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1124">
 <bp:stepProcess rdf:resource="#Pathway195" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2455">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1806" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1125">
 <bp:stepProcess rdf:resource="#BiochemicalReaction910" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2456">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1807" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1126">
 <bp:stepProcess rdf:resource="#Pathway196" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2457">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1808" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2450">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1802" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1120">
 <bp:stepProcess rdf:resource="#BiochemicalReaction906" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2451">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1803" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1121">
 <bp:stepProcess rdf:resource="#BiochemicalReaction907" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2452">
 <bp:stepProcess rdf:resource="#Pathway602" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1122">
 <bp:stepProcess rdf:resource="#BiochemicalReaction908" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2453">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1804" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence27">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis395">
 <bp:controlled rdf:resource="#BiochemicalReaction1323" />
</bp:Catalysis>

<bp:Evidence rdf:ID="Evidence26">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis394">
 <bp:controlled rdf:resource="#BiochemicalReaction1318" />
</bp:Catalysis>

<bp:Evidence rdf:ID="Evidence25">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis397">
 <bp:controlled rdf:resource="#BiochemicalReaction1330" />
</bp:Catalysis>

<bp:Evidence rdf:ID="Evidence24">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis396">
 <bp:controlled rdf:resource="#BiochemicalReaction1324" />
</bp:Catalysis>

<bp:Evidence rdf:ID="Evidence23">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis391">
 <bp:controlled rdf:resource="#BiochemicalReaction1312" />
</bp:Catalysis>

<bp:Evidence rdf:ID="Evidence22">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis390">
 <bp:controlled rdf:resource="#BiochemicalReaction1311" />
</bp:Catalysis>

<bp:Evidence rdf:ID="Evidence21">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis393">
 <bp:controlled rdf:resource="#BiochemicalReaction1316" />
</bp:Catalysis>

<bp:Evidence rdf:ID="Evidence20">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis392">
 <bp:controlled rdf:resource="#BiochemicalReaction1315" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep2429">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1790" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis399">
 <bp:controlled rdf:resource="#BiochemicalReaction1332" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep2425">
 <bp:stepProcess rdf:resource="#Pathway594" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence19">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis398">
 <bp:controlled rdf:resource="#BiochemicalReaction1331" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep2426">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1788" />
 <bp:stepProcess rdf:resource="#Catalysis661" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence18">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep2427">
 <bp:stepProcess rdf:resource="#Pathway595" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence17">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep2428">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1789" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2421">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1786" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2422">
 <bp:stepProcess rdf:resource="#Pathway592" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2423">
 <bp:stepProcess rdf:resource="#Pathway593" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2424">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1787" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2420">
 <bp:stepProcess rdf:resource="#Pathway591" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence16">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence15">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence14">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence13">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence12">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence11">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence10">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep1109">
 <bp:stepProcess rdf:resource="#BiochemicalReaction872" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1105">
 <bp:stepProcess rdf:resource="#Pathway192" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2436">
 <bp:stepProcess rdf:resource="#BiochemicalReaction628" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1106">
 <bp:stepProcess rdf:resource="#Pathway193" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2437">
 <bp:stepProcess rdf:resource="#Pathway596" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1107">
 <bp:stepProcess rdf:resource="#BiochemicalReaction896" />
 <bp:stepProcess rdf:resource="#Catalysis233" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2438">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1795" />
 <bp:stepProcess rdf:resource="#Catalysis662" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1108">
 <bp:stepProcess rdf:resource="#BiochemicalReaction897" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2439">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1796" />
 <bp:stepProcess rdf:resource="#Catalysis663" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1101">
 <bp:stepProcess rdf:resource="#BiochemicalReaction893" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2432">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1792" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1102">
 <bp:stepProcess rdf:resource="#Pathway191" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2433">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1793" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1103">
 <bp:stepProcess rdf:resource="#BiochemicalReaction894" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2434">
 <bp:stepProcess rdf:resource="#BiochemicalReaction627" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1104">
 <bp:stepProcess rdf:resource="#BiochemicalReaction895" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2435">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1794" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2430">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1791" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1100">
 <bp:stepProcess rdf:resource="#BiochemicalReaction892" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2431">
 <bp:stepProcess rdf:resource="#BiochemicalReaction626" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis331">
 <bp:controlled rdf:resource="#BiochemicalReaction1165" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis330">
 <bp:controlled rdf:resource="#BiochemicalReaction1156" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis337">
 <bp:controlled rdf:resource="#BiochemicalReaction1189" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep2407">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1773" />
 <bp:stepProcess rdf:resource="#Catalysis656" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis336">
 <bp:controlled rdf:resource="#BiochemicalReaction1187" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep2408">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1774" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis339">
 <bp:controlled rdf:resource="#BiochemicalReaction1193" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep2409">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1775" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis338">
 <bp:controlled rdf:resource="#BiochemicalReaction1190" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis333">
 <bp:controlled rdf:resource="#BiochemicalReaction1170" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep2403">
 <bp:stepProcess rdf:resource="#Catalysis653" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1769" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis332">
 <bp:controlled rdf:resource="#BiochemicalReaction1168" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep2404">
 <bp:stepProcess rdf:resource="#Catalysis654" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1770" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis335">
 <bp:controlled rdf:resource="#BiochemicalReaction1183" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep2405">
 <bp:stepProcess rdf:resource="#Catalysis655" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1771" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis334">
 <bp:controlled rdf:resource="#BiochemicalReaction1182" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep2406">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1772" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2400">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1766" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2401">
 <bp:stepProcess rdf:resource="#Catalysis652" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1767" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2402">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1768" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis340">
 <bp:controlled rdf:resource="#BiochemicalReaction1195" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis342">
 <bp:controlled rdf:resource="#BiochemicalReaction1206" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis341">
 <bp:controlled rdf:resource="#BiochemicalReaction1198" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis348">
 <bp:controlled rdf:resource="#BiochemicalReaction1215" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep2418">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1784" />
 <bp:stepProcess rdf:resource="#Catalysis660" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis347">
 <bp:controlled rdf:resource="#BiochemicalReaction1213" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep2419">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1785" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis349">
 <bp:controlled rdf:resource="#BiochemicalReaction1217" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis344">
 <bp:controlled rdf:resource="#BiochemicalReaction1208" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep2414">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1780" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis343">
 <bp:controlled rdf:resource="#BiochemicalReaction1207" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep2415">
 <bp:stepProcess rdf:resource="#Catalysis658" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1781" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis346">
 <bp:controlled rdf:resource="#BiochemicalReaction1212" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep2416">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1782" />
 <bp:stepProcess rdf:resource="#Catalysis659" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis345">
 <bp:controlled rdf:resource="#BiochemicalReaction1210" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep2417">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1783" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2410">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1776" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2411">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1777" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence900">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep2412">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1778" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2413">
 <bp:stepProcess rdf:resource="#Catalysis657" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1779" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence906">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence905">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence908">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence907">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence902">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence901">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence904">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence903">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis351">
 <bp:controlled rdf:resource="#BiochemicalReaction1222" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis350">
 <bp:controlled rdf:resource="#BiochemicalReaction1220" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis353">
 <bp:controlled rdf:resource="#BiochemicalReaction1226" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis352">
 <bp:controlled rdf:resource="#BiochemicalReaction1223" />
</bp:Catalysis>

<bp:Evidence rdf:ID="Evidence909">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis359">
 <bp:controlled rdf:resource="#BiochemicalReaction1236" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis358">
 <bp:controlled rdf:resource="#BiochemicalReaction1235" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis355">
 <bp:controlled rdf:resource="#BiochemicalReaction1231" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis354">
 <bp:controlled rdf:resource="#BiochemicalReaction1229" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis357">
 <bp:controlled rdf:resource="#BiochemicalReaction1234" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis356">
 <bp:controlled rdf:resource="#BiochemicalReaction1233" />
</bp:Catalysis>

<bp:Evidence rdf:ID="Evidence911">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence910">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence917">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence916">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence919">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence918">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence913">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence912">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence915">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence914">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis362">
 <bp:controlled rdf:resource="#BiochemicalReaction1245" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis361">
 <bp:controlled rdf:resource="#BiochemicalReaction1242" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis364">
 <bp:controlled rdf:resource="#BiochemicalReaction1249" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis363">
 <bp:controlled rdf:resource="#BiochemicalReaction1246" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis360">
 <bp:controlled rdf:resource="#BiochemicalReaction1237" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis369">
 <bp:controlled rdf:resource="#BiochemicalReaction1261" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis366">
 <bp:controlled rdf:resource="#BiochemicalReaction1252" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis365">
 <bp:controlled rdf:resource="#BiochemicalReaction1251" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis368">
 <bp:controlled rdf:resource="#BiochemicalReaction1260" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis367">
 <bp:controlled rdf:resource="#BiochemicalReaction1255" />
</bp:Catalysis>

<bp:Evidence rdf:ID="Evidence920">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence922">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence921">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep2040">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1578" />
 <bp:stepProcess rdf:resource="#Catalysis496" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2041">
 <bp:stepProcess rdf:resource="#Pathway419" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2042">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1579" />
 <bp:stepProcess rdf:resource="#Catalysis497" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep816">
 <bp:stepProcess rdf:resource="#BiochemicalReaction644" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep817">
 <bp:stepProcess rdf:resource="#BiochemicalReaction645" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep814">
 <bp:stepProcess rdf:resource="#BiochemicalReaction642" />
 <bp:stepProcess rdf:resource="#Catalysis167" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep815">
 <bp:stepProcess rdf:resource="#BiochemicalReaction643" />
 <bp:stepProcess rdf:resource="#Catalysis168" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep818">
 <bp:stepProcess rdf:resource="#Catalysis169" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction646" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep819">
 <bp:stepProcess rdf:resource="#BiochemicalReaction647" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2047">
 <bp:stepProcess rdf:resource="#Catalysis499" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1581" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2048">
 <bp:stepProcess rdf:resource="#Pathway423" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2049">
 <bp:stepProcess rdf:resource="#Catalysis500" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1582" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep812">
 <bp:stepProcess rdf:resource="#BiochemicalReaction640" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2043">
 <bp:stepProcess rdf:resource="#Pathway420" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep813">
 <bp:stepProcess rdf:resource="#BiochemicalReaction641" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2044">
 <bp:stepProcess rdf:resource="#Catalysis498" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1580" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep810">
 <bp:stepProcess rdf:resource="#Catalysis165" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction638" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2045">
 <bp:stepProcess rdf:resource="#Pathway421" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep811">
 <bp:stepProcess rdf:resource="#BiochemicalReaction639" />
 <bp:stepProcess rdf:resource="#Catalysis166" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2046">
 <bp:stepProcess rdf:resource="#Pathway422" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2050">
 <bp:stepProcess rdf:resource="#Pathway424" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2051">
 <bp:stepProcess rdf:resource="#Catalysis501" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1583" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2052">
 <bp:stepProcess rdf:resource="#Catalysis502" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1584" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2053">
 <bp:stepProcess rdf:resource="#Pathway425" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep805">
 <bp:stepProcess rdf:resource="#BiochemicalReaction633" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep806">
 <bp:stepProcess rdf:resource="#BiochemicalReaction634" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep803">
 <bp:stepProcess rdf:resource="#BiochemicalReaction631" />
 <bp:stepProcess rdf:resource="#Catalysis161" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep804">
 <bp:stepProcess rdf:resource="#BiochemicalReaction632" />
 <bp:stepProcess rdf:resource="#Catalysis162" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep809">
 <bp:stepProcess rdf:resource="#BiochemicalReaction637" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep807">
 <bp:stepProcess rdf:resource="#Catalysis163" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction635" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep808">
 <bp:stepProcess rdf:resource="#Catalysis164" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction636" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2058">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1587" />
 <bp:stepProcess rdf:resource="#Catalysis505" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2059">
 <bp:stepProcess rdf:resource="#Pathway428" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep801">
 <bp:stepProcess rdf:resource="#Pathway158" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2054">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1585" />
 <bp:stepProcess rdf:resource="#Catalysis503" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep802">
 <bp:stepProcess rdf:resource="#BiochemicalReaction630" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2055">
 <bp:stepProcess rdf:resource="#Pathway426" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2056">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1586" />
 <bp:stepProcess rdf:resource="#Catalysis504" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep800">
 <bp:stepProcess rdf:resource="#Pathway157" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2057">
 <bp:stepProcess rdf:resource="#Pathway427" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2020">
 <bp:stepProcess rdf:resource="#Pathway412" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2029">
 <bp:stepProcess rdf:resource="#Catalysis489" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1571" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2025">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1568" />
 <bp:stepProcess rdf:resource="#Catalysis486" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2026">
 <bp:stepProcess rdf:resource="#Pathway414" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2027">
 <bp:stepProcess rdf:resource="#Catalysis487" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1569" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2028">
 <bp:stepProcess rdf:resource="#Catalysis488" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1570" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2021">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1565" />
 <bp:stepProcess rdf:resource="#Catalysis483" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2022">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1566" />
 <bp:stepProcess rdf:resource="#Catalysis484" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2023">
 <bp:stepProcess rdf:resource="#Pathway413" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2024">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1567" />
 <bp:stepProcess rdf:resource="#Catalysis485" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2030">
 <bp:stepProcess rdf:resource="#Pathway415" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2031">
 <bp:stepProcess rdf:resource="#Catalysis490" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1572" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2036">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1575" />
 <bp:stepProcess rdf:resource="#Catalysis493" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2037">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1576" />
 <bp:stepProcess rdf:resource="#Catalysis494" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2038">
 <bp:stepProcess rdf:resource="#Pathway418" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2039">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1577" />
 <bp:stepProcess rdf:resource="#Catalysis495" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2032">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1573" />
 <bp:stepProcess rdf:resource="#Catalysis491" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2033">
 <bp:stepProcess rdf:resource="#Pathway416" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2034">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1574" />
 <bp:stepProcess rdf:resource="#Catalysis492" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2035">
 <bp:stepProcess rdf:resource="#Pathway417" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep860">
 <bp:stepProcess rdf:resource="#BiochemicalReaction684" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep858">
 <bp:stepProcess rdf:resource="#BiochemicalReaction682" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep859">
 <bp:stepProcess rdf:resource="#BiochemicalReaction683" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2007">
 <bp:stepProcess rdf:resource="#Pathway407" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2008">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1557" />
 <bp:stepProcess rdf:resource="#Catalysis475" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2009">
 <bp:stepProcess rdf:resource="#Pathway408" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep852">
 <bp:stepProcess rdf:resource="#BiochemicalReaction677" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2003">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1553" />
 <bp:stepProcess rdf:resource="#Catalysis471" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep853">
 <bp:stepProcess rdf:resource="#Pathway162" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2004">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1554" />
 <bp:stepProcess rdf:resource="#Catalysis472" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep850">
 <bp:stepProcess rdf:resource="#BiochemicalReaction675" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2005">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1555" />
 <bp:stepProcess rdf:resource="#Catalysis473" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep851">
 <bp:stepProcess rdf:resource="#BiochemicalReaction676" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2006">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1556" />
 <bp:stepProcess rdf:resource="#Catalysis474" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep856">
 <bp:stepProcess rdf:resource="#BiochemicalReaction680" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep857">
 <bp:stepProcess rdf:resource="#BiochemicalReaction681" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2000">
 <bp:stepProcess rdf:resource="#Catalysis469" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1551" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep854">
 <bp:stepProcess rdf:resource="#BiochemicalReaction678" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2001">
 <bp:stepProcess rdf:resource="#Pathway406" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep855">
 <bp:stepProcess rdf:resource="#BiochemicalReaction679" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2002">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1552" />
 <bp:stepProcess rdf:resource="#Catalysis470" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep849">
 <bp:stepProcess rdf:resource="#BiochemicalReaction674" />
 <bp:stepProcess rdf:resource="#Catalysis184" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep847">
 <bp:stepProcess rdf:resource="#BiochemicalReaction672" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep848">
 <bp:stepProcess rdf:resource="#BiochemicalReaction673" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2018">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1563" />
 <bp:stepProcess rdf:resource="#Catalysis481" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2019">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1564" />
 <bp:stepProcess rdf:resource="#Catalysis482" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep841">
 <bp:stepProcess rdf:resource="#BiochemicalReaction666" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2014">
 <bp:stepProcess rdf:resource="#Pathway410" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep842">
 <bp:stepProcess rdf:resource="#BiochemicalReaction667" />
 <bp:stepProcess rdf:resource="#Catalysis182" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2015">
 <bp:stepProcess rdf:resource="#Catalysis479" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1561" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2016">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1562" />
 <bp:stepProcess rdf:resource="#Catalysis480" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep840">
 <bp:stepProcess rdf:resource="#BiochemicalReaction665" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2017">
 <bp:stepProcess rdf:resource="#Pathway411" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep845">
 <bp:stepProcess rdf:resource="#BiochemicalReaction670" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2010">
 <bp:stepProcess rdf:resource="#Pathway409" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep846">
 <bp:stepProcess rdf:resource="#BiochemicalReaction671" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2011">
 <bp:stepProcess rdf:resource="#Catalysis476" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1558" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep843">
 <bp:stepProcess rdf:resource="#BiochemicalReaction668" />
 <bp:stepProcess rdf:resource="#Catalysis183" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2012">
 <bp:stepProcess rdf:resource="#Catalysis477" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1559" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep844">
 <bp:stepProcess rdf:resource="#BiochemicalReaction669" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2013">
 <bp:stepProcess rdf:resource="#Catalysis478" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1560" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep838">
 <bp:stepProcess rdf:resource="#BiochemicalReaction663" />
 <bp:stepProcess rdf:resource="#Catalysis181" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep839">
 <bp:stepProcess rdf:resource="#BiochemicalReaction664" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep836">
 <bp:stepProcess rdf:resource="#Catalysis179" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction661" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep837">
 <bp:stepProcess rdf:resource="#Catalysis180" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction662" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep830">
 <bp:stepProcess rdf:resource="#Catalysis177" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction657" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep831">
 <bp:stepProcess rdf:resource="#Pathway160" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep834">
 <bp:stepProcess rdf:resource="#Catalysis178" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction659" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep835">
 <bp:stepProcess rdf:resource="#BiochemicalReaction660" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep832">
 <bp:stepProcess rdf:resource="#BiochemicalReaction658" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep833">
 <bp:stepProcess rdf:resource="#Pathway161" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep827">
 <bp:stepProcess rdf:resource="#BiochemicalReaction654" />
 <bp:stepProcess rdf:resource="#Catalysis174" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep828">
 <bp:stepProcess rdf:resource="#BiochemicalReaction655" />
 <bp:stepProcess rdf:resource="#Catalysis175" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep825">
 <bp:stepProcess rdf:resource="#BiochemicalReaction652" />
 <bp:stepProcess rdf:resource="#Catalysis173" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep826">
 <bp:stepProcess rdf:resource="#BiochemicalReaction653" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep829">
 <bp:stepProcess rdf:resource="#BiochemicalReaction656" />
 <bp:stepProcess rdf:resource="#Catalysis176" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep820">
 <bp:stepProcess rdf:resource="#BiochemicalReaction648" />
 <bp:stepProcess rdf:resource="#Catalysis170" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep823">
 <bp:stepProcess rdf:resource="#BiochemicalReaction651" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep824">
 <bp:stepProcess rdf:resource="#Pathway159" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep821">
 <bp:stepProcess rdf:resource="#Catalysis171" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction649" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep822">
 <bp:stepProcess rdf:resource="#BiochemicalReaction650" />
 <bp:stepProcess rdf:resource="#Catalysis172" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence890">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence892">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence891">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep896">
 <bp:stepProcess rdf:resource="#BiochemicalReaction713" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence898">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep897">
 <bp:stepProcess rdf:resource="#BiochemicalReaction714" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence897">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep894">
 <bp:stepProcess rdf:resource="#BiochemicalReaction711" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep895">
 <bp:stepProcess rdf:resource="#Catalysis192" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction712" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence899">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence894">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence893">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep898">
 <bp:stepProcess rdf:resource="#BiochemicalReaction715" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence896">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep899">
 <bp:stepProcess rdf:resource="#BiochemicalReaction716" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence895">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep892">
 <bp:stepProcess rdf:resource="#BiochemicalReaction709" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep893">
 <bp:stepProcess rdf:resource="#BiochemicalReaction710" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep890">
 <bp:stepProcess rdf:resource="#BiochemicalReaction707" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep891">
 <bp:stepProcess rdf:resource="#Catalysis191" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction708" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis700">
 <bp:controlled rdf:resource="#BiochemicalReaction1872" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis702">
 <bp:controlled rdf:resource="#BiochemicalReaction1874" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis701">
 <bp:controlled rdf:resource="#BiochemicalReaction1873" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep885">
 <bp:stepProcess rdf:resource="#BiochemicalReaction703" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis708">
 <bp:controlled rdf:resource="#BiochemicalReaction1881" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep886">
 <bp:stepProcess rdf:resource="#BiochemicalReaction704" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis707">
 <bp:controlled rdf:resource="#BiochemicalReaction1880" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep883">
 <bp:stepProcess rdf:resource="#Pathway166" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep884">
 <bp:stepProcess rdf:resource="#BiochemicalReaction702" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis709">
 <bp:controlled rdf:resource="#BiochemicalReaction1882" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep889">
 <bp:stepProcess rdf:resource="#Pathway167" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis704">
 <bp:controlled rdf:resource="#BiochemicalReaction1876" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis703">
 <bp:controlled rdf:resource="#BiochemicalReaction1875" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep887">
 <bp:stepProcess rdf:resource="#BiochemicalReaction705" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis706">
 <bp:controlled rdf:resource="#BiochemicalReaction1879" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep888">
 <bp:stepProcess rdf:resource="#BiochemicalReaction706" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis705">
 <bp:controlled rdf:resource="#BiochemicalReaction1877" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep881">
 <bp:stepProcess rdf:resource="#Pathway164" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep882">
 <bp:stepProcess rdf:resource="#Pathway165" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep880">
 <bp:stepProcess rdf:resource="#BiochemicalReaction701" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis711">
 <bp:controlled rdf:resource="#BiochemicalReaction1884" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis710">
 <bp:controlled rdf:resource="#BiochemicalReaction1883" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis713">
 <bp:controlled rdf:resource="#BiochemicalReaction1886" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis712">
 <bp:controlled rdf:resource="#BiochemicalReaction1885" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep874">
 <bp:stepProcess rdf:resource="#BiochemicalReaction470" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis719">
 <bp:controlled rdf:resource="#BiochemicalReaction1892" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep875">
 <bp:stepProcess rdf:resource="#BiochemicalReaction697" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis718">
 <bp:controlled rdf:resource="#BiochemicalReaction1891" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep872">
 <bp:stepProcess rdf:resource="#BiochemicalReaction695" />
 <bp:stepProcess rdf:resource="#Catalysis189" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep873">
 <bp:stepProcess rdf:resource="#BiochemicalReaction696" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep878">
 <bp:stepProcess rdf:resource="#BiochemicalReaction699" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis715">
 <bp:controlled rdf:resource="#BiochemicalReaction1888" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep879">
 <bp:stepProcess rdf:resource="#BiochemicalReaction700" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis714">
 <bp:controlled rdf:resource="#BiochemicalReaction1887" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep876">
 <bp:stepProcess rdf:resource="#BiochemicalReaction698" />
 <bp:stepProcess rdf:resource="#Catalysis190" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis717">
 <bp:controlled rdf:resource="#BiochemicalReaction1890" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep877">
 <bp:stepProcess rdf:resource="#BiochemicalReaction477" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis716">
 <bp:controlled rdf:resource="#BiochemicalReaction1889" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep870">
 <bp:stepProcess rdf:resource="#BiochemicalReaction693" />
 <bp:stepProcess rdf:resource="#Catalysis186" />
 <bp:stepProcess rdf:resource="#Catalysis187" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep871">
 <bp:stepProcess rdf:resource="#BiochemicalReaction694" />
 <bp:stepProcess rdf:resource="#Catalysis188" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis722">
 <bp:controlled rdf:resource="#BiochemicalReaction1895" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis721">
 <bp:controlled rdf:resource="#BiochemicalReaction1894" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep869">
 <bp:stepProcess rdf:resource="#Pathway163" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis724">
 <bp:controlled rdf:resource="#BiochemicalReaction1898" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis723">
 <bp:controlled rdf:resource="#BiochemicalReaction1896" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis720">
 <bp:controlled rdf:resource="#BiochemicalReaction1893" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep863">
 <bp:stepProcess rdf:resource="#BiochemicalReaction687" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep864">
 <bp:stepProcess rdf:resource="#BiochemicalReaction688" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis729">
 <bp:controlled rdf:resource="#BiochemicalReaction1904" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep861">
 <bp:stepProcess rdf:resource="#BiochemicalReaction685" />
 <bp:stepProcess rdf:resource="#Catalysis185" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep862">
 <bp:stepProcess rdf:resource="#BiochemicalReaction686" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep867">
 <bp:stepProcess rdf:resource="#BiochemicalReaction691" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis726">
 <bp:controlled rdf:resource="#BiochemicalReaction1900" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep868">
 <bp:stepProcess rdf:resource="#BiochemicalReaction692" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis725">
 <bp:controlled rdf:resource="#BiochemicalReaction1899" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep865">
 <bp:stepProcess rdf:resource="#BiochemicalReaction689" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis728">
 <bp:controlled rdf:resource="#BiochemicalReaction1903" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep866">
 <bp:stepProcess rdf:resource="#BiochemicalReaction690" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis727">
 <bp:controlled rdf:resource="#BiochemicalReaction1901" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep2083">
 <bp:stepProcess rdf:resource="#Pathway441" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2084">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1599" />
 <bp:stepProcess rdf:resource="#Catalysis517" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2085">
 <bp:stepProcess rdf:resource="#Pathway442" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2086">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1600" />
 <bp:stepProcess rdf:resource="#Catalysis518" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2080">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1597" />
 <bp:stepProcess rdf:resource="#Catalysis515" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2081">
 <bp:stepProcess rdf:resource="#Pathway440" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2082">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1598" />
 <bp:stepProcess rdf:resource="#Catalysis516" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2087">
 <bp:stepProcess rdf:resource="#Pathway443" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2088">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1601" />
 <bp:stepProcess rdf:resource="#Catalysis519" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2089">
 <bp:stepProcess rdf:resource="#Pathway444" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2094">
 <bp:stepProcess rdf:resource="#Pathway447" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2095">
 <bp:stepProcess rdf:resource="#Pathway448" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2096">
 <bp:stepProcess rdf:resource="#Catalysis522" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1604" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2097">
 <bp:stepProcess rdf:resource="#Pathway449" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2090">
 <bp:stepProcess rdf:resource="#Pathway445" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2091">
 <bp:stepProcess rdf:resource="#Pathway446" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2092">
 <bp:stepProcess rdf:resource="#Catalysis520" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1602" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2093">
 <bp:stepProcess rdf:resource="#Catalysis521" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1603" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2098">
 <bp:stepProcess rdf:resource="#Catalysis523" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1605" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2099">
 <bp:stepProcess rdf:resource="#Pathway450" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2061">
 <bp:stepProcess rdf:resource="#Pathway429" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2062">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1589" />
 <bp:stepProcess rdf:resource="#Catalysis507" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2063">
 <bp:stepProcess rdf:resource="#Pathway430" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2064">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1590" />
 <bp:stepProcess rdf:resource="#Catalysis508" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2060">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1588" />
 <bp:stepProcess rdf:resource="#Catalysis506" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2069">
 <bp:stepProcess rdf:resource="#Pathway434" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2065">
 <bp:stepProcess rdf:resource="#Pathway431" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2066">
 <bp:stepProcess rdf:resource="#Pathway432" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2067">
 <bp:stepProcess rdf:resource="#Catalysis509" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1591" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2068">
 <bp:stepProcess rdf:resource="#Pathway433" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2072">
 <bp:stepProcess rdf:resource="#Catalysis511" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1593" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2073">
 <bp:stepProcess rdf:resource="#Pathway436" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2074">
 <bp:stepProcess rdf:resource="#Catalysis512" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1594" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2075">
 <bp:stepProcess rdf:resource="#Pathway437" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2070">
 <bp:stepProcess rdf:resource="#Catalysis510" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1592" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2071">
 <bp:stepProcess rdf:resource="#Pathway435" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2076">
 <bp:stepProcess rdf:resource="#Catalysis513" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1595" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2077">
 <bp:stepProcess rdf:resource="#Pathway438" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2078">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1596" />
 <bp:stepProcess rdf:resource="#Catalysis514" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2079">
 <bp:stepProcess rdf:resource="#Pathway439" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence807">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence806">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence809">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence808">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence803">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence802">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence805">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence804">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis650">
 <bp:controlled rdf:resource="#BiochemicalReaction1764" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis656">
 <bp:controlled rdf:resource="#BiochemicalReaction1773" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis655">
 <bp:controlled rdf:resource="#BiochemicalReaction1771" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis658">
 <bp:controlled rdf:resource="#BiochemicalReaction1781" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis657">
 <bp:controlled rdf:resource="#BiochemicalReaction1779" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis652">
 <bp:controlled rdf:resource="#BiochemicalReaction1767" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis651">
 <bp:controlled rdf:resource="#BiochemicalReaction1765" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis654">
 <bp:controlled rdf:resource="#BiochemicalReaction1770" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis653">
 <bp:controlled rdf:resource="#BiochemicalReaction1769" />
</bp:Catalysis>

<bp:Evidence rdf:ID="Evidence810">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence812">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence811">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis659">
 <bp:controlled rdf:resource="#BiochemicalReaction1782" />
</bp:Catalysis>

<bp:Evidence rdf:ID="Evidence818">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence817">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence819">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence814">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence813">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence816">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence815">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis661">
 <bp:controlled rdf:resource="#BiochemicalReaction1788" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis660">
 <bp:controlled rdf:resource="#BiochemicalReaction1784" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis667">
 <bp:controlled rdf:resource="#BiochemicalReaction1839" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis666">
 <bp:controlled rdf:resource="#BiochemicalReaction1838" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis669">
 <bp:controlled rdf:resource="#BiochemicalReaction1841" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis668">
 <bp:controlled rdf:resource="#BiochemicalReaction1840" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis663">
 <bp:controlled rdf:resource="#BiochemicalReaction1796" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis662">
 <bp:controlled rdf:resource="#BiochemicalReaction1795" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis665">
 <bp:controlled rdf:resource="#BiochemicalReaction1837" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis664">
 <bp:controlled rdf:resource="#BiochemicalReaction1833" />
</bp:Catalysis>

<bp:Evidence rdf:ID="Evidence821">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence820">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence823">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence822">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence829">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence828">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence825">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence824">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence827">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence826">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis670">
 <bp:controlled rdf:resource="#BiochemicalReaction1842" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis672">
 <bp:controlled rdf:resource="#BiochemicalReaction1844" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis671">
 <bp:controlled rdf:resource="#BiochemicalReaction1843" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis678">
 <bp:controlled rdf:resource="#BiochemicalReaction1850" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis677">
 <bp:controlled rdf:resource="#BiochemicalReaction1849" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis679">
 <bp:controlled rdf:resource="#BiochemicalReaction1851" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis674">
 <bp:controlled rdf:resource="#BiochemicalReaction1846" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis673">
 <bp:controlled rdf:resource="#BiochemicalReaction1845" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis676">
 <bp:controlled rdf:resource="#BiochemicalReaction1848" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis675">
 <bp:controlled rdf:resource="#BiochemicalReaction1847" />
</bp:Catalysis>

<bp:Evidence rdf:ID="Evidence832">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence831">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence834">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence833">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence830">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence839">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence836">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence835">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence838">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence837">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis681">
 <bp:controlled rdf:resource="#BiochemicalReaction1853" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis680">
 <bp:controlled rdf:resource="#BiochemicalReaction1852" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis683">
 <bp:controlled rdf:resource="#BiochemicalReaction1855" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis682">
 <bp:controlled rdf:resource="#BiochemicalReaction1854" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis689">
 <bp:controlled rdf:resource="#BiochemicalReaction1861" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis688">
 <bp:controlled rdf:resource="#BiochemicalReaction1860" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis685">
 <bp:controlled rdf:resource="#BiochemicalReaction1857" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis684">
 <bp:controlled rdf:resource="#BiochemicalReaction1856" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis687">
 <bp:controlled rdf:resource="#BiochemicalReaction1859" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis686">
 <bp:controlled rdf:resource="#BiochemicalReaction1858" />
</bp:Catalysis>

<bp:Evidence rdf:ID="Evidence843">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence842">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence845">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence844">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence841">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence840">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence847">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence846">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence849">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence848">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis612">
 <bp:controlled rdf:resource="#BiochemicalReaction1700" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis611">
 <bp:controlled rdf:resource="#BiochemicalReaction1699" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis614">
 <bp:controlled rdf:resource="#BiochemicalReaction1702" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis613">
 <bp:controlled rdf:resource="#BiochemicalReaction1701" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis610">
 <bp:controlled rdf:resource="#BiochemicalReaction1698" />
</bp:Catalysis>

<bp:Evidence rdf:ID="Evidence854">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence853">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis619">
 <bp:controlled rdf:resource="#BiochemicalReaction1707" />
</bp:Catalysis>

<bp:Evidence rdf:ID="Evidence856">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence855">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence850">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis616">
 <bp:controlled rdf:resource="#BiochemicalReaction1704" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis615">
 <bp:controlled rdf:resource="#BiochemicalReaction1703" />
</bp:Catalysis>

<bp:Evidence rdf:ID="Evidence852">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis618">
 <bp:controlled rdf:resource="#BiochemicalReaction1706" />
</bp:Catalysis>

<bp:Evidence rdf:ID="Evidence851">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis617">
 <bp:controlled rdf:resource="#BiochemicalReaction1705" />
</bp:Catalysis>

<bp:Evidence rdf:ID="Evidence858">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence857">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence859">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis623">
 <bp:controlled rdf:resource="#BiochemicalReaction1711" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis622">
 <bp:controlled rdf:resource="#BiochemicalReaction1710" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis625">
 <bp:controlled rdf:resource="#BiochemicalReaction1713" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis624">
 <bp:controlled rdf:resource="#BiochemicalReaction1712" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis621">
 <bp:controlled rdf:resource="#BiochemicalReaction1709" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis620">
 <bp:controlled rdf:resource="#BiochemicalReaction1708" />
</bp:Catalysis>

<bp:Evidence rdf:ID="Evidence865">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence864">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence867">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence866">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence861">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis627">
 <bp:controlled rdf:resource="#BiochemicalReaction1715" />
</bp:Catalysis>

<bp:Evidence rdf:ID="Evidence860">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis626">
 <bp:controlled rdf:resource="#BiochemicalReaction1714" />
</bp:Catalysis>

<bp:Evidence rdf:ID="Evidence863">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis629">
 <bp:controlled rdf:resource="#BiochemicalReaction1717" />
</bp:Catalysis>

<bp:Evidence rdf:ID="Evidence862">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis628">
 <bp:controlled rdf:resource="#BiochemicalReaction1716" />
</bp:Catalysis>

<bp:Evidence rdf:ID="Evidence869">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence868">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis634">
 <bp:controlled rdf:resource="#BiochemicalReaction1722" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis633">
 <bp:controlled rdf:resource="#BiochemicalReaction1721" />
</bp:Catalysis>

<bp:Evidence rdf:ID="Evidence870">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis636">
 <bp:controlled rdf:resource="#BiochemicalReaction1724" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis635">
 <bp:controlled rdf:resource="#BiochemicalReaction1723" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis630">
 <bp:controlled rdf:resource="#BiochemicalReaction1718" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis632">
 <bp:controlled rdf:resource="#BiochemicalReaction1720" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis631">
 <bp:controlled rdf:resource="#BiochemicalReaction1719" />
</bp:Catalysis>

<bp:Evidence rdf:ID="Evidence876">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence875">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence878">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence877">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence872">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis638">
 <bp:controlled rdf:resource="#BiochemicalReaction1731" />
</bp:Catalysis>

<bp:Evidence rdf:ID="Evidence871">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis637">
 <bp:controlled rdf:resource="#BiochemicalReaction1729" />
</bp:Catalysis>

<bp:Evidence rdf:ID="Evidence874">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence873">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis639">
 <bp:controlled rdf:resource="#BiochemicalReaction1739" />
</bp:Catalysis>

<bp:Evidence rdf:ID="Evidence879">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis645">
 <bp:controlled rdf:resource="#BiochemicalReaction1745" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis644">
 <bp:controlled rdf:resource="#BiochemicalReaction1744" />
</bp:Catalysis>

<bp:Evidence rdf:ID="Evidence881">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis647">
 <bp:controlled rdf:resource="#BiochemicalReaction1751" />
</bp:Catalysis>

<bp:Evidence rdf:ID="Evidence880">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis646">
 <bp:controlled rdf:resource="#BiochemicalReaction1748" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis641">
 <bp:controlled rdf:resource="#BiochemicalReaction1741" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis640">
 <bp:controlled rdf:resource="#BiochemicalReaction1740" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis643">
 <bp:controlled rdf:resource="#BiochemicalReaction1743" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis642">
 <bp:controlled rdf:resource="#BiochemicalReaction1742" />
</bp:Catalysis>

<bp:Evidence rdf:ID="Evidence887">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence886">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence889">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence888">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence883">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis649">
 <bp:controlled rdf:resource="#BiochemicalReaction1757" />
</bp:Catalysis>

<bp:Evidence rdf:ID="Evidence882">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis648">
 <bp:controlled rdf:resource="#BiochemicalReaction1756" />
</bp:Catalysis>

<bp:Evidence rdf:ID="Evidence885">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence884">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis692">
 <bp:controlled rdf:resource="#BiochemicalReaction1864" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis691">
 <bp:controlled rdf:resource="#BiochemicalReaction1863" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis694">
 <bp:controlled rdf:resource="#BiochemicalReaction1866" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis693">
 <bp:controlled rdf:resource="#BiochemicalReaction1865" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis690">
 <bp:controlled rdf:resource="#BiochemicalReaction1862" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis699">
 <bp:controlled rdf:resource="#BiochemicalReaction1871" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis696">
 <bp:controlled rdf:resource="#BiochemicalReaction1868" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis695">
 <bp:controlled rdf:resource="#BiochemicalReaction1867" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis698">
 <bp:controlled rdf:resource="#BiochemicalReaction1870" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis697">
 <bp:controlled rdf:resource="#BiochemicalReaction1869" />
</bp:Catalysis>

<bp:Evidence rdf:ID="Evidence801">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence800">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep2160">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1638" />
 <bp:stepProcess rdf:resource="#Catalysis551" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway734">
 <bp:pathwayOrder rdf:resource="#PathwayStep2718" />
 <bp:pathwayComponent rdf:resource="#Pathway735" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2659" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Diseases of Immune System</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The immune system is a complex network of the biological processes that provide defense mechanisms during infection or in response to an intrinsic danger signal. Compromised immune response may present itself as either overactivity or underactivity of the immune system leading to a broad spectrum of clinical phenotypes that can be categorized into four main groups - autoimmunity, immunodeficiency (ID) with a greater susceptibility to infectious diseases, hypersensitivity to compounds that are usually not harmful and malignancy. Several host conditions may cause the dysfunctional immunity. Among them are inherited and somatic mutations found in the components of immune signaling pathways. In addition to genetic defects, infection with pathogen such as human immunodeficiency virus (HIV), or interaction of immune cells with immunosuppressive drugs result in non-genetic immunodeficiencies. Age-associated alterations in immunity may also contribute to pathogenesis of immunodeficiency . The Reactome module represents selected defects of the immune system and provides a short description of their clinical phenotypes. The module also describes functional features of defective molecules by both providing a published source for experimental functional analysis data and linking to the corresponding normal process within the Reactome database.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep2161">
 <bp:stepProcess rdf:resource="#Pathway479" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway733">
 <bp:pathwayOrder rdf:resource="#PathwayStep2716" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1923" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2658" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Evasion of Oxidative Stress Induced Senescence Due to p14ARF Defects</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">One of the two main protein products of the CDKN2A gene, p14ARF (CDKN2A transcript 4, CDKN2A-4, ARF), contributes to oxidative stress induced cellular senescence by stabilizing TP53 (p53). The function of p14ARF in p53 stabilization through sequestration of MDM2, a p53 ubiquitin ligase, depends on the nuclear localization of p14ARF and its ability to interact with MDM2. The nuclear localization signal and the MDM2 interaction domain map to the first 15 amino acids of the N-terminus of p14ARF. This region is encoded by the p14ARF-specific exon 1beta of CDKN2A. An independent MDM2-binding domain is localized at the C-terminus of p14ARF (Lohrum et al. 2000). Insertion of 16 nucleotides in exon 1beta results in a frameshift truncation of p14ARF, responsible for a familial melanoma syndrome in which the p16INK4A product of the CDKN2A gene is unaffected. This mutation is rare and has so far been reported in one family only. The mutant protein, p14ARF V22Pfs*46 has the nucleotide localization signal and the N-terminal MDM2 interaction region preserved, but is unable to translocate from the cytosol to the nucleus, possibly due to aberrant conformation (Rizos, Puig et al. 2001), and also lacks the C-terminal MDM2 interaction region. Relocation of wild type p14ARF to the cytosol has been observed in melanoma (Rizos, Darmanian et al. 2001) and aggressive thyroid papillary carcinoma (Ferru et al. 2006). Genomic deletion of exon 1beta, with exons 1alpha, 2 and 3 intact, has been reported in about 30% of melanoma cases with genomic deletions involving the CDKN2A locus (Freedberg et al. 2008). Several different familial melanoma germline mutations map to the exon 1beta splice donor site (Harland et al. 2005). The ability of p14ARF to localize to the nucleolus also plays a role in p14ARF-mediated stabilization of p53. Mutations in exon 2 of the CDKN2A gene can lead to missense mutations in p14ARF that affect its nucleolar localization and p53 stabilization, but the exact mechanism has not been fully elucidated (Zhang and Xiong 1999, reviewed by Fontana et al. 2019).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep2162">
 <bp:stepProcess rdf:resource="#Catalysis552" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1639" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway736">
 <bp:pathwayOrder rdf:resource="#PathwayStep2720" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1926" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2661" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TLR3 deficiency - HSE</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Toll like receptor 3 (TLR3) recognizes double-stranded RNA (dsRNA), an intermediate product during viral replication for most viruses. TLR3 is expressed in various tissues and cells including cells of the central nervous system (CNS) (Bsibsi M et al. 2002). TLR3 activity in neurons and glial cells was found to be critical for controlling herpes simplex virus type 1 (HSV-1) infection in CNS (Lafaille FG et al. 2012). Children with inborn errors of TLR3-mediated immunity are prone to HSV-1 encephalitis (HSE), a rare life-threatening complication during HSV-1 infection (Casrouge A et al. 2006; Perez de Diego R et al. 2010; Zhang SY et al. 2007; Herman M et al. 2012; Lafaille FG et al. 2012). The functional defect in HSE patients with TLR3 deficiency is probably due to impaired induction of type I and III interferon (IFN) by cells of the CNS, which appears to be uniquely dependent upon TLR3 for protection against HSV1 (Zhang SY et al. 2007; Guo Y et al. 2011; Lafaille FG et al. 2012). Importantly, blood cells in the periphery produce normal amounts of interferons, even in TLR3-deficient patients, which perhaps can be explained by RIGI or MDA5-mediated antiviral responses. </bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep2163">
 <bp:stepProcess rdf:resource="#Pathway480" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway735">
 <bp:pathwayOrder rdf:resource="#PathwayStep2727" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2738" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2729" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2733" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2723" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2725" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2736" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2740" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2731" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2742" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2721" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2719" />
 <bp:pathwayComponent rdf:resource="#Pathway745" />
 <bp:pathwayComponent rdf:resource="#Pathway744" />
 <bp:pathwayComponent rdf:resource="#Pathway736" />
 <bp:pathwayComponent rdf:resource="#Pathway747" />
 <bp:pathwayComponent rdf:resource="#Pathway746" />
 <bp:pathwayComponent rdf:resource="#Pathway738" />
 <bp:pathwayComponent rdf:resource="#Pathway737" />
 <bp:pathwayComponent rdf:resource="#Pathway739" />
 <bp:pathwayComponent rdf:resource="#Pathway741" />
 <bp:pathwayComponent rdf:resource="#Pathway740" />
 <bp:pathwayComponent rdf:resource="#Pathway743" />
 <bp:pathwayComponent rdf:resource="#Pathway742" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2660" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Diseases associated with the TLR signaling cascade</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Toll like receptors (TLRs) are sensors of the innate immune system that detect danger signals derived from pathogens (pathogen-associated molecular patterns - PAMP) or damaged cells (damage-associated molecular patterns - DAMP) (Pasare C and Medzhitov R 2005; Barton GM and Kagan JC 2009; Kawai T and Akira S 2010). Signaling by these sensors promotes the activation and nuclear translocation of transcription factors (IRFs, NFkB and AP1). The transcription factors induce secretion of inflammatory cytokines such as IL-6, TNF and pro-IL1beta that direct the adaptive immune response. Inherited or acquired abnormalities in TLR-mediated processes may lead to increased susceptibility to infection, excessive inflammation, autoimmunity and malignancy (Picard C et al. 2010; Netea MG et al. 2012; Varettoni M et al. 2013). Here we describe four primary immunodeficiency (PID) disorders associated with defective TLR-mediated responses. First, MyD88 or IRAK4 deficiency is characterized with a greater susceptibility to pyogenic bacteria in affected patients (Picard C et al. 2003; von Bernuth H et al. 2008). Second, defects in the TLR3 signaling pathway are associated with a greater susceptibility to herpes simplex virus encephalitis (Zhang SY et al. 2013). Third, imunodeficiencies due to defects in NFkB signaling components are linked to impaired TLR-mediated responses (Courtois G et al. 2003; Fusco F et al. 2004). Finally, events are annotated showing constitutive activation of a somatically mutated MyD88 gene which results in malignancy (Varettoni M et al. 2013).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway738">
 <bp:pathwayOrder rdf:resource="#PathwayStep2724" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1928" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2665" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective regulation of TLR7 by endogenous ligand</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activation of innate immune receptors including Toll-like receptors (TLRs) by pathogen-associated molecular patterns (PAMPs) is crucial in the host defense against microbial infections. On the other hand, these receptors are also activated by diverse molecules of host-cell origin. These molecules are known as damage-associated molecular patterns (DAMPs). This Reactome module describes defects in activation of TLRs by the endogenous ligands.  DAMPs are released from necrotic cells or secreted from activated cells in response to tissue damage to mediate tissue repair by promoting inflammatory responses (reviewed by Piccinini AM et al., 2010; Gong T et al., 2020; Zindel LJ et al., 2020). However, DAMPs have also been implicated in the pathogenesis of many inflammatory and autoimmune diseases, including rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and atherosclerosis (Duffy L    O&#8217;Reilly SC 2016; Fukuda D et al., 2019; Gong T et al., 2020; Liu J et al., 2022). There is a correlation between high level of endogenous TLR ligands and different chronic inflammatory conditions in human subjects and mouse models (Duvvuri B    Lood C et al., 2019; Negishi H et al., 2019; Punnanitinont A et al., 2022). The mechanism underlying the switch from DAMPs that initiate controlled tissue repair, to those that mediate chronic, uncontrolled inflammation is still unclear. Studies suggest that an abnormal increase in protein citrullination is involved in disease pathophysiology (Anzilotti C et al., 2010; Sanchez-Pernaute O et al., 2013; Sokolove J et al., 2011; Sharma P et al., 2012; Olsen I et al., 2018). Moreover, gene polymorphisms within TLRs may predispose to the abnormal inflammatory responses associated with chronic diseases including autoimmune diseases (Devarapu SK    Anders HJ 2018; Zhang Y et al., 2021). For example, polymorphisms that increase expression of TLR7 are associated with a higher risk of SLE (reviewed in Fillatreau S et al., 2021). Further, inherited genetic variations can promote autoimmune responses. For example, TLR7 Y264H was identified as a gain-of-function mutation in a patient with SLE (Brown GJ et al., 2022). TLR7 Y264H exhibited enhanced affinity to endogenous guanosine-containing ligands (Brown GJ et al., 2022).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway737">
 <bp:pathwayOrder rdf:resource="#PathwayStep2722" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1927" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2663" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TRAF3 deficiency - HSE</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TNF Receptor Associated Factor 3 (TRAF3) is a cytoplasmic adaptor protein utilized by the tumor necrosis factor receptor superfamily and toll-like receptors (TLRs). TRAF3 deficiency is thought to mimic the previously reported TLR3 deficiency in terms of susceptibility to herpes simplex virus type 1 (HSV1) encephalitis (HSE) via impaired TLR3-mediated immunity against HSV1 infection of central nervous system (CNS) (P&#233;rez de Diego R et al. 2010; Guo Y et al. 2011). </bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway739">
 <bp:pathwayOrder rdf:resource="#PathwayStep2726" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1929" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2667" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MyD88 deficiency (TLR5)</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Myeloid differentiation primary response (MyD88) is an adaptor protein that mediates intracellular signaling pathways evoked by all Toll-like receptors (TLRs) (except for TLR3) and several interleukin-1 receptors (IL-1Rs) (Medzhitov R et al. 1998). Upon ligand binding, TLRs hetero- or homodimerize and recruit MyD88 through their respective TIR domains. Then, MyD88 oligomerizes via its death domain (DD) and TIR domain and interacts with the interleukin-1 receptor-associated kinases (IRAKs) to form the Myddosome complex (MyD88:IRAK4:IRAK1/2) (Motshwene PG et al. 2009; Lin SC et al. 2010). The Myddosome complex transmits the signal leading to activation of transcription factors such as nuclear factor-kappaB (NFkB) and activator protein 1 (AP1). Studies have identified patients with autosomal recessive (AR) form of MyD88 deficiency caused by homozygous or compound heterozygous mutations in MYD88 gene leading to abolished protein production (von Bernuth et al. 2008). AR MyD88 deficiency is a type of a primary immunodeficiency characterized by greater susceptibility to pyogenic bacteria such as invasive pneumococcal disease manifested in infancy and early childhood. Patients with MyD88-deficiency show delayed or weak signs of inflammatory responses (Picard C et al. 2010; Picard C et al. 2011). Functional assessment of MyD88 deficiency revealed that cytokine responses were abolished in patient-derived blood cells upon stimulation with bacterial flagellin, which is recognized by TLR5 (von Bernuth et al. 2008). An NFkB luciferase reporter gene assay using human embryonic kidney 293 (HEK293T) cells showed that MyD88 variants, S34Y, E52del, E53X, L93P, R98C, and R196C, were compromised in the ability to enhance NFkB activation (Yamamoto T et al. 2014). The molecular basis for the observed functional effects (reported for selected mutations) probably faulty Myddosome formation due to impaired MyD88 oligomerization and/or interaction with IRAK4 (George J et al. 2011; Nagpal K et al. 2011; Yamamoto T et al. 2014). While MyD88 deficiency might be expected to perturb MyD88?IRAK4 dependent TLR7 and TLR8 signaling events associated with the sensing viral infections in the endosome, patients with MyD88 and IRAK4 deficiencies have so far not been reported to be susceptible to viral infection.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep2168">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1642" />
 <bp:stepProcess rdf:resource="#Catalysis555" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2169">
 <bp:stepProcess rdf:resource="#Pathway483" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2164">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1640" />
 <bp:stepProcess rdf:resource="#Catalysis553" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway730">
 <bp:pathwayOrder rdf:resource="#PathwayStep2711" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2713" />
 <bp:pathwayComponent rdf:resource="#Pathway732" />
 <bp:pathwayComponent rdf:resource="#Pathway731" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2655" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Evasion of Oxidative Stress Induced Senescence Due to p16INK4A Defects</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The CDKN2A gene consists of four exons, exon 1beta, exon 1alpha, exon 2 and exon 3, going from the proximal to the distal gene end. There are two promoters in the CDKN2A gene locus. The promoter located between exons 1beta and 1alpha regulates transcription of the p16INK4A mRNA, which consists of exon 1alpha, exon 2 and exon 3 (only partially translated), and encodes a cyclin-dependent kinase inhibitor p16INK4A (also known as CDKN2A isoform 1, p16, INK4A, CDKN2A, CDK4I or MTS-1). The promoter located upstream of exon 1beta regulates transcription of the p14ARF mRNA, which consists of exon 1beta, exon 2 (partially translated) and exon 3 (untranslated). The p14ARF mRNA is translated in a different reading frame from the p16INK4A mRNA and produces the tumor suppressor ARF (also known as p14ARF or CDKN2A isoform 4), an inhibitor of MDM2 E3 ubiquitin ligase-mediated degradation of TP53 (p53). Wild type p16INK4A is able to form a complex with either CDK4 or CDK6 and prevent formation of catalytically active CDK complexes consisting of CDK4 or CDK6 and D-type cyclins (CCND). Thus, p16INK4A prevents hyperphosphorylation of RB-family proteins, required for initiation of DNA replication in RB1-competent cells. Expression of p16INK4A increases in response to oxidative stress, leading to cellular senescence (programmed cell cycle arrest) under conditions of prolonged oxidative stress. Loss-of-function of p16INK4A frequently occurs in cancer, usually through loss of p16INK4A protein expression due to promoter hypermethylation or CDKN2A gene deletion (Merlo et al. 1995, Herman et al. 1995, Gonzalez-Zulueta et al. 1995, Wong et al. 1997, Witkiewicz et al. 2011, Shima et al. 2011, Tamayo-Orrego et al. 2016). Missense, nonsense and frameshift mutations in the CDKN2A locus can also impair p16INK4A function through expression of non-functional substitution mutants or truncated proteins (Kamb et al. 1994, Bartsch et al. 1995, Castellano et al. 1997). Germline intronic CDKN2A mutations that create aberrant splicing sites and result in expression of non-functional splicing variants of p16INK4A have been reported in familial melanoma (Harland et al. 2001, Harland et al. 2005). A CDKN2A gene mutation in the region encoding the 5&apos;UTR of p16INK4A, reported in familial melanoma, creates a novel translation start codon and diminishes translation from the wild type start codon (Liu et al. 1999). However, mutations in the non coding regions of the CDKN2A gene are rare (Pollock et al. 2001). p16INK4A defects enable cancerous cells to evade cell cycle arrest and senescence under prolonged oxidative stress (Tanaka et al. 1999, Chen 2000, Chen et al. 2004, Vurusaner et al. 2012, Rayess et al. 2012, LaPak and Burd 2014, Sharpless and Sherr 2015, Zhang et al. 2017). A cell cycle-independent role of p16INK4A in regulation of intracellular oxidative stress has been reported (Jenkins et al. 2011, Vurusaner et al. 2012, Jenkins et al. 2013). Genomic deletions in the CDKN2A locus affect p14ARF, unless they are limited to exon 1alpha. The p14ARF promoter can also be hypermethylated in cancer, leading to loss of p14ARF expression. Some missense mutations occurring in exon 2 of the CDKN2A gene affect the p14ARF protein sequence. However, p14ARF mutants usually appear to be less functionally compromised than their p16INK4A counterparts. Most functional tests on p14ARF mutants examine the effect of mutations on MDM2 binding and TP53-mediated transcription of CDKN1A (p21), as well as sub-nuclear localization of p14ARF (Zhang and Xiong 1999, Schmitt et al. 1999, Eischen et al. 1999, Pinyol et al. 2000, Bostrom et al. 2001, Laud et al. 2006). Still, there are poorly explored functions of p14ARF that may be significantly affected in mutant p14ARF proteins detected in cancer (Itahana and Zhang 2008, Dominguez-Brauer et al. 2010). </bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep2165">
 <bp:stepProcess rdf:resource="#Pathway481" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2166">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1641" />
 <bp:stepProcess rdf:resource="#Catalysis554" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway732">
 <bp:pathwayOrder rdf:resource="#PathwayStep2714" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1925" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2657" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Evasion of Oxidative Stress Induced Senescence Due to Defective p16INK4A binding to CDK4</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Missense mutations and small indels in the CDKN2A gene, which result in amino acid changes in p16INK4A that impair its ability to bind to CDK4, interfere with p16INK4A-mediated, oxidative stress-induced, cellular senescence (Chen 2000, Vurusaner et al. 2012). Loss-of-function mutations in p16INK4A can also contribute to cancer by interfering with p16INK4A-mediated inhibition of NFKB signaling (Becker et al. 2005).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep2167">
 <bp:stepProcess rdf:resource="#Pathway482" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway731">
 <bp:pathwayOrder rdf:resource="#PathwayStep2712" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1924" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2656" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Evasion of Oxidative Stress Induced Senescence Due to Defective p16INK4A binding to CDK4 and CDK6</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Missense and nonsense mutations in the CDKN2A gene that result in amino acid substitutions in p16INK4A or p16INK4A truncations, respectively, impairing its ability to bind to CDK4 and CDK6, interfere with p16INK4A-mediated induction of cellular senescence in response to oxidative stress (Chen 2000, Vurusaner et al. 2012). Loss-of-function mutations in p16INK4A can also contribute to cancer by interfering with p16INK4A-mediated inhibition of NFKB signaling (Becker et al. 2005).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep2171">
 <bp:stepProcess rdf:resource="#Catalysis556" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1643" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway745">
 <bp:pathwayOrder rdf:resource="#PathwayStep2739" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1936" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2680" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">IRAK4 deficiency (TLR2/4)</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Interleukin-1 receptor-associated kinase 4 (IRAK4) is a serine/threonine kinase, that mediates activation of transcriptional factors such as NFkB and AP1 downstream of IL-1 receptors and all toll like receptors (TLR) except for TLR3 (Suzuki N et al. 2002). IRAK4 is recruited to the TLR receptor complex through a homophilic interaction of the death domains of IRAK4 and adaptor myeloid differentiation factor 88 protein (MyD88) (Motshwene PG et al. 2009; Lin SC et al. 2010). Studies have identified patients with an autosomal recessive (AR) form of IRAK4 deficiency, a health condition with clinical manifestation in infancy or early childhood, that predisposes affected patients to recurrent pyogenic bacterial infection (e.g., Streptococcus pneumoniae and Staphylococcus aureus) (Picard C et al. 2003; Ku CL et al. 2007; Picard C et al. 2010; Picard C et al. 2011). Leukocytes derived from IRAK4-deficient patients display a lack of production of inflammatory cytokines such as TNF alpha, IL-6 and IL-1 beta by whole blood or a lack of CD62 ligand (CD62L) shedding from granulocytes following activation with the most TLR agonists including those of TLR1/2 (Pam3CSK4), TLR2/6 (Pam2CSK4) and TLR4 (LPS) (Picard C et al. 2003; McDonald DR et al. 2006; Ku CL et al. 2007). However, LPS-induced TLR4-mediated production of some cytokines (IL8 and MIP-1beta) was reduced but not abolished (Ku CL et al. 2007). LPS-stimulated induction of type I IFN via MyD88-IRAK4 independent signaling axis was normal or weakly affected suggesting that TLR4 could induce some responses in IRAK4 deficient patients(Yang K et al. 2005). Patients with AR IRAK4 deficiency were found to bear homozygous or compound heterozygous mutations in the IRAK4 gene (Picard C et al. 2003; Ku CL et al. 2007; McDonald DR et al. 2006). Here we describe selected mutations, that have been functionally characterized. Cell-based assay as well as in vitro protein-interaction analyses with IRAK4 variants showed that the loss-of-function of defective IRAK4 is caused by either loss of protein production (reported for IRAK4 Q293* and E402*) or an impaired interaction with MyD88 as shown for missense mutation IRAK4 R12C (Ku CL et al. 2007; Yamamoto T et al. 2014). Besides defective TLR2/4 mediated signaling, the Reactome module describes the impact of functional deficiency of IRAK4 on TLR5 pathways. The module does not include defective TLR7, TLR8 and TLR9 signaling events, which are associated mostly with viral infections, although studies using patient-derived blood cells showed abolished cytokine production by peripheral blood mononuclear cells (PBMCs) and lack of CD62 ligand (CD62L) shedding from granulocytes in response to TLR7-9 agonists (McDonald DR et al. 2006; von Bernuth H et al. 2006; Ku CL et al. 2007). In addition to the TLR-NFkappaB signaling axis, endosomic TLR7-9 activates IFN-alpha/beta and IFN-gamma responses and these are also impaired in IRAK4-deficient PBMC (Yang K et al. 2005). Nevertheless, IFN-alpha/beta and -gamma production in IRAK-4-deficient blood cells in response to 9 of 11 viruses was normal or weakly affected, suggesting that IRAK-4-deficient patients may control viral infections by TLR7-9-independent production of IFNs such as IRAK4-independent antiviral RIGI and MDA5 pathways (Yang K et al. 2005). So it is not yet possible to annotate a definitive molecular pathway between IRAK-4 deficiency and changes in TLR7-9 signaling.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep2172">
 <bp:stepProcess rdf:resource="#Catalysis557" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1644" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway744">
 <bp:pathwayOrder rdf:resource="#PathwayStep2737" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1935" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2678" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">IKBKG deficiency causes anhidrotic ectodermal dysplasia with immunodeficiency (EDA-ID) (via TLR)</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Many signaling pathways rely on the activation of nuclear factor kappa B (NFkB), which is critical for the induction of the appropriate cellular function in response to various stimuli such as inflammatory cytokines, microbial products or various types of stress (Lawrence T 2009; Hoesel B and Schmid JA 2013). The NFkB family of transcription factors is kept inactive in the cytoplasm by inhibitor of kappa B (IkB) family members (Oeckinghaus A and Ghosh S 2009). Canonical NFkB activation depends on the phosphorylation of IkB by the I kappa B kinase (IKK) complex, which contains two catalytic subunits named IKK alpha, IKK beta and a regulatory subunit named NFkB essential modulator (NEMO or IKBKG) (Rothwarf DM et al. 1998). Phosphorylation of IkB leads to K48-linked ubiquitination and proteasomal degradation of IkB, allowing translocation of NFkB factor to the nucleus, where it can activate transcription of a variety of genes participating in the immune and inflammatory response, cell adhesion, growth control, and protection against apoptosis (Collins T et al. 1995; Kaltschmidt B et al. 2000; Lawrence T 2009). IKBKG is encoded by an X-linked gene. Null alleles of the gene are lethal in hemizygous males, whereas hypomorphic alleles typically result in the impaired NFkB signaling in patients with a broad spectrum of clinical phenotypes in terms of both developmental defects and immunodeficiency (D&#246;ffinger R et al. 2001; Hanson EP et al. 2008). Several categories of mutations affecting IKBKG have been reported in humans (D&#246;ffinger R et al. 2001; Vinolo E et al. 2006; Fusko F et al. 2008). The first category of these mutations consists of hypomorphic mutations typically involving the zinc finger domain and nearby C-terminal regions and causing hypohidrotic ectodermal dysplasia with immune deficiency (HED-ID) in males (Jain A et al. 2001; Shifera AS 2010). The second category consists of amorphic mutations causing incontinentia pigmenti (IP) in females and, generally, prenatal death in males (Aradhya S et al. 2001; Fusco F et al. 2004). The third category is composed of hypomorphic mutations involving the stop codon causing anhidrotic ectodermal dysplasia with immunodeficiency (EDA-ID), osteopetrosis and lymphedema (OL-EDA-ID) in males (D&#246;ffinger R et al. 2001). Also some patients with a defective IKBKG gene can develop immunodeficiency without ectodermal dysplasia (Orange JS et al. 2004). This module describes several EDA-ID-associated hypomorphic IKBKG mutations that have been reported to affect inflammatory responses initiated by toll like receptors (TLR).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep2173">
 <bp:stepProcess rdf:resource="#Pathway485" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway747">
 <bp:pathwayOrder rdf:resource="#PathwayStep2744" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2743" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1939" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1938" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2684" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">IkBA variant leads to EDA-ID</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The nuclear factor kappa B (NFkB) family of transcription factors is kept inactive in the cytoplasm by the inhibitor of kappa B (IkB) family members IKBA (IkB alpha, NFKBIA), IKBB (IkB beta, NFKBIB) and IKBE (IkB epsilon, NFKBIE) (Oeckinghaus A and Ghosh S 2009). Multiple stimuli such as inflammatory cytokines, microbial products or various types of stress activate NFkB signaling leading to stimuli-induced phosphorylation of IkB molecule (Scherer DC et al. 1995; Alkalay I et al. 1995; Lawrence T 2009; Hoesel B and Schmid JA 2013). The phosphorylation of IkB proteins triggers their polyubiquitination and subsequent degradation by 26S proteasome, allowing free NFkB dimer to translocate to the nucleus where it directs the expression of target genes. Studies have identified an autosomal dominant form of ectodermal dysplasia with immunodeficiency (AD-EDA-ID) caused by a hypermorphic heterozygous mutation of NFKBIA/IKBA gene. The IKBA defects prevent the phosphorylation and degradation of IKBA protein resulting in gain-of-function condition with the enhanced inhibitory capacity of IKBA in sequestering NF?B dimers in the cytoplasm (Courtois G et al. 2003; Lopes-Granados E et al. 2008; Schimke LF et al. 2013).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep2174">
 <bp:stepProcess rdf:resource="#Catalysis558" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1645" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway746">
 <bp:pathwayOrder rdf:resource="#PathwayStep2741" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1937" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2682" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TICAM1 deficiency - HSE</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Inborn errors of interferon immunity due to defects in toll like receptor 3 (TLR3)-mediated signaling underlie pathogenesis of herpes simplex virus type 1 (HSV1) encephalitis (HSE) in some children (Netea MG et al. 2012). Autosomal dominant (AD) and recessive (AR) deficiencies of (TIR) domain-containing adaptor inducing IFN-beta (TRIF or TICAM1) are also associated with impaired IFN production and predisposition to HSE in the course of primary infection by HSV1 (Sancho-Shimizu V et al. 2011).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep2170">
 <bp:stepProcess rdf:resource="#Pathway484" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2179">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1649" />
 <bp:stepProcess rdf:resource="#Catalysis562" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2175">
 <bp:stepProcess rdf:resource="#Catalysis559" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1646" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway741">
 <bp:pathwayOrder rdf:resource="#PathwayStep2730" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1931" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2671" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">IKBKB deficiency causes SCID</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Four patients with early-onset, life-threatening microbial infections and failure to thrive were found to carry a homozygous duplication c.1292dupG in exon 13 of IKBKB gene that results in a lack of expression of IKBKB (Pannicke U et al. 2013). IKBKB deficiency is associated with severe combined immunodeficiency (SCID), a health condition characterized by low levels of immunoglobulins (hypogammaglobulinemia). Further phenotype assessment revealed that patients peripheral-blood B cells and T cells had normal counts but were almost exclusively of naive phenotype. Regulatory T cells and gamma delta T cells were absent. </bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep2176">
 <bp:stepProcess rdf:resource="#Catalysis560" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1647" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway740">
 <bp:pathwayOrder rdf:resource="#PathwayStep2728" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1930" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2669" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">UNC93B1 deficiency - HSE</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">UNC93B1 is an endoplasmic reticulum protein with 12 membrane-spanning domains. Signaling cascades of nucleotide-sensing endosomal toll like receptors (TLR3 and TLR7-9) depends on functional UNC93B1, which is thought to deliver these TLRs from the ER to the endosome where they recognize specific pathogenic patterns and initiate host immune responses. UNC93B deficiency has been implicated in the increased susceptibility to herpes simplex virus type 1 (HSV1) encephalitis (HSE), a rare complication during HSV-1 infection of the central nervous system (CNS) (Casrouge A et al. 2006). Patients-derived UNC96B1-deficient fibroblasts showed an impaired production of IFN-beta and -gamma following stimulation with TLR3 agonist poly(I:C) (Casrouge A et al. 2006). These cells were also more susceptible to HSV1 infection, showing rapid viral replication together with high mortality rates. Furthermore, pluripotent stem cells (iPSC) derived from HSE patient dermal fibroblasts were differentiated into populations of neural stem cells (NSC), neurons, astrocytes and oligodendrocytes (Lafaille FG et al. 2012). The impaired induction of IFN beta and gamma was observed in all tested CNS cells upon stimulation with poly(I:C). However, HSV1 infection selectively affected type I and III IFN production in UNC93B1-deficient neurons and oligodendrocytes (Lafaille FG et al. 2012). Thus, impaired TLR3-mediated UNC93B-dependent type I and III IFN production in respose to HSV1 infection in CNS, in neurons and oligodendrocytes in particular, may underline the pathogenesis of HSE in patients with UNC93B1 deficiency (Casrouge A et al. 2006; Lafaille FG et al. 2012). Defective UNC93B1 also impairs the TLR7, TLR8 and TLR9 signaling pathways. Peripheral blood  mononuclear cells (PBMCs) from UNC93B-deficient patients did not respond to the stimulation of TLR7, TLR8, or TLR9, in terms of the production of type I and III interferons, and other cytokines tested (Casrouge A et al. 2006). Moreover, no inducible CD62L shedding on granulocytes was detected after stimulation of whole blood cells derived from UNC93B-deficients patients with R-848 (agonist of TLR7 and TLR8) (von Bernuth H. et al. 2008). However, no clinical condition has been so far associated with impaired TLR7, TLR8, TLR9 due to UNC93B1 deficiency so this defect is not annotated here.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep2177">
 <bp:stepProcess rdf:resource="#Pathway486" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway743">
 <bp:pathwayOrder rdf:resource="#PathwayStep2734" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2735" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1933" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1934" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2675" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MyD88 deficiency (TLR2/4)</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Myeloid differentiation primary response (MyD88) is an adaptor protein that mediates intracellular signaling pathways evoked by all Toll-like receptors (TLRs) except for TLR3 and by several interleukin-1 receptors (IL-1Rs) (Medzhitov R et al. 1998). Upon ligand binding, TLRs hetero- or homodimerize and recruit MyD88 through their respective TIR domains. Then, MyD88 oligomerizes via its death domain (DD) and TIR domain and interacts with the interleukin-1 receptor-associated kinases (IRAKs) to form the Myddosome complex (MyD88:IRAK4:IRAK1/2) (Motshwene PG et al. 2009; Lin SC et al. 2010). The Myddosome complex transmits the signal leading to activation of transcription factors such as nuclear factor-kappaB (NFkB) and activator protein 1 (AP1). Studies have identified patients with autosomal recessive (AR) form of MyD88 deficiency caused by homozygous or compound heterozygous mutations in MYD88 gene leading to abolished protein production (von Bernuth et al. 2008). AR MyD88 deficiency is a type of a primary immunodeficiency characterized by greater susceptibility to pyogenic bacteria (such as Streptococcus pneumoniae, Staphylococcus aureus or Pseudomonas aeruginosa) manifested in infancy and early childhood. Patients with MyD88 deficiency show delayed or weak signs of inflammation (Picard C et al. 2010; Picard C et al. 2011). Functional assessment of MyD88 deficiency revealed that cytokine responses were impaired in patient-derived blood cells upon stimulation with the agonists of TLR2 and TLR4 (PAM2CSK4 and LPS respectively), although some were produced in response to LPS. (von Bernuth et al. 2008). NFkB luciferase reporter gene assays using human embryonic kidney 293 (HEK293T) cells showed that MyD88 variants, S34Y, E52del, E53X, L93P, R98C, and R196C, were compromised in their ability to enhance NFkB activation (Yamamoto T et al. 2014). The molecular basis for the observed functional effects (reported for selected mutations)  probably faulty Myddosome formation due to impaired MyD88 oligomerization and/or interaction with IRAK4 (George J et al. 2011; Nagpal K et al. 2011; Yamamoto T et al. 2014). While MyD88-deficiency might be expected to perturb MyD88?IRAK4 dependent TLR7 and TLR8 signaling events associated with the sensing viral infections, patients with MyD88 and IRAK4 deficiencies have so far not been reported to be susceptible to viral infection.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep2178">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1648" />
 <bp:stepProcess rdf:resource="#Catalysis561" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway742">
 <bp:pathwayOrder rdf:resource="#PathwayStep2732" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1932" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2673" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">IRAK4 deficiency (TLR5)</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Toll like receptor 5 (TLR5) specifically recognizes bacterial infection through binding of flagellin from pathogenic bacteria. Upon ligand binding, TLR5 dimers recruit MyD88 through their TIR domains. Then, MyD88 oligomerizes via its death domain (DD) and TIR domain and interacts with the interleukin-1 receptor-associated kinases (IRAKs) to form the Myddosome complex (MyD88:IRAK4:IRAK1/2) (Motshwene PG et al. 2009; Lin SC et al. 2010). The Myddosome complex transmits the signal leading to activation of transcription factors such as nuclear factor-kappaB (NFkB) and activator protein 1 (AP1). Studies have identified patients with autosomal recessive (AR) form of IRAK4 deficiency, a health condition with clinical manifestation in infancy or early childhood, that predisposes affected patients to recurrent pyogenic bacterial infection (e.g., Streptococcus pneumoniae and Staphylococcus aureus) (Picard C et al. 2003; Ku CL et al. 2007; Picard C et al. 2010; Picard C et al. 2011). Leukocytes derived from IRAK4-deficient patients display a lack of production of inflammatory cytokines such as TNF alpha, IL-6 and IL-1beta or a lack of CD62 ligand (CD62L) shedding from granulocytes following activation with flagellin, the TLR5 agonist (Picard C et al. 2003; McDonald DR et al. 2006; Ku CL et al. 2007). Patients with AR IRAK4 deficiency were found to bear homozygous or compound heterozygous mutations in the IRAK4 gene (Picard C et al. 2003; Ku CL et al. 2007; McDonald DR et al. 2006). Here we describe selective mutations, that have been functionally characterized. Cell-based assays as well as in vitro protein-interaction analyses with IRAK4 variants showed that the loss-of-function of defective IRAK4 can be caused by either an abolished protein production as a result of nonsense mutations (e.g.,Q293* and E402*)  or an impaired interaction with MyD88 due to missense mutations (e.g., R12C) (Ku CL et al. 2007; Yamamoto T et al. 2014). IRAK4 mediates immune responses downstream of all TLRs except for TLR3. Besides defective TLR5 signaling, the Reactome module describes the impact of functional deficiency of IRAK4 on TLR2/4 signaling pathways. We did not include defective TLR7, TLR8 and TLR9 signaling events, which are stimulated by nucleic acids upon viral infections, although studies using patients-derived blood cells have showed abolished cytokines production by peripheral blood mononuclear cells (PBMCs) and lack of CD62 ligand (CD62L) shedding from granulocytes in response to TLR7-9 agonists, i.e.,3M-13 (TLR7), 3M-2 (TLR8), R848 (TLR7 and 8) and CpG (TLR9) (McDonald DR et al. 2006; von Bernuth H et al. 2006; Ku CL et al. 2007). In addition to TLR-NFkB signaling axis the endosomic TLR7-9 activate IFN-alpha/beta and IFN-gamma responses, which have been also impaired in IRAK4-deficient PBMC (Yang K et al. 2005). However, IFN-alpha/beta and IFN-gamma production in response to 9 of 11 viruses tested was normal or weakly affected in IRAK-4-deficient blood cells, suggesting that IRAK-4-deficient patients may control viral infections by TLR7-9-independent production of IFNs (Yang K et al. 2005). So it is not yet possible to annotate a definitive molecular pathway between IRAK-4 deficiency and changes in TLR7-9 signaling.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway712">
 <bp:pathwayOrder rdf:resource="#PathwayStep2670" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1904" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2615" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective ABCD1 causes ALD</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The 70-kDa peroxisomal membrane protein (PMP70) and the adrenoleukodystrophy protein (ALDP aka ABCD1) are half ATP binding cassette (ABC) transporters in the peroxisome membrane. They are involved in metabolic transport of long and very long chain fatty acids into peroxisomes. Mutations in the ALD gene result in the X-linked neurodegenerative disorder adrenoleukodystrophy (ALD; MIM:300100). ABCD1 deficiency impairs the peroxisomal beta-oxidation of very long-chain fatty acids (VLCFA) and facilitates their further chain elongation by ELOVL1 resulting in accumulation of VLCFA in plasma and tissues. While all patients with ALD have mutations in the ABCD1 gene, there is no general genotype-phenotype correlation. In addition to ABCD1, other genes and environmental factors determine clinical features of ALD (Kemp et al. 2012, Berger et al. 2014).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway711">
 <bp:pathwayOrder rdf:resource="#PathwayStep2668" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1903" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2613" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective ABCB6 causes MCOPCB7</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ATP-binding cassette sub-family B member 6 (ABCB6), uniquely located on the outer mitochondrial membrane in homodimeric form, plays a crucial role in haem synthesis by mediating porphyrin uptake into the mitochondria. Defects in ABCB6 can cause isolated colobomatous microphthalmia 7 (MCOPCB7; MIM:614497), a developmental defect of the eye resulting from abnormal or incomplete fusion of the optic fissure with associated microphthalmia (eyeballs are abnormally small). Coloboma is thought to play an important role in the early development of the CNS, including that of the eye (Wang et al. 2012).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep2140">
 <bp:stepProcess rdf:resource="#Pathway468" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway714">
 <bp:pathwayOrder rdf:resource="#PathwayStep2682" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1913" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2626" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective ABCA1 causes TGD</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">In an ATP-dependent reaction, ATP-binding cassette sub-family A member 1 (ABCA1) mediates the movement of intracellular cholesterol to the extracellular face of the plasma membrane. Cholesterol associated with cytosolic vesicles is a substrate for this reaction. Under physiologocal conditions, the active form of ABCA1 is post-translationally modified (palmitoylated and phosphorylated), predominantly a tetramer and is associated with apolipoprotein A-I (APOA1). Defects in ABCA1 can cause Tangier disease (TGD; MIM:205400 aka high density lipoprotein deficiency type 1), an autosomal recessive disorder characterised by significantly reduced levels of plasma high density lipoproteins (HDL) resulting in tissue accumulation of cholesterol esters (Brooks-Wilson et al. 1999). Low HDL levels are among the most common biochemical abnormalities observed in coronary heart disease (CHD) patients (Kolovou et al. 2006, Iatan et al. 2008, Iatan et al. 2012).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep2141">
 <bp:stepProcess rdf:resource="#Catalysis542" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1629" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway713">
 <bp:pathwayOrder rdf:resource="#PathwayStep2678" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2679" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2674" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2675" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2676" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2677" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2672" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2673" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1908" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1909" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1910" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1911" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1912" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1906" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1907" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1905" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2617" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective CFTR causes cystic fibrosis</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Cystic fibrosis transmembrane conductance regulator (CFTR) is a low conductance chloride-selective channel that mediates the transport of chloride ions in human airway epithelial cells. Chloride ions plays a key role in maintaining homoeostasis of epithelial secretions in the lungs. Defects in CFTR can cause cystic fibrosis (CF; MIM:602421), a common generalised disorder in Caucasians affecting the exocrine glands. CF results in an ionic imbalance that impairs clearance of secretions, not only in the lung, but also in the pancreas, gastrointestinal tract and liver. Wide-ranging manifestations of the disease include chronic lung disease, exocrine pancreatic insufficiency, blockage of the terminal ileum, male infertility and salty sweat. The median survival of CF patients in North America and Western Europe is around 40 years (Davis 2006, Radlovic 2012). </bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway716">
 <bp:pathwayOrder rdf:resource="#PathwayStep2686" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1915" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2630" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective ABCC2 causes DJS</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Canalicular multispecific organic anion transporter 1 (ABCC2 aka multidrug resistance-associated protein 2, MRP2), in addition to transporting many organic anions, mediates the ATP-dependent transport of glutathione and glucuronate conjugates from hepatocytes into bile. ABCC2 transports with high affinity and efficiency mono- and di-glucuronated bilirubin into bile. Bilirubin, the end product of heme breakdown, is an important constituent of bile and is responsible for its characteristic colour. Defects in ABCC2 can cause Dubin-Johnson syndrome (DJS; MIM:237500), an autosomal recessive disorder characterised by conjugated hyperbilirubinemia (Dubin    Johnson 1954, Keppler 2014, Erlinger et al. 2014). </bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway715">
 <bp:pathwayOrder rdf:resource="#PathwayStep2684" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1914" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2628" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective ABCC6 causes PXE</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The multidrug resistance associated protein (MRPs) subfamily of the ABC transporter family can transport a wide and diverse range of organic anions that can be endogenous compounds and xenobiotics and their metabolites. The multidrug resistance-associated protein 6 (ABCC6 aka MOAT-E) can actively transport organic anions. Defects in ABCC6 can cause pseudoxanthoma elasticum (PXE; MIM:264800), a rare multisystem disorder characterized by accumulation of mineralized and fragmented elastic fibers in the skin, vasculature and the Burch membrane of the eye (Finger et al. 2009).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway718">
 <bp:pathwayOrder rdf:resource="#PathwayStep2690" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1917" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2634" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective ABCB11 causes PFIC2 and BRIC2</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The bile salt export pump ABCB11 mediates the release of bile salts from liver cells into bile. Defects in ABCB11 can cause two clinically distinct forms of cholestasis; progressive familial intrahepatic cholestasis 2 (PFIC2; MIM:601847) and benign recurrent intrahepatic cholestasis 2 (BRIC2; MIM:605479). Cholestasis is characterized by the retention of bile acids or salts. Bile acids can damage hepatocytes and bile duct cells leading to inflammation, fibrosis, cirrhosis and eventually carcinogenesis. PFIC2 patients suffer from chronic cholestasis and develop liver fibrosis, cirrhosis and end-stage liver disease before adulthood. BRIC2 patients experience intermittent episodes of cholestasis that resolve spontaneously after weeks or months (Strubbe et al. 2012, Cuperus et al. 2014).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway717">
 <bp:pathwayOrder rdf:resource="#PathwayStep2688" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1916" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2632" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective ABCG5 causes sitosterolemia</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ATP-binding cassette sub-family G member 5 (ABCG5 aka sterolin-1), is a &quot;half transporter&quot;, that forms a complex with another half transporter ABCG8 (aka sterolin-2) in the endoplasmic reticulum. This complex translocates to the plasma membrane to mediate the ATP-dependent intestinal absorption and facilitation of biliary secretion of cholesterol and phytosterols (e.g. sitosterol). Defects in either of these half transporters result in loss of enterocyte discrimination between cholesterol and sitosterol causing sterol accumulation and predisposition for atherosclerosis. Defects in ABCG5 are the cause of sitosterolemia (MIM:210250), characterised by unrestricted intestinal absorption of both cholesterol and plant-derived sterols causing hypercholesterolemia and premature coronary atherosclerosis. Patients with sitosterolemia absorb between 15 and 60% of ingested sitosterol and excrete only a fraction of this into the bile (Berge et al. 2000, Othman et al. 2013, Yu et al. 2014).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway719">
 <bp:pathwayOrder rdf:resource="#PathwayStep2692" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1918" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2636" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective ABCA3 causes SMDP3</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ATP-binding cassette sub-family A member 3 (ABCA3) is thought to play a role in the formation of pulmonary surfactant by transporting lipids such as cholesterol into lamellar bodies (LBs) in alveolar type II cells. In LBs, surfactant proteins and lipids are assembled into bilayer membranes that are secreted into the alveolar airspace, where they form a surface film at the air&#8211;liquid interface. Defects in ABCA3 can cause pulmonary surfactant metabolism dysfunction 3 (SMDP3), a usually fatal pulmonary disease in newborns, characterised by the absence of normal LBs and the presence of electron-dense inclusions within small vesicular structures. Loss of secretion of lipid pulmonary surfactants causes excessive lipoprotein accumulation in the alveoli resulting in severe respiratory distress (Shulenin et al. 2004, Quazi    Molday 2011, Tarling et al. 2014, Whitsett et al. 2015).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep2146">
 <bp:stepProcess rdf:resource="#Pathway471" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2147">
 <bp:stepProcess rdf:resource="#Catalysis545" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1632" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2148">
 <bp:stepProcess rdf:resource="#Pathway472" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2149">
 <bp:stepProcess rdf:resource="#Catalysis546" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1633" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2142">
 <bp:stepProcess rdf:resource="#Pathway469" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2143">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1630" />
 <bp:stepProcess rdf:resource="#Catalysis543" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2144">
 <bp:stepProcess rdf:resource="#Pathway470" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway710">
 <bp:pathwayOrder rdf:resource="#PathwayStep2665" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2666" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1902" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1901" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2610" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective ABCC8 can cause hypo- and hyper-glycemias</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ATP-binding cassette sub-family C member 8 (ABCC8) is a subunit of the beta-cell ATP-sensitive potassium channel (KATP). KATP channels play an important role in the control of insulin release. Elevation of the ATP:ADP ratio closes KATP channels leading to cellular depolarisation, calcium influx and exocytosis of insulin from its storage granules. Defects in ABCC8 can cause dysregulation of insulin secretion resulting in hyperglycemias or hypoglycemias. Specific phenotypes observed are noninsulin-dependent diabetes mellitus (NIDDM; MIM:125853), permanent neonatal diabetes mellitus (PNDM; MIM:606176), transient neonatal diabetes mellitus 2 (TNDM2; MIM:610374), familial hyperinsulinemic hypoglycemia 1 (HHF1; MIM:256450) and leucine-induced hypoglycemia (LIH; MIM:240800) (Edghill et al. 2010, Flanagan et al. 2009, Yorifuji 2014, Yang et al. 2010, Chandran et al. 2014).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep2145">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1631" />
 <bp:stepProcess rdf:resource="#Catalysis544" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway723">
 <bp:pathwayOrder rdf:resource="#PathwayStep2700" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1922" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2644" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective ABCA12 causes ARCI4B</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ATP-binding cassette sub-family A member 12 (ABCA12) is thought to function as an epidermal keratinocyte lipid transporter. These lipids form extracellular lipid layers in the stratum corneum of the epidermis, essential for skin barrier function. Defects in ABCA12 results in the loss of the skin lipid barrier, leading to autosomal recessive congenital ichthyosis 4B (ARCI4B; MIM:242500, aka harlequin ichthyosis, HI). ARCI4B shows the most severe phenotype of the congenital ichthyoses, with newborns having a thick covering of armour-like scales. The skin dries out to form hard diamond-shaped plaques separated by fissures. Affected babies are often born prematurely and rarely survive the perinatal period (Akiyama et al. 2005, Akiyama 2010, 2014).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep2150">
 <bp:stepProcess rdf:resource="#Pathway473" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway722">
 <bp:pathwayOrder rdf:resource="#PathwayStep2698" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1921" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2642" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective ABCC9 causes CMD10, ATFB12 and Cantu syndrome</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ATP-binding cassette sub-family C member 9 (ABCC9) forms cardiac and smooth muscle-type KATP channels with ATP-sensitive inward rectifier potassium channel 11 (KCNJ11). KCNJ11 forms the channel pore while ABCC9 is required for activation and regulation (Babenko et al. 1998, Tammaro    Ashcroft 2007). Inward rectifier potassium channels favor the flow of potassium into the cell rather than out of it. KATP channels open and close in response to intracellular changes in the ADP/ATP ratio, thereby linking the metabolic state of the cell to its membrane potential. Inhibition of KATP channel activity causes membrane depolarization and thereby activation of voltage-dependent Ca2+ channels, leading to Ca2+ influx and a rise in intracellular Ca2+ concentration. Correct maintenance of calcium balance is essential for the normal functioning of the heart.  Defects in ABCC9 can cause dilated cardiomyopathy 10 (CMD10: MIM:608569), a disorder characterised by ventricular dilation and impaired systolic function, resulting in congestive heart failure and arrhythmia (Bienengraeber et al. 2004). Defects in ABCC9 can also cause familial atrial fibrillation 12 (ATFB12; MIM:614050), characterised by disorganized atrial electrical activity and ineffective atrial contraction resulting in blood stasis in the atria and reduces ventricular filling. It can result in palpitations, syncope, thromboembolic stroke, and congestive heart failure (Olson et al. 2007). Defects in ABCC9 can also cause hypertrichotic osteochondrodysplasia (Cantu syndrome; MIM:239850), a rare disorder characterised by congenital hypertrichosis, neonatal macrosomia, a distinct osteochondrodysplasia and cardiomegaly (van Bon et al. 2012, Harakalova et al. 2012).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep2151">
 <bp:stepProcess rdf:resource="#Pathway474" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway725">
 <bp:pathwayOrder rdf:resource="#PathwayStep2715" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2705" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2703" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2710" />
 <bp:pathwayComponent rdf:resource="#Pathway733" />
 <bp:pathwayComponent rdf:resource="#Pathway727" />
 <bp:pathwayComponent rdf:resource="#Pathway726" />
 <bp:pathwayComponent rdf:resource="#Pathway730" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2647" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Diseases of Cellular Senescence</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Cellular senescence plays an important role in normal aging, as well as in age-related diseases. Impaired cellular senescence contributes to malignant transformation and cancer development. Presence of an excessive number of senescent cells that are not cleared by the immune system, however, promotes tissue inflammation and creates a microenvironment suitable for growth of neighboring malignant cells. Besides cancer, senescence is also involved in atherosclerosis, osteoarthritis and diabetes (Childs et al. 2015, He and Sharpless 2017).  Evasion of oncogene-induced senescence, at least in cell culture, can occur due to loss-of-function (LOF) mutation in the CDKN2A gene product p16INK4A that acts as a cyclin-dependent kinase inhibitor (reviewed in Sharpless and Sherr 2015). LOF mutations in the CDKN2A gene that affect its other protein product, p14ARF, involved in stabilization of TP53 protein (p53), can contribute to evasion of oncogene-induced senescence (reviewed in Fontana et al. 2019).  LOF mutations in p16INK4A and p14ARF also contribute to evasion of oxidative stress-induced senescence (reviewed in Sharpless and Sherr 2015, and Fontana et al. 2019, respectively). </bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep2152">
 <bp:stepProcess rdf:resource="#Catalysis547" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1634" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway724">
 <bp:pathwayOrder rdf:resource="#PathwayStep2702" />
 <bp:pathwayComponent rdf:resource="#Pathway725" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2646" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Diseases of cellular response to stress</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Cells are subject to external and internal stressors, such as foreign molecules that perturb metabolic or signaling processes, cellular respiration-generated reactive oxygen species that can cause DNA damage, oxygen and nutrient deprivation, and changes in temperature or pH.  The ability of cells and tissues to respond to stress is essential to the maintenance of tissue homeostasis (Kultz 2005) and dysregulation of cellular response to stress is involved in disease.  So far, we have captured diseases of cellular senescence.  Impaired cellular senescence contributes to malignant transformation and cancer development by enabling continuous proliferation of damaged cells. On the other hand, presence of an excessive number of senescent cells that are not cleared by the immune system promotes tissue inflammation and creates a microenvironment suitable for growth of neighboring malignant cells. In addition to cancer, senescence is also involved in other age-related diseases such as atherosclerosis, osteoarthritis, chronic obstructive lung disease, and diabetes (Childs et al. 2015, He and Sharpless 2017, Hamsanathan et al. 2019, Faget et al. 2019, Gorgoulis et al. 2019, Rhinn et al. 2019). Senotherapy is a new field of pharmacology that aims to therapeutically target senescence to improve healthy aging and age-related diseases (Schmitt 2017, Gorgoulis et al. 2019).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway727">
 <bp:pathwayOrder rdf:resource="#PathwayStep2706" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2708" />
 <bp:pathwayComponent rdf:resource="#Pathway729" />
 <bp:pathwayComponent rdf:resource="#Pathway728" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2650" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Evasion of Oncogene Induced Senescence Due to p16INK4A Defects</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The CDKN2A gene consists of four exons, exon 1beta, exon 1alpha, exon 2 and exon 3, going from the proximal to the distal gene end. There are two promoters in the CDKN2A gene locus. The promoter located between exons 1beta and 1alpha regulates transcription of the p16INK4A mRNA, which consists of exon 1alpha, exon 2 and exon 3 (only partially translated), and encodes a cyclin-dependent kinase inhibitor p16INK4A (also known as CDKN2A isoform 1, p16, INK4A, CDKN2A, CDK4I or MTS-1). The promoter located upstream of exon 1beta regulates transcription of the p14-ARF mRNA, which consists of exon 1beta, exon 2 (partially translated) and exon 3 (untranslated). The p14ARF mRNA is translated in a different reading frame from the p16INK4A mRNA and produces the tumor suppressor ARF (also known as p14ARF or CDKN2A isoform 4), an inhibitor of MDM2 E3 ubiquitin ligase-mediated degradation of TP53 (p53). Wild type p16INK4A is able to form a complex with either CDK4 or CDK6 and prevent formation of catalytically active CDK complexes consisting of CDK4 or CDK6 and D-type cyclins (CCND). Thus, p16INK4A prevents hyperphosphorylation of RB-family proteins, required for initiation of DNA replication in RB1-competent cells. Expression of p16INK4A increases in response to strong oncogenic signaling, leading to accelerated cellular senescence (programmed cell cycle arrest). Expression of p16INK4A also increases after excessive proliferation, including that following oncogene activation by mutation in vivo. Loss-of-function of p16INK4A frequently occurs in cancer, usually through loss of p16INK4A protein expression due to promoter hypermethylation or CDKN2A gene deletion (Merlo et al. 1995, Herman et al. 1995, Gonzalez-Zulueta et al. 1995, Wong et al. 1997, Witkiewicz et al. 2011, Shima et al. 2011, Tamayo-Orrego et al. 2016). Missense, nonsense and frameshift mutations in the CDKN2A locus can also impair p16INK4A function through expression of non-functional substitution mutants or truncated proteins (Kamb et al. 1994, Bartsch et al. 1995, Castellano et al. 1997). Germline intronic CDKN2A mutations that create aberrant splicing sites and result in expression of non-functional splicing variants of p16INK4A have been reported in familial melanoma (Harland et al. 2001, Harland et al. 2005). A CDKN2A gene mutation in the region encoding the 5&apos;UTR of p16INK4A, reported in familial melanoma, creates a novel translation start codon and diminishes translation from the wild type start codon (Liu et al. 1999). However, mutations in the non-coding regions of the CDKN2A gene are rare (Pollock et al. 2001). Based on cell culture studies, p16INK4A defects enable precancerous and cancerous cells to delay or evade senescence under oncogenic signaling stress (Ruas et al. 1999, Haferkamp et al. 2008, Rayess et al. 2012, Jeanblanc et al. 2012, LaPak and Burd 2014, Sharpless and Sherr 2015). Establishment of an in vivo role of oncogene induced senescence, and thus an in vivo role of p16INK4A in this context, have been difficult owing to lack of specific biomarkers and interconnectedness of various senescence triggers (Baek and Ryeom 2017, reviewed in Sharpless and Sherr 2015). Genomic deletions in the CDKN2A locus affect p14ARF, unless they are limited to exon 1alpha. The p14ARF promoter can also be hypermethylated in cancer, leading to loss of p14ARF expression. Some missense mutations occurring in exon 2 of the CDKN2A gene affect the p14ARF protein sequence. However, p14ARF mutants usually appear to be less functionally compromised than their p16INK4A counterparts. Most functional tests on p14ARF mutants examine the effect of mutations on MDM2 binding and TP53-mediated transcription of CDKN1A (p21), as well as sub-nuclear localization of p14ARF (Zhang and Xiong 1999, Schmitt et al. 1999, Eischen et al. 1999, Pinyol et al. 2000, Bostrom et al. 2001, Laud et al. 2006). Still, there are poorly explored functions of p14ARF that may be significantly affected in mutant p14ARF proteins detected in cancer (Itahana and Zhang 2008, Dominguez-Brauer et al. 2010). </bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway726">
 <bp:pathwayOrder rdf:resource="#PathwayStep2704" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1923" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2648" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Evasion of Oncogene Induced Senescence Due to p14ARF Defects</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">In cell culture, p14ARF (CDKN2A transcript 4, CDKN2A-4, ARF), one of the two main protein products of the CDKN2A gene, contributes to oncogene induced senescence by stabilizing TP53 (p53). The function of p14ARF in p53 stabilization through sequestration of MDM2, a p53 ubiquitin ligase, depends on the nuclear localization of p14ARF and its ability to interact with MDM2. The nuclear localization signal and the MDM2 interaction domain map to the first 15 amino acids of the N-terminus of p14ARF. This region is encoded by the p14ARF-specific exon 1beta of CDKN2A. An independent MDM2-binding domain localized to the C-terminus of p14ARF (Lohrum et al. 2000). Insertion of 16 nucleotides in exon 1beta results in a frameshift truncation of p14ARF, responsible for a familial melanoma syndrome in which the p16INK4A product of the CDKN2A gene is unaffected. This mutation is rare and has so far been reported in one family only. The mutant protein, p14ARF V22Pfs*46 has the nucleotide localization signal and the N-terminal MDM2 interaction region preserved, but is unable to translocate from the cytosol to the nucleus, possibly due to aberrant conformation (Rizos, Puig et al. 2001), and also lacks the C-terminal MDM2 interaction region. Relocation of wild type p14ARF to the cytosol has been observed in melanoma (Rizos, Darmanian et al. 2001) and aggressive thyroid papillary carcinoma (Ferru et al. 2006). Genomic deletion of exon 1beta, with exons 1alpha, 2 and 3 intact, has been reported in about 30% of melanoma cases with genomic deletions involving the CDKN2A locus (Freedberg et al. 2008). Several different familial melanoma germline mutations map to the exon 1beta splice donor site (Harland et al. 2005). The ability of p14ARF to localize to the nucleolus also plays a role in p14ARF-mediated stabilization of p53. Mutations in exon 2 of the CDKN2A gene can lead to missense mutations in p14ARF that affect its nucleolar localization and p53 stabilization, but the exact mechanism has not been fully elucidated (Zhang and Xiong 1999, reviewed by Fontana et al. 2019).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway729">
 <bp:pathwayOrder rdf:resource="#PathwayStep2709" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1925" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2653" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Evasion of Oncogene Induced Senescence Due to Defective p16INK4A binding to CDK4</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Missense mutations and small indels in the CDKN2A gene, which result in amino acid changes in p16INK4A that impair its ability to bind to CDK4, interfere with p16INK4A-mediated induction of cellular senescence in response to oncogenic signaling (Jones et al. 2007). Loss-of-function mutations in p16INK4A can also contribute to cancer by interfering with p16INK4A-mediated inhibition of NFKB signaling (Becker et al. 2005).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway728">
 <bp:pathwayOrder rdf:resource="#PathwayStep2707" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1924" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2651" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Evasion of Oncogene Induced Senescence Due to Defective p16INK4A binding to CDK4 and CDK6</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Missense and nonsense mutations in the CDKN2A gene that result in amino acid substitutions in p16INK4A or p16INK4A truncations, impairing its ability to bind to CDK4 and CDK6, interfere with p16INK4A-mediated induction of cellular senescence in response to oncogenic signaling (Haferkamp et al. 2008). Loss-of-function mutations in p16INK4A can also contribute to cancer by interfering with p16INK4A-mediated inhibition of NFKB signaling (Becker et al. 2005).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep2157">
 <bp:stepProcess rdf:resource="#Pathway477" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2158">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1637" />
 <bp:stepProcess rdf:resource="#Catalysis550" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2159">
 <bp:stepProcess rdf:resource="#Pathway478" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2153">
 <bp:stepProcess rdf:resource="#Pathway475" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2154">
 <bp:stepProcess rdf:resource="#Catalysis548" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1635" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2155">
 <bp:stepProcess rdf:resource="#Pathway476" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway721">
 <bp:pathwayOrder rdf:resource="#PathwayStep2696" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1920" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2640" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective ABCG8 causes GBD4 and sitosterolemia</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ATP-binding cassette sub-family G member 8 (ABCG8 aka sterolin-2), is a &quot;half transporter&quot;, that forms a complex with another half transporter ABCG5 in the endoplasmic reticulum. This complex translocates to the plasma membrane to mediate the ATP-dependent intestinal absorption and facilitation of biliary secretion of cholesterol and phytosterols (eg sitosterol). Defects in either of these half transporters result in loss of enterocyte discrimination between cholesterol and sitosterol causing sterol accumulation and predisposition for atherosclerosis. Defects in ABCG8 are the cause of gallbladder disease 4 (GBD4; MIM:611465), one of the major digestive diseases. Gallstones are composed of cholesterol (cholelithiasis) and are the common manifestations of GBD in western countries (Buch et al. 2007, Rudkowska    Jones 2008, Jakulj et al. 2010). Defects in ABCG8 also cause sitosterolemia (MIM:210250), characterised by unrestricted intestinal absorption of both cholesterol and plant-derived sterols causing hypercholesterolemia and premature coronary atherosclerosis. Patients with sitosterolemia absorb between 15 and 60% of ingested sitosterol, and they excrete only a fraction into the bile (Berge et al. 2000, Othman et al. 2013, Yu et al. 2014).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep2156">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1636" />
 <bp:stepProcess rdf:resource="#Catalysis549" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway720">
 <bp:pathwayOrder rdf:resource="#PathwayStep2694" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1919" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2638" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective ABCB4 causes PFIC3, ICP3 and GBD1</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Multidrug resistance protein 3 (ATP-binding cassette sub-family B member 4, ABCB4 aka MDR3) mediates the ATP-dependent export of organic anions, phospholipids and drugs from hepatocytes into the canalicular lumen in the presence of bile salts, especially the export of phospholipids such as phosphatidylcholine (PC). Biliary phospholipids associate with bile salts and cholesterol in mixed micelles, thereby reducing the detergent activity and cytotoxicity of bile salts and preventing cholesterol crystallisation. Thus, ABCB4 plays a crucial role in bile formation and lipid homeostasis. Defects in ABCB4 result in a wide spectrum of cholestasis phenotypes, from progressive familial intrahepatic cholestasis 3 (PFIC3; MIM:602347) and intrahepatic cholestasis of pregnancy 3 (ICP3; MIM:614972) to gallbladder disease 1 (GBD1; MIM:600803) (Jacquemin et al. 2001, Davit-Spraul et al. 2010, Jacquemin 2012). In PFIC3, the biliary phospholipid level is substantially decreased despite the presence of bile acids. Cholestasis may be caused by the toxicity of detergent bile salts that are not associated with phospholipids, leading to bile canaliculus and biliary epithelium damage. ICP3 is a reversible form of cholestasis in the third trimester of pregnancy and quickly disappears after childbearing. GBD1 is one of the major digestive diseases. Gallstones composed of cholesterol (cholelithiasis) are the common manifestations of GBD1 in western countries. Most people with gallstones remain asymptomatic throughout their lifetimes but approximately 10-50% of individuals eventually develop symptoms. </bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep739">
 <bp:stepProcess rdf:resource="#BiochemicalReaction578" />
 <bp:stepProcess rdf:resource="#Catalysis153" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep737">
 <bp:stepProcess rdf:resource="#BiochemicalReaction576" />
 <bp:stepProcess rdf:resource="#Catalysis151" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep738">
 <bp:stepProcess rdf:resource="#BiochemicalReaction577" />
 <bp:stepProcess rdf:resource="#Catalysis152" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2128">
 <bp:stepProcess rdf:resource="#Pathway462" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2129">
 <bp:stepProcess rdf:resource="#Catalysis536" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1623" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep731">
 <bp:stepProcess rdf:resource="#BiochemicalReaction570" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2124">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1620" />
 <bp:stepProcess rdf:resource="#Catalysis533" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep732">
 <bp:stepProcess rdf:resource="#BiochemicalReaction571" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2125">
 <bp:stepProcess rdf:resource="#Pathway461" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2126">
 <bp:stepProcess rdf:resource="#Catalysis534" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1621" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep730">
 <bp:stepProcess rdf:resource="#BiochemicalReaction569" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2127">
 <bp:stepProcess rdf:resource="#Catalysis535" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1622" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep735">
 <bp:stepProcess rdf:resource="#BiochemicalReaction574" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2120">
 <bp:stepProcess rdf:resource="#Catalysis530" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1617" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep736">
 <bp:stepProcess rdf:resource="#BiochemicalReaction575" />
 <bp:stepProcess rdf:resource="#Catalysis150" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2121">
 <bp:stepProcess rdf:resource="#Catalysis531" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1618" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep733">
 <bp:stepProcess rdf:resource="#BiochemicalReaction572" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2122">
 <bp:stepProcess rdf:resource="#Catalysis532" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1619" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep734">
 <bp:stepProcess rdf:resource="#Catalysis149" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction573" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2123">
 <bp:stepProcess rdf:resource="#Pathway460" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway701">
 <bp:pathwayOrder rdf:resource="#PathwayStep2648" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1851" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2595" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Variant SLC6A20 contributes towards hyperglycinuria (HG) and iminoglycinuria (IG)</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SLC6A20 encodes the sodium- and chloride-dependent transporter SIT1 and mediates the sodium-dependent uptake of imino acids such as L-proline, N-methyl-L-proline and pipecolate as well as N-methylated amino acids and glycine (Broer    Gether 2012, Schweikhard    Ziegler 2012). The human protein is expressed in the intestine and kidney. A common SNP in the SLC6A20 gene, a 596C-T transition that results in a thr199-to-met (T199M) substitution can contribute towards iminoglycinuria (IG; MIM:242600) or hyperglycinuria (HG; MIM:138500) (Broer et al. 2008). Overall, mutations in SLC36A2 together with polymorphisms in the modifiers SLC6A20, SLC6A18, and SLC6A19 constitute the genetic basis for these phenotypes.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway700">
 <bp:pathwayOrder rdf:resource="#PathwayStep2646" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1894" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2593" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective SLC39A4 causes acrodermatitis enteropathica, zinc-deficiency type (AEZ)</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SLC39A4 encodes the human zinc transporter hZIP4 which plays an important role in cellular zinc homeostasis. Defects in SLC39A4 result in the inherited condition acrodermatitis enteropathica, zinc deficiency type (AEZ; MIM:201100), caused by the inability to absorb dietary zinc from the duodenum and jejunum. Clinical features include growth retardation, immune system dysfunction, severe dermatitis and mental disorders (Schmitt et al. 2009).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway703">
 <bp:pathwayOrder rdf:resource="#PathwayStep2652" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1896" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2598" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective SLC5A5 causes thyroid dyshormonogenesis 1 (TDH1)</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Human SLC5A5 encodes the Na+/I- symporter NIS which is localised in the basolateral membrane of thyrocytes facing the bloodstream where it mediates iodide accumulation into these cells. Defects in SLC5A5 can cause hyroid dyshormonogenesis 1 (TDH1; MIM:274400), a disorder characterised by the inability of the thyroid to maintain a concentration difference of readily exchangeable iodine between the plasma and the thyroid gland (termed iodine trapping) leading to congenital hypothyroidism (Spitzweg    Morris 2010, Grasberger    Refetoff 2011).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep2130">
 <bp:stepProcess rdf:resource="#Pathway463" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway702">
 <bp:pathwayOrder rdf:resource="#PathwayStep2650" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1895" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2596" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective SLC34A3 causes Hereditary hypophosphatemic rickets with hypercalciuria (HHRH)</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SLC34A3 is almost exclusively expressed at the apical membranes of kidney proximal tubules and encodes a Na+/Pi cotransporter. It cotransports 2 Na+ ions with every phosphate (Pi) (electroneutral transport). Defects in SLC34A3 are the cause of hereditary hypophosphatemic rickets with hypercalciuria (HHRH; MIM:241530), an autosomal recessive form of hypophosphatemia characterised by reduced renal phosphate reabsorption and rickets (Bergwitz et al. 2006, Segawa et al. 2013, Forster et al. 2013).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway705">
 <bp:pathwayOrder rdf:resource="#PathwayStep2656" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1898" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2602" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective SLC2A2 causes Fanconi-Bickel syndrome (FBS)</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The reversible facilitated diffusion of fructose, galactose, and glucose from the cytosol to the extracellular space is mediated by the SLC2A2 (GLUT2) transporter in the plasma membrane. In the epithelial cells of the small intestine, the basolateral localisation of SLC2A2 enables hexose sugars derived from the diet (and taken up by SLC5A1 and SLC2A5 transporters into cells) to be released into the circulation. SLC2A2 is a low affinity glucose transporter expressed mainly in the kidney, liver and pancreatic beta-cells. In beta-cells, it functions as a glucose-sensor for insulin secretion and in the liver, it allows for bi-directional glucose transport. Defects in SLC2A2 can cause Fanconi-Bickel syndrome (FBS; MIM:227810), a rare but well-defined disorder characterised by glycogen accumulation, proximal renal tubular dysfunction, and impaired utilisation of glucose and galactose (Leturque et al. 2009, Douard    Ferraris 2013).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway704">
 <bp:pathwayOrder rdf:resource="#PathwayStep2654" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1897" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2600" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective AVP does not bind AVPR1A,B and causes neurohypophyseal diabetes insipidus (NDI)</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Arginine vasopressin (AVP(20-28)) is a 9 amino-acid long signal peptide produced by cleavage of the precursor protein AVP in the hypothalamus. It mediates the reabsorption of water in the kidney and its synthesis and release are physiologically regulated by plasma osmolarity, blood pressure and/or blood volume. AVP(20-28) binds to vasopressin receptors AVPR1 and 2, located on the basolateral surface of the kidney collecting duct. This binding results in interaction of AVPRs with the G protein alpha-s. Following a cascade of downstream events, ultimately the water channel aquaporin 2 (AQP2) translocates from intracellular stores to the apical surface where it functions as the entry site for water reabsorption. When water balance is achieved, plasma levels of AVP(20-28) drop and AQP2 levels in the apical plasma membrane are decreased.  Mutations in AVP make it unavailable to its AVPRs in the kidney, resulting in dysregulation of water reabsorption. This can cause familial neurohypophyseal diabetes insipidus (FNDI), an autosomal dominant disorder characterised by persistent excessive thirst resulting in constant drinking (polydipsia) and passage of large volumes of urine (polyuria). In FNDI, the production and release of AVP from the posterior pituitary gland is impaired (Moeller et al. 2013). </bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway707">
 <bp:pathwayOrder rdf:resource="#PathwayStep2660" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1900" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2606" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective SLC17A8 causes autosomal dominant deafness 25 (DFNA25)</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">There are two classes of glutamate transporters; the excitatory amino acid transporters (EAATs) which depend on an electrochemical gradient of Na+ ions and vesicular glutamate transporters (VGLUTs) which are proton-dependent. Together, these transporters uptake and release glutamate to mediate this neurotransmitter&apos;s excitatory signal and are part of the glutamate-glutamine cycle. Three members of the SLC17A gene family (7, 6 and 8) encode VGLUTs 1-3 respectively. This uptake is thought to be coupled to the proton electrochemical gradient generated by the vacuolar type H+-ATPase. They are all expressed in the CNS in neuron-rich areas but SLC17A8 (VGLUT3) is also expressed on astrocytes and in the liver and kidney. Defects in SLC17A8 can cause autosomal dominant deafness 25 (DFNA25; MIM:605583), a form of non-syndromic sensorineural hearing loss. The cochlea expresses SLC17A8 and in mice which lack this transporter are congenitally deaf. Hearing loss is due to the lack of glutamate release by inner hair cells therefore a loss of synaptic transmission at the IHC-afferent nerve synapse. Successful restoration of hearing by gene replacement in mice could be a significant advance toward gene therapy of human deafness (Ruel et al. 2008, Akil et al. 2012).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway706">
 <bp:pathwayOrder rdf:resource="#PathwayStep2658" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1899" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2604" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective SLC24A1 causes congenital stationary night blindness 1D (CSNB1D)</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Five members of the NCKX (SLC24) family are all able to exchange one Ca2+ and one K+ for four Na+. SLC24A1 encodes an exchanger protein NCKX1 which is the most extensively studied member and is highly expressed in the eye. The light-induced lowering of calcium by efflux via this protein plays a key role in the process of light adaptation (Schnetkamp 2013). Defects in SLC24A1 can cause congenital stationary night blindness 1D (CSNB1D), an autosomal recessive, non-progressive retinal disorder characterised by impaired night vision and characterised by a Riggs-type of electroretinogram (Riazuddin et al. 2010).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway709">
 <bp:pathwayOrder rdf:resource="#PathwayStep2680" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2691" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2667" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2689" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2669" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2685" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2664" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2697" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2687" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2699" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2681" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2671" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2693" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2683" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2695" />
 <bp:pathwayComponent rdf:resource="#Pathway712" />
 <bp:pathwayComponent rdf:resource="#Pathway723" />
 <bp:pathwayComponent rdf:resource="#Pathway711" />
 <bp:pathwayComponent rdf:resource="#Pathway722" />
 <bp:pathwayComponent rdf:resource="#Pathway714" />
 <bp:pathwayComponent rdf:resource="#Pathway713" />
 <bp:pathwayComponent rdf:resource="#Pathway716" />
 <bp:pathwayComponent rdf:resource="#Pathway715" />
 <bp:pathwayComponent rdf:resource="#Pathway718" />
 <bp:pathwayComponent rdf:resource="#Pathway717" />
 <bp:pathwayComponent rdf:resource="#Pathway719" />
 <bp:pathwayComponent rdf:resource="#Pathway553" />
 <bp:pathwayComponent rdf:resource="#Pathway710" />
 <bp:pathwayComponent rdf:resource="#Pathway721" />
 <bp:pathwayComponent rdf:resource="#Pathway720" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2609" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ABC transporter disorders</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The ATP-binding cassette (ABC) transporters form a large family of transmembrane proteins that utilise the energy from the hydrolysis of ATP to facilitate the movement of a wide variety of substrates against a concentration gradient across membrane bilayers. Substrates include amino acids, lipids, inorganic ions, peptides, saccharides, peptides for antigen presentation, metals, drugs, and proteins. Of the 48 known ABC transporters in humans, 15 are associated with a defined human disease (Tarling et al. 2013, Woodward et al. 2011, Dean 2005, Kemp et al. 2011, Ueda 2011, Chen    Tiwari 2011).  </bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway708">
 <bp:pathwayOrder rdf:resource="#PathwayStep2662" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1858" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2608" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective SLC6A18 may confer susceptibility to iminoglycinuria and/or hyperglycinuria</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SLC6A18 encodes a neutral amino acid transporter B(0)AT3 which has preference for the amino acid glycine. It is abundantly expressed in the kidney, specifically the S2/3 segments of the kidney proximal tubule (Broer    Gether 2012, Schweikhard    Ziegler 2012). Iminoglycinuria (IG; MIM:242600) or hyperglycinuria (HG; MIM:138500) can arise from defects in SLC36A2, encoding a proton-coupled amino acid transporter 2 (PAT2), a high-affinity cotransporter of glycine and proline. Mutation in SLC6A18 may contribute to both IG and HG (Broer et al. 2008).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep728">
 <bp:stepProcess rdf:resource="#BiochemicalReaction567" />
 <bp:stepProcess rdf:resource="#Catalysis147" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep729">
 <bp:stepProcess rdf:resource="#BiochemicalReaction568" />
 <bp:stepProcess rdf:resource="#Catalysis148" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep726">
 <bp:stepProcess rdf:resource="#Pathway148" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep727">
 <bp:stepProcess rdf:resource="#BiochemicalReaction566" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2139">
 <bp:stepProcess rdf:resource="#Catalysis541" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1628" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep720">
 <bp:stepProcess rdf:resource="#BiochemicalReaction560" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2135">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1626" />
 <bp:stepProcess rdf:resource="#Catalysis539" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep721">
 <bp:stepProcess rdf:resource="#BiochemicalReaction561" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2136">
 <bp:stepProcess rdf:resource="#Pathway466" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2137">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1627" />
 <bp:stepProcess rdf:resource="#Catalysis540" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2138">
 <bp:stepProcess rdf:resource="#Pathway467" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep724">
 <bp:stepProcess rdf:resource="#BiochemicalReaction564" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2131">
 <bp:stepProcess rdf:resource="#Catalysis537" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1624" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep725">
 <bp:stepProcess rdf:resource="#BiochemicalReaction565" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2132">
 <bp:stepProcess rdf:resource="#Pathway464" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep722">
 <bp:stepProcess rdf:resource="#BiochemicalReaction562" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2133">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1625" />
 <bp:stepProcess rdf:resource="#Catalysis538" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep723">
 <bp:stepProcess rdf:resource="#BiochemicalReaction563" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2134">
 <bp:stepProcess rdf:resource="#Pathway465" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep717">
 <bp:stepProcess rdf:resource="#BiochemicalReaction557" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep718">
 <bp:stepProcess rdf:resource="#BiochemicalReaction558" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep715">
 <bp:stepProcess rdf:resource="#BiochemicalReaction555" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep716">
 <bp:stepProcess rdf:resource="#BiochemicalReaction556" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2106">
 <bp:stepProcess rdf:resource="#Catalysis526" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1609" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2107">
 <bp:stepProcess rdf:resource="#Pathway454" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep719">
 <bp:stepProcess rdf:resource="#BiochemicalReaction559" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2108">
 <bp:stepProcess rdf:resource="#Pathway455" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2109">
 <bp:stepProcess rdf:resource="#Pathway456" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2102">
 <bp:stepProcess rdf:resource="#Catalysis525" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1607" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep710">
 <bp:stepProcess rdf:resource="#Pathway146" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2103">
 <bp:stepProcess rdf:resource="#Pathway452" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2104">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1608" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2105">
 <bp:stepProcess rdf:resource="#Pathway453" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep713">
 <bp:stepProcess rdf:resource="#BiochemicalReaction553" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep714">
 <bp:stepProcess rdf:resource="#BiochemicalReaction554" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep711">
 <bp:stepProcess rdf:resource="#BiochemicalReaction552" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2100">
 <bp:stepProcess rdf:resource="#Catalysis524" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1606" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep712">
 <bp:stepProcess rdf:resource="#Pathway147" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2101">
 <bp:stepProcess rdf:resource="#Pathway451" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep706">
 <bp:stepProcess rdf:resource="#BiochemicalReaction548" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep707">
 <bp:stepProcess rdf:resource="#BiochemicalReaction549" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep704">
 <bp:stepProcess rdf:resource="#Pathway145" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep705">
 <bp:stepProcess rdf:resource="#BiochemicalReaction547" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2117">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1615" />
 <bp:stepProcess rdf:resource="#Catalysis528" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2118">
 <bp:stepProcess rdf:resource="#Pathway459" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep708">
 <bp:stepProcess rdf:resource="#BiochemicalReaction550" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2119">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1616" />
 <bp:stepProcess rdf:resource="#Catalysis529" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep709">
 <bp:stepProcess rdf:resource="#BiochemicalReaction551" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2113">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1613" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2114">
 <bp:stepProcess rdf:resource="#Pathway457" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2115">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1614" />
 <bp:stepProcess rdf:resource="#Catalysis527" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2116">
 <bp:stepProcess rdf:resource="#Pathway458" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep702">
 <bp:stepProcess rdf:resource="#BiochemicalReaction545" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep703">
 <bp:stepProcess rdf:resource="#BiochemicalReaction546" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2110">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1610" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep700">
 <bp:stepProcess rdf:resource="#BiochemicalReaction543" />
 <bp:stepProcess rdf:resource="#Catalysis146" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2111">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1611" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep701">
 <bp:stepProcess rdf:resource="#BiochemicalReaction544" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2112">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1612" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep782">
 <bp:stepProcess rdf:resource="#BiochemicalReaction616" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep783">
 <bp:stepProcess rdf:resource="#BiochemicalReaction617" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence769">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep780">
 <bp:stepProcess rdf:resource="#Catalysis159" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction614" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep781">
 <bp:stepProcess rdf:resource="#BiochemicalReaction615" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence771">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence770">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep775">
 <bp:stepProcess rdf:resource="#BiochemicalReaction609" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence777">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep776">
 <bp:stepProcess rdf:resource="#BiochemicalReaction610" />
 <bp:stepProcess rdf:resource="#Catalysis158" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence776">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep773">
 <bp:stepProcess rdf:resource="#BiochemicalReaction607" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence779">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep774">
 <bp:stepProcess rdf:resource="#BiochemicalReaction608" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence778">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep779">
 <bp:stepProcess rdf:resource="#BiochemicalReaction613" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence773">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence772">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep777">
 <bp:stepProcess rdf:resource="#BiochemicalReaction611" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence775">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep778">
 <bp:stepProcess rdf:resource="#BiochemicalReaction612" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence774">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep771">
 <bp:stepProcess rdf:resource="#BiochemicalReaction605" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep772">
 <bp:stepProcess rdf:resource="#BiochemicalReaction606" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep770">
 <bp:stepProcess rdf:resource="#Catalysis157" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction604" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence780">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence782">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence781">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep764">
 <bp:stepProcess rdf:resource="#BiochemicalReaction598" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence788">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep765">
 <bp:stepProcess rdf:resource="#BiochemicalReaction599" />
 <bp:stepProcess rdf:resource="#Catalysis156" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence787">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep762">
 <bp:stepProcess rdf:resource="#BiochemicalReaction596" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep763">
 <bp:stepProcess rdf:resource="#BiochemicalReaction597" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence789">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep768">
 <bp:stepProcess rdf:resource="#BiochemicalReaction602" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence784">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep769">
 <bp:stepProcess rdf:resource="#BiochemicalReaction603" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence783">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep766">
 <bp:stepProcess rdf:resource="#BiochemicalReaction600" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence786">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep767">
 <bp:stepProcess rdf:resource="#BiochemicalReaction601" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence785">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep760">
 <bp:stepProcess rdf:resource="#BiochemicalReaction594" />
 <bp:stepProcess rdf:resource="#Catalysis154" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep761">
 <bp:stepProcess rdf:resource="#BiochemicalReaction595" />
 <bp:stepProcess rdf:resource="#Catalysis155" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence791">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence790">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep759">
 <bp:stepProcess rdf:resource="#BiochemicalReaction593" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence793">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence792">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep753">
 <bp:stepProcess rdf:resource="#BiochemicalReaction590" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence799">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep754">
 <bp:stepProcess rdf:resource="#Pathway151" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence798">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep751">
 <bp:stepProcess rdf:resource="#BiochemicalReaction588" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep752">
 <bp:stepProcess rdf:resource="#BiochemicalReaction589" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep757">
 <bp:stepProcess rdf:resource="#BiochemicalReaction592" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence795">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep758">
 <bp:stepProcess rdf:resource="#Pathway152" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence794">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep755">
 <bp:stepProcess rdf:resource="#BiochemicalReaction591" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence797">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep756">
 <bp:stepProcess rdf:resource="#BiochemicalReaction590" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence796">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep750">
 <bp:stepProcess rdf:resource="#BiochemicalReaction587" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis601">
 <bp:controlled rdf:resource="#BiochemicalReaction1688" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis600">
 <bp:controlled rdf:resource="#BiochemicalReaction1687" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep748">
 <bp:stepProcess rdf:resource="#BiochemicalReaction585" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis603">
 <bp:controlled rdf:resource="#BiochemicalReaction1690" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep749">
 <bp:stepProcess rdf:resource="#BiochemicalReaction586" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis602">
 <bp:controlled rdf:resource="#BiochemicalReaction1689" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep742">
 <bp:stepProcess rdf:resource="#BiochemicalReaction581" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis609">
 <bp:controlled rdf:resource="#BiochemicalReaction1697" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep743">
 <bp:stepProcess rdf:resource="#Pathway149" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis608">
 <bp:controlled rdf:resource="#BiochemicalReaction1696" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep740">
 <bp:stepProcess rdf:resource="#BiochemicalReaction579" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep741">
 <bp:stepProcess rdf:resource="#BiochemicalReaction580" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep746">
 <bp:stepProcess rdf:resource="#BiochemicalReaction583" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis605">
 <bp:controlled rdf:resource="#BiochemicalReaction1692" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep747">
 <bp:stepProcess rdf:resource="#BiochemicalReaction584" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis604">
 <bp:controlled rdf:resource="#BiochemicalReaction1691" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep744">
 <bp:stepProcess rdf:resource="#Pathway150" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis607">
 <bp:controlled rdf:resource="#BiochemicalReaction1695" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep745">
 <bp:stepProcess rdf:resource="#BiochemicalReaction582" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis606">
 <bp:controlled rdf:resource="#BiochemicalReaction1694" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep2182">
 <bp:stepProcess rdf:resource="#Pathway487" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2183">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1652" />
 <bp:stepProcess rdf:resource="#Catalysis565" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2184">
 <bp:stepProcess rdf:resource="#Pathway488" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2185">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1653" />
 <bp:stepProcess rdf:resource="#Catalysis566" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2180">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1650" />
 <bp:stepProcess rdf:resource="#Catalysis563" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2181">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1651" />
 <bp:stepProcess rdf:resource="#Catalysis564" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep797">
 <bp:stepProcess rdf:resource="#BiochemicalReaction629" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep798">
 <bp:stepProcess rdf:resource="#Pathway155" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep795">
 <bp:stepProcess rdf:resource="#BiochemicalReaction627" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep796">
 <bp:stepProcess rdf:resource="#BiochemicalReaction628" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2186">
 <bp:stepProcess rdf:resource="#Pathway489" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2187">
 <bp:stepProcess rdf:resource="#Catalysis567" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1654" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep799">
 <bp:stepProcess rdf:resource="#Pathway156" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2188">
 <bp:stepProcess rdf:resource="#Pathway490" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2189">
 <bp:stepProcess rdf:resource="#Catalysis568" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1655" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2193">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1657" />
 <bp:stepProcess rdf:resource="#Catalysis570" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep790">
 <bp:stepProcess rdf:resource="#Pathway153" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2194">
 <bp:stepProcess rdf:resource="#Pathway493" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2195">
 <bp:stepProcess rdf:resource="#Catalysis571" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1658" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2196">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1659" />
 <bp:stepProcess rdf:resource="#Catalysis572" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep793">
 <bp:stepProcess rdf:resource="#BiochemicalReaction625" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep794">
 <bp:stepProcess rdf:resource="#BiochemicalReaction626" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2190">
 <bp:stepProcess rdf:resource="#Pathway491" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep791">
 <bp:stepProcess rdf:resource="#BiochemicalReaction624" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2191">
 <bp:stepProcess rdf:resource="#Catalysis569" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1656" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep792">
 <bp:stepProcess rdf:resource="#Pathway154" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2192">
 <bp:stepProcess rdf:resource="#Pathway492" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep786">
 <bp:stepProcess rdf:resource="#BiochemicalReaction620" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep787">
 <bp:stepProcess rdf:resource="#BiochemicalReaction621" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep784">
 <bp:stepProcess rdf:resource="#BiochemicalReaction618" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep785">
 <bp:stepProcess rdf:resource="#BiochemicalReaction619" />
 <bp:stepProcess rdf:resource="#Catalysis160" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2197">
 <bp:stepProcess rdf:resource="#Catalysis573" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1660" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2198">
 <bp:stepProcess rdf:resource="#Pathway494" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep788">
 <bp:stepProcess rdf:resource="#BiochemicalReaction622" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2199">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1661" />
 <bp:stepProcess rdf:resource="#Catalysis574" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep789">
 <bp:stepProcess rdf:resource="#BiochemicalReaction623" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis535">
 <bp:controlled rdf:resource="#BiochemicalReaction1622" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis534">
 <bp:controlled rdf:resource="#BiochemicalReaction1621" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis537">
 <bp:controlled rdf:resource="#BiochemicalReaction1624" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis536">
 <bp:controlled rdf:resource="#BiochemicalReaction1623" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis531">
 <bp:controlled rdf:resource="#BiochemicalReaction1618" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis530">
 <bp:controlled rdf:resource="#BiochemicalReaction1617" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis533">
 <bp:controlled rdf:resource="#BiochemicalReaction1620" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis532">
 <bp:controlled rdf:resource="#BiochemicalReaction1619" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis539">
 <bp:controlled rdf:resource="#BiochemicalReaction1626" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis538">
 <bp:controlled rdf:resource="#BiochemicalReaction1625" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis540">
 <bp:controlled rdf:resource="#BiochemicalReaction1627" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis546">
 <bp:controlled rdf:resource="#BiochemicalReaction1633" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis545">
 <bp:controlled rdf:resource="#BiochemicalReaction1632" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis548">
 <bp:controlled rdf:resource="#BiochemicalReaction1635" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis547">
 <bp:controlled rdf:resource="#BiochemicalReaction1634" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis542">
 <bp:controlled rdf:resource="#BiochemicalReaction1629" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis541">
 <bp:controlled rdf:resource="#BiochemicalReaction1628" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis544">
 <bp:controlled rdf:resource="#BiochemicalReaction1631" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis543">
 <bp:controlled rdf:resource="#BiochemicalReaction1630" />
</bp:Catalysis>

<bp:Evidence rdf:ID="Evidence700">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence702">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence701">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis549">
 <bp:controlled rdf:resource="#BiochemicalReaction1636" />
</bp:Catalysis>

<bp:Evidence rdf:ID="Evidence708">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence707">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence709">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence704">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence703">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence706">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence705">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis551">
 <bp:controlled rdf:resource="#BiochemicalReaction1638" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis550">
 <bp:controlled rdf:resource="#BiochemicalReaction1637" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis557">
 <bp:controlled rdf:resource="#BiochemicalReaction1644" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis556">
 <bp:controlled rdf:resource="#BiochemicalReaction1643" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis559">
 <bp:controlled rdf:resource="#BiochemicalReaction1646" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis558">
 <bp:controlled rdf:resource="#BiochemicalReaction1645" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis553">
 <bp:controlled rdf:resource="#BiochemicalReaction1640" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis552">
 <bp:controlled rdf:resource="#BiochemicalReaction1639" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis555">
 <bp:controlled rdf:resource="#BiochemicalReaction1642" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis554">
 <bp:controlled rdf:resource="#BiochemicalReaction1641" />
</bp:Catalysis>

<bp:Evidence rdf:ID="Evidence711">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence710">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence713">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence712">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence719">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence718">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence715">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence714">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence717">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence716">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis560">
 <bp:controlled rdf:resource="#BiochemicalReaction1647" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis562">
 <bp:controlled rdf:resource="#BiochemicalReaction1649" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis561">
 <bp:controlled rdf:resource="#BiochemicalReaction1648" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis568">
 <bp:controlled rdf:resource="#BiochemicalReaction1655" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis567">
 <bp:controlled rdf:resource="#BiochemicalReaction1654" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis569">
 <bp:controlled rdf:resource="#BiochemicalReaction1656" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis564">
 <bp:controlled rdf:resource="#BiochemicalReaction1651" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis563">
 <bp:controlled rdf:resource="#BiochemicalReaction1650" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis566">
 <bp:controlled rdf:resource="#BiochemicalReaction1653" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis565">
 <bp:controlled rdf:resource="#BiochemicalReaction1652" />
</bp:Catalysis>

<bp:Evidence rdf:ID="Evidence722">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence721">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence724">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence723">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence720">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence729">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence726">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence725">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence728">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence727">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence733">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence732">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence735">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence734">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence731">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence730">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence737">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence736">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence739">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence738">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis502">
 <bp:controlled rdf:resource="#BiochemicalReaction1584" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis501">
 <bp:controlled rdf:resource="#BiochemicalReaction1583" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis504">
 <bp:controlled rdf:resource="#BiochemicalReaction1586" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis503">
 <bp:controlled rdf:resource="#BiochemicalReaction1585" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis500">
 <bp:controlled rdf:resource="#BiochemicalReaction1582" />
</bp:Catalysis>

<bp:Evidence rdf:ID="Evidence744">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence743">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis509">
 <bp:controlled rdf:resource="#BiochemicalReaction1591" />
</bp:Catalysis>

<bp:Evidence rdf:ID="Evidence746">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence745">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence740">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis506">
 <bp:controlled rdf:resource="#BiochemicalReaction1588" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis505">
 <bp:controlled rdf:resource="#BiochemicalReaction1587" />
</bp:Catalysis>

<bp:Evidence rdf:ID="Evidence742">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis508">
 <bp:controlled rdf:resource="#BiochemicalReaction1590" />
</bp:Catalysis>

<bp:Evidence rdf:ID="Evidence741">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis507">
 <bp:controlled rdf:resource="#BiochemicalReaction1589" />
</bp:Catalysis>

<bp:Evidence rdf:ID="Evidence748">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence747">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence749">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis513">
 <bp:controlled rdf:resource="#BiochemicalReaction1595" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis512">
 <bp:controlled rdf:resource="#BiochemicalReaction1594" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis515">
 <bp:controlled rdf:resource="#BiochemicalReaction1597" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis514">
 <bp:controlled rdf:resource="#BiochemicalReaction1596" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis511">
 <bp:controlled rdf:resource="#BiochemicalReaction1593" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis510">
 <bp:controlled rdf:resource="#BiochemicalReaction1592" />
</bp:Catalysis>

<bp:Evidence rdf:ID="Evidence755">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence754">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence757">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence756">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence751">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis517">
 <bp:controlled rdf:resource="#BiochemicalReaction1599" />
</bp:Catalysis>

<bp:Evidence rdf:ID="Evidence750">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis516">
 <bp:controlled rdf:resource="#BiochemicalReaction1598" />
</bp:Catalysis>

<bp:Evidence rdf:ID="Evidence753">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis519">
 <bp:controlled rdf:resource="#BiochemicalReaction1601" />
</bp:Catalysis>

<bp:Evidence rdf:ID="Evidence752">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis518">
 <bp:controlled rdf:resource="#BiochemicalReaction1600" />
</bp:Catalysis>

<bp:Evidence rdf:ID="Evidence759">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence758">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis524">
 <bp:controlled rdf:resource="#BiochemicalReaction1606" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis523">
 <bp:controlled rdf:resource="#BiochemicalReaction1605" />
</bp:Catalysis>

<bp:Evidence rdf:ID="Evidence760">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis526">
 <bp:controlled rdf:resource="#BiochemicalReaction1609" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis525">
 <bp:controlled rdf:resource="#BiochemicalReaction1607" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis520">
 <bp:controlled rdf:resource="#BiochemicalReaction1602" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis522">
 <bp:controlled rdf:resource="#BiochemicalReaction1604" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis521">
 <bp:controlled rdf:resource="#BiochemicalReaction1603" />
</bp:Catalysis>

<bp:Evidence rdf:ID="Evidence766">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence765">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence768">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence767">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence762">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis528">
 <bp:controlled rdf:resource="#BiochemicalReaction1615" />
</bp:Catalysis>

<bp:Evidence rdf:ID="Evidence761">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis527">
 <bp:controlled rdf:resource="#BiochemicalReaction1614" />
</bp:Catalysis>

<bp:Evidence rdf:ID="Evidence764">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence763">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis529">
 <bp:controlled rdf:resource="#BiochemicalReaction1616" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep2209">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1668" />
 <bp:stepProcess rdf:resource="#Catalysis581" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2205">
 <bp:stepProcess rdf:resource="#Pathway496" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2206">
 <bp:stepProcess rdf:resource="#Catalysis579" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1666" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2207">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1667" />
 <bp:stepProcess rdf:resource="#Catalysis580" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2208">
 <bp:stepProcess rdf:resource="#Pathway497" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2201">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1662" />
 <bp:stepProcess rdf:resource="#Catalysis575" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2202">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1663" />
 <bp:stepProcess rdf:resource="#Catalysis576" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2203">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1664" />
 <bp:stepProcess rdf:resource="#Catalysis577" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2204">
 <bp:stepProcess rdf:resource="#Catalysis578" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1665" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2200">
 <bp:stepProcess rdf:resource="#Pathway495" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2216">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1672" />
 <bp:stepProcess rdf:resource="#Catalysis585" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2217">
 <bp:stepProcess rdf:resource="#Pathway501" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2218">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1673" />
 <bp:stepProcess rdf:resource="#Catalysis586" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2219">
 <bp:stepProcess rdf:resource="#Pathway502" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2212">
 <bp:stepProcess rdf:resource="#Catalysis583" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1670" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2213">
 <bp:stepProcess rdf:resource="#Catalysis584" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1671" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2214">
 <bp:stepProcess rdf:resource="#Pathway499" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2215">
 <bp:stepProcess rdf:resource="#Pathway500" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2210">
 <bp:stepProcess rdf:resource="#Pathway498" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2211">
 <bp:stepProcess rdf:resource="#Catalysis582" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1669" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis571">
 <bp:controlled rdf:resource="#BiochemicalReaction1658" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis570">
 <bp:controlled rdf:resource="#BiochemicalReaction1657" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis573">
 <bp:controlled rdf:resource="#BiochemicalReaction1660" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis572">
 <bp:controlled rdf:resource="#BiochemicalReaction1659" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis579">
 <bp:controlled rdf:resource="#BiochemicalReaction1666" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis578">
 <bp:controlled rdf:resource="#BiochemicalReaction1665" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis575">
 <bp:controlled rdf:resource="#BiochemicalReaction1662" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis574">
 <bp:controlled rdf:resource="#BiochemicalReaction1661" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis577">
 <bp:controlled rdf:resource="#BiochemicalReaction1664" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis576">
 <bp:controlled rdf:resource="#BiochemicalReaction1663" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis582">
 <bp:controlled rdf:resource="#BiochemicalReaction1669" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis581">
 <bp:controlled rdf:resource="#BiochemicalReaction1668" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis584">
 <bp:controlled rdf:resource="#BiochemicalReaction1671" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis583">
 <bp:controlled rdf:resource="#BiochemicalReaction1670" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis580">
 <bp:controlled rdf:resource="#BiochemicalReaction1667" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis589">
 <bp:controlled rdf:resource="#BiochemicalReaction1676" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis586">
 <bp:controlled rdf:resource="#BiochemicalReaction1673" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis585">
 <bp:controlled rdf:resource="#BiochemicalReaction1672" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis588">
 <bp:controlled rdf:resource="#BiochemicalReaction1675" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis587">
 <bp:controlled rdf:resource="#BiochemicalReaction1674" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis593">
 <bp:controlled rdf:resource="#BiochemicalReaction1680" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis592">
 <bp:controlled rdf:resource="#BiochemicalReaction1679" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis595">
 <bp:controlled rdf:resource="#BiochemicalReaction1682" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis594">
 <bp:controlled rdf:resource="#BiochemicalReaction1681" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis591">
 <bp:controlled rdf:resource="#BiochemicalReaction1678" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis590">
 <bp:controlled rdf:resource="#BiochemicalReaction1677" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis597">
 <bp:controlled rdf:resource="#BiochemicalReaction1684" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis596">
 <bp:controlled rdf:resource="#BiochemicalReaction1683" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis599">
 <bp:controlled rdf:resource="#BiochemicalReaction1686" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis598">
 <bp:controlled rdf:resource="#BiochemicalReaction1685" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep1390">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1133" />
 <bp:stepProcess rdf:resource="#Catalysis323" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1391">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1109" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1392">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1134" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1393">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1135" />
 <bp:stepProcess rdf:resource="#Catalysis324" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1398">
 <bp:stepProcess rdf:resource="#Catalysis325" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1137" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1399">
 <bp:stepProcess rdf:resource="#Catalysis326" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1138" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1394">
 <bp:stepProcess rdf:resource="#Pathway237" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1395">
 <bp:stepProcess rdf:resource="#Pathway238" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1396">
 <bp:stepProcess rdf:resource="#Pathway239" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1397">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1136" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1370">
 <bp:stepProcess rdf:resource="#Pathway236" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1371">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1114" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1376">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1119" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1377">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1120" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1378">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1121" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1379">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1122" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1372">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1115" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1373">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1116" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1374">
 <bp:stepProcess rdf:resource="#Catalysis317" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1117" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1375">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1118" />
 <bp:stepProcess rdf:resource="#Catalysis318" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1380">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1123" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1381">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1124" />
 <bp:stepProcess rdf:resource="#Catalysis319" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1382">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1125" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1387">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1130" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1388">
 <bp:stepProcess rdf:resource="#Catalysis321" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1131" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1389">
 <bp:stepProcess rdf:resource="#Catalysis322" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1132" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1383">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1126" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1384">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1127" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1385">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1128" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1386">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1129" />
 <bp:stepProcess rdf:resource="#Catalysis320" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence1590">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1591">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1592">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1593">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1594">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1595">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1596">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1597">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1598">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1599">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1579">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1580">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1581">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1582">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1583">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1584">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1585">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1586">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1587">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1588">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1589">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1667">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1668">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1669">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep2719">
 <bp:stepProcess rdf:resource="#Pathway736" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2726">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1929" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2727">
 <bp:stepProcess rdf:resource="#Pathway740" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2728">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1930" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2729">
 <bp:stepProcess rdf:resource="#Pathway741" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2722">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1927" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2723">
 <bp:stepProcess rdf:resource="#Pathway738" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2724">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1928" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2725">
 <bp:stepProcess rdf:resource="#Pathway739" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence1670">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1671">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1672">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep2720">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1926" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence1673">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep2721">
 <bp:stepProcess rdf:resource="#Pathway737" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence1674">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1675">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1676">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1677">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1656">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1657">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1658">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1659">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep1406">
 <bp:stepProcess rdf:resource="#Catalysis327" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1143" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2737">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1935" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1407">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1144" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2738">
 <bp:stepProcess rdf:resource="#Pathway745" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1408">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1145" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2739">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1936" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1409">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1146" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1402">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1141" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2733">
 <bp:stepProcess rdf:resource="#Pathway743" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1403">
 <bp:stepProcess rdf:resource="#Pathway240" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2734">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1933" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1404">
 <bp:stepProcess rdf:resource="#Pathway241" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2735">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1934" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1405">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1142" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2736">
 <bp:stepProcess rdf:resource="#Pathway744" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence1660">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep2730">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1931" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1400">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1139" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence1661">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep2731">
 <bp:stepProcess rdf:resource="#Pathway742" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1401">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1140" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence1662">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep2732">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1932" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence1663">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1664">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1665">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1666">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1689">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep2704">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1923" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2705">
 <bp:stepProcess rdf:resource="#Pathway727" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2706">
 <bp:stepProcess rdf:resource="#Pathway728" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2707">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1924" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2700">
 <bp:stepProcess rdf:resource="#Catalysis743" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1922" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2701">
 <bp:stepProcess rdf:resource="#Pathway724" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence1690">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep2702">
 <bp:stepProcess rdf:resource="#Pathway725" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence1691">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep2703">
 <bp:stepProcess rdf:resource="#Pathway726" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence1692">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1693">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1694">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1695">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1696">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1697">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1698">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1699">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1678">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1679">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep2708">
 <bp:stepProcess rdf:resource="#Pathway729" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2709">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1925" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2715">
 <bp:stepProcess rdf:resource="#Pathway733" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2716">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1923" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2717">
 <bp:stepProcess rdf:resource="#Pathway734" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2718">
 <bp:stepProcess rdf:resource="#Pathway735" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2711">
 <bp:stepProcess rdf:resource="#Pathway731" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2712">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1924" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2713">
 <bp:stepProcess rdf:resource="#Pathway732" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence1680">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep2714">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1925" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence1681">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1682">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1683">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1684">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep2710">
 <bp:stepProcess rdf:resource="#Pathway730" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence1685">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1686">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1687">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1688">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1623">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1624">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1625">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1626">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1627">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1628">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1629">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1630">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1631">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1632">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1633">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1612">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1613">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1614">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1615">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1616">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1617">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1618">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1619">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1620">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1621">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1622">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1645">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1646">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1647">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1648">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1649">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1650">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1651">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1652">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1653">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1654">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1655">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1634">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1635">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1636">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1637">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1638">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1639">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1640">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1641">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1642">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1643">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1644">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep1470">
 <bp:stepProcess rdf:resource="#Pathway254" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1479">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1186" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1475">
 <bp:stepProcess rdf:resource="#Pathway256" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1476">
 <bp:stepProcess rdf:resource="#Catalysis335" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1183" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1477">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1184" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1478">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1185" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1471">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1180" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1472">
 <bp:stepProcess rdf:resource="#Pathway255" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1473">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1181" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1474">
 <bp:stepProcess rdf:resource="#Catalysis334" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1182" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1480">
 <bp:stepProcess rdf:resource="#Catalysis336" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1187" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1481">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1188" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1486">
 <bp:stepProcess rdf:resource="#Pathway258" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1487">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1192" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1488">
 <bp:stepProcess rdf:resource="#Catalysis339" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1193" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1489">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1194" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1482">
 <bp:stepProcess rdf:resource="#Catalysis337" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1189" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1483">
 <bp:stepProcess rdf:resource="#Pathway257" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1484">
 <bp:stepProcess rdf:resource="#Catalysis338" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1190" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1485">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1191" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence1601">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1602">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1603">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1604">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1605">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1606">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1607">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1608">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1609">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep1457">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1173" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1458">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1174" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1459">
 <bp:stepProcess rdf:resource="#Pathway248" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1453">
 <bp:stepProcess rdf:resource="#Pathway247" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1454">
 <bp:stepProcess rdf:resource="#Catalysis333" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1170" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1455">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1171" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1456">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1172" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1450">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1168" />
 <bp:stepProcess rdf:resource="#Catalysis332" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1451">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1169" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence1610">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep1452">
 <bp:stepProcess rdf:resource="#Pathway246" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence1611">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep1468">
 <bp:stepProcess rdf:resource="#Pathway253" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1469">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1179" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1464">
 <bp:stepProcess rdf:resource="#Pathway251" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1465">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1177" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1466">
 <bp:stepProcess rdf:resource="#Pathway252" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1467">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1178" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1460">
 <bp:stepProcess rdf:resource="#Pathway249" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1461">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1175" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1462">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1176" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1463">
 <bp:stepProcess rdf:resource="#Pathway250" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence1600">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep1439">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1150" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1435">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1145" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1436">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1147" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1437">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1148" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1438">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1149" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1431">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1142" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1432">
 <bp:stepProcess rdf:resource="#Catalysis327" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1143" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1433">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1144" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1434">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1164" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1430">
 <bp:stepProcess rdf:resource="#Pathway245" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1446">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1157" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1447">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1158" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1448">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1160" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1449">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1161" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1442">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1166" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1443">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1154" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1444">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1167" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1445">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1156" />
 <bp:stepProcess rdf:resource="#Catalysis330" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1440">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1151" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1441">
 <bp:stepProcess rdf:resource="#Catalysis331" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1165" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1417">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1154" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1418">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1155" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1419">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1156" />
 <bp:stepProcess rdf:resource="#Catalysis330" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1413">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1150" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2744">
 <bp:stepProcess rdf:resource="#Catalysis744" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1939" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1414">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1151" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1415">
 <bp:stepProcess rdf:resource="#Catalysis328" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1152" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1416">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1153" />
 <bp:stepProcess rdf:resource="#Catalysis329" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2740">
 <bp:stepProcess rdf:resource="#Pathway746" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1410">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1147" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2741">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1937" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1411">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1148" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2742">
 <bp:stepProcess rdf:resource="#Pathway747" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1412">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1149" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2743">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1938" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1428">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1163" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1429">
 <bp:stepProcess rdf:resource="#Pathway244" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1424">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1161" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1425">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1162" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1426">
 <bp:stepProcess rdf:resource="#Pathway242" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1427">
 <bp:stepProcess rdf:resource="#Pathway243" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1420">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1157" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1421">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1158" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1422">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1159" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1423">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1160" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep39">
 <bp:stepProcess rdf:resource="#BiochemicalReaction19" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep937">
 <bp:stepProcess rdf:resource="#Catalysis213" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction748" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep38">
 <bp:stepProcess rdf:resource="#Pathway21" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep938">
 <bp:stepProcess rdf:resource="#BiochemicalReaction749" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep935">
 <bp:stepProcess rdf:resource="#Catalysis212" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction746" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep936">
 <bp:stepProcess rdf:resource="#BiochemicalReaction747" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep939">
 <bp:stepProcess rdf:resource="#BiochemicalReaction750" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep31">
 <bp:stepProcess rdf:resource="#BiochemicalReaction15" />
 <bp:stepProcess rdf:resource="#Catalysis8" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep30">
 <bp:stepProcess rdf:resource="#Pathway17" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep930">
 <bp:stepProcess rdf:resource="#BiochemicalReaction742" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep33">
 <bp:stepProcess rdf:resource="#BiochemicalReaction16" />
 <bp:stepProcess rdf:resource="#Catalysis9" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep32">
 <bp:stepProcess rdf:resource="#Pathway18" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep35">
 <bp:stepProcess rdf:resource="#BiochemicalReaction17" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep933">
 <bp:stepProcess rdf:resource="#BiochemicalReaction745" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep34">
 <bp:stepProcess rdf:resource="#Pathway19" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep934">
 <bp:stepProcess rdf:resource="#Pathway171" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep37">
 <bp:stepProcess rdf:resource="#Pathway20" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep931">
 <bp:stepProcess rdf:resource="#BiochemicalReaction743" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep36">
 <bp:stepProcess rdf:resource="#BiochemicalReaction18" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep932">
 <bp:stepProcess rdf:resource="#BiochemicalReaction744" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep28">
 <bp:stepProcess rdf:resource="#Pathway16" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep926">
 <bp:stepProcess rdf:resource="#Catalysis210" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction739" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep27">
 <bp:stepProcess rdf:resource="#BiochemicalReaction13" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep927">
 <bp:stepProcess rdf:resource="#BiochemicalReaction740" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep924">
 <bp:stepProcess rdf:resource="#Catalysis209" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction737" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep29">
 <bp:stepProcess rdf:resource="#BiochemicalReaction14" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep925">
 <bp:stepProcess rdf:resource="#BiochemicalReaction738" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep928">
 <bp:stepProcess rdf:resource="#BiochemicalReaction741" />
 <bp:stepProcess rdf:resource="#Catalysis211" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep929">
 <bp:stepProcess rdf:resource="#Pathway170" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep20">
 <bp:stepProcess rdf:resource="#BiochemicalReaction10" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep22">
 <bp:stepProcess rdf:resource="#Pathway13" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep21">
 <bp:stepProcess rdf:resource="#Pathway12" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep24">
 <bp:stepProcess rdf:resource="#Pathway14" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep922">
 <bp:stepProcess rdf:resource="#Catalysis208" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction735" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep23">
 <bp:stepProcess rdf:resource="#Catalysis7" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction11" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep923">
 <bp:stepProcess rdf:resource="#BiochemicalReaction736" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep26">
 <bp:stepProcess rdf:resource="#Pathway15" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep920">
 <bp:stepProcess rdf:resource="#BiochemicalReaction733" />
 <bp:stepProcess rdf:resource="#Catalysis207" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep25">
 <bp:stepProcess rdf:resource="#BiochemicalReaction12" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep921">
 <bp:stepProcess rdf:resource="#BiochemicalReaction734" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep51">
 <bp:stepProcess rdf:resource="#Pathway29" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep50">
 <bp:stepProcess rdf:resource="#Pathway28" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep915">
 <bp:stepProcess rdf:resource="#BiochemicalReaction527" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep916">
 <bp:stepProcess rdf:resource="#BiochemicalReaction729" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep913">
 <bp:stepProcess rdf:resource="#BiochemicalReaction728" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep914">
 <bp:stepProcess rdf:resource="#Pathway169" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep919">
 <bp:stepProcess rdf:resource="#BiochemicalReaction732" />
 <bp:stepProcess rdf:resource="#Catalysis206" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep917">
 <bp:stepProcess rdf:resource="#BiochemicalReaction730" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep918">
 <bp:stepProcess rdf:resource="#BiochemicalReaction731" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep53">
 <bp:stepProcess rdf:resource="#BiochemicalReaction24" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep52">
 <bp:stepProcess rdf:resource="#Pathway30" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep55">
 <bp:stepProcess rdf:resource="#BiochemicalReaction26" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep54">
 <bp:stepProcess rdf:resource="#BiochemicalReaction25" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep57">
 <bp:stepProcess rdf:resource="#BiochemicalReaction28" />
 <bp:stepProcess rdf:resource="#Catalysis13" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep911">
 <bp:stepProcess rdf:resource="#Catalysis204" />
 <bp:stepProcess rdf:resource="#Catalysis203" />
 <bp:stepProcess rdf:resource="#Catalysis202" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction726" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep56">
 <bp:stepProcess rdf:resource="#BiochemicalReaction27" />
 <bp:stepProcess rdf:resource="#Catalysis12" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep912">
 <bp:stepProcess rdf:resource="#Catalysis205" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction727" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep59">
 <bp:stepProcess rdf:resource="#BiochemicalReaction30" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep58">
 <bp:stepProcess rdf:resource="#Catalysis14" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction29" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep910">
 <bp:stepProcess rdf:resource="#Catalysis201" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction725" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep40">
 <bp:stepProcess rdf:resource="#Pathway22" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep904">
 <bp:stepProcess rdf:resource="#BiochemicalReaction720" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep49">
 <bp:stepProcess rdf:resource="#Pathway27" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep905">
 <bp:stepProcess rdf:resource="#BiochemicalReaction721" />
 <bp:stepProcess rdf:resource="#Catalysis195" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep902">
 <bp:stepProcess rdf:resource="#BiochemicalReaction718" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep903">
 <bp:stepProcess rdf:resource="#BiochemicalReaction719" />
 <bp:stepProcess rdf:resource="#Catalysis193" />
 <bp:stepProcess rdf:resource="#Catalysis194" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep908">
 <bp:stepProcess rdf:resource="#Catalysis200" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction724" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep909">
 <bp:stepProcess rdf:resource="#BiochemicalReaction541" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep906">
 <bp:stepProcess rdf:resource="#BiochemicalReaction722" />
 <bp:stepProcess rdf:resource="#Catalysis196" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep907">
 <bp:stepProcess rdf:resource="#Catalysis197" />
 <bp:stepProcess rdf:resource="#Catalysis199" />
 <bp:stepProcess rdf:resource="#Catalysis198" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction723" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep42">
 <bp:stepProcess rdf:resource="#Pathway23" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep41">
 <bp:stepProcess rdf:resource="#Catalysis10" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction20" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep44">
 <bp:stepProcess rdf:resource="#Pathway24" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep43">
 <bp:stepProcess rdf:resource="#Catalysis11" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction21" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep46">
 <bp:stepProcess rdf:resource="#Pathway25" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep900">
 <bp:stepProcess rdf:resource="#BiochemicalReaction717" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep45">
 <bp:stepProcess rdf:resource="#BiochemicalReaction22" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep901">
 <bp:stepProcess rdf:resource="#Pathway168" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep48">
 <bp:stepProcess rdf:resource="#Pathway26" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep47">
 <bp:stepProcess rdf:resource="#BiochemicalReaction23" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep980">
 <bp:stepProcess rdf:resource="#Catalysis215" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction786" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep981">
 <bp:stepProcess rdf:resource="#BiochemicalReaction787" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep979">
 <bp:stepProcess rdf:resource="#BiochemicalReaction785" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep973">
 <bp:stepProcess rdf:resource="#BiochemicalReaction779" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep974">
 <bp:stepProcess rdf:resource="#BiochemicalReaction780" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep971">
 <bp:stepProcess rdf:resource="#BiochemicalReaction777" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep972">
 <bp:stepProcess rdf:resource="#BiochemicalReaction778" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep977">
 <bp:stepProcess rdf:resource="#BiochemicalReaction783" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep978">
 <bp:stepProcess rdf:resource="#BiochemicalReaction784" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep975">
 <bp:stepProcess rdf:resource="#BiochemicalReaction781" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep976">
 <bp:stepProcess rdf:resource="#BiochemicalReaction782" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep970">
 <bp:stepProcess rdf:resource="#BiochemicalReaction776" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep968">
 <bp:stepProcess rdf:resource="#Pathway176" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep969">
 <bp:stepProcess rdf:resource="#BiochemicalReaction775" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep962">
 <bp:stepProcess rdf:resource="#BiochemicalReaction769" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep963">
 <bp:stepProcess rdf:resource="#BiochemicalReaction770" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep960">
 <bp:stepProcess rdf:resource="#Pathway174" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep961">
 <bp:stepProcess rdf:resource="#Pathway175" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep966">
 <bp:stepProcess rdf:resource="#BiochemicalReaction773" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep967">
 <bp:stepProcess rdf:resource="#BiochemicalReaction774" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep964">
 <bp:stepProcess rdf:resource="#BiochemicalReaction771" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep965">
 <bp:stepProcess rdf:resource="#BiochemicalReaction772" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1490">
 <bp:stepProcess rdf:resource="#Catalysis340" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1195" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1491">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1196" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1492">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1197" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep17">
 <bp:stepProcess rdf:resource="#Pathway10" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep959">
 <bp:stepProcess rdf:resource="#BiochemicalReaction768" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep16">
 <bp:stepProcess rdf:resource="#Catalysis5" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction8" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep19">
 <bp:stepProcess rdf:resource="#Pathway11" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep957">
 <bp:stepProcess rdf:resource="#BiochemicalReaction766" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep18">
 <bp:stepProcess rdf:resource="#Catalysis6" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction9" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep958">
 <bp:stepProcess rdf:resource="#BiochemicalReaction767" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep951">
 <bp:stepProcess rdf:resource="#Pathway173" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1497">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1199" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep952">
 <bp:stepProcess rdf:resource="#BiochemicalReaction761" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1498">
 <bp:stepProcess rdf:resource="#Pathway262" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep11">
 <bp:stepProcess rdf:resource="#BiochemicalReaction6" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1499">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1200" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep10">
 <bp:stepProcess rdf:resource="#BiochemicalReaction5" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep950">
 <bp:stepProcess rdf:resource="#BiochemicalReaction760" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep13">
 <bp:stepProcess rdf:resource="#Pathway8" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep955">
 <bp:stepProcess rdf:resource="#BiochemicalReaction764" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1493">
 <bp:stepProcess rdf:resource="#Catalysis341" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1198" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep12">
 <bp:stepProcess rdf:resource="#Pathway7" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep956">
 <bp:stepProcess rdf:resource="#BiochemicalReaction765" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1494">
 <bp:stepProcess rdf:resource="#Pathway259" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep15">
 <bp:stepProcess rdf:resource="#Pathway9" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep953">
 <bp:stepProcess rdf:resource="#BiochemicalReaction762" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1495">
 <bp:stepProcess rdf:resource="#Pathway260" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep14">
 <bp:stepProcess rdf:resource="#BiochemicalReaction7" />
 <bp:stepProcess rdf:resource="#Catalysis4" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep954">
 <bp:stepProcess rdf:resource="#BiochemicalReaction763" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1496">
 <bp:stepProcess rdf:resource="#Pathway261" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep948">
 <bp:stepProcess rdf:resource="#Catalysis214" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction758" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep949">
 <bp:stepProcess rdf:resource="#BiochemicalReaction759" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep946">
 <bp:stepProcess rdf:resource="#BiochemicalReaction756" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep947">
 <bp:stepProcess rdf:resource="#BiochemicalReaction757" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep940">
 <bp:stepProcess rdf:resource="#Pathway172" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep941">
 <bp:stepProcess rdf:resource="#BiochemicalReaction751" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep944">
 <bp:stepProcess rdf:resource="#BiochemicalReaction754" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep945">
 <bp:stepProcess rdf:resource="#BiochemicalReaction755" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep942">
 <bp:stepProcess rdf:resource="#BiochemicalReaction752" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep943">
 <bp:stepProcess rdf:resource="#BiochemicalReaction753" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep995">
 <bp:stepProcess rdf:resource="#Catalysis220" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction801" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep996">
 <bp:stepProcess rdf:resource="#BiochemicalReaction802" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep993">
 <bp:stepProcess rdf:resource="#BiochemicalReaction799" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep994">
 <bp:stepProcess rdf:resource="#BiochemicalReaction800" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep999">
 <bp:stepProcess rdf:resource="#BiochemicalReaction805" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep997">
 <bp:stepProcess rdf:resource="#BiochemicalReaction803" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep998">
 <bp:stepProcess rdf:resource="#BiochemicalReaction804" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep991">
 <bp:stepProcess rdf:resource="#BiochemicalReaction797" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep992">
 <bp:stepProcess rdf:resource="#BiochemicalReaction798" />
 <bp:stepProcess rdf:resource="#Catalysis219" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep990">
 <bp:stepProcess rdf:resource="#BiochemicalReaction796" />
 <bp:stepProcess rdf:resource="#Catalysis218" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep984">
 <bp:stepProcess rdf:resource="#BiochemicalReaction790" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep985">
 <bp:stepProcess rdf:resource="#Catalysis216" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction791" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep982">
 <bp:stepProcess rdf:resource="#BiochemicalReaction788" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep983">
 <bp:stepProcess rdf:resource="#BiochemicalReaction789" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep988">
 <bp:stepProcess rdf:resource="#BiochemicalReaction794" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep989">
 <bp:stepProcess rdf:resource="#Catalysis217" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction795" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep986">
 <bp:stepProcess rdf:resource="#BiochemicalReaction792" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep987">
 <bp:stepProcess rdf:resource="#BiochemicalReaction793" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep71">
 <bp:stepProcess rdf:resource="#BiochemicalReaction42" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep70">
 <bp:stepProcess rdf:resource="#BiochemicalReaction41" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep73">
 <bp:stepProcess rdf:resource="#Catalysis15" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction44" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep72">
 <bp:stepProcess rdf:resource="#BiochemicalReaction43" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep75">
 <bp:stepProcess rdf:resource="#Catalysis16" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction46" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep74">
 <bp:stepProcess rdf:resource="#BiochemicalReaction45" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep77">
 <bp:stepProcess rdf:resource="#Pathway32" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep76">
 <bp:stepProcess rdf:resource="#Pathway31" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep79">
 <bp:stepProcess rdf:resource="#BiochemicalReaction48" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep78">
 <bp:stepProcess rdf:resource="#BiochemicalReaction47" />
 <bp:stepProcess rdf:resource="#Catalysis17" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep60">
 <bp:stepProcess rdf:resource="#BiochemicalReaction31" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep62">
 <bp:stepProcess rdf:resource="#BiochemicalReaction33" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep61">
 <bp:stepProcess rdf:resource="#BiochemicalReaction32" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep64">
 <bp:stepProcess rdf:resource="#BiochemicalReaction35" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep63">
 <bp:stepProcess rdf:resource="#BiochemicalReaction34" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep66">
 <bp:stepProcess rdf:resource="#BiochemicalReaction37" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep65">
 <bp:stepProcess rdf:resource="#BiochemicalReaction36" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep68">
 <bp:stepProcess rdf:resource="#BiochemicalReaction39" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep67">
 <bp:stepProcess rdf:resource="#BiochemicalReaction38" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep69">
 <bp:stepProcess rdf:resource="#BiochemicalReaction40" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep91">
 <bp:stepProcess rdf:resource="#BiochemicalReaction57" />
 <bp:stepProcess rdf:resource="#Catalysis21" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep90">
 <bp:stepProcess rdf:resource="#BiochemicalReaction56" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep93">
 <bp:stepProcess rdf:resource="#BiochemicalReaction59" />
 <bp:stepProcess rdf:resource="#Catalysis23" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep92">
 <bp:stepProcess rdf:resource="#Catalysis22" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction58" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep95">
 <bp:stepProcess rdf:resource="#BiochemicalReaction61" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep94">
 <bp:stepProcess rdf:resource="#Catalysis24" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction60" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep97">
 <bp:stepProcess rdf:resource="#Catalysis25" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction63" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep96">
 <bp:stepProcess rdf:resource="#BiochemicalReaction62" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep99">
 <bp:stepProcess rdf:resource="#BiochemicalReaction65" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep98">
 <bp:stepProcess rdf:resource="#BiochemicalReaction64" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep80">
 <bp:stepProcess rdf:resource="#BiochemicalReaction49" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep82">
 <bp:stepProcess rdf:resource="#BiochemicalReaction51" />
 <bp:stepProcess rdf:resource="#Catalysis19" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep81">
 <bp:stepProcess rdf:resource="#Catalysis18" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction50" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep84">
 <bp:stepProcess rdf:resource="#BiochemicalReaction53" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep83">
 <bp:stepProcess rdf:resource="#BiochemicalReaction52" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep86">
 <bp:stepProcess rdf:resource="#BiochemicalReaction55" />
 <bp:stepProcess rdf:resource="#Catalysis20" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep85">
 <bp:stepProcess rdf:resource="#BiochemicalReaction54" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep88">
 <bp:stepProcess rdf:resource="#Pathway34" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep87">
 <bp:stepProcess rdf:resource="#Pathway33" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep89">
 <bp:stepProcess rdf:resource="#Pathway35" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence1788">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1789">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep1509">
 <bp:stepProcess rdf:resource="#Pathway269" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1516">
 <bp:stepProcess rdf:resource="#Pathway273" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1517">
 <bp:stepProcess rdf:resource="#Catalysis343" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1207" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1518">
 <bp:stepProcess rdf:resource="#Catalysis344" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1208" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1519">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1209" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1512">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1205" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1513">
 <bp:stepProcess rdf:resource="#Pathway271" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1514">
 <bp:stepProcess rdf:resource="#Pathway272" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1515">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1206" />
 <bp:stepProcess rdf:resource="#Catalysis342" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence1790">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1791">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1792">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep1510">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1204" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence1793">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep1511">
 <bp:stepProcess rdf:resource="#Pathway270" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence1794">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1795">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1796">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1797">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1798">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1777">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1778">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1779">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep1527">
 <bp:stepProcess rdf:resource="#Catalysis348" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1215" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1528">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1216" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1529">
 <bp:stepProcess rdf:resource="#Catalysis349" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1217" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1523">
 <bp:stepProcess rdf:resource="#Pathway274" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1524">
 <bp:stepProcess rdf:resource="#Pathway275" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1525">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1213" />
 <bp:stepProcess rdf:resource="#Catalysis347" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1526">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1214" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence1780">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep1520">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1210" />
 <bp:stepProcess rdf:resource="#Catalysis345" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence1781">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep1521">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1211" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence1782">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep1522">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1212" />
 <bp:stepProcess rdf:resource="#Catalysis346" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence1783">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1784">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1785">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1786">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1787">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1799">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep1505">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1202" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1506">
 <bp:stepProcess rdf:resource="#Pathway267" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1507">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1203" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1508">
 <bp:stepProcess rdf:resource="#Pathway268" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1501">
 <bp:stepProcess rdf:resource="#Pathway264" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1502">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1201" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1503">
 <bp:stepProcess rdf:resource="#Pathway265" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1504">
 <bp:stepProcess rdf:resource="#Pathway266" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1500">
 <bp:stepProcess rdf:resource="#Pathway263" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence1744">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1745">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1746">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1747">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1748">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1749">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis733">
 <bp:controlled rdf:resource="#BiochemicalReaction1912" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis732">
 <bp:controlled rdf:resource="#BiochemicalReaction1910" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis735">
 <bp:controlled rdf:resource="#BiochemicalReaction1914" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis734">
 <bp:controlled rdf:resource="#BiochemicalReaction1913" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis731">
 <bp:controlled rdf:resource="#BiochemicalReaction1909" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis730">
 <bp:controlled rdf:resource="#BiochemicalReaction1905" />
</bp:Catalysis>

<bp:Evidence rdf:ID="Evidence1750">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1751">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis737">
 <bp:controlled rdf:resource="#BiochemicalReaction1916" />
</bp:Catalysis>

<bp:Evidence rdf:ID="Evidence1752">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis736">
 <bp:controlled rdf:resource="#BiochemicalReaction1915" />
</bp:Catalysis>

<bp:Evidence rdf:ID="Evidence1753">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis739">
 <bp:controlled rdf:resource="#BiochemicalReaction1918" />
</bp:Catalysis>

<bp:Evidence rdf:ID="Evidence1754">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis738">
 <bp:controlled rdf:resource="#BiochemicalReaction1917" />
</bp:Catalysis>

<bp:Evidence rdf:ID="Evidence1733">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1734">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1735">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1736">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1737">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1738">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1739">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis744">
 <bp:controlled rdf:resource="#BiochemicalReaction1939" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis743">
 <bp:controlled rdf:resource="#BiochemicalReaction1922" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis740">
 <bp:controlled rdf:resource="#BiochemicalReaction1919" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis742">
 <bp:controlled rdf:resource="#BiochemicalReaction1921" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis741">
 <bp:controlled rdf:resource="#BiochemicalReaction1920" />
</bp:Catalysis>

<bp:Evidence rdf:ID="Evidence1740">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1741">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1742">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1743">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1766">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1767">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1768">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1769">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1770">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1771">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1772">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1773">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1774">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1775">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1776">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1755">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1756">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1757">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1758">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1759">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1760">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1761">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1762">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1763">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1764">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1765">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1700">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1701">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep1590">
 <bp:stepProcess rdf:resource="#Pathway293" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence1702">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep1591">
 <bp:stepProcess rdf:resource="#Catalysis369" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1261" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence1703">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1704">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1705">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1706">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1707">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep4">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1" />
 <bp:stepProcess rdf:resource="#Catalysis1" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence1708">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep3">
 <bp:stepProcess rdf:resource="#Pathway4" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence1709">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep6">
 <bp:stepProcess rdf:resource="#Catalysis2" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction2" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep5">
 <bp:stepProcess rdf:resource="#Pathway5" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep8">
 <bp:stepProcess rdf:resource="#Pathway6" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep7">
 <bp:stepProcess rdf:resource="#BiochemicalReaction3" />
 <bp:stepProcess rdf:resource="#Catalysis3" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep9">
 <bp:stepProcess rdf:resource="#BiochemicalReaction4" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1596">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1266" />
 <bp:stepProcess rdf:resource="#Catalysis373" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1597">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1267" />
 <bp:stepProcess rdf:resource="#Catalysis374" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1598">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1268" />
 <bp:stepProcess rdf:resource="#Catalysis375" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1599">
 <bp:stepProcess rdf:resource="#Catalysis376" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1269" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1592">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1262" />
 <bp:stepProcess rdf:resource="#Catalysis370" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1593">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1263" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1594">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1264" />
 <bp:stepProcess rdf:resource="#Catalysis371" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1595">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1265" />
 <bp:stepProcess rdf:resource="#Catalysis372" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence1710">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1722">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1723">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1724">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1725">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1726">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1727">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1728">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1729">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep1578">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1254" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1579">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1255" />
 <bp:stepProcess rdf:resource="#Catalysis367" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1574">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1250" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1575">
 <bp:stepProcess rdf:resource="#Catalysis365" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1251" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1576">
 <bp:stepProcess rdf:resource="#Catalysis366" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1252" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1577">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1253" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1570">
 <bp:stepProcess rdf:resource="#Pathway285" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1571">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1249" />
 <bp:stepProcess rdf:resource="#Catalysis364" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence1730">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep1572">
 <bp:stepProcess rdf:resource="#Pathway286" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence1731">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep1573">
 <bp:stepProcess rdf:resource="#Pathway287" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence1732">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1711">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1712">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1713">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep1580">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1256" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence1714">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1715">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1716">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1717">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1718">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1719">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep1589">
 <bp:stepProcess rdf:resource="#Catalysis368" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1260" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1585">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1258" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1586">
 <bp:stepProcess rdf:resource="#Pathway291" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1587">
 <bp:stepProcess rdf:resource="#Pathway292" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1588">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1259" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1581">
 <bp:stepProcess rdf:resource="#Pathway288" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1582">
 <bp:stepProcess rdf:resource="#Pathway289" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1583">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1257" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence1720">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep1584">
 <bp:stepProcess rdf:resource="#Pathway290" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence1721">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep1556">
 <bp:stepProcess rdf:resource="#Catalysis359" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1236" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1557">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1237" />
 <bp:stepProcess rdf:resource="#Catalysis360" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1558">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1238" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1559">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1239" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1552">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1234" />
 <bp:stepProcess rdf:resource="#Catalysis357" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1553">
 <bp:stepProcess rdf:resource="#Pathway282" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1554">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1235" />
 <bp:stepProcess rdf:resource="#Catalysis358" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1555">
 <bp:stepProcess rdf:resource="#Pathway283" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1550">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1233" />
 <bp:stepProcess rdf:resource="#Catalysis356" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1551">
 <bp:stepProcess rdf:resource="#Pathway281" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1567">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1246" />
 <bp:stepProcess rdf:resource="#Catalysis363" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1568">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1247" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1569">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1248" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1563">
 <bp:stepProcess rdf:resource="#Pathway284" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1564">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1243" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1565">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1244" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1566">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1245" />
 <bp:stepProcess rdf:resource="#Catalysis362" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1560">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1240" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1561">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1241" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1562">
 <bp:stepProcess rdf:resource="#Catalysis361" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1242" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1538">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1224" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1539">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1225" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1534">
 <bp:stepProcess rdf:resource="#Catalysis350" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1220" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1535">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1221" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1536">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1222" />
 <bp:stepProcess rdf:resource="#Catalysis351" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1537">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1223" />
 <bp:stepProcess rdf:resource="#Catalysis352" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1530">
 <bp:stepProcess rdf:resource="#Pathway276" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1531">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1218" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1532">
 <bp:stepProcess rdf:resource="#Pathway277" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1533">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1219" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1549">
 <bp:stepProcess rdf:resource="#Pathway280" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1545">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1230" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1546">
 <bp:stepProcess rdf:resource="#Catalysis355" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1231" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2">
 <bp:stepProcess rdf:resource="#Pathway3" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1547">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1232" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1">
 <bp:stepProcess rdf:resource="#Pathway2" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1548">
 <bp:stepProcess rdf:resource="#Pathway279" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1541">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1226" />
 <bp:stepProcess rdf:resource="#Catalysis353" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1542">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1227" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1543">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1228" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1544">
 <bp:stepProcess rdf:resource="#Catalysis354" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1229" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1540">
 <bp:stepProcess rdf:resource="#Pathway278" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1192">
 <bp:stepProcess rdf:resource="#Catalysis273" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction965" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1193">
 <bp:stepProcess rdf:resource="#BiochemicalReaction966" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1194">
 <bp:stepProcess rdf:resource="#Catalysis274" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction967" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1195">
 <bp:stepProcess rdf:resource="#BiochemicalReaction968" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1190">
 <bp:stepProcess rdf:resource="#BiochemicalReaction964" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1191">
 <bp:stepProcess rdf:resource="#Pathway207" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1196">
 <bp:stepProcess rdf:resource="#BiochemicalReaction969" />
 <bp:stepProcess rdf:resource="#Catalysis275" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1197">
 <bp:stepProcess rdf:resource="#Pathway208" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1198">
 <bp:stepProcess rdf:resource="#BiochemicalReaction970" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1199">
 <bp:stepProcess rdf:resource="#BiochemicalReaction971" />
 <bp:stepProcess rdf:resource="#Catalysis276" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1170">
 <bp:stepProcess rdf:resource="#BiochemicalReaction948" />
 <bp:stepProcess rdf:resource="#Catalysis264" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1171">
 <bp:stepProcess rdf:resource="#BiochemicalReaction949" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1172">
 <bp:stepProcess rdf:resource="#Pathway203" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1173">
 <bp:stepProcess rdf:resource="#Pathway204" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1178">
 <bp:stepProcess rdf:resource="#BiochemicalReaction954" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1179">
 <bp:stepProcess rdf:resource="#Pathway205" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1174">
 <bp:stepProcess rdf:resource="#BiochemicalReaction950" />
 <bp:stepProcess rdf:resource="#Catalysis265" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1175">
 <bp:stepProcess rdf:resource="#BiochemicalReaction951" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1176">
 <bp:stepProcess rdf:resource="#BiochemicalReaction952" />
 <bp:stepProcess rdf:resource="#Catalysis266" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1177">
 <bp:stepProcess rdf:resource="#BiochemicalReaction953" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1181">
 <bp:stepProcess rdf:resource="#BiochemicalReaction956" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1182">
 <bp:stepProcess rdf:resource="#BiochemicalReaction957" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1183">
 <bp:stepProcess rdf:resource="#Catalysis268" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction958" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1184">
 <bp:stepProcess rdf:resource="#Catalysis269" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction959" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1180">
 <bp:stepProcess rdf:resource="#Catalysis267" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction955" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1189">
 <bp:stepProcess rdf:resource="#BiochemicalReaction963" />
 <bp:stepProcess rdf:resource="#Catalysis272" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1185">
 <bp:stepProcess rdf:resource="#Pathway206" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1186">
 <bp:stepProcess rdf:resource="#BiochemicalReaction960" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1187">
 <bp:stepProcess rdf:resource="#BiochemicalReaction961" />
 <bp:stepProcess rdf:resource="#Catalysis270" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1188">
 <bp:stepProcess rdf:resource="#BiochemicalReaction962" />
 <bp:stepProcess rdf:resource="#Catalysis271" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2480">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1819" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1150">
 <bp:stepProcess rdf:resource="#BiochemicalReaction931" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2481">
 <bp:stepProcess rdf:resource="#Pathway615" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1151">
 <bp:stepProcess rdf:resource="#Catalysis256" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction932" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2482">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1820" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1156">
 <bp:stepProcess rdf:resource="#BiochemicalReaction937" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2487">
 <bp:stepProcess rdf:resource="#Pathway618" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1157">
 <bp:stepProcess rdf:resource="#Pathway200" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2488">
 <bp:stepProcess rdf:resource="#Pathway619" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1158">
 <bp:stepProcess rdf:resource="#Catalysis257" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction938" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2489">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1823" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1159">
 <bp:stepProcess rdf:resource="#Catalysis258" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction939" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1152">
 <bp:stepProcess rdf:resource="#BiochemicalReaction933" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2483">
 <bp:stepProcess rdf:resource="#Pathway616" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1153">
 <bp:stepProcess rdf:resource="#BiochemicalReaction934" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2484">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1821" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1154">
 <bp:stepProcess rdf:resource="#BiochemicalReaction935" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2485">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1822" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1155">
 <bp:stepProcess rdf:resource="#BiochemicalReaction936" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2486">
 <bp:stepProcess rdf:resource="#Pathway617" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2490">
 <bp:stepProcess rdf:resource="#Pathway620" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1160">
 <bp:stepProcess rdf:resource="#Catalysis259" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction940" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2491">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1824" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1161">
 <bp:stepProcess rdf:resource="#BiochemicalReaction941" />
 <bp:stepProcess rdf:resource="#Catalysis260" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2492">
 <bp:stepProcess rdf:resource="#Pathway621" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1162">
 <bp:stepProcess rdf:resource="#BiochemicalReaction942" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2493">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1825" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1167">
 <bp:stepProcess rdf:resource="#BiochemicalReaction945" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2498">
 <bp:stepProcess rdf:resource="#Pathway624" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1168">
 <bp:stepProcess rdf:resource="#BiochemicalReaction946" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2499">
 <bp:stepProcess rdf:resource="#Pathway625" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1169">
 <bp:stepProcess rdf:resource="#Catalysis263" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction947" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1163">
 <bp:stepProcess rdf:resource="#BiochemicalReaction943" />
 <bp:stepProcess rdf:resource="#Catalysis261" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2494">
 <bp:stepProcess rdf:resource="#Pathway622" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1164">
 <bp:stepProcess rdf:resource="#Catalysis262" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction944" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2495">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1826" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1165">
 <bp:stepProcess rdf:resource="#Pathway201" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2496">
 <bp:stepProcess rdf:resource="#Pathway623" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1166">
 <bp:stepProcess rdf:resource="#Pathway202" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2497">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1827" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2460">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1809" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1138">
 <bp:stepProcess rdf:resource="#BiochemicalReaction920" />
 <bp:stepProcess rdf:resource="#Catalysis246" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2469">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1813" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1139">
 <bp:stepProcess rdf:resource="#Catalysis247" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction921" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1134">
 <bp:stepProcess rdf:resource="#Catalysis244" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction917" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2465">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1811" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1135">
 <bp:stepProcess rdf:resource="#Pathway198" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2466">
 <bp:stepProcess rdf:resource="#Pathway608" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1136">
 <bp:stepProcess rdf:resource="#BiochemicalReaction918" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2467">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1812" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1137">
 <bp:stepProcess rdf:resource="#Catalysis245" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction919" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2468">
 <bp:stepProcess rdf:resource="#Pathway609" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1130">
 <bp:stepProcess rdf:resource="#Catalysis240" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction913" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2461">
 <bp:stepProcess rdf:resource="#Pathway605" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1131">
 <bp:stepProcess rdf:resource="#Catalysis241" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction914" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2462">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1810" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1132">
 <bp:stepProcess rdf:resource="#BiochemicalReaction915" />
 <bp:stepProcess rdf:resource="#Catalysis242" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2463">
 <bp:stepProcess rdf:resource="#Pathway606" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1133">
 <bp:stepProcess rdf:resource="#BiochemicalReaction916" />
 <bp:stepProcess rdf:resource="#Catalysis243" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2464">
 <bp:stepProcess rdf:resource="#Pathway607" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2470">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1814" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1140">
 <bp:stepProcess rdf:resource="#Catalysis248" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction922" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2471">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1815" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1149">
 <bp:stepProcess rdf:resource="#BiochemicalReaction930" />
 <bp:stepProcess rdf:resource="#Catalysis255" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1145">
 <bp:stepProcess rdf:resource="#BiochemicalReaction927" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2476">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1817" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1146">
 <bp:stepProcess rdf:resource="#Pathway199" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2477">
 <bp:stepProcess rdf:resource="#Pathway613" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1147">
 <bp:stepProcess rdf:resource="#BiochemicalReaction928" />
 <bp:stepProcess rdf:resource="#Catalysis253" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2478">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1818" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1148">
 <bp:stepProcess rdf:resource="#BiochemicalReaction929" />
 <bp:stepProcess rdf:resource="#Catalysis254" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2479">
 <bp:stepProcess rdf:resource="#Pathway614" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1141">
 <bp:stepProcess rdf:resource="#Catalysis249" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction923" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2472">
 <bp:stepProcess rdf:resource="#Pathway610" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1142">
 <bp:stepProcess rdf:resource="#BiochemicalReaction924" />
 <bp:stepProcess rdf:resource="#Catalysis250" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2473">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1816" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1143">
 <bp:stepProcess rdf:resource="#Catalysis251" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction925" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2474">
 <bp:stepProcess rdf:resource="#Pathway611" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1144">
 <bp:stepProcess rdf:resource="#Catalysis252" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction926" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2475">
 <bp:stepProcess rdf:resource="#Pathway612" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction831">
 <bp:evidence rdf:resource="#Evidence1009" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">N binds to heme</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction832">
 <bp:evidence rdf:resource="#Evidence1011" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Association of Cx43 with TJP1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction830">
 <bp:evidence rdf:resource="#Evidence1008" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SARS-CoV-2 3a tetramer binds to CAV1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction839">
 <bp:evidence rdf:resource="#Evidence1019" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">AP2 binds chlorpromazine</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction837">
 <bp:evidence rdf:resource="#Evidence1017" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">CRBN binds IMiDs</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction838">
 <bp:evidence rdf:resource="#Evidence1018" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">IFNAR1:TYK2 binds TYK2 inhibitors</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction835">
 <bp:evidence rdf:resource="#Evidence1014" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SARS-CoV-2 E pentamer binds TJP1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction836">
 <bp:evidence rdf:resource="#Evidence1016" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">CYSLTR1 binds CYSLTR1 antagonists</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction833">
 <bp:evidence rdf:resource="#Evidence1012" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MPP5 binds SARS-CoV-2 E pentamer</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction834">
 <bp:evidence rdf:resource="#Evidence1013" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Crumbs forms a ternary complex with Pals1 and PATJ at tight junctions</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction820">
 <bp:evidence rdf:resource="#Evidence996" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SARS-CoV-2 3CLpro dimer cleaves TAB1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction821">
 <bp:evidence rdf:resource="#Evidence997" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SARS-CoV-2 N binds NLRP3</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction828">
 <bp:evidence rdf:resource="#Evidence1006" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SARS-CoV-2 N binds to 14-3-3 proteins</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction829">
 <bp:evidence rdf:resource="#Evidence1007" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SARS-CoV-2 M, N bind to PDPK1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction826">
 <bp:evidence rdf:resource="#Evidence1003" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SARS-CoV-2 M protein binds MAP1LC3B</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction827">
 <bp:evidence rdf:resource="#Evidence1005" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">PDPK1 phosphorylates AKT at T308</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction824">
 <bp:evidence rdf:resource="#Evidence1001" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SARS-CoV-2 3a tetramer binds to VPS39 within HOPS complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction825">
 <bp:evidence rdf:resource="#Evidence1002" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SARS-CoV-2 3a binds to UVRAG</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction822">
 <bp:evidence rdf:resource="#Evidence999" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SARS-CoV-2 M protein binds TUFM</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction823">
 <bp:evidence rdf:resource="#Evidence1000" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SARS-COV 7a translocates to the late endosome membrane</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction819">
 <bp:evidence rdf:resource="#Evidence995" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TBK1, IKBKE are autophosphorylated at Ser172</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction853">
 <bp:evidence rdf:resource="#Evidence1033" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NS5B binds ribavirin</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction854">
 <bp:evidence rdf:resource="#Evidence1034" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TBK1 binds amlexanox</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction851">
 <bp:evidence rdf:resource="#Evidence1031" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">C-ter TLR9 dimer binds HCQ</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction852">
 <bp:evidence rdf:resource="#Evidence1032" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FKBP1A binds sirolimus</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction850">
 <bp:evidence rdf:resource="#Evidence1030" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TUBB binds colchicine</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction859">
 <bp:evidence rdf:resource="#Evidence1039" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">IFNAR2:JAK1:STAT2 binds type 1 interferon analogs</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction857">
 <bp:evidence rdf:resource="#Evidence1037" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NR3C1 binds NR3C1 agonists</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction858">
 <bp:evidence rdf:resource="#Evidence1038" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FNTB inhibitors bind FNTA:FNTB</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction855">
 <bp:evidence rdf:resource="#Evidence1035" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SIGMAR1 binds dextromethorphan</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction856">
 <bp:evidence rdf:resource="#Evidence1036" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">IL6R binds IL6R inhibitors</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction842">
 <bp:evidence rdf:resource="#Evidence1022" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FURIN binds furin inhibitors</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction843">
 <bp:evidence rdf:resource="#Evidence1023" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">BRD4 binds fedratinib</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction840">
 <bp:evidence rdf:resource="#Evidence1020" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">IFNAR2:JAK1:STAT2 binds JAK1,2 inhibitors</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction841">
 <bp:evidence rdf:resource="#Evidence1021" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NFE2L2 inducers bind to KEAP1:CUL3:RBX1:NFE2L2</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction848">
 <bp:evidence rdf:resource="#Evidence1028" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">IMPDH tetramers binds IMPDH inhibitors</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction849">
 <bp:evidence rdf:resource="#Evidence1029" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">S1PR1 binds S1PR1 agonists</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction846">
 <bp:evidence rdf:resource="#Evidence1026" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">BTK binds BTK inhibitors</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction847">
 <bp:evidence rdf:resource="#Evidence1027" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FKBP1A binds tacrolimus</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction844">
 <bp:evidence rdf:resource="#Evidence1024" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">COMT binds COMT Inhibitors</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction845">
 <bp:evidence rdf:resource="#Evidence1025" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">RIPK1 binds ponatinib</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction810">
 <bp:evidence rdf:resource="#Evidence986" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">DDX58 binds SARS-CoV-2 dsRNA intermediates</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction817">
 <bp:evidence rdf:resource="#Evidence993" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SARS-CoV-2 N protein binds STAT1, STAT2</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction818">
 <bp:evidence rdf:resource="#Evidence994" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TLR2:TLR1 binds SARS-CoV-2 E pentamer</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction815">
 <bp:evidence rdf:resource="#Evidence991" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SARS-CoV-2 N binds TAK1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction816">
 <bp:evidence rdf:resource="#Evidence992" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated TAK1 mediates phosphorylation of the IKK Complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction813">
 <bp:evidence rdf:resource="#Evidence989" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SARS-CoV-2 N binds MAVS</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction814">
 <bp:evidence rdf:resource="#Evidence990" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SARS-CoV-2 nsp3 deISGylates ISGylated IFIH1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction811">
 <bp:evidence rdf:resource="#Evidence987" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SARS-CoV-2 nsp13 binds TBK1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction812">
 <bp:evidence rdf:resource="#Evidence988" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SARS-CoV-2 3a binds to STING</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction808">
 <bp:evidence rdf:resource="#Evidence984" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SARS-CoV-2 E pentamer transports Ca2+ </bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction809">
 <bp:evidence rdf:resource="#Evidence985" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">IFIH1:TKFC binds SARS-CoV-2 dsRNA intermediates </bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction99">
 <bp:evidence rdf:resource="#Evidence139" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">iRHOM2 transports ADAM17 from ER to the Golgi-network</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction806">
 <bp:evidence rdf:resource="#Evidence982" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SARS-CoV-2 nsp3 deISGylates ISGylated IRF3</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction807">
 <bp:evidence rdf:resource="#Evidence983" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">LARP1 binds SARS-CoV-2 RNA</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction804">
 <bp:evidence rdf:resource="#Evidence980" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">C-ter TLR7 dimer binds SARS-CoV-2 GU-rich ssRNA</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction805">
 <bp:evidence rdf:resource="#Evidence981" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SARS-CoV-2 nsp6 binds TBK1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction802">
 <bp:evidence rdf:resource="#Evidence978" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SARS-CoV-2 M binds TBK1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction803">
 <bp:evidence rdf:resource="#Evidence979" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TBK1/IKK epsilon complex interacts with MAVS bound TRAF3</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction800">
 <bp:evidence rdf:resource="#Evidence976" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SARS-CoV-2 N binds to G3BP1,G3BP2</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction801">
 <bp:evidence rdf:resource="#Evidence977" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">DDX58 is K63 polyubiquitinated</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction88">
 <bp:evidence rdf:resource="#Evidence126" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">cAMP binds PKA tetramer</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction89">
 <bp:evidence rdf:resource="#Evidence127" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">IL6 gene produces IL6 protein</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction90">
 <bp:evidence rdf:resource="#Evidence128" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">PKA catalytic subunit translocates to the nucleus</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction95">
 <bp:evidence rdf:resource="#Evidence134" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">GGT1, 5 dimers hydrolyse LTC4 to LTD4</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction96">
 <bp:evidence rdf:resource="#Evidence135" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">LTD4 is converted to LTE4 by DPEP1/2</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction97">
 <bp:evidence rdf:resource="#Evidence136" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">LTC4 binds CyslTR1,2</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction98">
 <bp:evidence rdf:resource="#Evidence138" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">CD163 gene produces CD163 protein</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction91">
 <bp:evidence rdf:resource="#Evidence129" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">cAMP induces dissociation of inactive PKA tetramers</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction92">
 <bp:evidence rdf:resource="#Evidence130" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Adenylate cyclase converts ATP to 3&apos;,5&apos;-cyclic AMP (cAMP) and pyrophosphate</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction93">
 <bp:evidence rdf:resource="#Evidence131" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">G alpha (s) activates adenylate cyclase</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction94">
 <bp:evidence rdf:resource="#Evidence132" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ADORA2B:Ade-Rib:GsGTP dissociates</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence1898">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1899">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction77">
 <bp:evidence rdf:resource="#Evidence112" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">RAC1:GTP and PIP3 bind WAVE Regulatory Complex (WRC)</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction78">
 <bp:evidence rdf:resource="#Evidence113" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">IgG:Lma antigens binds FCGR3A:CD3 dimers</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction79">
 <bp:evidence rdf:resource="#Evidence114" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">(WASPs, WAVE):G-actin:ARP2/3 binds F-actin</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction84">
 <bp:evidence rdf:resource="#Evidence122" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">PKA phosphorylates CREB1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction85">
 <bp:evidence rdf:resource="#Evidence123" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ADORA2B binds Ade-Rib</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction86">
 <bp:evidence rdf:resource="#Evidence124" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ADORA2B (in Ade-Rib:ADORA2B:Heterotrimeric G-protein Gs) exchanges GDP for GTP on Gs</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction87">
 <bp:evidence rdf:resource="#Evidence125" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">CREB binds IL6 promoter</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction80">
 <bp:evidence rdf:resource="#Evidence115" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">p-ERK phosphorylates WAVEs and ABI</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction81">
 <bp:evidence rdf:resource="#Evidence116" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SYK binds IgG:Lma antigens:FCGR3A:p-CD3 dimers</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction82">
 <bp:evidence rdf:resource="#Evidence117" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Src phosphorylates CD3 dimers in IgG:Lma antigens:FCGR3A:CD3 dimers</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction83">
 <bp:evidence rdf:resource="#Evidence121" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ADORA2B:Ade-Rib binds heterometric G-protein Gs</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction66">
 <bp:evidence rdf:resource="#Evidence101" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activation of WASP and N-WASP by CDC42</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction67">
 <bp:evidence rdf:resource="#Evidence102" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Detachment of WASP/WAVE</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction68">
 <bp:evidence rdf:resource="#Evidence103" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">An unknown GEF exchanges GTP for GDP on CDC42:GDP</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction69">
 <bp:evidence rdf:resource="#Evidence104" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">WIP binds WASP,N-WASP, activating them</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction73">
 <bp:evidence rdf:resource="#Evidence108" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">VAV1,2,3:PI(3,4,5)P3 binds p-6Y-SYK</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction74">
 <bp:evidence rdf:resource="#Evidence109" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">PI(3,4,5)P3 binds VAV1,2,3</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction75">
 <bp:evidence rdf:resource="#Evidence110" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">IgG:Leishmania surface:FCGR3A translocates from plasma membrane to the parasitophorous vacuole</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction76">
 <bp:evidence rdf:resource="#Evidence111" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Extension of pseudopodia by myosin-X in a PI3K dependent manner</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction70">
 <bp:evidence rdf:resource="#Evidence105" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">CDC42:GTP binds PtdIns(4,5)P2:WASP,N-WASP</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction71">
 <bp:evidence rdf:resource="#Evidence106" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Src phosphorylate SYK in IgG:Leishmania surface:p-FCGR3A:SYK</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction72">
 <bp:evidence rdf:resource="#Evidence107" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">IgG binds the surface of the amastigote form of Leishmania</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction59">
 <bp:evidence rdf:resource="#Evidence94" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">p-VAV1,2,3 exchanges GTP for GDP on RAC1:GDP</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction55">
 <bp:evidence rdf:resource="#Evidence87" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Unknown kinase phosphorylates p-DVL</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction56">
 <bp:evidence rdf:resource="#Evidence91" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Branching and elongation of mother and daughter filaments</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction57">
 <bp:evidence rdf:resource="#Evidence92" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ABL phosphorylates WAVEs</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction58">
 <bp:evidence rdf:resource="#Evidence93" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">DOCK180 exchanges GTP for GDP on RAC1:GDP</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction62">
 <bp:evidence rdf:resource="#Evidence97" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">WASPs or WAVEs activate the ARP2/3 complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction63">
 <bp:evidence rdf:resource="#Evidence98" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Src phosphorylate WASP,N-WASP</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction64">
 <bp:evidence rdf:resource="#Evidence99" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">PtdIns(4,5)P2 binds WASP, N-WASP</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction65">
 <bp:evidence rdf:resource="#Evidence100" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">IgG binds LPG1G2 in the amastigote form of Leishmania</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction60">
 <bp:evidence rdf:resource="#Evidence95" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">p-6Y-SYK phosphorylates VAV1,2,3</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction61">
 <bp:evidence rdf:resource="#Evidence96" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">CRKII:DOCK180:ELMO binds FCGR3A</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction48">
 <bp:evidence rdf:resource="#Evidence80" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ppDVL binds RAC1:GTP</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction875">
 <bp:evidence rdf:resource="#Evidence1058" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">EsxA binds TLR2</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence1865">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction49">
 <bp:evidence rdf:resource="#Evidence81" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">p-T,Y-MAPK8 translocates from the cytosol to the nucleoplasm</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction876">
 <bp:evidence rdf:resource="#Evidence1059" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">EsxA binds B2M</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence1866">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction873">
 <bp:evidence rdf:resource="#Evidence1056" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Rv2779c binds TLR2</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence1867">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction874">
 <bp:evidence rdf:resource="#Evidence1057" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">PstS1 binds MRC1</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence1868">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction44">
 <bp:evidence rdf:resource="#Evidence74" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NT5E:Zn2+ hydrolyses NMN</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction871">
 <bp:evidence rdf:resource="#Evidence1051" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">HDAC1:2-containing complex binds HDAC2 Inhibitors</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence1869">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction45">
 <bp:evidence rdf:resource="#Evidence75" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">C3a receptor binds anaphylatoxin C3a</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction872">
 <bp:evidence rdf:resource="#Evidence1055" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">PtpA binds Ubiquitin</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction46">
 <bp:evidence rdf:resource="#Evidence76" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">CTSG cleaves CASP1(1-404)</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction47">
 <bp:evidence rdf:resource="#Evidence79" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated JNK phosphorylates c-JUN</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction870">
 <bp:evidence rdf:resource="#Evidence1050" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SIGMAR1 binds fluvoxamine</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction879">
 <bp:evidence rdf:resource="#Evidence1063" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">RNAP transcribes Mtb RNA polyanion</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction877">
 <bp:evidence rdf:resource="#Evidence1060" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">EsxA translocates from Mtb cytosol to the host&apos;s ER</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction878">
 <bp:evidence rdf:resource="#Evidence1062" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective RpoB in Mtb RNAP transcribes RNA polyanion</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction51">
 <bp:evidence rdf:resource="#Evidence83" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NOX1 complex:pp-DVL:RAC1:GTP generates superoxide from oxygen</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction52">
 <bp:evidence rdf:resource="#Evidence84" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">WNT5 binds FZD7</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction53">
 <bp:evidence rdf:resource="#Evidence85" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">WNT5:FZD7 binds p-DVL</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence1870">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction54">
 <bp:evidence rdf:resource="#Evidence86" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ppDVL:RAC1:GTP binds NOX1 complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence1871">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1872">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1873">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1874">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction50">
 <bp:evidence rdf:resource="#Evidence82" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">GTP-bound RAC1 contributes to MAPK8 activation</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence1875">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction37">
 <bp:evidence rdf:resource="#Evidence67" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NLRP3 recruits PYCARD (ASC) via a PYD-PYD interaction</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction864">
 <bp:evidence rdf:resource="#Evidence1044" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">PDCD1 binds PDCD1 inhibitors</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence1854">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction38">
 <bp:evidence rdf:resource="#Evidence68" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TXNIP binds reduced thioredoxin</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction865">
 <bp:evidence rdf:resource="#Evidence1045" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ITGA4:ITGB1 binds natalizumab</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence1855">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction39">
 <bp:evidence rdf:resource="#Evidence69" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SGT1 binds HSP90</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction862">
 <bp:evidence rdf:resource="#Evidence1042" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">JAK3 binds JAK3 inhibitors</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence1856">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction863">
 <bp:evidence rdf:resource="#Evidence1043" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ROCK1,2 bind ROCKi</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence1857">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction33">
 <bp:evidence rdf:resource="#Evidence63" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TXNIP binds NLRP3</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction860">
 <bp:evidence rdf:resource="#Evidence1040" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">C-ter TLR7 dimer binds HCQ</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence1858">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction34">
 <bp:evidence rdf:resource="#Evidence64" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Expression of NLRP3 gene</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction861">
 <bp:evidence rdf:resource="#Evidence1041" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">VEGFA-165 dimer binds VEGFA inhibitors</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence1859">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction35">
 <bp:evidence rdf:resource="#Evidence65" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SGT1:HSP90 binds inactive NLRP3</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction36">
 <bp:evidence rdf:resource="#Evidence66" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NLRP3 activation by small molecules</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction868">
 <bp:evidence rdf:resource="#Evidence1048" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ACE2 is glycosylated to glycosylated-ACE2</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction869">
 <bp:evidence rdf:resource="#Evidence1049" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ATP1A:ATP1B:FXYD binds cardiac glycosides</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction866">
 <bp:evidence rdf:resource="#Evidence1046" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">IL1R1 binds IL1R1 inhibitors</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction867">
 <bp:evidence rdf:resource="#Evidence1047" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">IFNGR1:JAK1:INFGR2:JAK2 binds JAK1,2 inhibitors</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction40">
 <bp:evidence rdf:resource="#Evidence70" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">PYCARD recruits procaspase-1 via CARD</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction41">
 <bp:evidence rdf:resource="#Evidence71" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ATP translocates from cytosol to extracellular space (stimuated by C3AR1:C3a)</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction42">
 <bp:evidence rdf:resource="#Evidence72" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ATP binds P2RX4,7</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction43">
 <bp:evidence rdf:resource="#Evidence73" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Interleukin-1 family are secreted</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence1860">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1861">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1862">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1863">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1864">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction26">
 <bp:evidence rdf:resource="#Evidence56" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ROS oxidize thioredoxin</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction897">
 <bp:evidence rdf:resource="#Evidence1090" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">LpdC binds to CORO1A</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence1887">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction27">
 <bp:evidence rdf:resource="#Evidence57" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NTPDase5 hydrolyzes nucleoside diphosphates</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction898">
 <bp:evidence rdf:resource="#Evidence1091" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">LprG dissociates from LAM,LM</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence1888">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction28">
 <bp:evidence rdf:resource="#Evidence58" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Interleukin-1 family precursors are cleaved by caspase-1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction895">
 <bp:evidence rdf:resource="#Evidence1086" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">EsxA binds PGK1</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence1889">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction29">
 <bp:evidence rdf:resource="#Evidence59" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NTPDase1 hydrolyzes nucleoside triphosphates</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction896">
 <bp:evidence rdf:resource="#Evidence1089" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NdkA dephosphorylates RAB5A:GTP,RAB7A:GTP</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction22">
 <bp:evidence rdf:resource="#Evidence46" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">GP1BA variant binds to VWF multimer:collagen</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction893">
 <bp:evidence rdf:resource="#Evidence1083" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Rv3364c binds cathepsin G</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction23">
 <bp:evidence rdf:resource="#Evidence48" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">VWF variant does not bind to collagen type I </bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction894">
 <bp:evidence rdf:resource="#Evidence1085" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">EsxA binds ENO1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction24">
 <bp:evidence rdf:resource="#Evidence54" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TXNIP is released from oxidized thioredoxin</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction891">
 <bp:evidence rdf:resource="#Evidence1081" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Rv3654c binds SFPQ</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction25">
 <bp:evidence rdf:resource="#Evidence55" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Pyrin binds ASC</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction892">
 <bp:evidence rdf:resource="#Evidence1082" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Mce3E binds MAPK3</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction899">
 <bp:evidence rdf:resource="#Evidence1092" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">LprG binds to LAM,LM</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence1890">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction30">
 <bp:evidence rdf:resource="#Evidence60" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Caspase-1 active tetramer formation</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction890">
 <bp:evidence rdf:resource="#Evidence1080" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">PtpA dephosphorylates GSK3A</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence1891">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction31">
 <bp:evidence rdf:resource="#Evidence61" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">PSTPIP1 binds Pyrin</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence1892">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction32">
 <bp:evidence rdf:resource="#Evidence62" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">P2RX4,7 binds itself to form trimeric non-selective cation channels</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence1893">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1894">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1895">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1896">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1897">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction15">
 <bp:evidence rdf:resource="#Evidence32" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">F8 variant is not cleaved by thrombin</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction886">
 <bp:evidence rdf:resource="#Evidence1075" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Eis acetylates DUSP16</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence1876">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction16">
 <bp:evidence rdf:resource="#Evidence34" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">F8 variant is not sulfonated at Y1699</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction887">
 <bp:evidence rdf:resource="#Evidence1077" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Mce3E binds MAPK1</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence1877">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction17">
 <bp:evidence rdf:resource="#Evidence36" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defects in F8 A2 domain accelerate dissociation of the A2 domain</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction884">
 <bp:evidence rdf:resource="#Evidence1072" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">EsxG:EsxH binds HGS</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence1878">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction18">
 <bp:evidence rdf:resource="#Evidence37" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defects in F8 A1 domain accelerate dissociation of the A2 domain</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction885">
 <bp:evidence rdf:resource="#Evidence1074" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SapM binds RAB7A</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence1879">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction11">
 <bp:evidence rdf:resource="#Evidence24" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FVIIIa variant:FIXa does not convert FX to the active FXa</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction882">
 <bp:evidence rdf:resource="#Evidence1070" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">EsxG binds esxH</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction12">
 <bp:evidence rdf:resource="#Evidence26" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">F8 variant is not secreted</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction883">
 <bp:evidence rdf:resource="#Evidence1071" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">EsxG:EsxH translocates from MTb cytosol to host phagosomal lumen</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction13">
 <bp:evidence rdf:resource="#Evidence28" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">F8 variant does not bind von Willebrand factor</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction880">
 <bp:evidence rdf:resource="#Evidence1064" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Rifampicin binds Mtb RNAP</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction14">
 <bp:evidence rdf:resource="#Evidence30" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">F8 variant does not bind the cell membrane</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction881">
 <bp:evidence rdf:resource="#Evidence1067" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">CpnT hydrolyses NAD+</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction19">
 <bp:evidence rdf:resource="#Evidence40" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">VWF variant does not bind GPIb:IX:V</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction888">
 <bp:evidence rdf:resource="#Evidence1078" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">PtpA binds TRIM27</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction889">
 <bp:evidence rdf:resource="#Evidence1079" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Rv3655c binds RNF213</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence1880">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction20">
 <bp:evidence rdf:resource="#Evidence42" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ADAMTS13 cleaves VWF variant multimer</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence1881">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction21">
 <bp:evidence rdf:resource="#Evidence44" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ADAMTS13 variant does not cleave VWF multimer</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence1882">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1883">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1884">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1885">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1886">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1821">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1822">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1823">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1824">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1825">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1826">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1827">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1828">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1829">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep1237">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1004" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2568">
 <bp:stepProcess rdf:resource="#Catalysis686" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1858" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1238">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1005" />
 <bp:stepProcess rdf:resource="#Catalysis294" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2569">
 <bp:stepProcess rdf:resource="#Pathway662" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1239">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1006" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1233">
 <bp:stepProcess rdf:resource="#BiochemicalReaction842" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2564">
 <bp:stepProcess rdf:resource="#Catalysis684" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1856" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1234">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1001" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2565">
 <bp:stepProcess rdf:resource="#Pathway660" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1235">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1002" />
 <bp:stepProcess rdf:resource="#Catalysis293" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2566">
 <bp:stepProcess rdf:resource="#Catalysis685" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1857" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction10">
 <bp:evidence rdf:resource="#Evidence21" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">F9 variant is not secreted</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep1236">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1003" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2567">
 <bp:stepProcess rdf:resource="#Pathway661" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2560">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1854" />
 <bp:stepProcess rdf:resource="#Catalysis682" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1230">
 <bp:stepProcess rdf:resource="#BiochemicalReaction998" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2561">
 <bp:stepProcess rdf:resource="#Pathway658" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1231">
 <bp:stepProcess rdf:resource="#Catalysis291" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction999" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence1830">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep2562">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1855" />
 <bp:stepProcess rdf:resource="#Catalysis683" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1232">
 <bp:stepProcess rdf:resource="#Catalysis292" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1000" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence1831">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep2563">
 <bp:stepProcess rdf:resource="#Pathway659" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence1810">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1811">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1812">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1813">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep2570">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1840" />
 <bp:stepProcess rdf:resource="#Catalysis668" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence1814">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1815">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1816">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1817">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1818">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1819">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep1248">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1012" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2579">
 <bp:stepProcess rdf:resource="#Pathway667" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1249">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1013" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1244">
 <bp:stepProcess rdf:resource="#Pathway214" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2575">
 <bp:stepProcess rdf:resource="#Pathway665" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1245">
 <bp:stepProcess rdf:resource="#Pathway215" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2576">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1861" />
 <bp:stepProcess rdf:resource="#Catalysis689" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1246">
 <bp:stepProcess rdf:resource="#Catalysis296" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1010" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2577">
 <bp:stepProcess rdf:resource="#Pathway666" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1247">
 <bp:stepProcess rdf:resource="#Catalysis297" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1011" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2578">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1862" />
 <bp:stepProcess rdf:resource="#Catalysis690" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1240">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1007" />
 <bp:stepProcess rdf:resource="#Catalysis295" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2571">
 <bp:stepProcess rdf:resource="#Pathway663" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1241">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1008" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2572">
 <bp:stepProcess rdf:resource="#Catalysis687" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1859" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1242">
 <bp:stepProcess rdf:resource="#Pathway213" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2573">
 <bp:stepProcess rdf:resource="#Pathway664" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1243">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1009" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence1820">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep2574">
 <bp:stepProcess rdf:resource="#Catalysis688" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1860" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence1843">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1844">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1845">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1846">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1847">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1848">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1849">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep1219">
 <bp:stepProcess rdf:resource="#Catalysis284" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction988" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1215">
 <bp:stepProcess rdf:resource="#Pathway211" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2546">
 <bp:stepProcess rdf:resource="#Catalysis676" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1848" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1216">
 <bp:stepProcess rdf:resource="#BiochemicalReaction985" />
 <bp:stepProcess rdf:resource="#Catalysis283" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2547">
 <bp:stepProcess rdf:resource="#Pathway651" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1217">
 <bp:stepProcess rdf:resource="#BiochemicalReaction986" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2548">
 <bp:stepProcess rdf:resource="#Catalysis677" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1849" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1218">
 <bp:stepProcess rdf:resource="#BiochemicalReaction987" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2549">
 <bp:stepProcess rdf:resource="#Pathway652" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1211">
 <bp:stepProcess rdf:resource="#BiochemicalReaction981" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2542">
 <bp:stepProcess rdf:resource="#Pathway494" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1212">
 <bp:stepProcess rdf:resource="#BiochemicalReaction982" />
 <bp:stepProcess rdf:resource="#Catalysis281" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2543">
 <bp:stepProcess rdf:resource="#Pathway649" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1213">
 <bp:stepProcess rdf:resource="#BiochemicalReaction983" />
 <bp:stepProcess rdf:resource="#Catalysis282" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2544">
 <bp:stepProcess rdf:resource="#Catalysis675" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1847" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1214">
 <bp:stepProcess rdf:resource="#BiochemicalReaction984" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2545">
 <bp:stepProcess rdf:resource="#Pathway650" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence1850">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1851">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1852">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep2540">
 <bp:stepProcess rdf:resource="#Pathway648" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1210">
 <bp:stepProcess rdf:resource="#BiochemicalReaction980" />
 <bp:stepProcess rdf:resource="#Catalysis280" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence1853">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep2541">
 <bp:stepProcess rdf:resource="#Catalysis674" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1846" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence1832">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1833">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1834">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1835">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1836">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1837">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1838">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1839">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep1226">
 <bp:stepProcess rdf:resource="#BiochemicalReaction994" />
 <bp:stepProcess rdf:resource="#Catalysis288" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2557">
 <bp:stepProcess rdf:resource="#Pathway656" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1227">
 <bp:stepProcess rdf:resource="#BiochemicalReaction995" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2558">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1853" />
 <bp:stepProcess rdf:resource="#Catalysis681" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1228">
 <bp:stepProcess rdf:resource="#BiochemicalReaction996" />
 <bp:stepProcess rdf:resource="#Catalysis289" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2559">
 <bp:stepProcess rdf:resource="#Pathway657" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1229">
 <bp:stepProcess rdf:resource="#BiochemicalReaction997" />
 <bp:stepProcess rdf:resource="#Catalysis290" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1222">
 <bp:stepProcess rdf:resource="#BiochemicalReaction990" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2553">
 <bp:stepProcess rdf:resource="#Pathway654" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1223">
 <bp:stepProcess rdf:resource="#BiochemicalReaction991" />
 <bp:stepProcess rdf:resource="#Catalysis285" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2554">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1851" />
 <bp:stepProcess rdf:resource="#Catalysis679" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1224">
 <bp:stepProcess rdf:resource="#BiochemicalReaction992" />
 <bp:stepProcess rdf:resource="#Catalysis286" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2555">
 <bp:stepProcess rdf:resource="#Pathway655" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1225">
 <bp:stepProcess rdf:resource="#BiochemicalReaction993" />
 <bp:stepProcess rdf:resource="#Catalysis287" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2556">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1852" />
 <bp:stepProcess rdf:resource="#Catalysis680" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence1840">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep2550">
 <bp:stepProcess rdf:resource="#Catalysis676" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1848" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1220">
 <bp:stepProcess rdf:resource="#BiochemicalReaction989" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence1841">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep2551">
 <bp:stepProcess rdf:resource="#Pathway653" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1221">
 <bp:stepProcess rdf:resource="#Pathway212" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence1842">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep2552">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1850" />
 <bp:stepProcess rdf:resource="#Catalysis678" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2528">
 <bp:stepProcess rdf:resource="#Pathway642" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2529">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1840" />
 <bp:stepProcess rdf:resource="#Catalysis668" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2524">
 <bp:stepProcess rdf:resource="#Pathway640" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2525">
 <bp:stepProcess rdf:resource="#Catalysis666" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1838" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2526">
 <bp:stepProcess rdf:resource="#Pathway641" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2527">
 <bp:stepProcess rdf:resource="#Catalysis667" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1839" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2520">
 <bp:stepProcess rdf:resource="#Pathway637" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2521">
 <bp:stepProcess rdf:resource="#Pathway638" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2522">
 <bp:stepProcess rdf:resource="#Pathway639" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2523">
 <bp:stepProcess rdf:resource="#Catalysis665" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1837" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1208">
 <bp:stepProcess rdf:resource="#BiochemicalReaction979" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2539">
 <bp:stepProcess rdf:resource="#Catalysis673" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1845" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1209">
 <bp:stepProcess rdf:resource="#Pathway210" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1204">
 <bp:stepProcess rdf:resource="#BiochemicalReaction975" />
 <bp:stepProcess rdf:resource="#Catalysis278" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2535">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1843" />
 <bp:stepProcess rdf:resource="#Catalysis671" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1205">
 <bp:stepProcess rdf:resource="#Catalysis279" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction976" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2536">
 <bp:stepProcess rdf:resource="#Pathway646" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1206">
 <bp:stepProcess rdf:resource="#BiochemicalReaction977" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2537">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1844" />
 <bp:stepProcess rdf:resource="#Catalysis672" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1207">
 <bp:stepProcess rdf:resource="#BiochemicalReaction978" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2538">
 <bp:stepProcess rdf:resource="#Pathway647" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1200">
 <bp:stepProcess rdf:resource="#BiochemicalReaction972" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2531">
 <bp:stepProcess rdf:resource="#Catalysis669" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1841" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1201">
 <bp:stepProcess rdf:resource="#BiochemicalReaction973" />
 <bp:stepProcess rdf:resource="#Catalysis277" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2532">
 <bp:stepProcess rdf:resource="#Pathway644" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1202">
 <bp:stepProcess rdf:resource="#BiochemicalReaction974" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2533">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1842" />
 <bp:stepProcess rdf:resource="#Catalysis670" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1203">
 <bp:stepProcess rdf:resource="#Pathway209" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2534">
 <bp:stepProcess rdf:resource="#Pathway645" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2530">
 <bp:stepProcess rdf:resource="#Pathway643" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence1800">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1801">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1802">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1803">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1804">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1805">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1806">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1807">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1808">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1809">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep2506">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1831" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2507">
 <bp:stepProcess rdf:resource="#Pathway629" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2508">
 <bp:stepProcess rdf:resource="#Pathway630" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2509">
 <bp:stepProcess rdf:resource="#Pathway631" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2502">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1829" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2503">
 <bp:stepProcess rdf:resource="#Pathway627" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2504">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1830" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2505">
 <bp:stepProcess rdf:resource="#Pathway628" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2500">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1828" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2501">
 <bp:stepProcess rdf:resource="#Pathway626" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2517">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1835" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2518">
 <bp:stepProcess rdf:resource="#Pathway636" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2519">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1836" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2513">
 <bp:stepProcess rdf:resource="#Pathway634" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2514">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1833" />
 <bp:stepProcess rdf:resource="#Catalysis664" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2515">
 <bp:stepProcess rdf:resource="#Pathway635" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2516">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1834" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2510">
 <bp:stepProcess rdf:resource="#Pathway632" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2511">
 <bp:stepProcess rdf:resource="#Pathway633" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2512">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1832" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1291">
 <bp:stepProcess rdf:resource="#Pathway220" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1292">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1051" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1293">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1052" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1294">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1053" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1290">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1050" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1299">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1058" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1295">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1054" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1296">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1055" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1297">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1056" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1298">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1057" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1270">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1030" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1271">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1031" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1272">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1032" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1277">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1037" />
 <bp:stepProcess rdf:resource="#Catalysis308" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1278">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1038" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1279">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1039" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1273">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1033" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1274">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1034" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1275">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1035" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1276">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1036" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1280">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1040" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1281">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1041" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1282">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1042" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1283">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1043" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1288">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1048" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1289">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1049" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1284">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1044" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1285">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1045" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1286">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1046" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1287">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1047" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2580">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1863" />
 <bp:stepProcess rdf:resource="#Catalysis691" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1250">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1014" />
 <bp:stepProcess rdf:resource="#Catalysis298" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2581">
 <bp:stepProcess rdf:resource="#Pathway668" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1259">
 <bp:stepProcess rdf:resource="#Catalysis301" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1022" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1255">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1018" />
 <bp:stepProcess rdf:resource="#Catalysis299" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2586">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1866" />
 <bp:stepProcess rdf:resource="#Catalysis694" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1256">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1019" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2587">
 <bp:stepProcess rdf:resource="#Pathway671" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1257">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1020" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2588">
 <bp:stepProcess rdf:resource="#Catalysis695" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1867" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1258">
 <bp:stepProcess rdf:resource="#Catalysis300" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1021" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2589">
 <bp:stepProcess rdf:resource="#Pathway672" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1251">
 <bp:stepProcess rdf:resource="#Pathway216" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2582">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1864" />
 <bp:stepProcess rdf:resource="#Catalysis692" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1252">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1015" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2583">
 <bp:stepProcess rdf:resource="#Pathway669" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1253">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1016" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2584">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1865" />
 <bp:stepProcess rdf:resource="#Catalysis693" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1254">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1017" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2585">
 <bp:stepProcess rdf:resource="#Pathway670" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2590">
 <bp:stepProcess rdf:resource="#Catalysis696" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1868" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1260">
 <bp:stepProcess rdf:resource="#Pathway217" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2591">
 <bp:stepProcess rdf:resource="#Pathway673" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1261">
 <bp:stepProcess rdf:resource="#Pathway218" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2592">
 <bp:stepProcess rdf:resource="#Catalysis697" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1869" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1266">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1026" />
 <bp:stepProcess rdf:resource="#Catalysis305" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2597">
 <bp:stepProcess rdf:resource="#Pathway676" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1267">
 <bp:stepProcess rdf:resource="#Catalysis306" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1027" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2598">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1872" />
 <bp:stepProcess rdf:resource="#Catalysis700" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1268">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1028" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2599">
 <bp:stepProcess rdf:resource="#Pathway677" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1269">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1029" />
 <bp:stepProcess rdf:resource="#Catalysis307" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1262">
 <bp:stepProcess rdf:resource="#Pathway219" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2593">
 <bp:stepProcess rdf:resource="#Pathway674" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1263">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1023" />
 <bp:stepProcess rdf:resource="#Catalysis302" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2594">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1870" />
 <bp:stepProcess rdf:resource="#Catalysis698" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1264">
 <bp:stepProcess rdf:resource="#Catalysis303" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1024" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2595">
 <bp:stepProcess rdf:resource="#Pathway675" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1265">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1025" />
 <bp:stepProcess rdf:resource="#Catalysis304" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2596">
 <bp:stepProcess rdf:resource="#Catalysis699" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1871" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction952">
 <bp:evidence rdf:resource="#Evidence1156" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">botB HC transports botB LC from target cell synaptic vesicle membrane into cytosol</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction953">
 <bp:evidence rdf:resource="#Evidence1157" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Transcytosis and dissociation of botB:NTNHA:HA</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction950">
 <bp:evidence rdf:resource="#Evidence1154" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">botB LC cleaves target cell VAMP2</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction951">
 <bp:evidence rdf:resource="#Evidence1155" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">botB HC:LC binds SYT1 or 2 and GT1b on the target cell surface</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction958">
 <bp:evidence rdf:resource="#Evidence1163" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">botG LC cleaves target cell VAMP2</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction959">
 <bp:evidence rdf:resource="#Evidence1164" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">botG LC cleaves target cell VAMP1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction956">
 <bp:evidence rdf:resource="#Evidence1161" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">botG HC:LC binds SYT1 and GT1b on the target cell surface</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction957">
 <bp:evidence rdf:resource="#Evidence1162" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">botG:SYT1:GT1b internalized from target cell plasma membrane to synaptic vesicle membrane</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction954">
 <bp:evidence rdf:resource="#Evidence1158" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">botB:SYT:GT1b internalized from target cell plasma membrane to synaptic vesicle membrane</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction955">
 <bp:evidence rdf:resource="#Evidence1160" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">botG HC transports botG LC from target cell synaptic vesicle membrane into cytosol</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction941">
 <bp:evidence rdf:resource="#Evidence1141" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">AhpC reduces H2O2</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction942">
 <bp:evidence rdf:resource="#Evidence1142" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">H2O2 gets scavenged by unsaturated lipid</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction940">
 <bp:evidence rdf:resource="#Evidence1140" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SodB gets secreted</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction949">
 <bp:evidence rdf:resource="#Evidence1151" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">DT A:B binds HBEGF and CD9 on the target cell surface</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction947">
 <bp:evidence rdf:resource="#Evidence1149" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">DT fragment B transports DT fragment A from target cell endosome membrane</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction948">
 <bp:evidence rdf:resource="#Evidence1150" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">DT fragment A ADP-ribosylates target cell EEF</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction945">
 <bp:evidence rdf:resource="#Evidence1147" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">DT:HBEGF:CD9 is transported from clathrin-coated vesicle to endosome</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction946">
 <bp:evidence rdf:resource="#Evidence1148" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Clathrin-mediated endocytosis of DT:HBEGF:CD9</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction943">
 <bp:evidence rdf:resource="#Evidence1143" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SodC reduces superoxide to H2O2</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction944">
 <bp:evidence rdf:resource="#Evidence1144" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">KatG reduces H2O2</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction974">
 <bp:evidence rdf:resource="#Evidence1182" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Transcytosis and dissociation of botA:NTNHA:HA</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction975">
 <bp:evidence rdf:resource="#Evidence1184" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">tetX LC cleaves target cell VAMP2</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction972">
 <bp:evidence rdf:resource="#Evidence1180" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">botA:SV2:GT1b internalized from target cell plasma membrane to synaptic vesicle membrane</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction973">
 <bp:evidence rdf:resource="#Evidence1181" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">botA LC cleaves target cell SNAP25</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction970">
 <bp:evidence rdf:resource="#Evidence1178" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">botA HC:LC binds SV2A, B, or C and GT1b on the target cell surface</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction971">
 <bp:evidence rdf:resource="#Evidence1179" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">botA HC transports botA LC from target cell synaptic vesicle membrane into cytosol</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction978">
 <bp:evidence rdf:resource="#Evidence1187" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Retrograde transport of internalized tetX HC:LC:gangliosides</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction979">
 <bp:evidence rdf:resource="#Evidence1188" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Clathrin-mediated endocytosis of tetX HC:LC:gangliosides</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction976">
 <bp:evidence rdf:resource="#Evidence1185" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">tetX HC transports tetX LC from target cell endosome membrane into cytosol</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction977">
 <bp:evidence rdf:resource="#Evidence1186" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">tetX HC:LC binds target cell-surface gangliosides</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction963">
 <bp:evidence rdf:resource="#Evidence1169" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">botD HC transports botD LC from target cell synaptic vesicle membrane into cytosol</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction964">
 <bp:evidence rdf:resource="#Evidence1170" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">botD:SV2:GD2 internalized from target cell plasma membrane to synaptic vesicle membrane</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction961">
 <bp:evidence rdf:resource="#Evidence1167" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">botD LC cleaves target cell VAMP2</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction962">
 <bp:evidence rdf:resource="#Evidence1168" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">botD LC cleaves target cell VAMP1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction960">
 <bp:evidence rdf:resource="#Evidence1166" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">botD HC:LC binds SV2A or B or C and GD2 on the target cell surface</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction969">
 <bp:evidence rdf:resource="#Evidence1176" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">botC HC transports botC LC from target cell synaptic vesicle membrane to cytosol</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction967">
 <bp:evidence rdf:resource="#Evidence1174" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">botC LC cleaves target cell SNAP25</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction968">
 <bp:evidence rdf:resource="#Evidence1175" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">botC HC:LC binds GT1b on the target cell surface</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction965">
 <bp:evidence rdf:resource="#Evidence1172" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">botC LC cleaves target cell STX1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction966">
 <bp:evidence rdf:resource="#Evidence1173" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">botC:GT1b internalized from target cell plasma membrane to synaptic vesicle membrane</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction916">
 <bp:evidence rdf:resource="#Evidence1113" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TrxA reactivates AhpC</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction917">
 <bp:evidence rdf:resource="#Evidence1114" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">DlaT reactivates AhpD</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction914">
 <bp:evidence rdf:resource="#Evidence1111" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TrxB reactivates TrxA</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction915">
 <bp:evidence rdf:resource="#Evidence1112" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TrxA/B1 reactivates Tpx</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction912">
 <bp:evidence rdf:resource="#Evidence1109" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">AhpD reactivates AhpC</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction913">
 <bp:evidence rdf:resource="#Evidence1110" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Fgd1 reactivates F420</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction910">
 <bp:evidence rdf:resource="#Evidence1105" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">PtpA binds ATP6V1H</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction911">
 <bp:evidence rdf:resource="#Evidence1108" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">LpdC dimer reactivates DlaT</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction909">
 <bp:evidence rdf:resource="#Evidence1103" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">PPE2:KPNA1:KPNB1 dissociates, releasing PPE2 into the nucleus</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction907">
 <bp:evidence rdf:resource="#Evidence1101" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">PPE2:KPNA1:KPNB1 translocates to the nucleus</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction908">
 <bp:evidence rdf:resource="#Evidence1102" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">PPE2 binds NOS2 gene</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction905">
 <bp:evidence rdf:resource="#Evidence1099" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">PPE2 binds KPNA1:KPNB1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction906">
 <bp:evidence rdf:resource="#Evidence1100" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NOS2 gene produces NOS2 protein</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction903">
 <bp:evidence rdf:resource="#Evidence1096" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SecA2 transports SapM from cytoplasm to cytosol</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction904">
 <bp:evidence rdf:resource="#Evidence1097" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">PtpA:Ub dephosphorylates p-Y133-VPS33B</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction901">
 <bp:evidence rdf:resource="#Evidence1094" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">LAM translocates from the cell wall to the plasma membrane</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction902">
 <bp:evidence rdf:resource="#Evidence1095" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Rv1410c transports LprG:LM,LAM from cytosol to the cell wall</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction900">
 <bp:evidence rdf:resource="#Evidence1093" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SapM dephosphorylates PI3P</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction930">
 <bp:evidence rdf:resource="#Evidence1129" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">BfrA stores iron</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction931">
 <bp:evidence rdf:resource="#Evidence1130" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">LTF:2xCO3(2-) dissociates from Carbocymycobactin:Fe3+</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction938">
 <bp:evidence rdf:resource="#Evidence1138" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">AhpC reduces peroxidated lipids</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction939">
 <bp:evidence rdf:resource="#Evidence1139" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SodB reduces superoxide to H2O2</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction936">
 <bp:evidence rdf:resource="#Evidence1135" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Mycobactin is exported</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction937">
 <bp:evidence rdf:resource="#Evidence1136" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Carboxymycobactin gets secreted</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction934">
 <bp:evidence rdf:resource="#Evidence1133" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Carbocymycobactin binds Fe3+ from LTF:2xFe3+:2xCO3(2-)</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction935">
 <bp:evidence rdf:resource="#Evidence1134" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Carboxymycobactin binds LTF:2xFe3+:2xCO3(2-)</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction932">
 <bp:evidence rdf:resource="#Evidence1131" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Loaded mycobactin gets imported</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction933">
 <bp:evidence rdf:resource="#Evidence1132" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Carboxymycobactin and mycobactin exchange their iron load</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction929">
 <bp:evidence rdf:resource="#Evidence1128" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">BfrB stores iron</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction920">
 <bp:evidence rdf:resource="#Evidence1118" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Nitrosoglutathione gets cleaved to Cys(NO)-Gly</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction927">
 <bp:evidence rdf:resource="#Evidence1125" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Mycothiol scavenges nitrosyl</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction928">
 <bp:evidence rdf:resource="#Evidence1127" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Iron is reduced and separates from mycobactin</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction925">
 <bp:evidence rdf:resource="#Evidence1123" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Peroxynitrite is reduced to nitrite by Tpx</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction926">
 <bp:evidence rdf:resource="#Evidence1124" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Nitric oxide is oxidized to nitrate</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction923">
 <bp:evidence rdf:resource="#Evidence1121" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MscR reduces nitrosomycothiol to ammonia</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction924">
 <bp:evidence rdf:resource="#Evidence1122" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Peroxynitrite is reduced by AhpE</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction921">
 <bp:evidence rdf:resource="#Evidence1119" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MsrA/B reduces peptide-methionine S/R-sulfoxides</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction922">
 <bp:evidence rdf:resource="#Evidence1120" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Glutathione is taken up by the bacterium</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction918">
 <bp:evidence rdf:resource="#Evidence1116" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Nitrogen dioxide is reduced to NO by F420</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction919">
 <bp:evidence rdf:resource="#Evidence1117" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Peroxynitrite is reduced to nitrite by AhpC</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep2605">
 <bp:stepProcess rdf:resource="#Pathway680" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2606">
 <bp:stepProcess rdf:resource="#Catalysis684" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1856" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2607">
 <bp:stepProcess rdf:resource="#Pathway681" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2608">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1875" />
 <bp:stepProcess rdf:resource="#Catalysis703" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2601">
 <bp:stepProcess rdf:resource="#Pathway678" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2602">
 <bp:stepProcess rdf:resource="#Catalysis702" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1874" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2603">
 <bp:stepProcess rdf:resource="#Pathway679" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2604">
 <bp:stepProcess rdf:resource="#Catalysis665" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1837" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2600">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1873" />
 <bp:stepProcess rdf:resource="#Catalysis701" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2609">
 <bp:stepProcess rdf:resource="#Pathway682" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2616">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1879" />
 <bp:stepProcess rdf:resource="#Catalysis706" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2617">
 <bp:stepProcess rdf:resource="#Pathway686" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2618">
 <bp:stepProcess rdf:resource="#Catalysis707" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1880" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2619">
 <bp:stepProcess rdf:resource="#Pathway687" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2612">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1877" />
 <bp:stepProcess rdf:resource="#Catalysis705" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2613">
 <bp:stepProcess rdf:resource="#Pathway684" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2614">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1878" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2615">
 <bp:stepProcess rdf:resource="#Pathway685" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2610">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1876" />
 <bp:stepProcess rdf:resource="#Catalysis704" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2611">
 <bp:stepProcess rdf:resource="#Pathway683" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction996">
 <bp:evidence rdf:resource="#Evidence1208" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Anthrax lef cleaves target cell MAP2K4 (MEK4)</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence1986">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction997">
 <bp:evidence rdf:resource="#Evidence1209" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">pagA(197-794):ANTRX2 oligomer transports cya and lef (target cell endosome to cytosol)</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence1987">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction994">
 <bp:evidence rdf:resource="#Evidence1206" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Anthrax lef cleaves target cell MAP2K2 (MEK2)</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence1988">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction995">
 <bp:evidence rdf:resource="#Evidence1207" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ANTXR1-bound pagA(197-794) forms oligomers</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence1989">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction992">
 <bp:evidence rdf:resource="#Evidence1204" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Anthrax cya catalyzes the conversion of ATP to cAMP</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction993">
 <bp:evidence rdf:resource="#Evidence1205" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Anthrax lef cleaves target cell MAP2K7 (MEK7)</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction990">
 <bp:evidence rdf:resource="#Evidence1202" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ANTXR2-bound pagA(197-794) forms oligomers</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction991">
 <bp:evidence rdf:resource="#Evidence1203" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Furin cleaves ANTXR1-bound pagA to yield pagA(197-794)</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction998">
 <bp:evidence rdf:resource="#Evidence1210" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Endocytosis of cya:lef:(pagA(197-794):ANTXR1 oligomer) (plasma membrane to endosome membrane)</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction999">
 <bp:evidence rdf:resource="#Evidence1211" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Furin cleaves ANTXR2-bound pagA to yield pagA(197-794)</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence1990">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1991">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1992">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1993">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1994">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1995">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1996">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction985">
 <bp:evidence rdf:resource="#Evidence1196" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">botE HC transports botE LC from target cell synaptic vesicle membrane into cytosol</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence1975">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction986">
 <bp:evidence rdf:resource="#Evidence1197" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">botE HC:LC binds SV2A or B and GT1b on the target cell surface</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence1976">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction983">
 <bp:evidence rdf:resource="#Evidence1193" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">botF HC transports botF LC from target cell synaptic vesicle membrane into cytosol</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence1977">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction984">
 <bp:evidence rdf:resource="#Evidence1194" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">botF HC:LC binds SV2A or B or C and GT1b on the target cell surface</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence1978">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction981">
 <bp:evidence rdf:resource="#Evidence1191" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">botF:SV2:GT1b internalized from target cell plasma membrane to synaptic vesicle membrane</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence1979">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction982">
 <bp:evidence rdf:resource="#Evidence1192" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">botF LC cleaves target cell VAMP1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction980">
 <bp:evidence rdf:resource="#Evidence1190" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">botF LC cleaves target cell VAMP2</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction989">
 <bp:evidence rdf:resource="#Evidence1200" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Transcytosis and dissociation of botE:NTNHA</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction987">
 <bp:evidence rdf:resource="#Evidence1198" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">botE:SV2:GT1b internalized from target cell plasma membrane to synaptic vesicle membrane</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction988">
 <bp:evidence rdf:resource="#Evidence1199" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">botE LC cleaves target cell SNAP25</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence1980">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1981">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1982">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1983">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1984">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1985">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1997">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1998">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1999">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1942">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1943">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1944">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1945">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep2680">
 <bp:stepProcess rdf:resource="#Pathway553" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence1946">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1947">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1948">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1949">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep1358">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1103" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2689">
 <bp:stepProcess rdf:resource="#Pathway718" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1359">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1104" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1354">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1099" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2685">
 <bp:stepProcess rdf:resource="#Pathway716" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1355">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1100" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2686">
 <bp:stepProcess rdf:resource="#Catalysis736" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1915" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1356">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1101" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2687">
 <bp:stepProcess rdf:resource="#Pathway717" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1357">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1102" />
 <bp:stepProcess rdf:resource="#Catalysis312" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2688">
 <bp:stepProcess rdf:resource="#Catalysis737" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1916" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1350">
 <bp:stepProcess rdf:resource="#Pathway234" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2681">
 <bp:stepProcess rdf:resource="#Pathway714" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1351">
 <bp:stepProcess rdf:resource="#Catalysis311" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1096" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence1950">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep2682">
 <bp:stepProcess rdf:resource="#Catalysis734" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1913" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1352">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1097" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence1951">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep2683">
 <bp:stepProcess rdf:resource="#Pathway715" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1353">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1098" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence1952">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep2684">
 <bp:stepProcess rdf:resource="#Catalysis735" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1914" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence1931">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1932">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1933">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep2690">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1917" />
 <bp:stepProcess rdf:resource="#Catalysis738" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1360">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1105" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence1934">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep2691">
 <bp:stepProcess rdf:resource="#Pathway719" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence1935">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1936">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1937">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1938">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1939">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep1369">
 <bp:stepProcess rdf:resource="#Pathway235" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1365">
 <bp:stepProcess rdf:resource="#Catalysis315" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1110" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2696">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1920" />
 <bp:stepProcess rdf:resource="#Catalysis741" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1366">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1111" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2697">
 <bp:stepProcess rdf:resource="#Pathway722" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1367">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1112" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2698">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1921" />
 <bp:stepProcess rdf:resource="#Catalysis742" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1368">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1113" />
 <bp:stepProcess rdf:resource="#Catalysis316" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2699">
 <bp:stepProcess rdf:resource="#Pathway723" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1361">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1106" />
 <bp:stepProcess rdf:resource="#Catalysis313" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2692">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1918" />
 <bp:stepProcess rdf:resource="#Catalysis739" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1362">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1107" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2693">
 <bp:stepProcess rdf:resource="#Pathway720" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1363">
 <bp:stepProcess rdf:resource="#Catalysis314" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1108" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence1940">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep2694">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1919" />
 <bp:stepProcess rdf:resource="#Catalysis740" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1364">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1109" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence1941">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep2695">
 <bp:stepProcess rdf:resource="#Pathway721" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence1964">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1965">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1966">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1967">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1968">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1969">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep1336">
 <bp:stepProcess rdf:resource="#Pathway226" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2667">
 <bp:stepProcess rdf:resource="#Pathway711" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1337">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1090" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2668">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1903" />
 <bp:stepProcess rdf:resource="#Catalysis728" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1338">
 <bp:stepProcess rdf:resource="#Pathway227" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2669">
 <bp:stepProcess rdf:resource="#Pathway712" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1339">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1091" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1332">
 <bp:stepProcess rdf:resource="#Pathway224" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2663">
 <bp:stepProcess rdf:resource="#Pathway709" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1333">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1088" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2664">
 <bp:stepProcess rdf:resource="#Pathway710" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1334">
 <bp:stepProcess rdf:resource="#Pathway225" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2665">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1901" />
 <bp:stepProcess rdf:resource="#Catalysis727" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1335">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1089" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence1970">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep2666">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1902" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence1971">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1972">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep2660">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1900" />
 <bp:stepProcess rdf:resource="#Catalysis726" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1330">
 <bp:stepProcess rdf:resource="#Pathway223" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence1973">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep2661">
 <bp:stepProcess rdf:resource="#Pathway708" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1331">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1087" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence1974">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep2662">
 <bp:stepProcess rdf:resource="#Catalysis686" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1858" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence1953">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1954">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1955">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1956">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1957">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1958">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1959">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep1347">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1094" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2678">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1911" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1348">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1095" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2679">
 <bp:stepProcess rdf:resource="#Catalysis733" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1912" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1349">
 <bp:stepProcess rdf:resource="#Pathway233" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1343">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1093" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2674">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1907" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1344">
 <bp:stepProcess rdf:resource="#Pathway230" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2675">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1908" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1345">
 <bp:stepProcess rdf:resource="#Pathway231" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2676">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1909" />
 <bp:stepProcess rdf:resource="#Catalysis731" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1346">
 <bp:stepProcess rdf:resource="#Pathway232" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2677">
 <bp:stepProcess rdf:resource="#Catalysis732" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1910" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence1960">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep2670">
 <bp:stepProcess rdf:resource="#Catalysis729" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1904" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1340">
 <bp:stepProcess rdf:resource="#Pathway228" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence1961">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep2671">
 <bp:stepProcess rdf:resource="#Pathway713" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1341">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1092" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence1962">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep2672">
 <bp:stepProcess rdf:resource="#Catalysis730" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1905" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1342">
 <bp:stepProcess rdf:resource="#Pathway229" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence1963">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep2673">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1906" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence1900">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1901">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1902">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1903">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1904">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1905">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1906">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1907">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1908">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1909">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep1318">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1077" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2649">
 <bp:stepProcess rdf:resource="#Pathway702" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1319">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1078" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1314">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1073" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2645">
 <bp:stepProcess rdf:resource="#Pathway700" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1315">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1074" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2646">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1894" />
 <bp:stepProcess rdf:resource="#Catalysis721" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1316">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1075" />
 <bp:stepProcess rdf:resource="#Catalysis309" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2647">
 <bp:stepProcess rdf:resource="#Pathway701" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1317">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1076" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2648">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1851" />
 <bp:stepProcess rdf:resource="#Catalysis679" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1310">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1069" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2641">
 <bp:stepProcess rdf:resource="#Pathway698" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1311">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1070" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2642">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1892" />
 <bp:stepProcess rdf:resource="#Catalysis719" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1312">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1071" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2643">
 <bp:stepProcess rdf:resource="#Pathway699" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1313">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1072" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2644">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1893" />
 <bp:stepProcess rdf:resource="#Catalysis720" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2640">
 <bp:stepProcess rdf:resource="#Catalysis718" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1891" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1329">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1086" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1325">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1084" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2656">
 <bp:stepProcess rdf:resource="#Catalysis724" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1898" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1326">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1085" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2657">
 <bp:stepProcess rdf:resource="#Pathway706" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1327">
 <bp:stepProcess rdf:resource="#Pathway221" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2658">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1899" />
 <bp:stepProcess rdf:resource="#Catalysis725" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1328">
 <bp:stepProcess rdf:resource="#Pathway222" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2659">
 <bp:stepProcess rdf:resource="#Pathway707" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1321">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1080" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2652">
 <bp:stepProcess rdf:resource="#Catalysis723" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1896" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1322">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1081" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2653">
 <bp:stepProcess rdf:resource="#Pathway704" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1323">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1082" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2654">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1897" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1324">
 <bp:stepProcess rdf:resource="#Catalysis310" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1083" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2655">
 <bp:stepProcess rdf:resource="#Pathway705" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2650">
 <bp:stepProcess rdf:resource="#Catalysis722" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1895" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1320">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1079" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2651">
 <bp:stepProcess rdf:resource="#Pathway703" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence1920">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1921">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1922">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1923">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1924">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1925">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1926">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1927">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1928">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1929">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep2627">
 <bp:stepProcess rdf:resource="#Pathway691" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2628">
 <bp:stepProcess rdf:resource="#Catalysis712" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1885" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2629">
 <bp:stepProcess rdf:resource="#Pathway692" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2623">
 <bp:stepProcess rdf:resource="#Pathway689" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2624">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1883" />
 <bp:stepProcess rdf:resource="#Catalysis710" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2625">
 <bp:stepProcess rdf:resource="#Pathway690" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2626">
 <bp:stepProcess rdf:resource="#Catalysis711" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1884" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2620">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1881" />
 <bp:stepProcess rdf:resource="#Catalysis708" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2621">
 <bp:stepProcess rdf:resource="#Pathway688" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2622">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1882" />
 <bp:stepProcess rdf:resource="#Catalysis709" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence1930">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1910">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1911">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1912">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1913">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1914">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1915">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1916">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1917">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1918">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1919">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep1307">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1066" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2638">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1890" />
 <bp:stepProcess rdf:resource="#Catalysis717" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1308">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1067" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2639">
 <bp:stepProcess rdf:resource="#Pathway697" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1309">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1068" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1303">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1062" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2634">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1888" />
 <bp:stepProcess rdf:resource="#Catalysis715" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1304">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1063" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2635">
 <bp:stepProcess rdf:resource="#Pathway695" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1305">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1064" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2636">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1889" />
 <bp:stepProcess rdf:resource="#Catalysis716" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1306">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1065" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2637">
 <bp:stepProcess rdf:resource="#Pathway696" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2630">
 <bp:stepProcess rdf:resource="#Catalysis713" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1886" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1300">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1059" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2631">
 <bp:stepProcess rdf:resource="#Pathway693" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1301">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1060" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2632">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1887" />
 <bp:stepProcess rdf:resource="#Catalysis714" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1302">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1061" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep2633">
 <bp:stepProcess rdf:resource="#Pathway694" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence252">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence251">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence254">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence253">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence250">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence259">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence256">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence255">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence258">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence257">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence263">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence262">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence265">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence264">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence261">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence260">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence267">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence266">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence269">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence268">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence274">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence273">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence276">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence275">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence270">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence272">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence271">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence278">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence277">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence279">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence285">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence284">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence287">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence286">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence281">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence280">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence283">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence282">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence289">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence288">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence290">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence296">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence295">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1190">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence298">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1191">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence297">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1192">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence292">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1193">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence291">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1194">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence294">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1195">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence293">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1196">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1197">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1198">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1199">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence299">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1180">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1181">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1182">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1183">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1184">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1185">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1186">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1187">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1188">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1189">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2480">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1150">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2481">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1151">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2482">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1152">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2483">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1153">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2484">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1154">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2485">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1155">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2486">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1156">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2487">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1157">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2488">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1158">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2489">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1159">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1139">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep1802">
 <bp:stepProcess rdf:resource="#Pathway349" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1803">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1410" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1804">
 <bp:stepProcess rdf:resource="#Pathway350" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1805">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1411" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence2470">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1140">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep1800">
 <bp:stepProcess rdf:resource="#Pathway348" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence2471">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1141">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep1801">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1409" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence2472">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1142">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2473">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1143">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2474">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1144">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2475">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1145">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2476">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1146">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2477">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1147">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2478">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1148">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2479">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1149">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction611">
 <bp:evidence rdf:resource="#Evidence763" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SARS-CoV-1 M protein interacts with TBK1/IKBKE </bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction612">
 <bp:evidence rdf:resource="#Evidence764" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SARS-CoV-1 9b binds MAVS and PCBP2</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction610">
 <bp:evidence rdf:resource="#Evidence762" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SARS-CoV-1 9b recruits ITCH to MAVS </bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction619">
 <bp:evidence rdf:resource="#Evidence771" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SARS-CoV-1 nsp3 deubiquinates K48-linked pUb IkBA</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction617">
 <bp:evidence rdf:resource="#Evidence769" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SARS-CoV-1 9b binds TOMM70</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction618">
 <bp:evidence rdf:resource="#Evidence770" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SARS-CoV-1 8b binds NLRP3</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction615">
 <bp:evidence rdf:resource="#Evidence767" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SARS-CoV-1 8b binds to IRF3</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction616">
 <bp:evidence rdf:resource="#Evidence768" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SARS-CoV-1 3a tetramerizes</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction613">
 <bp:evidence rdf:resource="#Evidence765" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SARS-CoV-1 nsp3 binds to IRF3</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction614">
 <bp:evidence rdf:resource="#Evidence766" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SARS-CoV-1 3a tetramer induces potassium efflux</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence1170">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1171">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1172">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1173">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1174">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1175">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1176">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1177">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1178">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1179">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction600">
 <bp:evidence rdf:resource="#Evidence752" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SARS-CoV-1 6 binds to NMI</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction601">
 <bp:evidence rdf:resource="#Evidence753" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SARS-CoV-1 6 binds KPNA2</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction608">
 <bp:evidence rdf:resource="#Evidence760" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SARS-CoV-1 3a binds to caspase-1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction609">
 <bp:evidence rdf:resource="#Evidence761" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SARS-CoV-1 nsp1 binds to RCAN3</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction606">
 <bp:evidence rdf:resource="#Evidence758" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">C-ter TLR7 dimer binds TLR7, TLR8 ligands</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction607">
 <bp:evidence rdf:resource="#Evidence759" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SARS-CoV-1 N protein binds TRIM25</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction604">
 <bp:evidence rdf:resource="#Evidence756" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SARS-CoV-1 nsp3 deubiquinates K63-linked pUb oligo-TRAF6 (TLR7/8 signaling)</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction605">
 <bp:evidence rdf:resource="#Evidence757" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SARS-CoV-1 S binds SFTPD 12mer</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction602">
 <bp:evidence rdf:resource="#Evidence754" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SARS-CoV-1 3a binds TRAF3 within NLRP3 inflammasome</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction603">
 <bp:evidence rdf:resource="#Evidence755" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SARS-CoV-1 nsp1 binds to PPIase</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence2490">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1160">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2491">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1161">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2492">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1162">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2493">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1163">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2494">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence205">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1164">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2495">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence204">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1165">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2496">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence207">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1166">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2497">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence206">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1167">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2498">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence201">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1168">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2499">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence200">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1169">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence203">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence202">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1106">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2437">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1107">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2438">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1108">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2439">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1109">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence209">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence208">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence210">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence216">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2440">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence215">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1110">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2441">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence218">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1111">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2442">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence217">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1112">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2443">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence212">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1113">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2444">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence211">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1114">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2445">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence214">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1115">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2446">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence213">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1116">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2447">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2426">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2427">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2428">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2429">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence219">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence221">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence220">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence227">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence226">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2430">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence229">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1100">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2431">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence228">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1101">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2432">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence223">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1102">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2433">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence222">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1103">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2434">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence225">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1104">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2435">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence224">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1105">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2436">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1128">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2459">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1129">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence230">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway190">
 <bp:pathwayOrder rdf:resource="#PathwayStep1095" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1096" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1101" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1097" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1098" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1099" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1100" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction887" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction893" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction891" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction892" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction890" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction888" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction889" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1076" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Suppression of apoptosis</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">In order to survive and grow within the phagocyte, Mtb has to inhibit programmed cell death. Several proteins are secreted by Mtb that block different pathways leading to complete arrest of apoptosis (Moraco    Kornfeld 2014).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence232">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway192">
 <bp:pathwayOrder rdf:resource="#PathwayStep1106" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1118" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1124" />
 <bp:pathwayComponent rdf:resource="#Pathway194" />
 <bp:pathwayComponent rdf:resource="#Pathway193" />
 <bp:pathwayComponent rdf:resource="#Pathway195" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1087" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Suppression of phagosomal maturation</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The fate of phagosomes is usually directed by factors in the host phagocyte and involves flooding itself with superoxide, nitric oxide, and protons. Acidification is the prerequisite for later fusion with a lysosome. Mycobacterium tuberculosis (Mtb) releases substances that inhibit all of these processes, effectively arresting the phagosome in the present state and creating a protected niche for Mtb multiplication (Russell 2011, Stutz et al. 2018).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence231">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway191">
 <bp:pathwayOrder rdf:resource="#PathwayStep1103" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1104" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction895" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction894" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1084" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Manipulation of host energy metabolism</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Mtb secretes proteins that enhance enzymatic activity of glucose metabolism in the phagocyte. The same proteins also appear to increase glucose uptake and to cause accumulation of DHAP, ultimately increasing the host cell&apos;s lipid production (Singh et al. 2015).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway194">
 <bp:pathwayOrder rdf:resource="#PathwayStep1119" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1123" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1120" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1121" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1122" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction909" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction907" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction908" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction905" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction906" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1098" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Inhibition of nitric oxide production</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Phagocytes produce nitric oxide to damage interned bacteria before fusion of the phagosome with lysosomes. While Mtb has several pathways to neutralize NO it also attempts to block the host enzymes used for NO production (Fang 2004, Bhat 2017).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway193">
 <bp:pathwayOrder rdf:resource="#PathwayStep1109" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1116" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1117" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1107" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1108" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1112" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1113" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1114" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1115" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1110" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1111" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction897" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction898" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction884" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction896" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction872" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction903" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction904" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction901" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction902" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction899" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction900" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1088" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Prevention of phagosomal-lysosomal fusion</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Lipoarabinomannan (LAM) is transported to Mtb&apos;s outer cell wall. When Mtb is interned by the phagocyte, LAM is shedded into the phagocyte&apos;s membrane, gets incorporated into lipid rafts of the phagosomal membrane, where it acts to prevent phagosomal-lysosomal fusion (Welin et al. 2008, Gaur et al. 2014). Other processes that get inhibited include the cytoskeletal protein coronin-1A and the fusion mediator vacuolar protein sorting-associated protein 33B (VPS33B) (Deghmane et al. 2007, Bach et al. 2008). Also the Ras-related protein (Rab5) effector phosphatidylinositol 3-phosphate (PI3P) gets enzymatically depleted (Vergne et al. 2005).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway196">
 <bp:pathwayOrder rdf:resource="#PathwayStep1127" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1135" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1146" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1157" />
 <bp:pathwayComponent rdf:resource="#Pathway198" />
 <bp:pathwayComponent rdf:resource="#Pathway197" />
 <bp:pathwayComponent rdf:resource="#Pathway200" />
 <bp:pathwayComponent rdf:resource="#Pathway199" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1106" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Latent infection - Other responses of Mtb to phagocytosis</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string"> Mtb  encounters a vastly changed environment, soon after it gets internalized by macrophages. The compartment it resides in, the phagosome, is acidified and devoid of important metal ions. It is flooded with reactive oxygen and nitrogen species. And steps will be soon taken by the macrophage to &quot;mature&quot; the phagosome with all kinds of lysosomal digestive enzymes. However, unlike most other bacteria species  Mtb.  has evolved solutions to each of these threats and, after making sure these are installed, it soon will enter a dormant state (de Chastellier, 2009; Flannagan et al, 2009). A combination of the host defense and the response of the infecting bacillus (active and passive) ensure suppression of bacterial metabolic activity and replication, resulting in a non-replicating state (Russell 2011, Russell et al. 2010).   </bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence2460">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway195">
 <bp:pathwayOrder rdf:resource="#PathwayStep1125" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction910" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1104" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Blockage of phagosome acidification</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Acidification of the phagosome occurs by insertion of ATPases into the phagosomal membrane in preparation for fusion with lysosomes. The pH of phagosomes containing Mtb never drops below 6.5 due to Mtb interfering with several acidification mechanisms (Queval et al. 2017).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence1130">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2461">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence238">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway198">
 <bp:pathwayOrder rdf:resource="#PathwayStep1140" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1138" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1139" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1145" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1136" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1137" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1141" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1142" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1143" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1144" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction920" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction918" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction919" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction927" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction925" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction926" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction923" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction924" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction921" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction922" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1115" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Tolerance by Mtb to nitric oxide produced by macrophages</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Reactive nitrogen species (RNS), like reactive oxygen species, have numerous target molecules in the bacterial cell, and  Mtb  has developed remedies to the most important ones of them. This is a key reason for its ability to stay alive in the hostile environment of the late phagosome within human macrophages.  Mtb  repairs single-base DNA damage caused by DNA alkylation; it scavenges nitric oxide with large amounts of mycothiol and methionine-rich proteins (the nitroso compounds later being reduced). Nitric oxide and peroxynitrite are also directly reduced by a battery of hemoglobins and peroxiredoxins, supported by a network of thioredoxins and respective NADPH-dependent reductases (Fang. 2004).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence1131">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2462">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence237">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway197">
 <bp:pathwayOrder rdf:resource="#PathwayStep1128" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1129" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1134" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1130" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1131" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1132" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1133" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction916" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction917" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction914" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction915" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction912" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction913" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction911" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1107" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Cell redox homeostasis</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The most important response of  Mtb  to oxidative stress is provided by catalase and peroxiredoxins, both of which get their reducing equivalents through a network of disulfide proteins and, finally, from NAD(P)H. Multiple redundancies make choosing a good drug target difficult (Koul et al. 2011). Optimum efficacy can only be expected from inhibitors of the most upstream components of the redox cascades, i.e. the NAD(P)H-dependent reductases TrxB and Lpd (Jaeger    Flohe 2006).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence1132">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2463">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1133">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2464">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence239">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway199">
 <bp:pathwayOrder rdf:resource="#PathwayStep1150" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1151" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1149" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1156" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1147" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1148" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1152" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1153" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1154" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1155" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction930" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction931" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction929" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction928" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction936" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction937" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction934" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction935" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction932" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction933" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1126" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Mtb iron assimilation by chelation</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Uptake of iron in  Mtb , especially when the bacterium is in the host, strongly depends on siderophores. Humans, through secretion of lactoferrin, maintain an iron concentration of 10^(-18) M within macrophages, and the bacterium has evolved the siderophores mycobactin T and exomycobactin T (formerly exochelin) to cope with this shortage. While nonpolar mycobactin T stays in the cell wall and only moves around in liquid droplets, polar exochelin is abundantly secreted. As it can bind iron with higher affinity than lactoferrin, it frequently scavenges iron ions from this molecule (Miethke    Marahiel 2007).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence1134">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2465">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence234">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1135">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2466">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence233">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1136">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2467">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence236">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1137">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2468">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence235">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1138">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2469">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1117">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2448">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1118">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2449">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1119">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence241">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence240">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence243">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence242">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2450">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence249">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1120">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2451">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence248">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1121">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2452">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1122">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2453">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1123">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2454">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence245">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1124">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2455">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence244">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1125">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2456">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence247">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1126">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2457">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence246">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1127">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2458">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction677">
 <bp:evidence rdf:resource="#Evidence838" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">mRNA1 is translated to pp1a</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence2514">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction678">
 <bp:evidence rdf:resource="#Evidence840" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">nsp13 binds nsp12</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence2515">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction675">
 <bp:evidence rdf:resource="#Evidence836" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">nsp3 binds to PLpro inhibitors</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence2516">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction676">
 <bp:evidence rdf:resource="#Evidence837" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">nsp4 is glycosylated</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence2517">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction673">
 <bp:evidence rdf:resource="#Evidence834" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">nsp3 is glycosylated</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence2518">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction674">
 <bp:evidence rdf:resource="#Evidence835" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">3CLp cleaves nsp6-11</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence2519">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction671">
 <bp:evidence rdf:resource="#Evidence832" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">nsp3-4 is glycosylated</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction672">
 <bp:evidence rdf:resource="#Evidence833" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">nsp9 forms a homotetramer</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction679">
 <bp:evidence rdf:resource="#Evidence841" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">nsp16 binds nsp10</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep1879">
 <bp:stepProcess rdf:resource="#Pathway373" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway291">
 <bp:pathwayOrder rdf:resource="#PathwayStep1590" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1587" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1609" />
 <bp:pathwayComponent rdf:resource="#Pathway293" />
 <bp:pathwayComponent rdf:resource="#Pathway292" />
 <bp:pathwayComponent rdf:resource="#Pathway294" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1549" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">PI3K/AKT Signaling in Cancer</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Class IA PI3K is a heterodimer of a p85 regulatory subunit (encoded by PIK3R1, PIK3R2 or PIK3R3) and a p110 catalytic subunit (encoded by PIK3CA, PIK3CB or PIK3CD). In the absence of activating signals, the regulatory subunit stabilizes the catalytic subunit while inhibiting its activity. The complex becomes activated when extracellular signals stimulate the phosphorylation of the cytoplasmic domains of transmembrane receptors or receptor-associated proteins. The p85 regulatory subunit binds phosphorylated motifs of activator proteins, which induces a conformational change that relieves p85-mediated inhibition of the p110 catalytic subunit and enables PI3K to phosphorylate PIP2 to form PIP3. The phosphoinositide kinase activity of PI3K is opposed by the phosphoinositide phosphatase activity of PTEN.   PIP3 acts as a messenger that recruits PDPK1 (PDK1) and AKT (AKT1, AKT2 or AKT3) to the plasma membrane. PDPK1 also possesses a low affinity for PIP2, so small amounts of PDPK1 are always present at the membrane. Binding of AKT to PIP3 induces a conformational change that enables TORC2 complex to phosphorylate AKT at a conserved serine residue (S473 in AKT1). Phosphorylation at the serine residue enables AKT to bind to PDPK1 and exposes a conserved threonine residue (T308) that is phosphorylated by PDPK1. AKT phosphorylated at both serine and threonine residues dissociates from the plasma membrane and acts as a serine/threonine kinase that phosphorylates a number of cytosolic and nuclear targets involved in regulation of cell metabolism, survival and gene expression.  For a recent review, please refer to Manning and Cantley, 2007.     Signaling by PI3K/AKT is frequently constitutively activated in cancer. This activation can be via gain-of-function mutations in PI3KCA (encoding catalytic subunit p110alpha), PIK3R1 (encoding regulatory subunit p85alpha) and AKT1. The PI3K/AKT pathway can also be constitutively activated by loss-of-function mutations in tumor suppressor genes such as PTEN.   Gain-of-function mutations activate PI3K signaling by diverse mechanisms. Mutations affecting the helical domain of PIK3CA and mutations affecting nSH2 and iSH2 domains of PIK3R1 impair inhibitory interactions between these two subunits while preserving their association. Mutations in the catalytic domain of PIK3CA enable the kinase to achieve an active conformation. PI3K complexes with gain-of-function mutations therefore produce PIP3 and activate downstream AKT in the absence of growth factors (Huang et al. 2007, Zhao et al. 2005, Miled et al. 2007, Horn et al. 2008, Sun et al. 2010, Jaiswal et al. 2009, Zhao and Vogt 2010, Urick et al. 2011).  While AKT1 gene copy number, expression level and phosphorylation are often increased in cancer, only one low frequency point mutation has been repeatedly reported in cancer and functionally studied. This mutation represents a substitution of a glutamic acid residue with lysine at position 17 of AKT1, and acts by enabling AKT1 to bind PIP2. PIP2-bound AKT1 is phosphorylated by TORC2 complex and by PDPK1 that is always present at the plasma membrane, due to low affinity for PIP2. Therefore, E17K substitution abrogates the need for PI3K in AKT1 activation (Carpten et al. 2007, Landgraf et al. 2008).    Loss-of-function mutations affecting the phosphatase domain of PTEN are frequently found in sporadic cancers (Kong et al. 1997, Lee et al. 1999, Han et al. 2000), as well as in PTEN hamartoma tumor syndromes (PHTS) (Marsh et al. 1998). PTEN can also be inactivated by gene deletion or epigenetic silencing, or indirectly by overexpression of microRNAs that target PTEN mRNA (Huse et al. 2009). Cells with deficient PTEN function have increased levels of PIP3, and therefore increased AKT activity. For a recent review, please refer to Hollander et al. 2011.  Because of their clear involvement in human cancers, PI3K and AKT are targets of considerable interest in the development of small molecule inhibitors. Although none of the currently available inhibitors display preference for mutant variants of PIK3CA or AKT, several inhibitors targeting the wild-type kinases are undergoing clinical trials. These include dual PI3K/mTOR inhibitors, class I PI3K inhibitors, pan-PI3K inhibitors, and pan-AKT inhibitors. While none have yet been approved for clinical use, these agents show promise for future therapeutics. In addition, isoform-specific PI3K and AKT inhibitors are currently being developed, and may provide more specific treatments along with reduced side-effects. For a recent review, please refer to Liu et al. 2009.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway290">
 <bp:pathwayOrder rdf:resource="#PathwayStep1585" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1258" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1547" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Signaling by RAS GAP mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">This pathway describes RAS mutants whose intrinsic GTPase activity can&apos;t be stimulated by GTPase activating proteins (GAPs). These RAS mutants therefore support increased RAS pathway activity (reviewed in Prior et al, 2012; Pylayeva and Gupta, 2011, King et al, 2013; Cox and Der, 2010).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway293">
 <bp:pathwayOrder rdf:resource="#PathwayStep1591" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1608" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1604" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1605" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1606" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1607" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1600" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1601" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1602" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1603" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1596" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1597" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1598" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1599" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1592" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1593" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1594" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1595" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1270" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1271" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1263" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1274" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1264" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1275" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1261" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1272" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1262" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1273" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1267" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1278" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1268" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1265" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1276" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1266" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1277" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1269" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1553" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Constitutive Signaling by AKT1 E17K in Cancer</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">While AKT1 gene copy number, expression level and phosphorylation are often increased in cancer, only one low frequency point mutation has been repeatedly reported in cancer and functionally studied. This mutation represents a substitution of a glutamic acid residue with lysine at position 17 of AKT1, and acts by enabling AKT1 to bind PIP2. PIP2-bound AKT1 is phosphorylated by TORC2 complex and by PDPK1 that is always present at the plasma membrane, due to low affinity for PIP2. Therefore, E17K substitution abrogates the need for PI3K in AKT1 activation (Carpten et al. 2007, Landgraf et al. 2008).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep1875">
 <bp:stepProcess rdf:resource="#Pathway371" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway292">
 <bp:pathwayOrder rdf:resource="#PathwayStep1589" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1588" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1259" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1260" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1550" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Constitutive Signaling by Aberrant PI3K in Cancer</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Signaling by PI3K/AKT is frequently constitutively activated in cancer via gain-of-function mutations in one of the two PI3K subunits - PI3KCA (encoding the catalytic subunit p110alpha) or PIK3R1 (encoding the regulatory subunit p85alpha). Gain-of-function mutations activate PI3K signaling by diverse mechanisms. Mutations affecting the helical domain of PIK3CA and mutations affecting nSH2 and iSH2 domains of PIK3R1 impair inhibitory interactions between these two subunits while preserving their association. Mutations in the catalytic domain of PIK3CA enable the kinase to achieve an active conformation. PI3K complexes with gain-of-function mutations therefore produce PIP3 and activate downstream AKT in the absence of growth factors (Huang et al. 2007, Zhao et al. 2005, Miled et al. 2007, Horn et al. 2008, Sun et al. 2010, Jaiswal et al. 2009, Zhao and Vogt 2010, Urick et al. 2011).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep1876">
 <bp:stepProcess rdf:resource="#Pathway372" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway295">
 <bp:pathwayOrder rdf:resource="#PathwayStep1615" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1612" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1613" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1614" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1281" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1282" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1280" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1283" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1574" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Signaling by LTK in cancer</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">LTK is a member of the anaplastic lymphoma kinase (ALK)/LTK subfamily within the insulin receptor superfamily of RTKs. LTK encodes an 864-amino-acid protein consisting of extracellular, transmembrane, and tyrosine kinase domains and a short carboxy terminus. The LTK kinase domain shares 80% identity with ALK (Roll and Reuther, 2012). The biological role of LTK is not well defined under normal physiological conditions, and unlike ALK, a clear role for LTK in cancer is also not yet well established. LTK is overexpressed in leukemia, and high expression of LTK in early-stage non-small cell lung cancer (NSCLC) has been associated with greater risk of metastasis (Mueller-Tidow et al, 2005; Roll and Reuther, 2012). More recently, a novel CLIP1-LTK fusion protein has been identified in a small proportion of NSCLC cases (Izumi et al, 2021).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep1877">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1461" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway294">
 <bp:pathwayOrder rdf:resource="#PathwayStep1610" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1279" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1572" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">PTEN Loss of Function in Cancer</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Loss-of-function mutations affecting the phosphatase domain of PTEN are frequently found in sporadic cancers (Kong et al. 1997, Lee et al. 1999, Han et al. 2000), as well as in PTEN hamartoma tumor syndromes (PHTS) (Marsh et al. 1998). PTEN can also be inactivated by gene deletion or epigenetic silencing, or indirectly by overexpression of microRNAs that target PTEN mRNA (Huse et al. 2009). Cells with deficient PTEN function have increased levels of PIP3, and therefore increased AKT activity. For a recent review, please refer to Hollander et al. 2011.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep1878">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1462" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway297">
 <bp:pathwayOrder rdf:resource="#PathwayStep1618" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1622" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1623" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1624" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1625" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1620" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1621" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1619" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1289" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1287" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1288" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1290" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1291" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1285" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1286" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1284" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1580" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Constitutive Signaling by Overexpressed ERBB2</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Overexpression of ERBB2 (HER2), usually as a consequence of ERBB2 gene amplification, results in formation of ERBB2 homodimers. Under normal conditions, only ERBB2 heterodimers form, as ERBB2 is expressed at low levels. ERBB2 homodimerization leads to activation of ERBB2 signaling in the absence of growth factors. Signaling by ERBB2 homodimers mainly activates the RAS/RAF/MAPK signaling cascade, while PI3K/AKT signaling is not significantly affected (Pickl and Ries 2009). Trastuzumab (Herceptin), a recombinant antibody clinically approved as an anti-cancer therapeutic for ERBB2-overexpressing cancers, preferentially binds to ERBB2 homodimers (Pickl and Ries 2009). Accurate functional analysis of ERBB2 signaling may require 3D instead of 2D cell culture (Pickl and Ries 2009).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep1871">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1457" />
 <bp:stepProcess rdf:resource="#Catalysis428" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction670">
 <bp:evidence rdf:resource="#Evidence831" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">nsp6 localizes to the nuclear envelope</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway296">
 <bp:pathwayOrder rdf:resource="#PathwayStep1626" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1617" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1645" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1679" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1643" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1661" />
 <bp:pathwayComponent rdf:resource="#Pathway307" />
 <bp:pathwayComponent rdf:resource="#Pathway309" />
 <bp:pathwayComponent rdf:resource="#Pathway308" />
 <bp:pathwayComponent rdf:resource="#Pathway297" />
 <bp:pathwayComponent rdf:resource="#Pathway310" />
 <bp:pathwayComponent rdf:resource="#Pathway298" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1579" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Signaling by ERBB2 in Cancer</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Gene amplification of the ERBB2 (HER2) oncogene is observed across various different cancer types. In addition to HER2 gene amplification, sequencing of tumour samples have revealed HER2 mutations, which fall within three major regions:  the extracellular domain (ECD), transmembrane domain/ juxtamembrane domain (TMD/JMD) and kinase domain (KD). Based on the functional studies of their catalytic activity, signaling and drug sensitivity, as well as their time of occurence with respect to treatment, these mutation can be classified as primary mutations, that can be activating or silent, and may confer drug resistance, and secondary mutations, associated with development of drug resistance upon initial response to targeted therapy.  Overexpression of ERBB2 (HER2) protein, usually as a consequence of ERBB2 gene amplification, leads to formation of constitutively active, growth factor independent, ERBB2 homodimers, which are sensitive to the therapeutic antibody trastuzumab (herceptin) (Pickl and Ries 2009). Co-overexpression of ERBB2 and its dimerization partner ERBB3 leads to formation of both ERBB2 homodimers and ERRB2:ERBB3 heterodimers and is associated with chemotherapy resistance and reduced relapse-free and overall survival (Spears et al. 2012).  Mutations in the kinase domain (KD) of ERBB2 result in constitutive activation of ERBB2 signaling, facilitate heterodimerization of ERBB2 with other EGFR family members and increase the signaling intensity (Kancha et al. 2011). Functionally studied ERBB2 KD mutants include ERBB2 L755S, ERBB2 L755P, ERBB2 I767M, ERBB2 D769H, ERBB2 V777L, ERBB2 G778_P780dup, ERBB2 T798I, ERBB2 T798M, ERBB2 V842I, ERBB2 T862A, ERBB2 L869R, ERBB2 H878Y and ERBB2 R896C (Kancha et al. 2011, Bose et al. 2013, Collier et al. 2013, Hu, Wan et al. 2015; Hu, Hu et al. 2015, Hanker et al. 2017, Croessmann et al. 2019).  Sensitivity to tyrosine kinase inhibitors (TKIs) and the therapeutic antibody trastuzumab (herceptin) differs between different ERBB2 KD mutants (Bose et al. 2013, Rexer et al. 2013, Nagano et al. 2018).  ERBB2 extracellular domain (ECD) mutants harbor missense mutations that lead to substitutions of amino acid residues in the heterodimerization arm contact surface, involved in formation of ERBB2 heterodimers (Greulich et al. 2012).  Recurrent missense mutations in regions encoding the transmembrane domain (TMD) and the juxtamembrane domain (JMD) are frequently reported in cancer. TMD and JMD mutations can activate ERBB2 signaling by improving the active dimer interface or by stabilizing the active conformation (Ou et al. 2017, Pahuja et al. 2018).  ERBB2 TMD/JMD mutants differ in their sensitivity to the therapeutic antibody pertuzumab, which blocks ligand-driven heterodimerization of ERBB2 (Pahuja et al. 2018).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep1872">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1458" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway299">
 <bp:pathwayOrder rdf:resource="#PathwayStep1628" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1292" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1590" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Resistance of ERBB2 KD mutants to sapitinib</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">This pathway describes resistance of ERBB2 KD mutants to tyrosine kinase inhibitor sapitinib (Nagano et al. 2018).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep1873">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1459" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway298">
 <bp:pathwayOrder rdf:resource="#PathwayStep1637" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1627" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1639" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1629" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1633" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1635" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1641" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1631" />
 <bp:pathwayComponent rdf:resource="#Pathway305" />
 <bp:pathwayComponent rdf:resource="#Pathway304" />
 <bp:pathwayComponent rdf:resource="#Pathway306" />
 <bp:pathwayComponent rdf:resource="#Pathway299" />
 <bp:pathwayComponent rdf:resource="#Pathway301" />
 <bp:pathwayComponent rdf:resource="#Pathway300" />
 <bp:pathwayComponent rdf:resource="#Pathway303" />
 <bp:pathwayComponent rdf:resource="#Pathway302" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1589" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Drug resistance in ERBB2 KD mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ERBB2 kinase domain (KD) mutants vary in their resistance to various tyrosine kinase inhibitors and therapeutic antibody trastuzumab (herceptin). The following ERBB2 KD mutants are resistant to the therapeutic antibody trastuzumab (herceptin):  ERBB2 L755P (Nagano et al. 2018); ERBB2 L755S (Nagano et al. 2018); ERBB2 I767M (Bose et al. 2013); ERBB2 D769Y (Nagano et al. 2018); ERBB2 V777L (Nagano et al. 2018); ERBB2 G778_P780dup (Bose et al. 2013, Nagano et al. 2018); ERBB2 T798M (Rexer et al. 2013); ERBB2 V842I (Nagano et al. 2018); ERBB2 T862A (Nagano et al. 2018); ERBB2 L869R (Hanker et al. 2017);  For ERBB2 R896C, both resistance (Bose et al. 2013) and sensitivity (Nagano et al. 2018) to trastuzumab have been reported. </bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep1874">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1460" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence2520">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2521">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2522">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2523">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep1870">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1456" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence2524">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction666">
 <bp:evidence rdf:resource="#Evidence827" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">3CLp dimer binds 3CLp inhibitors</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence2503">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction667">
 <bp:evidence rdf:resource="#Evidence828" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">nsp3 cleaves nsp1-4</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence2504">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction664">
 <bp:evidence rdf:resource="#Evidence825" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">pp1a forms a dimer</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence2505">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction665">
 <bp:evidence rdf:resource="#Evidence826" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">nsp12 acquires Fe-S cluster cofactors</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence2506">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction662">
 <bp:evidence rdf:resource="#Evidence823" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">3CLp cleaves pp1a</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence2507">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction663">
 <bp:evidence rdf:resource="#Evidence824" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">pp1a cleaves itself</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence2508">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction660">
 <bp:evidence rdf:resource="#Evidence821" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">nsp16 localizes to the nucleus</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence2509">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction661">
 <bp:evidence rdf:resource="#Evidence822" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">nsp3-4 cleaves itself</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction668">
 <bp:evidence rdf:resource="#Evidence829" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">nsp1-4 cleaves itself</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction669">
 <bp:evidence rdf:resource="#Evidence830" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">3CLp forms a homodimer</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep1886">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1468" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1887">
 <bp:stepProcess rdf:resource="#Pathway375" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1888">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1469" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1889">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1470" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1882">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1465" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1883">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1466" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1884">
 <bp:stepProcess rdf:resource="#Pathway374" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1885">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1467" />
 <bp:stepProcess rdf:resource="#Catalysis430" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence2510">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2511">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep1880">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1463" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence2512">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep1881">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1464" />
 <bp:stepProcess rdf:resource="#Catalysis429" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence2513">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction699">
 <bp:evidence rdf:resource="#Evidence862" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Fusion and Release of SARS-CoV-2 Nucleocapsid</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence1205">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2536">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1206">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2537">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction697">
 <bp:evidence rdf:resource="#Evidence860" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Spike binds Spike inhibitors</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence1207">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2538">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction698">
 <bp:evidence rdf:resource="#Evidence861" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TMPRSS2 Mediated SARS-CoV-2 Spike Protein Cleavage and Endocytosis</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence1208">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2539">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction695">
 <bp:evidence rdf:resource="#Evidence858" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Cleavage of S protein into S1:S2</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence1209">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction696">
 <bp:evidence rdf:resource="#Evidence859" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Endocytosis of SARS-CoV-2 Virion</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction693">
 <bp:evidence rdf:resource="#Evidence856" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Direct Host Cell Membrane Membrane Fusion and Release of SARS-CoV-2 Nucleocapsid</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction694">
 <bp:evidence rdf:resource="#Evidence857" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FURIN Mediated SARS-CoV-2 Spike Protein Cleavage and Endocytosis</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep1857">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1445" />
 <bp:stepProcess rdf:resource="#Catalysis423" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1858">
 <bp:stepProcess rdf:resource="#Pathway369" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1859">
 <bp:stepProcess rdf:resource="#Catalysis424" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1446" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway271">
 <bp:pathwayOrder rdf:resource="#PathwayStep1516" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1514" />
 <bp:pathwayComponent rdf:resource="#Pathway273" />
 <bp:pathwayComponent rdf:resource="#Pathway272" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1476" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Hh mutants abrogate ligand secretion</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Hh signaling is required for a number of developmental processes, and mutations that disrupt the normal processing and biogenesis of Hh ligand can result in neonatal abnormalities.  SHH is one of a number of genes that have been associated with the congenital disorder holoprosencephaly, which causes abnormalities in brain and craniofacial development (Roessler et al, 2009; reviewed in Roessler and Muenke, 2011).  SHH variants associated with the condition affect the autocatalytic processing of the precursor and dramatically impair the production of the secreted active Hh-Np, abrogating signaling (reviewed in Pan et al, 2013). Aberrant Hh signaling is also associated with gondal dysgenesis syndromes in which palmitoylation of DHH is abrogated by mutation of the acyltransferase HHAT (Callier et al, 2014).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep1853">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1441" />
 <bp:stepProcess rdf:resource="#Catalysis421" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway270">
 <bp:pathwayOrder rdf:resource="#PathwayStep1512" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1205" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1474" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TGFBR2 MSI Frameshift Mutants in Cancer</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The short adenine repeat in the coding sequence of TGF-beta receptor II (TGFBR2) gene is frequently targeted by loss-of-function frameshift mutations in colon cancers with microsatellite instability (MSI). The 1- or 2-bp deletions in the adenine stretch of TGFBR2 cDNA introduce a premature stop codon that leads to degradation of the majority of mutant transcripts through nonsense-mediated decay or to production of a truncated TGFBR2 that cannot be presented on the cell surface. Cells that harbor TGFBR2 MSI frameshift mutations are resistant to TGF-beta (TGFB1)-mediated growth inhibition.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep1854">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1442" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway273">
 <bp:pathwayOrder rdf:resource="#PathwayStep1517" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1518" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1519" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1520" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1521" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1522" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1212" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1210" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1211" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1209" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1207" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1208" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1479" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Hh mutants are degraded by ERAD</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Hh signaling is required for a number of developmental processes, and mutations that disrupt the normal processing and biogenesis of Hh ligand can result in neonatal abnormalities.  SHH is one of a number of genes that have been associated with the congenital disorder holoprosencephaly, which causes abnormalities in brain and craniofacial development (Roessler et al, 2009; reviewed in Roessler and Muenke, 2011).  SHH variants associated with the condition affect the autocatalytic processing of the precursor and dramatically impair the production of the secreted active Hh-Np, abrogating signaling (reviewed in Pan et al, 2013).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep1855">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1443" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway272">
 <bp:pathwayOrder rdf:resource="#PathwayStep1515" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1206" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1477" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">HHAT G278V doesn&apos;t palmitoylate Hh-Np</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">A loss-of-function mutation in HHAT that abrogates palmitoylation of Hh ligand is associated with Syndromic 46, XY Disorder of Sex Development, which results in testis dysgenesis (Callier et al, 2014). </bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep1856">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1444" />
 <bp:stepProcess rdf:resource="#Catalysis422" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction691">
 <bp:evidence rdf:resource="#Evidence853" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">nsp8 binds MAP1LC3B</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway275">
 <bp:pathwayOrder rdf:resource="#PathwayStep1527" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1528" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1529" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1525" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1526" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1213" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1216" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1217" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1214" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1215" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1487" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Signaling by BRAF and RAF1 fusions</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">In addition to the more prevalent point mutations, BRAF and RAF1 are also subject to activation as a result of translocation events that yield truncated or fusion products (Jones et al, 2008; Cin et al, 2011; Palanisamy et al, 2010; Ciampi et al, 2005; Stransky et al, 2014; Hutchinson et al, 2013; Zhang et al, 2013; Lee et al, 2012; Ricarte-Filho et al, 2013; reviewed in Lavoie and Therrien et al, 2015). In general these events put the C-terminal kinase domain of BRAF or RAF1 downstream of an N-terminal sequence provided by a partner protein. This removes the N-terminal region of the RAF protein, relieving the autoinhibition imposed by this region of the protein. In addition, some but not all of the fusion partner proteins have been shown to contain coiled-coil or other dimerization domains. Taken together, the fusion proteins are thought to dimerize constitutively and activate downstream signaling (Jones et al, 2008; Lee et al, 2012; Hutchinson et al, 2013; Ciampi et al, 2005; Cin et al, 2011; Stransky et al, 2014).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction692">
 <bp:evidence rdf:resource="#Evidence854" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">mRNA1 is translated to pp1ab</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway274">
 <bp:pathwayOrder rdf:resource="#PathwayStep1524" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1548" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1530" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1563" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1553" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1532" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1555" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1570" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1572" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1540" />
 <bp:pathwayComponent rdf:resource="#Pathway282" />
 <bp:pathwayComponent rdf:resource="#Pathway284" />
 <bp:pathwayComponent rdf:resource="#Pathway283" />
 <bp:pathwayComponent rdf:resource="#Pathway275" />
 <bp:pathwayComponent rdf:resource="#Pathway286" />
 <bp:pathwayComponent rdf:resource="#Pathway285" />
 <bp:pathwayComponent rdf:resource="#Pathway277" />
 <bp:pathwayComponent rdf:resource="#Pathway276" />
 <bp:pathwayComponent rdf:resource="#Pathway279" />
 <bp:pathwayComponent rdf:resource="#Pathway278" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1486" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Oncogenic MAPK signaling</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The importance of the RAS/RAF/MAPK cascade in regulating cellular proliferation, differentiation and survival is highlighted by the fact that components of the pathway are mutated with high frequency in a large number of human cancers. Activating mutations in RAS are found in approximately one third of human cancers, while ~8% of tumors express an activated form of BRAF. RAS pathway activation is also achieved in a smaller subset of cancers by loss-of-function mutations in negative regulators of RAS signaling, such as the RAS GAP NF1(reviewed in Prior et al, 2012; Pylayeva-Gupta et al, 2011; Stephen et al, 2014; Lavoie and Therrien, 2015; Lito et al, 2013; Samatar and Poulikakos, 2014; Maertens and Cichowski, 2014).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep1850">
 <bp:stepProcess rdf:resource="#Pathway367" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence2540">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1210">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway277">
 <bp:pathwayOrder rdf:resource="#PathwayStep1538" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1539" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1534" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1535" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1536" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1537" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1533" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1223" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1224" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1221" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1222" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1225" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1219" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1220" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1495" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Signaling by RAF1 mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">RAF1, also known as CRAF, is mutated in a number of germline RASopathies including Noonan Syndrome, Costello Syndrome and others, and also at low frequency in a number of cancers (reviewed in Rauen, 2013; Samatar and Poulikakos, 2015). Activating mutations cluster around conserved region 2 (CR2) which is required for regulation of the protein and the activation segment in CR3 (reviewed in Rauen, 2013).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep1851">
 <bp:stepProcess rdf:resource="#Pathway368" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence2541">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction690">
 <bp:evidence rdf:resource="#Evidence852" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Enhanced autophagosome formation</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence1211">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway276">
 <bp:pathwayOrder rdf:resource="#PathwayStep1531" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1218" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1493" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">RAS signaling downstream of NF1 loss-of-function variants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NF1 is a RAS GAP that stimulates the intrinsic RAS GTPase activity, thereby shifting the RAS pathway towards the inactive state (reviewed in King et al, 2013).  Loss-of-function mutations in NF1 have been identified both in germline diseases like neurofibromatosis 1 and in a range of sporadically occurring cancers.  These mutations, which range from complete gene deletions to missense or frameshift mutations, generally decrease NF1 protein levels and abrogate RAS GAP activity in the cells, resulting in constitutive RAS pathway activation (reviewed in Maertens and Cichowski, 2014; Tidyman and Rauen, 2009; Ratner and Miller, 2015).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep1852">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1440" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence2542">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1212">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway279">
 <bp:pathwayOrder rdf:resource="#PathwayStep1549" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1551" />
 <bp:pathwayComponent rdf:resource="#Pathway280" />
 <bp:pathwayComponent rdf:resource="#Pathway281" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1511" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Signaling by MRAS-complex mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">A complex of MRAS, SHOC2 and the phosphatase PP1 contributes to the activation of RAF proteins by removing an inhibitory phosphorylation that mediates binding to 14-3-3 (also known as YWHAB) proteins (Rodriguez-Viciano et al, 2006; Young et al, 2013;reviewed in Simanshu et al, 2017; Lavoie and Therrien, 2015). Activating and inactivating mutations in each of the components of this dephosphorylating complex have been identified in RASopathies as well as at low frequency in some cancers (Cordeddu et al, 2009; Hannig et al, 2014; Gripp et al, 2016; Higgin et al, 2017; Motta et al, 2016; Motta et al, 2019a,b).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence2543">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1213">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway278">
 <bp:pathwayOrder rdf:resource="#PathwayStep1545" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1546" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1547" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1541" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1542" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1543" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1544" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1232" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1227" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1228" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1226" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1229" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1230" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1231" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1503" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Paradoxical activation of RAF signaling by kinase inactive BRAF</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">While BRAF-specific inhibitors inhibit MAPK/ERK activation in the presence of the BRAF V600E mutant, paradoxical activation of ERK signaling has been observed after treatment of cells with inhibitor in the presence of WT BRAF (Wan et al, 2004; Garnett et al, 2005; Heidorn et al, 2010; Hazivassiliou et al, 2010; Poulikakos et al, 2010). This paradoxical ERK activation is also seen in cells expressing kinase-dead or impaired versions of BRAF such as D594V, which occur with low frequency in some cancers (Wan et al, 2004; Heidorn et al, 2010).  Unlike BRAF V600E, which occurs exclusively of activating RAS mutations, kinase-impaired versions of BRAF are coincident with RAS mutations in human cancers, and indeed, paradoxical activation of ERK signaling in the presence of inactive BRAF is enhanced in the presence of oncogenic RAS (Heidorn et al, 2010; reviewed in Holderfield et al, 2014).  Although the details remain to be worked out, paradoxical ERK activation in the presence of inactive BRAF appears to rely on enhanced dimerization with and transactivation of CRAF (Heidorn et al, 2010; Hazivassiliou et al, 2010; Poulikakos et al, 2010;  Roring et al, 2012; Rajakulendran et al, 2009; Holderfield et al, 2013; Freeman et al, 2013; reviewed in Roskoski, 2010; Samatar and Poulikakos, 2014; Lavoie and Therrien, 2015). RAF inhibitors can promote association of RAF-RAS interaction and enhanced RAF dimerization through disruption of intramolecular interactions between the kinase domain and its N-terminal regulatory region. Moreover, specific BRAF inhibitors can only occupy one protomer within the transcactivated BRAF dimer due to negative co-operativity leading to paradoxical ERK activation. (Karoulia et al, 2016; Jin et al, 2017, reviewed in Karoulia et al, 2017).   </bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence2544">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1214">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2545">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1215">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2546">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction688">
 <bp:evidence rdf:resource="#Evidence850" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">nsp14 binds nsp12</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence2525">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction689">
 <bp:evidence rdf:resource="#Evidence851" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">nsp12 binds nsp7 and nsp8</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence2526">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction686">
 <bp:evidence rdf:resource="#Evidence848" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">nsp7 binds nsp8</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence2527">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction687">
 <bp:evidence rdf:resource="#Evidence849" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">nsp3 binds to nsp7-8 and nsp12-16</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence2528">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction684">
 <bp:evidence rdf:resource="#Evidence846" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Nsp3:nsp4 binds to nsp6</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence2529">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction685">
 <bp:evidence rdf:resource="#Evidence847" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">nsp12 guanylates nsp7</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction682">
 <bp:evidence rdf:resource="#Evidence844" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">nsp10:nsp14 binds to ExoN inhibitors</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction683">
 <bp:evidence rdf:resource="#Evidence845" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">nsp15 forms a hexamer</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep1868">
 <bp:stepProcess rdf:resource="#Pathway370" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1869">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1455" />
 <bp:stepProcess rdf:resource="#Catalysis427" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway280">
 <bp:pathwayOrder rdf:resource="#PathwayStep1550" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1233" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1512" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Gain-of-function MRAS complexes activate RAF signaling</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">This pathway describes the effect of activating mutations of MRAS-complex components on RAF activation (reivewed in Simanshu et al, 2017).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway282">
 <bp:pathwayOrder rdf:resource="#PathwayStep1554" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1235" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1516" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Signaling by MAP2K mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activating mutations in MAP2K1 and MAP2K2, the genes encoding MEK1 and MEK2, have been identified at low frequency in a variety of cancers as well as in germline diseases such as Noonan syndrome, cardiofaciocutaneous syndromes and other RASopathies (reviewed in Samatar and Poulikakos, 2014; Bezniakow et al, 2014; Rauen, 2013).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep1864">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1451" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway281">
 <bp:pathwayOrder rdf:resource="#PathwayStep1552" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1234" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1514" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SHOC2 M1731 mutant abolishes MRAS complex function</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">This pathway describes the effect of a loss-of-function mutation in SHOC2 on RAF activation (Rodriguez-Viciano et al, 2006; Hannig et al, 2014). How both loss- and gain-of-function SHOC2 mutants can  contribute to RAF pathway activation remains to be elucidated.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep1865">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1452" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway284">
 <bp:pathwayOrder rdf:resource="#PathwayStep1567" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1568" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1569" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1564" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1565" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1566" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1245" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1246" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1243" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1244" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1247" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1248" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1526" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Signaling by high-kinase activity BRAF mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">BRAF is mutated in about 8% of human cancers, with high prevalence in hairy cell leukemia, melanoma, papillary thyroid and ovarian carcinomas, colorectal cancer and a variety of other tumors (Davies et al, 2002; reviewed in Samatar and Poulikakos, 2014). Most BRAF mutations fall in the activation loop region of the kinase or the adjacent glycine rich region. These mutations promote increased kinase activity either by mimicking the effects of activation loop phosphorylations or by promoting the active conformation of the enzyme (Davies et al, 2002; Wan et al, 2004). Roughly 90% of BRAF mutants are represented by the single missense mutation BRAF V600E (Davies et al, 2002; Wan et al, 2004). Other highly active kinase mutants of BRAF include BRAF G469A and BRAF T599dup. G469 is in the glycine rich region of the kinase domain which plays a role in orienting ATP for catalysis, while T599 is one of the two conserved regulatory phosphorylation sites of the activation loop. Each of these mutants has highly enhanced basal kinase activities, phosphorylates MEK and ERK in vitro and in vivo and is transforming when expressed in vivo (Davies et al, 2002; Wan et al, 2004; Eisenhardt et al, 2011). Further functional characterization shows that these highly active mutants are largely resistant to disruption of the BRAF dimer interface, suggesting that they are able to act as monomers (Roring et al, 2012; Brummer et al, 2006; Freeman et al, 2013; Garnett et al, 2005). Activating BRAF mutations occur for the most part independently of RAS activating mutations, and RAS activity levels are generally low in BRAF mutant cells. Moreover, the kinase activity of these mutants is only slightly elevated by coexpression of G12V KRAS, and biological activity of the highly active BRAF mutants is independent of RAS binding (Brummer et al, 2006; Wan et al, 2004; Davies et al, 2002; Garnett et al, 2005). Although BRAF V600E is inhibited by RAF inhibitors such as vemurafenib, resistance frequently develops, in some cases mediated by the expression of a splice variant that lacks the RAS binding domain and shows elevated dimerization compared to the full length V600E mutant (Poulikakos et al, 2011; reviewed in Lito et al, 2013).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep1866">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1453" />
 <bp:stepProcess rdf:resource="#Catalysis426" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway283">
 <bp:pathwayOrder rdf:resource="#PathwayStep1556" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1557" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1558" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1559" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1560" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1561" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1562" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1238" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1239" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1236" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1237" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1241" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1242" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1240" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1518" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Signaling by moderate kinase activity BRAF mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">In addition to the highly prevalent and activating V600E BRAF mutations, numerous moderately activating and less common mutations have also been identified in human cancers (Forbes et al, 2015).  Unlike the case for their highly activating counterparts, signaling through these mutant versions of BRAF depends both upon RAS binding and RAF dimerization (Wan et al, 2004; Freeman et al, 2013; Roring et al, 2012; reviewed in Lito et al, 2013; Lavoie and Therrien, 2015)</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep1867">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1454" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction680">
 <bp:evidence rdf:resource="#Evidence842" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">nsp14 binds nsp10</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway286">
 <bp:pathwayOrder rdf:resource="#PathwayStep1581" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1573" />
 <bp:pathwayComponent rdf:resource="#Pathway288" />
 <bp:pathwayComponent rdf:resource="#Pathway287" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1535" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Signaling by RAS mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Members of the RAS gene family were the first oncogenes to be identified, and mutations in RAS are present in ~20-30% of human cancers (reviewed in Prior et al, 2012). Mutations in the KRAS gene are the most prevalent, and are found with high frequency in colorectal cancer, non-small cell lung cancer and pancreatic cancer, among others. The reasons for the lower prevalence of HRAS and NRAS mutations in human cancers are not fully understood, but may reflect gene-specific functions as well as differential codon usage and spatio-temporal regulation (reviewed in Prior et al, 2012; Stephen et al, 2014; Pylayeva-Gupta et al, 2011). Activating RAS mutations contribute to cellular proliferation, transformation and survival by activating the MAPK signaling pathway, the AKT pathway and the RAL GDS pathway, among others (reviewed in Stephen et al, 2014; Pylayeva-Gupta et al, 2011).  Although the frequency and distribution varies between RAS genes and cancer types, the vast majority of activating RAS mutations occur at one of three residues - G12, G13 and Q61. Mutations at these sites favour the RAS:GTP bound form and yield constitutively active versions of the protein (reviewed in Prior et al, 2012).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep1860">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1447" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction681">
 <bp:evidence rdf:resource="#Evidence843" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">nsp15 binds nsp8</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway285">
 <bp:pathwayOrder rdf:resource="#PathwayStep1571" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1249" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1533" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Signaling by MAPK mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Mutations in ERK proteins (MAPK1 and MAPK2) are rare, with mutations reported in ~8% of cervical cancers and 1.5% of head and neck squamous cell carcinomas (Ojesina et al, 2014; Cancer Genome Atlas, 2015; reviewed in Najafi et al, 2019). MAPK proteins with activating mutations are often still dependent on upstream phosphorylation by MAP2K proteins, but support sustained downstream signaling by virtue of being resistant to inactivating dephosphorylations (reviewed in Samatar and Poulikakos, 2014; Liu et al, 2018).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep1861">
 <bp:stepProcess rdf:resource="#Catalysis425" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1448" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway288">
 <bp:pathwayOrder rdf:resource="#PathwayStep1582" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1584" />
 <bp:pathwayComponent rdf:resource="#Pathway290" />
 <bp:pathwayComponent rdf:resource="#Pathway289" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1544" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">RAS GTPase cycle mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">RAS proteins cycle between an active GTP-bound state and an inactive GDP-bound state. GTPase activating proteins (GAPs) stimulate the low intrinsic GTPase activity of RAS proteins, converting the active to the inactive form, while guanine nucleotide exchange factors (GEFs) stimulate the intrinsic dissociation of GDP, allowing its replacement with GTP and consequent activation of RAS. Disease-causing mutations in RAS promote constitutive signaling by favouring the accumulation of RAS:GTP. The vast majority of these mutations are loss of function mutations at G12, G13 and Q61. These mutations disrupt the GTPase activity of RAS proteins by interfering with nucleophilic attack on the gamma phosphate of GTP. A smaller proportion of RAS mutations increase the intrinsic GDP dissociation rate, while other mutations interfere with RAS interactions with GAPs (reviewed in Prior et al, 2012; Pylayeva-Gupta et al, 2011; Stephen et al, 2014; Samatar and Poulikakos, 2014).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep1862">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1449" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence2530">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1200">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway287">
 <bp:pathwayOrder rdf:resource="#PathwayStep1580" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1578" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1579" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1574" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1575" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1576" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1577" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1256" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1254" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1255" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1252" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1253" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1250" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1251" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1536" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Signaling downstream of RAS mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Disease-causing mutations in RAS favour the active RAS:GTP bound form and yield constitutively active forms of the protein (reviewed in Prior et al, 2011; Maertens and Cichowski, 2014).  Mutations in RAS contribute to cellular proliferation, transformation and survival by activating the MAPK signaling pathway, the AKT pathway and the RAL GDS pathway, among others (reviewed in Stephen et al, 2014; Pylayeva-Gupta et al, 2011)</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep1863">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1450" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence2531">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1201">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2532">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1202">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway289">
 <bp:pathwayOrder rdf:resource="#PathwayStep1583" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1257" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1545" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Signaling by RAS GTPase mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">This pathway describes RAS mutants with decreased intrinsic GTPase activity that therefore support increased RAS pathway activity (reviewed in Prior et al, 2012; Pylayeva and Gupta, 2011, King et al, 2013; Cox and Der, 2010).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence2533">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1203">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2534">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1204">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2535">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction633">
 <bp:evidence rdf:resource="#Evidence791" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Replication transcription complex binds SARS-CoV-2 genomic RNA</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction634">
 <bp:evidence rdf:resource="#Evidence792" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">nsp15 binds RB1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction631">
 <bp:evidence rdf:resource="#Evidence789" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">nsp15 cleaves viral poly(U)-RNA</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction632">
 <bp:evidence rdf:resource="#Evidence790" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">nsp14 acts as a cap N7 methyltransferase to modify SARS-CoV-2 gRNA (plus strand)</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction630">
 <bp:evidence rdf:resource="#Evidence788" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SARS-CoV-2 gRNA complement (minus strand):RTC binds RTC inhibitors</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction639">
 <bp:evidence rdf:resource="#Evidence797" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">nsp16 acts as a cap 2&apos;-O-methyltransferase to modify SARS-CoV-2 gRNA complement (minus strand)</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction637">
 <bp:evidence rdf:resource="#Evidence795" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ZCRB1 binds 5&apos;UTR of SARS-CoV-2 genomic RNA</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep1828">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1427" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction638">
 <bp:evidence rdf:resource="#Evidence796" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">nsp13 helicase melts secondary structures in SARS-CoV-2 genomic RNA template</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep1829">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1428" />
 <bp:stepProcess rdf:resource="#Catalysis419" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction635">
 <bp:evidence rdf:resource="#Evidence793" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">RTC completes synthesis of the minus strand genomic RNA complement</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction636">
 <bp:evidence rdf:resource="#Evidence794" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">RTC synthesizes SARS-CoV-2 plus strand genomic RNA</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep1835">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1431" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1836">
 <bp:stepProcess rdf:resource="#Pathway361" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1837">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1432" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1838">
 <bp:stepProcess rdf:resource="#Pathway362" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1831">
 <bp:stepProcess rdf:resource="#Pathway358" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1832">
 <bp:stepProcess rdf:resource="#Pathway359" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway251">
 <bp:pathwayOrder rdf:resource="#PathwayStep1465" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1177" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1427" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Imatinib-resistant PDGFR mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">A number of PDGFRA mutations found in GIST and other cancers are resistant to inhibition with imatinib (reviewed in Corless et al, 2011). These include the most common allele D842V, which occurs in the activation loop of the receptor, as well as S601P and the gatekeeper mutation T674I (reviewed in Roskoski, 2018; Klug et al, 2018).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep1833">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1430" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway250">
 <bp:pathwayOrder rdf:resource="#PathwayStep1470" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1468" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1464" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1466" />
 <bp:pathwayComponent rdf:resource="#Pathway251" />
 <bp:pathwayComponent rdf:resource="#Pathway253" />
 <bp:pathwayComponent rdf:resource="#Pathway252" />
 <bp:pathwayComponent rdf:resource="#Pathway254" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1426" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Drug resistance of PDGFR mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">PDGFRA is mutated in ~10% of gastrointestinal stromal tumors in a mutually exclusive manner with KIT mtutations. In contrast to KIT, PDGFRA GIST mutations occur more frequently in the activation domain, rather than the juxtamembrane domain. In addition to GIST, PDGFRA is subject to missense or small in-frame deletion mutations in haematological cancers and melanoma. In contrast, missense mutations in PDGFRB are rare (Heinrich et al, 2003; Corless et al, 2005; reviewed in Corless et al, 2011). Both PDGFRA and PDGFRB are also subject to oncogenic translocation events leading to the expression of fusion proteins (Cools et al, 2003; Simon et al, 2008; Salemi et al, 2009; Ohashi et al, 2010; reviewed in Appiah-Kubi et al, 2017). Imatinib is a type II TKIs that is approved as first-line treatment of KIT- and PDGFR-driven tumors; however secondary mutations frequently contribute to the development of imatinib resistance. These secondary mutations further shift the equilibrium of the receptor toward the activated state, making imatinib and even approved second-line type II TKIs less effective. In consequence, considerable effort is devoted to discovery of type II and, in particular, type I TKIs that are active against highly activated PDGFR alleles (Smith et al, 2019; Lierman et al, 2019; reviewed in Roskoski, 2018; Klug et al, 2018).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep1834">
 <bp:stepProcess rdf:resource="#Pathway360" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway253">
 <bp:pathwayOrder rdf:resource="#PathwayStep1469" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1179" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1431" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Sunitinib-resistant PDGFR mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Sunitinib is a class II TKI that is often used as a second-line treatment in PDGFR- and KIT-driven cancers that develop resistance to imatinib (reviewed in Corless et al, 2011; Klug et al, 2018). Sunintib is approved for the treatment of renal cell carcinoma, GIST and pancreatic tumors. A number of PDGFR mutations exhibit resistance to inhibition by sunitinib (Roskoski, 2007; reviewed in Roskoski, 2018; Klug et al, 2018).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway252">
 <bp:pathwayOrder rdf:resource="#PathwayStep1467" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1178" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1429" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Sorafenib-resistant PDGFR mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Sorafenib is a type II tyrosine kinase inhibitor that is approved for use in hepatocellular and renal cell carcinoma, and that is often used as a second-line treatment for imatinib-resistant tumors. Despite its initial efficacy, resistance to sorafenib often develops (reviewed in Molina-Ruiz et al, 2017).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway255">
 <bp:pathwayOrder rdf:resource="#PathwayStep1473" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1474" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1182" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1181" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1435" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Signaling by membrane-tethered fusions of PDGFRA or PDGFRB</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">In addition to activating missensse and in-frame deletion mutations, PDGFRA and PDGFRB are also subject to low frequency gene fusion events arising from chromosomal rearrangements. To date there are about 35 identified PDGFRA or B fusion partners, with PDGFRB being the more common partner (reviewed in Appiah-Kubi et al, 2017). Although some of the PDGF fusions proteins are cytosolic by virtue of removal of the PDGFR transmembrane region (TMD), a number of fusions retain the TMD and are linked to the plasma membrane (Hidalgo-Curtis et al, 2010; Ozawa et al, 2010; Curtis et al, 2007; Medves et al, 2010; reviewed in Appiah-Kubi et al, 2017). The most common transmembrane fusion partner of PDGFRA and PDGFRB is ETV6 (also known as TEL1), a transcriptional repressor with known ability to homodimerize (Curtis et al, 2007; Golub et al, 1994; Andrae et al, 2008; reviewed in de Braekeleer et al, 2012; Wang et al, 2016; Appiah-Kubi et al, 2017). </bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway254">
 <bp:pathwayOrder rdf:resource="#PathwayStep1471" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1180" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1433" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Regorafenib-resistant PDGFR mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Regorafenib is a type II TKI that is approved for the treatment of advanced gastrointestinal stromal tumors. Although regorafenib is effective against a number of KIT and PDGFR mutations, it only weakly inhibits the activity of the most prevalent PDGFRA allele, D842V (Evans et al, 2017).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep1830">
 <bp:stepProcess rdf:resource="#Catalysis420" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1429" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway257">
 <bp:pathwayOrder rdf:resource="#PathwayStep1484" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1485" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1190" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1191" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1446" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Signaling by cytosolic PDGFRA and PDGFRB fusion proteins</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">In addition to activating missense mutations and in-frame deletions, PDGFRA and PDGFRB are also subject to gene fusion events arising from chromosomal rearrangements. PDGFR fusions often consist of the cytosolic domain of the receptor tyrosine kinase fused to the N-terminal oligomerization domain of an intracellular protein, leading to ligand-independent dimerization and constitutive activation (reviewed in Wang et al, 2016; Appiah-Kubi et al, 2017). To date there are about 35 identified PDGFR fusion partners, most of which form fusions with PDGFRB (reviewed in Appiah-Kubi et al, 2017). The most common cytosolic fusion partners of PDGFRA is FIP1L1, an RNA processing factor (Cools et al, 2003; Stover et al, 2006; Simon et al, 2008; Andrae et al, 2008; Ozawa et al, 2010; Appiah-Kubi et al, 2017). Fusion partners with PDGFRB are numerous but occurrence of these proteins is rare (Hidalgo-Curtis et al, 2010; reviewed in Wang et al, 2016; Appiah-Kubi et al, 2017).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway256">
 <bp:pathwayOrder rdf:resource="#PathwayStep1480" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1481" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1479" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1476" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1477" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1478" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1482" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1188" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1189" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1183" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1186" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1187" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1184" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1185" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1438" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Signaling by PDGFRA extracellular domain mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Mutations in the extracellular domain of receptor tyrosine kinases like PDGRFA have the potential to interfere with glycosylation, which is required for proper trafficking to the cell surface. Versions of PDGFRA bearing mutations in the extracellular domain have been identified in some cancers, and while some of these are inactive, some have also been shown to signal constitutively from the endoplasmic reticulum (Ip et al, 2018; Velghe et al, 2014; Ozawa et al, 2010; Paugh et al, 2013; Clarke et al, 2003). PDGFRA Y288C carries a mutation in the extracellular domain of the receptor that prevents the normal trafficking of the protein to the plasma membrane. PDGFRA Y288C is trapped in the endoplasmic reticulum membrane, from where it is able to signal constitutively in the absence of ligand (Ip et al, 2018). Similarly, a version of PDGFRA bearing an in-frame deletion of exons 8 and 9 has been identified in glioblastoma. The resulting protein is constitutively active in the absence of ligand despite the low fraction of protein expressed at the cell surface (Clarke et al, 2003; Ozawa et al, 2010).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway259">
 <bp:pathwayOrder rdf:resource="#PathwayStep1508" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1503" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1500" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1495" />
 <bp:pathwayComponent rdf:resource="#Pathway260" />
 <bp:pathwayComponent rdf:resource="#Pathway263" />
 <bp:pathwayComponent rdf:resource="#Pathway265" />
 <bp:pathwayComponent rdf:resource="#Pathway268" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1457" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Signaling by TGF-beta Receptor Complex in Cancer</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Signaling by the TGF-beta receptor complex is tumor suppressive, as it inhibits cell growth and promotes cell differentiation and apoptosis (Shipley et al. 1986, Hannon et al. 1994, Datto et al. 1995, Chen et al. 2002, Azar et al. 2009). TGF-beta signaling is frequently impaired in cancer, mostly through SMAD4 gene deletion or loss-of-function mutations (described in the pathway Loss of Function of SMAD4 in Cancer), which are especially frequent in pancreatic cancer (Hahn et al. 1996, Shi et al. 1997, Fleming et al. 2013). Signaling by TGF-beta receptor complex can also be disrupted by loss-of-function mutations in SMAD2 and SMAD3 (Fleming et al. 2013), as described in the pathway Loss of Function of SMAD2/SMAD3 in Cancer, or loss-of-function mutations in TGFBR2 (TGF-beta receptor II) (Markowitz et al. 1995, Garrigue-Antar et al. 1995, Parsons et al. 1995, Grady et al. 1999), as described in the pathway Loss of Function of TGFBR2 in Cancer, or TGFBR1 (TGF-beta receptor I) (Chen et al. 1998, Chen et al. 2001, Goudie et al. 2011), as described in the pathway Loss of Function of TGFBR1 in Cancer.  In advanced cancer, signaling by TGF-beta may be tumor promoting, as it induces epithelial-to-mesenchymal transition (EMT), thereby increasing invasiveness (Cui et al. 1996, Guasch et al. 2007, reviewed by Heldin et al. 2012).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway258">
 <bp:pathwayOrder rdf:resource="#PathwayStep1490" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1491" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1492" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1487" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1488" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1489" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1493" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1193" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1194" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1192" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1197" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1198" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1195" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1196" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1449" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">PDGFRA is a type III  transmembrane receptor tyrosine kinase. The extracellular domain consists of 5 immunoglobulin (IG) domains that contribute to dimerization and ligand binding. The intracellular region has a juxtamembrane domain that plays a role in autoinhibiting the receptor in the absence of ligand, and a bi-lobed kinase region with an activation loop and the catalytic cleft (reviewed in Klug et al, 2018). Upon ligand binding, PDGFRA undergoes dimerization and transautophosphorylation at at least 11 tyrosine residues in the intracellular domain. These phosphorylated residues are binding sites for downstream effectors of PDGFRA-responsive signaling pathways (reviewed in Klug et al, 2018; Roskoski, 2018).  PDGFRA is subject to activating mutations in a number of cancers, including gastrointestinal stromal tumors (GIST), melanoma and haematological cancers (reviewed in Corless et al, 2011; Wang et al, 2016; Roskoski, 2018). The most prevalent mutations in PDGFRA are at residue V561 in the juxtamembrane domain, N659 in the small lobe of the kinase domain and D842 in the activation loop of the kinase domain. PDGFRA is also subject to short deletions in the activation loop segment (reviewed in Roskoski, 2018). Acitvated forms of the protein may signal from the plasma membrane, similar to the wild type receptor, however there is also evidence that some mutants, notably D842V and V561D localize primarily to the Golgi membrane (Bahlawane et al, 2014). Activated PDGFRA mutants signal constitutively in the absence of ligand (reviewed in Roskoski, 2018; Wang et al, 2016; Klug et al, 2018).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction622">
 <bp:evidence rdf:resource="#Evidence774" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SARS-CoV-1 6 binds to NPIPB3</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction623">
 <bp:evidence rdf:resource="#Evidence775" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SARS-CoV-1 SUMO1-K62-p-S177-N dimer binds to PKL</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction620">
 <bp:evidence rdf:resource="#Evidence772" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SARS-CoV-1 dsRNA intermediates bind DDX58</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction621">
 <bp:evidence rdf:resource="#Evidence773" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SARS-CoV-1 dsRNA intermediates bind IFIH1:TKFC</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction628">
 <bp:evidence rdf:resource="#Evidence782" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SARS-CoV-1 3a binds the lysosomal membrane</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction629">
 <bp:evidence rdf:resource="#Evidence783" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SARS-CoV-1 7a binds BCL2L1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction626">
 <bp:evidence rdf:resource="#Evidence780" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SARS-CoV-1 3a binds RIPK1:RIPK3 oligomer</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep1839">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1433" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction627">
 <bp:evidence rdf:resource="#Evidence781" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SARS-CoV-1 3a oligomerizes</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction624">
 <bp:evidence rdf:resource="#Evidence777" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MPP5 binds SARS-CoV-1 E pentamer</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction625">
 <bp:evidence rdf:resource="#Evidence779" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SARS-CoV-1 E binds BCL2L1</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep1846">
 <bp:stepProcess rdf:resource="#Pathway366" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1847">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1437" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1848">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1438" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1849">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1439" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway260">
 <bp:pathwayOrder rdf:resource="#PathwayStep1498" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1496" />
 <bp:pathwayComponent rdf:resource="#Pathway262" />
 <bp:pathwayComponent rdf:resource="#Pathway261" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1458" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Loss of Function of SMAD2/3 in Cancer</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Loss-of-function of SMAD2 and SMAD3 in cancer occurs less frequently than the loss of SMAD4 function and was studied in most detail in colorectal cancer (Fleming et al. 2013).  Similarly to SMAD4, coding sequence mutations in SMAD2 and SMAD3 in cancer cluster in the MH2 domain, involved in the formation of transcriptionally active heterotrimers with SMAD4. Another region of SMAD2 and SMAD3 that is frequently mutated in cancer is the phosphorylation motif Ser-Ser-X-Ser at the very C-terminus (Fleming et al. 2013). The phosphorylation of this conserved motif by the activated TGF-beta receptor complex is an essential step in SMAD2 and SMAD3 activation and a prerequisite for the formation of heterotrimers with SMAD4 (Chacko et al. 2001, Chacko et al. 2004).  Smad2 knockout mice die at embryonic day 8.5, with impaired visceral endoderm function and deficiency in mesoderm formation. Smad2+/- heterozygotes appear normal and are fertile (Hamamoto et al. 2002). While polyps of compound Smad2+/-;Apc+/- mice show no difference in the number, size or histopathology from the polyps of Apc+/- mice (Takaku et al. 2002, Hamamoto et al. 2002), Smad2+/-;Apc+/- mice develop extremely large intestinal tumors and multiple invasive cancers not observed in Apc+/- mice. Therefore, loss of Smad2 does not contribute to initiation of intestinal tumorigenesis, but accelerates malignant progression (Hamamoto et al. 2002). Smad3 knockout mice are viable and fertile but die between 4 and 6 months of age from colorectal adenocarcinoma (Zhu et al. 1998), indicating that the loss of Smad3 initiates intestinal tumorigenesis.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep1842">
 <bp:stepProcess rdf:resource="#Pathway364" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1843">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1435" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway262">
 <bp:pathwayOrder rdf:resource="#PathwayStep1499" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1200" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1461" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SMAD2/3 Phosphorylation Motif Mutants in Cancer</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The conserved phosphorylation motif Ser-Ser-X-Ser at the C-terminus of SMAD2 and SMAD3 is subject to disruptive mutations in cancer. The last two serine residues in this conserved motif, namely Ser465 and Ser467 in SMAD2 and Ser423 and Ser425 in SMAD3, are phosphorylated by the activated TGF beta receptor complex (Macias Silva et al. 1996, Nakao et al. 1997). Once phosphorylated, SMAD2 and SMAD3 form transcriptionally active heterotrimers with SMAD4 (Chacko et al. 2001, Chacko et al. 2004). Phosphorylation motif mutants of SMAD2 and SMAD3 cannot be activated by the TGF-beta receptor complex either because serine residues are substituted with amino acid residues that cannot be phosphorylated or because the phosphorylation motif is deleted from the protein sequence or truncated (Fleming et al. 2013).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep1844">
 <bp:stepProcess rdf:resource="#Pathway365" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway261">
 <bp:pathwayOrder rdf:resource="#PathwayStep1497" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1199" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1459" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SMAD2/3 MH2 Domain Mutants in Cancer</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Mutations in the MH2 domain of SMAD2 and SMAD3 affect their ability to form heterotrimers with SMAD4, thereby impairing TGF-beta signaling (Fleming et al. 2013).  The SMAD2 and SMAD3 MH2 domain residues most frequently targeted by missense mutations are those that are homologous to SMAD4 MH2 domain residues shown to be involved in the formation of SMAD heterotrimers. Asp300 of SMAD2 and Asp258 of SMAD3 correspond to the frequently mutated Asp351 of SMAD4. Pro305 of SMAD2 corresponds to the frequently mutated Pro356 of SMAD4, while Ala354 of SMAD2 corresponds to Ala406 of SMAD4. Arg268 of SMAD3 corresponds to the frequently mutated Arg361 of SMAD4. SMAD2 and SMAD3 MH2 domain mutations have been examined in most detail in colorectal cancer (Fleming et al. 2013).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep1845">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1436" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway264">
 <bp:pathwayOrder rdf:resource="#PathwayStep1502" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1201" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1464" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SMAD4 MH2 Domain Mutants in Cancer</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The MH2 domain of SMAD4 is the most frequently mutated SMAD4 region in cancer. MH2 domain mutations result in the loss of function of SMAD4 by abrogating the formation of transcriptionally active heterotrimers of SMAD4 and TGF-beta receptor complex-activated R-SMADs - SMAD2 and SMAD3 (Shi et al. 1997, Chacko et al. 2001, Chacko et al. 2004, Fleming et al. 2013).  The hotspot MH2 domain amino acid residues that are targeted by missense mutations are Asp351 (D351), Pro356 (P356) and Arg361 (R361). These three hotspot residues map to the L1 loop which is conserved in SMAD2 and SMAD3 and is involved in intermolecular interactions that contribute to the formation of SMAD heterotrimers and homotrimers (Shi et al. 1997, Fleming et al. 2013). Other frequently mutated residues in the MH2 domain of SMAD4 - Ala406 (A406), Lys428 (K428) and Arg515 (R515) - are involved in binding the phosphorylation motif (Ser-Ser-X-Ser) of SMAD2 and SMAD3, with Arg515 in the L3 loop being critical for this interaction (Chacko et al. 2001, Chacko et al. 2004, Fleming et al. 2013).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway263">
 <bp:pathwayOrder rdf:resource="#PathwayStep1501" />
 <bp:pathwayComponent rdf:resource="#Pathway264" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1463" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Loss of Function of SMAD4 in Cancer</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SMAD4 was identified as a gene homozygously deleted in ~30% of pancreatic cancers and was named DPC4 (DPC stands for deleted in pancreatic cancer). SMAD4 maps to the chromosomal band 18q21.1, and about 90% of pancreatic carcinomas show allelic loss at chromosomal arm 18q (Hahn et al. 1996), while ~50% of pancreatic cancers show some alteration of the SMAD4 gene (reviewed by Schutte et al. 1999).  Based on COSMIC database (Catalogue Of Somatic Mutations In Cancer) (Forbes et al. 2011), mutations in the coding sequence of SMAD4 gene are frequently found in pancreatic cancer, biliary duct carcinoma and colorectal cancer (reviewed by Schutte et al. 1999). Germline SMAD4 mutations are the cause of juvenile polyposis, an autosomal dominant disease that predisposes affected individuals to hamartomatous polyps and gastrointestinal cancer (Howe et al. 1998). Homozygous Smad4 loss is embryonic lethal in mice (Takaku et al. 1998). Smad4 +/- heterozygotes appear normal but develop intestinal polyps between 6 and12 months of age and these polyps can progress to cancer. Loss of the remaining wild-type Smad4 allele is detectable only at later stages of tumor progression in Smad4+/- mice (Xu et al. 2000). Compound Apc+/-;Smad4+/- mice develop malignant tumors from intestinal polyps more rapidly than Apc+/- mice (Takaku et al. 1998).  SMAD4 coding sequence mutations are most frequently found in the MH2 domain and impair the formation of SMAD4 heterotrimers with phosphorylated SMAD2 and SMAD3 (Shi et al. 1997, Fleming et al. 2013), thereby impairing SMAD4:SMAD2/3 heterotrimer-mediated transcriptional regulation of TGF-beta responsive genes. MH2 domain is also involved in the formation of SMAD4 homotrimers which may play a role in SMAD4 protein stability (Shi et al. 1997).  Coding sequence mutations are also found in the MH1 domain of SMAD4. MH1 domain is involved in DNA binding (Dai et al. 1999) and it is also involved in the formation of SMAD4 homotrimers (Hata et al. 1997).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway266">
 <bp:pathwayOrder rdf:resource="#PathwayStep1505" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1202" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1467" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TGFBR1 KD Mutants in Cancer</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Mutations in the kinase domain (KD) of TGF-beta receptor 1 (TGFBR1) have been found in Ferguson-Smith tumor i.e. multiple self-healing squamous epithelioma - MSSE (Goudie et al. 2011), breast cancer (Chen et al. 1998), ovarian cancer (Chen et al. 2001) and head-and-neck cancer (Chen et al. 2001). KD mutations reported in MSSE are nonsense and frameshift mutations that cause premature termination of TGFBR1 translation, resulting in truncated receptors that lack substantial portions of the kinase domain, or cause nonsense-mediated decay of mutant transcripts. A splice site KD mutation c.806-2A&gt;C is predicted to result in the skipping of exon 5 and the absence of KD amino acid residues 269-324 from the mutant receptor. The splice site mutant is expressed at the cell surface but unresponsive to TGF-beta stimulation (Goudie et al. 2004).   TGFBR1 KD mutations reported in breast, ovarian and head-and-neck cancer are missense mutations, and it appears that these mutant proteins are partially functional but that their catalytic activity or protein stability is decreased (Chen et al. 1998, Chen et al. 2001a and b). These mutants are not shown.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep1840">
 <bp:stepProcess rdf:resource="#Pathway363" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway265">
 <bp:pathwayOrder rdf:resource="#PathwayStep1506" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1504" />
 <bp:pathwayComponent rdf:resource="#Pathway266" />
 <bp:pathwayComponent rdf:resource="#Pathway267" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1466" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Loss of Function of TGFBR1 in Cancer</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TGF-beta receptor 1 (TGFBR1) loss-of-function is a less frequent mechanism for inactivation of TGF-beta signaling in cancer compared to SMAD4 and TGFBR2 inactivation. Genomic deletion of TGFBR1 locus has been reported in pancreatic cancer (Goggins et al. 1998), biliary duct cancer (Goggins et al. 1998) and lymphoma (Schiemann et al. 1999), while loss-of-function mutations have been reported in breast (Chen et al. 1998) and ovarian cancer (Chen et al. 2001), metastatic head-and-neck cancer (Chen et al. 2001), and in Ferguson-Smith tumors (multiple self-healing squamous epithelioma - MSSE) (Goudie et al. 2011). Loss-of-function mutations mainly affect the ligand-binding extracellular domain of TGFBR1 and the kinase domain of TGFBR1 (Goudie et al. 2011). In the mouse model of colorectal cancer, Tgfbr1 haploinsufficiency cooperates with Apc haploinsufficiency in the development of intestinal tumors (Zeng et al. 2009).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep1841">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1434" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway268">
 <bp:pathwayOrder rdf:resource="#PathwayStep1511" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1509" />
 <bp:pathwayComponent rdf:resource="#Pathway270" />
 <bp:pathwayComponent rdf:resource="#Pathway269" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1471" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Loss of Function of TGFBR2 in Cancer</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Loss-of-function of transforming growth factor-beta receptor II (TGFBR2) is most prevalent in colorectal cancer. Over 60% of colorectal cancers with microsatellite instability (MSI) harbor inactivating mutations in both alleles of TGFBR2, mostly 1 or 2 bp deletions in the 10 bp adenine repeat that codes for three lysine residues in the extracellular domain of TGFBR2. These small deletions result in a frameshift and a premature stop codon (Markowitz et al. 1995). TGFBR2 kinase domain (KD) mutations are found in ~20% of microsatellite stable (MSS) colorectal cancers and these are mostly missense mutations that results in substitution of conserved amino acids in the kinase domain (Grady et al. 1999), likely impairing the catalytic activity of TGFBR2 KD mutants. The silencing of TGFBR2 gene via promoter methylation has been reported in B-cell lymphoma (Chen et al. 2007). Knockout of murine Tgfbr2 in colonic epithelium promotes azoxymethane-induced colon cancer formation (Biswas et al. 2004) and increases the number of adenomas and adenocarcinomas in Apc+/- mice (Munoz et al. 2006).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway267">
 <bp:pathwayOrder rdf:resource="#PathwayStep1507" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1203" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1469" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TGFBR1 LBD Mutants in Cancer</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Mutations in the ligand-binding domain (LBD) of TGF-beta receptor 1 (TGFBR1) have been reported as germline mutations in Ferguson-Smith tumor (multiple self-healing squamous epithelioma - MSSE), an autosomal-dominant skin cancer condition (Ferguson-Smith et al. 1934, Ferguson-Smith et al. 1971), with tumors frequently showing loss of heterozygosity of the wild-type TGFBR1 allele (Goudie et al. 2011). Somatic mutations in the LBD of TGFBR1 have been reported in esophageal carcinoma (Dulak et al. 2013).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway269">
 <bp:pathwayOrder rdf:resource="#PathwayStep1510" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1204" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1472" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TGFBR2 Kinase Domain Mutants in Cancer</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Missense mutations in the kinase domain (KD) of TGF-beta receptor II (TGFBR2) are found in ~20% of microsatellite stable (MSS) colon cancers and make affected tumors resistant to TGF-beta (TGFB1)-mediated growth inhibition (Grady et al. 1999). While both alleles of TGFBR2 are affected by inactivating mutations in MSS colorectal cancer (Grady et al. 1999), a study of MSS esophageal carcinoma indicates that TGFBR2 KD mutations may function in a dominant-negative way (Tanaka et al. 2000). KD mutations in TGFBR2 are rarely reported in microsatellite instable (MSI) colorectal cancer (Parsons et al. 1995, Takenoshita et al. 1997).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction655">
 <bp:evidence rdf:resource="#Evidence814" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Synthesis of SARS-CoV-2 minus strand subgenomic mRNAs by template switching</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway239">
 <bp:pathwayOrder rdf:resource="#PathwayStep1402" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1398" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1399" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1400" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1401" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1397" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1136" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1139" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1137" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1138" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1140" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1141" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1374" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Constitutive Signaling by NOTCH1 HD Domain Mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The heterodimerization (HD) domain of NOTCH1, responsible for association of NOTCH1 extracellular and transmembrane regions after furin-mediated cleavage of NOTCH1 precursor, is one of the hotspots for gain-of-function NOTCH1 mutations in T-cell acute lymphoblastic leukemia (T-ALL) (Weng et al. 2004). NOTCH1 HD domain mutants are responsive to ligand binding, but the activation (through cleavage of S2 and S3 sites and release of the intracellular domain NICD1) also happens spontaneously, in the absence of DLL and JAG ligands (Malecki et al. 2006). The following NOTCH1 HD domain mutants were directly functionally studied by Malecki et al.: NOTCH1 V1576E, NOTCH1 F1592S, NOTCH1 L1593P, NOTCH1 L1596H, NOTCH1 R1598P, NOTCH1 I1616N, NOTCH1 I1616T, NOTCH1 V1676D, NOTCH1 L1678P, NOTCH1 I1680N, NOTCH1 A1701P and NOTCH1 I1718T; other frequent NOTCH1 HD domain mutants (NOTCH1 L1574P, NOTCH1 L1574Q and NOTCH1 L1600P) are assumed to behave in a similar way. </bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction656">
 <bp:evidence rdf:resource="#Evidence815" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Synthesis of SARS-CoV-2 plus strand subgenomic mRNAs</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway238">
 <bp:pathwayOrder rdf:resource="#PathwayStep1396" />
 <bp:pathwayComponent rdf:resource="#Pathway239" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1373" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Signaling by NOTCH1 HD Domain Mutants in Cancer</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NOTCH1 heterodimerization domain mutations are frequently found in T-cell acute lymphoblastic leukemia (T-ALL) (Weng et al. 2004) and result in constitutive activity of NOTCH1 mutants (Malecki et al. 2006).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction653">
 <bp:evidence rdf:resource="#Evidence812" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Polyadenylation of SARS-CoV-2 subgenomic mRNAs (plus strand)</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction654">
 <bp:evidence rdf:resource="#Evidence813" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">nsp12 transfers guanylyl onto SARS-CoV-2 plus strand subgenomic RNAs</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction651">
 <bp:evidence rdf:resource="#Evidence809" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SARS-CoV-2 gRNA:RTC:RNA primer binds RTC inhibitors</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction652">
 <bp:evidence rdf:resource="#Evidence811" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">nsp14 acts as a cap N7 methyltransferase to modify SARS-CoV-2 mRNAs</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction650">
 <bp:evidence rdf:resource="#Evidence808" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">nsp12 synthesizes minus strand SARS-CoV-2 genomic RNA complement</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction659">
 <bp:evidence rdf:resource="#Evidence820" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">3CLp cleaves pp1ab</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep1806">
 <bp:stepProcess rdf:resource="#Pathway351" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1807">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1412" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction657">
 <bp:evidence rdf:resource="#Evidence816" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">nsp16 acts as a cap 2&apos;-O-methyltransferase to modify SARS-CoV-2 mRNAs</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep1808">
 <bp:stepProcess rdf:resource="#Pathway352" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction658">
 <bp:evidence rdf:resource="#Evidence818" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Nsp3, nsp4, and nsp6 produce replicative organelles</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep1809">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1413" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1813">
 <bp:stepProcess rdf:resource="#Pathway355" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1814">
 <bp:stepProcess rdf:resource="#Catalysis415" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1415" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1815">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1416" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1816">
 <bp:stepProcess rdf:resource="#Pathway356" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1810">
 <bp:stepProcess rdf:resource="#Pathway353" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1811">
 <bp:stepProcess rdf:resource="#Pathway354" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1812">
 <bp:stepProcess rdf:resource="#Catalysis414" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1414" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway231">
 <bp:pathwayOrder rdf:resource="#PathwayStep1346" />
 <bp:pathwayComponent rdf:resource="#Pathway232" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1324" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Signaling by Overexpressed Wild-Type EGFR in Cancer</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Signaling by EGFR is frequently activated in cancer through genomic amplification of the EGFR locus, resulting in over-expression of the wild-type protein (Wong et al. 1987).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway230">
 <bp:pathwayOrder rdf:resource="#PathwayStep1369" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1349" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1345" />
 <bp:pathwayComponent rdf:resource="#Pathway231" />
 <bp:pathwayComponent rdf:resource="#Pathway233" />
 <bp:pathwayComponent rdf:resource="#Pathway235" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1323" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Signaling by EGFR in Cancer</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The pathway &quot;Signaling by EGFR in Cancer&quot; shows signaling by constitutively active EGFR cancer variants in the context of &quot;Signaling by EGFR&quot;, allowing users to compare cancer events with the wild-type EGFR events. Red lines emphasize cancer related events and physical entities, while wild-type entities and events are shaded. Please refer to &quot;Signaling by Ligand-Responsive EGFR Variants in Cancer&quot;, &quot;Signaling by EGFRvIII in Cancer&quot; and &quot;Signaling by Overexpressed Wild-Type EGFR in Cancer&quot; for detailed pathway summations.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway233">
 <bp:pathwayOrder rdf:resource="#PathwayStep1350" />
 <bp:pathwayComponent rdf:resource="#Pathway234" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1328" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Signaling by EGFRvIII in Cancer</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">EGFRvIII (EGFR V30_R297delinsG) is the most prevalent EGFR variant in glioblastoma, but it is also found in other cancer types. In-frame deletion of the ligand binding domain in EGFRvIII is frequently accompanied with genomic amplification, resulting in over-expression of EGFRvIII. EGFRvIII dimerizes and autophosphorylates spontaneously and is therefore constitutively active (Fernandes et al. 2001)</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway232">
 <bp:pathwayOrder rdf:resource="#PathwayStep1347" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1348" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1094" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1095" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1325" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Inhibition of Signaling by Overexpressed EGFR</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Recombinant monoclonal antibody Cetuximab acts as an antagonist of EGFR ligand binding, and is approved for the treatment of tumors that over-express wild-type EGFR receptor (Cunningham et al. 2004, Li et al. 2005, Burtness et al. 2005). Effective concentrations of covalent tyrosine kinase inhibitors (TKIs) inhibit wild-type EGFR, causing severe side effects (Zhou et al. 2009). Hence, covalent TKIs have not shown much promise in clinical trials (Reviewed by Pao and Chmielecki in 2010).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway235">
 <bp:pathwayOrder rdf:resource="#PathwayStep1370" />
 <bp:pathwayComponent rdf:resource="#Pathway236" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1348" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Signaling by Ligand-Responsive EGFR Variants in Cancer</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Ligand-responsive EGFR cancer variants harbor mutations in the kinase domain or point mutations in the extracellular domain. These altered EGFR proteins are able to signal in the absence of ligands, but their ligand binding ability is preserved and downstream signaling is potentiated when ligand is available (Greulich et al. 2005, Lee et al. 2006).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway234">
 <bp:pathwayOrder rdf:resource="#PathwayStep1360" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1358" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1359" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1354" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1365" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1355" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1366" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1356" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1367" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1357" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1368" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1361" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1351" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1362" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1352" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1363" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1353" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1364" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1098" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1099" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1110" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1096" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1097" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1102" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1113" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1103" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1100" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1111" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1101" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1112" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1106" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1107" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1104" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1105" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1108" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1109" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1329" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Constitutive Signaling by EGFRvIII</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">In glioblastoma, the most prevalent EGFR mutation, present in ~25% of tumors, is the deletion of the ligand binding domain of EGFR, accompanied with amplification of the mutated allele, which results in over-expression of the mutant protein known as EGFRvIII. EGFRvIII mutant is not able to bind a ligand, but dimerizes and autophosphorylates spontaneously and is therefore constitutively active (Fernandes et al. 2001). Point mutations in the extracellular domain of EGFR are also frequently found in glioblastoma, but ligand binding ability and responsiveness are preserved (Lee et al. 2006).  Similar to EGFR kinase domain mutants, EGFRvIII mutant needs to maintain association with the chaperone heat shock protein 90 (HSP90) for proper functioning (Shimamura et al. 2005, Lavictoire et al. 2003). CDC37 is a co-chaperone of HSP90 that acts as a scaffold and regulator of interaction between HSP90 and its protein kinase clients. CDC37 is frequently over-expressed in cancers involving mutant kinases and acts as an oncogene (Roe et al. 2004, reviewed by Gray Jr. et al. 2008).  Expression of EGFRvIII mutant results in aberrant activation of downstream signaling cascades, namely RAS/RAF/MAP kinase signaling and PI3K/AKT signaling, and possibly signaling by PLCG1, which leads to increased cell proliferation and survival, providing selective advantage to cancer cells that harbor EGFRvIII (Huang et al. 2007).   EGFRvIII mutant does not autophosorylate on the tyrosine residue Y1069 (i.e. Y1045 in the mature protein), a docking site for CBL, and is therefore unable to recruit CBL ubiquitin ligase, which enables it to escape degradation (Han et al. 2006)</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence2500">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway237">
 <bp:pathwayOrder rdf:resource="#PathwayStep1429" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1403" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1426" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1395" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1452" />
 <bp:pathwayComponent rdf:resource="#Pathway238" />
 <bp:pathwayComponent rdf:resource="#Pathway240" />
 <bp:pathwayComponent rdf:resource="#Pathway242" />
 <bp:pathwayComponent rdf:resource="#Pathway244" />
 <bp:pathwayComponent rdf:resource="#Pathway246" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1372" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Signaling by NOTCH1 in Cancer</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Human NOTCH1 was cloned as a chromosome 9 gene, translocated to the T-cell beta receptor (TCBR) promoter on chromosome 7 in T-cell acute lymphoblastic leukemia (T-ALL) (Ellisen et al. 1991). This translocation, present in only a small percentage of T-ALL patients, results in the overexpression of a truncated NOTCH1 receptor, which lacks almost the entire extracellular domain, in T lymphocytes. Oncogenic NOTCH1 mutations were subsequently found to be present in &gt;50% of T-ALL patients, with hotspots in the heterodimerization domain (HD domain) and PEST domain of NOTCH1 (Weng et al. 2004).   Normal NOTCH1 becomes activated by binding DLL (DLL1 or DLL4) or JAG (JAG1 or JAG2) ligands expressed on the surface of a neighboring cell, which leads to proteolytic cleavage of NOTCH1 by ADAM10/17 and gamma-secretase, and release of the NOTCH1 intracellular domain (NICD1) which regulates expression of genes that play important roles in the development of T lymphocytes (Washburn et al. 1997. Radtke et al. 1999, Maillard et al. 2004, Sambandam et al. 2005, Tan et al. 2005). Mutations in the HD domain, responsible for association of NOTCH1 extracellular and transmembrane regions after furin-mediated cleavage of NOTCH1 precursor, as well as the truncation of the NOTCH1 extracellular domain by the rare T-ALL translocation, enable constitutive production of NICD1, in the absence of ligand binding (Malecki et al. 2006, Ellisen et al. 1991).  Mutations in the NOTCH1 PEST domain interfere with FBXW7 (FBW7)-mediated ubiquitination and degradation of NICD1, resulting in prolonged half-life and increased transcriptional activity of NICD1, which promotes growth and division of T-lymphocytes (Weng et al. 2004, Thompson et al. 2007, O&apos;Neil et al. 2007).  Mutations in the HD domain and PEST domain of NOTCH1 are frequently found in cis in T-ALL. While HD mutations alone result in up to ~10-fold increase in NOTCH1 transcriptional activity and PEST domain mutations alone result in up to ~2-fold increase in NOTCH1 transcriptional activity, in cis mutations of HD and PEST domains act synergistically, increasing NOTCH1 transcriptional activity up to ~40-fold (Weng et al. 2004).  FBXW7 (FBW7), a component of the SCF (SKP1, CUL1, and F-box protein) ubiquitin ligase complex SCF-FBW7 involved in the degradation of NOTCH1 (Oberg et al. 2001, Wu et al. 2001, Fryer et al. 2004), is subject to loss of function mutations in T-ALL (Akhoondi et al. 2007, Thompson et al. 2007, O&apos;Neil et al. 2007) which are mutually exclusive with NOTCH1 PEST domain mutations (Thompson et al. 2007, O&apos;Neil et al. 2007).  Although gamma-secretase inhibitors (GSIs) are successfully used in vitro to inhibit NOTCH1 signaling in T-ALL cell lines, the gamma-secretase complex has many other substrates besides NOTCH. The specificity of GSIs is therefore limited and, as they are not considered to be particularly promising drugs for the clinical treatment of T-ALL (reviewed by Purow, 2012), they have not been annotated.  For a recent review of NOTCH1 signaling in cancer, please refer to Grabher et al. 2006.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence2501">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway236">
 <bp:pathwayOrder rdf:resource="#PathwayStep1390" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1380" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1391" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1381" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1392" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1371" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1382" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1393" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1376" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1387" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1377" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1388" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1378" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1389" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1379" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1372" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1383" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1373" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1384" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1374" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1385" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1375" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1386" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1120" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1131" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1121" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1132" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1130" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1124" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1135" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1114" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1125" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1122" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1133" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1123" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1134" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1117" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1128" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1118" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1129" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1115" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1126" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1116" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1127" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1119" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1109" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1349" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Signaling by EGFR is frequently activated in cancer through activating mutations in the coding sequence of the EGFR gene, resulting in expression of a constitutively active mutant protein.   Epidermal growth factor receptor kinase domain mutants are present in ~16% of non-small-cell lung cancers (NSCLCs), but are also found in other cancer types, such as breast cancer, colorectal cancer, ovarian cancer and thyroid cancer. EGFR kinase domain mutants harbor activating mutations in exons 18-21 which code for the kinase domain (amino acids 712-979) . Small deletions, insertions or substitutions of amino acids within the kinase domain lock EGFR in its active conformation in which the enzyme can dimerize and undergo autophosphorylation spontaneously, without ligand binding (although ligand binding ability is preserved), and activate downstream signaling pathways that promote cell survival (Greulich et al. 2005, Zhang et al. 2006, Yun et al. 2007, Red Brewer et al. 2009).   Point mutations in the extracellular domain of EGFR are frequently found in glioblastoma. Similar to kinase domain mutations, point mutations in the extracellular domain result in constitutively active EGFR proteins that signal in the absence of ligands, but ligand binding ability and responsiveness are preserved (Lee et al. 2006).    EGFR kinase domain mutants need to maintain association with the chaperone heat shock protein 90 (HSP90) for proper functioning (Shimamura et al. 2005, Lavictoire et al. 2003). CDC37 is a co-chaperone of HSP90 that acts as a scaffold and regulator of interaction between HSP90 and its protein kinase clients. CDC37 is frequently over-expressed in cancers involving mutant kinases and acts as an oncogene (Roe et al. 2004, reviewed by Gray Jr. et al. 2008).   Over-expression of the wild-type EGFR or EGFR cancer mutants results in aberrant activation of downstream signaling cascades, namely RAS/RAF/MAP kinase signaling and PI3K/AKT signaling, and possibly signaling by PLCG1, which leads to increased cell proliferation and survival, providing selective advantage to cancer cells that harbor activating mutations in the EGFR gene (Sordella et al. 2004, Huang et al. 2007).   While growth factor activated wild-type EGFR is promptly down-regulated by internalization and degradation, cancer mutants of EGFR demonstrate prolonged activation (Lynch et al. 2004). Association of HSP90 with EGFR kinase domain mutants negatively affects CBL-mediated ubiquitination, possibly through decreasing the affinity of EGFR kinase domain mutants for phosphorylated CBL, so that CBL dissociates from the complex upon phosphorylation and cannot perform ubiquitination (Yang et al. 2006, Padron et al. 2007).    Various molecular therapeutics are being developed to target aberrantly activated EGFR in cancer. Non-covalent (reversible) small tyrosine kinase inhibitors (TKIs), such as gefitinib and erlotinib, selectively bind kinase domain of EGFR, competitively inhibiting ATP binding and subsequent autophosphorylation of EGFR dimers. EGFR kinase domain mutants sensitive to non-covalent TKIs exhibit greater affinity for TKIs than ATP compared with the wild-type EGFR protein, and are therefore preferential targets of non-covalent TKI therapeutics (Yun et al. 2007). EGFR proteins that harbor point mutations in the extracellular domain also show sensitivity to non-covalent tyrosine kinase inhibitors (Lee et al. 2006). EGFR kinase domain mutants harboring small insertions in exon 20 or a secondary T790M mutation are resistant to reversible TKIs (Balak et al. 2006) due to increased affinity for ATP (Yun et al. 2008), and are targets of covalent (irreversible) TKIs that form a covalent bond with EGFR cysteine residue C397. However, effective concentrations of covalent TKIs also inhibit wild-type EGFR, causing severe side effects (Zhou et al. 2009). Hence, covalent TKIs have not shown much promise in clinical trials (Reviewed by Pao and Chmielecki in 2010). </bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence2502">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction644">
 <bp:evidence rdf:resource="#Evidence802" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Polyadenylation of SARS-CoV-2 genomic RNA (plus strand)</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction645">
 <bp:evidence rdf:resource="#Evidence803" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">nsp13 binds DDX5</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway249">
 <bp:pathwayOrder rdf:resource="#PathwayStep1461" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1462" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1175" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1176" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1423" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">PDGFR mutants bind TKIs</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Aberrant signaling by activated forms of PDGFR can be inhibited by tyrosine kinase inhibitors (TKIs). PDGF receptors are class III receptor tyrosine kinase receptors, also known as dual-switch. Dual-switch receptors are activated through a series of phosphorylation and conformational changes that move the receptor from the inactive form to the fully activated form. Type II TKIs bind to the inactive form of the receptor at a site adjacent to the ATP-binding cleft, while type I TKIs bind to the active form (reviewed in Roskoski, 2018; Klug et al, 2018).  Primary mutations in PDGRFA occur in the activation loop, with a minor fraction found in the juxtamembrane domain (reviewed in Roskoski, 2018; Klug et al, 2018). Juxtamembrane domain mutations affect an autoinhibitory loop, shifting the equilibrium of the receptor towards the activated state; despite this, however, juxtamembrane domain mutants remain predominantly in the inactive state and as such are susceptible to inhibition by type II TKIs. Activation loop mutations more strongly favor the active conformation of the receptor and are susceptible to inhibition by both type II and type I TKI. The most prevalent PDGFRA mutation, D842V, promotes the active conformation strongly enough to be resistant to type II TKIs (reviewed in Roskoski, 2018; Klug et al, 2018). </bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction642">
 <bp:evidence rdf:resource="#Evidence800" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">nsp14 acts as a cap N7 methyltransferase to modify SARS-CoV-2 gRNA complement (minus strand)</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction643">
 <bp:evidence rdf:resource="#Evidence801" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">nsp16 acts as a cap 2&apos;-O-methyltransferase to modify SARS-CoV-2 gRNA (plus strand)</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction640">
 <bp:evidence rdf:resource="#Evidence798" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">nsp16 binds VHL</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction641">
 <bp:evidence rdf:resource="#Evidence799" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">RTC binds SARS-CoV-2 genomic RNA complement (minus strand)</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction648">
 <bp:evidence rdf:resource="#Evidence806" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">nsp12 misincorporates a nucleotide in nascent RNA minus strand</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep1817">
 <bp:stepProcess rdf:resource="#Catalysis416" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1417" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction649">
 <bp:evidence rdf:resource="#Evidence807" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">nsp14 acts as a 3&apos;-to-5&apos; exonuclease to remove misincorporated nucleotides from nascent RNA</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep1818">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1418" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction646">
 <bp:evidence rdf:resource="#Evidence804" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">nsp8 generates RNA primers</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep1819">
 <bp:stepProcess rdf:resource="#Pathway357" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction647">
 <bp:evidence rdf:resource="#Evidence805" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SARS-CoV-2 gRNA:RTC:nascent RNA minus strand binds RTC inhibitors</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep1824">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1423" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1825">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1424" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1826">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1425" />
 <bp:stepProcess rdf:resource="#Catalysis418" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1827">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1426" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1820">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1419" />
 <bp:stepProcess rdf:resource="#Catalysis417" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1821">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1420" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway240">
 <bp:pathwayOrder rdf:resource="#PathwayStep1404" />
 <bp:pathwayComponent rdf:resource="#Pathway241" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1381" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Mutations in the heterodimerization domain (HD) and PEST domain of NOTCH1 are frequently found in cis in T-cell acute lymphoblastic leukemia. While HD mutations alone result in up to ~10-fold increase in NOTCH1 transcriptional activity and PEST domain mutations alone result in up to ~2-fold increase in NOTCH1 transcriptional activity, in cis mutations of HD and PEST domains act synergistically, increasing NOTCH1 transcriptional activity up to ~40-fold (Weng et al. 2004).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep1822">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1421" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1823">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1422" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway242">
 <bp:pathwayOrder rdf:resource="#PathwayStep1427" />
 <bp:pathwayComponent rdf:resource="#Pathway243" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1404" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FBXW7 Mutants and NOTCH1 in Cancer</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FBXW7 (FBW7) is a component of the SCF (SKP1, CUL1, and F-box protein) ubiquitin ligase complex SCF-FBW7 which is involved in the degradation of NOTCH1 (Oberg et al. 2001, Wu et al. 2001, Fryer et al. 2004). Loss of function mutations in FBXW7 are frequently found in T-cell acute lymphoblastic leukemia (Akhoondi et al. 2007, Thompson et al. 2007, O&apos;Neil et al. 2007) and are mutually exclusive with NOTCH1 PEST domain mutations (Thompson et al. 2007, O&apos;Neil et al. 2007).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway241">
 <bp:pathwayOrder rdf:resource="#PathwayStep1406" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1417" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1407" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1418" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1408" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1419" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1409" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1413" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1424" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1414" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1425" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1415" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1405" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1416" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1420" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1410" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1421" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1411" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1422" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1412" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1423" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1160" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1150" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1161" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1142" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1153" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1143" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1154" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1151" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1162" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1152" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1146" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1157" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1147" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1158" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1144" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1155" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1145" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1156" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1148" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1159" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1149" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1382" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">When found in cis, HD and PEST domain mutations act synergistically, increasing NOTCH1 transcriptional activity up to ~40-fold, compared with up to ~10-fold and up to ~2-fold increase with HD mutations alone and PEST domain mutations alone, respectively (Weng et al. 2004). HD domain mutations enable spontaneous, ligand-independent, proteolytic release of the NICD1 fragment, although mutants remain responsive to ligand binding (Malecki et al. 2006), while PEST domain mutations prolong NICD1 half-life and transcriptional activity through interference with FBXW7 (FBW7)-mediated ubiquitination and degradation (Thompson et al. 2007, O&apos;Neil et al. 2007). NOTCH1 HD+PEST domain mutants annotated here are NOTCH1 L1600P;P2514Rfs*4, NOTCH1 L1600P;Q2440*, NOTCH1 L1600P;Q2395* and NOTCH1 L1574P;P2474Afs*4.  </bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway244">
 <bp:pathwayOrder rdf:resource="#PathwayStep1430" />
 <bp:pathwayComponent rdf:resource="#Pathway245" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1407" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Signaling by NOTCH1 PEST Domain Mutants in Cancer</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NOTCH1 PEST domain mutations are frequently found in T-cell acute lymphoblastic leukemia (T-ALL). PEST domain mutations interfere with ubiquitination-mediated NOTCH1 downregulation and result in prolonged half-life of the intracellular NOTCH1 fragment, NICD1, and increased NICD1 transcriptional activity (Weng et al. 2004, Thompson et al. 2007, O&apos;Neil et al. 2007).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway243">
 <bp:pathwayOrder rdf:resource="#PathwayStep1428" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1163" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1405" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Loss of Function of FBXW7 in Cancer and NOTCH1 Signaling</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Loss of function mutations found in FBXW7 in T-cell acute lymphoblastic leukemia are predominantly dominant negative missense mutations that target one of the three highly conserved arginine residues in the WD repeats of FBXW7 (Thompson et al. 2007, O&apos;Neil et al. 2007). These three arginine residues are part of the FBXW7 substrate binding pocket and each one of them contacts the phosphorylated threonine residue in the conserved substrate phosphodegron region (Orlicky et al. 2003). Specifically, FBXW7 interacts with the PEST domain of NOTCH1 upon phosphorylation of the PEST domain by CDK8 (Fryer et al. 2004). FBXW7 mutants are therefore unable to bind and promote ubiquitination of the NOTCH1 intracellular domain (NICD1), leading to prolonged NICD1 transcriptional activity (Thompson et al. 2007, O&apos;Neil et al. 2007).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway246">
 <bp:pathwayOrder rdf:resource="#PathwayStep1453" />
 <bp:pathwayComponent rdf:resource="#Pathway247" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1415" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Human NOTCH1 was cloned as a chromosome 9 gene, translocated to the T-cell beta receptor (TCBR) promoter on chromosome 7 in T-cell acute lymphoblastic leukemia (T-ALL) (Ellisen et al. 1991). The translocated gene was found to be homologous to Drosophila Notch, and was initially named TAN-1 (translocation-associated Notch homolog). Although the translocation t(7;9)(q34;q34.3) is present in a small percentage of T-ALL patients, the mutant protein is highly oncogenic and its overexpression causes T-ALL-like illness in mice (Pear et al. 1996).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway245">
 <bp:pathwayOrder rdf:resource="#PathwayStep1439" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1435" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1446" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1436" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1447" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1437" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1448" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1438" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1449" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1431" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1442" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1432" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1443" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1433" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1444" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1434" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1445" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1450" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1440" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1451" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1441" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1160" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1150" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1161" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1142" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1164" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1143" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1165" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1154" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1151" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1157" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1168" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1147" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1158" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1169" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1144" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1166" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1145" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1167" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1156" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1148" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1149" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1408" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Constitutive Signaling by NOTCH1 PEST Domain Mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">As NOTCH1 PEST domain is intracellular, NOTCH1 PEST domain mutants are expected to behave as the wild-type NOTCH1 with respect to ligand binding and proteolytic cleavage mediated activation of signaling. However, once the NICD1 fragment of NOTCH1 is released, PEST domain mutations prolong its half-life and transcriptional activity through interference with FBXW7 (FBW7)-mediated ubiquitination and degradation of NICD1 (Weng et al. 2004, Thompson et al. 2007, O&apos;Neil et al. 2007). All NOTCH1 PEST domain mutants annotated here (NOTCH1 Q2395*, NOTCH1 Q2440*, NOTCH1 P2474Afs*4 and NOTCH1 P2514Rfs*4) either have a truncated PEST domain or lack the PEST domain completely.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway248">
 <bp:pathwayOrder rdf:resource="#PathwayStep1475" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1486" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1460" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1472" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1483" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1463" />
 <bp:pathwayComponent rdf:resource="#Pathway249" />
 <bp:pathwayComponent rdf:resource="#Pathway250" />
 <bp:pathwayComponent rdf:resource="#Pathway255" />
 <bp:pathwayComponent rdf:resource="#Pathway257" />
 <bp:pathwayComponent rdf:resource="#Pathway256" />
 <bp:pathwayComponent rdf:resource="#Pathway258" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1422" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Signaling by PDGFR in disease</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">PDGFRA and PDGFRB are type III receptor tyrosine kinases that promote development and maintenance of mesenchymal tissues, including vascular smooth muscle, kidney, intestine, skin and lung, among others (reviewed in Tallquist and Kazlauskas, 2004; reviewed in Wang et al, 2016). Signaling through PDGF receptors stimulates cell proliferation and survival through activation of downstream signaling pathways including the RAS-MAP kinase cascade, PI3K signaling and STAT signaling (reviewed in Roskoski, 2018). Aberrant signaling through PDGF receptors is implicated in a number of human diseases. Point mutations in PDGFRA and, to a lesser extent, PDGFRB are implicated in a number of cancers, such as gastrointestinal stromal tumors (GIST; 5-10% mutation frequency in PDGFRA) and haematological cancers (Corless et al, 2005; Wang et al, 2016; reviewed in Klug et al, 2018). In addition, amplified signaling through the PDGF pathway can arise through gene fusion events or overexpression of ligand or receptor through gene amplification (Ozawa et al, 2010; Verhaak et al, 2010; reviewed in Appiah-Kubi et al, 2017).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway247">
 <bp:pathwayOrder rdf:resource="#PathwayStep1457" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1458" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1454" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1455" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1456" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1171" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1172" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1170" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1173" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1174" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1416" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Constitutive Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NOTCH1 t(7;9)(NOTCH1:M1580_K2555) mutant is expressed in a small subset of T-cell acute lymphoblastic leukemia (T-ALL) patients. This mutant protein results from a translocation that joins a portion of intron 24 of the NOTCH1 gene to the promoter sequence of T-cell receptor beta (TCRB), leading to overexpression of a truncated NOTCH1 protein in T-cells and their precursors. The truncated NOTCH1 contains amino acids 1580 to 2555 of the wild-type NOTCH1, lacking almost the entire extracellular domain, including EGF and LIN12 repeats (Ellisen et al. 1991). As EGF repeats are needed for NOTCH1 interaction with its ligands (DLL1, DLL4, JAG1, JAG2), the mutant NOTCH1 t(7;9)(NOTCH1:M1580_K2555) does not bind a ligand. The constitutive activity of NOTCH1 t(7;9)(NOTCH1:M1580_K2555) is based on its constitutive proteolytic processing into NOTCH1 intracellular domain (NICD1) by ADAM10/17 protease and gamma-secretase complex, as proteolytic cleavage sites are exposed in the absence of ligand binding in the mutant protein. Constitutively produced NICD1 accumulates in the nucleus, leading to aberrant activation of NOTCH1 target genes which play important roles in the development of T lymphocytes (Washburn et al. 1997. Radtke et al. 1999, Maillard et al. 2004, Sambandam et al. 2005, Tan et al. 2005). Infection of bone marrow cells with recombinant retroviruses that code for truncated NOTCH1 that resembles t(7;9)(NOTCH1:M1580_K2555) resulted in T-ALL-like illness in a portion of mice that received the infected bone-marrow transplant, with all tumors overexpressing truncated forms of NOTCH1 (Pear et al. 1996). </bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway217">
 <bp:pathwayOrder rdf:resource="#PathwayStep1261" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1616" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1523" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1611" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1513" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1810" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1459" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1344" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1586" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1773" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1850" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1394" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1494" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1693" />
 <bp:pathwayComponent rdf:resource="#Pathway218" />
 <bp:pathwayComponent rdf:resource="#Pathway291" />
 <bp:pathwayComponent rdf:resource="#Pathway271" />
 <bp:pathwayComponent rdf:resource="#Pathway295" />
 <bp:pathwayComponent rdf:resource="#Pathway230" />
 <bp:pathwayComponent rdf:resource="#Pathway274" />
 <bp:pathwayComponent rdf:resource="#Pathway296" />
 <bp:pathwayComponent rdf:resource="#Pathway332" />
 <bp:pathwayComponent rdf:resource="#Pathway353" />
 <bp:pathwayComponent rdf:resource="#Pathway367" />
 <bp:pathwayComponent rdf:resource="#Pathway311" />
 <bp:pathwayComponent rdf:resource="#Pathway237" />
 <bp:pathwayComponent rdf:resource="#Pathway248" />
 <bp:pathwayComponent rdf:resource="#Pathway259" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1239" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Diseases of signal transduction by growth factor receptors and second messengers</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Signaling processes are central to human physiology (e.g., Pires-da Silva    Sommer 2003), and their disruption by either germ-line and somatic mutation can lead to serious disease. Here, the molecular consequences of mutations affecting visual signal transduction and signaling by diverse growth factors are annotated.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway216">
 <bp:pathwayOrder rdf:resource="#PathwayStep1259" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1255" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1256" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1257" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1258" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1252" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1253" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1254" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1015" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1018" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1019" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1016" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1017" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1021" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1022" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1020" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1230" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">InlB-mediated entry of Listeria monocytogenes into host cell</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">InlB, a cell wall protein of Listeria monocytogenes, binds MET receptor, acting as an HGF agonist (Shen et al. 2000, Veiga and Cossart 2005). Listeria monocytogenes InlB proteins dimerize through their leucine-rich repeat regions (LRRs), promoting dimerization of MET receptors that they are bound to (Ferraris et al. 2010). InlB-induced MET receptor dimerization is followed by MET trans-autophosphorylation and activation of downstream RAS/RAF/MAPK signaling and PI3K/AKT signaling (Niemann et al. 2007, Ferraris et al. 2010). InlB-bound phosphorylated MET receptor recruits the E3 ubiquitin ligase CBL through GRB2. CBL-mediated monoubiquitination of InlB-bound MET promotes endocytosis and entry of Listeria monocytogenes to host cells (Veiga and Cossart 2005). CIN85 is necessary for endocytosis-mediated entry of Listeria monocytogenes triggered by CBL-mediated monoubiquitination of MET (Veiga and Cossart 2005). Proteins involved in clathrin-mediated endocytosis EPS15 and HGS (Hrs) are both necessary for CBL and MET-mediated entry of Listeria monocytogenes into host cells (Veiga and Cossart 2005). A potential coreceptor role of CD44 in InlB-mediated MET activation is contradictory (Jung et al. 2009, Dortet et al. 2010).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway219">
 <bp:pathwayOrder rdf:resource="#PathwayStep1291" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1270" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1271" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1272" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1290" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1277" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1278" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1279" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1273" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1274" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1275" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1276" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1280" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1281" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1282" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1283" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1325" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1326" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1266" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1288" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1267" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1289" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1268" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1269" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1324" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1284" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1263" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1285" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1264" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1286" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1265" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1287" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1050" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1032" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1033" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1030" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1031" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1025" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1047" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1026" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1048" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1023" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1045" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1024" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1046" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1029" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1027" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1049" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1028" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1083" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1040" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1084" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1043" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1044" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1041" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1085" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1042" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1036" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1037" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1034" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1035" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1038" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1039" />
 <bp:pathwayComponent rdf:resource="#Pathway220" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1241" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Signaling by ALK fusions and activated point mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ALK is activated in a range of cancers as a result of amplification or overexpression, fusion event or activating point mutations, resulting, in general, in constitutive activation of intracellular signaling. The major pathways initiated downstream of activated ALK are STAT3 and, to a lesser extent, STAT5 signaling and signaling through the MAP kinase, PI3K/AKT and PLC gamma cascades (reviewed in Della Corte et al, 2018; Hallberg and Palmer, 2013; Hallberg and Palmer, 2016; Chiarle et al, 2008).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1908">
 <bp:evidence rdf:resource="#Evidence2621" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Ivacaftor binds CFTR G551D</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway218">
 <bp:pathwayOrder rdf:resource="#PathwayStep1327" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1262" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1342" />
 <bp:pathwayComponent rdf:resource="#Pathway219" />
 <bp:pathwayComponent rdf:resource="#Pathway229" />
 <bp:pathwayComponent rdf:resource="#Pathway221" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1240" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Signaling by ALK in cancer</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Anaplastic lymphoma kinase (ALK) was first identified in the context of an oncogenic fusion with nucleophosmin (NPM) in anaplastic large cell lymphoma (ALCL) (Morris et al, 1994). NPM-ALK fusions occur in approximately 75-80% of ALCL cases and at lower frequencies in other cancers, including non-small cell lung cancer, neuroblastoma and inflammatory myofibroblastic tumors (IFTs) (Morris et al, 1994; Shiota et al, 1994; reviewed in Della Corte et al, 2018; Werner et al, 2017).   In addition to NPM, fusions of ALK with nearly 30 other 5&apos; partners have since been identified, although these tend to occur at lower frequencies in the cancers in which they appear (reviewed in Chiarle et al, 2008; Della Corte et al, 2018; Roskoski, 2013; Hallberg and Palmer, 2016). In general, ALK fusions combine the 5&apos; end of the partner gene which contributes a dimerization domain with the intracellular portion of the ALK receptor including the kinase domain, and lead to constitutive signaling by virtue of the partner-domain mediated dimerization (reviewed in Roskoski, 2013; Della Corte et al, 2018).   In addition to translocation events that lead to fusion proteins, the ALK gene also contributes to oncogenesis as a result of gene amplification and overexpression events, as well as being subject to activating missense mutations (reviewed in Della Corte et al, 2018; Hallberg and Palmer, 2016).    Oncogenic ALK activity can be targeted with tyrosine kinase inhibitors, although resistance often arises due to secondary mutations or activation of bypass pathways (reviewed in Roskoski, 2013; Della Corte et al, 2018; Hallberg and Palmer, 2016; Werner et al, 2017; Lovly and Pao, 2012).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1909">
 <bp:evidence rdf:resource="#Evidence2622" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">CFTR F508del is degraded by the 26S proteasome</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis41">
 <bp:controlled rdf:resource="#BiochemicalReaction105" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis40">
 <bp:controlled rdf:resource="#BiochemicalReaction103" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis38">
 <bp:controlled rdf:resource="#BiochemicalReaction99" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis37">
 <bp:controlled rdf:resource="#BiochemicalReaction96" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis36">
 <bp:controlled rdf:resource="#BiochemicalReaction95" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis35">
 <bp:controlled rdf:resource="#BiochemicalReaction93" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis34">
 <bp:controlled rdf:resource="#BiochemicalReaction92" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis33">
 <bp:controlled rdf:resource="#BiochemicalReaction91" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis32">
 <bp:controlled rdf:resource="#BiochemicalReaction86" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis31">
 <bp:controlled rdf:resource="#BiochemicalReaction84" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1902">
 <bp:evidence rdf:resource="#Evidence2612" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective ABCC8 does not form functional KATP channels, causing hyperinsulinemic hypoglycemia</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1903">
 <bp:evidence rdf:resource="#Evidence2614" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective ABCB6 does not transport porphyrin from cytosol into mitochondria matrix</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway211">
 <bp:pathwayOrder rdf:resource="#PathwayStep1219" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1216" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1217" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1218" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1220" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction985" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction986" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction989" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction987" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction988" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1195" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Toxicity of botulinum toxin type E (botE)</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Botulinum toxin type E (botE, also known as BoNT/E), a disulfide-bonded heavy chain (HC) - light chain (LC) heterodimer (&#8220;dichain&#8221;), enters the gut typically as a result of consuming contaminated food (Hatheway 1995), as a complex with nontoxic nonhemagglutinin protein (NTNHA, encoded by the C. botulinum ntnha gene) (Benefield et al. 2013). The complex protects the toxin from degradation in the gut and mediates its association with the gut epithelium and transcytosis to enter the circulation (Fujinaga et al. 2013). Circulating toxin molecules associate with gangliosides and synaptic vesicle protein 2 (SV2) exposed by exocytosis at a synapse of a target neuron (Dong et al. 2008; Yowler    Schengrund 2004). Vesicle recycling brings the toxin into the neuron where the vesicle is acidified (Sudhoff 2004). The lowered pH induces a conformational change in the toxin: its HC forms a passage in the vesicle membrane through which its LC is extruded into the neuronal cytosol and released by reduction of the HC - LC disulfide bond (Montal 2010). The LC then catalyzes the cleavage of synaptosome-associated protein 25 (SNAP25) on the cytosolic face of the neuronal plasma membrane (Binz et al. 1994; Schiavo et al. 1993), thereby inhibiting synaptic vesicle fusion with the plasma membrane and exocytosis.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1900">
 <bp:evidence rdf:resource="#Evidence2607" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective SLC17A8 does not exchange cytosolic L-Glu for synaptic vesicle H+</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway210">
 <bp:pathwayOrder rdf:resource="#PathwayStep1211" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1212" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1213" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1214" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1210" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction983" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction984" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction981" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction982" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction980" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1189" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Toxicity of botulinum toxin type F (botF)</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Botulinum toxin type F (botF) is only very rarely associated with human disease (Hatheway 1995) and a pathway by which it might enter the circulation from the human gut has not been described. Nevertheless, the toxin itself, a disulfide-bonded heavy chain (HC) - light chain (LC) heterodimer (&quot;dichain&quot;), is capable of binding to neurons by interactions with cell-surface ganglioside and synaptic vesicle protein 2 (SV2) (Fu et al. 2009; Rummel et al. 2009), the bound toxin can enter synaptic vesicles and release its LC moiety into the cytosol of targeted cells (Montal 2010), and the botF LC can cleave vesicle-associated membrane proteins 1 and 2 (VAMP1 and 2) on the cytosolic face of the synaptic vesicle membrane (Yamasaki et al. 1994). These four events are annotated here.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1901">
 <bp:evidence rdf:resource="#Evidence2611" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activating ABCC8 mutants cause hyperglycemia in permanent neonatal diabetes mellitus (PNDM) and transient neonatal DM (TNDM)</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway213">
 <bp:pathwayOrder rdf:resource="#PathwayStep1243" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1009" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1221" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Intestinal infectious diseases</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Gastroenteritis, also known as infectious diarrhea, is an inflammatory disease of the stomach and small intestine caused by infections by viruses, bacteria, parasites and fungi. Signs and symptoms include diarrhea, vomiting, abdominal pain, fever, lack of energy, and dehydration. Gastroenteritis is usually an acute and self-limiting disease that does not require medication but the preferred method of treatment is oral rehydration therapy. Enterotoxigenic Escherichia coli (ETEC) is one of the leading bacterial causes of gastroenteritis worldwide (Kopic    Geibel 2010, Gonzales-Siles    Sjoling 2016).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1906">
 <bp:evidence rdf:resource="#Evidence2619" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">CFTR F508del binds CFTR correctors</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway212">
 <bp:pathwayOrder rdf:resource="#PathwayStep1226" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1237" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1227" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1238" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1228" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1239" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1229" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1222" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1233" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1223" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1234" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1224" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1235" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1225" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1236" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1240" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1230" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1241" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1231" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1232" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction996" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction842" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction997" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction994" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction995" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction992" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction993" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction990" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction991" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1000" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction998" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction999" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1003" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1004" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1001" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1002" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1007" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1008" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1005" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1006" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1201" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Uptake and function of anthrax toxins</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Bacillus anthracis bacteria target cells in an infected human through the action of three secreted bacterial proteins, lef (also known as LF, lethal factor), cya (also known as EF, edema factor), and pagA (also known as PA, protective antigen) (Turk 2007; Young and Collier 2007). lef is a protease that cleaves and inactivates many MAP2K (MAP kinase kinase, MEK) proteins (Duesbery et al. 1998; Vitale et al. 2000), disrupting MAP kinase signaling pathways. cya is an adenylate cyclase that mediates the constitutive production of cAMP (Leppla 1982), a molecule normally generated transiently in tightly regulated amounts in response to extracellular signals. Both lef and cya depend on pagA to enter their target cells, a strategy characteristic of bacterial binary toxins (Barth et al. 2004). pagA binds to the target cell receptors, is cleaved by furin or other cellular proteases, and thereupon forms an oligomer that exposes binding sites for lef and cya molecules (Young and Collier 2007). This complex is taken into the target cell by clathrin mediated endocytosis and delivered to endosomes. The low pH of the endosome causes the bacterial toxin complex to rearrange: the pagA oligomer forms a pore in the endosome membrane through which lef and cya molecules enter the target cell cytosol.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1907">
 <bp:evidence rdf:resource="#Evidence2620" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">CFTR F508del binds components of the ERAD machinery for ubiquitination and degradation</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway215">
 <bp:pathwayOrder rdf:resource="#PathwayStep1250" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1248" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1249" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1246" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1247" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1014" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1012" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1013" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1010" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1011" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1224" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">InlA-mediated entry of Listeria monocytogenes into host cells</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The pathogenic bacteria Listeria monocytogenes can enter host cells through endocytosis triggered by binding of the bacterial cell wall protein internalin (InlA) to the E-cadherin (CDH1) complex at the host cell plasma membrane (Mengaud et al. 1996, Lecuit et al. 1999). Binding of InlA to CDH1, similar to CDH1 engagement during normal cell-to-cell adhesion, triggers activation of the SRC protein tyrosine kinase and phosphorylation of CDH1 and CDH1-bound beta-catenin (CTNNB1) (Fujita et al. 2002, McLachlan et al. 2007, Sousa et al. 2007, Bonazzi et al. 2008). Integrins likely contribute to CDH1-triggered SRC activation, and ERKs (MAPK1 and MAPK3), ROCKs and MLCK may also be involved (Avizienyte et al. 2002, Avizienyte et al. 2004, Martinez-Rico et al. 2010). FAK1 (PTK2), a SRC-regulated protein tyrosine kinase, may contribute to SRC-mediated regulation of CDH1 (Avizienyte et al. 2002). Phosphorylation of CDH1 and CTNNB1 by SRC creates docking sites for a CBL-like ubiquitin protein ligase Hakai (CBLL1). CBLL1 ubiquitinates SRC-phosphorylated CDH1 and CTNNB1 upon InlA binding, as well as in the context of CDH1-mediated cell-to-cell adhesion, thus triggering CDH1 endocytosis (Fujita et al. 2002, Bonazzi et al. 2008, Mukherjee et al. 2012). CBLL1 may also undergo SRC-mediated phosphorylation and subsequent autoubiquitination (Fujita et al. 2002). Both clathrin-mediated and caveolin-mediated endocytosis are implicated in the InlA-mediated entry of Listeria monocytogenes to host cells (Veiga et al. 2007). SRC-mediated phosphorylation of cortactin and the ARP2/3 complex involved in actin polymerization is implicated in CDH1 endocytosis and Listeria monocytogenes internalization (Sousa et al. 2007, Ren et al. 2009).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1904">
 <bp:evidence rdf:resource="#Evidence2616" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective ABCD1 does not transfer LCFAs from cytosol to peroxisomal matrix</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis39">
 <bp:controlled rdf:resource="#BiochemicalReaction101" />
</bp:Catalysis>

<bp:Pathway rdf:ID="Pathway214">
 <bp:pathwayOrder rdf:resource="#PathwayStep1245" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1251" />
 <bp:pathwayComponent rdf:resource="#Pathway216" />
 <bp:pathwayComponent rdf:resource="#Pathway215" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1223" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Listeria monocytogenes entry into host cells</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Listeria monocytogenes is a short, gram-positive, nonspore-forming motile rod. Serotypes 1/2a, 1/2b and 4b make up more than 95% of isolates from humans, with serotype 4b causing most of the food-borne outbreaks. Listeria monocytogenes enters the body through the gastrointestinal tract after ingestion of contaminated food. The bacteria can survive food preservation procedures, such as refrigeration, low pH and high salt. Listeria monocytogenes expresses several adhesin proteins at the cell surface that facilitate bacterial binding and entry to host cells. The bacteria can enter host cells through endocytosis mediated by binding of the bacterial InlA (internalin) protein to CDH1 (E-cadherin) at the host cell plasma membrane. Listeria monocytogenes can also enter host cells through endocytosis mediated by binding of the bacterial InlB protein to MET receptor tyrosine kinase at the host cell plasma membrane. Listeria monocytogenes proliferates inside the host cells and triggers formation of filopods, elongated protrusions of the host plasma membrane that contain bacteria. Filopods are ingested by adjacent cells, allowing Listeria monocytogenes to spread from cell to cell, invisible to the immune system of the host. Listeria monocytogenes can cross the intestinal, blood-brain and placental barriers. In immunocompetent adults Listeria monocytogenes infection usually causes gastroenteritis. In infants infected in utero and in immunocompromised adults Listeria monocytogenes infection can result in meningoencephalitis and bacteremia (sepsis). InlA is critical for crossing the intestinal barrier while both InlA and InlB are needed for crossing the placental barrier (Gessain et al. 2015) and, based on in vitro studies, the blood-cerebrospinal fluid barrier (Grundler et al. 2013). It seems that the intrinsic level of PI3K activity in Listeria-targeted host cells determines whether the entry depends on InlA only or InlA and InlB. The interaction of InlA with E-cadherin does not activate PI3K/AKT signaling while the interaction of InlB with the MET receptor activated the PI3K/AKT signal transduction cascade. Therefore, InlB-MET interaction may be important in tissues with low intrinsic PI3K activity (Gessain et al. 2015). Even if InlA-E-cadherin route is sufficient for bacterial entry, InlB may accelerate bacterial invasion (Pentecost et al. 2010). Cholesterol levels in host cell plasma membrane may also influence the preferred route for bacterial endocytosis (Seveau et al. 2004). In addition to InlA and InlB, many other virulence factors are involved in the Listeria monocytogenes infection cycle (Camejo et al. 2011) and will be annotated as mechanistic details become available. For review, please refer to Bonazzi et al. 2009, Brooks et al. 2010, Camejo et al. 2011, Pizarro-Cerda et al. 2012.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1905">
 <bp:evidence rdf:resource="#Evidence2618" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">RNF5 and RNF185 ubiquitinate CFTR F508del</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway228">
 <bp:pathwayOrder rdf:resource="#PathwayStep1341" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1092" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1319" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">alectinib-resistant ALK mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Alectinib is a second generation tyrosine kinase inhibitor that is approved for use in ALK positive non-small cell lung cancers (NSCLCs). Alectinib is effective against a number of ALK mutants that arise after treatment with crizotinib, however resistance to alectinib has also been reported. This pathway describes ALK mutants that are resistant to inhibition with alectinib (reviewed in Lovly and Pao, 2012; Lin et al, 2017; Della Corte et al, 2018; Hallberg and Palmer, 2016).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway227">
 <bp:pathwayOrder rdf:resource="#PathwayStep1339" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1091" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1317" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NVP-TAE684-resistant ALK mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NVP TAE684 is a second generation tyrosine kinase inhibitor with activity against some ALK mutants, including some that show resistance to crizotinib (George et al, 2008; Sasaki et al, 2011; Heuckmann et al, 2011; Ceccon et al, 2013). This pathway describes ALK mutants that show resistance to inhibition by NVP TAE684.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1919">
 <bp:evidence rdf:resource="#Evidence2639" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective ABCB4 does not transport PC from plasma membrane to extracellular region</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway229">
 <bp:pathwayOrder rdf:resource="#PathwayStep1343" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1093" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1321" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ALK mutants bind TKIs</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Aberrant signaling by activated forms of ALK can be inhibited by tyrosine kinase inhibitors (TKIs). ALK, like other tyrosine kinase receptors, is activated through a series of phosphorylation and conformational changes that move the receptor from the inactive form to the fully activated form. Type II TKIs bind to the inactive form of the receptor at a site adjacent to the ATP-binding cleft, while type I TKIs bind to the active form (reviewed in Roskoski, 2013). Type I inhibitors crizotinib, brigatinib, alectinib, ceritinib and lorlatinib are all approved for treatment of ALK-dependent cancer. Development of resistance to TKIs is not uncommon, however, either through acquisition of secondary mutations or through activation of bypass pathways that remove the dependence on ALK signaling (reviewed in Lovly and Pao, 2012; Lin et al, 2017; Della Corte et al, 2018).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Catalysis rdf:ID="Catalysis30">
 <bp:controlled rdf:resource="#BiochemicalReaction82" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis27">
 <bp:controlled rdf:resource="#BiochemicalReaction71" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis26">
 <bp:controlled rdf:resource="#BiochemicalReaction68" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis25">
 <bp:controlled rdf:resource="#BiochemicalReaction63" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis24">
 <bp:controlled rdf:resource="#BiochemicalReaction60" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis23">
 <bp:controlled rdf:resource="#BiochemicalReaction59" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis22">
 <bp:controlled rdf:resource="#BiochemicalReaction58" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1910">
 <bp:evidence rdf:resource="#Evidence2623" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Ivacaftor:CFTR G551D transports Cl- from cytosol to extracellular region</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis21">
 <bp:controlled rdf:resource="#BiochemicalReaction57" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis20">
 <bp:controlled rdf:resource="#BiochemicalReaction55" />
</bp:Catalysis>

<bp:Pathway rdf:ID="Pathway220">
 <bp:pathwayOrder rdf:resource="#PathwayStep1292" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1293" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1294" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1318" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1319" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1314" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1315" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1316" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1317" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1299" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1310" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1311" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1312" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1313" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1295" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1296" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1297" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1298" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1307" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1308" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1309" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1303" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1304" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1305" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1306" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1321" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1300" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1322" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1301" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1323" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1302" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1320" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1072" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1051" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1073" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1070" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1071" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1054" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1076" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1055" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1077" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1052" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1074" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1053" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1075" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1069" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1067" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1068" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1080" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1061" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1062" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1081" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1060" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1082" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1065" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1066" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1063" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1064" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1058" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1059" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1056" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1078" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1057" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1079" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1270" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Nuclear events stimulated by ALK signaling in cancer</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Signaling through oncogenic forms of ALK activate nuclear events that drive cellular survival, escape from apoptosis and transformation (reviewed in Della Corte et al, 2018; Roskoski, 2013; Chiarle et al, 2008). Changes to gene expression are effected both by epigenetic mechanisms and by inducing expression of key transcription factors and cell cycle regulators, among other critical targets. Many of these gene expression events are dependent on activation of STAT3 and to a lesser extent, MAP kinase signaling downstream of ALK (reviewed in Hallberg and Palmer, 2013; Hallberg and Palmer, 2016; Ducray et al, 2019). Unique among fusion proteins identified to date, the well-studied NPM-ALK fusion appears to be partially localized to the nucleus by virtue of oligomerization with endogenous full-length NPM.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1913">
 <bp:evidence rdf:resource="#Evidence2627" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective ABCA1 does not transport CHOL from transport vesicle membrane to plasma membrane</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1914">
 <bp:evidence rdf:resource="#Evidence2629" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective ABCC6 does not transport organic anion from cytosol to extracellular region</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway222">
 <bp:pathwayOrder rdf:resource="#PathwayStep1329" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1086" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1307" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ceritinib-resistant ALK mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Ceritinib is a type I TKI that is effective against ALK driven cancers and is approved for treatment of NSCLC. Ceritinib is a second-generation TKI that shows activity against a number of crizotinib-resistant ALK alleles, however, resistance to ceritinib has also been documented. This pathway describes ALK mutants that are resistant to inhibition with ceritinib (reviewed in Lovly and Pao, 2012; Lin et al, 2017; Della Corte et al, 2018).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1911">
 <bp:evidence rdf:resource="#Evidence2624" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">VCP-catalyzed ATP hydrolysis promotes the translocation of CFTR F508del into the cytosol</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway221">
 <bp:pathwayOrder rdf:resource="#PathwayStep1336" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1338" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1328" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1332" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1334" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1340" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1330" />
 <bp:pathwayComponent rdf:resource="#Pathway228" />
 <bp:pathwayComponent rdf:resource="#Pathway227" />
 <bp:pathwayComponent rdf:resource="#Pathway222" />
 <bp:pathwayComponent rdf:resource="#Pathway224" />
 <bp:pathwayComponent rdf:resource="#Pathway223" />
 <bp:pathwayComponent rdf:resource="#Pathway226" />
 <bp:pathwayComponent rdf:resource="#Pathway225" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1306" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Drug resistance of ALK mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Aberrant ALK activity arises through fusions, point mutations, overexpression or amplifications and has been shown to be an oncogenic driver in a number of cancers including anaplastic large cell lymphoma (ALCL), non-small cell lung cancer (NSCLC), inflammatory myofibroblastic tumors (IMTs) neuroblastomas and more (reviewed in Della Corte et al, 2018; Lin et al, 2017). As a result, ALK is a promising therapeutic target for inhibition with tyrosine kinase inhibitors. Crizotinib, ceritinib, brigatinib, alectinib and lorlatinib are all approved for the treatment of ALK-driven cancers, however resistance commonly develops either as a result of accumulating secondary mutations, or through activation of bypass pathways that remove the dependence on ALK signaling (reviewed in Della Corte et al, 2017; Roskoski, 2013; Lin et al, 2017).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1912">
 <bp:evidence rdf:resource="#Evidence2625" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective CFTR does not transport Cl- from cytosol to extracellular region</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway224">
 <bp:pathwayOrder rdf:resource="#PathwayStep1333" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1088" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1311" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">lorlatinib-resistant ALK mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Lorlatinib is a third generation tyrosine kinase inhibitor with effectiveness against ALK and ROS rearranged cancers. This pathway describes ALK mutants that are resistant to inhibition by lorlatinib (Yoda et al, 2018; Takahashi et al, 2020; reviewed in Della Corte et al, 2018; Lin et al, 2017; Facchinietti et al, 2016).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1917">
 <bp:evidence rdf:resource="#Evidence2635" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective ABCB11 does not transport bile salts from cytosol to extracellular region</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway223">
 <bp:pathwayOrder rdf:resource="#PathwayStep1331" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1087" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1309" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">crizotinib-resistant ALK mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Crizotinib is a type I tyrosine kinase inhibitor that is approved for treatment of ALK-positive non-small cell lung cancer. Crizotinib is also effective against ALCL and IMTs. Development of resistance to crizotinib is not uncommon, however, with patients acquiring secondary mutations or amplifications of the ALK gene that limit the effectiveness of the drug. This pathway describes ALK mutants that are resistant to crizotinib-mediated inhibition (reviewed in Roskoski, 2013; Lin et al, 2017; Della Corte et al, 2018).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1918">
 <bp:evidence rdf:resource="#Evidence2637" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective ABCA3 does not transport PC, PG from ER membrane to lamellar body</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis29">
 <bp:controlled rdf:resource="#BiochemicalReaction80" />
</bp:Catalysis>

<bp:Pathway rdf:ID="Pathway226">
 <bp:pathwayOrder rdf:resource="#PathwayStep1337" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1090" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1315" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">brigatinib-resistant ALK mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Brigatinib is a second generation tyrosine kinase inhibitor with activity against ALK. This pathway describes ALK mutants that are resistant to inhibition by brigatinib (reviewed in Della Corte et al, 2018; Roskoski, 2013; Lin and Pao, 2017; Hallberg and Palmer, 2013).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1915">
 <bp:evidence rdf:resource="#Evidence2631" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective ABCC2 does not transport BMG,BDG from cytosol to extracellular region</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis28">
 <bp:controlled rdf:resource="#BiochemicalReaction76" />
</bp:Catalysis>

<bp:Pathway rdf:ID="Pathway225">
 <bp:pathwayOrder rdf:resource="#PathwayStep1335" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1089" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1313" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ASP-3026-resistant ALK mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ASP3026 is a second generation tyrosine kinase inhibitor with activity against ALK fusions in non-small cell lung cancers (NSCLC) and anaplastic large cell lymphomas (ALCLs). This pathway describes ALK mutants that are resistant to inhibition by ASP3026 (Amin et al, 2016; Katayama et al, 2014; George et al, 2008; Mori et al, 2014; reviewed Roskoski, 2013; Lovly and Pao, 2012)</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1916">
 <bp:evidence rdf:resource="#Evidence2633" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective ABCG5 (in ABCG5:ABCG8) does not transport sterols from cytosol to extracellular region</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis16">
 <bp:controlled rdf:resource="#BiochemicalReaction46" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis15">
 <bp:controlled rdf:resource="#BiochemicalReaction44" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis14">
 <bp:controlled rdf:resource="#BiochemicalReaction29" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis13">
 <bp:controlled rdf:resource="#BiochemicalReaction28" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis12">
 <bp:controlled rdf:resource="#BiochemicalReaction27" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1920">
 <bp:evidence rdf:resource="#Evidence2641" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective ABCG8 (in ABCG5:ABCG8) does not transport sterols from cytosol to extracellular region</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis11">
 <bp:controlled rdf:resource="#BiochemicalReaction21" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1921">
 <bp:evidence rdf:resource="#Evidence2643" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective ABCC9 (in KCNJ11:ABCC9) does not transport K+ from extracellular region to cytosol</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis10">
 <bp:controlled rdf:resource="#BiochemicalReaction20" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1924">
 <bp:evidence rdf:resource="#Evidence2652" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">p16INK4A mutants do not bind CDK4,CDK6</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1925">
 <bp:evidence rdf:resource="#Evidence2654" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">p16INK4A mutants do not bind CDK4</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1922">
 <bp:evidence rdf:resource="#Evidence2645" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective ABCA12 does not transport lipids from cytosol to extracellular region</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1923">
 <bp:evidence rdf:resource="#Evidence2649" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">p14ARF mutant does not translocate to the nucleus</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1928">
 <bp:evidence rdf:resource="#Evidence2666" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">G or G analog binds C-ter TLR7 GoF variant </bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis19">
 <bp:controlled rdf:resource="#BiochemicalReaction51" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1929">
 <bp:evidence rdf:resource="#Evidence2668" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective MyD88 does not oligomerize within the complex of activated TLR5</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis18">
 <bp:controlled rdf:resource="#BiochemicalReaction50" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1926">
 <bp:evidence rdf:resource="#Evidence2662" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective TLR3 does not bind viral dsRNA</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis17">
 <bp:controlled rdf:resource="#BiochemicalReaction47" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1927">
 <bp:evidence rdf:resource="#Evidence2664" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective TRAF3 does not transmit the signal</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway206">
 <bp:pathwayOrder rdf:resource="#PathwayStep1190" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1189" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1186" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1187" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1188" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction963" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction964" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction961" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction962" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction960" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1165" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Toxicity of botulinum toxin type D (botD)</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Botulinum toxin type D (botD) is only very rarely associated with human disease (Hatheway 1995) and a pathway by which it might enter the circulation from the human gut has not been described. Nevertheless, the toxin itself, a disulfide-bonded heavy chain (HC) - light chain (LC) heterodimer (&#8220;dichain&#8221;), is capable of binding to neurons by interactions with cell surface ganglioside (Kroken et al. 2011) and synaptic vesicle protein 2 (SV2) (Peng et al. 2011), the bound toxin can enter synaptic vesicles and release its LC moiety into the cytosol of targeted cells (Montal 2010), and the botD LC can cleave vesicle associated membrane proteins 1 and 2 (VAMP1 and 2) on the cytosolic face of the synaptic vesicle membrane (Schiavo et al. 1993; Yamasaki et al. 1994). These four events are annotated here.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway205">
 <bp:pathwayOrder rdf:resource="#PathwayStep1181" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1182" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1183" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1184" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1180" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction958" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction959" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction956" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction957" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction955" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1159" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Toxicity of botulinum toxin type G (botG)</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Botulinum toxin type G (botG) is rarely if ever associated with human disease (Hatheway 1995) and a pathway by which it might enter the circulation from the human gut has not been described. Nevertheless, the toxin itself, a disulfide-bonded heavy chain (HC) - light chain (LC) heterodimer (&quot;dichain&quot;), is capable of binding to neurons by interactions with cell-surface ganglioside and syntagmin 1 (SYT1) (Peng et al. 2012; Willjes et al. 2013), the bound toxin can enter synaptic vesicles and release its LC moiety into the cytosol of targeted cells (Montal 2010), and the botG LC can cleave vesicle-associated membrane proteins 1 and 2 (VAMP1 and 2) on the cytosolic face of the synaptic vesicle membrane (Schiavo et al. 1994; Yamasaki et al. 1994). These four events are annotated here.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway208">
 <bp:pathwayOrder rdf:resource="#PathwayStep1200" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1201" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1202" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1198" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1199" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction974" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction972" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction973" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction970" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction971" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1177" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Toxicity of botulinum toxin type A (botA)</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Botulinum toxin type A (botA, also known as BoNT/A), a disulfide bonded heavy chain (HC) - light chain (LC) heterodimer (&quot;dichain&quot;), enters the gut typically as a result of consuming contaminated food (Hatheway 1995), as a complex with nontoxic nonhemagglutinin protein (NTNHA, encoded by the C. botulinum ntnha gene) and multiple copies of three hemagglutinin proteins (HA, encoded by the C. botulinum ha17, ha34, and ha70 genes) (Lee et al. 2013). The complex protects the toxin from degradation in the gut and mediates its association with the gut epithelium and transcytosis to enter the circulation. Recent studies in vitro raise the possibility that the toxin may also directly disrupt the basolateral membrane of the gut epithelium (Fujinaga et al. 2013). Circulating toxin molecules associate with gangliosides and synaptic vesicle protein 2 (SV2) exposed by exocytosis at a synapse of a target neuron in the neuromuscular junction (Yowler    Schengrund 2004; Dong et al. 2006). Vesicle recycling brings the toxin into the neuron where the vesicle is acidified (Sudhoff 2004). The lowered pH induces a conformational change in the toxin: its HC forms a passage in the vesicle membrane through which its LC is extruded into the neuronal cytosol and released by reduction of the HC - LC disulfide bond (Montal 2010). The cytosolic LC then catalyzes the cleavage of synaptosomal associated protein 25 (SNAP25) on the cytosolic face of the neuronal plasma membrane (Binz et al. 1994; Schiavo et al. 1993), thereby inhibiting synaptic vesicle fusion with the plasma membrane and exocytosis.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway207">
 <bp:pathwayOrder rdf:resource="#PathwayStep1192" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1193" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1194" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1195" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1196" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction969" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction967" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction968" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction965" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction966" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1171" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Toxicity of botulinum toxin type C (botC)</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Botulinum toxin type C (botC, also known as BoNT/C) is only very rarely associated with human disease (Hatheway 1995) and a pathway by which it might enter the circulation from the human gut has not been described. Nevertheless, the toxin itself, a disulfide-bonded heavy chain (HC) - light chain (LC) heterodimer (&#8220;dichain&#8221;), is capable of binding to neurons by interactions with cell surface gangliosides (Karalewitz et al. 2012), the bound toxin can enter synaptic vesicles and release its LC moiety into the cytosol of targeted cells (Montal 2010), and the botC LC can cleave synaptosomal associated protein 25 (SNAP25) and syntaxin 1 (STX1) on the cytosolic face of the neuronal plasma membrane (Foran et al. 1996). These four events are annotated here.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway209">
 <bp:pathwayOrder rdf:resource="#PathwayStep1208" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1204" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1205" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1206" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1207" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction975" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction978" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction979" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction976" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction977" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1183" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Toxicity of tetanus toxin (tetX)</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Tetanus toxin (tetX, also known as TeNT), a disulfide-bonded heavy chain (HC) - light chain (LC) dimer, is secreted from bacteria growing in an infected wound directly into the circulation. Circulating toxin molecules associate with gangliosides at a synapse of a target neuron. The toxin is taken up into clathrin-coated vesicles that reach the neuron cell body by retrograde transport and then possibly other neurons before undergoing acidification. Vesicle acidification causes a conformational change in the toxin, allowing its HC part to function as a channel through which its LC part is extruded into the neuronal cytosol. Cleavage of the HC - LC disulfide bond releases the LC into the cytosol, where it functions as a zinc metalloprotease to cleave vesicle-associated membrane protein 2 (VAMP2), thereby blocking synaptic vesicle exocytosis (Lalli et al. 2003).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1931">
 <bp:evidence rdf:resource="#Evidence2672" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective IKBKB (IKK2) does not form a complex with IKBKA and IKBKG</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1932">
 <bp:evidence rdf:resource="#Evidence2674" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">IRAK4 deficiency blocks formation of the MyD88-IRAK4 Myddosome in the TLR5 pathway</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1930">
 <bp:evidence rdf:resource="#Evidence2670" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective UNC93B1 does not bind TLR3</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1935">
 <bp:evidence rdf:resource="#Evidence2679" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective IKBKG (NEMO) destabilizes the association of IKBKA:IKBKB:IKBKG (via TLR)</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1936">
 <bp:evidence rdf:resource="#Evidence2681" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective IRAK4 does not bind MyD88:MAL:BTK:activated TLR2/4</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway200">
 <bp:pathwayOrder rdf:resource="#PathwayStep1160" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1161" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1162" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1158" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1159" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1163" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1164" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction941" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction942" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction940" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction938" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction939" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction943" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction944" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1137" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Tolerance of reactive oxygen produced by macrophages</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The expression of  AhpC  in Mycobacteria does not correlate with virulence; instead, the most important parts of the antioxidant system in  Mtb  appear to be the lipid cell wall, the enzymes SodB/SodC (superoxide dismutases), and the catalase/peroxidase KatG. Together with the enzyme system that acts on nitrosative stress and the sequestration of iron, these appear to be critical in defending against the macrophage&apos;s production of ROS/RNS, and enable the bacterium to exist in the phagosome for extended periods (Zahrt    Deretic 2002).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1933">
 <bp:evidence rdf:resource="#Evidence2676" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective MyD88 does not bind MAL(TIRAP):TLR2/4</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1934">
 <bp:evidence rdf:resource="#Evidence2677" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective MyD88 does not oligomerize within the activated TLR2/4 complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway202">
 <bp:pathwayOrder rdf:resource="#PathwayStep1170" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1171" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1167" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1168" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1169" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction949" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction947" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction948" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction945" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction946" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1146" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Uptake and function of diphtheria toxin</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Diphtheria is a serious, often fatal human disease associated with damage to many tissues. Bacteria in infected individuals, however, are typically confined to the lining of the throat or to a skin lesion; systemic effects are due to the secretion of an exotoxin encoded by a lysogenic bacteriophage. The toxin is encoded as a single polypeptide but is cleaved by host furin-like proteases to yield an aminoterminal fragment A and a carboxyterminal fragment B, linked by a disulfide bond. Toxin cleavage can occur when it first contacts the target cell surface, as annotated here, or as late as the point at which fragment A is released into the cytosol. Fragment B mediates toxin uptake into target cell endocytic vesicles, where acidification promotes a conformational change enabling fragment B to form a channel in the vesicle membrane through which fragment A is extruded into the target cell cytosol. Cleavage of the inter-fragment disulfide bond frees DT fragment A, which catalyzes ADP ribosylation of the translation elongation factor 2 (EEF2) in a target cell, thereby blocking protein synthesis. Neither fragment is toxic to human cells by itself (Collier 1975; Pappenheim 1977; Murphy 2011).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1939">
 <bp:evidence rdf:resource="#Evidence2686" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NFKBIA variant is not phosphorylated within IkBA:NF-kappaB</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway201">
 <bp:pathwayOrder rdf:resource="#PathwayStep1172" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1242" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1166" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1221" />
 <bp:pathwayComponent rdf:resource="#Pathway202" />
 <bp:pathwayComponent rdf:resource="#Pathway213" />
 <bp:pathwayComponent rdf:resource="#Pathway212" />
 <bp:pathwayComponent rdf:resource="#Pathway203" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1145" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Uptake and actions of bacterial toxins</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The toxic effects of many bacteria on their human hosts are mediated by proteins released from the bacteria that enter human cells and disrupt critical cellular functions (Henkel et al. 2010). All of the ones annotated here share a bipartiite mechanism of host intoxication: one moiety binds target cells and mediates the delivery of the other part to the intracellular compartment where it can function as an enzyme to degrade or derivatize and inactivate critical target cell proteins or to activate constitutive synthesis of high levels of cAMP.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway204">
 <bp:pathwayOrder rdf:resource="#PathwayStep1178" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1174" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1175" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1176" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1177" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction952" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction953" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction950" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction951" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction954" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1153" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Toxicity of botulinum toxin type B (botB)</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Botulinum toxin type B (botB, also known as BoNT/B), a disulfide-bonded heavy chain (HC) - light chain (LC) heterodimer, enters the gut typically as a result of consuming contaminated food (Hatheway 1995), as a complex with nontoxic nonhemagglutinin protein  (NTNHA, encoded by the C. botulinum ntnha gene) and multiple copies of three hemagglutinin proteins (HA, encoded by the C. botulinum ha17, ha34, and ha70 genes) (Amatsu et al. 2013). The complex protects the toxin from degradation in the gut and mediates its association with the gut epithelium and transcytosis to enter the circulation (Fujinaga et al. 2013). Circulating toxin molecules associate with gangliosides and synaptotagmin (SYT) proteins exposed by exocytosis at a synapse of a target neuron (Dong et al. 2003; Yowler    Schengrund 2004). Vesicle recycling brings the toxin into the neuron where the vesicle is acidified (Sudhoff 2004). The lowered pH induces a conformational change in the toxin: its HC forms a passage in the vesicle membrane through which its LC is extruded into the neuronal cytosol. Tthe HC - LC disulfide bond is reduced (Montal 2010). The LC then catalyzes the cleavage of vesicle-associated membrane protein 2 (VAMP2) on the cytosolic face of synaptic vesicle membranes (Foran et al. 1994; Schiavo et al. 1992), thereby inhibiting synaptic vesicle fusion with the plasma membrane and exocytosis.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1937">
 <bp:evidence rdf:resource="#Evidence2683" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TICAM1 deficiency blocks TLR3 pathway</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway203">
 <bp:pathwayOrder rdf:resource="#PathwayStep1209" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1173" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1215" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1191" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1179" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1203" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1185" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1197" />
 <bp:pathwayComponent rdf:resource="#Pathway206" />
 <bp:pathwayComponent rdf:resource="#Pathway205" />
 <bp:pathwayComponent rdf:resource="#Pathway208" />
 <bp:pathwayComponent rdf:resource="#Pathway207" />
 <bp:pathwayComponent rdf:resource="#Pathway209" />
 <bp:pathwayComponent rdf:resource="#Pathway211" />
 <bp:pathwayComponent rdf:resource="#Pathway210" />
 <bp:pathwayComponent rdf:resource="#Pathway204" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1152" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Neurotoxicity of clostridium toxins</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Clostridial neurotoxins, when taken up by human neurons, block synaptic transmission by cleaving proteins required for the fusion of synaptic vesicles with the plasma membrane. They are remarkably efficient so that very small doses cause paralysis of an affected person (Lalli et al. 2003; Turton et al. 2002). All characterized clostridial neurotoxins are synthesized as products of chromosomal, plasmid  or prophage-borne bacterial genes. The nascent toxin may be cleaved into light (LC) and heavy (HC) chain moieties that remain attached by noncovalent interactions and a disulfide bond (Turton et al. 2002). Strains of Clostridium botulinum produce seven serologically distinct toxins, BoNT/A, B, C, D, E, F, and G. An eighth toxin, BoNT/H has recently been identified (Barash    Arnon 2014) but its molecular properties have not yet been described. Human poisoning most commonly  result from ingestion of toxin contaminated food. More rarely, it is due to wound infection or clostridial colonization of the gut of an infant whose own gut flora have not yet developed or of an older individual whose flora have been suppressed. While all seven characterized toxins can cleave human target proteins, three, BoNT/A, B, and E, are most commonly associated with human disease (Hatheway 1995; Sakaguchi 1982). BoNT/F is also able to cause human botulism. Once ingested, the botulinum toxin must be taken up from the gut lumen into the circulation, a process mediated by four accessory proteins. These proteins form a complex that mediates transcytosis of the toxin molecule across the gut epithelium, allowing its entry into the circulation. The accessory proteins produced by different C. botulinum strains differ in their affinities for polarized epithelia of different species (e.g., human versus canine), and may thus be a key factor in human susceptibility to the toxins of strains A, B, and E and resistance to the others (Simpson 2004). Clostridium tetani produces TeNT toxin. Human poisoning is the result of toxin secretion by bacteria growing in an infected wound and the toxin is released directly into the circulation. Circulating clostridial toxins are taken up by neurons at neuromuscular junctions. They bind to specific gangliosides (BoNT/C, TeNT) or to both gangliosides and synaptic vesicle proteins (BoNT/A, B, D G) exposed on the neuronal plasma membrane during vesicle exocytosis (Montal 2010). All seven characterized forms of BoNT are thought to be taken up into synaptic vesicles as these re-form at the neuromuscular junction. These vesicles remain close to the site of uptake and are rapidly re-loaded with neurotransmitter and acidified (Sudhoff 2004). TeNT, in contrast, is taken up into clathrin coated vesicles that reach the neuron cell body by retrograde transport and then possibly other neurons before undergoing acidification. Vesicle acidification causes a conformational change in the toxin, allowing its HC part to function as a channel through which its LC part is extruded into the neuronal cytosol. The HC - LC disulfide bond is cleaved and the cytosolic LC functions as a zinc metalloprotease to cleave specific bonds in proteins on the cytosolic faces of synaptic vesicles and plasma membranes that normally mediate exocytosis (Lalli et al. 2003; Montal 2010).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1938">
 <bp:evidence rdf:resource="#Evidence2685" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NFKBIA variant binds NFkB complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis85">
 <bp:controlled rdf:resource="#BiochemicalReaction310" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis84">
 <bp:controlled rdf:resource="#BiochemicalReaction304" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis83">
 <bp:controlled rdf:resource="#BiochemicalReaction295" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis82">
 <bp:controlled rdf:resource="#BiochemicalReaction294" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis81">
 <bp:controlled rdf:resource="#BiochemicalReaction291" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis80">
 <bp:controlled rdf:resource="#BiochemicalReaction271" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis79">
 <bp:controlled rdf:resource="#BiochemicalReaction270" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis78">
 <bp:controlled rdf:resource="#BiochemicalReaction269" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis77">
 <bp:controlled rdf:resource="#BiochemicalReaction267" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis76">
 <bp:controlled rdf:resource="#BiochemicalReaction266" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis75">
 <bp:controlled rdf:resource="#BiochemicalReaction264" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis74">
 <bp:controlled rdf:resource="#BiochemicalReaction263" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis73">
 <bp:controlled rdf:resource="#BiochemicalReaction262" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis72">
 <bp:controlled rdf:resource="#BiochemicalReaction259" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis71">
 <bp:controlled rdf:resource="#BiochemicalReaction258" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis70">
 <bp:controlled rdf:resource="#BiochemicalReaction253" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis69">
 <bp:controlled rdf:resource="#BiochemicalReaction251" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis68">
 <bp:controlled rdf:resource="#BiochemicalReaction245" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis67">
 <bp:controlled rdf:resource="#BiochemicalReaction240" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis66">
 <bp:controlled rdf:resource="#BiochemicalReaction215" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis65">
 <bp:controlled rdf:resource="#BiochemicalReaction214" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis64">
 <bp:controlled rdf:resource="#BiochemicalReaction212" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis63">
 <bp:controlled rdf:resource="#BiochemicalReaction210" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis62">
 <bp:controlled rdf:resource="#BiochemicalReaction200" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis61">
 <bp:controlled rdf:resource="#BiochemicalReaction197" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis60">
 <bp:controlled rdf:resource="#BiochemicalReaction195" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis59">
 <bp:controlled rdf:resource="#BiochemicalReaction189" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis58">
 <bp:controlled rdf:resource="#BiochemicalReaction188" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis57">
 <bp:controlled rdf:resource="#BiochemicalReaction184" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis56">
 <bp:controlled rdf:resource="#BiochemicalReaction183" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep1897">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1478" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis55">
 <bp:controlled rdf:resource="#BiochemicalReaction166" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep1898">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1479" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis54">
 <bp:controlled rdf:resource="#BiochemicalReaction165" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep1899">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1480" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis53">
 <bp:controlled rdf:resource="#BiochemicalReaction163" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep1893">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1474" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1894">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1475" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1895">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1476" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1896">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1477" />
 <bp:stepProcess rdf:resource="#Catalysis434" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1890">
 <bp:stepProcess rdf:resource="#Catalysis431" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1471" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1891">
 <bp:stepProcess rdf:resource="#Catalysis432" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1472" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1892">
 <bp:stepProcess rdf:resource="#Catalysis433" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1473" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis52">
 <bp:controlled rdf:resource="#BiochemicalReaction160" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis51">
 <bp:controlled rdf:resource="#BiochemicalReaction159" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis50">
 <bp:controlled rdf:resource="#BiochemicalReaction158" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis49">
 <bp:controlled rdf:resource="#BiochemicalReaction157" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis48">
 <bp:controlled rdf:resource="#BiochemicalReaction154" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis47">
 <bp:controlled rdf:resource="#BiochemicalReaction138" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis46">
 <bp:controlled rdf:resource="#BiochemicalReaction118" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis45">
 <bp:controlled rdf:resource="#BiochemicalReaction117" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis44">
 <bp:controlled rdf:resource="#BiochemicalReaction114" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis43">
 <bp:controlled rdf:resource="#BiochemicalReaction111" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis42">
 <bp:controlled rdf:resource="#BiochemicalReaction106" />
</bp:Catalysis>

<bp:Evidence rdf:ID="Evidence131">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1861">
 <bp:evidence rdf:resource="#Evidence2526" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective SLC17A5 does not cotransport Neu5Ac, H+ from lysosomal lumen to cytosol</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence130">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1862">
 <bp:evidence rdf:resource="#Evidence2528" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective SLC33A1 does not transport Ac-CoA from cytosol to Golgi lumen</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence133">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence132">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1860">
 <bp:evidence rdf:resource="#Evidence2524" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective SLC12A6 does not cotransport K+, Cl- from cytosol to extracellular region</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1865">
 <bp:evidence rdf:resource="#Evidence2534" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective SLC29A3 does not transport nucleosides from lysosomal lumen to cytosol</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1866">
 <bp:evidence rdf:resource="#Evidence2536" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective SLC1A3 does not cotransport L-Glu,L-Asp,D-Asp,H+,3Na+ from extracellular region to cytosol</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1863">
 <bp:evidence rdf:resource="#Evidence2530" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective CP does not oxidise Fe2+ to Fe3+</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1864">
 <bp:evidence rdf:resource="#Evidence2532" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective SLC40A1 does not transport Fe3+ from extracellular region to cytosol</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence139">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1869">
 <bp:evidence rdf:resource="#Evidence2542" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective SLC2A10 does not transport Glc from extracellular region to cytosol</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence138">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1867">
 <bp:evidence rdf:resource="#Evidence2538" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective HK1 does not phosphorylate Glc to form G6P</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1868">
 <bp:evidence rdf:resource="#Evidence2540" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective SLCO1B3 does not transport BIL from extracellular region (blood) to cytosol (hepatocyte)</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence135">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence134">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence137">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence136">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1880">
 <bp:evidence rdf:resource="#Evidence2566" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SLC2A1 tetramer does not transport Glc from extracellular region to cytosol</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence142">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1872">
 <bp:evidence rdf:resource="#Evidence2548" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SLC1A1 does not cotransport L-Glu,L-Asp,D-Asp,H+,3Na+ from extracellular region to cytosol</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence141">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1873">
 <bp:evidence rdf:resource="#Evidence2550" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective SLC22A18 does not exchange extracellular organic cations for cytosolic H+</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence144">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1870">
 <bp:evidence rdf:resource="#Evidence2544" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective SLC22A12 does not exchange extracellular urate for cytosolic LACT</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence143">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1871">
 <bp:evidence rdf:resource="#Evidence2546" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective SLC16A1 does not cotransport monocarboxylates, H+ from extracellular region to cytosol</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1876">
 <bp:evidence rdf:resource="#Evidence2558" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SLC26A4 does not transport I- from cytosol to extracellular region</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1877">
 <bp:evidence rdf:resource="#Evidence2560" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective SLC36A2 does not cotransport Gly, L-Pro with H+ from extracellular region to cytosol</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence140">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1874">
 <bp:evidence rdf:resource="#Evidence2552" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective SLC34A2 does not cotransport Pi, 3Na+</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1875">
 <bp:evidence rdf:resource="#Evidence2556" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective SLC2A9 does not transport Fru, Glc, urate</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence149">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1878">
 <bp:evidence rdf:resource="#Evidence2562" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective AVP mutants do not bind AVPR2</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1879">
 <bp:evidence rdf:resource="#Evidence2564" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective SLC34A1 does not cotransport Pi, 3Na+</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence146">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence145">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence148">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence147">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1890">
 <bp:evidence rdf:resource="#Evidence2586" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective SLC9A6 does not exchange Na+ for H+ across the early endosome membrane</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1891">
 <bp:evidence rdf:resource="#Evidence2588" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective SLCO2A1 does not transport PGT substrates from extracellular region to cytosol</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence153">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1883">
 <bp:evidence rdf:resource="#Evidence2572" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective SLC22A5 does not cotransport CAR, Na+ from extracellular region to cytosol</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence152">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1884">
 <bp:evidence rdf:resource="#Evidence2574" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective SLC9A9 does not exchange Na+ for H+ across the late endosome membrane</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence155">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1881">
 <bp:evidence rdf:resource="#Evidence2568" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective SLC5A2 does not cotransport Glc and Na+ from extracellular region to cytosol</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence154">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1882">
 <bp:evidence rdf:resource="#Evidence2570" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective RHAG does not transport NH4+ from cytosol to extracellular region (rbc)</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1887">
 <bp:evidence rdf:resource="#Evidence2580" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective SLC40A1 does not transport Fe2+ from cytosol to extracellular region</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis99">
 <bp:controlled rdf:resource="#BiochemicalReaction389" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1888">
 <bp:evidence rdf:resource="#Evidence2582" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective SLC11A2 does not cotransport Fe2+, H+ from extracellular region to cytosol</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence151">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis98">
 <bp:controlled rdf:resource="#BiochemicalReaction388" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1885">
 <bp:evidence rdf:resource="#Evidence2576" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective SLC24A4 does not exchange extracellular 4Na+ for cytosolic Ca2+, K+</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence150">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis97">
 <bp:controlled rdf:resource="#BiochemicalReaction387" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1886">
 <bp:evidence rdf:resource="#Evidence2578" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective SLC4A4 does not cotransport Na+ with 3HCO3-</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1889">
 <bp:evidence rdf:resource="#Evidence2584" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective SLC4A1 does not exchange Cl- for HCO3- (in erythrocytes)</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence157">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence156">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence159">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence158">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis96">
 <bp:controlled rdf:resource="#BiochemicalReaction386" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis95">
 <bp:controlled rdf:resource="#BiochemicalReaction384" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis94">
 <bp:controlled rdf:resource="#BiochemicalReaction376" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis93">
 <bp:controlled rdf:resource="#BiochemicalReaction373" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis92">
 <bp:controlled rdf:resource="#BiochemicalReaction364" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis91">
 <bp:controlled rdf:resource="#BiochemicalReaction355" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis90">
 <bp:controlled rdf:resource="#BiochemicalReaction353" />
</bp:Catalysis>

<bp:Evidence rdf:ID="Evidence164">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1894">
 <bp:evidence rdf:resource="#Evidence2594" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective SLC39A4 does not transport Zn2+ from extracellular region to cytosol</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence163">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1895">
 <bp:evidence rdf:resource="#Evidence2597" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective SLC34A3 does not cotransport Pi, 2Na+</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence166">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1892">
 <bp:evidence rdf:resource="#Evidence2590" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Variant SLC6A14 cotransports SLC6A14 ligands, Cl-, 2Na+ from extracellular region to cytosol</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence165">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1893">
 <bp:evidence rdf:resource="#Evidence2592" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective SLC6A5 does not cotransport Gly, Cl-, Na+ from extracellular region to cytosol</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence160">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis89">
 <bp:controlled rdf:resource="#BiochemicalReaction350" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1898">
 <bp:evidence rdf:resource="#Evidence2603" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective SLC2A2 does not transport Fru, Gal, Glc from cytosol to extracellular region</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis88">
 <bp:controlled rdf:resource="#BiochemicalReaction335" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1899">
 <bp:evidence rdf:resource="#Evidence2605" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective SLC24A1 does not exchange extracellular 4Na+ for cytosolic Ca2+, K+</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence162">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis87">
 <bp:controlled rdf:resource="#BiochemicalReaction334" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1896">
 <bp:evidence rdf:resource="#Evidence2599" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective SLC5A5 does not cotransport Na+ with I- from extracellular region to cytosol</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence161">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis86">
 <bp:controlled rdf:resource="#BiochemicalReaction311" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1897">
 <bp:evidence rdf:resource="#Evidence2601" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective AVP mutants do not bind AVPR1A,B</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence168">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence167">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence169">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence175">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence174">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence177">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence176">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence171">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence170">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence173">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence172">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence179">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence178">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence180">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence186">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence185">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence188">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence187">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence182">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence181">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence184">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence183">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence189">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence191">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence190">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence197">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence196">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence199">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence198">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence193">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence192">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence195">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence194">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction710">
 <bp:evidence rdf:resource="#Evidence877" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">3a is externalized together with membrane structures</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction711">
 <bp:evidence rdf:resource="#Evidence878" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Protein 3a forms a homotetramer</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction718">
 <bp:evidence rdf:resource="#Evidence886" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Spike translocates to ERGIC</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep1909">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1487" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction719">
 <bp:evidence rdf:resource="#Evidence887" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">N-glycan glucose trimming of Spike</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction716">
 <bp:evidence rdf:resource="#Evidence883" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">mRNA5 is translated to protein M</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction717">
 <bp:evidence rdf:resource="#Evidence884" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">mRNA3 is translated to protein 3a</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction714">
 <bp:evidence rdf:resource="#Evidence881" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">mRNA2 is translated to Spike</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep1905">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1485" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction715">
 <bp:evidence rdf:resource="#Evidence882" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">mRNA4 is translated to protein E</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep1906">
 <bp:stepProcess rdf:resource="#Pathway377" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction712">
 <bp:evidence rdf:resource="#Evidence879" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">GalNAc is transferred onto 3a</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep1907">
 <bp:stepProcess rdf:resource="#Pathway378" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction713">
 <bp:evidence rdf:resource="#Evidence880" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Endocytosis of protein 3a</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep1908">
 <bp:stepProcess rdf:resource="#Catalysis438" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1486" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1912">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1490" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1913">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1491" />
 <bp:stepProcess rdf:resource="#Catalysis440" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1914">
 <bp:stepProcess rdf:resource="#Pathway379" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1915">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1492" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence1270">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1271">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction709">
 <bp:evidence rdf:resource="#Evidence876" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">3a translocates to the ERGIC</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence1272">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep1910">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1488" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence1273">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep1911">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1489" />
 <bp:stepProcess rdf:resource="#Catalysis439" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence1274">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1275">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1276">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1277">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1278">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1279">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction700">
 <bp:evidence rdf:resource="#Evidence863" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Uncoating of SARS-CoV-2 Genome</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction707">
 <bp:evidence rdf:resource="#Evidence874" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">3a localizes to the cell membrane</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction708">
 <bp:evidence rdf:resource="#Evidence875" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">O-glycosylation of 3a is terminated</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction705">
 <bp:evidence rdf:resource="#Evidence871" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Ubiquination of protein E</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction706">
 <bp:evidence rdf:resource="#Evidence872" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">E protein gets palmitoylated</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction703">
 <bp:evidence rdf:resource="#Evidence869" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">E pentamer is transported to the Golgi</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep1916">
 <bp:stepProcess rdf:resource="#Catalysis441" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1493" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction704">
 <bp:evidence rdf:resource="#Evidence870" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">E protein gets N-glycosylated</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep1917">
 <bp:stepProcess rdf:resource="#Pathway380" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction701">
 <bp:evidence rdf:resource="#Evidence864" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Spike glycoprotein of SARS-CoV-2 binds ACE2 on host cell</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep1918">
 <bp:stepProcess rdf:resource="#Catalysis442" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1494" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction702">
 <bp:evidence rdf:resource="#Evidence868" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Protein E forms a homopentamer</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep1919">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1495" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1923">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1499" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1924">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1500" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1925">
 <bp:stepProcess rdf:resource="#Catalysis443" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1501" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1926">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1502" />
 <bp:stepProcess rdf:resource="#Catalysis444" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence2590">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1260">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep1920">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1496" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence2591">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1261">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep1921">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1497" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence2592">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1262">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep1922">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1498" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence2593">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1263">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2594">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1264">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2595">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1265">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2596">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1266">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2597">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1267">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2598">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1268">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2599">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1269">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction732">
 <bp:evidence rdf:resource="#Evidence901" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">GSK3 phosphorylates nucleoprotein</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction733">
 <bp:evidence rdf:resource="#Evidence902" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Nucleoprotein is methylated by PRMT1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction730">
 <bp:evidence rdf:resource="#Evidence899" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Nucleoprotein translocates to the ERGIC outer membrane</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction731">
 <bp:evidence rdf:resource="#Evidence900" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Nucleoprotein translocates to the nucleolus</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction738">
 <bp:evidence rdf:resource="#Evidence907" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Dimerisation of nucleoprotein</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction739">
 <bp:evidence rdf:resource="#Evidence908" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SRPK1/2 phosphorylates nucleoprotein</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction736">
 <bp:evidence rdf:resource="#Evidence905" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Nucleoprotein is SUMOylated</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction737">
 <bp:evidence rdf:resource="#Evidence906" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Nucleoprotein is ADP-ribosylated</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction734">
 <bp:evidence rdf:resource="#Evidence903" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Unphosphorylated nucleoprotein translocates to the plasma membrane</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction735">
 <bp:evidence rdf:resource="#Evidence904" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">CSNK1A1 phosphorylates nucleoprotein</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence1290">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1291">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1292">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1293">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1294">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1295">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1296">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1297">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1298">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1299">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction721">
 <bp:evidence rdf:resource="#Evidence889" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Spike protein gets N-glycosylated</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction722">
 <bp:evidence rdf:resource="#Evidence890" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Addition of sialic acids on some Spike glycosyl sidechains</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction720">
 <bp:evidence rdf:resource="#Evidence888" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Spike trimer moves into the ERGIC membrane</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction729">
 <bp:evidence rdf:resource="#Evidence898" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Nucleoprotein translocates to the plasma membrane</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction727">
 <bp:evidence rdf:resource="#Evidence895" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Trimmed spike protein binds to calnexin</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction728">
 <bp:evidence rdf:resource="#Evidence896" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Spike protein forms a homotrimer</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction725">
 <bp:evidence rdf:resource="#Evidence893" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">N-glycan mannose trimming of Spike</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction726">
 <bp:evidence rdf:resource="#Evidence894" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Spike trimer glycoside chains are extended</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction723">
 <bp:evidence rdf:resource="#Evidence891" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Spike trimer glycoside chains get additional branches</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction724">
 <bp:evidence rdf:resource="#Evidence892" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Spike protein gets palmitoylated</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep1901">
 <bp:stepProcess rdf:resource="#Catalysis436" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1482" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1902">
 <bp:stepProcess rdf:resource="#Pathway376" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1903">
 <bp:stepProcess rdf:resource="#Catalysis437" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1483" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence1280">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep1904">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1484" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence1281">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1282">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1283">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1284">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep1900">
 <bp:stepProcess rdf:resource="#Catalysis435" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1481" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence1285">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1286">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1287">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1288">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1289">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1227">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2558">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1228">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2559">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1229">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2560">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1230">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2561">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1231">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2562">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1232">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2563">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1233">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2564">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1234">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2565">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1235">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2566">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1236">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2567">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1237">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2568">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1216">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2547">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1217">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2548">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1218">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2549">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1219">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence100">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence106">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2550">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence105">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1220">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2551">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence108">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1221">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2552">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence107">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1222">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2553">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence102">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1223">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2554">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence101">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1224">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2555">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence104">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1225">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2556">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence103">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1226">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2557">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1249">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence109">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence111">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence110">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2580">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1250">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2581">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1251">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2582">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence117">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1252">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2583">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence116">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1253">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2584">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence119">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1254">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2585">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence118">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1255">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2586">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence113">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1256">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2587">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence112">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1257">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2588">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence115">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1258">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2589">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence114">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1259">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1238">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2569">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1239">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence120">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence122">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence121">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2570">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1240">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2571">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence128">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1241">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2572">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence127">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1242">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2573">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1243">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2574">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence129">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1244">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2575">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence124">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1245">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2576">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence123">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1246">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2577">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence126">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1247">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2578">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence125">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1248">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2579">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction798">
 <bp:evidence rdf:resource="#Evidence974" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">CREBBP acetylates SARS-CoV-2 N at K375</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence1304">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2635">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction799">
 <bp:evidence rdf:resource="#Evidence975" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Dimerized phospho-IRF3, IRF7 is transported to the nucleus</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence1305">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2636">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction796">
 <bp:evidence rdf:resource="#Evidence972" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SARS-CoV-2 3CLpro dimer cleaves NLRP12</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence1306">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2637">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction797">
 <bp:evidence rdf:resource="#Evidence973" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TLR8 dimer binds SARS-CoV-2 GU-rich ssRNA </bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence1307">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2638">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction794">
 <bp:evidence rdf:resource="#Evidence970" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SARS-CoV-2 N binds MASP2</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence1308">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2639">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction795">
 <bp:evidence rdf:resource="#Evidence971" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SARS-CoV-2 nsp3 cleaves IRF3</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence1309">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction792">
 <bp:evidence rdf:resource="#Evidence968" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SARS-CoV-2 M protein binds MAVS</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction793">
 <bp:evidence rdf:resource="#Evidence969" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SARS-CoV-2 8 binds class I MHC</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway170">
 <bp:pathwayOrder rdf:resource="#PathwayStep930" />
 <bp:pathwayOrder rdf:resource="#PathwayStep931" />
 <bp:pathwayOrder rdf:resource="#PathwayStep932" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction743" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction744" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction742" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence911" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Maturation of protein M</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">This COVID-19 pathway has been created by a combination of computational inference from SARS-CoV-1 data (https://reactome.org/documentation/inferred-events) and manual curation, as described in the summation for the overall SARS-CoV-2 infection pathway.  Protein M, part of which is N-glycosylated, accumulates in the Golgi complex and recruits Spike protein to the sites of virus assembly and budding in the ERGIC (Voss et al, 2006; Voss et al, 2009)</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway172">
 <bp:pathwayOrder rdf:resource="#PathwayStep948" />
 <bp:pathwayOrder rdf:resource="#PathwayStep949" />
 <bp:pathwayOrder rdf:resource="#PathwayStep946" />
 <bp:pathwayOrder rdf:resource="#PathwayStep947" />
 <bp:pathwayOrder rdf:resource="#PathwayStep941" />
 <bp:pathwayOrder rdf:resource="#PathwayStep950" />
 <bp:pathwayOrder rdf:resource="#PathwayStep944" />
 <bp:pathwayOrder rdf:resource="#PathwayStep945" />
 <bp:pathwayOrder rdf:resource="#PathwayStep942" />
 <bp:pathwayOrder rdf:resource="#PathwayStep943" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction754" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction755" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction752" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction753" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction751" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction760" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction758" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction759" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction756" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction757" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence922" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Translation of Accessory Proteins</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Accessory proteins are encoded after the polymerase/replicase genes by mRNA6 (protein 6), mRNA7 (protein 7a), mRNA8 (protein 8), and bicistronic mRNA9b (protein 9b). These proteins are not essential for viral replication and assembly in vitro, but likely influence the pathogenesis of the SARS-CoV-2, like the accessory ORFs of other coronaviruses (Frieman et al, 2006; Narayanan et al, 2008). </bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep1996">
 <bp:stepProcess rdf:resource="#Catalysis467" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1549" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway171">
 <bp:pathwayOrder rdf:resource="#PathwayStep937" />
 <bp:pathwayOrder rdf:resource="#PathwayStep938" />
 <bp:pathwayOrder rdf:resource="#PathwayStep935" />
 <bp:pathwayOrder rdf:resource="#PathwayStep936" />
 <bp:pathwayOrder rdf:resource="#PathwayStep939" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction750" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction749" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction747" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction748" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction746" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence916" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Induction of Cell-Cell Fusion</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Many enveloped viruses induce multinucleated cells (syncytia) in later stages of viral infection. The membrane fusion that drives these cell-cell fusion events are caused by the same machinery that underlies viral entry. The presence of infected syncytial pneumocytes in severe COVID-19 patients is well established (Zhang et al., 2021). However, it is currently unclear if syncytia formation is also a feature of milder or asymptomatic SARS-CoV-2 infections. These syncytia are also thought to facilitate replication and evasion of the host immune response (for a recent review on Spike-mediated fusion and syncytia formation see Rajah et al, 2022). Experiments that utilize co-cultures of human cells expressing the receptor ACE2 with cells expressing SARS-CoV-2 spike protein, result in synapse-like intercellular contacts that initiate cell-cell fusion, producing syncytia resembling those we identify in lungs of COVID-19 patients (Sanders et al., 2021). Studies on SARS-CoV-2 identified similar syncytia (Buchrieser et al., 2020; Hoffmann et al., 2020a; Ou et al., 2020; Xia et al., 2020). Formation of the ACE2/spike protein complex drives fusion events that proceed from finger-like projections, forming synapses between cells to development of a fusion pore and subsequent membrane fusion (reviewed in Rajah et al, 2022; Rey, 2021). Notably cleaving the spike protein into S1 and S2 sub-fragments appears to increase the probability of S1/ACE2 fusion (Hoffmann et al., 2020a). The Alpha, Beta, and Delta variants of SARS-CoV-2 display enhanced syncytia formation (Cheng et al, 2021; Rajah et al, 2021). An additional phenomenon with SARS-CoV-2 syncytia is their targeting of lymphocytes for internalization and cell-in-cell mediated elimination, potentially contributing to lymphopenia and pathogenesis in COVID-19 patients (Zhang et al, 2021).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep1997">
 <bp:stepProcess rdf:resource="#Pathway404" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway174">
 <bp:pathwayOrder rdf:resource="#PathwayStep968" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1028" />
 <bp:pathwayOrder rdf:resource="#PathwayStep961" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1016" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1022" />
 <bp:pathwayComponent rdf:resource="#Pathway176" />
 <bp:pathwayComponent rdf:resource="#Pathway175" />
 <bp:pathwayComponent rdf:resource="#Pathway178" />
 <bp:pathwayComponent rdf:resource="#Pathway177" />
 <bp:pathwayComponent rdf:resource="#Pathway179" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence942" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SARS-CoV-2-host interactions</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Coronaviruses are a group of enveloped viruses with single&#8209;stranded, positive&#8209;sense RNA genomes. Each of the steps of viral replication - attachment and entry, translation of viral replicase, genome transcription and replication, translation of structural proteins, and virion assembly and release - involves host factors. These interactions can cause alterations in cellular structure and physiology, and activate host stress responses, autophagy, cell death, and processes of innate immunity (Fung TS    Liu DX 2019). This Reactome module describes molecular mechanisms by which severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) modulates innate and adaptive immune responses, autophagy, host translation, intracellular signaling and regulatory pathways, and PDZ-mediated cell-cell junctions, mostly annotated from studies of cells infected with SARS-CoV-2.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep1998">
 <bp:stepProcess rdf:resource="#Catalysis468" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1550" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway173">
 <bp:pathwayOrder rdf:resource="#PathwayStep959" />
 <bp:pathwayOrder rdf:resource="#PathwayStep957" />
 <bp:pathwayOrder rdf:resource="#PathwayStep958" />
 <bp:pathwayOrder rdf:resource="#PathwayStep952" />
 <bp:pathwayOrder rdf:resource="#PathwayStep955" />
 <bp:pathwayOrder rdf:resource="#PathwayStep956" />
 <bp:pathwayOrder rdf:resource="#PathwayStep953" />
 <bp:pathwayOrder rdf:resource="#PathwayStep954" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction765" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction766" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction763" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction764" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction761" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction762" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction767" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction768" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence933" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Virion Assembly and Release</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">This COVID-19 pathway has been created by a combination of computational inference from SARS-CoV-1 data (https://reactome.org/documentation/inferred-events) and manual curation, as described in the summation for the overall SARS-CoV-2 infection pathway.  The structures of complete SARS-CoV-2 virions, as well as their assembly stages, have been elucidated in great detail by cryo-electron microscopy methods. In particular, the Spike trimer is localized to ERGIC or Golgi compartments upon coexpression of E or M, which prevents syncytia formation (Boson et al, 2020). It is then transported via small transport vesicles to assembly sites (Klein et al, 2020; Mendon&#231;a et al, 2021; reviewed by Hardenbrook and Zhang, 2021). Based on work done in related coronaviruses, viral assembly is expected to occur at the ERGIC membrane (reviewed in Masters, 2006; Fehr and Perlman, 2015; Fung and Liu, 2019). Membrane protein components of the virus concentrate at the ERGIC membrane but are also found throughout the secretory system including at the plasma membrane. Accumulation at the site of viral assembly has been shown to depend on interaction between retrieval signals in the cytoplasmic tails of viral proteins and host factors such as the COPI coat, and likely involves repeated rounds of anterograde and retrograde traffic (McBride et al, 2007; Ujike et al, 2016; Tan et al, 2004; Tan et al, 2005; reviewed in McBride and Fielding, 2012; Chang et al, 2014). Viral assembly is initiated by homotypic interactions of M protein (Tseng et al, 2010; Siu et al, 2008). This forms an M-lattice that contributes to the induction of membrane curvature and additionally acts as a scaffold for the recruitment of the other structural components of the virus (Voss et al, 2009). M protein makes interactions with each of the main components of the mature virus, including E, S and N (He et al, 2004; Luo et al, 2006; Siu et al, 2008; reviewed in Masters, 2006). Electron micrographic studies suggest the final size of the mature virus is ~100 nm. The ribonuclear particle is predominantly helical and is packaged with an outer diamter of ~ 16 nm (Neuman et al, 2006; Neuman et al, 2011; reviewed in Chang et al, 2014). These physical constraints suggest a final stoichiometry in the mature virion of 75 S trimers:1200 M proteins:300 N:1 RNA genome (Neuman et al, 2011; reviewed in Chang et al, 2014). Minor amounts of other viral proteins, including proteins E, 3a and 7a may also be components of the mature virus, although their functions are not well established (reviewed in Schoeman and Fielding, 2019; Liu et al, 2014).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep1999">
 <bp:stepProcess rdf:resource="#Pathway405" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway176">
 <bp:pathwayOrder rdf:resource="#PathwayStep980" />
 <bp:pathwayOrder rdf:resource="#PathwayStep981" />
 <bp:pathwayOrder rdf:resource="#PathwayStep979" />
 <bp:pathwayOrder rdf:resource="#PathwayStep973" />
 <bp:pathwayOrder rdf:resource="#PathwayStep995" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1013" />
 <bp:pathwayOrder rdf:resource="#PathwayStep974" />
 <bp:pathwayOrder rdf:resource="#PathwayStep996" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1014" />
 <bp:pathwayOrder rdf:resource="#PathwayStep971" />
 <bp:pathwayOrder rdf:resource="#PathwayStep993" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1015" />
 <bp:pathwayOrder rdf:resource="#PathwayStep972" />
 <bp:pathwayOrder rdf:resource="#PathwayStep994" />
 <bp:pathwayOrder rdf:resource="#PathwayStep977" />
 <bp:pathwayOrder rdf:resource="#PathwayStep999" />
 <bp:pathwayOrder rdf:resource="#PathwayStep978" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1010" />
 <bp:pathwayOrder rdf:resource="#PathwayStep975" />
 <bp:pathwayOrder rdf:resource="#PathwayStep997" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1011" />
 <bp:pathwayOrder rdf:resource="#PathwayStep976" />
 <bp:pathwayOrder rdf:resource="#PathwayStep998" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1012" />
 <bp:pathwayOrder rdf:resource="#PathwayStep991" />
 <bp:pathwayOrder rdf:resource="#PathwayStep970" />
 <bp:pathwayOrder rdf:resource="#PathwayStep992" />
 <bp:pathwayOrder rdf:resource="#PathwayStep990" />
 <bp:pathwayOrder rdf:resource="#PathwayStep969" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1006" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1007" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1008" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1009" />
 <bp:pathwayOrder rdf:resource="#PathwayStep984" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1002" />
 <bp:pathwayOrder rdf:resource="#PathwayStep985" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1003" />
 <bp:pathwayOrder rdf:resource="#PathwayStep982" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1004" />
 <bp:pathwayOrder rdf:resource="#PathwayStep983" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1005" />
 <bp:pathwayOrder rdf:resource="#PathwayStep988" />
 <bp:pathwayOrder rdf:resource="#PathwayStep989" />
 <bp:pathwayOrder rdf:resource="#PathwayStep986" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1000" />
 <bp:pathwayOrder rdf:resource="#PathwayStep987" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1001" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction776" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction798" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction777" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction799" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction810" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction796" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction775" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction797" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction794" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction795" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction792" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction793" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction817" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction818" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction815" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction816" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction813" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction814" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction778" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction811" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction779" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction812" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction808" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction809" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction790" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction791" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction787" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction820" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction788" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction821" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction785" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction786" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction783" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction784" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction781" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction782" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction806" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction807" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction804" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction805" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction802" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction803" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction789" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction800" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction801" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction819" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction780" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence950" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SARS-CoV-2 activates/modulates innate and adaptive immune responses</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Coronaviruses (CoVs) are positive-sense RNA viruses that replicate in the interior of double membrane vesicles (DMV) in the cytoplasm of infected cells (Stertz S et al. 2007; Knoops K et al. 2008; V&apos;kovski P et al. 2021). The viral replication and transcription are facilitated by virus-encoded non-structural proteins (SARS-CoV-2 nsp1&#8211;nsp16) that assemble to form a DMV-bound replication-transcription complex (RTC) (V&apos;kovski P et al. 2021). The replication strategy of CoVs can generate both single-stranded RNA (ssRNA) and double-stranded RNA (dsRNA) species, that may act as pathogen-associated molecular patterns (PAMPs) recognized by pattern recognition receptor (PRR) such as toll-like receptor 7 (TLR7) and TLR8, antiviral innate immune response receptor RIG-I (also known as DEAD box protein 58, DDX58) and interferon-induced helicase C domain-containing protein 1 (IFIH1, also known as MDA5) (Salvi V et al. 2021; Campbell GR et al. 2021; Rebendenne A et al. 2021). The activated PRRs trigger signaling pathways to produce type I and type III interferons IFNs and proinflammatory mediators that perform antiviral functions. This Reactome module describes the mechanisms underlying PRR-mediated sensing of the severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) infection. First, endosomal recognition of viral ssRNA occurs by means of TLR7 and TLR8, which detect GU-rich ssRNA sequences (Salvi V et al. 2021; Campbell GR et al. 2021). Second, SARS-CoV-2 dsRNA replication intermediates can be recognized by cytoplasmic receptors DDX58 and IFIH1 which bind to mitochondrial antiviral-signaling protein (MAVS, IPS-1) to induce the IFN-mediated antiviral response (Rebendenne A et al. 2021; Yin X et al. 2021). In addition, SARS-CoV-2 E can be sensed by TLR2 (Zheng M et al. 2021). Further, cellular nucleic acid-binding protein (CNBP) and La-related protein 1 (LARP1) can directly bind SARS-CoV-2 gRNA to repress SARS-CoV-2 replication (Schmidt N et al. 2021). This module also describes several strategies developed by SARS-CoV-2 to evade or alter host immunity, including escaping innate immune sensors, inhibiting IFN production and signaling, and evading antiviral function of IFN stimulated gene (ISG) products. For example, SARS-CoV-2 encodes nsp14 and nsp16 which possess guanine-N7-methyltransferase activity and 2&#8217;-O-methyl-transferase activity respectively (Ogando NS et al. 2020; Krafcikova P et al. 2020; Viswanatha T et al. 2020; Lin S et al. 2021; Yan L et al. 2021). In human coronaviruses nsp14 generates 5&apos; cap-0 viral RNA (m7GpppN, guanine N7-methylated) and nsp16 further methylates cap-0 viral RNA. These viral RNA modifications mimic the 5&apos;-cap structure of host mRNAs allowing the virus to efficiently evade recognition by cytosolic DDX58 and IFIH1 (Chen Y et al. 2009, 2011; Daffis S et al. 2010, shown for CoVs such as SARS-CoV-1 and MERS-CoV). Structural studies and computational analysis suggest that properties and biological functions of SARS-CoV-2 nsp14 and nsp16 could be very similar to these of SARS-CoV-1 (Rosas-Lemus M et al. 2020; Lin S et al. 2020; Viswanathan T et al. 2020; Krafcikova P et al. 2020; Jiang Y et al. 2020; Wilamowski M et al. 2021). Further, the uridylate&#8208;specific endoribonuclease (EndoU) activity of SARS-CoV-2 nsp15 degrades viral RNA to hide it from innate immune sensors (Frazier MN et al. 2021). Moreover, SARS-CoV-2 encodes several proteins that directly bind to host targets associated with SARS&#8209;CoV&#8209;2 infection and cytokine production (Shin D et al. 2020; Viswanathan T et al. 2020; Xia H et al. 2020; Matsuyama T et al. 2020; Yuen CK et al. 2020; reviewed by Park A    Iwasaki A 2020). This Reactome module describes several such binding events and their consequences. For example, as a deubiquitinating and deISGylating enzyme, viral nsp3 binds to and removes ISG15 from signaling proteins such as IRF3 and IFIH1 thereby modulating the formation of signaling complexes and the activation of IRF3/7 and NF-kappaB (Liu CQ et al. 2021). Binding of SARS-CoV-2 nsp6, nsp13 or membrane (M) protein to cytosolic TBK1 prevents IRF3/7 activation and inhibits IFN production downstream of DDX58, IFIH1, MAVS and STING signaling pathways (Xia H et al. 2020; Sui L et al. 2021). Next, M protein targets MAVS to prevent the formation of the MAVS signalosome complex and thereby inhibits downstream signaling pathways of DDX58 and IFIH1 (Fu YZ et al. 2021). Binding of SARS-CoV-2 nucleocapsid (N) protein to E3 ubiquitin ligase TRIM25 inhibits TRIM25-mediated DDX58 ubiquitination and the DDX58 signaling pathway (Gori SG et al. 2021). N interacts with NLRP3 to promote the assembly and activation of the NLRP3 inflammasome (Pan P et al. 2021). The interaction between viral N and MASP2 promotes MASP2-mediated cleavage of C4 (Ali YM et al. 2021) and C2 (Kang S et al. 2021) leading to the hyperactivation of the complement system. Besides, viral N promotes NF-kappaB activation by targeting signaling complexes of TAK1 and IKK (Wu Y et al. 2021). The ion channel activities of accessory protein ORF3a or 3a (open reading frame 3a) and SARS&#8209;CoV&#8209;2 envelope (E) protein contribute to activation of the NLRP3 inflammasome leading to highly inflammatory pyroptotic cell death (based on findings for SARS-CoV-1, Siu KL et al. 2019). SARS-CoV-2 nsp5 protease (3CLpro) cleaves TAB1, a component of the TAK1 complex, thus inhibiting NF-kappaB activation (Moustaqil M et al .2021). 3CLpro targets NLRP12 which modulates the expression of inflammatory cytokines through the regulation of the NFkappaB and MAPK pathways (Moustaqil M et al. 2021). SARS-CoV-2 6 (ORF6) interacts with importin KPNA2 and components of the nuclear pore complex, NUP98 and RAE1, to block nuclear translocation of IRF3, STAT1 and STAT2 (Xia H et al. 2020; Miorin L et al. 2020). SARS-CoV-2 9b (ORF9b) inhibits the MAVS-mediated production of type I IFNs by targeting TOMM70 on the mitochondria (Jiang HW et al. 2020). Binding of mitochondrial viral 9 to IKBKG prevents MAVS-dependent NF-kappaB activation (Wu J et al. 2021). Although the evasion mechanisms are mainly conserved between SARS-CoV-1 and SARS-CoV-2 (Gordon DE et al. 2020), studies identified SARS-CoV-2-specific modulations of host immune response that may contribute to pathophysiological determinants of COVID-19 (Gordon DE et al. 2020; Schiller HB et al. 2021). This Reactome module describes several virus-host interactions identified in cells during SARS-CoV-2, but not SARS-CoV-1, infection. For example, SARS-CoV-2 8 (ORF8) regulates the expression of class I MHC on the surface of the infected cells through an autophagy-dependent lysosomal degradation of class I MHC (Zhang Y et al. 2021). At the plasma membrane, binding of secreted viral 8 to IL17RA activates IL17 signaling pathway leading to an increased secretion of cytokines/chemokines thus contributing to cytokine storm during SARS-CoV-2 infection (Lin X et al. 2021). Furthermore, SARS-CoV-2-host interactome and proteomics studies identified various human proteins that are targeted by SARS-CoV-2 proteins (Gordon DE et al. 2020a, b; Bojkova D et al. 2020; Stukalov A et al. 2021; Li J et al. 2021; Messina F et al. 2021). This Reactome module does not cover all identified SARS-CoV-2&#8211;human interactions; the module describes those associations that were functionally validated. </bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction790">
 <bp:evidence rdf:resource="#Evidence966" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SARS-CoV-2 3CLpro dimer binds to STING</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep1992">
 <bp:stepProcess rdf:resource="#Catalysis465" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1547" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway175">
 <bp:pathwayOrder rdf:resource="#PathwayStep962" />
 <bp:pathwayOrder rdf:resource="#PathwayStep963" />
 <bp:pathwayOrder rdf:resource="#PathwayStep966" />
 <bp:pathwayOrder rdf:resource="#PathwayStep967" />
 <bp:pathwayOrder rdf:resource="#PathwayStep964" />
 <bp:pathwayOrder rdf:resource="#PathwayStep965" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction774" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction772" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction773" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction770" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction771" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction769" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence943" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SARS-CoV-2 modulates host translation machinery</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SARS-CoV-2 encodes several proteins that have been implicated in shutting off host expression (Banerjee AK et al. 2020; Finkel Y et al. 2021). This Reactome module describes SARS-CoV-2 nonstructural protein 1 (nsp1)-mediated shutdown of host protein translation by binding to the mRNA entrance channel on the 40S subunit (Banerjee AK et al. 2020), SARS-CoV-2 nsp16-mediated disruption of global mRNA splicing via binding to the 5&#8242; splice site recognition sequence of U1 snRNA and the branchpoint recognition site of U2 snRNA, both parts of the spliceosome (Banerjee et al, 2020), and SARS-CoV-2 nsp8, nsp9-mediated suppression of protein integration into the cell membrane (Banerjee et al, 2020).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction791">
 <bp:evidence rdf:resource="#Evidence967" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Phosphorylation of STAT1</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep1993">
 <bp:stepProcess rdf:resource="#Pathway402" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway178">
 <bp:pathwayOrder rdf:resource="#PathwayStep1024" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1025" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1026" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1027" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1023" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction831" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction830" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction828" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction829" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction827" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1004" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SARS-CoV-2 targets host intracellular signalling and regulatory pathways</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Severe acute respiratory syndrome coronavirus type 2 (SARS&#8209;CoV&#8209;2) encodes several proteins that modulate host intracellular signaling and regulatory pathways. Among them are membrane M, nucleocapsid N and 3a proteins that directly bind to host targets associated with SARS&#8209;CoV&#8209;2 infection and cytokine production. This Reactome module describes several such binding events and their consequences. First, SARS&#8209;CoV&#8209;2 M binds to 3&#8209;phosphoinositide&#8209;dependent protein kinase 1 (PDPK1) to inhibit PKB/Akt activation (Ren Y et al. 2021). Second, SARS&#8209;CoV&#8209;1 N binds to the host 14-3-3 protein, which regulates nucleocytoplasmic shuttling and other functions of N (Tugaeva KV et al. 2021). Third, binding of viral 3a to the regulator and scaffolding protein caveolin&#8209;1 (CAV1) may regulate virus uptake as well as the trafficking of viral structural proteins (inferred from the orthologous protein in SARS-CoV-1).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep1994">
 <bp:stepProcess rdf:resource="#Catalysis466" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1548" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence2640">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway177">
 <bp:pathwayOrder rdf:resource="#PathwayStep1017" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1018" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1019" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1020" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1021" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction826" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction824" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction825" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction822" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction823" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence998" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SARS-CoV-2 modulates autophagy</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Autophagy is activated during microbial infection to exert antimicrobial defense mechanisms by targeting pathogen-associated components for lysosomal degradation. Pathogens evolved various strategies to manipulate autophagy responses. This Reactome module describes the impact of SARS-CoV-2 infection on autophagy. SARS-CoV-2-encoded proteins, such as open reading frame 3a (ORF3a, 3a) and ORF7a (7a), were shown to colocalize with markers of late endosomal membrane, lysosomal membrane and trans-Golgi network (Hayn M et al. 2021; Koepke L et al. 2021; Zhang Y et al. 2021). Both 3a and 7a block autophagic flux in human cells, but use different strategies (Hayn M et al. 2021; Koepke L et al. 2021). While 7a lowers the acidity of lysosome (Koepke L et al. 2021), ORF3a prevents autophagosome-lysosome fusion (Zhang Y et al. 2021; Qu Y et al. 2021; Miao G et al. 2021). Thus, the SARS-CoV-2 infection stimulates autophagy and leads to an accumulation of autophagosomes but blocks fusion between autophagosome and lysosome thereby preventing degradation of the cargo. In addition, SARS-CoV-2 membrane (M) protein associates with the mitochondrion to promote mitophagy (Hui X et al. 2021).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence1310">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep1995">
 <bp:stepProcess rdf:resource="#Pathway403" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence2641">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1311">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2642">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway179">
 <bp:pathwayOrder rdf:resource="#PathwayStep1030" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1029" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1031" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1032" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction832" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction835" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction833" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction834" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1010" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SARS-CoV-2 targets PDZ proteins in cell-cell junction</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">PSD95/Dlg1/ZO-1 (PDZ) domains are protein-protein recognition sequences, consisting of 80&#8211;90 amino acids that bind to a PDZ-binding motif (PBM), usually located at the end of the carboxy-terminus of a target protein (Hung AY    Sheng M 2002; Gerek ZN et al. 2009; Munz M et al. 2012). Proteins containing PDZ domains are typically found in the cell cytoplasm or in association with the plasma membrane and play a role in a variety of cellular processes such as cell-cell junctions, cellular polarity, and signal transduction pathways. The multidomain structure of PDZ-containing proteins enables them to interact with multiple binding partners simultaneously, thereby assembling larger protein complexes (Harris BZ    Lim WA 2001). Viruses also encode PBM-containing proteins that bind to cellular PDZ proteins. Viral PBMs target cellular PDZ-containing proteins involved in tight junction formation, cell polarity establishment, and apoptosis (Javier RT    Rice AP 2011).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence1312">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2643">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1313">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep1990">
 <bp:stepProcess rdf:resource="#Pathway400" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence2644">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1314">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep1991">
 <bp:stepProcess rdf:resource="#Pathway401" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence2645">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction787">
 <bp:evidence rdf:resource="#Evidence963" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SARS-CoV-2 6 binds NUP98:RAE1 within NPC</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence2624">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction788">
 <bp:evidence rdf:resource="#Evidence964" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Capturing cargo and formation of prebudding complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence2625">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction785">
 <bp:evidence rdf:resource="#Evidence961" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SARS-CoV-2 8:class I MHC binds BECN1</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence2626">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction786">
 <bp:evidence rdf:resource="#Evidence962" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SARS-CoV-2 3a induces potassium efflux</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence2627">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction783">
 <bp:evidence rdf:resource="#Evidence959" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SARS-CoV-2 S binds SFTPD 12mer</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence2628">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction784">
 <bp:evidence rdf:resource="#Evidence960" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SARS-CoV-2 9b binds TOMM70</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence2629">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction781">
 <bp:evidence rdf:resource="#Evidence957" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">CNBP binds SARS-CoV-2 G-rich RNA</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction782">
 <bp:evidence rdf:resource="#Evidence958" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SARS-CoV-2 N binds to TRIM25</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction789">
 <bp:evidence rdf:resource="#Evidence965" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SARS-CoV-2 N binds DDX58</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway181">
 <bp:pathwayOrder rdf:resource="#PathwayStep1071" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1244" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1165" />
 <bp:pathwayComponent rdf:resource="#Pathway182" />
 <bp:pathwayComponent rdf:resource="#Pathway201" />
 <bp:pathwayComponent rdf:resource="#Pathway214" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1052" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Bacterial Infection Pathways</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Bacterial infection pathways aim to capture molecular mechanisms of human bacterial diseases related to bacterial adhesion to and invasion of human host cells and tissues, toxigenicity (interaction of bacterially-produced toxins with the human host), and evasion of the host&apos;s immune defense.  Bacterial infection pathways currently include some metabolic processes mediated by intracellular Mycobacterium tuberculosis, the actions of clostridial, anthrax, and diphtheria toxins, and the entry of Listeria monocytogenes into human cells.  Clostridial toxins are produced by anaerobic spore-forming gram-positive bacilli of the genus Clostridium. Clostridium tetani causes tetanus, Clostridium botulinum causes botulism, Clostridium perfringens causes gas gangrene, and Clostridium difficile causes pseudomembranous colitis. The anthrax toxin is produced by the aerobic spore-forming gram-positive bacilli of the species Bacillus anthracis. The diphtheria toxin is produced by aerobic nonspore-forming gram-positive bacilli of the species Corynebacterium diphtheriae infected with the bacterial virus corynephage beta. Enterobacterial toxins are produced by pathogenic strains of Enterobacteriaceae, aerobic gram-negative bacilli that are part of normal intestinal flora, such as Escherichia coli.  Mycobacterium tuberculosis bacteria are acid-fast, aerobic, nonspore-forming bacilli that cause tuberculosis, a wide-spread disease that usually affects the lungs.  Listeria monocytogenes bacteria are aerobic nonspore-forming gram-positive bacilli that cause listeriosis. </bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway180">
 <bp:pathwayOrder rdf:resource="#PathwayStep1050" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1051" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1052" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1039" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1035" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1057" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1036" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1058" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1037" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1059" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1038" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1053" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1054" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1055" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1034" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1056" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1060" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1061" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1040" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1062" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1041" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1063" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1046" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1068" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1047" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1069" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1048" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1049" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1042" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1064" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1043" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1065" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1044" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1066" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1045" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1067" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction853" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction854" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction851" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction852" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction871" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction850" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction870" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction839" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction837" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction859" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction838" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction857" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction836" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction858" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction855" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction856" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction842" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction864" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction843" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction865" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction840" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction862" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction841" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction863" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction860" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction861" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction848" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction849" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction846" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction868" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction847" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction869" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction844" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction866" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction845" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction867" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1015" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Potential therapeutics for SARS</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The search for drugs to prevent or reduce the severity of human infection with SARS-CoV-1 or SARS-CoV-2 has centered on ones that are effective in treatment of human infections with other RNA viruses or in diminishing cytokine storms and other pathologies due to destructive host reactions. The interactions of a large number of these candidate drugs with their known viral and human protein targets are annotated, as are some drugs that inhibit Cytochrome P450 (CYP) oxidoreductases to prolong the plasma half-lives of antiviral drugs. In addition, effects of these drugs on unrelated essential human proteins, that might limit their use in vivo, are annotated. A notable success of this search is a combination treatment, Paxlovid (NCT04960202), involving ritonavir, an inhibitor of CYP3A4 and CYP2B6 oxidoreductases, and nirmatrelvir, an inhibitor of SARS-CoV-2 3CLp protease, to block steps in maturation of viral replicase proteins (Hashemian et al. 2023).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway183">
 <bp:pathwayOrder rdf:resource="#PathwayStep1073" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1074" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1075" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1076" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1077" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1078" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction875" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction876" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction873" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction874" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction872" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction877" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1054" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Modulation by Mtb of host immune system</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Mtb enhances its chances for being taken up by a phagocyte by blocking adaptive immune responses, as well as other innate immune system responses. Components of the bacterial cell wall also specifically promote phagocytosis via both the opsonic pathway and the presentation of adhesins (Esparza et al. 2015).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway182">
 <bp:pathwayOrder rdf:resource="#PathwayStep1072" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1083" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1079" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1126" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1086" />
 <bp:pathwayComponent rdf:resource="#Pathway183" />
 <bp:pathwayComponent rdf:resource="#Pathway185" />
 <bp:pathwayComponent rdf:resource="#Pathway196" />
 <bp:pathwayComponent rdf:resource="#Pathway184" />
 <bp:pathwayComponent rdf:resource="#Pathway187" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1053" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Infection with Mycobacterium tuberculosis</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Infection with Mycobacterium tuberculosis (Mtb) is soon countered by the host&apos;s immune system, the organism is however almost never eradicated; ten per cent of infections will develop into &quot;open tuberculosis&quot;, while the other ninety per cent become &quot;latent&quot;, a state that can persist for decades until loss of immune control. Approximately 25% of the world&apos;s population is estimated to harbour latent tuberculosis. Latent infection involves the bacterium being internalized by phagocytes where it stops and counters the innate immune answer (Russell 2011, Russell et al. 2010). When a status-quo is reached, Mtb enters a non-replicating persistent state (Barry et al. 2009, Boshoff    Barry 2005). Weakening of the immune defense sooner or later enables the waking up and multiplication of the bacterium inside the phagocyte, necrosis of the cell, and escape, analogous to the burst of lytic viruses (Repasy 2013).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway185">
 <bp:pathwayOrder rdf:resource="#PathwayStep1084" />
 <bp:pathwayComponent rdf:resource="#Pathway186" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1065" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Escape of Mtb from the phagocyte</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The roughly constant numbers of Mycobacterium tuberculosis (Mtb) during the chronic phase of infection are due to a balance between rapid replication and death (McDaniel et al. 2016). The relatively safe environment for Mtb in the phagocyte&apos;s phagosome is overcome when about 20-25 bacterial cells accumulate (Repasy et al. 2013). First, the phagosomal membrane is destroyed. Then, by injuring mitochondria and depleting NAD+, cell necrosis is started, resulting in Mtb escape (Lee et al. 2011).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway184">
 <bp:pathwayOrder rdf:resource="#PathwayStep1082" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1080" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1081" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction880" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction879" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction878" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1061" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Antimicrobial action and antimicrobial resistance in Mtb</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Antimicrobial compounds kill microorganisms or inhibit their growth, either in the host, outside on the skin (antiseptics), or in the environment (disinfectants). In the host they are named after the target symbiont, for example antibiotics, antifungals, and antiparasitics. It suffices to permanently stop an essential pathway in the symbiont to kill it. Broad spectrum antimicrobials usually target a conserved pathway like protein synthesis or cell wall construction, in order to affect a whole taxonomic group (Arenz    Wilson 2016, Barry et al. 2007, Green 2002).  Resistance of microorganisms (bacteria, viruses, parasites) to antimicrobials is one of the most important public health problems. Many mechanisms exist, and they are either acquired by mutation, by horizontal gene transfer, or are already intrinsic to the organism. The main mechanisms are modification of the antimicrobial, or its removal from the place of action, modification of its binding partner in the affected pathway, or usage of a back-up pathway. Participation of the organism in a consortium (like in biofilms) enables additional resistance mechanisms (Aminov    Mackie 2007, Peterson    Kaur 2018, van Acker et al. 2014, van Acker    Coenye 2016).  The events described here are specific to Mtb infection.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway187">
 <bp:pathwayOrder rdf:resource="#PathwayStep1094" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1105" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1091" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1102" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1087" />
 <bp:pathwayComponent rdf:resource="#Pathway190" />
 <bp:pathwayComponent rdf:resource="#Pathway192" />
 <bp:pathwayComponent rdf:resource="#Pathway191" />
 <bp:pathwayComponent rdf:resource="#Pathway189" />
 <bp:pathwayComponent rdf:resource="#Pathway188" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1068" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Response of Mtb to phagocytosis</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Mycobacterium tuberculosis (Mtb) encounters a vastly changed environment shortly after being internalized by macrophages. The compartment it resides in, the phagosome, is acidified and devoid of important metal ions and is flooded with reactive oxygen and nitrogen species. Steps will be soon taken by the macrophage to &quot;mature&quot; the phagosome with all kinds of lysosomal digestive enzymes. However, unlike most other bacteria species, Mtb has evolved solutions to each of these threats. As a last resort to a strong immune response, some bacteria will enter a dormant state (de Chastellier 2009, Flannagan et al. 2009). To what extent this is true is still unclear (McDaniel et al. 2016). Upon weakening of the immune defense, Mtb reawakens from its dormant state and starts to multiply inside the phagocyte (Repasy et al. 2013).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction780">
 <bp:evidence rdf:resource="#Evidence956" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">IL17RA and IL17RC bind IL17A dimer,IL17F dimer,IL17A:IL17F</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway186">
 <bp:pathwayOrder rdf:resource="#PathwayStep1085" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction881" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1066" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Phagocyte cell death caused by cytosolic Mtb</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Mycobacterium tuberculosis (Mtb), when located in the cytosol of phagocytes, induce cell death similar to necrosis as a means to exit the host cell, ultimately spreading the infection (Moraco    Kornfeld 2014).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway189">
 <bp:pathwayOrder rdf:resource="#PathwayStep1093" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1092" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction886" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction885" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1073" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Suppression of autophagy</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Autophagy, a distinct pathway of programmed cell death, is used by the phagocyte primarily to eradicate damaged cell organelles or unused proteins. As Mtb damages the phagosomal membrane it has to block autophagy processes to ensure maximum replication before exit from the cell (Jo 2013).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway188">
 <bp:pathwayOrder rdf:resource="#PathwayStep1090" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1088" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1089" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction884" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction882" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction883" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1069" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Inhibition of membrane repair</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">When the phagosomal membrane is injured, this is sensed and acted upon both by the host phagocyte and Mtb. While the host repair system is activated, the bacterium is secreting proteins that block host repair components, effectively inhibiting repair (Mittal et al. 2018).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence2630">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1300">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2631">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1301">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2632">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1302">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2633">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1303">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2634">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1326">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2657">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1327">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2658">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1328">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2659">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1329">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep1978">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1542" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1979">
 <bp:stepProcess rdf:resource="#Pathway393" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway150">
 <bp:pathwayOrder rdf:resource="#PathwayStep748" />
 <bp:pathwayOrder rdf:resource="#PathwayStep749" />
 <bp:pathwayOrder rdf:resource="#PathwayStep750" />
 <bp:pathwayOrder rdf:resource="#PathwayStep751" />
 <bp:pathwayOrder rdf:resource="#PathwayStep746" />
 <bp:pathwayOrder rdf:resource="#PathwayStep747" />
 <bp:pathwayOrder rdf:resource="#PathwayStep745" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction587" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction588" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction585" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction586" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction583" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction584" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction582" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence731" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SARS-CoV-1 targets host intracellular signalling and regulatory pathways</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Severe acute respiratory syndrome coronavirus type 1 (SARS&#8209;CoV&#8209;1) encodes several proteins that modulate host intracellular signaling and regulatory pathways. Among them are nucleocapsid N, membrane M and 3a proteins that directly bind to host targets associated with SARS&#8209;CoV&#8209;1 infection and cytokine production. This Reactome module describes several such binding events and their consequences. First, SARS&#8209;CoV&#8209;1 M binds to 3&#8209;phosphoinositide&#8209;dependent protein kinase 1 (PDPK1) to inhibit PKB/Akt activation (Chan et al. 2007; Tsoi et al. 2014). Second, SARS&#8209;CoV&#8209;1 N binds to SMAD3 to alter transforming growth factor&#8209;&#946; (TGF&#8209;&#946;) signaling (Zhao et al. 2008). This interaction prevents SMAD3 from complexing with SMAD4, thereby blocking TGF-&#946;-sensitized apoptosis. The association of N with SMAD3 also enhances the TGF-&#946;-induced expression of PAI-1 (SERPINE1) promoting tissue fibrosis (Zhao et al. 2008). Third, N protein binding to proteasome subunit p42 (PSMC6) modulates proteasome&#8209;regulated degradation of proteins (Wang et al. 2010). Fourth, SARS&#8209;CoV&#8209;1 N binds SUMO-conjugating enzyme UBC9 (UBE2I) to regulate the activity of UBE2I, affecting downstream signaling factors involved in the cell cycle, in addition to its function in the process of sumoylation (Fan et al. 2006). Finally, binding of viral 3a to the regulator and scaffolding protein caveolin&#8209;1 (CAV1) may regulate virus uptake as well as the trafficking of viral structural proteins (Padhan et al. 2007).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep1974">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1540" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1975">
 <bp:stepProcess rdf:resource="#Pathway391" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway152">
 <bp:pathwayOrder rdf:resource="#PathwayStep760" />
 <bp:pathwayOrder rdf:resource="#PathwayStep782" />
 <bp:pathwayOrder rdf:resource="#PathwayStep761" />
 <bp:pathwayOrder rdf:resource="#PathwayStep783" />
 <bp:pathwayOrder rdf:resource="#PathwayStep780" />
 <bp:pathwayOrder rdf:resource="#PathwayStep781" />
 <bp:pathwayOrder rdf:resource="#PathwayStep759" />
 <bp:pathwayOrder rdf:resource="#PathwayStep775" />
 <bp:pathwayOrder rdf:resource="#PathwayStep776" />
 <bp:pathwayOrder rdf:resource="#PathwayStep773" />
 <bp:pathwayOrder rdf:resource="#PathwayStep774" />
 <bp:pathwayOrder rdf:resource="#PathwayStep779" />
 <bp:pathwayOrder rdf:resource="#PathwayStep777" />
 <bp:pathwayOrder rdf:resource="#PathwayStep778" />
 <bp:pathwayOrder rdf:resource="#PathwayStep771" />
 <bp:pathwayOrder rdf:resource="#PathwayStep772" />
 <bp:pathwayOrder rdf:resource="#PathwayStep770" />
 <bp:pathwayOrder rdf:resource="#PathwayStep764" />
 <bp:pathwayOrder rdf:resource="#PathwayStep786" />
 <bp:pathwayOrder rdf:resource="#PathwayStep765" />
 <bp:pathwayOrder rdf:resource="#PathwayStep787" />
 <bp:pathwayOrder rdf:resource="#PathwayStep762" />
 <bp:pathwayOrder rdf:resource="#PathwayStep784" />
 <bp:pathwayOrder rdf:resource="#PathwayStep763" />
 <bp:pathwayOrder rdf:resource="#PathwayStep785" />
 <bp:pathwayOrder rdf:resource="#PathwayStep768" />
 <bp:pathwayOrder rdf:resource="#PathwayStep769" />
 <bp:pathwayOrder rdf:resource="#PathwayStep766" />
 <bp:pathwayOrder rdf:resource="#PathwayStep788" />
 <bp:pathwayOrder rdf:resource="#PathwayStep767" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction611" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction612" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction598" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction599" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction610" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction596" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction597" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction594" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction595" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction619" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction617" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction618" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction615" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction616" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction613" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction614" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction593" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction600" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction622" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction601" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction620" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction621" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction608" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction609" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction606" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction607" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction604" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction605" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction602" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction603" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence744" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SARS-CoV-1 activates/modulates innate immune responses</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Coronaviruses (CoVs) are positive-sense RNA viruses that replicate in the interior of double membrane vesicles (DMV) in the cytoplasm of infected cells (Stertz S et al. 2007; Knoops K et al. 2008). The viral replication and transcription are facilitated by virus-encoded non-structural proteins (SARS-CoV-1 nsp1&#8211;nsp16) that assemble to form a DMV-bound replication-transcription complex (RTC). The replication strategy of CoVs can generate both single-stranded RNA (ssRNA) and double-stranded RNA (dsRNA) species, that may act as pathogen-associated molecular patterns (PAMPs) recognized by pattern recognition receptor (PRR) such as toll-like receptor 7 (TLR7) and TLR8, antiviral innate immune response receptor RIG-I (also known as DEAD box protein 58, DDX58) and interferon-induced helicase C domain-containing protein 1 (IFIH1, also known as MDA5) (Cervantes-Barragan L et al. 2007; Chen Y et al. 2009, 2011; Daffis S et al. 2010; Li Y et al. 2013). The activated PRRs trigger signaling pathways to produce type I and type III interferons IFNs and proinflammatory mediators that perform antiviral functions. This Reactome module describes the mechanisms underlying PRR-mediated sensing of the severe acute respiratory syndrome coronavirus type 1 (SARS-CoV-1) infection. First, endosomal recognition of viral ssRNA occurs by means of TLR7 and TLR8 which detect GU-rich ssRNA sequences. Specifically, GU-rich ssRNA oligonucleotides derived from SARS-CoV-1 stimulated mononuclear phagocytes to release considerable levels of pro&#8209;inflammatory cytokines TNF&#8209;a, IL&#8209;6 and IL&#8209;12 via TLR7 and TLR8 (Li Y et al. 2013). Second, SARS-CoV-1 dsRNA replication intermediates can be recognized by cytoplasmic receptors DDX58 and IFIH1 which bind to mitochondrial antiviral-signaling protein (MAVS, IPS-1) to induce the IFN-mediated antiviral response. In addition, the module shows an antiviral function of interferon-induced protein with tetratricopeptide repeats 1 (IFIT1) that directly binds and sequesters viral single-stranded uncapped 5&#8242;-ppp RNA and cap-0 RNA (Daffis S et al. 2010). This module also describes several strategies developed by SARS-CoV-1 to evade or alter host immunity, including escaping innate immune sensors, inhibiting IFN production and signaling, and evading antiviral function of IFN stimulated gene (ISG) products. For example, viral dsRNA replication intermediates derived from SARS&#8209;CoV&#8209;1 were shown to associate with RTC bound to double membrane vesicles, which protected viral RNA from sensing by DDX58 or IFIH1 (Stertz S et al. 2007; Knoops K et al. 2008). Further, SARS-CoV-1 encodes nsp14 and nsp16 which possess guanine-N7-methyltransferase activity and 2&#8217;-O-methyl-transferase activity respectively (Chen Y et al. 2009, 2011). SARS-CoV-1 nsp14 generates 5&apos; cap-0 viral RNA (m7GpppN, guanine N7-methylated) and nsp16 further methylates cap-0 viral RNA. These viral RNA modifications mimic the 5&apos;-cap structure of host mRNAs allowing the virus to efficiently evade recognition by cytosolic DDX58 and IFIH1 (Chen Y et al. 2009, 2011; Daffis S et al. 2010). The nsp16-mediated ribose 2&#8242;-O-methylation of viral RNA also blocks the antiviral function of IFIT1 complexes (Menachery VD et al. 2014). Further, the uridylate&#8208;specific endoribonuclease (EndoU) activity of viral nsp15 degrades viral RNA to hide it from innate immune sensors (Bhardwaj K et al. 2006; Ricagno S et al. 2006). Moreover, SARS-CoV-1 encodes several proteins that directly bind to host targets associated with SARS&#8209;CoV&#8209;1 infection and cytokine production (Frieman M et al. 2009; Hu Y et al. 2017; Kopecky-Bromberg SA et al. 2007; Lindner H et al. 2005; Siu KL et al. 2009). This Reactome module describes several such binding events and their consequences. For example, as a de-ubiquitinating enzyme, viral nsp3 binds to and removes polyubiquitin chains of signaling proteins such as TRAF3, TRAF6, STING, IkBA, and IRF3 thereby modulating the formation of signaling complexes and the activation of IRF3/7 and NFkappaB (Sun L et al. 2012; Chen X et al. 2014; Li SW et al. 2016). This inhibits IFN production downstream of TLR7/8, DDX58, IFIH1, MAVS and STING signaling pathways. Binding of SARS-CoV-1 nucleocapsid (N) protein to E3 ubiquitin ligase TRIM25 inhibits TRIM25-mediated DDX58 ubiquitination and DDX58-mediated signaling pathway (Hu Y et al. 2017). Next, SARS&#8209;CoV&#8209;1 membrane (M) protein targets IBK1/IKBKE and TRAF3 to prevent the formation of the TRAF3:TANK:TBK1/IKBKE complex and thereby inhibits TBK1/IKBKE&#8209;dependent activation of IRF3/IRF7 transcription factors downstream of DDX58, IFIH1 and adaptor MAVS (Siu KL et al. 2009; 2014). The ion channel activities of open reading frame 3a (orf3a or 3a) and E contribute to activation of the NLRP3 inflammasome leading to highly inflammatory pyroptotic cell death (Nieto&#8209;Torres JL et al. 2015; Chen IY et al. 2019; Yue Y et al. 2018). Viral 3a promoted the NLRP3-mediated formation of PYCARD (ASC) speck by interaction with both TRAF3 and PYCARD (ASC) (Siu KL et al. 2019). Binding of 3a to caspase-1 (CASP1) enhanced CASP1-mediated cleavage of interleukin 1 beta (IL&#8209;1&#946;) downstream of the NLRP3 inflammasome pathway (Yue Y et al. 2018). Like 3a, SARS-CoV-1 8b was found to bind to NLRP3 activating the NLRP3 inflammasome and triggering IL&#8209;1&#946; release (Shi CS et al. 2019). 8b was also shown to bind IRF3, inhibiting subsequent IRF3 dimerization (Wong et al. 2018). At the plasma membrane, binding of SARS-CoV-1 7a to host BST2 disrupts the antiviral tethering function of BST2 which restricts the release of diverse mammalian enveloped viruses (Taylor JK et al. 2015). SARS-CoV-1 9b (orf9b) inhibits the MAVS-mediated production of type I IFNs by targeting TOMM70 on the mitochondria (Jiang HW et al. 2020). SARS-CoV-1 6 (orf6) inhibits the IFN signaling pathway by tethering karyopherins KPNA2 and KPNB1 to the endoplasmic reticulum (ER)/Golgi intermediate compartment (ERGIC) and thus blocking the KPNA1:KPNB1-dependent nuclear import of STAT1 (Frieman M et al. 2007). Binding of SARS-CoV-1 nsp1 to peptidyl-prolyl isomerases (PPIases) and calcipressin-3 (RCAN3) significantly activates the cyclophilin A/NFAT pathway, ultimately enhancing the induction of the IL-2 promoter (Pfefferle et al, 2011; Law et al, 2007). At last, SARS&#8209;CoV&#8209;1 3b, after translocating to the nucleus, binds to transcription factor RUNX1 and increases its promoting activity (Varshney et al, 2012). </bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep1976">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1541" />
 <bp:stepProcess rdf:resource="#Catalysis462" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway151">
 <bp:pathwayOrder rdf:resource="#PathwayStep757" />
 <bp:pathwayOrder rdf:resource="#PathwayStep755" />
 <bp:pathwayOrder rdf:resource="#PathwayStep756" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction592" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction590" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction591" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence741" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SARS-CoV-1 modulates host translation machinery</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Severe acute respiratory syndrome coronavirus type 1 (SARS-CoV-1) nonstructural protein 1 (nsp1) and nucleocapsid protein (N) disrupt mRNA translation upon SARS-CoV-1 infection in human cells. </bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep1977">
 <bp:stepProcess rdf:resource="#Pathway392" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway154">
 <bp:pathwayOrder rdf:resource="#PathwayStep793" />
 <bp:pathwayOrder rdf:resource="#PathwayStep794" />
 <bp:pathwayOrder rdf:resource="#PathwayStep797" />
 <bp:pathwayOrder rdf:resource="#PathwayStep795" />
 <bp:pathwayOrder rdf:resource="#PathwayStep796" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction628" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction629" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction626" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction627" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction625" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence778" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SARS-CoV-1-mediated effects on programmed cell death</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Programmed cell death (PCD) pathways, including pyroptosis, apoptosis, and necroptosis, are induced in infected host cells as an integral part of host defense to restrict microbial infections and regulate inflammatory responses (reviewed in Jorgensen I et al. 2017; Galluzzi L et al. 2018). Apoptosis is a noninflammatory form of cell death driven by the initiator caspase&#8209;mediated cleavage of executioner caspase&#8209;3 and &#8209;7. It facilitates degradation of the cellular contents but these are not released to the extracellular space. Necroptosis and pyroptosis are highly inflammatory forms of cell death that lead to cell lysis and release of pro&#8209;inflammatory cytokines such as interleukin (IL)&#8209;1&#946;, tumour necrosis factor alpha (TNF&#8209;&#945;), IL6, IL18 and cellular contents, which can cause severe inflammation (reviewed in Jorgensen I et al. 2017; Galluzzi L et al. 2018; Pasparakis M    Vandenabeele P 2015). Gasdermins (GSDMs) exert pore&#8209;forming activity in inflammasome&#8209;dependent pyroptosis, while the mixed lineage kinase domain&#8209;like (MLKL) protein functions as the executioner during necroptosis (Shi J et AL. 2015; Upton JW et al. 2017). Inflammation is a fundamental protective mechanism in elimination of microorganisms, and is normally tightly regulated by certain mediators, in particular IL10, to promote resolution of inflammation (reviewed in Sugimoto MA et al. 2016). Microbial pathogens are able to trigger and/or modulate host PCD and inflammatory response through multiple mechanisms. This Reactome module describes the roles of severe acute respiratory syndrome&#8209;associated coronavirus type 1 (SARS&#8209;CoV&#8209;1) 3a, E, and 7a proteins in the induction of host cell death pathways. SARS&#8209;CoV&#8209;1 open reading frame&#8209;3a (3a) binds host receptor interacting serine/threonine protein kinase 3 (RIPK3), facilitating RIPK3 oligomerization and the ion channel functionality of viral 3a, inducing inflammatory cell death and release of cellular contents (Yue Y et al. 2018). Enhanced production and release of proinflammatory cytokines leads to the cytokine storm that is considered to play a major role in SARS&#8209;CoV type 1and 2 infections (reviewed in Channappanavar R    Perlman S 2017; Yang L et al. 2020). The module also describes induction of apoptosis by SARS&#8209;CoV&#8209;1 E and 7a proteins through their interaction with anti&#8209;apoptotic BCL2L1 (Yang Y et al. 2005; Tan YX et al. 2007). Low levels of BCL2L1 may lead to enhanced function of pro&#8209;apoptotic molecules, contributing to the depletion of T lymphocytes by apoptosis (Yang Y et al. 2005). This may lead to the lymphopenia observed in SARS patients, particularly in severe cases (Diao B et al. 2020; Chen Z    Wherry EJ 2020). </bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep1970">
 <bp:stepProcess rdf:resource="#Pathway388" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence2660">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway153">
 <bp:pathwayOrder rdf:resource="#PathwayStep791" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction624" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence776" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SARS-CoV-1 targets PDZ proteins in cell-cell junction</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">PDZ domains are protein&#8209;protein recognition sequences, consisting of 80&#8211;90 amino acids that bind to a PDZ&#8209;binding motif (PBM), usually located at the carboxy&#8209;terminus of a target protein (Hung AY    Sheng M 2002; Gerek ZN et al. 2009; Munz M et al. 2012). Proteins containing PDZ domains are typically found in the cell cytoplasm or in association with the plasma membrane and play a role in cell&#8209;cell junction formation, establishment of cellular polarity, and signal transduction pathways. The multidomain structure of PDZ-containing proteins enables them to interact with multiple binding partners simultaneously, thereby assembling larger protein complexes (Harris BZ    Lim WA 2001). Viruses also encode PBM-containing proteins that bind to cellular PDZ proteins. Viral PBMs target cellular PDZ-containing proteins involved in tight junction formation, cell polarity establishment, and apoptosis (Javier RT    Rice AP 2011).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence1330">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep1971">
 <bp:stepProcess rdf:resource="#Pathway389" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence2661">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway156">
 <bp:pathwayOrder rdf:resource="#PathwayStep869" />
 <bp:pathwayOrder rdf:resource="#PathwayStep831" />
 <bp:pathwayOrder rdf:resource="#PathwayStep800" />
 <bp:pathwayComponent rdf:resource="#Pathway160" />
 <bp:pathwayComponent rdf:resource="#Pathway163" />
 <bp:pathwayComponent rdf:resource="#Pathway157" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence785" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Early SARS-CoV-2 Infection Events</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The initial steps of SARS-CoV-2 infection involve the specific binding of the coronavirus spike (S) protein to the cellular entry receptor, angiotensin-converting enzyme 2 (ACE2). The expression and tissue distribution of entry receptors consequently influence viral tropism and pathogenicity. Besides receptor binding, the proteolytic cleavage of coronavirus S proteins by host cell-derived proteases is essential to permit fusion. SARS-CoV has been shown to use the cell-surface serine protease TMPRSS2 for priming and entry, although the endosomal cysteine proteases cathepsin B (CatB) and CatL can also assist in this process. During the intracellular life cycle SARS-CoV-2 express and replicate their genomic RNA to produce full-length copies that are incorporated into newly produced viral particles. Coronaviruses possess remarkably large RNA genomes flanked by 5&apos; and 3&apos; untranslated regions that contain cis-acting secondary RNA structures essential for RNA synthesis. At the 5&apos; end, the genomic RNA features two large open reading frames (ORFs; ORF1a and ORF1b) that occupy two-thirds of the capped and polyadenylated genome.  Coronavirus S proteins are homotrimeric class I fusion glycoproteins that are divided into two functionally distinct parts (S1 and S2). The surface-exposed S1 contains the receptor-binding domain (RBD) that specifically engages the host cell receptor, thereby determining virus cell tropism and pathogenicity.  Besides receptor binding, the proteolytic cleavage of coronavirus S proteins by host cell-derived proteases is essential to permit fusion. SARS-CoV has been shown to use the cell-surface serine protease TMPRSS2 for priming and entry, although the endosomal cysteine proteases cathepsin B (CatB) and CatL can also assist in this process  The release of the coronavirus genome into the host cell cytoplasm upon entry marks the onset of a complex programme of viral gene expression, which is highly regulated in space and time. The translation of ORF1a and ORF1b from the genomic RNA produces two polyproteins, pp1a and pp1ab, respectively.  ORF1a and ORF1b encode 15-16 non-structural proteins (nsp), of which 15 compose the viral replication and transcription complex (RTC) that includes, amongst others, RNA-processing and RNA-modifying enzymes and an RNA proofreading function necessary for maintaining the integrity of the &gt;30kb coronavirus genome. The establishment of the viral RTC is crucial for virus replication  The release of the coronavirus genome into the host cell cytoplasm upon entry marks the onset of a complex programme of viral gene expression, here divided into early and late.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence1331">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep1972">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1539" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence2662">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway155">
 <bp:pathwayOrder rdf:resource="#PathwayStep881" />
 <bp:pathwayOrder rdf:resource="#PathwayStep960" />
 <bp:pathwayOrder rdf:resource="#PathwayStep799" />
 <bp:pathwayComponent rdf:resource="#Pathway174" />
 <bp:pathwayComponent rdf:resource="#Pathway164" />
 <bp:pathwayComponent rdf:resource="#Pathway156" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence784" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SARS-CoV-2 Infection</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">This pathway, SARS-CoV-2 infection of human cells (COVID-19), was initially generated via electronic inference from the manually curated and reviewed Reactome SARS-CoV-1 (Human SARS coronavirus) infection pathway. The inference process created SARS-CoV-2 events corresponding to each event in the SARS-CoV-1 pathway and populated those events with SARS-CoV-2 protein-containing physical entities based on orthology to SARS-CoV-1 proteins (https://reactome.org/documentation/inferred-events). All of these computationally created events and entities have been reviewed by Reactome curators and modified as appropriate where recently published experimental data indicate the existences of differences between the molecular details of the SARS-CoV-1 and SARS-CoV-2 infection pathways.  SARS&#8209;CoV&#8209;2 infection begins with the binding of viral S (spike) protein to cell surface angiotensin converting enzyme 2 (ACE2) and endocytosis of the bound virion. Within the endocytic vesicle, host proteases mediate cleavage of S protein into S1 and S2 fragments, leading to S2&#8209;mediated fusion of the viral and host endosome membranes and release of the viral capsid into the host cell cytosol. The capsid is uncoated to free the viral genomic RNA, whose cap&#8209;dependent translation produces polyprotein pp1a and, by means of a 1&#8209;base frameshift, polyprotein pp1ab. Autoproteolytic cleavage of pp1a and pp1ab generates 15 or 16 nonstructural proteins (nsps) with various functions. Importantly, the RNA dependent RNA polymerase (RdRP) activity is encoded in nsp12. Nsp3, 4, and 6 induce rearrangement of the cellular endoplasmic reticulum membrane to form cytosolic double membrane vesicles (DMVs) where the viral replication transcription complex is assembled and anchored. With viral genomic RNA as a template, viral replicase&#8209;transcriptase synthesizes a full length negative sense antigenome, which in turn serves as a template for the synthesis of new genomic RNA. The replicase&#8209;transcriptase can also switch template during discontinuous transcription of the genome at transcription regulated sequences to produce a nested set of negative&#8209;sense subgenomic (sg) RNAs, which are used as templates for the synthesis of positive&#8209;sense sgRNAs that are translated to generate viral proteins. Finally, viral particle assembly occurs in the ER Golgi intermediate compartment (ERGIC). Viral M protein provides the scaffold for virion morphogenesis (Hartenian et al. 2020; Fung    Liu 2019; Masters 2006). This Reactome module also describes molecular mechanisms by which SARS-CoV-2 modulates innate and adaptive immune responses, autophagy, host translation, intracellular signaling and regulatory pathways, and PDZ-mediated cell-cell junctions, mostly annotated from studies of cells infected with SARS-CoV-2.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence1332">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep1973">
 <bp:stepProcess rdf:resource="#Pathway390" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence2663">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway158">
 <bp:pathwayOrder rdf:resource="#PathwayStep805" />
 <bp:pathwayOrder rdf:resource="#PathwayStep816" />
 <bp:pathwayOrder rdf:resource="#PathwayStep806" />
 <bp:pathwayOrder rdf:resource="#PathwayStep817" />
 <bp:pathwayOrder rdf:resource="#PathwayStep803" />
 <bp:pathwayOrder rdf:resource="#PathwayStep814" />
 <bp:pathwayOrder rdf:resource="#PathwayStep804" />
 <bp:pathwayOrder rdf:resource="#PathwayStep815" />
 <bp:pathwayOrder rdf:resource="#PathwayStep809" />
 <bp:pathwayOrder rdf:resource="#PathwayStep807" />
 <bp:pathwayOrder rdf:resource="#PathwayStep818" />
 <bp:pathwayOrder rdf:resource="#PathwayStep808" />
 <bp:pathwayOrder rdf:resource="#PathwayStep819" />
 <bp:pathwayOrder rdf:resource="#PathwayStep820" />
 <bp:pathwayOrder rdf:resource="#PathwayStep812" />
 <bp:pathwayOrder rdf:resource="#PathwayStep823" />
 <bp:pathwayOrder rdf:resource="#PathwayStep802" />
 <bp:pathwayOrder rdf:resource="#PathwayStep813" />
 <bp:pathwayOrder rdf:resource="#PathwayStep810" />
 <bp:pathwayOrder rdf:resource="#PathwayStep821" />
 <bp:pathwayOrder rdf:resource="#PathwayStep811" />
 <bp:pathwayOrder rdf:resource="#PathwayStep822" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction633" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction644" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction634" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction645" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction631" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction642" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction632" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction643" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction640" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction651" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction630" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction641" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction650" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction639" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction637" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction648" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction638" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction649" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction635" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction646" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction636" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction647" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence787" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Replication of the SARS-CoV-2 genome</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">This COVID-19 pathway has been created by a combination of computational inference from SARS-CoV-1 data (https://reactome.org/documentation/inferred-events) and manual curation, as described in the summation for the overall SARS-CoV-2 infection pathway. Steps of SARS-CoV-2 genome replication that have been studied directly include binding of the replication transcription complex (RTC) to the RNA template and the polymerase activity of nsp12 (Hillen et al. 2020, Wang et al. 2020, Yin et al. 2020), helicase activity of nsp13 (Chen et al. 2020, Ji et al. 2020, Shu et al. 2020), capping activity of nsp16 (Viswanathan et al. 2020), and polyadenylation of SARS-CoV-2 genomic RNA (Kim et al. 2020). Replication is localized in double-membrane vesicles (DMVs) that are created by distortion of ER membranes (Cortese et al, 2020; Snijder et al, 2020). One host factor needed for formation of these replication organelles is phosphatidic acid (Tabata et al, 2021). Other steps have been inferred from previous studies in SARS-CoV-1 and related coronaviruses.  The plus strand RNA genome of the human SARS coronavirus 1 (SARS-CoV-1) is replicated by the viral replication-transcription complex (RTC) composed of nonstructural proteins nsp3-nsp16, encoded by open reading frames ORF1a and ORF1b. Two RTC proteins, nsp8 and nsp12, possess 5&apos;-3&apos; RNA-dependent RNA polymerase activity. nsp12 is the main RNA polymerase, while nsp8 is thought to act as an RNA primase. nsp14 acts as a 3&apos;-5&apos; exonuclease, increasing the fidelity of the RTC. nsp14 also has the RNA capping activity and, in concert with nsp16, it caps viral plus strand and minus strand genomic and subgenomic RNAs, which confers stability to viral RNAs by enabling them to escape interferon-mediated innate immune responses of the host. nsp13 is an RNA helicase which is thought to melt secondary structures in the genomic RNA during replication and transcription. The plus strand genomic RNA is first used to synthesize the minus strand genomic RNA complement, which is subsequently used as a template for synthesis of plus strand viral RNA genomes that are packaged into mature virions. For review, please refer to Yang and Leibowitz 2015, Snijder et al. 2016, Fung and Liu 2019.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence1333">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2664">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway157">
 <bp:pathwayOrder rdf:resource="#PathwayStep801" />
 <bp:pathwayOrder rdf:resource="#PathwayStep824" />
 <bp:pathwayComponent rdf:resource="#Pathway158" />
 <bp:pathwayComponent rdf:resource="#Pathway159" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence786" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SARS-CoV-2 Genome Replication and Transcription</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">This COVID-19 pathway has been created by a combination of computational inference from SARS-CoV-1 data (https://reactome.org/documentation/inferred-events) and manual curation, as described in the summation for the overall SARS-CoV-2 infection pathway. Specifically, binding of the replication-transcription complex (RTC) to the RNA template and the polymerase activity of nsp12 (Hillen et al. 2020, Wang et al. 2020, Yin et al. 2020), helicase activity of nsp13 (Chen et al. 2020, Ji et al. 2020, Shu et al. 2020), capping activity of nsp16 (Viswanathan et al. 2020), and polyadenylation of SARS-CoV-2 genomic RNA and transcripts (Kim et al. 2020, Ravindra et al. 2020) have been studied directly, and the remaining steps have been inferred from previous studies in SARS-CoV-1 and related coronaviruses.  Using the genomic RNA as a template, the coronavirus replicase synthesizes full-length negative-sense antigenome, which in turn serves as a template for the synthesis of new genomic RNA (Masters 2006). The polymerase can also switch template during discontinuous transcription of the genome at specific sites called transcription-regulated sequences, thereby producing a 5&apos;-nested set of negative-sense sgRNAs, which are used as templates for the synthesis of a 3&apos;-nested set of positive-sense sgRNAs (Masters 2006). Although genome replication/transcription is mainly mediated by the viral replicase and confines in the RTC, the involvement of various additional viral and host factors has been implicated. For instance, coronavirus N protein is known to serve as an RNA chaperone and facilitate template switching (Z&#250;&#241;iga et al. 2007, Z&#250;&#241;iga et al. 2010). Importantly, the N protein of SARS-CoV-1 and mouse hepatitis virus (MHV-JHM) is also phosphorylated by the host glycogen synthase kinase 3 (GSK3), and inhibition of GSK3 was shown to inhibit viral replication in Vero E6 cells infected with SARS-CoV-1 (Wu et al. 2009). Additionally, GSK3-mediated phosphorylation of the MHV-JHM N protein recruits an RNA-binding protein DEAD-box helicase 1 (DDX1), which facilitates template read-through, favoring the synthesis of genomic RNA and longer sgRNAs (Wu et al. 2014). Another RNA-binding protein called heterogeneous nuclear ribonucleoprotein A1 (hnRNPA1) can also bind tightly to SARS-CoV-1 N protein and potentially regulate viral RNA synthesis (Luo et al. 2005). Host RNA-binding proteins could also bind directly to untranslated regions (UTRs) of the coronavirus genome to modulate replication/transcription, such as zinc finger CCHC-type and RNA-binding motif 1 (ZCRB1) binding to the 5-UTR of IBV (Tan et al. 2012), mitochondrial aconitase binding to the 3&apos; UTR of MHV (Nanda and Leibowitz 2001), and poly(A)-binding protein (PABP) to the poly(A) tail of bovine coronavirus (Spagnolo and Hogue 2000). For review, please refer to Snijder et al. 2016 and Fung and Liu 2019.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence1334">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2665">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1335">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2666">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway159">
 <bp:pathwayOrder rdf:resource="#PathwayStep827" />
 <bp:pathwayOrder rdf:resource="#PathwayStep828" />
 <bp:pathwayOrder rdf:resource="#PathwayStep825" />
 <bp:pathwayOrder rdf:resource="#PathwayStep826" />
 <bp:pathwayOrder rdf:resource="#PathwayStep829" />
 <bp:pathwayOrder rdf:resource="#PathwayStep830" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction655" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction656" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction653" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction654" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction652" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction657" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence810" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Transcription of SARS-CoV-2 sgRNAs</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">This COVID&#8209;19 pathway has been created by a combination of computational inference from SARS-CoV-1 data (https://reactome.org/documentation/inferred-events) and manual curation, as described in the summation for the overall SARS-CoV-2 infection pathway. Steps of SARS&#8209;CoV&#8209;2 transcription that have been studied directly include binding of the replication&#8209;transcription complex (RTC) to the RNA template and the polymerase activity of nsp12 (Hillen et al. 2020, Wang et al. 2020, Yin et al. 2020), helicase activity of nsp13 (Chen et al. 2020, Ji et al. 2020, Shu et al. 2020), capping activity of nsp16 (Viswanathan et al. 2020), and polyadenylation of SARS&#8209;CoV&#8209;2 transcripts (Kim et al. 2020, Ravindra et al. 2020). Remaining steps have been inferred from previous studies in SARS&#8209;CoV&#8209;1 and related coronaviruses.  SARS-CoV-1 encodes eight subgenomic RNAs, mRNA2 to mRNA9. mRNA1 corresponds to the genomic RNA. The 5&apos; and 3&apos; ends of subgenomic RNAs are identical, in accordance with the template switch model of coronavirus RNA transcription (Snijder et al. 2003, Thiel et al. 2003, Yount et al. 2003). Genomic positive strand RNA is first transcribed into negative sense (minus strand) subgenomic mRNAs by template switching. Negative sense mRNAs subsequently serve as templates for the synthesis of positive strand subgenomic mRNAs. As shown in murine hepatitis virus (MHV), which is closely related to SARS-CoV-1, negative-sense viral RNAs are present in much smaller amounts than positive-sense RNAs (Irigoyen et al. 2016). Of the eight subgenomic mRNAs of SARS-CoV-1, mRNA2 encodes the S protein, mRNA3 is bicistronic and encodes proteins 3a and 3b, mRNA4 encodes the E protein, mRNA5 encodes the M protein, mRNA6 encodes protein 6, and bicistronic mRNA7, mRNA8 and mRNA9 encode proteins 7a and 7b (mRNA7), 8a and 8b (mRNA8), and 9a and N (mRNA9), respectively (Snijder et al. 2003, Thiel et al. 2003, Yount et al. 2003). The template switch model of coronavirus involves discontinuous transcription of subgenomic RNA, with the leader body joining occurring during the synthesis of minus strand RNAs. Each subgenomic RNA contains a leader transcription regulatory sequence (leader TRS) that is identical to the leader of the genome, appended via polymerase &#8220;jumping&#8221; during negative strand synthesis to the body transcription regulatory sequence (body TRS), a short, AU-rich motif of about 10 nucleotides found upstream of each ORF that is destined to become 5&apos; proximal in one of the subgenomic mRNAs. The 3&apos; and 5&apos;UTRs may interact through RNA&#8211;RNA and/or RNA&#8211;protein plus protein&#8211;protein interactions to promote circularization of the coronavirus genome, placing the elongating minus strand in a favorable topology for leader-body joining. The host protein PABP was found to bind to the coronavirus 3&apos; poly(A) tail and to interact with the host protein eIF-4G, a component of the three-subunit complex that binds to mRNA cap structures, which may promote the circularization of the coronavirus genome. Two viral proteins that bind to the coronavirus 5&apos;UTR, the N protein and nsp1, may play a role in template switching. The poly(A) tail is necessary for the initiation of minus-strand RNA synthesis at the 3&apos; end of genomic RNA.  Elongation of nascent minus strand RNA continues until the first functional body TRS motif is encountered. A fixed proportion of replication-transcription complexes (RTCs) will either disregard the TRS motif and continue to elongate the nascent strand or stop synthesis of the nascent minus strand and relocate to the leader TRS, extending the minus strand by copying the 5&apos; end of the genome. The completed minus-strand RNAs then serve as templates for positive strand mRNA synthesis (reviewed by Sawicki et al. 2007, Yang and Leibowitz 2015).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence1336">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2667">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1315">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2646">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1316">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2647">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1317">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2648">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1318">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2649">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1319">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep1989">
 <bp:stepProcess rdf:resource="#Pathway399" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway161">
 <bp:pathwayOrder rdf:resource="#PathwayStep838" />
 <bp:pathwayOrder rdf:resource="#PathwayStep849" />
 <bp:pathwayOrder rdf:resource="#PathwayStep839" />
 <bp:pathwayOrder rdf:resource="#PathwayStep836" />
 <bp:pathwayOrder rdf:resource="#PathwayStep847" />
 <bp:pathwayOrder rdf:resource="#PathwayStep837" />
 <bp:pathwayOrder rdf:resource="#PathwayStep848" />
 <bp:pathwayOrder rdf:resource="#PathwayStep841" />
 <bp:pathwayOrder rdf:resource="#PathwayStep842" />
 <bp:pathwayOrder rdf:resource="#PathwayStep850" />
 <bp:pathwayOrder rdf:resource="#PathwayStep840" />
 <bp:pathwayOrder rdf:resource="#PathwayStep851" />
 <bp:pathwayOrder rdf:resource="#PathwayStep834" />
 <bp:pathwayOrder rdf:resource="#PathwayStep845" />
 <bp:pathwayOrder rdf:resource="#PathwayStep835" />
 <bp:pathwayOrder rdf:resource="#PathwayStep846" />
 <bp:pathwayOrder rdf:resource="#PathwayStep843" />
 <bp:pathwayOrder rdf:resource="#PathwayStep844" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction666" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction667" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction664" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction675" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction665" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction676" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction662" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction673" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction663" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction674" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction660" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction671" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction661" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction672" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction659" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction668" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction669" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction670" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence819" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Maturation of replicase proteins</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">This COVID-19 pathway has been created by a combination of computational inference from SARS-CoV-1 data (https://reactome.org/documentation/inferred-events) and manual curation, as described in the summation for the overall SARS-CoV-2 infection pathway.  Production of polyprotein fragments (so called replicase proteins) involves the repeated autocleavage of the polyprotein, liberating the two endopeptidases that finally cleave all fragments efficiently. Only nsp3 and nsp4 are post-translationally modified, they are glycosylated (Muramatsu et al, 2015; Harcourt et al, 2004; Oostra et al, 2007).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep1985">
 <bp:stepProcess rdf:resource="#Pathway396" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway160">
 <bp:pathwayOrder rdf:resource="#PathwayStep852" />
 <bp:pathwayOrder rdf:resource="#PathwayStep853" />
 <bp:pathwayOrder rdf:resource="#PathwayStep867" />
 <bp:pathwayOrder rdf:resource="#PathwayStep868" />
 <bp:pathwayOrder rdf:resource="#PathwayStep832" />
 <bp:pathwayOrder rdf:resource="#PathwayStep833" />
 <bp:pathwayOrder rdf:resource="#PathwayStep866" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction677" />
 <bp:pathwayComponent rdf:resource="#Pathway161" />
 <bp:pathwayComponent rdf:resource="#Pathway162" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction691" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction692" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction690" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction658" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence817" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Translation of Replicase and Assembly of the Replication Transcription Complex</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">This COVID-19 pathway has been created by a combination of computational inference from SARS-CoV-1 data (https://reactome.org/documentation/inferred-events) and manual curation, as described in the summation for the overall SARS-CoV-2 infection pathway.  After entry and uncoating, the genomic RNA serves as a transcript to allow cap dependent translation of ORF1a to produce polyprotein pp1a. A slippery sequence and an RNA pseudoknot near the end of ORF1a enable 25 - 30% of ribosomes to undergo -1 frameshifting, to continue translation of ORF1b to produce a longer polyprotein pp1ab. Autoproteolytic cleavage of pp1a and pp1ab generates 15-16 nonstructural proteins (nsps) with various functions. RNA dependent RNA polymerase (RdRP) activity is encoded in nsp12, and papain like protease (PLPro) and main protease (Mpro) activities are encoded in nsp3 and nsp5, respectively. nsp3, 4, and 6 induce rearrangement of the cellular membrane to form double membrane vesicles (DMVs) where the coronavirus replication transcription complex (RTC) is assembled and anchored.  Programmed ribosomal frameshifting (PRF) may be regulated by viral or host factors in addition to viral RNA secondary structures. For example, PRF in the related arterivirus porcine reproductive and respiratory syndrome virus (PRRSV) is transactivated by the viral protein nsp1, which interacts with the PRF signal via a putative RNA binding motif. A host RNA-binding protein called annexin A2 (ANXA2) binds the pseudoknot structure in the IBV genome. Host factors in the early secretory pathway appear to be involved in DMV formation and RTC assembly: Golgi specific brefeldin A resistance guanine nucleotide exchange factor 1 (GBF1) and its effector ADP ribosylation factor 1 (ARF1) are both required for normal DMV formation and efficient RNA replication of mouse hepatitis virus (MHV), a prototypic betacoronavirus that infects mice (Fung    Liu 2019).  </bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep1986">
 <bp:stepProcess rdf:resource="#Pathway397" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway163">
 <bp:pathwayOrder rdf:resource="#PathwayStep870" />
 <bp:pathwayOrder rdf:resource="#PathwayStep871" />
 <bp:pathwayOrder rdf:resource="#PathwayStep880" />
 <bp:pathwayOrder rdf:resource="#PathwayStep874" />
 <bp:pathwayOrder rdf:resource="#PathwayStep875" />
 <bp:pathwayOrder rdf:resource="#PathwayStep872" />
 <bp:pathwayOrder rdf:resource="#PathwayStep873" />
 <bp:pathwayOrder rdf:resource="#PathwayStep878" />
 <bp:pathwayOrder rdf:resource="#PathwayStep879" />
 <bp:pathwayOrder rdf:resource="#PathwayStep876" />
 <bp:pathwayOrder rdf:resource="#PathwayStep877" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction699" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction700" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction697" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction477" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction698" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction695" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction696" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction693" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction694" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction470" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction701" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence855" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Attachment and Entry</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">This COVID-19 event has been created by a combination of computational inference (see https://reactome.org/documentation/inferred-events) from SARS-CoV-1 data and manual curation, as described in the summation for the overall SARS-CoV-2 infection pathway.  Coronavirus replication is initiated by the binding of S protein to the cell surface receptor(s). The S protein is composed of two functional domains, S1 (bulb) which mediates receptor binding and S2 (stalk) which mediates membrane fusion. Specific interaction between S1 and the cognate receptor triggers a drastic conformational change in S2, leading to fusion between the virus envelope and the cellular membrane and release of the viral nucleocapsid into the host cell cytosol. Receptor binding is the major determinant of the host range and tissue tropism for a coronavirus. Some human coronaviruses (HCoVs) have adopted cell surface enzymes as receptors, angiotensin converting enzyme 2 (ACE2) for SARS-CoV-2 (reviewed by Jackson et al, 2022), SARS-CoV-1, and HCoV NL63. The receptor-bound S protein is activated by cleavage into S1 and S2, mediated by one of two host proteases, the endosomal cysteine protease cathepsin L and another trypsin like serine protease. Type II transmembrane serine proteases TMPRSS2 and TMPRSS11D have also been implicated in the activation of S protein of SARS-CoV-2. Host factors may play additional roles in viral entry (not annotated here). Valosin containing protein (VCP) contributes by a poorly understood mechanism to the release of coronavirus from early endosomes. Host factors may also restrict the attachment and entry of HCoV.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep1987">
 <bp:stepProcess rdf:resource="#Pathway398" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway162">
 <bp:pathwayOrder rdf:resource="#PathwayStep858" />
 <bp:pathwayOrder rdf:resource="#PathwayStep859" />
 <bp:pathwayOrder rdf:resource="#PathwayStep860" />
 <bp:pathwayOrder rdf:resource="#PathwayStep863" />
 <bp:pathwayOrder rdf:resource="#PathwayStep864" />
 <bp:pathwayOrder rdf:resource="#PathwayStep861" />
 <bp:pathwayOrder rdf:resource="#PathwayStep862" />
 <bp:pathwayOrder rdf:resource="#PathwayStep856" />
 <bp:pathwayOrder rdf:resource="#PathwayStep857" />
 <bp:pathwayOrder rdf:resource="#PathwayStep854" />
 <bp:pathwayOrder rdf:resource="#PathwayStep865" />
 <bp:pathwayOrder rdf:resource="#PathwayStep855" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction688" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction678" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction689" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction686" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction687" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction684" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction685" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction682" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction683" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction680" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction681" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction679" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence839" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Assembly of the SARS-CoV-2 Replication-Transcription Complex (RTC)</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">This COVID-19 pathway has been created by a combination of computational inference from SARS-CoV-1 data (https://reactome.org/documentation/inferred-events) and manual curation, as described in the summation for the overall SARS-CoV-2 infection pathway.  In a sequence of ten reactions, mature non-structural proteins (nsp) generated by cleavage of the SARS-CoV-1 pp1a / pp1ab polyproteins are assembled to form the RTC (Fung    Liu 2019; Kirchdoerfer    Ward 2019). Six of these ten steps have been directly studied in SARS-CoV-2: binding of nsp7 to nsp8 (Gao et al. 2020, Li et al. 2020, Konkolova et al. 2020), recruitment of nsp12 (Gao et al. 2020, Hillen et al. 2020, Li et al. 2020, Yin et al. 2020), binding of nsp14 and nsp10 (Li et al. 2020), binding of nsp13 to nsp12 (Chen et al. 2020) formation of the nsp15 hexamer (Kim et al. 2020), and binding of nsp16 to nsp12 (Li et al. 2020, Rosas-Lemus et al. 2020, Viswanathan et al. 2020).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep1988">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1546" />
 <bp:stepProcess rdf:resource="#Catalysis464" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway165">
 <bp:pathwayOrder rdf:resource="#PathwayStep914" />
 <bp:pathwayOrder rdf:resource="#PathwayStep929" />
 <bp:pathwayOrder rdf:resource="#PathwayStep897" />
 <bp:pathwayOrder rdf:resource="#PathwayStep883" />
 <bp:pathwayOrder rdf:resource="#PathwayStep889" />
 <bp:pathwayOrder rdf:resource="#PathwayStep900" />
 <bp:pathwayOrder rdf:resource="#PathwayStep933" />
 <bp:pathwayOrder rdf:resource="#PathwayStep901" />
 <bp:pathwayOrder rdf:resource="#PathwayStep898" />
 <bp:pathwayOrder rdf:resource="#PathwayStep899" />
 <bp:pathwayComponent rdf:resource="#Pathway170" />
 <bp:pathwayComponent rdf:resource="#Pathway167" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction716" />
 <bp:pathwayComponent rdf:resource="#Pathway166" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction717" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction714" />
 <bp:pathwayComponent rdf:resource="#Pathway169" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction715" />
 <bp:pathwayComponent rdf:resource="#Pathway168" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction745" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence866" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Translation of Structural Proteins</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">This COVID-19 pathway has been created by a combination of computational inference from SARS-CoV-1 data (https://reactome.org/documentation/inferred-events) and manual curation, as described in the summation for the overall SARS-CoV-2 infection pathway.  Virus mRNA is translated according to the ribosomal scanning model. It is capped and polyadenylated, with regions of nontranslated sequences on both the 5&apos; and 3&apos; ends. Structural proteins are encoded after the polymerase/replicase genes by mRNAs 2 (Spike protein), 3, 4 (Envelope protein), 5 (Membrane protein), and 9. mRNA 3 and 9 are bicistronic, the proteins 3a and 9a (Nucleocapsid protein) having functions in virus assembly and structure. Translation happens in the ER with the exception of 9a which is translated by cytosolic free ribosomes (Fung and Liu, 2019).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep1981">
 <bp:stepProcess rdf:resource="#Pathway394" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway164">
 <bp:pathwayOrder rdf:resource="#PathwayStep882" />
 <bp:pathwayOrder rdf:resource="#PathwayStep940" />
 <bp:pathwayOrder rdf:resource="#PathwayStep951" />
 <bp:pathwayOrder rdf:resource="#PathwayStep934" />
 <bp:pathwayComponent rdf:resource="#Pathway172" />
 <bp:pathwayComponent rdf:resource="#Pathway171" />
 <bp:pathwayComponent rdf:resource="#Pathway173" />
 <bp:pathwayComponent rdf:resource="#Pathway165" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence865" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Late SARS-CoV-2 Infection Events</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The coronavirus virion consists of structural proteins, namely spike (S), envelope (E), membrane (M), nucleocapsid (N) and, for some betacoronaviruses, haemagglutinin-esterase. The positive-sense, single-stranded RNA genome (+ssRNA) is encapsidated by N, whereas M and E ensure its incorporation in the viral particle during the assembly process. S trimers protrude from the host-derived viral envelope and provide specificity for cellular entry receptors. SARS-CoV-2 particles bind to angiotensin-converting enzyme 2 (ACE2) cellular receptors and together with host factors (such as the cell surface serine protease TMPRSS2), promote viral uptake and fusion at the cellular or endosomal membrane.  Following entry, the release and uncoating of the incoming genomic RNA subject it to the immediate translation of two large open reading frames, ORF1a and ORF1b.  ORF1a and ORF1b encode 1516 non-structural proteins (nsp), of which 15 compose the viral replication and transcription complex (RTC) that includes, amongst others, RNA-processing and RNA-modifying enzymes and an RNA proofreading function necessary for maintaining the integrity of the &gt;30kb coronavirus genome. ORFs that encode structural proteins and interspersed ORFs that encode accessory proteins are transcribed from the 3&apos; one-third of the genome to form a nested set of subgenomic mRNAs (sg mRNAs).  The resulting polyproteins pp1a and pp1ab are co-translationally and post-translationally processed into the individual non-structural proteins (nsps) that form the viral replication and transcription complex. Concordant with the expression of nsps, the biogenesis of viral replication organelles consisting of characteristic perinuclear double-membrane vesicles (DMVs), convoluted membranes (CMs) and small open double-membrane spherules (DMSs) create a protective microenvironment for viral genomic RNA replication and transcription of subgenomic mRNAs comprising the characteristic nested set of coronavirus mRNAs.  Translated structural proteins translocate into endoplasmic reticulum (ER) membranes and transit through the ER-to-Golgi intermediate compartment (ERGIC), where interaction with N-encapsidated, newly produced genomic RNA results in budding into the lumen of secretory vesicular compartments. Finally, virions are secreted from the infected cell by exocytosis.  A successful intracellular coronavirus life cycle invariably relies on critical molecular interactions with host proteins that are repurposed to support the requirements of the virus. This includes host factors required for virus entry (such as the entry receptor and host cell proteases), factors required for viral RNA synthesis and virus assembly (such as ER and Golgi components and associated vesicular trafficking pathways) and factors required for the translation of viral mRNAs (such as critical translational initiation factors)</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep1982">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1544" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence2650">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway167">
 <bp:pathwayOrder rdf:resource="#PathwayStep892" />
 <bp:pathwayOrder rdf:resource="#PathwayStep893" />
 <bp:pathwayOrder rdf:resource="#PathwayStep890" />
 <bp:pathwayOrder rdf:resource="#PathwayStep891" />
 <bp:pathwayOrder rdf:resource="#PathwayStep896" />
 <bp:pathwayOrder rdf:resource="#PathwayStep894" />
 <bp:pathwayOrder rdf:resource="#PathwayStep895" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction710" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction711" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction709" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction707" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction708" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction712" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction713" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence873" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Maturation of protein 3a</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">This COVID-19 pathway has been created by a combination of computational inference from SARS-CoV-1 data (https://reactome.org/documentation/inferred-events) and manual curation, as described in the summation for the overall SARS-CoV-2 infection pathway.  Protein 3a is associated with protein M and is found in the virion, although its function in the structure seems non-essential. 3a is O-glycosylated and forms a homotetramer with porin function (Oostra et al, 2006; Lu et al, 2006)</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence1320">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep1983">
 <bp:stepProcess rdf:resource="#Pathway395" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence2651">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway166">
 <bp:pathwayOrder rdf:resource="#PathwayStep885" />
 <bp:pathwayOrder rdf:resource="#PathwayStep886" />
 <bp:pathwayOrder rdf:resource="#PathwayStep884" />
 <bp:pathwayOrder rdf:resource="#PathwayStep887" />
 <bp:pathwayOrder rdf:resource="#PathwayStep888" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction705" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction706" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction703" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction704" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction702" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence867" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Maturation of protein E</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">This COVID-19 pathway has been created by a combination of computational inference from SARS-CoV-1 data (https://reactome.org/documentation/inferred-events) and manual curation, as described in the summation for the overall SARS-CoV-2 infection pathway.  The envelope protein (E) gets palmitoylated and ubiquitinated after translation. It forms trimers that show porin activity but does not localize to the cell membrane (Tan et al, 2004; Liao et al, 2006; Alvarez et al, 2011)</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence1321">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep1984">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1545" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence2652">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway169">
 <bp:pathwayOrder rdf:resource="#PathwayStep915" />
 <bp:pathwayOrder rdf:resource="#PathwayStep926" />
 <bp:pathwayOrder rdf:resource="#PathwayStep916" />
 <bp:pathwayOrder rdf:resource="#PathwayStep927" />
 <bp:pathwayOrder rdf:resource="#PathwayStep924" />
 <bp:pathwayOrder rdf:resource="#PathwayStep925" />
 <bp:pathwayOrder rdf:resource="#PathwayStep919" />
 <bp:pathwayOrder rdf:resource="#PathwayStep917" />
 <bp:pathwayOrder rdf:resource="#PathwayStep928" />
 <bp:pathwayOrder rdf:resource="#PathwayStep918" />
 <bp:pathwayOrder rdf:resource="#PathwayStep922" />
 <bp:pathwayOrder rdf:resource="#PathwayStep923" />
 <bp:pathwayOrder rdf:resource="#PathwayStep920" />
 <bp:pathwayOrder rdf:resource="#PathwayStep921" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction732" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction733" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction730" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction741" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction731" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction740" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction729" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction738" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction739" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction527" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction736" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction737" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction734" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction735" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence897" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Maturation of nucleoprotein</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">This COVID-19 pathway has been created by a combination of computational inference from SARS-CoV-1 data (https://reactome.org/documentation/inferred-events) and manual curation, as described in the summation for the overall SARS-CoV-2 infection pathway.  Nucleoprotein, the most abundant viral protein expressed during infection, is found in the host cell cytosol, the nucleus and plasma membrane. After phosphorylation and sumoylation it di-/tetramerizes and is moved to the Golgi, the virion budding site (Li et al, 2005; Surjit et al, 2005).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence1322">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2653">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway168">
 <bp:pathwayOrder rdf:resource="#PathwayStep904" />
 <bp:pathwayOrder rdf:resource="#PathwayStep905" />
 <bp:pathwayOrder rdf:resource="#PathwayStep902" />
 <bp:pathwayOrder rdf:resource="#PathwayStep913" />
 <bp:pathwayOrder rdf:resource="#PathwayStep903" />
 <bp:pathwayOrder rdf:resource="#PathwayStep908" />
 <bp:pathwayOrder rdf:resource="#PathwayStep909" />
 <bp:pathwayOrder rdf:resource="#PathwayStep906" />
 <bp:pathwayOrder rdf:resource="#PathwayStep907" />
 <bp:pathwayOrder rdf:resource="#PathwayStep911" />
 <bp:pathwayOrder rdf:resource="#PathwayStep912" />
 <bp:pathwayOrder rdf:resource="#PathwayStep910" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction721" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction722" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction720" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction541" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction718" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction719" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction727" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction728" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction725" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction726" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction723" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction724" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence885" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Maturation of spike protein</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">This COVID-19 pathway has been created by a combination of computational inference from SARS-CoV-1 data (https://reactome.org/documentation/inferred-events) and manual curation, as described in the summation for the overall SARS-CoV-2 infection pathway.  The viral Spike protein of SARS-CoV-1 is subject to N-glycosylation and palmitoylation. The chaperone calnexin exclusively helps with protein folding. The end product is a homotrimer (Nal et al, 2005). In SARS-CoV-2 the Spike glycosylation patterns were extensively characterized, and consist of both N-glycans and O-glycans attached to about twenty amino acids (reviewed by Petrovi&#263; et al, 2021; Gong et al, 2021; Shajahan et al, 2021). Although there is no reason for the host&apos;s glycosylation enzymes behaving differently than with other host or non-host proteins, direct involvement of host enzymes and chaperones with SARS-CoV-2 Spike glycosylation has not been shown. Indirect evidence from inhibition experiments (Reyes et al, 2021; Franco et al, 2022) is confounded by simultaneous inhibition of glycosylation of other proteins like the ACE2 receptor.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence1323">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2654">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1324">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2655">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1325">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep1980">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1543" />
 <bp:stepProcess rdf:resource="#Catalysis463" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence2656">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction754">
 <bp:evidence rdf:resource="#Evidence926" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">6 localizes to the nuclear envelope</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway139">
 <bp:pathwayOrder rdf:resource="#PathwayStep661" />
 <bp:pathwayOrder rdf:resource="#PathwayStep662" />
 <bp:pathwayOrder rdf:resource="#PathwayStep660" />
 <bp:pathwayOrder rdf:resource="#PathwayStep665" />
 <bp:pathwayOrder rdf:resource="#PathwayStep666" />
 <bp:pathwayOrder rdf:resource="#PathwayStep663" />
 <bp:pathwayOrder rdf:resource="#PathwayStep664" />
 <bp:pathwayOrder rdf:resource="#PathwayStep659" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction512" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction513" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction510" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction511" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction509" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction507" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction508" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction514" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence645" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Virion Assembly and Release</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SARS viral assembly occurs at the ERGIC membrane (reviewed in Masters, 2006; Fehr and Perlman, 2015; Fung and Liu, 2019). Membrane protein components of the virus concentrate at the ERGIC membrane but are also found throughout the secretory system including at the plasma membrane. Accumulation at the site of viral assembly has been shown to depend on interaction between retrieval signals in the cytoplasmic tails of viral proteins and host factors such as the COPI coat, and likely involves repeated rounds of anterograde and retrograde traffic (McBride et al, 2007; Ujike et al, 2016; Tan et al, 2004; Tan et al, 2005; reviewed in McBride and Fielding, 2012; Chang et al, 2014). Viral assembly is intitiated by homotypic interactions of M protein (Tseng et al, 2010; Siu et al, 2008). This forms an M-lattice that contributes to the induction of membrane curvature and additionally acts as a scaffold for the recruitment of the other structural components of the virus (Voss et al, 2009). M protein makes interactions with each of the main components of the mature virus, including E, S and N (He et al, 2004; Luo et al, 2006; Siu et al, 2008; reviewed in Masters, 2006). Electron micrographic studies suggest the final size of the mature virus is ~100 nm. The ribonuclear particle is predominantly helical and is packaged with an outer diamter of ~ 16 nm (Neuman et al, 2006; Neuman et al, 2011; reviewed in Chang et al, 2014). These physical constraints suggest a final stoichiometry in the mature virion of 75 S trimers:1200 M proteins:300 N:1 RNA genome (Neuman et al, 2011; reviewed in Chang et al, 2014). Minor amounts of other viral proteins, including proteins E, 3a and 7a may also be components of the mature virus, although their functions are not well established (reviewed in Schoeman and Fielding, 2019; Liu et al, 2014).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction755">
 <bp:evidence rdf:resource="#Evidence927" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">mRNA6 is translated to protein 6</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction752">
 <bp:evidence rdf:resource="#Evidence924" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">mRNA8 is translated to protein 8</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction753">
 <bp:evidence rdf:resource="#Evidence925" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">7a localizes to the ERGIC membrane</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction750">
 <bp:evidence rdf:resource="#Evidence921" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Spike Trimer Translocates to the Plasma Membrane</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction751">
 <bp:evidence rdf:resource="#Evidence923" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">8 forms a homodimer</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction758">
 <bp:evidence rdf:resource="#Evidence930" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Unknown kinase phosphorylates 9b</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep1949">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1520" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction759">
 <bp:evidence rdf:resource="#Evidence931" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">9b homodimer localizes to the mitochondrial outer membrane</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction756">
 <bp:evidence rdf:resource="#Evidence928" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">mRNA7 is translated to protein 7a</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction757">
 <bp:evidence rdf:resource="#Evidence929" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">mRNA9 is translated to protein 9b</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep1956">
 <bp:stepProcess rdf:resource="#Catalysis457" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1526" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1957">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1527" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1958">
 <bp:stepProcess rdf:resource="#Catalysis458" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1528" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1959">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1529" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1952">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1522" />
 <bp:stepProcess rdf:resource="#Catalysis455" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1953">
 <bp:stepProcess rdf:resource="#Catalysis456" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1523" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway130">
 <bp:pathwayOrder rdf:resource="#PathwayStep596" />
 <bp:pathwayOrder rdf:resource="#PathwayStep597" />
 <bp:pathwayOrder rdf:resource="#PathwayStep598" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction455" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction453" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction454" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence582" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">2-LTR circle formation</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The formation of 2-LTR circles requires the action of the cellular non-homologous DNA end-joining pathway.  Specifically the cellular Ku, XRCC4 and ligase IV proteins are needed.  Evidence for this is provided by the observation that cells mutant in these functions do not support detectable formation of 2-LTR circles, though integration and formation of 1-LTR circles are mostly normal.  The reaction takes place in the nucleus, and formation of 2-LTR circles has been used as a surrogate assay for nuclear transport.  It has also been suggested that the NHEJ system affects the toxicity of retroviral infection.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep1954">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1524" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1955">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1525" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway132">
 <bp:pathwayOrder rdf:resource="#PathwayStep607" />
 <bp:pathwayOrder rdf:resource="#PathwayStep608" />
 <bp:pathwayOrder rdf:resource="#PathwayStep609" />
 <bp:pathwayOrder rdf:resource="#PathwayStep610" />
 <bp:pathwayOrder rdf:resource="#PathwayStep611" />
 <bp:pathwayOrder rdf:resource="#PathwayStep614" />
 <bp:pathwayOrder rdf:resource="#PathwayStep612" />
 <bp:pathwayOrder rdf:resource="#PathwayStep613" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction468" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction469" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction466" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction467" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction464" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction465" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction462" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction463" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence593" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Binding and entry of HIV virion</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">HIV enters cells by fusion at the cell surface, that results in a productive infection. The envelope (Env) protein of HIV mediates entry. Env is composed of a  surface subunit, gp120, and a transmembrane subunit, gp41, which assemble as heterotrimers on the virion surface.The trimeric, surface gp120 protein (SU) on the virion engages CD4 on the host cell, inducing conformational changes that promote binding to select chemokine receptors CCR5 and CXCR4. The sequential interplay between SU, CD4 and chemokine coreceptors prompts a conformational change in the transmembrane gp41.  This coiled coil protein, assembled as a trimer on the virion membrane, springs open to project three peptide fusion domains that &apos;harpoon&apos; the lipid bilayer of the target cell.  A hairpin structure (also referred to as a &quot;coiled coil bundle&quot;) is subsequently formed when the extracellular portion of gp41 collapses, and this hairpin formation promotes the fusion of virion and target cell membranes by bringing them into close proximity.  Virion and target cell membrane fusion leads to the release of HIV viral cores into the cell interior. </bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway131">
 <bp:pathwayOrder rdf:resource="#PathwayStep603" />
 <bp:pathwayOrder rdf:resource="#PathwayStep604" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction460" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction459" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence589" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Autointegration results in viral DNA circles</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">In this  pathway, the viral integration machinery uses a site within the viral DNA as an integration target.  This results in a covalent rearrangment of the viral DNA.  The resulting DNA forms are not substrates for integration. It has been suggested that the cellular BAF protein binds to viral DNA and diminishes autointegration by coating and condensing the viral DNA, thereby making it a less efficient integration target. </bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway134">
 <bp:pathwayOrder rdf:resource="#PathwayStep629" />
 <bp:pathwayOrder rdf:resource="#PathwayStep617" />
 <bp:pathwayOrder rdf:resource="#PathwayStep710" />
 <bp:pathwayOrder rdf:resource="#PathwayStep743" />
 <bp:pathwayOrder rdf:resource="#PathwayStep658" />
 <bp:pathwayOrder rdf:resource="#PathwayStep667" />
 <bp:pathwayComponent rdf:resource="#Pathway139" />
 <bp:pathwayComponent rdf:resource="#Pathway140" />
 <bp:pathwayComponent rdf:resource="#Pathway136" />
 <bp:pathwayComponent rdf:resource="#Pathway135" />
 <bp:pathwayComponent rdf:resource="#Pathway146" />
 <bp:pathwayComponent rdf:resource="#Pathway149" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence603" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SARS-CoV-1 Infection</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The SARS-CoV-1 coronavirus is the causative agent of the outbreak of severe acute respiratory syndrome in 2003 that caused 8,098 known cases of the disease and 774 deaths. The molecular events involved in viral infection and the response of the human host to it have since been studied in detail and are annotated here (de Wit et al. 2016; Marra et al. 2003). The SARS-CoV-1 viral infection pathway here uses entries listed in the UniProt &quot;Human SARS coronavirus (SARS-CoV) (Severe acute respiratory syndrome coronavirus)&quot; taxonomy.  SARS-CoV-1 infection begins with the binding of viral S (spike) protein to cell surface angiotensin converting enzyme 2 (ACE2) and endocytosis of the bound virion. Within the endocytic vesicle, host proteases mediate cleavage of S protein into S1 and S2 fragments, leading to S2-mediated fusion of the viral and host endosome membranes and release of the viral capsid into the host cell cytosol. The capsid is uncoated to free the viral genomic RNA, whose cap-dependent translation produces polyprotein pp1a and, by means of a 1-base frameshift, polyprotein pp1ab. Autoproteolytic cleavage of pp1a and pp1ab generates 15 or 16 nonstructural proteins (nsps) with various functions. Importantly, the RNA dependent RNA polymerase (RdRP) activity is encoded in nsp12. Nsp3, 4, and 6 induce rearrangement of the cellular endoplasmic reticulum membrane to form cytosolic double membrane vesicles (DMVs) where the viral replication transcription complex is assembled and anchored. With viral genomic RNA as a template, viral replicase-transcriptase synthesizes a full length negative sense antigenome, which in turn serves as a template for the synthesis of new genomic RNA. The replicase-transcriptase can also switch template during discontinuous transcription of the genome at transcription regulated sequences to produce a nested set of negative-sense subgenomic (sg) RNAs, which are used as templates for the synthesis of positive-sense sgRNAs that are translated to generate viral proteins. Finally, viral particle assembly occurs in the ER Golgi intermediate compartment (ERGIC). Viral M protein provides the scaffold for virion morphogenesis (Fung    Liu 2019; Masters 2006).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep1950">
 <bp:stepProcess rdf:resource="#Pathway386" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway133">
 <bp:pathwayOrder rdf:resource="#PathwayStep616" />
 <bp:pathwayOrder rdf:resource="#PathwayStep798" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1033" />
 <bp:pathwayComponent rdf:resource="#Pathway180" />
 <bp:pathwayComponent rdf:resource="#Pathway134" />
 <bp:pathwayComponent rdf:resource="#Pathway155" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence602" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SARS-CoV Infections</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Coronaviruses (CoVs) are large, enveloped, positive strand RNA viruses that can be classified into four genera: alpha, beta, delta, and gamma. Coronaviruses are ecologically diverse, infecting animals including camels, cattle, cats, and bats, with the greatest variety seen in bats, suggesting that bats are the reservoirs for many of these viruses. Rarely, A and B lineage beta coronaviruses of non-human origin can infect people and then spread directly between people. Four human coronaviruses (HCoVs), HCoV 229E, NL63, OC43, and HKU1, are endemic globally and account for 10% to 30% of upper respiratory tract infections in adults, typically presenting as common colds (van der Hoek 2007). However, in the 21st century, three highly pathogenic HCoVs - severe acute respiratory syndrome coronavirus (SARS-CoV-1) in 2003, Middle East Respiratory Syndrome coronavirus (MERS CoV) in 2012, and SARS-CoV-2 in 2019 - emerged from animal reservoirs to cause global epidemics with alarming morbidity and mortality (De Wit et al. 2016; Fung    Liu 2019; Marra et al. 2003; Paules et al. 2020).  During the 2003 outbreak of SARS-CoV-1, 8,098 people worldwide became sick. Of these, 774 died. In the United States, only eight people had laboratory evidence of SARS-CoV-1 infection. All of these people had traveled to other parts of the world where the disease was spreading. Community spread was not observed in the United States (De Wit et al. 2016; WHO - SARS). A second human coronavirus, MERS-CoV, first observed in 2012, has been identified in 2,494 patients with respiratory distress of whom 858 have died. Human-to-human transmission of the virus appears to be limited (De Wit et al. 2016; WHO &#8211; MERS).   In December 2019, yet another pathogenic HCoV, 2019 novel coronavirus (2019 nCoV), was recognized, initially in Wuhan, China. The World Health Organization has named the disease caused by the 2019 novel coronavirus COronaVIrus Disease 2019, or COVID-19. The disease has also been referred to as 2019 novel coronavirus or 2019 nCoV.   SARS-CoV-1 and SARS-CoV-2 viral infection pathways are annotated in this section, as are drugs that potentially modulate the infection processes. Many of the steps of SARS-CoV-1 infection have been characterized experimentally in the past 15 years (Fung    Liu 2019; Masters 2006), and this experimental work has allowed the annotation here of the infection process and interactions with host proteins in molecular detail. Less comparable data is yet available for SARS-CoV-2 infection, but the similarity in the genomes and predicted proteomes of the two viruses allows the inference of a detailed infection pathway for SARS-CoV-2 that has been manually annotated as well with experimental results published in the first half of 2020.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep1951">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1521" />
 <bp:stepProcess rdf:resource="#Catalysis454" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway136">
 <bp:pathwayOrder rdf:resource="#PathwayStep630" />
 <bp:pathwayOrder rdf:resource="#PathwayStep636" />
 <bp:pathwayComponent rdf:resource="#Pathway138" />
 <bp:pathwayComponent rdf:resource="#Pathway137" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence616" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SARS-CoV-1 Genome Replication and Transcription</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Using the genomic RNA as a template, the coronavirus replicase synthesizes full-length negative-sense antigenome, which in turn serves as a template for the synthesis of new genomic RNA (Masters 2006). The polymerase can also switch template during discontinuous transcription of the genome at specific sites called transcription-regulated sequences, thereby producing a 5&apos;-nested set of negative-sense sgRNAs, which are used as templates for the synthesis of a 3&apos;-nested set of positive-sense sgRNAs (Masters 2006). Although genome replication/transcription is mainly mediated by the viral replicase and confines in the replication-transcription complex (RTC), the involvement of various additional viral and host factors has been implicated. For instance, coronavirus N protein is known to serve as an RNA chaperone and facilitate template switching (Z&#250;&#241;iga et al. 2007, Z&#250;&#241;iga et al. 2010). Importantly, the N protein of SARS-CoV-1 and mouse hepatitis virus (MHV-JHM) is also phosphorylated by the host glycogen synthase kinase 3 (GSK3), and inhibition of GSK3 was shown to inhibit viral replication in Vero E6 cells infected with SARS-CoV-1 (Wu et al. 2009). Additionally, GSK3-mediated phosphorylation of the MHV-JHM N protein recruited an RNA-binding protein DEAD-box helicase 1 (DDX1), which facilitates template read-through, favoring the synthesis of genomic RNA and longer sgRNAs (Wu et al. 2014). Another RNA-binding protein called heterogeneous nuclear ribonucleoprotein A1 (hnRNPA1) can also bind tightly to SARS-CoV N protein and potentially regulate viral RNA synthesis (Luo et al. 2005). Host RNA-binding proteins could also bind directly to untranslated regions (UTRs) of the coronavirus genome to modulate replication/transcription, such as zinc finger CCHC-type and RNA-binding motif 1 (ZCRB1) binding to the 5-UTR of IBV (Tan et al. 2012), mitochondrial aconitase binding to the 3&apos; UTR of MHV (Nanda and Leibowitz 2001), and poly(A)-binding protein (PABP) to the poly(A) tail of bovine coronavirus (Spagnolo and Hogue 2000). For review, please refer to Snijder et al. 2016 and Fung and Liu 2019. </bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway135">
 <bp:pathwayOrder rdf:resource="#PathwayStep618" />
 <bp:pathwayOrder rdf:resource="#PathwayStep619" />
 <bp:pathwayOrder rdf:resource="#PathwayStep627" />
 <bp:pathwayOrder rdf:resource="#PathwayStep628" />
 <bp:pathwayOrder rdf:resource="#PathwayStep621" />
 <bp:pathwayOrder rdf:resource="#PathwayStep622" />
 <bp:pathwayOrder rdf:resource="#PathwayStep620" />
 <bp:pathwayOrder rdf:resource="#PathwayStep625" />
 <bp:pathwayOrder rdf:resource="#PathwayStep626" />
 <bp:pathwayOrder rdf:resource="#PathwayStep623" />
 <bp:pathwayOrder rdf:resource="#PathwayStep624" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction479" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction477" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction478" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction475" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction476" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction473" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction474" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction471" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction472" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction480" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction470" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence604" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Attachment and Entry</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Coronavirus replication is initiated by the binding of S protein to the cell surface receptor(s). The S protein is composed of two functional domains, S1 (bulb) which mediates receptor binding and S2 (stalk) which mediates membrane fusion. Specific interaction between S1 and the cognate receptor triggers a drastic conformational change in S2, leading to fusion between the virus envelope and the cellular membrane and release of the viral nucleocapsid into the host cell cytosol. Receptor binding is the major determinant of the host range and tissue tropism for a coronavirus. Some human coronaviruses (HCoVs ) have adopted cell surface enzymes as receptors, angiotensin converting enzyme 2 (ACE2) for SARS-CoV-1 and HCoV NL63. The receptor-bound S protein is activated by cleavage into S1 and S2, mediated by one of two of two host proteases, the endosomal cysteine protease cathepsin L and another trypsin like serine protease. Type II transmembrane serine proteases TMPRSS2 and TMPRSS11D have also been implicated in the activation of S protein of SARS-CoV-1. Host factors may play additional roles in viral entry (not annotated here). Valosin containing protein (VCP) contributes by a poorly understood mechanism to the release of coronavirus from early endosomes. Host factors may also restrict the attachment and entry of HCoV. Some interferon inducible transmembrane proteins (IFITMs) exhibited broad spectrum antiviral functions against various RNA viruses including SARS-CoV-1 while others may facilitate HCoV entry into host cells (Fung    Liu 2019).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway138">
 <bp:pathwayOrder rdf:resource="#PathwayStep650" />
 <bp:pathwayOrder rdf:resource="#PathwayStep640" />
 <bp:pathwayOrder rdf:resource="#PathwayStep651" />
 <bp:pathwayOrder rdf:resource="#PathwayStep638" />
 <bp:pathwayOrder rdf:resource="#PathwayStep649" />
 <bp:pathwayOrder rdf:resource="#PathwayStep639" />
 <bp:pathwayOrder rdf:resource="#PathwayStep643" />
 <bp:pathwayOrder rdf:resource="#PathwayStep654" />
 <bp:pathwayOrder rdf:resource="#PathwayStep644" />
 <bp:pathwayOrder rdf:resource="#PathwayStep655" />
 <bp:pathwayOrder rdf:resource="#PathwayStep641" />
 <bp:pathwayOrder rdf:resource="#PathwayStep652" />
 <bp:pathwayOrder rdf:resource="#PathwayStep642" />
 <bp:pathwayOrder rdf:resource="#PathwayStep653" />
 <bp:pathwayOrder rdf:resource="#PathwayStep647" />
 <bp:pathwayOrder rdf:resource="#PathwayStep637" />
 <bp:pathwayOrder rdf:resource="#PathwayStep648" />
 <bp:pathwayOrder rdf:resource="#PathwayStep645" />
 <bp:pathwayOrder rdf:resource="#PathwayStep656" />
 <bp:pathwayOrder rdf:resource="#PathwayStep646" />
 <bp:pathwayOrder rdf:resource="#PathwayStep657" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction501" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction502" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction488" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction499" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction489" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction500" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction486" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction497" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction487" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction498" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction495" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction496" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction505" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction506" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction503" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction504" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction493" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction494" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction491" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction492" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction490" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence623" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Replication of the SARS-CoV-1 genome</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The plus strand RNA genome of the human SARS coronavirus 1 (SARS-CoV-1) is replicated by the viral replication-transcription complex (RTC) composed of nonstructural proteins nsp3-nsp16, encoded by open reading frames ORF1a and ORF1b. Two RTC proteins, nsp8 and nsp12, possess 5&apos;-3&apos; RNA-dependent RNA polymerase activity. nsp12 is the main RNA polymerase, while nsp8 is thought to act as an RNA primase. nsp14 acts as a 3&apos;-5&apos; exonuclease, increasing the fidelity of the RTC. nsp14 also has the RNA capping activity and, in concert with nsp16, it caps viral plus strand and minus strand genomic and subgenomic RNAs, which confers stability to viral RNAs by enabling them to escape interferon-mediated innate immune responses of the host. nsp13 is an RNA helicase which is thought to melt secondary structures in the genomic RNA during replication and transcription. The plus strand genomic RNA is first used to synthesize the minus strand genomic RNA complement, which is subsequently used as a template for synthesis of plus strand viral RNA genomes that are packaged into mature virions. For review, please refer to Yang and Leibowitz 2015, Snijder et al. 2016, Fung and Liu 2019.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence2600">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway137">
 <bp:pathwayOrder rdf:resource="#PathwayStep632" />
 <bp:pathwayOrder rdf:resource="#PathwayStep633" />
 <bp:pathwayOrder rdf:resource="#PathwayStep631" />
 <bp:pathwayOrder rdf:resource="#PathwayStep634" />
 <bp:pathwayOrder rdf:resource="#PathwayStep635" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction484" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction485" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction482" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction483" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction481" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence617" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Transcription of SARS-CoV-1 sgRNAs</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SARS-CoV-1 encodes eight subgenomic RNAs, mRNA2 to mRNA9. mRNA1 corresponds to the genomic RNA. The 5&apos; and 3&apos; ends of subgenomic RNAs are identical, in accordance with the template switch model of coronavirus RNA transcription (Snijder et al. 2003, Thiel et al. 2003, Yount et al. 2003). Genomic positive strand RNA is first transcribed into negative sense (minus strand) subgenomic mRNAs by template switching. Negative sense mRNAs subsequently serve as templates for the synthesis of positive strand subgenomic mRNAs. As shown in murine hepatitis virus (MHV), which is closely related to SARS-CoV-1, negative-sense viral RNAs are present in much smaller amounts than positive-sense RNAs (Irigoyen et al. 2016). Of the eight subgenomic mRNAs of SARS-CoV-1, mRNA2 encodes the S protein, mRNA3 is bicistronic and encodes proteins 3a and 3b, mRNA4 encodes the E protein, mRNA5 encodes the M protein, mRNA6 encodes protein 6, and bicistronic mRNA7, mRNA8 and mRNA9 encode proteins 7a and 7b (mRNA7), 8a and 8b (mRNA8), and 9a and N (mRNA9), respectively (Snijder et al. 2003, Thiel et al. 2003, Yount et al. 2003). The template switch model of coronavirus involves discontinuous transcription of subgenomic RNA, with the leader body joining occurring during the synthesis of minus strand RNAs. Each subgenomic RNA contains a leader transcription regulatory sequence (leader TRS) that is identical to the leader of the genome, appended via polymerase &#8220;jumping&#8221; during negative strand synthesis to the body transcription regulatory sequence (body TRS), a short, AU-rich motif of about 10 nucleotides found upstream of each ORF that is destined to become 5&apos; proximal in one of the subgenomic mRNAs. The 3&apos; and 5&apos;UTRs may interact through RNA&#8211;RNA and/or RNA&#8211;protein plus protein&#8211;protein interactions to promote circularization of the coronavirus genome, placing the elongating minus strand in a favorable topology for leader-body joining. The host protein PABP was found to bind to the coronavirus 3&apos; poly(A) tail and to interact with the host protein eIF-4G, a component of the three-subunit complex that binds to mRNA cap structures, which may promote the circularization of the coronavirus genome. Two viral proteins that bind to the coronavirus 5&apos;UTR, the N protein and nsp1, may play a role in template switching. The poly(A) tail is necessary for the initiation of minus-strand RNA synthesis at the 3&apos; end of genomic RNA.  Elongation of nascent minus strand RNA continues until the first functional body TRS motif is encountered. A fixed proportion of replication-transcription complexes (RTCs) will either disregard the TRS motif and continue to elongate the nascent strand or stop synthesis of the nascent minus strand and relocate to the leader TRS, extending the minus strand by copying the 5&apos; end of the genome. The completed minus-strand RNAs then serve as templates for positive strand mRNA synthesis (reviewed by Sawicki et al. 2007, Yang and Leibowitz 2015).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence2601">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction743">
 <bp:evidence rdf:resource="#Evidence913" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Glycosylated M localizes to the Golgi membrane</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction744">
 <bp:evidence rdf:resource="#Evidence914" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Protein M localizes to the Golgi membrane</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction741">
 <bp:evidence rdf:resource="#Evidence910" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Unknown kinase phosphorylates nucleoprotein</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction742">
 <bp:evidence rdf:resource="#Evidence912" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">M protein gets N-glycosylated</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction740">
 <bp:evidence rdf:resource="#Evidence909" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">PRMT1 binds type I PRMT inhibitors</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction749">
 <bp:evidence rdf:resource="#Evidence920" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Viral Spike Binds to ACE2 on Uninfected Cell</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction747">
 <bp:evidence rdf:resource="#Evidence918" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">S1,S2 Dissociate from S1:ACE2:S2</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction748">
 <bp:evidence rdf:resource="#Evidence919" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FURIN Mediated SARS-CoV-2 Spike Protein Cleavage</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction745">
 <bp:evidence rdf:resource="#Evidence915" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">mRNA9a is translated to Nucleoprotein</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction746">
 <bp:evidence rdf:resource="#Evidence917" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">S2 Cleavage by TMPRSS2 Exposes S2&apos; Initiating Cell-Cell Fusion</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep1967">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1537" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1968">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1538" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1969">
 <bp:stepProcess rdf:resource="#Pathway387" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1963">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1533" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1964">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1534" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway141">
 <bp:pathwayOrder rdf:resource="#PathwayStep670" />
 <bp:pathwayOrder rdf:resource="#PathwayStep671" />
 <bp:pathwayOrder rdf:resource="#PathwayStep669" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction516" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction517" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction515" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence655" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Maturation of protein M</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Protein M, part of which is N-glycosylated, accumulates in the Golgi complex and recruits Spike protein to the sites of virus assembly and budding in the ERGIC (Voss et al, 2006; Voss et al, 2009).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep1965">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1535" />
 <bp:stepProcess rdf:resource="#Catalysis461" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway140">
 <bp:pathwayOrder rdf:resource="#PathwayStep704" />
 <bp:pathwayOrder rdf:resource="#PathwayStep672" />
 <bp:pathwayOrder rdf:resource="#PathwayStep673" />
 <bp:pathwayOrder rdf:resource="#PathwayStep692" />
 <bp:pathwayOrder rdf:resource="#PathwayStep682" />
 <bp:pathwayOrder rdf:resource="#PathwayStep674" />
 <bp:pathwayOrder rdf:resource="#PathwayStep702" />
 <bp:pathwayOrder rdf:resource="#PathwayStep703" />
 <bp:pathwayOrder rdf:resource="#PathwayStep668" />
 <bp:pathwayOrder rdf:resource="#PathwayStep701" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction545" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction546" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction544" />
 <bp:pathwayComponent rdf:resource="#Pathway141" />
 <bp:pathwayComponent rdf:resource="#Pathway143" />
 <bp:pathwayComponent rdf:resource="#Pathway142" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction518" />
 <bp:pathwayComponent rdf:resource="#Pathway145" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction519" />
 <bp:pathwayComponent rdf:resource="#Pathway144" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence654" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Translation of Structural Proteins</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SARS-CoV-1 mRNA is translated according to the ribosomal scanning model. Virus mRNA is capped and polyadenylated, with regions of nontranslated sequences on both the 5&apos; and 3&apos; ends. Structural proteins are encoded after the polymerase/replicase genes by mRNAs 2 (Spike protein), 3, 4 (Envelope protein), 5 (Membrane protein), and 9. mRNA 3 and 9 are bicistronic, the proteins 3a and 9a (Nucleocapsid protein) having functions in virus assembly and structure. Translation happens in the ER with the exception of 9a which is translated by cytosolic free ribosomes (Fung and Liu, 2019).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep1966">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1536" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway143">
 <bp:pathwayOrder rdf:resource="#PathwayStep690" />
 <bp:pathwayOrder rdf:resource="#PathwayStep691" />
 <bp:pathwayOrder rdf:resource="#PathwayStep683" />
 <bp:pathwayOrder rdf:resource="#PathwayStep684" />
 <bp:pathwayOrder rdf:resource="#PathwayStep687" />
 <bp:pathwayOrder rdf:resource="#PathwayStep688" />
 <bp:pathwayOrder rdf:resource="#PathwayStep685" />
 <bp:pathwayOrder rdf:resource="#PathwayStep686" />
 <bp:pathwayOrder rdf:resource="#PathwayStep689" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction534" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction535" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction532" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction533" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction530" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction531" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction529" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction527" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction528" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence669" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Maturation of nucleoprotein</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Nucleoprotein, the most abundant viral protein expressed during infection, is found in the cytosol and plasma membrane. After phosphorylation and sumoylation it trimerizes and is moved to the Golgi, the virion budding site (Li et al, 2005; Surjit et al, 2005).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway142">
 <bp:pathwayOrder rdf:resource="#PathwayStep680" />
 <bp:pathwayOrder rdf:resource="#PathwayStep681" />
 <bp:pathwayOrder rdf:resource="#PathwayStep676" />
 <bp:pathwayOrder rdf:resource="#PathwayStep677" />
 <bp:pathwayOrder rdf:resource="#PathwayStep675" />
 <bp:pathwayOrder rdf:resource="#PathwayStep678" />
 <bp:pathwayOrder rdf:resource="#PathwayStep679" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction523" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction524" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction521" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction522" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction520" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction525" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction526" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence661" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Maturation of protein 3a</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Protein 3a is associated with protein M and is found in the virion, although its function in the structure seems non-essential. 3a is O-glycosylated and forms a homotetramer with porin function (Oostra et al, 2006; Lu et al, 2006).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep1960">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1530" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway145">
 <bp:pathwayOrder rdf:resource="#PathwayStep706" />
 <bp:pathwayOrder rdf:resource="#PathwayStep707" />
 <bp:pathwayOrder rdf:resource="#PathwayStep705" />
 <bp:pathwayOrder rdf:resource="#PathwayStep708" />
 <bp:pathwayOrder rdf:resource="#PathwayStep709" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction550" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction551" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction549" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction547" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction548" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence691" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Maturation of protein E</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The envelope protein (E) gets palmitoylated and ubiquitinated after translation. It forms trimers that show porin activity but does not localize to the cell membrane (Tan et al, 2004; Liao et al, 2006; Alvarez et al, 2011).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep1961">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1531" />
 <bp:stepProcess rdf:resource="#Catalysis459" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway144">
 <bp:pathwayOrder rdf:resource="#PathwayStep694" />
 <bp:pathwayOrder rdf:resource="#PathwayStep695" />
 <bp:pathwayOrder rdf:resource="#PathwayStep693" />
 <bp:pathwayOrder rdf:resource="#PathwayStep698" />
 <bp:pathwayOrder rdf:resource="#PathwayStep699" />
 <bp:pathwayOrder rdf:resource="#PathwayStep696" />
 <bp:pathwayOrder rdf:resource="#PathwayStep697" />
 <bp:pathwayOrder rdf:resource="#PathwayStep700" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction543" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction541" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction542" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction540" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction538" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction539" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction536" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction537" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence679" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Maturation of spike protein</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Spike protein of SARS-Cov is subject to N-glycosylation and palmitoylation. The chaperone calnexin exclusively helps with protein folding. The end product is a homotrimer (Nal et al, 2005).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep1962">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1532" />
 <bp:stepProcess rdf:resource="#Catalysis460" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway147">
 <bp:pathwayOrder rdf:resource="#PathwayStep717" />
 <bp:pathwayOrder rdf:resource="#PathwayStep718" />
 <bp:pathwayOrder rdf:resource="#PathwayStep715" />
 <bp:pathwayOrder rdf:resource="#PathwayStep716" />
 <bp:pathwayOrder rdf:resource="#PathwayStep719" />
 <bp:pathwayOrder rdf:resource="#PathwayStep720" />
 <bp:pathwayOrder rdf:resource="#PathwayStep721" />
 <bp:pathwayOrder rdf:resource="#PathwayStep713" />
 <bp:pathwayOrder rdf:resource="#PathwayStep714" />
 <bp:pathwayOrder rdf:resource="#PathwayStep722" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction556" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction557" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction554" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction555" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction553" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction561" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction562" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction560" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction558" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction559" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence699" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Assembly of the SARS-CoV-1 Replication-Transcription Complex (RTC)</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">In a sequence of ten reactions, mature non-structural proteins (nsp) generated by cleavage of the SARS-CoV-1 pp1a / pp1ab polyproteins are assembled to form a replication &#8211; transcription complex (Fung    Liu 2019; Kirchdoerfer    Ward 2019).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway146">
 <bp:pathwayOrder rdf:resource="#PathwayStep726" />
 <bp:pathwayOrder rdf:resource="#PathwayStep742" />
 <bp:pathwayOrder rdf:resource="#PathwayStep741" />
 <bp:pathwayOrder rdf:resource="#PathwayStep724" />
 <bp:pathwayOrder rdf:resource="#PathwayStep725" />
 <bp:pathwayOrder rdf:resource="#PathwayStep711" />
 <bp:pathwayOrder rdf:resource="#PathwayStep712" />
 <bp:pathwayOrder rdf:resource="#PathwayStep723" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction565" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction552" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction563" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction564" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction581" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction580" />
 <bp:pathwayComponent rdf:resource="#Pathway147" />
 <bp:pathwayComponent rdf:resource="#Pathway148" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence697" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Translation of Replicase and Assembly of the Replication Transcription Complex</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">After entry and uncoating, the SARS-CoV-1 genomic RNA serves as a transcript to allow cap dependent translation of ORF1a to produce polyprotein pp1a. A slippery sequence and an RNA pseudoknot near the end of ORF1a enable 25 - 30% of the ribosomes to undergo -1 frameshifting, to continue translation of ORF1b to produce a longer polyprotein pp1ab. The autoproteolytic cleavage of pp1a and pp1ab generates 15-16 nonstructural proteins (nsps) with various functions. The RNA dependent RNA polymerase (RdRP) activity is encoded in nsp12, and papain like protease (PLPro) and main protease (Mpro) activities are encoded in nsp3 and nsp5, respectively. nsp3, 4, and 6 induce rearrangement of the cellular membrane to form double membrane vesicles (DMVs) where the coronavirus replication transcription complex (RTC) is assembled and anchored.  Programmed ribosomal frameshifting (PRF) may be regulated by viral or host factors in addition to viral RNA secondary structures. For example, PRF in the related arterivirus porcine reproductive and respiratory syndrome virus (PRRSV) is transactivated by the viral protein nsp1, which interacts with the PRF signal via a putative RNA binding motif. A host RNA-binding protein called annexin A2 (ANXA2) binds the pseudoknot structure in the IBV genome. Host factors in the early secretory pathway appear to be involved in DMV formation and RTC assembly: Golgi specific brefeldin A resistance guanine nucleotide exchange factor 1 (GBF1) and its effector ADP ribosylation factor 1 (ARF1) are both required for normal DMV formation and efficient RNA replication of mouse hepatitis virus (MHV), a prototypic betacoronavirus that infects mice (Fung    Liu 2019).  </bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway149">
 <bp:pathwayOrder rdf:resource="#PathwayStep790" />
 <bp:pathwayOrder rdf:resource="#PathwayStep792" />
 <bp:pathwayOrder rdf:resource="#PathwayStep753" />
 <bp:pathwayOrder rdf:resource="#PathwayStep754" />
 <bp:pathwayOrder rdf:resource="#PathwayStep752" />
 <bp:pathwayOrder rdf:resource="#PathwayStep758" />
 <bp:pathwayOrder rdf:resource="#PathwayStep744" />
 <bp:pathwayOrder rdf:resource="#PathwayStep789" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction589" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction623" />
 <bp:pathwayComponent rdf:resource="#Pathway150" />
 <bp:pathwayComponent rdf:resource="#Pathway152" />
 <bp:pathwayComponent rdf:resource="#Pathway151" />
 <bp:pathwayComponent rdf:resource="#Pathway154" />
 <bp:pathwayComponent rdf:resource="#Pathway153" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction590" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence730" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SARS-CoV-1-host interactions</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Coronaviruses are a group of enveloped viruses with single&#8209;stranded, positive&#8209;sense RNA genomes. Each of the steps of viral replication - attachment and entry, translation of viral replicase, genome transcription and replication, translation of structural proteins, and virion assembly and release - involves host factors. These interactions can cause alterations in cellular structure and physiology, and activate host stress responses, autophagy, cell death, and processes of innate immunity (Fung TS    Liu DX 2019). This Reactome module describes molecular mechanisms by which severe acute respiratory syndrome coronavirus type 1 (SARS-CoV-1) modulates host cell death pathways, innate immune responses, translation, intracellular signaling and regulatory pathways, and PDZ-mediated cell-cell junctions.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway148">
 <bp:pathwayOrder rdf:resource="#PathwayStep728" />
 <bp:pathwayOrder rdf:resource="#PathwayStep739" />
 <bp:pathwayOrder rdf:resource="#PathwayStep729" />
 <bp:pathwayOrder rdf:resource="#PathwayStep737" />
 <bp:pathwayOrder rdf:resource="#PathwayStep727" />
 <bp:pathwayOrder rdf:resource="#PathwayStep738" />
 <bp:pathwayOrder rdf:resource="#PathwayStep731" />
 <bp:pathwayOrder rdf:resource="#PathwayStep732" />
 <bp:pathwayOrder rdf:resource="#PathwayStep740" />
 <bp:pathwayOrder rdf:resource="#PathwayStep730" />
 <bp:pathwayOrder rdf:resource="#PathwayStep735" />
 <bp:pathwayOrder rdf:resource="#PathwayStep736" />
 <bp:pathwayOrder rdf:resource="#PathwayStep733" />
 <bp:pathwayOrder rdf:resource="#PathwayStep734" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction567" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction578" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction568" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction579" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction576" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction566" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction577" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction574" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction575" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction572" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction573" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction569" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction570" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction571" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence713" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Maturation of replicase proteins</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Production of polyprotein fragments (so called replicase proteins) involves the repeated autocleavage of the polyprotein, liberating the two endopeptidases that finally cleave all fragments efficiently. Only nsp3 and nsp4 are post-translationally modified, they are glycosylated (Muramatsu et al, 2015; Harcourt et al, 2004; Oostra et al, 2007)</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway118">
 <bp:pathwayOrder rdf:resource="#PathwayStep544" />
 <bp:pathwayOrder rdf:resource="#PathwayStep543" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction413" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction412" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence529" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Formation of HIV elongation complex in the absence of HIV Tat</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">During the formation of the HIV elongation complex in the absence of HIV Tat, eongation factors are recruited to form the  HIV-1 elongation complex (Hill and Sundquist 2013) and P-TEFb complex hyperphosphorylates RNA Pol II CTD (Hermann and Rice, 2005, Zhou et al., 2000).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction776">
 <bp:evidence rdf:resource="#Evidence952" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SARS-CoV-2 N binds IKBKB</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence2613">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway117">
 <bp:pathwayOrder rdf:resource="#PathwayStep539" />
 <bp:pathwayOrder rdf:resource="#PathwayStep540" />
 <bp:pathwayOrder rdf:resource="#PathwayStep541" />
 <bp:pathwayOrder rdf:resource="#PathwayStep537" />
 <bp:pathwayOrder rdf:resource="#PathwayStep538" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction411" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction410" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction408" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction409" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction407" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence523" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Formation of the HIV-1 Early Elongation Complex</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">This HIV-1 event was inferred from the corresponding human RNA Poll II transcription event. The details relevant to HIV-1 are described below.  Formation of the early elongation complex involves hypophosphorylation of RNA Pol II CTD by FCP1P protein, association of the DSIF complex with RNA Pol II, and formation of DSIF:NELF:HIV-1 early elongation complex as described below (Mandal et al 2002; Kim et al 2003; Yamaguchi et al 2002).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction777">
 <bp:evidence rdf:resource="#Evidence953" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SARS-CoV-2 9b binds IKBKG</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence2614">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction774">
 <bp:evidence rdf:resource="#Evidence949" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SARS-CoV-2 nsp8 binds to 7SL RNA</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence2615">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway119">
 <bp:pathwayOrder rdf:resource="#PathwayStep554" />
 <bp:pathwayOrder rdf:resource="#PathwayStep546" />
 <bp:pathwayOrder rdf:resource="#PathwayStep547" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction414" />
 <bp:pathwayComponent rdf:resource="#Pathway120" />
 <bp:pathwayComponent rdf:resource="#Pathway122" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence532" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Assembly Of The HIV Virion</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Virion assembly packages all the components required for infectivity. These steps include two copies of the positive sense genomic viral RNA, cellular tRNALys, the viral envelope (Env) protein, the Gag polyprotein, and the three viral enzymes: protease (PR), reverse transcriptase (RT), and integrase (IN). The viral enzymes are packaged as domains within the Gag-Pro-Pol polyprotein.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction775">
 <bp:evidence rdf:resource="#Evidence951" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SARS-CoV-2 8 binds IL17RA</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence2616">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction772">
 <bp:evidence rdf:resource="#Evidence947" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">snRNP complex assembly</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence2617">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction773">
 <bp:evidence rdf:resource="#Evidence948" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SARS-CoV-2 nsp16 binds to U1 snRNA</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence2618">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction770">
 <bp:evidence rdf:resource="#Evidence945" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SARS-CoV-2 nsp1 binds to 40S ribosomal complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence2619">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction771">
 <bp:evidence rdf:resource="#Evidence946" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SARS-CoV-2 nsp16 binds to U2 snRNA</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep1927">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1503" />
 <bp:stepProcess rdf:resource="#Catalysis445" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1928">
 <bp:stepProcess rdf:resource="#Pathway381" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction778">
 <bp:evidence rdf:resource="#Evidence954" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SARS-CoV-2 6 binds KPNA2</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep1929">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1504" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction779">
 <bp:evidence rdf:resource="#Evidence955" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MAVS:TOMM70 recruits HSP90:TBK1:IRF3</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep1934">
 <bp:stepProcess rdf:resource="#Catalysis448" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1509" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1935">
 <bp:stepProcess rdf:resource="#Pathway382" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1936">
 <bp:stepProcess rdf:resource="#Pathway383" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1937">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1510" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1930">
 <bp:stepProcess rdf:resource="#Catalysis446" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1505" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1931">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1506" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1932">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1507" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1933">
 <bp:stepProcess rdf:resource="#Catalysis447" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1508" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway110">
 <bp:pathwayOrder rdf:resource="#PathwayStep508" />
 <bp:pathwayOrder rdf:resource="#PathwayStep509" />
 <bp:pathwayOrder rdf:resource="#PathwayStep506" />
 <bp:pathwayOrder rdf:resource="#PathwayStep507" />
 <bp:pathwayOrder rdf:resource="#PathwayStep511" />
 <bp:pathwayOrder rdf:resource="#PathwayStep512" />
 <bp:pathwayOrder rdf:resource="#PathwayStep510" />
 <bp:pathwayOrder rdf:resource="#PathwayStep513" />
 <bp:pathwayOrder rdf:resource="#PathwayStep514" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction389" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction387" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction388" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction385" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction386" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction384" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction392" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction390" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction391" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence493" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">RNA Polymerase II HIV Promoter Escape</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">RNA Polymerase II promoter escape occurs after the first phosphodiester bond has been created.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway112">
 <bp:pathwayOrder rdf:resource="#PathwayStep520" />
 <bp:pathwayOrder rdf:resource="#PathwayStep521" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction396" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction397" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence507" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Pausing and recovery of Tat-mediated HIV elongation</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">After Pol II pauses by back tracking 2 -4 nuleotides on the HIV-1 template, elongation of the  HIV-1 transcript resumes.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway111">
 <bp:pathwayOrder rdf:resource="#PathwayStep517" />
 <bp:pathwayOrder rdf:resource="#PathwayStep518" />
 <bp:pathwayOrder rdf:resource="#PathwayStep516" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction394" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction395" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction393" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence503" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">HIV elongation arrest and recovery</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">RNA Pol II arrest is believed to be a result of irreversible backsliding of the enzyme by ~7-14 nucleotides. TFIIS reactivates arrested RNA Pol II by promoting the  excision of nascent transcript ~7-14 nucleotides upstream of the 3&apos; end. </bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway114">
 <bp:pathwayOrder rdf:resource="#PathwayStep526" />
 <bp:pathwayOrder rdf:resource="#PathwayStep527" />
 <bp:pathwayOrder rdf:resource="#PathwayStep524" />
 <bp:pathwayOrder rdf:resource="#PathwayStep525" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction400" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction398" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction399" />
 <bp:pathwayComponent rdf:resource="#Pathway115" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence511" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Tat-mediated elongation of the HIV-1 transcript</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The Tat protein is a viral transactivator protein that regulates HIV-1 gene expression by controlling RNA Pol II-mediated elongation (reviewed in Karn  1999; Taube et al. 1999; Liou et al. 2004; Barboric and Peterlin 2005).  Tat appears to be required in order to overcome the arrest of RNA Pol II by the negative transcriptional elongation factors DSIF and NELF (Wada et al. 1998; Yamaguchi et al. 1999; Yamaguchi et al 2002; Fujinaga et al. 2004). While Pol II can associate with the proviral LTR and initiate transcription in the absence of Tat, these polymerase complexes are non-processive and dissociate from the template prematurely producing very short transcripts (Kao et al. 1987). Tat associates with the RNA element, TAR, which forms a stem loop structure in the leader RNA sequence (Dingwall et al. 1989). Tat also associates with the cellular kinase complex P-TEFb(Cyclin T1:Cdk9) and recruits it to the TAR stem loop structure (Herrmann, 1995) (Wei et al. 1998). This association between Tat, TAR and  P-TEFb(Cyclin T1:Cdk9) is believed to bring the catalytic subunit of this kinase complex (Cdk9) in close proximity to Pol II where it hyperphosphorylates the CTD of RNA Pol II (Zhou et al. 2000). The RD subunits of NELF and the SPT5 subunit of DSIF, which associate through RD with the bottom stem of TAR, are also phosphorylated by P-TEFb(Cyclin T1:Cdk9)  (Yamaguchi et al. 2002; Fujinaga et al. 2004; Ivanov et al. 2000). Phosphorylation of RD results in its dissociation from TAR. Thus, Tat appears to facilitate transcriptional elongation of the HIV-1 transcript by hyperphosphorylating the RNA Poll II CTD and by removing the negative transcription elongation factors from TAR.  In addition, there is evidence that the association of Tat with P-TEFb(Cyclin T1:Cdk9) alters the substrate specificity of P-TEFb enhancing phosphorylation of ser5 residues in the CTD of RNA Pol II (Zhou  et al. 2000).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence2620">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway113">
 <bp:pathwayOrder rdf:resource="#PathwayStep533" />
 <bp:pathwayOrder rdf:resource="#PathwayStep523" />
 <bp:pathwayOrder rdf:resource="#PathwayStep536" />
 <bp:pathwayComponent rdf:resource="#Pathway117" />
 <bp:pathwayComponent rdf:resource="#Pathway114" />
 <bp:pathwayComponent rdf:resource="#Pathway116" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence510" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">HIV Transcription Elongation</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">In the absence of the HIV-1 protein Tat, transcription of the proviral DNA is inefficient and results in the production of truncated transcripts (Kao et al., 1987). While initiation of transcription from the HIV-1 LTR and formation of the early elongation complex occurs normally, transcription elongation is incomplete with non-processive polymerases disengaging from the proviral DNA template prematurely (reviewed in Karn 1999). The mechanism of Tat-mediated elongation is described below.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence2621">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway116">
 <bp:pathwayOrder rdf:resource="#PathwayStep534" />
 <bp:pathwayOrder rdf:resource="#PathwayStep535" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction406" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction405" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence520" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Abortive elongation of HIV-1 transcript in the absence of Tat</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">This event was inferred from the corresponding Reactome human Poll II transcription elongation event. The details specific to HIV-1 transcription elongation are described below. In the absence of  the HIV-1 Tat protein, the RNA Pol II complexes associated with the HIV-1 template are non-processive. RNA Pol II is arrested after promoter clearance by the negative transcriptional elongation factors DSIF and NELF as occurs during early elongation of endogenous templates (Wada et al, 1998; Yamaguchi et al. 1999). This arrest cannot be overcome by P-TEFb mediated phosphorylation in the absence of Tat however, and elongation aborts resulting in the accumulation of short transcripts (Kao et al., 1987).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence2622">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway115">
 <bp:pathwayOrder rdf:resource="#PathwayStep528" />
 <bp:pathwayOrder rdf:resource="#PathwayStep529" />
 <bp:pathwayOrder rdf:resource="#PathwayStep530" />
 <bp:pathwayOrder rdf:resource="#PathwayStep531" />
 <bp:pathwayOrder rdf:resource="#PathwayStep532" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction402" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction403" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction401" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction363" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction404" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence515" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Formation of HIV-1 elongation complex containing HIV-1 Tat</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">This HIV-1 event was inferred from the corresponding human RNA Poll II transcription event in Reactome. The details relevant to HIV-1 are described below. For a more detailed description of the general mechanism, see the link to the corresponding RNA Pol II transcription event below.  The formation of the HIV-1 elongation complex involves Tat mediated recruitment of P-TEFb(Cyclin T1:Cdk9)  to the TAR sequence (Wei et al, 1998) and P-TEFb(Cyclin T1:Cdk9) mediated phosphorylation of the RNA Pol II CTD as well as the negative transcriptional elongation factors DSIF and NELF (Herrmann, 1995;  Ivanov et al. 2000; Fujinaga et al. 2004; Zhou et al., 2004).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence2623">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway129">
 <bp:pathwayOrder rdf:resource="#PathwayStep591" />
 <bp:pathwayOrder rdf:resource="#PathwayStep592" />
 <bp:pathwayOrder rdf:resource="#PathwayStep593" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction451" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction450" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction449" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence577" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Integration of viral DNA into host genomic DNA</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Following nuclear entry, the viral preintegration complex (PIC) must select a site for integration in a host cell chromosome, and then carry out the chemical steps of the reaction.  At the chromosomal level, HIV has been found to favor active transcription units for integration. Subsequent studies established that the cellular PSIP1/LEDGF/p75 protein is important in this reaction. PSIP1/LEDGF/p75 binds tightly to HIV integrase, and also to chromatin. Knocking down PSIP1/LEDGF/p75 in cells resulted in several perturbations of integration targeting in vivo, including reduced integration in transcription units. Thus PSIP1/LEDGF/p75 has been hypothesized to act as a tethering factor that dictates at least in part the placement of HIV integration sites.  The integration target DNA is also expected to be coated with nucleosomes. Tests of integration into mononucleosomes in vitro have shown that wrapping integration target DNA actually boosts integration activity. Kinked positions on the DNA gyre are particularly favored for integration.  Integration does not take place at a unique sequence in the integration target DNA (i.e. it is not like a restriction enzyme). However, favored and disfavored primary sequences can be detected when many integration sites are aligned. Synthesis and testing of favored HIV integration sites showed that they were favored for integration by PICs in vitro.  After a target DNA is bound, the integration reactions take place via a single-step transesterification. Integration of both ends of the viral DNA, followed by melting of the target DNA segments between the points of joining, yields single stranded gaps at each host-virus DNA junction, and a two base overhang derived from the viral DNA. The manner by which this intermediate is subsequently repaired to yield the fully integrated provirus is unclear. For many parasitic DNA replication reactions, the parasite carries out reaction steps only up to a point that the host cannot easily reverse, forcing the host to complete the job (Bushman 2001; Craig et al. 2002). For retroviral integration, it is reasonable to infer that host DNA repair enzymes complete provirus formation. DNA gap repair enzymes are known to be involved in a variety of DNA repair pathways, so their recruitment to gaps at host-virus DNA junctions is readily envisioned. Consistent with this, known gap repair enzymes have been shown to act on model host-virus DNA junctions in vitro (Yoder and Bushman, 2000).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction765">
 <bp:evidence rdf:resource="#Evidence938" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">M protein oligomerization</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence2602">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway128">
 <bp:pathwayOrder rdf:resource="#PathwayStep605" />
 <bp:pathwayOrder rdf:resource="#PathwayStep590" />
 <bp:pathwayOrder rdf:resource="#PathwayStep595" />
 <bp:pathwayOrder rdf:resource="#PathwayStep594" />
 <bp:pathwayOrder rdf:resource="#PathwayStep599" />
 <bp:pathwayOrder rdf:resource="#PathwayStep589" />
 <bp:pathwayOrder rdf:resource="#PathwayStep600" />
 <bp:pathwayOrder rdf:resource="#PathwayStep601" />
 <bp:pathwayOrder rdf:resource="#PathwayStep602" />
 <bp:pathwayComponent rdf:resource="#Pathway129" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction457" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction458" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction456" />
 <bp:pathwayComponent rdf:resource="#Pathway130" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction452" />
 <bp:pathwayComponent rdf:resource="#Pathway131" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction461" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction448" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence575" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Integration of provirus</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">For retroviral DNA to direct production of progeny virions it must become covalently integrated into the host cell chromosome (reviewed in Coffin et al. 1997; Hansen et al. 1998). Analyses of mutants have identified the viral integrase coding region (part of the retroviral pol gene) as essential for the integration process (Donehower 1988; Donehower and Varmus 1984; Panganiban and Temin 1984; Quinn and Grandgenett 1988; Schwartzberg et al. 1984). Also essential are regions at the ends of the viral long terminal repeats (LTRs) that serve as recognition sites for integrase protein (Colicelli and Goff 1985, 1988; Panganiban and Temin 1983). The viral genomic RNA is reverse transcribed to form a linear double-stranded DNA molecule, the precursor to the integrated provirus (Brown et al. 1987, 1989; Fujiwara and Mizuuchi 1988). The provirus is colinear with unintegrated linear viral DNA (Dhar et al. 1980; Hughes et al. 1978) but differs from the reverse transcription product in that it is missing two bases from each end (Hughes et al. 1981). Flanking the integrated HIV provirus are direct repeats of the cellular DNA that are 5 base pairs in length (Vincent et al. 1990). This duplication of cellular sequences flanking the viral DNA is generated as a consequence of the integration mechanism (Coffin et al., 1997).  Linear viral DNA is found in a complex with proteins in the cytoplasm of infected cells. These complexes (termed &quot;preintegration complexes&quot;, PICs) can be isolated and have been shown to mediate integration of viral DNA into target DNA in vitro (Bowerman et al. 1989; Brown et al. 1987; Ellison et al. 1990; Farnet and Haseltine 1990, 1991).  The development of in vitro assays with purified integrase has allowed its enzymatic functions to be elucidated. The provirus is formed by two reactions catalyzed by the viral integrase: terminal cleavage and strand transfer. Studies with purified integrase have shown that it is sufficient for both 3&apos; end cleavage (Bushman and Craigie 1991; Craigie et al. 1990; Katzman et al. 1989; Sherman and Fyfe 1990) and joining of the viral DNA to the cellular chromosome or naked target DNA (Bushman et al. 1990; Craigie et al. 1990; Katz et al. 1990). HIV integrase catalyze the removal of two bases from the 3&apos; end of each viral DNA strand, leaving recessed 3&apos; hydroxyl groups (Brown et al. 1989; Fujiwara and Mizuuchi 1988; Roth et al. 1989; Sherman and Fyfe 1990). This terminal cleavage reaction is required for proper integration. It may allow the virus to create a standard end from viral DNA termini that can be heterogeneous due to the terminal transferase activity of reverse transcriptase (Miller et al. 1997; Patel and Preston 1994). In addition, the terminal cleavage step is coupled to the formation of a stable integrase-DNA complex (Ellison and Brown 1994; Vink et al. 1994). Following terminal cleavage, a recessed hydroxyl is exposed that immediately follows a CA dinucleotide. More internal LTR sites are also important for integration (Balakrishnan and Jonsson 1997; Bushman and Craigie 1990; Leavitt et al. 1992). After end processing, integrase catalyzes the covalent attachment of hydroxyl groups at the viral DNA termini to protruding 5&apos; phosphoryl ends of the host cell DNA (Brown et al. 1987; Brown et al. 1989; Fujiwara and Mizuuchi 1988). The DNA cleavage and joining reactions involved in integration are shown in the figure below. Both the viral DNA 3&apos; end cleavage and strand transfer reactions are mediated by single-step transesterification chemistry as shown by stereochemical analysis of reaction products (Engelman et al. 1991). Biochemical analysis of purified integrase revealed that it requires a divalent metal - either Mg2+ or Mn2+ - to carry out reactions with model substrates, that probably mediate the reaction chemistry (Bushman and Craigie 1991; Craigie et al. 1990; Katzman et al. 1989; Sherman and Fyfe 1990; Gao et al. 2004).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction766">
 <bp:evidence rdf:resource="#Evidence939" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SUMO-p-N protein dimer binds genomic RNA</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence2603">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction763">
 <bp:evidence rdf:resource="#Evidence936" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Recruitment of Spike trimer to assembling virion</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence2604">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction764">
 <bp:evidence rdf:resource="#Evidence937" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Encapsidation of SARS coronavirus genomic RNA</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence2605">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction761">
 <bp:evidence rdf:resource="#Evidence934" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">E and N are recruited to the M lattice</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence2606">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction762">
 <bp:evidence rdf:resource="#Evidence935" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SARS virus buds into ERGIC lumen</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence2607">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2608">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction760">
 <bp:evidence rdf:resource="#Evidence932" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">9b forms a homodimer</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence2609">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction769">
 <bp:evidence rdf:resource="#Evidence944" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SARS-CoV-2 nsp9 binds to 7SL RNA</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep1938">
 <bp:stepProcess rdf:resource="#Catalysis449" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1511" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1939">
 <bp:stepProcess rdf:resource="#Pathway384" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction767">
 <bp:evidence rdf:resource="#Evidence940" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Accessory proteins are recruited to the maturing virion</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction768">
 <bp:evidence rdf:resource="#Evidence941" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Viral release</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep1945">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1516" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1946">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1517" />
 <bp:stepProcess rdf:resource="#Catalysis452" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1947">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1518" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1948">
 <bp:stepProcess rdf:resource="#Catalysis453" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1519" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1941">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1513" />
 <bp:stepProcess rdf:resource="#Catalysis450" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1942">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1514" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1943">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1515" />
 <bp:stepProcess rdf:resource="#Catalysis451" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1944">
 <bp:stepProcess rdf:resource="#Pathway385" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway121">
 <bp:pathwayOrder rdf:resource="#PathwayStep551" />
 <bp:pathwayOrder rdf:resource="#PathwayStep552" />
 <bp:pathwayOrder rdf:resource="#PathwayStep550" />
 <bp:pathwayOrder rdf:resource="#PathwayStep553" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction419" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction417" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction418" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction416" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence536" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Membrane binding and targetting of GAG proteins</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">One of the mysteries of Gag protein involvement in HIV virion assembly is how the proteins are targeted to the proper membrane for budding. Infectious retroviruses do not bud from all of the available membrane surfaces within an infected cell, but primarily from the plasma membrane, which constitutes a small proportion of the total membrane surface in most cells. In polarized cells, the sites of budding are further restricted to the basolateral membrane.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway120">
 <bp:pathwayOrder rdf:resource="#PathwayStep548" />
 <bp:pathwayOrder rdf:resource="#PathwayStep549" />
 <bp:pathwayComponent rdf:resource="#Pathway121" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction415" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence534" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Synthesis And Processing Of GAG, GAGPOL Polyproteins</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Evidence suggests that the RNA molecules used for the synthesis of Gag and Gag-Pro-Pol are not the same molecules that are packaged into virions. Gag proteins do not appear to aggregate around and capture the RNA contained in the polyribosome from which they emerged, but rather bind to and ultimately encapsidate free transcripts elsewhere. During the replication of retroviruses, large numbers of Gag molecules must be generated to serve as precursors to the structural proteins of the virions. Retroviruses have developed a mechanism that permits expression of the Gag protein at high levels relative to the protein sequences encoded in the pro and pol genes, while retaining coregulated expression. This linkage results from the use of the same initiation codon in the same mRNA to express the gag, pro, and pol genes. Translation of this RNA leads occasionally to synthesis of a fusion protein that is usually called the Gag-Pol precursor but is now more appropriately called the Gag-Pro-Pol precursor</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway123">
 <bp:pathwayOrder rdf:resource="#PathwayStep606" />
 <bp:pathwayOrder rdf:resource="#PathwayStep584" />
 <bp:pathwayOrder rdf:resource="#PathwayStep582" />
 <bp:pathwayOrder rdf:resource="#PathwayStep583" />
 <bp:pathwayOrder rdf:resource="#PathwayStep588" />
 <bp:pathwayOrder rdf:resource="#PathwayStep567" />
 <bp:pathwayOrder rdf:resource="#PathwayStep587" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction447" />
 <bp:pathwayComponent rdf:resource="#Pathway128" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction444" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction443" />
 <bp:pathwayComponent rdf:resource="#Pathway132" />
 <bp:pathwayComponent rdf:resource="#Pathway124" />
 <bp:pathwayComponent rdf:resource="#Pathway127" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence553" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Early Phase of HIV Life Cycle</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">In the  early phase   of HIV lifecycle, an active virion binds and enters a target cell mainly by specific interactions of the viral envelope proteins with host cell surface receptors.  The virion core is uncoated to expose a viral nucleoprotein complex containing RNA and viral proteins.  HIV RNA genome is reverse transcribed by the viral Reverse Transcriptase to form a cDNA copy, that gets inserted into host cell DNA.  The viral Integrase enzyme is vital to carry out the integration of the viral cDNA into the host genome.  The host DNA repair enzymes probably repair the breaks in DNA at the sites of integration.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway122">
 <bp:pathwayOrder rdf:resource="#PathwayStep562" />
 <bp:pathwayOrder rdf:resource="#PathwayStep563" />
 <bp:pathwayOrder rdf:resource="#PathwayStep560" />
 <bp:pathwayOrder rdf:resource="#PathwayStep561" />
 <bp:pathwayOrder rdf:resource="#PathwayStep555" />
 <bp:pathwayOrder rdf:resource="#PathwayStep556" />
 <bp:pathwayOrder rdf:resource="#PathwayStep564" />
 <bp:pathwayOrder rdf:resource="#PathwayStep559" />
 <bp:pathwayOrder rdf:resource="#PathwayStep557" />
 <bp:pathwayOrder rdf:resource="#PathwayStep558" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction424" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction425" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction422" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction423" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction420" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction421" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction428" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction429" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction426" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction427" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence541" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Synthesis and processing of ENV and VPU</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The two viral membrane proteins, Env and the accessory protein Vpu, which are encoded by the same mRNA, are translated on the rough ER. All virion components need to traffic from their point of synthesis to sites of assembly on the plasma membrane. Env is an integral membrane protein. It is inserted cotranslationally into ER membranes and then travels through the cellular secretory pathway where it is glycosylated, assembled into trimeric complexes, processed into the gp41 and gp120 subunits by the cellular protease furin.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep1940">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1512" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway125">
 <bp:pathwayOrder rdf:resource="#PathwayStep570" />
 <bp:pathwayOrder rdf:resource="#PathwayStep571" />
 <bp:pathwayOrder rdf:resource="#PathwayStep572" />
 <bp:pathwayOrder rdf:resource="#PathwayStep569" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction433" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction434" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction431" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction432" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence555" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Plus-strand DNA synthesis</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Two specific polypurine tracts (PPT sequences) in the viral RNA, one within the pol gene (central or cPPT) and one immediately preceding the U3 sequence (3&apos; PPT), are spared from degradation during minus strand DNA synthesis and prime plus-strand synthesis. At least two discrete steps of DNA replication, removal of the PPT RNAs and the tRNA primer that initiated minus-strand synthesis, and a strand transfer lead to the synthesis of a linear duplex DNA corresponding to the full length of the HIV genomic RNA with long terminal repeat (LTR) sequences at both ends. Both DNA synthesis and RNA degradation are catalyzed by domains of the HIV-1 reverse transcriptase (RT) heterodimer. During plus-strand synthesis, Preston and colleagues observed  secondary sites of plus-strand initiation at low frequency both in the cell-free system and in cultured virus-infected cells (Klarman et al., 1997).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway124">
 <bp:pathwayOrder rdf:resource="#PathwayStep573" />
 <bp:pathwayOrder rdf:resource="#PathwayStep568" />
 <bp:pathwayComponent rdf:resource="#Pathway125" />
 <bp:pathwayComponent rdf:resource="#Pathway126" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence554" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Reverse Transcription of HIV RNA</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The RNA genome of HIV-1, like that of other retroviruses, is reverse-transcribed (Baltimore 1970; Temin and Mizutani 1970) into double-stranded DNA, which is then integrated into a host cell chromosome and transcribed to yield both viral mRNAs and viral genomic RNAs. HIV-1 reverse transcription takes place in the cytosol of a newly infected host cell and involves multiple steps of RNA synthesis and degradation of the RNA strand of RNA:DNA duplexes mediated by the HIV-1 RT protein, as well as two template switches, to yield a DNA duplex colinear with the viral genomic RNA but with additional Long Terminal Repeat (LTR) sequence motifs at both ends (Telesnitsky and Goff 1997; Jonckheere et al. 2000). HIV-1 RT has two catalytic activities essential for transcription of a DNA duplex copy of the viral genomic RNA: a reverse transcriptase activity and an RNase H activity. The reverse transcriptase is primer dependent and can transcribe both RNA and DNA templates in a 5&apos;-3&apos; direction. The RNaseH acts on the RNA strand of RNA:DNA duplexes and can catalyze both endo- and exonucleolytic cleavage of such an RNA strand. RT is a heterodimer of 66 and 51 kD polypeptides, both generated by cleavage of the HIV-1 Pol gene product: p66 contains Pol amino acid residues 599-1158; p51 contains residues 599-1038. Both active sites of the HIV-1 RT enzyme are contained in the p66 polypeptide, the polymerase activity in its aminoterminal region, and the RNase in its carboxyterminus. The p51 subunit lacks an RNaseH domain, and while its polymerase domain is intact, its conformation in the p66:p51 heterodimer occludes the active site (Hughes et al. 1996; Jacobo-Molina et al. 1993; Kohlstaedt et al. 1992; Wang et al. 1994). The process of reverse transcription is outlined in the figure below: viral genomic RNA and primer tRNA are shown in black, &quot;minus&quot; strand DNA is shown in red, and &quot;plus&quot; strand DNA is shown in blue.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence2610">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway127">
 <bp:pathwayOrder rdf:resource="#PathwayStep585" />
 <bp:pathwayOrder rdf:resource="#PathwayStep586" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction446" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction445" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence571" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Uncoating of the HIV Virion</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">HIV-1 uncoating is a poorly understood process. It likely involves a progressive and partial dissembly of matrix and capsid layers.  While viral proteins like MA and Nef are thought to be involved, the primary cause seems to be the cytosolic pH and a simple dilution effect. Successful uncoating generates the viral reverse transcription complex, which comprises the diploid viral RNA genome, tRNALys primer, RT, IN, MA, nucleocapsid (NC), viral protein R (Vpr) and various host proteins; the reverse-transcription complex is thus liberated from the plasma membrane. It is believed that the transiting viral nucleoprotein complex associates with the elements of cytoskeleton like actin microfilaments.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence2611">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway126">
 <bp:pathwayOrder rdf:resource="#PathwayStep580" />
 <bp:pathwayOrder rdf:resource="#PathwayStep581" />
 <bp:pathwayOrder rdf:resource="#PathwayStep574" />
 <bp:pathwayOrder rdf:resource="#PathwayStep577" />
 <bp:pathwayOrder rdf:resource="#PathwayStep578" />
 <bp:pathwayOrder rdf:resource="#PathwayStep575" />
 <bp:pathwayOrder rdf:resource="#PathwayStep576" />
 <bp:pathwayOrder rdf:resource="#PathwayStep579" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction435" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction436" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction442" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction440" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction441" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction439" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction437" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction438" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence560" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Minus-strand DNA synthesis</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">In the first part of reverse transcription, minus-strand synthesis, a DNA strand complementary to the HIV genomic RNA is synthesized, using the viral RNA as a template and a host cell lysine tRNA molecule as primer. The synthesis proceeds in two discrete steps, separated by a strand transfer event. As minus strand DNA is synthesized, the viral genomic RNA is degraded, also in several discrete steps. Two specific polypurine tracts (PPT sequences) in the viral RNA, one within the pol gene (central or cPPT) and one immediately preceding the U3 sequence (3&apos; PPT) are spared from degradation and serve to prime synthesis of DNA complementary to the minus strand (plus-strand synthesis). During plus-strand synthesis, Preston and colleagues observed secondary sites of plus-strand initiation at low frequency both in the cell-free system and in cultured virus (Klarman et al., 1997). Both DNA synthesis and RNA degradation activities are catalyzed by the HIV-1 reverse transcriptase (RT) heterodimer. </bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence2612">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway107">
 <bp:pathwayOrder rdf:resource="#PathwayStep493" />
 <bp:pathwayOrder rdf:resource="#PathwayStep496" />
 <bp:pathwayOrder rdf:resource="#PathwayStep497" />
 <bp:pathwayOrder rdf:resource="#PathwayStep494" />
 <bp:pathwayOrder rdf:resource="#PathwayStep495" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction378" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction376" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction377" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction374" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction375" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence480" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">RNA Pol II CTD phosphorylation and interaction with CE during HIV infection</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">To facilitate co-transcriptional capping, and thereby restrict the cap structure to RNAs made by RNA polymerase II, the capping enzymes bind directly to the RNA polymerase II.  The C-terminal domain of the largest Pol II subunit contains several phosphorylation sites on its heptapeptide repeats.  The capping enzyme guanylyltransferase and the methyltransferase bind  specifically to CTD phosphorylated at Serine 5 within the CTD.  Kinase subunit of TFIIH, Cdk7, catalyzes this phosphorylation event that occurs near the promoter.  In addition, it has been shown that binding of capping enzyme to the Serine-5 phosphorylated CTD stimulates guanylyltransferase activity in vitro.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway106">
 <bp:pathwayOrder rdf:resource="#PathwayStep490" />
 <bp:pathwayOrder rdf:resource="#PathwayStep489" />
 <bp:pathwayOrder rdf:resource="#PathwayStep487" />
 <bp:pathwayOrder rdf:resource="#PathwayStep488" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction369" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction372" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction370" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction371" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence474" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">HIV Transcription Initiation</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Formation of the open  complex exposes the template strand to the catalytic center of the RNA polymerase II enzyme. This facilitates formation of the first phosphodiester bond, which marks transcription initiation. As a result of this, the TFIIB basal transcription factor dissociates from the initiation complex. The open transcription initiation complex is unstable and can revert to the closed state. Initiation at this stage requires continued (d)ATP-hydrolysis by TFIIH. Dinucleotide transcripts are not stably associated with the transcription complex. Upon dissociation they form abortive products. The transcription complex is also sensitive to inhibition by small oligo-nucleotides.  Dinucleotides complementary to position -1 and +1 in the template can also direct first phosphodiester bond formation. This reaction is independent on the basal transcription factors TFIIE  and TFIIH and does not involve open complex formation.  This reaction is sensitive to inhibition by single-stranded oligonucleotides.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway109">
 <bp:pathwayOrder rdf:resource="#PathwayStep504" />
 <bp:pathwayOrder rdf:resource="#PathwayStep503" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction383" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction382" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence490" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Pausing and recovery of HIV elongation</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">After Pol II pauses by back tracking 2 -4 nuleotides on the HIV-1 template, elongation of the  HIV-1 transcript resumes.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway108">
 <bp:pathwayOrder rdf:resource="#PathwayStep500" />
 <bp:pathwayOrder rdf:resource="#PathwayStep501" />
 <bp:pathwayOrder rdf:resource="#PathwayStep499" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction379" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction381" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction380" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence486" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Tat-mediated HIV elongation arrest and recovery</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">RNA Pol II arrest is believed to be a result of irreversible backsliding of the enzyme by ~7-14 nucleotides. TFIIS reactivates arrested RNA Pol II by promoting the  excision of nascent transcript ~7-14 nucleotides upstream of the 3&apos; end. </bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway101">
 <bp:pathwayOrder rdf:resource="#PathwayStep474" />
 <bp:pathwayOrder rdf:resource="#PathwayStep475" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction363" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction362" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence462" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Interactions of Tat with host cellular proteins</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The elongation of HIV-1 mRNA depends upon the interaction of Tat with the host P-TEFb complex (Hermann and Rice, 1995; Wei et al., 1998).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway100">
 <bp:pathwayOrder rdf:resource="#PathwayStep471" />
 <bp:pathwayOrder rdf:resource="#PathwayStep472" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction361" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction360" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence459" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Vpr-mediated induction of apoptosis by mitochondrial outer membrane permeabilization</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">In one model of Vpr mediated induction of apoptosis, Vpr acts directly on the mitochondrial permeability transition pore complex through its interaction with adenine nucleotide translocator (ANT). This interaction promotes the permeabiliztion of  the mitochondrial membranes resulting in the release of cytochrome c and apoptosis-inducing factors.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway103">
 <bp:pathwayOrder rdf:resource="#PathwayStep483" />
 <bp:pathwayOrder rdf:resource="#PathwayStep484" />
 <bp:pathwayOrder rdf:resource="#PathwayStep478" />
 <bp:pathwayOrder rdf:resource="#PathwayStep545" />
 <bp:pathwayOrder rdf:resource="#PathwayStep565" />
 <bp:pathwayComponent rdf:resource="#Pathway119" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction430" />
 <bp:pathwayComponent rdf:resource="#Pathway94" />
 <bp:pathwayComponent rdf:resource="#Pathway105" />
 <bp:pathwayComponent rdf:resource="#Pathway104" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence466" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Late Phase of HIV Life Cycle</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The late phase of the HIV-1 life cycle includes the regulated expression of the HIV gene products and the assembly of viral particles. The assembly of viral particles will be covered in a later release of Reactome. HIV-1 gene expression is regulated by both cellular and viral proteins. Although the initial activation of the HIV-1 transcription is facilitated by cellular transcription factors including NF-kappa B (Nabel and Baltimore, 1987), this activation results in the production of primarily short transcripts (Kao et al., 1987). Expression of high levels of the full length HIV-1 transcript requires the function of the HIV-1 Tat protein which promotes elongation of the HIV-1 transcript (reviewed in Karn, 1999; Taube et al. 1999; Liou et al., 2004; Barboric and Peterlin 2005).  The HIV-1 Rev protein is required post-transcriptionally for the expression of the late genes. Rev functions by promoting the nuclear export of unspliced and partially spliced transcripts that encode the major structural proteins Gag, Pol and Env, and the majority of the accessory proteins (Malim et al., 1989;  reviewed in Pollard and Malim 1998 .</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway102">
 <bp:pathwayOrder rdf:resource="#PathwayStep566" />
 <bp:pathwayOrder rdf:resource="#PathwayStep477" />
 <bp:pathwayComponent rdf:resource="#Pathway123" />
 <bp:pathwayComponent rdf:resource="#Pathway103" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence465" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">HIV Life Cycle</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The life cycle of HIV-1 is divided into early and late phases, shown schematically in the figure. In the  early  phase, an HIV-1 virion binds to receptors and co-receptors on the human host cell surface (a), viral and host cell membranes fuse and the viral particle is uncoated (b), the viral genome is reverse transcribed and the viral preintegration complex (PIC) forms (c), the PIC is transported through the nuclear pore into the nucleoplasm (d), and the viral reverse transcript is integrated into a host cell chromosome (e). In the  late  phase, viral RNAs are transcribed from the integrated viral genome and processed to generate viral mRNAs and full-length viral genomic RNAs (f), the viral RNAs are exported through the nuclear pore into the cytosol (g), viral mRNAs are translated and the resulting viral proteins are post-translationally processed (h), core particles containing viral genomic RNA and proteins assemble at the host cell membrane and immature viral particles are released by budding. The released particles mature to become infectious (j), completing the cycle (Frankel and Young 1998; Miller and Bushman 1997). Most of the crucial concepts used to describe these processes were originally elucidated in studies of retroviruses associated with tumors in chickens, birds, and other animal model systems, and the rapid elucidation of the basic features of the HIV-1 life cycle was critically dependent on the intellectual framework provided by these earlier studies. This earlier work has been very well summarized (e.g., Weiss et al. 1984; Coffin et al. 1997); here for brevity and clarity we focus on experimental studies specific to the HIV-1 life cycle.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway105">
 <bp:pathwayOrder rdf:resource="#PathwayStep492" />
 <bp:pathwayOrder rdf:resource="#PathwayStep519" />
 <bp:pathwayOrder rdf:resource="#PathwayStep491" />
 <bp:pathwayOrder rdf:resource="#PathwayStep485" />
 <bp:pathwayOrder rdf:resource="#PathwayStep486" />
 <bp:pathwayOrder rdf:resource="#PathwayStep522" />
 <bp:pathwayOrder rdf:resource="#PathwayStep498" />
 <bp:pathwayOrder rdf:resource="#PathwayStep542" />
 <bp:pathwayOrder rdf:resource="#PathwayStep515" />
 <bp:pathwayOrder rdf:resource="#PathwayStep505" />
 <bp:pathwayOrder rdf:resource="#PathwayStep502" />
 <bp:pathwayComponent rdf:resource="#Pathway107" />
 <bp:pathwayComponent rdf:resource="#Pathway118" />
 <bp:pathwayComponent rdf:resource="#Pathway106" />
 <bp:pathwayComponent rdf:resource="#Pathway109" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction368" />
 <bp:pathwayComponent rdf:resource="#Pathway108" />
 <bp:pathwayComponent rdf:resource="#Pathway110" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction373" />
 <bp:pathwayComponent rdf:resource="#Pathway112" />
 <bp:pathwayComponent rdf:resource="#Pathway111" />
 <bp:pathwayComponent rdf:resource="#Pathway113" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence472" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Transcription of the HIV genome</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Expression of the integrated HIV-1 provirus is dependent on the host cell Pol II transcription machinery, but is regulated in critical ways by HIV-1 Tat and Rev proteins. The long terminal repeats (LTR) located at either end of the proviral DNA contain regulatory sequences that recruit cellular transcription factors. The U3 region of the 5&apos; LTR contains numerous cis-acting elements that regulate Pol II-mediated transcription initiation. The full-length transcript, which encodes nine genes, functions as an mRNA and is packaged as genomic RNA.  Smaller (subgenomic) viral mRNAs are generated by alternative splicing. The activities of Tat and Rev create two phases of gene expression (see Karn 1999; Cullen 1991). The Tat protein is an RNA specific trans-activator of LTR-mediated transcription. Association of Tat with TAR, a RNA stem-loop within the RNA leader sequence, is required for efficient elongation of the HIV-1 transcript.  In the early phase of viral transcription, a multiply-spliced set of mRNAs is generated, producing the transcripts of the regulatory proteins, Tat, Rev, and Nef. In the late phase, Rev regulates nuclear export of HIV-1 mRNAs, repressing expression of the early regulatory mRNAs and promoting expression of viral structural proteins. Nuclear export of the unspliced and partially spliced late HIV-1 transcripts that encode the structural proteins requires the association of Rev with a cis-acting RNA sequence in the transcripts (Rev Response Element, RRE).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway104">
 <bp:pathwayOrder rdf:resource="#PathwayStep481" />
 <bp:pathwayOrder rdf:resource="#PathwayStep482" />
 <bp:pathwayOrder rdf:resource="#PathwayStep480" />
 <bp:pathwayOrder rdf:resource="#PathwayStep479" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction367" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction365" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction366" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction364" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence467" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Budding and maturation of HIV virion</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">With the virus components precariously assembled on the inner leaflet of the plasma membrane, the host cell machinery is required for viral budding. The virus takes advantage of the host ESCRT pathway to terminate Gag polymerization and catalyze release. The ESCRT pathway is normally responsible for membrane fission that creates cytoplasm filled vesicular bodies. In this case HIV (and other viruses) take advantage of the ESCRT cellular machinery to facilitate virion budding from the host.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1809">
 <bp:evidence rdf:resource="#Evidence2413" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective MUTYH mutants do not bind adenine mispaired with 8-oxoguanine</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1800">
 <bp:evidence rdf:resource="#Evidence2401" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective NTHL1 truncation mutants do not bind dihydrouracil (DHU)</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1803">
 <bp:evidence rdf:resource="#Evidence2404" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective NTHL1 truncation mutants do not bind thymine glycol (Tg)</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1804">
 <bp:evidence rdf:resource="#Evidence2406" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NEIL1 Q282TER does not translocate to the nucleus</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1801">
 <bp:evidence rdf:resource="#Evidence2402" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective NTHL1 truncation mutants do not bind formamidopyrimidine (FapyA)</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1802">
 <bp:evidence rdf:resource="#Evidence2403" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective NTHL1 truncation mutants do not bind cytosine glycol (Cg)</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1807">
 <bp:evidence rdf:resource="#Evidence2409" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NEIL1 G83D does not cleave FapyG</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1808">
 <bp:evidence rdf:resource="#Evidence2410" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NEIL1 G83D does not cleave DHU</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1805">
 <bp:evidence rdf:resource="#Evidence2407" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective NEIL1 variants do not cleave Tg</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1806">
 <bp:evidence rdf:resource="#Evidence2408" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NEIL1 G83D does not cleave FapyA</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1810">
 <bp:evidence rdf:resource="#Evidence2415" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective MUTYH mutants do not cleave adenine mispaired with 8-oxoguanine</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1811">
 <bp:evidence rdf:resource="#Evidence2418" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective OGG1 mutants show decreased binding to 8-oxoguanine</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1814">
 <bp:evidence rdf:resource="#Evidence2423" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">OGG1 S326C is oxidized</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1815">
 <bp:evidence rdf:resource="#Evidence2424" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective OGG1 mutants do not excise 8-oxoguanine</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1812">
 <bp:evidence rdf:resource="#Evidence2420" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">OGG1beta G12E does not translocate to mitochondria</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1813">
 <bp:evidence rdf:resource="#Evidence2422" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective OGG1 mutants do not excise FapyG</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1818">
 <bp:evidence rdf:resource="#Evidence2431" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">PMS2 variants-defective DNA mismatch repair</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1819">
 <bp:evidence rdf:resource="#Evidence2433" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MSH6 variant:MSH2-defective DNA mismatch repair</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1816">
 <bp:evidence rdf:resource="#Evidence2426" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NEIL3 D132V does not cleave 5-guanidinohydantoin (Gh)</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1817">
 <bp:evidence rdf:resource="#Evidence2429" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MLH1 variants-defective DNA mismatch repair</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1821">
 <bp:evidence rdf:resource="#Evidence2437" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MSH2 variant:MSH3-defective DNA mismatch repair</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1822">
 <bp:evidence rdf:resource="#Evidence2438" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MSH2 variant:MSH6-defective DNA mismatch repair</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1820">
 <bp:evidence rdf:resource="#Evidence2435" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MSH3 variant:MSH2-defective DNA mismatch repair</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1825">
 <bp:evidence rdf:resource="#Evidence2446" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective BARD1 does not bind BRCA1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1826">
 <bp:evidence rdf:resource="#Evidence2448" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective D-loop formation mediated by PALB2, BRCA2 and RAD51 due to loss-of-function of BRCA1 in PALB2 binding</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1823">
 <bp:evidence rdf:resource="#Evidence2442" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective D-loop formation mediated by PALB2, BRCA2 and RAD51 due to loss-of-function of PALB2 in BRCA1 binding</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1824">
 <bp:evidence rdf:resource="#Evidence2444" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective D-loop formation mediated by PALB2, BRCA2 and RAD51 due to loss-of-function of PALB2 in binding to BRCA2/RAD51/RAD51C</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1829">
 <bp:evidence rdf:resource="#Evidence2455" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">BRCA2 mutants do not bind SEM1 (DSS1)</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1827">
 <bp:evidence rdf:resource="#Evidence2450" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Some pathogenic BRCA1 mutants do not bind BARD1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1828">
 <bp:evidence rdf:resource="#Evidence2453" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective BRCA2 does not translocate to the nucleus</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1832">
 <bp:evidence rdf:resource="#Evidence2465" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MECP2 mutants R133C ,D121G, R133H and S134F do not bind 5hmC-DNA</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1833">
 <bp:evidence rdf:resource="#Evidence2467" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Active PKA, CaMK IV do not phosphorylate MECP2 mutants R306C,(R306H) at T308</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1830">
 <bp:evidence rdf:resource="#Evidence2457" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective recruitment of BRCA2 and RAD51 due to loss of BRCA2 function in PALB2 binding</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1831">
 <bp:evidence rdf:resource="#Evidence2459" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">BRCA2 mutants with BRC defects or a defect in the C-terminal RAD51 binding site do not bind RAD51</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1836">
 <bp:evidence rdf:resource="#Evidence2472" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MECP2 mutants P302R,K304E,K305R,R306C,(R306H) do not bind NCoR/SMRT complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1837">
 <bp:evidence rdf:resource="#Evidence2476" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective SLC5A7 does not cotransport Cho, Cl-, Na+ from extracellular region to cytosol</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1834">
 <bp:evidence rdf:resource="#Evidence2469" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MECP2 T158A:SIN3A complex does not bind BDNF gene promoter</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1835">
 <bp:evidence rdf:resource="#Evidence2470" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MECP2 mutants R106W, D121G, R133H, S134F, T158M and T158A do not bind to 5mC-DNA</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1838">
 <bp:evidence rdf:resource="#Evidence2478" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective SLC3A1 (in SLC7A9:SLC3A1) does not exchange L-Arg, CySS-, L-Lys for L-Leu</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1839">
 <bp:evidence rdf:resource="#Evidence2480" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective SLC5A1 does not cotransport Glc and Na+</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1840">
 <bp:evidence rdf:resource="#Evidence2482" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective SLC35A1 does not exchange CMP-Neu5Ac for CMP</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1843">
 <bp:evidence rdf:resource="#Evidence2488" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective SLCO1B1 does not transport BIL from extracellular region (blood) to cytosol (hepatocyte)</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1844">
 <bp:evidence rdf:resource="#Evidence2490" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective SLC20A2 does not cotransport Pi, Na+ from extracellular region to cytosol</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1841">
 <bp:evidence rdf:resource="#Evidence2484" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective NPC does not transport GCK1:GKRP from cytosol to nucleoplasm</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1842">
 <bp:evidence rdf:resource="#Evidence2486" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective SLC12A1 does not cotransport Na+, K+, 2Cl- from extracellular region to cytosol</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1847">
 <bp:evidence rdf:resource="#Evidence2496" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective SLC7A7 does not exchange L-Arg for L-Leu, Na+ across the plasma membrane</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1848">
 <bp:evidence rdf:resource="#Evidence2498" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective SLC6A3 does not cotransport DA, Na+ from extracellular region to cytosol</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1845">
 <bp:evidence rdf:resource="#Evidence2492" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective SLC27A4 does not transport LCFAs from extracellular region to cytosol</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1846">
 <bp:evidence rdf:resource="#Evidence2494" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective SLC6A2 does not cotransport NAd, Na+ from extracellular region to cytosol</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1849">
 <bp:evidence rdf:resource="#Evidence2500" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective SLC35A3 does not exchange UDP-GlcNAc for UMP</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1850">
 <bp:evidence rdf:resource="#Evidence2503" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective SLC12A3 does not cotransport Cl-, Na+ from extracellular region to cytosol</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1851">
 <bp:evidence rdf:resource="#Evidence2505" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Variant SLC6A20 does not cotransport L-Pro, Na+ from extracellulare region to cytosol</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1854">
 <bp:evidence rdf:resource="#Evidence2511" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective GCK does not phosphorylate Glc to form G6P</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1855">
 <bp:evidence rdf:resource="#Evidence2513" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective SLC35C1 does not transport UDP-Fuc from cytosol to Golgi lumen</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1852">
 <bp:evidence rdf:resource="#Evidence2507" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SLC26A3 does not exchange Cl- for HCO3-</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1853">
 <bp:evidence rdf:resource="#Evidence2509" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective SLC35A2 does not exchange UDP-Gal, UDP-GalNAc for UMP</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1858">
 <bp:evidence rdf:resource="#Evidence2519" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective SLC6A18 does not transport Gly from extracellular region to cytosol</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1859">
 <bp:evidence rdf:resource="#Evidence2522" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective SLC24A5 does not exchange cytosolic 4Na+ for Golgi luminal Ca2+, K+</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1856">
 <bp:evidence rdf:resource="#Evidence2515" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective SLC6A19 does not cotransport neutral amino acids, Na+ from extracellular region to cytosol</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1857">
 <bp:evidence rdf:resource="#Evidence2517" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective SLC7A9 (in SLC7A9:SLC3A1) does not exchange L-Arg, CySS-, L-Lys for L-Leu</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1740">
 <bp:evidence rdf:resource="#Evidence2301" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective extracellular BTD does not hydrolyse BCTN</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1741">
 <bp:evidence rdf:resource="#Evidence2303" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective HLCS does not biotinylate 6x(PCCA:PCCB)</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1744">
 <bp:evidence rdf:resource="#Evidence2306" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective HLCS does not biotinylate ACACA:Mn2+</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1745">
 <bp:evidence rdf:resource="#Evidence2311" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective RDH12 does not reduce atRAL to atROL</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1742">
 <bp:evidence rdf:resource="#Evidence2304" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective HLCS does not biotinylate PC:Mn2+</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1743">
 <bp:evidence rdf:resource="#Evidence2305" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective HLCS does not biotinylate 6xMCCC1:6xMCCC2</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1748">
 <bp:evidence rdf:resource="#Evidence2315" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">A2PE hydrolyses to A2E</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1749">
 <bp:evidence rdf:resource="#Evidence2316" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NRPE condenses with atRAL to form A2PE</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1746">
 <bp:evidence rdf:resource="#Evidence2313" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">A2E translocates to RPE cells</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1747">
 <bp:evidence rdf:resource="#Evidence2314" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">atRAL can spontaneously react with PE to form NRPE</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1751">
 <bp:evidence rdf:resource="#Evidence2319" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective LRAT does not esterify RBP1:atROL and FACYLs to atREs</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1752">
 <bp:evidence rdf:resource="#Evidence2321" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective OPN1SW does not bind 11cRAL</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1750">
 <bp:evidence rdf:resource="#Evidence2317" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">A2E is phagocytosed</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1755">
 <bp:evidence rdf:resource="#Evidence2327" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective OPN1MW does not bind 11cRAL</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1756">
 <bp:evidence rdf:resource="#Evidence2329" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective RDH5 does not oxidise 11cROL to 11cRAL and causes RPA</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1753">
 <bp:evidence rdf:resource="#Evidence2323" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective STRA6 does not transport atROL</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1754">
 <bp:evidence rdf:resource="#Evidence2325" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective OPN1LW does not bind 11cRAL</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1759">
 <bp:evidence rdf:resource="#Evidence2339" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective DAXX does not bind ATRX</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1757">
 <bp:evidence rdf:resource="#Evidence2331" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective ABCA4 does not transport NRPE from disc membranes</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1758">
 <bp:evidence rdf:resource="#Evidence2333" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective RBP4 does not bind atROL</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1770">
 <bp:evidence rdf:resource="#Evidence2360" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">p25-bound CDK5 phosphorylates CDC25B</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1762">
 <bp:evidence rdf:resource="#Evidence2347" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective RB1 does not translocate to the nucleus</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1763">
 <bp:evidence rdf:resource="#Evidence2349" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective RB1 does not form a complex with SKP2 and FZR1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1760">
 <bp:evidence rdf:resource="#Evidence2341" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective ATRX does not bind DAXX</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1761">
 <bp:evidence rdf:resource="#Evidence2345" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective RB1 does not bind E2F1,(E2F2,E2F3)</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1766">
 <bp:evidence rdf:resource="#Evidence2356" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">CDC25C binds YWHAE (14-3-3-epsilon)</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1767">
 <bp:evidence rdf:resource="#Evidence2357" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">CDK5:p25 phosphorylates PRDX2</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1764">
 <bp:evidence rdf:resource="#Evidence2354" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">CDK5:p25 phosphorylates lamin A</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1765">
 <bp:evidence rdf:resource="#Evidence2355" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">CDK5:p25 phosphorylates JUN</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1768">
 <bp:evidence rdf:resource="#Evidence2358" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">BCL2L11 (BIM) gene expression</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1769">
 <bp:evidence rdf:resource="#Evidence2359" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">CDK5:p25 phosphorylates FOXO3</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1780">
 <bp:evidence rdf:resource="#Evidence2370" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Phosphorylated FOXO3 translocates to the nucleus</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1781">
 <bp:evidence rdf:resource="#Evidence2371" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">CDK5:p25 phosphorylates GOLGA2</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1773">
 <bp:evidence rdf:resource="#Evidence2363" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">CDK5:p25 phosphorylates PRDX1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1774">
 <bp:evidence rdf:resource="#Evidence2364" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FASLG (FasL) gene expression</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1771">
 <bp:evidence rdf:resource="#Evidence2361" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">CDK5:p25 phosphorylates lamin B1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1772">
 <bp:evidence rdf:resource="#Evidence2362" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">APP gene expression</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1777">
 <bp:evidence rdf:resource="#Evidence2367" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Influx of extracellular calcium</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1778">
 <bp:evidence rdf:resource="#Evidence2368" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">CDK5:p25 translocates to the nucleus</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1775">
 <bp:evidence rdf:resource="#Evidence2365" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SOD2 (MnSOD) gene expression</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1776">
 <bp:evidence rdf:resource="#Evidence2366" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Calpain activation</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1779">
 <bp:evidence rdf:resource="#Evidence2369" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">p25-bound CDK5 phosphorylates CDC25C</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1791">
 <bp:evidence rdf:resource="#Evidence2386" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">HSV1 RIR1 binds RIPK1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1792">
 <bp:evidence rdf:resource="#Evidence2387" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">HCMV UL36 binds MLKL</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1790">
 <bp:evidence rdf:resource="#Evidence2385" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">HSV1 RIR1 binds RIPK3</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1784">
 <bp:evidence rdf:resource="#Evidence2374" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">p25-bound CDK5 phosphorylates CDC25A</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1785">
 <bp:evidence rdf:resource="#Evidence2375" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">CAST binds Ca2+ bound calpain</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1782">
 <bp:evidence rdf:resource="#Evidence2372" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Calpain cleaves p35 to p25</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1783">
 <bp:evidence rdf:resource="#Evidence2373" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">CDK5 binds p25</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1788">
 <bp:evidence rdf:resource="#Evidence2382" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">RIPK1 variant is not cleaved by CASP8</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1789">
 <bp:evidence rdf:resource="#Evidence2384" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Viral serpin blocks caspase-8 activity</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1786">
 <bp:evidence rdf:resource="#Evidence2377" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">p14ARF mutants do not bind C1QBP</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1787">
 <bp:evidence rdf:resource="#Evidence2380" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective TP53 does not tetramerize</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1795">
 <bp:evidence rdf:resource="#Evidence2391" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The GSDME gene promoter is hypermethylated</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1796">
 <bp:evidence rdf:resource="#Evidence2392" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Decitabine triphosphate incorporates into DNA</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1793">
 <bp:evidence rdf:resource="#Evidence2388" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">IAV NS1 binds MLKL</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1794">
 <bp:evidence rdf:resource="#Evidence2389" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">HSV1 RIR1 binds CASP8</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1799">
 <bp:evidence rdf:resource="#Evidence2399" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NTHL1 D239Y does not cleave dihydrouracil (DHU)</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1797">
 <bp:evidence rdf:resource="#Evidence2393" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">GSDME variant does not bind PIPs</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1798">
 <bp:evidence rdf:resource="#Evidence2398" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NTHL1 D239Y does not cleave thymine glycol (Tg)</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence1390">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1391">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1392">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1393">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1394">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1395">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1396">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1397">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1398">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1399">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1380">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1381">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1382">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1383">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1384">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1385">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1386">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1387">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1388">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1389">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1348">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2679">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1349">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2680">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1350">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2681">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1351">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2682">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1352">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2683">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1353">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2684">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1354">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2685">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1355">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2686">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1356">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1357">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1358">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1337">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2668">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1338">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2669">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1339">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2670">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1340">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2671">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1341">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2672">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1342">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2673">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1343">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2674">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1344">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2675">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1345">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2676">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1346">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2677">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1347">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2678">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1370">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1371">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1372">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1373">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1374">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1375">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1376">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1377">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1378">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1379">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1359">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1360">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1361">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1362">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1363">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1364">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1365">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1366">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1367">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1368">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1369">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction435">
 <bp:evidence rdf:resource="#Evidence561" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Minus strand DNA synthesis resumes</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence1425">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction436">
 <bp:evidence rdf:resource="#Evidence562" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Synthesis of minus strand strong stop DNA (-sssDNA)</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence1426">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction433">
 <bp:evidence rdf:resource="#Evidence558" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">3&apos; PPT-primed initiation of plus-strand DNA synthesis </bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence1427">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction434">
 <bp:evidence rdf:resource="#Evidence559" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Second strand transfer by annealing complementary PBS sequences</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence1428">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction431">
 <bp:evidence rdf:resource="#Evidence556" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Synthesis of full-length duplex viral DNA with a discontinuous plus strand</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence1429">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction432">
 <bp:evidence rdf:resource="#Evidence557" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">RNase H-mediated digestion of tRNA, 3&apos;PPT and cPPT RNA primers</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction430">
 <bp:evidence rdf:resource="#Evidence552" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Myristoylation of Nef</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction439">
 <bp:evidence rdf:resource="#Evidence565" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">RTC binds NRTIs</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction437">
 <bp:evidence rdf:resource="#Evidence563" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">RNase H-mediated degradation of the template strand</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction438">
 <bp:evidence rdf:resource="#Evidence564" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">RNase H-mediated degradation of the RNA strand of the -sssDNA:RNA duplex</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep1637">
 <bp:stepProcess rdf:resource="#Pathway304" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1638">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1297" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1639">
 <bp:stepProcess rdf:resource="#Pathway305" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1633">
 <bp:stepProcess rdf:resource="#Pathway302" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1634">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1295" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1635">
 <bp:stepProcess rdf:resource="#Pathway303" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1636">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1296" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1630">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1293" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence1430">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep1631">
 <bp:stepProcess rdf:resource="#Pathway301" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence1431">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep1632">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1294" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence1432">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1433">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1434">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1435">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction424">
 <bp:evidence rdf:resource="#Evidence546" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Synthesis of VPU protein</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence1414">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction425">
 <bp:evidence rdf:resource="#Evidence547" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Transport of trimeric ENV precursor to Golgi apparatus</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence1415">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction422">
 <bp:evidence rdf:resource="#Evidence544" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Synthesis of ENV polyprotein</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence1416">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction423">
 <bp:evidence rdf:resource="#Evidence545" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Cleavage of the viral Env gp160 precursor polyprotein</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence1417">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction420">
 <bp:evidence rdf:resource="#Evidence542" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Glycosylation of ENV polyprotein</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence1418">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction421">
 <bp:evidence rdf:resource="#Evidence543" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Transport of trimeric gp41:gp120 to plasma membrane</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence1419">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction428">
 <bp:evidence rdf:resource="#Evidence550" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Transport of VPU to Plasma Membrane</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction429">
 <bp:evidence rdf:resource="#Evidence551" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Transport of VPU to Golgi apparatus</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction426">
 <bp:evidence rdf:resource="#Evidence548" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Folding and Oligomerization of ENV glycoprotein</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction427">
 <bp:evidence rdf:resource="#Evidence549" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Splicing of HIV RNA transcript</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep1648">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1303" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1649">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1304" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1644">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1300" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1645">
 <bp:stepProcess rdf:resource="#Pathway308" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1646">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1301" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1647">
 <bp:stepProcess rdf:resource="#Catalysis388" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1302" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1640">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1298" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1641">
 <bp:stepProcess rdf:resource="#Pathway306" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1642">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1299" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence1420">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep1643">
 <bp:stepProcess rdf:resource="#Pathway307" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence1421">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1422">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1423">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1424">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction457">
 <bp:evidence rdf:resource="#Evidence587" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Terminal (3&apos; end) cleavage of viral DNA</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence1447">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction458">
 <bp:evidence rdf:resource="#Evidence588" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Formation of RTC with integration competent viral DNA:BANF1:HMGA1:PSIP1</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence1448">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction455">
 <bp:evidence rdf:resource="#Evidence585" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Association of Ku heterodimer with viral DNA ends</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence1449">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction456">
 <bp:evidence rdf:resource="#Evidence586" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Formation of Pre-Integration Complex (PIC)</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction453">
 <bp:evidence rdf:resource="#Evidence583" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Association of  XRCC4:DNA ligase IV complex with viral DNA ends</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction454">
 <bp:evidence rdf:resource="#Evidence584" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">2-LTR formation due to circularization of viral DNA</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction451">
 <bp:evidence rdf:resource="#Evidence580" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Target DNA binding</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction452">
 <bp:evidence rdf:resource="#Evidence581" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Import of PIC to the Host Nucleus</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep1608">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1278" />
 <bp:stepProcess rdf:resource="#Catalysis382" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1609">
 <bp:stepProcess rdf:resource="#Pathway294" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction459">
 <bp:evidence rdf:resource="#Evidence590" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Suicidal integration leading to inverted circle formation</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep1615">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1283" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1616">
 <bp:stepProcess rdf:resource="#Pathway296" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1617">
 <bp:stepProcess rdf:resource="#Pathway297" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1618">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1284" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1611">
 <bp:stepProcess rdf:resource="#Pathway295" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1612">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1280" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1613">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1281" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1614">
 <bp:stepProcess rdf:resource="#Catalysis384" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1282" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence1450">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction450">
 <bp:evidence rdf:resource="#Evidence579" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Gap repair completes provirus integration</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence1451">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1452">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1453">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep1610">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1279" />
 <bp:stepProcess rdf:resource="#Catalysis383" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence1454">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1455">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1456">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1457">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction446">
 <bp:evidence rdf:resource="#Evidence573" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Disassembly of viral capsid</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence1436">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction447">
 <bp:evidence rdf:resource="#Evidence574" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Formation of RTC (Reverse Transcription Complex)</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence1437">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction444">
 <bp:evidence rdf:resource="#Evidence570" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Annealing of 3&apos;-end of unwound transfer RNA primer with genomic RNA</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence1438">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction445">
 <bp:evidence rdf:resource="#Evidence572" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Disintegration of matrix layer</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence1439">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction442">
 <bp:evidence rdf:resource="#Evidence568" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">RNase H-mediated cleavage of the template strand</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction443">
 <bp:evidence rdf:resource="#Evidence569" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Removal of plus-strand flap and gap closure complete synthesis of linear duplex viral DNA</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction440">
 <bp:evidence rdf:resource="#Evidence566" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">First strand transfer mediated by Repeated (R) sequence</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction441">
 <bp:evidence rdf:resource="#Evidence567" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">RNase H-mediated cleavage of the RNA strand of the -sssDNA:RNA duplex</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep1619">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1285" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction448">
 <bp:evidence rdf:resource="#Evidence576" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">1-LTR circle formation</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction449">
 <bp:evidence rdf:resource="#Evidence578" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Transesterification to connect viral DNA 3&apos; ends to host DNA 5&apos; ends</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep1626">
 <bp:stepProcess rdf:resource="#Pathway298" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1627">
 <bp:stepProcess rdf:resource="#Pathway299" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1628">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1292" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1629">
 <bp:stepProcess rdf:resource="#Pathway300" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1622">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1288" />
 <bp:stepProcess rdf:resource="#Catalysis386" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1623">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1289" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1624">
 <bp:stepProcess rdf:resource="#Catalysis387" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1290" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1625">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1291" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence1440">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1441">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep1620">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1286" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence1442">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep1621">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1287" />
 <bp:stepProcess rdf:resource="#Catalysis385" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence1443">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1444">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1445">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1446">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep1604">
 <bp:stepProcess rdf:resource="#Catalysis379" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1274" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1605">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1275" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1606">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1276" />
 <bp:stepProcess rdf:resource="#Catalysis380" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1607">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1277" />
 <bp:stepProcess rdf:resource="#Catalysis381" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1600">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1270" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1601">
 <bp:stepProcess rdf:resource="#Catalysis377" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1271" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1602">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1272" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1603">
 <bp:stepProcess rdf:resource="#Catalysis378" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1273" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction413">
 <bp:evidence rdf:resource="#Evidence531" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Recruitment of elongation factors to form HIV-1 elongation complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence1403">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction414">
 <bp:evidence rdf:resource="#Evidence533" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Packaging of HIV virion on the host cell plasma membrane</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence1404">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction411">
 <bp:evidence rdf:resource="#Evidence528" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Hypophosphorylation of RNA Pol II CTD by FCP1P protein</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence1405">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction412">
 <bp:evidence rdf:resource="#Evidence530" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Hyperphosphorylation (Ser2) of RNA Pol II CTD by P-TEFb complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence1406">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1407">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction410">
 <bp:evidence rdf:resource="#Evidence527" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Recognition and binding of the HIV-1 mRNA cap by the cap-binding complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence1408">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1409">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction419">
 <bp:evidence rdf:resource="#Evidence540" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Monoubiquitination of N-myristoyl GAG polyprotein</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction417">
 <bp:evidence rdf:resource="#Evidence538" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Transport of GAG to the Plasma Membrane</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction418">
 <bp:evidence rdf:resource="#Evidence539" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">N-myristoylation of GAG polyprotein by NMT2</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction415">
 <bp:evidence rdf:resource="#Evidence535" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Synthesis of GAG polyprotein</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction416">
 <bp:evidence rdf:resource="#Evidence537" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Monoubiquitinated N-myristoyl GAG polyprotein is targeted to the late endosomal vesicle membrane by the ESCRT-I complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence1410">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1411">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1412">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1413">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction402">
 <bp:evidence rdf:resource="#Evidence517" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Hyperphosphorylation (Ser2) of RNA Pol II CTD by the P-TEFb(Cyclin T1:Cdk9) complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction403">
 <bp:evidence rdf:resource="#Evidence518" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Phosphorylation of DSIF by the P-TEFb(Cyclin T1:Cdk9) complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction400">
 <bp:evidence rdf:resource="#Evidence514" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Pol II elongation complex moves on the HIV-1 template as transcript elongates</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction401">
 <bp:evidence rdf:resource="#Evidence516" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Recruitment of elongation factors to form HIV-1 elongation complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction408">
 <bp:evidence rdf:resource="#Evidence525" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">DSIF complex binds to RNA Pol II (hypophosphorylated)</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction409">
 <bp:evidence rdf:resource="#Evidence526" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Abortive termination of HIV-1 early transcription elongation by DSIF:NELF</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction406">
 <bp:evidence rdf:resource="#Evidence522" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Separation of abortive HIV-1 transcript from template</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction407">
 <bp:evidence rdf:resource="#Evidence524" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Formation of DSIF:NELF:HIV-1 early elongation complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction404">
 <bp:evidence rdf:resource="#Evidence519" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Phosphorylation of  NEFL by the P-TEFb(Cyclin T1:Cdk9) complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction405">
 <bp:evidence rdf:resource="#Evidence521" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Limited elongation of the HIV-1 transcript</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence1400">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1401">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1402">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep1690">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1343" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1699">
 <bp:stepProcess rdf:resource="#Pathway315" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1695">
 <bp:stepProcess rdf:resource="#Pathway313" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1696">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1346" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1697">
 <bp:stepProcess rdf:resource="#Pathway314" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1698">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1347" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1691">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1344" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1692">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1345" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1693">
 <bp:stepProcess rdf:resource="#Pathway311" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1694">
 <bp:stepProcess rdf:resource="#Pathway312" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction479">
 <bp:evidence rdf:resource="#Evidence614" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">glycosylated-ACE2 binds ACE2 inhibitors</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction477">
 <bp:evidence rdf:resource="#Evidence612" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">CTSL bind CTSL inhibitors</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction478">
 <bp:evidence rdf:resource="#Evidence613" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Endocytois of SARS-CoV-1 Virion</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction475">
 <bp:evidence rdf:resource="#Evidence610" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">CQ, HCQ diffuses from cytosol to endocytic vesicle lumen</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction476">
 <bp:evidence rdf:resource="#Evidence611" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Cleavage of S protein into S1:S2</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction473">
 <bp:evidence rdf:resource="#Evidence608" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Fusion and Release of SARS-CoV-1 Nucleocapsid</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction474">
 <bp:evidence rdf:resource="#Evidence609" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Uncoating of SARS-CoV-1 Genome</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep1677">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1331" />
 <bp:stepProcess rdf:resource="#Catalysis398" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1700">
 <bp:evidence rdf:resource="#Evidence2226" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective CYP11B2 does not oxidise 18HCORST</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep1678">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1332" />
 <bp:stepProcess rdf:resource="#Catalysis399" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1701">
 <bp:evidence rdf:resource="#Evidence2227" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective CYP11B2 does not oxidise CORST</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep1679">
 <bp:stepProcess rdf:resource="#Pathway310" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction471">
 <bp:evidence rdf:resource="#Evidence606" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">CQ, HCQ are protonated to CQ2+, HCQ2+</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep1673">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1327" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1704">
 <bp:evidence rdf:resource="#Evidence2232" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective CYP24A1 does not 24-hydroxylate CALTOL</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction472">
 <bp:evidence rdf:resource="#Evidence607" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TMPRSS2 Mediated SARS-CoV-1 Spike Protein Cleavage and Endocytosis</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep1674">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1328" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1705">
 <bp:evidence rdf:resource="#Evidence2234" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective CYP21A2 does not 21-hydroxylate PROG</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep1675">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1329" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1702">
 <bp:evidence rdf:resource="#Evidence2228" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective CYP11B2 does not oxidise 11DCORST</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction470">
 <bp:evidence rdf:resource="#Evidence605" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TMPRSS2 binds TMPRSS2 inhibitors</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep1676">
 <bp:stepProcess rdf:resource="#Catalysis397" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1330" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1703">
 <bp:evidence rdf:resource="#Evidence2230" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective CYP2U1 does not omega-hydroxylate ARA</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1708">
 <bp:evidence rdf:resource="#Evidence2240" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective CYP11B1 does not oxidise 11DCORT</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep1670">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1324" />
 <bp:stepProcess rdf:resource="#Catalysis396" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1709">
 <bp:evidence rdf:resource="#Evidence2242" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective UGT1A4 does not transfer GlcA from UDP-GlcA to BIL</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep1671">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1325" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1706">
 <bp:evidence rdf:resource="#Evidence2236" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective SLC35D1 does not transport UDP-GlcA, UDPGlcNAc</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep1672">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1326" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1707">
 <bp:evidence rdf:resource="#Evidence2238" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective GGT1 does not hydrolyse GSH</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction468">
 <bp:evidence rdf:resource="#Evidence600" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Conformational changes in gp120 exposes gp41</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction469">
 <bp:evidence rdf:resource="#Evidence601" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Fusogenic activation of gp41</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction466">
 <bp:evidence rdf:resource="#Evidence598" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Insertion of gp41 fusion peptide into the target membrane</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction467">
 <bp:evidence rdf:resource="#Evidence599" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">CD4:gp120  binds to chemokine co-receptor CCR5/CXCR4</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction464">
 <bp:evidence rdf:resource="#Evidence596" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">N and C terminal heptad repeat helices of gp41 form six-helix bundle</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction465">
 <bp:evidence rdf:resource="#Evidence597" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Conformational change in gp120 of Env oligomer</bp:displayName>
</bp:BiochemicalReaction>

<bp:Provenance rdf:ID="Provenance1">
 <bp:name rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Reactome</bp:name>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">http://www.reactome.org</bp:comment>
</bp:Provenance>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction462">
 <bp:evidence rdf:resource="#Evidence594" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Binding of gp120 of ENV oligomer to the host CD4</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction463">
 <bp:evidence rdf:resource="#Evidence595" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Fusion of viral membrane with host cell membrane</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep1688">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1341" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1711">
 <bp:evidence rdf:resource="#Evidence2245" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective FMO3 does not N-oxidise TMA</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep1689">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1342" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1712">
 <bp:evidence rdf:resource="#Evidence2247" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective AHCY does not hydrolyse AdoHcy</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1710">
 <bp:evidence rdf:resource="#Evidence2243" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective UGT1A4 does not transfer GlcA from UDP-GlcA to BMG</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction460">
 <bp:evidence rdf:resource="#Evidence591" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Suicidal integration leading to smaller circles of viral DNA</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep1684">
 <bp:stepProcess rdf:resource="#Catalysis403" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1337" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1715">
 <bp:evidence rdf:resource="#Evidence2252" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective GCLC does not ligate L-Glu to L-Cys</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction461">
 <bp:evidence rdf:resource="#Evidence592" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Integrase binds viral DNA ends</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep1685">
 <bp:stepProcess rdf:resource="#Catalysis404" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1338" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1716">
 <bp:evidence rdf:resource="#Evidence2254" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective OPLAH does not hydrolyse OPRO</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep1686">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1339" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1713">
 <bp:evidence rdf:resource="#Evidence2249" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">CYP27A1 does not 27-hydroxylate 5bCHOL3a,7a,12a-triol</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep1687">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1340" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1714">
 <bp:evidence rdf:resource="#Evidence2250" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective CYP27A1 does not 27-hydroxylate 5&#946;-CHOL3&#945;,7&#945;,24(s)-triol</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep1680">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1333" />
 <bp:stepProcess rdf:resource="#Catalysis400" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1719">
 <bp:evidence rdf:resource="#Evidence2260" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective CYP26C1 does not 4-hydroxylate 9cRA</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep1681">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1334" />
 <bp:stepProcess rdf:resource="#Catalysis401" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1682">
 <bp:stepProcess rdf:resource="#Catalysis402" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1335" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1717">
 <bp:evidence rdf:resource="#Evidence2256" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TPMT does not transfer CH3 from AdoMet to 6MP</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep1683">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1336" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1718">
 <bp:evidence rdf:resource="#Evidence2258" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective CYP4F22 does not 20-hydroxylate TrXA3</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction499">
 <bp:evidence rdf:resource="#Evidence637" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">nsp16 binds VHL</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction497">
 <bp:evidence rdf:resource="#Evidence635" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">RTC binds SARS-CoV-1 genomic RNA complement (minus strand)</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction498">
 <bp:evidence rdf:resource="#Evidence636" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">nsp16 acts as a cap 2&apos;-O-methyltransferase to modify SARS-CoV-1 gRNA complement (minus strand)</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction495">
 <bp:evidence rdf:resource="#Evidence633" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">nsp12 misincorporates a nucleotide in nascent RNA minus strand</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction496">
 <bp:evidence rdf:resource="#Evidence634" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SARS-CoV-1 gRNA:RTC:nascent RNA minus strand binds RTC inhibitors</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep1659">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1314" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1655">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1310" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1722">
 <bp:evidence rdf:resource="#Evidence2266" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective CYP1B1 does not 4-hydroxylate EST17b</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep1656">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1311" />
 <bp:stepProcess rdf:resource="#Catalysis390" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1723">
 <bp:evidence rdf:resource="#Evidence2268" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective UGT1A1 does not transfer GlcA from UDP-GlcA to BMG</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep1657">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1312" />
 <bp:stepProcess rdf:resource="#Catalysis391" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1720">
 <bp:evidence rdf:resource="#Evidence2262" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective ACY1 does not hydrolyse mercapturic acids</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep1658">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1313" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1721">
 <bp:evidence rdf:resource="#Evidence2264" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective GSS does not synthesize GSH</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction493">
 <bp:evidence rdf:resource="#Evidence631" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">RTC completes synthesis of the minus strand genomic RNA complement</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep1651">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1306" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1726">
 <bp:evidence rdf:resource="#Evidence2275" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective MTR does not transfer CH3 group from MeCbl to HCYS</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction494">
 <bp:evidence rdf:resource="#Evidence632" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Replication transcription complex binds SARS-CoV-1 genomic RNA</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep1652">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1307" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1727">
 <bp:evidence rdf:resource="#Evidence2276" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective MTR does not transfer CH3 group from MTHF to cob(I)alamin</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction491">
 <bp:evidence rdf:resource="#Evidence629" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">nsp13 helicase melts secondary structures in SARS-CoV-1 genomic RNA template</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep1653">
 <bp:stepProcess rdf:resource="#Catalysis389" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1308" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1724">
 <bp:evidence rdf:resource="#Evidence2269" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective UGT1A1 does not transfer GlcA from UDP-GlcA to BIL</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction492">
 <bp:evidence rdf:resource="#Evidence630" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">nsp16 acts as a cap 2&apos;-O-methyltransferase to modify SARS-CoV-1 gRNA (plus strand)</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep1654">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1309" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1725">
 <bp:evidence rdf:resource="#Evidence2273" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective CD320 does not transport extracellular TCII:Cbl to endosome</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction490">
 <bp:evidence rdf:resource="#Evidence628" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">nsp13 binds DDX5</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1728">
 <bp:evidence rdf:resource="#Evidence2278" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective TCII does not bind Cbl in the circulation</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep1650">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1305" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1729">
 <bp:evidence rdf:resource="#Evidence2280" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective MMAB does not transfer adenosyl group from ATP to B12s</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction488">
 <bp:evidence rdf:resource="#Evidence626" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">nsp14 acts as a 3&apos;-to-5&apos; exonuclease to remove misincorporated nucleotides from nascent RNA</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction489">
 <bp:evidence rdf:resource="#Evidence627" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SARS coronavirus gRNA:RTC:RNA primer binds RTC inhibitors</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction486">
 <bp:evidence rdf:resource="#Evidence624" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Polyadenylation of SARS-CoV-1 genomic RNA (plus strand)</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction487">
 <bp:evidence rdf:resource="#Evidence625" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">nsp12 synthesizes minus strand SARS-CoV-1 genomic RNA complement</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction484">
 <bp:evidence rdf:resource="#Evidence621" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Synthesis of SARS-CoV-1 plus strand subgenomic mRNAs</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction485">
 <bp:evidence rdf:resource="#Evidence622" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Polyadenylation of SARS-CoV-1 subgenomic mRNAs (plus strand)</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1730">
 <bp:evidence rdf:resource="#Evidence2282" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective MTRR does not convert cob(II)alamin to MeCbl</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep1666">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1320" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1733">
 <bp:evidence rdf:resource="#Evidence2288" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective CUBN does not transport GIF:Cbl</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep1667">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1321" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1734">
 <bp:evidence rdf:resource="#Evidence2290" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective MMADHC does not bind MMACHC:B12r</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep1668">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1322" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1731">
 <bp:evidence rdf:resource="#Evidence2284" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective ABCD4:LMBRD1 does not transport Cbl from lysosomal lumen to cytosol</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep1669">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1323" />
 <bp:stepProcess rdf:resource="#Catalysis395" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1732">
 <bp:evidence rdf:resource="#Evidence2286" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective AMN does not transport GIF:Cbl</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction482">
 <bp:evidence rdf:resource="#Evidence619" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">nsp14 acts as a cap N7 methyltransferase to modify SARS-CoV-1 mRNAs</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep1662">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1316" />
 <bp:stepProcess rdf:resource="#Catalysis393" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1737">
 <bp:evidence rdf:resource="#Evidence2295" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective MMACHC does not reduce Cbl</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction483">
 <bp:evidence rdf:resource="#Evidence620" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">nsp16 acts as a cap 2&apos;-O-methyltransferase to modify SARS-CoV-1 mRNAs</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep1663">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1317" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1738">
 <bp:evidence rdf:resource="#Evidence2297" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective MMAA does not protect MUT</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction480">
 <bp:evidence rdf:resource="#Evidence615" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Spike glycoprotein of SARS coronavirus binds ACE2 on host cell</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep1664">
 <bp:stepProcess rdf:resource="#Catalysis394" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1318" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1735">
 <bp:evidence rdf:resource="#Evidence2292" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective CBLIF does not bind Cbl</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction481">
 <bp:evidence rdf:resource="#Evidence618" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Synthesis of SARS-CoV-1 minus strand subgenomic mRNAs by template switching</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep1665">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1319" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1736">
 <bp:evidence rdf:resource="#Evidence2294" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective MMACHC does not decyanate CNCbl</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep1660">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1315" />
 <bp:stepProcess rdf:resource="#Catalysis392" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1739">
 <bp:evidence rdf:resource="#Evidence2300" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective mitochondrial BTD does not hydrolyse BCTN</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep1661">
 <bp:stepProcess rdf:resource="#Pathway309" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1620">
 <bp:evidence rdf:resource="#Evidence2080" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective ALG3 does not add mannose to the N-glycan precursor</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1623">
 <bp:evidence rdf:resource="#Evidence2085" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective RFT1 does not flip the N-glycan precursor</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1624">
 <bp:evidence rdf:resource="#Evidence2087" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective ALG8 does not add glucose to the N-glycan precursor</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1621">
 <bp:evidence rdf:resource="#Evidence2082" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective ALG9 does not add the seventh mannose to the N-glycan precursor</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1622">
 <bp:evidence rdf:resource="#Evidence2083" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective ALG9 does not add the last mannose to the N-glycan precursor</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1627">
 <bp:evidence rdf:resource="#Evidence2093" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective ALG6 does not add glucose to the N-glycan precursor</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1628">
 <bp:evidence rdf:resource="#Evidence2095" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective DPAGT1 does not transfer GlcNAc to DOLP</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1625">
 <bp:evidence rdf:resource="#Evidence2089" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective MOGS does not cleave glucose from an N-glycosylated protein</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1626">
 <bp:evidence rdf:resource="#Evidence2091" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective MGAT2 does not transfer GlcNAc to N-glycans</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1629">
 <bp:evidence rdf:resource="#Evidence2097" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective B4GALT1 does not add Gal to N-glycan</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1630">
 <bp:evidence rdf:resource="#Evidence2099" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective NEU1 does not hydrolyse Neu5Ac from glycoconjugates</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1631">
 <bp:evidence rdf:resource="#Evidence2101" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective ALG12 does not add mannose to the N-glycan precursor</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1634">
 <bp:evidence rdf:resource="#Evidence2108" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective B3GALTL does not transfer glucose to O-fucosyl-proteins</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1635">
 <bp:evidence rdf:resource="#Evidence2110" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective C1GALT1C1 does not bind C1GALT1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1632">
 <bp:evidence rdf:resource="#Evidence2103" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective ALG1 does not transfer the first Man to the N-glycan precursor</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1633">
 <bp:evidence rdf:resource="#Evidence2105" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective ALG2 does not transfer a second Man to N-glycan precursor</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1638">
 <bp:evidence rdf:resource="#Evidence2116" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective LARGE does not transfer Xyl from UDP-Xyl to GlcA</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1639">
 <bp:evidence rdf:resource="#Evidence2118" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective GALNT3 does not transfer GalNAc to mucins</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1636">
 <bp:evidence rdf:resource="#Evidence2112" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective POMT1 does not transfer Man from Dol-P-Man to DAG1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1637">
 <bp:evidence rdf:resource="#Evidence2114" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective GALNT12 does not transfer GalNAc to mucins</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1641">
 <bp:evidence rdf:resource="#Evidence2122" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective POMGNT1 does not transfer GlcNAc from UDP-GlcNAc to Man-O-Ser-DAG1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1642">
 <bp:evidence rdf:resource="#Evidence2124" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective POMT2 does not transfer Man from Dol-P-Man to DAG1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1640">
 <bp:evidence rdf:resource="#Evidence2120" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective LFNG does not transfer GlcNAc to Pre-NOTCH</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1645">
 <bp:evidence rdf:resource="#Evidence2130" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective HEXA does not cleave the terminal GalNAc from DS</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1646">
 <bp:evidence rdf:resource="#Evidence2131" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective HEXA does not cleave the terminal GalNAc from keratan sulfate</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1643">
 <bp:evidence rdf:resource="#Evidence2127" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective CHSY1 does not transfer GalNAc to chondroitin</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1644">
 <bp:evidence rdf:resource="#Evidence2128" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective CHSY1 does not transfer GlcA to chondroitin</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1649">
 <bp:evidence rdf:resource="#Evidence2135" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective EXT2 (in EXT1:EXT2) does not transfer GlcNAc to heparan</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1647">
 <bp:evidence rdf:resource="#Evidence2132" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective HEXA does not cleave the terminall GalNAc from small HA fragments</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1648">
 <bp:evidence rdf:resource="#Evidence2134" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective EXT2 (in EXT1:EXT2) does not transfer GlcA to heparan</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1660">
 <bp:evidence rdf:resource="#Evidence2153" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective HEXB does not cleave the terminal GalNAc from keratan sulfate</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1652">
 <bp:evidence rdf:resource="#Evidence2139" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective B4GALT7 does not transfer Gal to xylosyl-unit of the tetrasaccharide linker</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1653">
 <bp:evidence rdf:resource="#Evidence2141" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective B3GAT3 does not transfer GlcA to tetrasaccharide linker</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1650">
 <bp:evidence rdf:resource="#Evidence2136" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective EXT2 (in EXT1:EXT2) does not transfer GlcNAc to the heparan chain</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1651">
 <bp:evidence rdf:resource="#Evidence2137" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective EXT2 (in EXT1:EXT2) does not transfer GlcA to heparan</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1656">
 <bp:evidence rdf:resource="#Evidence2147" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective CHST14 does not transfer SO4(2-) to GalNAc in dermatan or DS</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1657">
 <bp:evidence rdf:resource="#Evidence2149" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective B3GALT6 does not transfer Gal to the tetrasaccharide linker</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1654">
 <bp:evidence rdf:resource="#Evidence2143" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective CHST6 does not transfer SO4(2-) to GlcNAc residues on keratan-PG</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1655">
 <bp:evidence rdf:resource="#Evidence2145" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective CHST3 does not transfer SO4(2-) to chondroitin</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1658">
 <bp:evidence rdf:resource="#Evidence2151" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective HEXB does not cleave the terminal GalNAc from DS</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1659">
 <bp:evidence rdf:resource="#Evidence2152" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective HEXB does not cleave the terminal GalNAc from HA fragments</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1670">
 <bp:evidence rdf:resource="#Evidence2168" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective B4GALT1 does not transfer Gal to the N-glycan precursor</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1671">
 <bp:evidence rdf:resource="#Evidence2169" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective B4GALT1 does not transfer Gal to the keratan chain</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1663">
 <bp:evidence rdf:resource="#Evidence2158" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective EXT1 (in EXT1:EXT2) does not transfer GlcA to heparan</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1664">
 <bp:evidence rdf:resource="#Evidence2159" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective EXT1 (in EXT1:EXT2) does not transfer GlcNAc to the terminal GlcA residue</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1661">
 <bp:evidence rdf:resource="#Evidence2155" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective SLC26A2 does not cotransport extracellular SO4(2-), H+ to cytosol</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1662">
 <bp:evidence rdf:resource="#Evidence2157" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective EXT1 (in EXT1:EXT2) does not transfer GlcA to heparan</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1667">
 <bp:evidence rdf:resource="#Evidence2163" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective PAPSS2 does not transfer PO4(2-) group from ATP to APS to form PAPS</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1668">
 <bp:evidence rdf:resource="#Evidence2165" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective ST3GAL3 does not transfer SA to keratan</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1665">
 <bp:evidence rdf:resource="#Evidence2160" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective EXT1 (in EXT1:EXT2) does not transfer GlcNAc to the heparan chain</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1666">
 <bp:evidence rdf:resource="#Evidence2162" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective PAPSS2 does not transfer SO4(2-) group to ATP to form APS</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1669">
 <bp:evidence rdf:resource="#Evidence2167" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective B4GALT1 does not transfer Gal to a branch of keratan</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1681">
 <bp:evidence rdf:resource="#Evidence2189" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective GNE does not hydrolyse UDP-GlcNAc</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1682">
 <bp:evidence rdf:resource="#Evidence2191" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective GALK1 does not phosphorylate Gal</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1680">
 <bp:evidence rdf:resource="#Evidence2188" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective GNE does not phosphorylate ManNAc to ManNAc-6-P</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1674">
 <bp:evidence rdf:resource="#Evidence2176" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective DPM1 does not transfer mannose to DOLP to form DOLPman</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1675">
 <bp:evidence rdf:resource="#Evidence2178" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective DOLK does not phosphorylate DCHOL</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1672">
 <bp:evidence rdf:resource="#Evidence2172" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective PMM2 does not isomerise Man6P to Man1P</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1673">
 <bp:evidence rdf:resource="#Evidence2174" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective DPM2 does not transfer mannose to DOLP to form DOLPman</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1678">
 <bp:evidence rdf:resource="#Evidence2184" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective DHDDS does not elongate E,E-FPP</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1679">
 <bp:evidence rdf:resource="#Evidence2186" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective GALT does not transfer UMP to Gal1P</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1676">
 <bp:evidence rdf:resource="#Evidence2180" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective SRD5A3 does not reduce pPNOL to DCHOL</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1677">
 <bp:evidence rdf:resource="#Evidence2182" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective MPI does not  isomerize Fru6P to Man6P</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1692">
 <bp:evidence rdf:resource="#Evidence2210" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective CYP2R1 does not 25-hydroxylate vitamin D</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1693">
 <bp:evidence rdf:resource="#Evidence2212" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective CYP11A1 does not cleave 20a,22b-DHCHOL</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1690">
 <bp:evidence rdf:resource="#Evidence2206" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective CYP19A1 does not convert ANDST to E1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1691">
 <bp:evidence rdf:resource="#Evidence2208" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective MAT1A does not transfer Ado from ATP to L-Met</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1685">
 <bp:evidence rdf:resource="#Evidence2197" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective PGM1 does not isomerise G6P to G1P</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1686">
 <bp:evidence rdf:resource="#Evidence2199" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective GFPT1 does not transfer an amino group from L-Gln to F6P to form GlcN6P</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1683">
 <bp:evidence rdf:resource="#Evidence2193" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective GALE does not epimerise UDP-Gal to UDP-Glc</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1684">
 <bp:evidence rdf:resource="#Evidence2195" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective DPM3 does not transfer mannose to DOLP to form DOLPman</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1689">
 <bp:evidence rdf:resource="#Evidence2204" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective CYP17A1 does not 17-hydroxylate PREG</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1687">
 <bp:evidence rdf:resource="#Evidence2202" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective CYP17A1 does not cleave 17aHPROG</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1688">
 <bp:evidence rdf:resource="#Evidence2203" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective CYP17A1 does not 17-hydroxylate P4</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1696">
 <bp:evidence rdf:resource="#Evidence2218" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective CYP7B1 does not 7-hydroxylate 25OH-CHOL</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1697">
 <bp:evidence rdf:resource="#Evidence2220" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective MAOA does not oxidatively deaminate 5HT</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1694">
 <bp:evidence rdf:resource="#Evidence2214" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective GGT1 does not hydrolyse glutamate from AFXBO-SG, AFNBO-SG</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1695">
 <bp:evidence rdf:resource="#Evidence2216" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective TBXAS1 does not isomerise PGH2 to TXA2</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1698">
 <bp:evidence rdf:resource="#Evidence2222" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective CYP26B1 does not 4-hydroxylate atRA</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1699">
 <bp:evidence rdf:resource="#Evidence2224" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective CYP27B1 does not hydroxylate CDL</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence1469">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1470">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1471">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1472">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1473">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1474">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1475">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1476">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1477">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1478">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1479">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1458">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1459">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1460">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1461">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1462">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1463">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1464">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1465">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1466">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1467">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1468">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1490">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1491">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1492">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1493">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1494">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1495">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1496">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1497">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1498">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1499">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1480">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1481">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1482">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1483">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1484">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1485">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1486">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1487">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1488">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1489">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction556">
 <bp:evidence rdf:resource="#Evidence703" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">nsp12 binds nsp7 and nsp8</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence1546">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction557">
 <bp:evidence rdf:resource="#Evidence704" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">nsp3 binds to nsp7-8 and nsp12-16</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence1547">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction554">
 <bp:evidence rdf:resource="#Evidence701" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Nsp3:nsp4 binds to nsp6</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence1548">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction555">
 <bp:evidence rdf:resource="#Evidence702" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">nsp15 forms a hexamer</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence1549">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction552">
 <bp:evidence rdf:resource="#Evidence698" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">mRNA1 is translated to pp1a</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction553">
 <bp:evidence rdf:resource="#Evidence700" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">nsp7 binds nsp8</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction550">
 <bp:evidence rdf:resource="#Evidence695" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Protein E forms a homopentamer</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction551">
 <bp:evidence rdf:resource="#Evidence696" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">E pentamer is transported to the Golgi</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction558">
 <bp:evidence rdf:resource="#Evidence705" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">nsp16 binds nsp10</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction559">
 <bp:evidence rdf:resource="#Evidence706" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">nsp14 binds nsp10</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep1758">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1389" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1759">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1368" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1754">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1387" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1755">
 <bp:stepProcess rdf:resource="#Pathway331" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1756">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1388" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1757">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1366" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1750">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1383" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence1550">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep1751">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1384" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence1551">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep1752">
 <bp:stepProcess rdf:resource="#Catalysis411" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1385" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence1552">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep1753">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1386" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence1553">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1554">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1555">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1556">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction545">
 <bp:evidence rdf:resource="#Evidence689" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">mRNA9 is translated to Nucleoprotein</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence1535">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction546">
 <bp:evidence rdf:resource="#Evidence690" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">mRNA3 is translated to protein 3a</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence1536">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction543">
 <bp:evidence rdf:resource="#Evidence687" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Spike trimer glycoside chains are extended</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence1537">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction544">
 <bp:evidence rdf:resource="#Evidence688" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">mRNA5 is translated to protein M</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence1538">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction541">
 <bp:evidence rdf:resource="#Evidence685" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ER-alpha glucosidases bind ER-alpha glucosidase inhibitors</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence1539">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction542">
 <bp:evidence rdf:resource="#Evidence686" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Spike protein forms a homotrimer</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction540">
 <bp:evidence rdf:resource="#Evidence684" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Spike protein gets palmitoylated</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction549">
 <bp:evidence rdf:resource="#Evidence694" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">E protein gets N-glycosylated</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction547">
 <bp:evidence rdf:resource="#Evidence692" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Ubiquination of protein E</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction548">
 <bp:evidence rdf:resource="#Evidence693" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">E protein gets palmitoylated</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep1769">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1377" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1765">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1372" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1766">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1373" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1767">
 <bp:stepProcess rdf:resource="#Catalysis412" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1393" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1768">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1394" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1761">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1369" />
 <bp:stepProcess rdf:resource="#Catalysis407" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1762">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1391" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence1540">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep1763">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1371" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence1541">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep1764">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1392" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence1542">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1543">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1544">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1545">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep1760">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1390" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction578">
 <bp:evidence rdf:resource="#Evidence726" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">3CLp cleaves pp1a</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence1568">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction579">
 <bp:evidence rdf:resource="#Evidence727" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">nsp3-4 is glycosylated</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence1569">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction576">
 <bp:evidence rdf:resource="#Evidence724" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">3CLp cleaves nsp6-11</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction577">
 <bp:evidence rdf:resource="#Evidence725" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">nsp1-4 cleaves itself</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction574">
 <bp:evidence rdf:resource="#Evidence722" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">nsp9 forms a homodimer</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction575">
 <bp:evidence rdf:resource="#Evidence723" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">3CLp cleaves pp1ab</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction572">
 <bp:evidence rdf:resource="#Evidence720" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">pp1a forms a dimer</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction573">
 <bp:evidence rdf:resource="#Evidence721" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">pp1a cleaves itself</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep1729">
 <bp:stepProcess rdf:resource="#Catalysis405" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1365" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1736">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1372" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1737">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1373" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1738">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1374" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1739">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1375" />
 <bp:stepProcess rdf:resource="#Catalysis408" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1732">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1368" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1733">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1369" />
 <bp:stepProcess rdf:resource="#Catalysis407" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1734">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1370" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence1570">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep1735">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1371" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction570">
 <bp:evidence rdf:resource="#Evidence718" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">3CLp forms a homodimer</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence1571">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction571">
 <bp:evidence rdf:resource="#Evidence719" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">3CLp dimer binds &#945;-Ketoamides</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence1572">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1573">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep1730">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1366" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence1574">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep1731">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1367" />
 <bp:stepProcess rdf:resource="#Catalysis406" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence1575">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1576">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1577">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1578">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction567">
 <bp:evidence rdf:resource="#Evidence715" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">nsp3-4 cleaves itself</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence1557">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction568">
 <bp:evidence rdf:resource="#Evidence716" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">nsp3 cleaves nsp1-4</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence1558">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction565">
 <bp:evidence rdf:resource="#Evidence712" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">8b binds MAP1LC3B</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence1559">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction566">
 <bp:evidence rdf:resource="#Evidence714" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">nsp4 is glycosylated</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction563">
 <bp:evidence rdf:resource="#Evidence710" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Nsp3, nsp4, and nsp6 produce replicative organelles</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction564">
 <bp:evidence rdf:resource="#Evidence711" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Enhanced autophagosome formation</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction561">
 <bp:evidence rdf:resource="#Evidence708" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">nsp13 binds nsp12</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction562">
 <bp:evidence rdf:resource="#Evidence709" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">nsp14 binds nsp12</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction569">
 <bp:evidence rdf:resource="#Evidence717" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">nsp3 is glycosylated</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep1747">
 <bp:stepProcess rdf:resource="#Pathway330" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1748">
 <bp:stepProcess rdf:resource="#Catalysis410" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1381" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1749">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1382" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1743">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1378" />
 <bp:stepProcess rdf:resource="#Catalysis409" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1744">
 <bp:stepProcess rdf:resource="#Pathway329" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1745">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1379" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1746">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1380" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence1560">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction560">
 <bp:evidence rdf:resource="#Evidence707" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">nsp15 binds nsp8</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence1561">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep1740">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1376" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence1562">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep1741">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1377" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence1563">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep1742">
 <bp:stepProcess rdf:resource="#Pathway328" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence1564">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1565">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1566">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1567">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction512">
 <bp:evidence rdf:resource="#Evidence651" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SUMO-p-N protein dimer binds genomic RNA</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence1502">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction513">
 <bp:evidence rdf:resource="#Evidence652" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Viral release</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence1503">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction510">
 <bp:evidence rdf:resource="#Evidence649" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Encapsidation of SARS coronavirus genomic RNA</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence1504">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction511">
 <bp:evidence rdf:resource="#Evidence650" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SARS virus buds into ERGIC lumen</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence1505">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1506">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1507">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1508">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1509">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction518">
 <bp:evidence rdf:resource="#Evidence659" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">mRNA4 is translated to protein E</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction519">
 <bp:evidence rdf:resource="#Evidence660" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">mRNA2 is translated to Spike</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction516">
 <bp:evidence rdf:resource="#Evidence657" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Protein M localizes to the Golgi membrane</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep1707">
 <bp:stepProcess rdf:resource="#Pathway319" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction517">
 <bp:evidence rdf:resource="#Evidence658" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">M protein gets N-glycosylated</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep1708">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1352" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction514">
 <bp:evidence rdf:resource="#Evidence653" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Recruitment of Spike trimer to assembling virion</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep1709">
 <bp:stepProcess rdf:resource="#Pathway320" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction515">
 <bp:evidence rdf:resource="#Evidence656" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Glycosylated M localizes to the Golgi membrane</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep1714">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1355" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1715">
 <bp:stepProcess rdf:resource="#Pathway323" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1716">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1356" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1717">
 <bp:stepProcess rdf:resource="#Pathway324" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1710">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1353" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1711">
 <bp:stepProcess rdf:resource="#Pathway321" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1712">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1354" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1713">
 <bp:stepProcess rdf:resource="#Pathway322" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence1510">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1511">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1512">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction501">
 <bp:evidence rdf:resource="#Evidence639" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SARS-CoV-1 gRNA complement (minus strand):RTC binds RTC inhibitors</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction502">
 <bp:evidence rdf:resource="#Evidence640" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ZCRB1 binds 5&apos;UTR of SARS-CoV-1 genomic RNA</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction500">
 <bp:evidence rdf:resource="#Evidence638" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">nsp15 binds RB1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction509">
 <bp:evidence rdf:resource="#Evidence648" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">M protein oligomerization</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction507">
 <bp:evidence rdf:resource="#Evidence646" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Accessory proteins are recruited to the maturing virion</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction508">
 <bp:evidence rdf:resource="#Evidence647" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">E and N are recruited to the M lattice</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction505">
 <bp:evidence rdf:resource="#Evidence643" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">nsp14 acts as a cap N7 methyltransferase to modify SARS-CoV-1 gRNA complement (minus strand)</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep1718">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1357" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction506">
 <bp:evidence rdf:resource="#Evidence644" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">nsp8 generates RNA primers</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep1719">
 <bp:stepProcess rdf:resource="#Pathway325" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction503">
 <bp:evidence rdf:resource="#Evidence641" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">RTC synthesizes SARS-CoV-1 plus strand genomic RNA</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction504">
 <bp:evidence rdf:resource="#Evidence642" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">nsp14 acts as a cap N7 methyltransferase to modify SARS-CoV-1 gRNA (plus strand)</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep1725">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1361" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1726">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1362" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1727">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1363" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1728">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1364" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1721">
 <bp:stepProcess rdf:resource="#Pathway326" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1722">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1359" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1723">
 <bp:stepProcess rdf:resource="#Pathway327" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1724">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1360" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1720">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1358" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence1500">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1501">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction534">
 <bp:evidence rdf:resource="#Evidence677" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Unphosphorylated nucleoprotein translocates to the plasma membrane</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence1524">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction535">
 <bp:evidence rdf:resource="#Evidence678" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Dimerisation of nucleoprotein</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence1525">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction532">
 <bp:evidence rdf:resource="#Evidence675" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Nucleoprotein is SUMOylated</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence1526">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction533">
 <bp:evidence rdf:resource="#Evidence676" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">GSK3 phosphorylates Nucleoprotein</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence1527">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction530">
 <bp:evidence rdf:resource="#Evidence673" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Nucleoprotein translocates to the ERGIC outer membrane</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence1528">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction531">
 <bp:evidence rdf:resource="#Evidence674" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Nucleoprotein translocates to the nucleolus</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence1529">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction538">
 <bp:evidence rdf:resource="#Evidence682" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Spike protein gets N-glycosylated</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction539">
 <bp:evidence rdf:resource="#Evidence683" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Spike trimer translocates to ERGIC</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction536">
 <bp:evidence rdf:resource="#Evidence680" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Trimmed spike protein binds to calnexin</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction537">
 <bp:evidence rdf:resource="#Evidence681" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">N-glycan trimming of Spike</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence1530">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1531">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1532">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1533">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1534">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction523">
 <bp:evidence rdf:resource="#Evidence665" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">GalNAc is transferred onto 3a</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence1513">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction524">
 <bp:evidence rdf:resource="#Evidence666" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">3a translocates to the ERGIC</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence1514">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction521">
 <bp:evidence rdf:resource="#Evidence663" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">O-glycosylation of 3a is terminated</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence1515">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction522">
 <bp:evidence rdf:resource="#Evidence664" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">3a is externalized together with membrane structures</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence1516">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1517">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction520">
 <bp:evidence rdf:resource="#Evidence662" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Endocytosis of protein 3a</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence1518">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1519">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction529">
 <bp:evidence rdf:resource="#Evidence672" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Nucleoprotein translocates to the plasma membrane</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction527">
 <bp:evidence rdf:resource="#Evidence670" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">GSK3B binds GSKi</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction528">
 <bp:evidence rdf:resource="#Evidence671" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Nucleoprotein is ADP-ribosylated</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction525">
 <bp:evidence rdf:resource="#Evidence667" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Protein 3a forms a homotetramer</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction526">
 <bp:evidence rdf:resource="#Evidence668" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">3a localizes to the cell membrane</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep1703">
 <bp:stepProcess rdf:resource="#Pathway317" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1704">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1350" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1705">
 <bp:stepProcess rdf:resource="#Pathway318" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1706">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1351" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1700">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1348" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1701">
 <bp:stepProcess rdf:resource="#Pathway316" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1702">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1349" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence1520">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1521">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1522">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1523">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction598">
 <bp:evidence rdf:resource="#Evidence750" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SARS-CoV-1 7a binds BST2</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction599">
 <bp:evidence rdf:resource="#Evidence751" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SARS-CoV-1 E transports Ca2+ </bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction596">
 <bp:evidence rdf:resource="#Evidence748" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SARS-CoV-1 M protein interacts with TRAF3</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction597">
 <bp:evidence rdf:resource="#Evidence749" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">6:KPNA2 binds KPNB1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction594">
 <bp:evidence rdf:resource="#Evidence746" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">nsp15 cleaves viral poly(U)-RNA</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction595">
 <bp:evidence rdf:resource="#Evidence747" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SARS-CoV-1 nsp3 deubiquinates K63-linked pUb-STING</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep1798">
 <bp:stepProcess rdf:resource="#Pathway347" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1799">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1408" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction592">
 <bp:evidence rdf:resource="#Evidence743" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SARS-CoV-1 nsp1 binds to 40S ribosomal subunit</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep1794">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1406" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction593">
 <bp:evidence rdf:resource="#Evidence745" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SARS-CoV-1 3b binds to RUNX1</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep1795">
 <bp:stepProcess rdf:resource="#Pathway345" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction590">
 <bp:evidence rdf:resource="#Evidence740" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SARS-CoV-1 SUMO1-K62-p-S177-N dimer binds to HNRNPA1</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep1796">
 <bp:stepProcess rdf:resource="#Pathway346" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction591">
 <bp:evidence rdf:resource="#Evidence742" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SARS-CoV-1 SUMO1-K62-p-S177-N dimer binds to EEF1A1</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep1797">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1407" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1790">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1404" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1791">
 <bp:stepProcess rdf:resource="#Pathway343" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1792">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1405" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1793">
 <bp:stepProcess rdf:resource="#Pathway344" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction589">
 <bp:evidence rdf:resource="#Evidence739" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SARS-CoV-1 SUMO-p-N binds to NPM1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction587">
 <bp:evidence rdf:resource="#Evidence737" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SARS-CoV-1 SUMO1-K62-p-S177-N dimer binds to UBE2I</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction588">
 <bp:evidence rdf:resource="#Evidence738" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SARS-CoV-1 SUMO1-K62-p-S177-N dimer binds to PSMC6</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction585">
 <bp:evidence rdf:resource="#Evidence735" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SARS-CoV-1 N binds SMAD3 and EP300 at the SERPINE1 gene promoter</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction586">
 <bp:evidence rdf:resource="#Evidence736" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SARS-CoV-1 SUMO1-K62-p-S177-N dimer binds to SMAD3</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction583">
 <bp:evidence rdf:resource="#Evidence733" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SARS-CoV-1 M binds to PDPK1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction584">
 <bp:evidence rdf:resource="#Evidence734" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SARS-CoV-1 SUMO1-K62-p-S177-N dimer binds to 14-3-3 proteins</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction581">
 <bp:evidence rdf:resource="#Evidence729" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">nsp8 binds MAP1LC3B</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction582">
 <bp:evidence rdf:resource="#Evidence732" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SARS-CoV-1 3a tetramer binds to CAV1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction580">
 <bp:evidence rdf:resource="#Evidence728" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">mRNA1 is translated to pp1ab</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep1776">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1398" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1601">
 <bp:evidence rdf:resource="#Evidence2044" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">IVD mutants don&apos;t synthesize beta-methylcrotonyl-CoA</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep1777">
 <bp:stepProcess rdf:resource="#Pathway335" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1602">
 <bp:evidence rdf:resource="#Evidence2048" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective PNP does not convert (deoxy)inosine to hypoxanthine and (deoxy)ribose</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep1778">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1399" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1779">
 <bp:stepProcess rdf:resource="#Pathway336" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1600">
 <bp:evidence rdf:resource="#Evidence2042" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">AUH mutants don&apos;t synthesize 3-hydroxy-methylglutaryl-CoA</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep1772">
 <bp:stepProcess rdf:resource="#Catalysis413" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction1397" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1605">
 <bp:evidence rdf:resource="#Evidence2054" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective ADA does not deaminate (deoxy)adenosine</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep1773">
 <bp:stepProcess rdf:resource="#Pathway332" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1606">
 <bp:evidence rdf:resource="#Evidence2056" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective APRT does not convert adenine to AMP</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep1774">
 <bp:stepProcess rdf:resource="#Pathway333" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1603">
 <bp:evidence rdf:resource="#Evidence2049" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective PNP does not convert (deoxy)guanosine to guanine and (deoxy)ribose</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep1775">
 <bp:stepProcess rdf:resource="#Pathway334" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1604">
 <bp:evidence rdf:resource="#Evidence2052" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective HPRT1 does not convert guanine or hypoxanthine to GMP or IMP</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1609">
 <bp:evidence rdf:resource="#Evidence2062" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">2-oxoglutarate + NADPH + H+ =&gt; (R)-2-hydroxyglutarate + NADP+ [mutant IDH1]</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep1770">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1395" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1607">
 <bp:evidence rdf:resource="#Evidence2058" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective PAH does not hydroxylate L-Phe to L-Tyr</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep1771">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1396" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1608">
 <bp:evidence rdf:resource="#Evidence2060" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective ACTH does not bind MCR2</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep1787">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1403" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1612">
 <bp:evidence rdf:resource="#Evidence2068" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective MPDU1 does not promote transfer of Man to N-glycan precursor (GlcNAc)2 (Man)7 (PP-Dol)1 by ALG12</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep1788">
 <bp:stepProcess rdf:resource="#Pathway341" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1613">
 <bp:evidence rdf:resource="#Evidence2069" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective MPDU1 does not promote transfer of Man to (GlcNAc)2 (Man)5 (PP-Dol)1 by ALG3</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep1789">
 <bp:stepProcess rdf:resource="#Pathway342" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1610">
 <bp:evidence rdf:resource="#Evidence2066" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective MPDU1 does not promote transfer of Man to (GlcNAc)2 (Man)8 (PP-Dol)1 by ALG9</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1611">
 <bp:evidence rdf:resource="#Evidence2067" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective MPDU1 does not promote transfer of Man to (GlcNAc)2 (Man)6 (PP-Dol)1 by ALG9</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep1783">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1401" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1616">
 <bp:evidence rdf:resource="#Evidence2075" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective MAN1B1 does not hydrolyse 1,2-linked mannose (c branch)</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep1784">
 <bp:stepProcess rdf:resource="#Pathway339" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1617">
 <bp:evidence rdf:resource="#Evidence2076" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective MAN1B1 does not hydrolyse 1,2-linked mannose (a branch)</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep1785">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1402" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1614">
 <bp:evidence rdf:resource="#Evidence2071" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective ALG11 does not transfer Man to the N-glycan precursor</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep1786">
 <bp:stepProcess rdf:resource="#Pathway340" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1615">
 <bp:evidence rdf:resource="#Evidence2073" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective ALG14 does not transfer GlcNAc from UDP-GlcNAc to GlcNAcDOLP</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep1780">
 <bp:stepProcess rdf:resource="#BiochemicalReaction1400" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep1781">
 <bp:stepProcess rdf:resource="#Pathway337" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1618">
 <bp:evidence rdf:resource="#Evidence2077" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective MAN1B1 does not hydrolyse 1,2-linked mannose (b branch)</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep1782">
 <bp:stepProcess rdf:resource="#Pathway338" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1619">
 <bp:evidence rdf:resource="#Evidence2078" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective MAN1B1 does not hydrolyse a second 1,2-linked mannose (a branch)</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway613">
 <bp:pathwayOrder rdf:resource="#PathwayStep2478" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1818" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2430" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective Mismatch Repair Associated With PMS2</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">PMS2 heterodimerizes with MLH1 to form the MutL alpha complex involved in DNA mismatch repair. Mutations in this PMS2 are associated with hereditary nonpolyposis colorectal cancer, Turcot syndrome, and are a cause of supratentorial primitive neuroectodermal tumors. Heterozygous truncating mutations in PMS2 play a role in a small subset of hereditary nonpolyposis colorectal carcinoma (Lynch syndrome, HNPCC-like) families. PMS2 mutations lead to microsatellite instability with carriers showing a microsatellite instability high phenotype and loss of PMS2 protein expression in all tumors.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway612">
 <bp:pathwayOrder rdf:resource="#PathwayStep2476" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1817" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2428" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective Mismatch Repair Associated With MLH1</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The MLH1:PMS2 complex is homologous to the E. coli MutL gene and is involved in DNA mismatch repair. Heterozygous mutations in the MLH1 gene result in hereditary nonpolyposis colorectal cancer-2 (Papadopoulos et al., 1994).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway615">
 <bp:pathwayOrder rdf:resource="#PathwayStep2482" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1820" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2434" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective Mismatch Repair Associated With MSH3</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MSH3 forms a heterodimer with MSH2 to form the MSH3:MSH2 complex, part of the post-replicative DNA mismatch repair system. This complex initiates mismatch repair by binding to a mismatch and then forming a complex with MutL alpha heterodimer. This gene contains a polymorphic 9 bp tandem repeat sequence in the first exon. Defects in this gene are a cause of susceptibility to endometrial cancer.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway614">
 <bp:pathwayOrder rdf:resource="#PathwayStep2480" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1819" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2432" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective Mismatch Repair Associated With MSH6</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MSH6 encodes a G/T mismatch-binding protein encoded by a gene localized to within 1 megabase of the related hMSH2 gene on chromosome 2. Unlike other mismatch repair genes, the  MSH6 deficient cells showed alterations primarily in mononucleotide tracts, indicating the role MSH6 plays in maintaining the integrity of the human genome. Cells deficient in MSH6, accrue mutations in tracts of repeated nucleotides. MSH6 defects seem to be less common than MLH1 and MSH2 defects. They have been mostly observed in atypical HNPCC families and are characterized by a weaker family history of tumor development, higher age at disease onset, and low degrees of microsatellite instability (MSI) that predominantly involving mononucleotide runs.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway617">
 <bp:pathwayOrder rdf:resource="#PathwayStep2492" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2487" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2498" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2494" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2496" />
 <bp:pathwayComponent rdf:resource="#Pathway624" />
 <bp:pathwayComponent rdf:resource="#Pathway623" />
 <bp:pathwayComponent rdf:resource="#Pathway618" />
 <bp:pathwayComponent rdf:resource="#Pathway622" />
 <bp:pathwayComponent rdf:resource="#Pathway621" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2439" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Diseases of DNA Double-Strand Break Repair</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Diseases of DNA double-strand break repair (DSBR) are caused by mutations in genes involved in repair of double strand breaks (DSBs), one of the most cytotoxic types of DNA damage. Unrepaired DSBs can lead to cell death, cellular senescence, or malignant transformation.  Germline mutations in DSBR genes are responsible for several developmental disorders associated with increased predisposition to cancer: Ataxia telangiectasia, characterized by cerebellar neurodegeneration, hematologic malignancies and immunodeficiency, is usually caused by germline mutations in the ATM gene; Nijmegen breakage syndrome 1, characterized by microcephaly, short stature and recurrent infections, is caused by germline mutations in the NBN (NBS1) gene; Seckel syndrome, characterized by short stature, skeletal deformities and microcephaly, is caused by germline mutations in the ATR or RBBP8 (CtIP) genes.  Heterozygous germline mutations in BRCA1, BRCA2 or PALB2 cause the hereditary breast and ovarian cancer syndrome (HBOC), while homozygous germline mutations in BRCA2 and PALB2 cause Fanconi anemia, a developmental disorder characterized by short stature, microcephaly, skeletal defects, bone marrow failure, and predisposition to cancer.  Somatic mutations in DSBR genes are also frequently found in sporadic cancers.  The pathways &quot;Defective DNA double strand break response due to BRCA1 loss of function&quot; describes defects in DSB response caused by loss-of-function mutations in BRCA1 which prevent the formation of the BRCA1:BARD1 complex.  The pathway &quot;Defective DNA double strand break response due to BARD1 loss of function&quot; describes defects in DSB response caused by loss-of-function mutations in BARD1, the heterodimerization partner of BRCA1, which prevent the formation of the BRCA1:BARD1 complex.  The pathway &quot;Defective homologous recombination repair (HRR) due to BRCA1 loss of function&quot; describes defects in HRR caused by loss-of-function mutations in BRCA1 that impair its association with PALB2.  The pathway &quot;Defective homologous recombination repair (HRR) due to BRCA2 loss of function&quot; describes defects in HRR caused by loss-of-function mutations in BRCA2 that impair either it association with SEM1 (DSS1), its translocation to the nucleus, its binding to RAD51, or its binding to PALB2.  The pathway &quot;Defective homologous recombination repair (HRR) due to PALB2 loss of function&quot; describes defects in HRR caused by loss-of-function mutations in PALB2 that impair its association with BRCA2/RAD51/RAD51C.  For review, please refer to McKinnon and Caldecott 2007, Keijzers et al. 2017, and Jachimowicz et al. 2019. </bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway616">
 <bp:pathwayOrder rdf:resource="#PathwayStep2484" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2485" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1821" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1822" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2436" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective Mismatch Repair Associated With MSH2</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MSH2 is homologous to the E. coli MutS gene and is involved in DNA mismatch repair (MMR) (Fishel et al., 1994). Heterozygous mutations in the MSH2 gene result in hereditary nonpolyposis colorectal cancer-1. Variants of MSH2 are associated with hereditary nonpolyposis colorectal cancer. Alteration of MSH2 is also involved in Muir-Torre syndrome and mismatch repair cancer syndrome.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway619">
 <bp:pathwayOrder rdf:resource="#PathwayStep2489" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1823" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2441" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA1 binding function</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Mutations in the N-terminal coiled-coil domain of PALB2 (amino acids 9-44), involved in self-interaction and BRCA1 binding, impair the interaction of PALB2 with BRCA1 (Sy et al. 2009, Foo et al. 2017, Boonen et al. 2020). Phosphorylation of PALB2 by ATR on serine residue S59 promotes BRCA1-PALB2 interaction and the localization of PALB2 to DNA damage sites (Buisson et al. 2017). Mutations in the coiled-coil domain can also affect PALB2 self-interaction, recruitment to double-strand break sites, homologous recombination repair, and RAD51 foci formation (Buisson and Masson 2012).  PALB2 missense mutants that do not bind to BRCA1 can still be recruited to DNA double-strand break repair (DSBR) sites, probably through interaction with other proteins involved in DSBR, but they are unable to restore efficient gene conversion in PALB2-deficient cells and they render cells hypersensitive to the DNA damaging agent mitomycin C (Sy et al. 2009). Some variants in this region are also sensitive to PARP inhibitors (Foo et al. 2017).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway618">
 <bp:pathwayOrder rdf:resource="#PathwayStep2490" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2488" />
 <bp:pathwayComponent rdf:resource="#Pathway619" />
 <bp:pathwayComponent rdf:resource="#Pathway620" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2440" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective homologous recombination repair (HRR) due to PALB2 loss of function</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Biallelic loss-of-function mutations in  PALB2  results in Fanconi anemia subtype N (FA-N), which is phenotypically very similar to Fanconi anemia subtype D1, caused by biallelic loss-of-function of  BRCA2  (Reid et al. 2007). FA-D1 and FA-N are characterized by developmental abnormalities, bone marrow failure and childhood cancer susceptibility, especially childhood solid tumors, such as Wilms tumor and medulloblastoma. Monoallelic  PALB2  loss-of-function is an underlying cause of hereditary breast cancer in particular, but inactivating  PALB2  mutations are also to a lesser extent found in some other cancer types, including pancreatic cancer (Erkko et al. 2007, Erkko et al. 2008, Antoniou et al. 2014, Yang et al. 2020). Germline  PALB2  mutations are somewhat less frequent than those occurring in  BRCA1  and  BRCA2 , but cause a comparably high risk of developing breast cancer. Therefore,  PALB2  is a high-risk breast cancer predisposing gene (Nepomuceno et al. 2021).  PALB2 interacts with both BRCA1 and BRCA2, and serves as a bridge that connects BRCA2 with BRCA1 at sites of DNA double-strand break repair (DSBR). PALB2 also interacts directly with DNA and takes part in the regulation of RAD51-mediated homologous recombination (Buisson et al. 2010; Dray et al. 2010). PALB2 loss-of-function mutations can affect its interaction with BRCA1 when they affect the N-terminal coiled-coil domain that is necessary for BRCA1 binding (Sy et al. 2009, Foo et al. 2017). Mutations in the coiled-coil domain can also affect PALB2 self-interaction, recruitment to double-strand break sites, homologous recombination repair and RAD51 foci formation (Buisson and Masson 2012). PALB2 missense mutants that do not bind to BRCA1 can still be recruited to DSBR sites, probably through interaction with other proteins involved in DSBR, but they are unable to restore efficient gene conversion in PALB2-deficient cells and they render cells hypersensitive to the DNA damaging agent mitomycin C (Sy et al. 2009), with some variants also presenting sensitivity to PARP inhibitors (Foo et al. 2017).  Mutations evaluated so far in the central region of PALB2, which contains the ChAM motif and the MRG15-binding region, have shown no functional impact on the protein.  Mutations affecting the C-terminal WD40 domain of PALB2 impair its ability to interact with BRCA2, RAD51 and/or RAD51C (Erkko et al. 2007, Park et al. 2014, Simhadri et al. 2019). In addition, disruption of the WD40 domain can lead to the exposure of a nuclear export signal (NES), leading to cytoplasmic translocation of PALB2 (Pauty et al. 2017). Mutations affecting the C-terminal domain of PALB2 are more frequent than mutations that affect the N-terminus and have been observed, as germline mutations, in familial breast cancer and in Fanconi anemia, but somatic mutations also occur in sporadic cancers. Cells that express PALB2 mutants defective in BRCA2, RAD51 and/or RAD51C binding show reduced ability to perform DSBR via homologous recombination repair, form fewer RAD51 foci at DSBR sites, and are sensitive to DNA crosslinking agents such as mitomycin C (Erkko et al. 2007, Parker et al. 2014).  For review, please refer to Tischkowitz and Xia 2010, Pauty et al. 2014, Park et al. 2014, Nepomuceno et al. 2017, Ducy et al. 2019, Wu et al. 2020, Nepomuceno et al. 2021.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence2080">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2081">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2082">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2083">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1502">
 <bp:evidence rdf:resource="#Evidence1882" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated FGFR3 point and translocation mutants phosphorylate PLCG1</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence2084">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1503">
 <bp:evidence rdf:resource="#Evidence1883" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated FGFR3 point, translocation and fusion mutant-associated PI3K phosphorylates PIP2 to PIP3</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence2085">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1500">
 <bp:evidence rdf:resource="#Evidence1880" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated FGFR3 point and translocation mutants bind PLCG1</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence2086">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1501">
 <bp:evidence rdf:resource="#Evidence1881" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated FGFR3 point, translocation and fusion mutants:p-FRS2:GRB2:SOS1 activates RAS nucleotide exchange</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence2087">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1506">
 <bp:evidence rdf:resource="#Evidence1887" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated FGFR1 mutants and fusions bind PLCG1</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence2088">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1507">
 <bp:evidence rdf:resource="#Evidence1888" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated FGFR1 mutants:p-FRS2:GRB2:GAB1:PIK3R1 binds PIK3CA</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence2089">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1504">
 <bp:evidence rdf:resource="#Evidence1885" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated FGFR1 mutants:p-FRS2 binds GRB2:GAB1:PIK3R1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1505">
 <bp:evidence rdf:resource="#Evidence1886" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated FGFR1 mutant-associated PI3K phosphorylates PIP2 to PIP3</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1508">
 <bp:evidence rdf:resource="#Evidence1889" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated FGFR1 mutants:p-FRS2:GRB2:SOS1 activates RAS nucleotide exchange</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway611">
 <bp:pathwayOrder rdf:resource="#PathwayStep2481" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2477" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2479" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2483" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2475" />
 <bp:pathwayComponent rdf:resource="#Pathway613" />
 <bp:pathwayComponent rdf:resource="#Pathway612" />
 <bp:pathwayComponent rdf:resource="#Pathway615" />
 <bp:pathwayComponent rdf:resource="#Pathway614" />
 <bp:pathwayComponent rdf:resource="#Pathway616" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2427" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Diseases of Mismatch Repair (MMR)</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defects in mammalian DNA mismatch repair (MMR) genes (MLH1, PMS2, MSH2, and MSH6) are characterized by microsatellite instability and reduced fidelity during replication and repair steps. The MMR proteins interact with each other to execute steps within the mismatch repair pathway. Defective variants of these proteins are associated with nonpolyposis colorectal cancer. The MutS proteins are thought to directly contact double-stranded DNA, scanning along the genomic DNA for mismatches analogous to a &quot;sliding clamp&quot; until they encounter a base pair containing a mismatch. The MutS proteins interact with multiple proteins including other MLH and MutL, the later have significant amino acid identify and structural similarity to the MLH proteins, as well as RPA, EXO1, RFC, possibly HMGB1, and other less well-characterized proteins.  With respect to the mutator function, the MSH2/MutSaplha heterodimer is thought primarily to repair single-base substitutions and 1 bp insertiondeletion mutations, while MSH2/MutSbeta is thought primarily to repair 1-4 bp insertiondeletion mutations. The MLH and MutL heterodimer proteins interact with heterodimers of MutS proteins to help catalyze different functions. MLH1:MutLalpha is the primary complex that interacts with both MutS alpha and beta complex in mechanisms thought to be relevant to cancer prevention. Recent studies suggest that MLH1:MLH3 may also contributes to some of these processes as well, but in all mechanisms tested to a lesser degree than MLH1:PMS2.  Heterozygous mutations in the MLH1 gene result in hereditary nonpolyposis colorectal cancer-2 (Papadopoulos et al., 1994).  Variants of the MSH2 gene are associated with hereditary nonpolyposis colorectal cancer. Alteration of MSH2 is also involved in Muir-Torre syndrome and mismatch repair cancer syndrome (Fishel et al. 1993).  Defects in the MSH3 gene are a cause of susceptibility to endometrial cancer (Risinger et al. 1996).  Defects in the MSH6 gene are less common than MLH1 and MSH2 defects. They have been mostly observed in atypical HNPCC families and are characterized by a weaker family history of tumor development, higher age at disease onset, and low degrees of microsatellite instability (MSI) (Lucci-Cordisco et al. 2001).  Mutations in the PMS2 gene are associated with hereditary nonpolyposis colorectal cancer, Turcot syndrome, and are a cause of supratentorial primitive neuroectodermal tumors. Heterozygous truncating mutations in PMS2 play a role in a small subset of hereditary nonpolyposis colorectal carcinoma (Lynch syndrome, HNPCC-like) families. PMS2 mutations lead to microsatellite instability with carriers showing a microsatellite instability high phenotype and loss of PMS2 protein expression in all tumors (Hamilton et al. 1995, Hendriks et al. 2006).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1509">
 <bp:evidence rdf:resource="#Evidence1890" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated FGFR1 mutants phosphorylate FRS2</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway610">
 <bp:pathwayOrder rdf:resource="#PathwayStep2473" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1816" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2425" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective Base Excision Repair Associated with NEIL3</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NEIL3 is a DNA N-glycosylase involved in base excision repair (BER), the primary repair pathway for oxidative DNA damage. NEIL3 can detect and remove oxidized guanine, in the form of 5-guanidinohydatoin and spiroiminodihydantoin, and oxidized thymine, in the form of thymine glycol. NEIL3 has a preference for single strand DNA (ssDNA) and is implicated in repair of oxidative DNA damage at telomeres (Zhou et al. 2013). A NEIL3 disease variant NEIL3 D132 is unable to cleave 5 guanidinohydantoin (Gh) from oxidatively damaged DNA. Individuals harboring a NEIL3 D132V homozygous mutation are predisposed to development of autoimmune diseases (Massaad et al. 2016) and NEIL3 depletion is also associated with an increase in telomere damage and loss (Zhou et al. 2017). NEIL3 unhooks DNA interstrand cross-links (ICLs) during DNA replication. NEIL3 resolves psoralen- and abasic site-induced ICLs in a Fanconi anemia (FA) pathway-independent manner (Semlow et al. 2016, Martin et al. 2017). A polymorphism in one of the NEIL3 gene splice sites may increase the risk of myocardial infarction (Skarpengland et al. 2015). NEIL3 expression in the heart increases after heart failure in humans and after myocardial infarction in mouse disease models. Neil3 knockout mice show increased mortality after myocardial infarction, but there is no increase in the amount of DNA damage in Neil3 knockout hearts. In the heart, NEIL3 may function in the epigenetic regulation of gene expression and facilitate transcriptional response to myocardial infarction (Olsen et al. 2017). NEIL3 mRNA expression is increased in human carotid plaques and Neil3 deficiency accelerates plaque formation in Apoe knockout mice, but it appears that this is not correlated with oxidative DNA damage (Skarpengland et al. 2016). The function of NEIL3 in removal of hydantoins from single strand DNA may be important for removal of replication blocks in proliferating cells. Mouse embryonic fibroblasts and neuronal stem cell derived from Neil3 knockout mouse embryos show decreased proliferation capacity and increased sensitivity to DNA damaging agents (Rolseth et al. 2013). NEIL3 may be required for maintenance of adult neurogenesis, as Neil3 knockout mice exhibit learning and memory deficits and synaptic irregularities in the hippocampus (Regnell et al. 2012). In addition, NEIL3 deficient neuronal stem cells exhibits signs of premature senescence (Reis and Hermanson 2012) and Neil3 knockout mice show reduced ability to augment neurogenesis to repair damage induced hypoxia ischemia (Sejersted et al. 2011). Mice that are triple knockout for Neil1, Neil2 and Neil3 do not show a predisposition to tumour formation or changes in telomere length (Rolseth et al. 2017). </bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway624">
 <bp:pathwayOrder rdf:resource="#PathwayStep2503" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2505" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2499" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2501" />
 <bp:pathwayComponent rdf:resource="#Pathway626" />
 <bp:pathwayComponent rdf:resource="#Pathway625" />
 <bp:pathwayComponent rdf:resource="#Pathway628" />
 <bp:pathwayComponent rdf:resource="#Pathway627" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2451" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective homologous recombination repair (HRR) due to BRCA2 loss of function</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">BRCA2 (FANCD1) is a tumor suppressor gene located on chromosomal arm 13q. BRCA2 protein is a mediator of the core mechanism of homologous recombination repair (HRR), essential for the recruitment of RAD51 recombinase to resected DNA double-strand breaks (DSBs). Monoallelic pathogenic germline mutations in BRCA2 are one of the underlying causes of the hereditary breast and ovarian cancer (HBOC) syndrome, with carriers having close to 50% lifetime risk for development of breast cancer and about 15% lifetime risk for development of ovarian cancer. In addition, BRCA2 germline mutation carriers are predisposed to cancers of the fallopian tube, pancreas, stomach, larynx and prostate. Biallelic germline mutations in BRCA2 cause Fanconi anemia subtype characterized by brain and soft tissue tumors, including medulloblastoma and Wilms tumor. BRCA2-deficient cells are defective in the formation of RAD51 foci upon treatment with DSB-inducing DNA damaging agents and accumulate chromatid breaks and radial chromosomes.  Besides its crucial role in HRR, BRCA2 is also implicated in protection of replication forks, centrosome duplication, spindle assembly checkpoint and cytokinesis. Recently published studies show the involvement of BRCA2 in the turnover of R-loops (hybrids between RNA and single strand DNA that are generated as intermediates of gene transcription). Unscheduled accumulated R-loops may be processed into DSBs, leading to genomic instability. Finally, BRCA2 is involved in pathway choice of DSB repair by inhibiting DNA polymerase theta-mediated end-joining (TMEJ) until M-phase (reviewed in Petropoulos and Halazonetis 2021, and Llorens-Agost et al. 2021). TMEJ is the predominant pathway for microhomology-mediated end joining MMEJ/alternative-nonhomologous end joining (alt-NHEJ, a-EJ) in mammals (reviewed in Ramsden et al. 2022).  BRCA2 haploinsufficiency is frequently observed in cancers, with close to 50% of BRCA2-mutant breast cancers retaining one wild type allele, suggesting that in some tissues at least heterozygous loss of BRCA2 function is sufficient for carcinogenesis. Promoter hypermethylation is not an obvious contributor to BRCA2 gene inactivation and no pathogenic mutations in the promoter region have been identified so far.  For review, please refer to Roy et al. 2011, Nalepa and Clapp 2018, Santana dos Santos et al. 2018, Venkitaraman 2019, Le et al. 2021, and Llorens-Agost et al. 2021. </bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway623">
 <bp:pathwayOrder rdf:resource="#PathwayStep2497" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1827" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2449" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective DNA double strand break response due to BRCA1 loss of function</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Germline mutations in the BRCA1 or BRCA2 tumor suppressor genes are implicated in up to 10% of breast cancers overall and 40% of familial breast cancers. Carriers of either BRCA1 or BRCA2 germline mutation are predisposed to hereditary breast and ovarian cancer (the HBOC syndrome), which is inherited in an autosomal dominant manner. Besides early onset breast and ovarian cancer, HBOC patients also have a modestly increased risk of developing other tumor types, including pancreatic, stomach, laryngeal, fallopian tube, and prostate cancer. The BRCA1 gene encodes a large protein of 1863 amino acids, which contains a RING finger domain at the N-terminus and two BRCT repeats at the C-terminus. The RING domain is responsible for heterodimerization with BARD1, which increases stability of BRCA1 and activates its E3 ubiquitin ligase activity. BRCA1 plays an important role in homology-directed repair of DNA double-strand breaks (DSBs). Brca1-null knockout mice die early during embryonic development and cells depleted of BRCA1 show genomic instability (reviewed by Roy et al. 2011). Cancer mutations that affect the RING domain of BRCA1 frequently result in the inability of BRCA1 to bind to BARD1 and participate in DNA DSB response (Wu et al. 1996, Ransburgh et al. 2010). Some mutations in the RING domain of BRCA1 were shown to affect the ubiquitin ligase activity of BRCA1 (Brzovic et al. 2001), but it is uncertain if the ubiquitin ligase activity is essential for the tumor suppressor role of BRCA1 (Shakya et al. 2011).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway626">
 <bp:pathwayOrder rdf:resource="#PathwayStep2502" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1829" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2454" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Impaired BRCA2 binding to SEM1 (DSS1)</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">This pathway describes BRCA2 cancer mutations that affect the ability of BRCA2 to bind to SEM1 (DSS1), a small protein of 70 amino acids that regulates BRCA2 stability and its nuclear localization (reviewed in Le et al. 2021).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway625">
 <bp:pathwayOrder rdf:resource="#PathwayStep2500" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1828" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2452" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Impaired BRCA2 translocation to the nucleus</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">This pathway describes truncating mutations in BRCA2 that result in mutant proteins lacking nuclear localization signals (NLSs) in the C-terminal domain. These truncated BRCA2 proteins mainly localize to the cytosol, impairing the ability of BRCA2 mutants to participate in homologous recombination repair (HRR) in the nucleus. Truncating mutations are the most frequent BRCA2 mutations detected in cancer (Spain et al. 1999, Yano et al. 2000, Ma et al. 2017). </bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway628">
 <bp:pathwayOrder rdf:resource="#PathwayStep2506" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1831" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2458" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Impaired BRCA2 binding to RAD51</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">A critical function of BRCA2 is to bind RAD51 and nucleate RAD51 filament formation on single-stranded DNA. BRCA2 has two regions that interact with RAD51: 8 BRC repeats encoded by exon11 (Bork et al. 1996, Wong et al. 1997) and a C-terminal RAD51 binding domain called TR2 (Sharan et al. 1997). </bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway627">
 <bp:pathwayOrder rdf:resource="#PathwayStep2504" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1830" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2456" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Impaired BRCA2 binding to PALB2</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">This pathway describes BRCA2 missense mutations that affect the N-terminus of BRCA2 and impair the ability of BRCA2 to bind PALB2, which is a crucial step in homologous recombination repair (HRR) of DNA double-strand breaks (DSBs) (Xia et al. 2006).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway629">
 <bp:pathwayOrder rdf:resource="#PathwayStep2508" />
 <bp:pathwayComponent rdf:resource="#Pathway630" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2460" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Disorders of Developmental Biology</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Developmental disorders affect formation of body organs and organ systems. The causes of defects in human development are diverse and incompletely understood, and include environmental insults such as nutrient deficiency, exposure to toxins and infections (Gilbert 2000, National Research Council (US) Committee on Developmental Toxicology 2000, Taylor and Rogers 2005, Zilbauer et al. 2016, Izvolskaia et al. 2018), as well as genetic causes such as aneuploidy and other chromosomal abnormalities, and germline mutations in genes that regulate normal development. It is estimated that about 40% of human developmental disabilities can be attributed to genetic aberrations (Sun et al. 2015), of which at least 25% are due to mutations affecting single genes (Chong et al. 2015), and this latter group of Mendelian developmental disorders is the focus of curation in Reactome.  Disorders of nervous system development affect the function of the central nervous system (CNS) and impair motor skills, cognition, communication and/or behavior (reviewed by Ismail and Shapiro 2019). So far,we have annotated the role of loss-of-function mutations in methyl-CpG-binding protein 2 (MECP2), an epigenetic regulator of transcription, in Rett syndrome, a pervasive developmental disorder (Pickett and London 2005, Ferreri 2014).  Disorders of myogenesis are rare hereditary muscle diseases that in the case of congenital myopathies are defined by architectural abnormalities in the muscle fibres (Pelin and Wallgren-Pettersson 2019, Phadke 2019, Radke et al. 2019, Claeys 2020) and in the case of muscular dystrophies by increased muscle breakdown that progresses with age (Pasrija and Tadi 2020). Mutations in cadherin family genes are present in some types of muscular dystrophy (Puppo et al. 2015).  Disorders of pancreas development result in pancreatic agenesis, where a critical mass of pancreatic tissue is congenitally absent. For example, the PDX1 gene is a master regulator of beta cell differentiation and homozygous deletions or inactivating mutations in PDX1 gene cause whole pancreas agenesis. PDX1 gene haploinsufficiency impairs glucose tolerance and leads to development of diabetes mellitus (Hui and Perfetti 2002, Babu et al. 2007, Chen et al. 2008).  Left-right asymmetry disorders are caused by mutations in genes that regulate the characteristic asymmetry of internal organs in vertebrates. Normally, cardiac apex, stomach and spleen are positioned towards the left side, while the liver and gallbladder are on the right. Loss-of-function mutations in the CFC1 gene, whose protein product functions as a co-factor in Nodal signaling, result in heterotaxic phenotype in affected patients, manifested by randomized organ positioning (Bamford et al. 2000).  Congenital lipodystrophies are characterized by a lack of adipose tissue, which predisposes affected patient to development of insulin resistance and related metabolic disorders. The severity of metabolic complications is correlates with the extent of adipose tissue loss. Loss-of-function mutations in the PPARG gene, encoding a key transcriptional regulator of adipocyte development and function, are a well-established cause of familial partial lipodystrophy type 3 (FPLD3) (Broekema et al. 2019).  Congenital stem cell disorders are caused by mutations in genes that regulate the balance between stem cells maintenance and commitment to differentiated lineages. Loss-of-function mutations in the SOX2 gene, which encodes a transcription factor involved in the maintenance of totipotency during embryonic preimplantation period, pluripotency of embryonic stem cells, and multipotency of neural stem cells, are the cause of anophthalmia (the absence of an eye) and microphthalmia (the presence of a small eye within the orbit (Verma and Fitzpatrick 2007, Sarlak and Vincent 2016).  HOX-related structural birth defects are caused by loss-of-function mutations in HOX family genes.HOX transcription factors play a fundamental role in body patterning during embryonic development, and HOX mutation are an underlying cause of many congenital limb malformations (Goodman 2002).  Congenital keratinization disorders are caused by dominant negative mutation in keratin genes and depending on where the affected keratin gene is expressed, they affect epithelial tissues such as skin, cornea, hair and/or nails (McLean and Moore 2011).  Disorders of immune system development are caused by mutations in genes that regulate differentiation of blood cell lineages involved in immune defense, leading to immune system defects. For example, mutations in the gene encoding CSF3R, a receptor for the granulocyte-colony stimulating factor, result in congenital neutropenia, characterized by a maturation arrest of granulopoiesis at the level of promyelocytes. Patients with severe congenital neutropenia are prone to recurrent, often life-threatening infections from an early age and may be predisposed to myelodysplastic syndromes or acute myeloid leukemia (Germeshausen et al. 2008; Skokowa et al. 2017).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1510">
 <bp:evidence rdf:resource="#Evidence1893" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Plasma membrane FGFR1 fusions dimerize</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence2070">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2071">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2072">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1513">
 <bp:evidence rdf:resource="#Evidence1897" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Autocatalytic phosphorylation of FGFR1 mutants with enhanced kinase activity</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence2073">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1514">
 <bp:evidence rdf:resource="#Evidence1898" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FGFR1c P252X mutants bind ligand with enhanced affinity</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence2074">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1511">
 <bp:evidence rdf:resource="#Evidence1894" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Plasma membrane FGFR1 fusions autophosphorylate</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence2075">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1512">
 <bp:evidence rdf:resource="#Evidence1896" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Dimerization of FGFR1 point mutants with enhanced kinase activity</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence2076">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1517">
 <bp:evidence rdf:resource="#Evidence1902" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Ligand-independent phosphorylation of overexpressed FGFR1</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence2077">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1518">
 <bp:evidence rdf:resource="#Evidence1903" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Tyrosine kinase inhibitors bind and inhibit overexpressed FGFR1 dimers</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence2078">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1515">
 <bp:evidence rdf:resource="#Evidence1899" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Autocatalytic phosphorylation of FGFR1c P252X mutant dimers</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence2079">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1516">
 <bp:evidence rdf:resource="#Evidence1901" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Ligand-independent dimerization of overexpressed FGFR1b</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway620">
 <bp:pathwayOrder rdf:resource="#PathwayStep2491" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1824" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2443" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA2/RAD51/RAD51C binding function</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Mutations affecting the C-terminal WD40 domain of PALB2 (amino acids 853-1186) impair its ability to interact with BRCA2, RAD51 and/or RAD51C (Erkko et al. 2007, Park et al. 2014). In addition, disruption of the WD40 domain can lead to the exposure of the nuclear export signal (NES) and cytoplasmic translocation of PALB2 (Pauty et al. 2017). Mutations affecting the C-terminal domain of PALB2 are more frequent than mutations that affect the N-terminus and have been observed, as germline mutations, in familial breast cancer and in Fanconi anemia, but somatic mutations also occur in sporadic cancers. Cells that express PALB2 mutants defective in BRCA2, RAD51 and/or RAD51C binding show reduced ability to perform DSBR via homologous recombination repair, form fewer RAD51 foci at DSBR sites, and are sensitive to DNA crosslinking agents such as mitomycin C (Erkko et al. 2007, Park et al. 2014).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1519">
 <bp:evidence rdf:resource="#Evidence1904" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Ligand-independent phosphorylation of overexpressed FGFR1c</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway622">
 <bp:pathwayOrder rdf:resource="#PathwayStep2495" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1826" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2447" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective homologous recombination repair (HRR) due to BRCA1 loss of function</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">In addition to its role in DNA double-strand break (DSB) signaling, BRCA1 plays an important role in homologous recombination repair (HRR) of DSBs by directly promoting recruitment of PALB2 and indirectly BRCA2 to DSB repair sites. In addition, BRCA1 increases the speed and processivity of DNA end resection which consists of 5&#8242;&#8211;3&#8242; nucleolytic degradation of DSBs (Cruz-Garcia et al. 2014). The direct BRCA1 interaction with PALB2 helps to fine-tune the localization of BRCA2 and RAD51 at DSBs (Zhang et al. 2009, Sy et al. 2009). PALB2 simultaneously interacts with RAD51, BRCA2 and RAD51AP1 (Modesti et al. 2007, Wiese et al. 2007, Buisson et al. 2010, Dray et al. 2010). PALB2 and RAD51AP1 synergistically stimulate RAD51 recombinase activity, thus enhancing RAD51-mediated strand exchange (branch migration) and promoting the formation of D-loop structures (synaptic complex assembly). A D-loop structure is formed when complementary duplex DNA (sister chromatid arm) is progressively invaded by the RAD51 nucleoprotein filament, with base pairing of the invading ssDNA and the complementary sister chromatid DNA strand (Sung et al. 2003).  The N-terminal region of BRCA1 contains the RING domain (residues 7-98), required for the heterodimerization of BRCA1 with BARD1. BRCA1:BARD1 heterodimer has E3 ubiquitin ligase activity which is important for DNA repair (Drost et al. 2011). Several missense mutations within the RING domain have been linked to increased risks of developing breast/ovarian cancers (Bouwman et al. 2013; Starita et al. 2018). BRCA1 mutant proteins impaired in BARD1 binding are annotated in the pathway &quot;Defective DNA double strand break response due to BRCA1 loss of function&quot;.  The C-terminal region of BRCA1 which contains two coiled coil domains (residues 1397-1424) and two BRCT domains (residues 1642-1736 for BRCT 1; residues 1756-1855 for BRCT 2) is involved in PALB2 binding, with the second coiled coil domain being essential (Sy et al. 2009). Several cancer-associated BRCA1 missense mutants that affect the C-terminal region were shown to have reduced ability to bind PALB2 (Sy et al. 2009). In addition, many nonsense and frameshift mutations in BRCA1 reported in cancer result in truncated proteins that lack the PALB2-binding domain.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway621">
 <bp:pathwayOrder rdf:resource="#PathwayStep2493" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1825" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2445" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective DNA double strand break response due to BARD1 loss of function</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Although germline mutations of BARD1 are implicated in some cases of hereditary breast and ovarian cancer (HBOC), they occur less frequently that those of the BRCA1 or BRCA2 genes (De Brakeleer et al. 2010, Alenezi et al. 2020). From animal studies, it is known that the loss of BARD1 function results in a phenotype very similar to that caused by loss of BRCA1 function, characterized by embryonic lethality (McCarthy et al. 2003), genomic instability (McCarthy et al. 2003) and defects in homology-directed repair (Lee et al. 2015). A small number of clinically-relevant BARD1 missense mutants that have been functionally characterized and shown to be impaired in BRCA1 binding (Xia et al. 2003, Lee et al. 2015) are annotated in this pathway.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1520">
 <bp:evidence rdf:resource="#Evidence1905" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Ligand-independent dimerization of overexpressed FGFR1c</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1521">
 <bp:evidence rdf:resource="#Evidence1907" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">BCR-FGFR1-associated PI3K phosphorylates PIP2 to PIP3</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1524">
 <bp:evidence rdf:resource="#Evidence1910" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Cytosolic FGFR1 fusion proteins bind PIK3R1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1525">
 <bp:evidence rdf:resource="#Evidence1911" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">BCR-FGFR1:GRB2:p-GAB2 binds PIK3R1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1522">
 <bp:evidence rdf:resource="#Evidence1908" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FGFR1OP-FGFR1 phosphorylates STAT1 and STAT3</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1523">
 <bp:evidence rdf:resource="#Evidence1909" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">p-BCR-p-FGFR1 phosphorylates GAB2</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1528">
 <bp:evidence rdf:resource="#Evidence1914" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Cytosolic FGFR1 fusion protein-associated PI3K phosphorylates PIP2 to PIP3</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1529">
 <bp:evidence rdf:resource="#Evidence1915" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">p-BCR-pFGFR1 binds GRB2:GAB2</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1526">
 <bp:evidence rdf:resource="#Evidence1912" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Phosphorylation of STAT5 by cytosolic FGFR1 fusions</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1527">
 <bp:evidence rdf:resource="#Evidence1913" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated cytosolic FGFR1 fusions bind PIK3CA</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway602">
 <bp:pathwayOrder rdf:resource="#PathwayStep2454" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2455" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2456" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2457" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2453" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1804" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1807" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1808" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1805" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1806" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2405" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective Base Excision Repair Associated with NEIL1</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NEIL1 is an enzyme with dual DNA glycosylase and beta/delta lyase activity involved in base excision repair pathway (BER), the primary repair pathway for oxidative DNA damage. NEIL1 can detect and remove DNA damage resulting from oxidation of adenine, guanine and thymine, in the form of 4,6-diamino-5-formamidopyrimidine (FapyA), 2,6-diamino-4-hydroxy-5-formamidopyrimidine (FapyG), and thymine glycol (Tg), respectively. NEIL1 can also detect and remove dihydrouracil (DHU), which results from deamination of cytosine. Several low frequency NEIL1 polymorphisms, present in about 1% of general population in the United States have been reported. Different polymorphisms have different effects on NEIL1 function, and it was suggested that NEIL1 polymorphisms and NEIL1 deficiency or haploinsuficiency may be involved in predisposition to cancer and in metabolic syndrome (Roy et al. 2007, Vartanian et al. 2006, Sampath et al. 2011, Prakash et al. 2014). One polymorphism, NEIL1 G83D, is associated with primary sclerosing cholangitis and cholangiocarcinoma (Forsbring et al. 2009). NEIL1 G83D variant exhibits impaired DNA glycosylase activity towards different damaged DNA bases (Roy et al. 2007, Prakash et al. 2014) and induces genomic instability (Galick et al. 2017). NEIL1 E28del, an in frame deletion variant of NEIL1 reported in gastric (stomach) cancer, where glutamate at position 28 is deleted, does not cleave Tg from damaged DNA (Shinmura et al. 2004). NEIL1 Q282TER, a NEIL1 variant which lacks the putative nuclear localization signal (NLS), localizes to the cytosol and is therefore not able to access damaged DNA substrates, but its involvement in cancer is uncertain (Shinmura et al. 2015). Reduced expression of NEIL1 and NEIL2 genes, accompanied with increased NEIL3 gene expression was detected in various cancers. NEIL1 gene silencing by promoter hypermethylation may be one of the underlying mechanisms for reduced NEIL1 expression in cancer (Shinmura et al. 2016). Infection with the Hepatitis C virus (HCV) leads to decreased NEIL1 expression in liver cells, through an unknown mechanism (Pal et al. 2010). Mice that are double knockout for Neil1 and Nthl1 genes accumulate DNA damage in the form of FapyA and FapyG and are more prone to development of lung adenocarcinoma than single Neil1 or Nthl1 gene knockouts (Chan et al. 2009). Another study reported that Neil1 knockout mice did not show a predisposition to tumour formation, and neither did double knockouts of Neil1 and Neil2, nor triple knockouts of Neil1, Neil2 and Neil3. Neil1 knockout mice are obese, consistent with the metabolic syndrome, but double knockouts of Neil1 and Neil2 do not display obesity (Rolseth et al. 2017). </bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway601">
 <bp:pathwayOrder rdf:resource="#PathwayStep2448" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2449" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2450" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2451" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1800" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1803" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1801" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1802" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2400" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective NTHL1 substrate binding</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Several different mutations that result in truncation of NTHL1 protein have been described and associated with cancer. NTHL1 Q90TER (NTHL1 Gln90*) truncation mutant results from a nonsense mutation that replaces codon for glutamine 90 with a STOP codon. NTHL1 Q90TER has not been studied at the protein level, but is predicted to lack the DNA binding domain and the glycosylase domain, thus resulting in a complete loss of the base excision repair (BER) related DNA glycosylase function. Homozygous or compound heterozygous germline NTHL1 Q90TER mutation result in a cancer syndrome (NTHL1 associated tumor syndrome) that involves adenomatous polyposis, colorectal cancer breast cancer and multiple other types of cancer and benign tumors (Weren et al. 2015, Rivera et al. 2015, Grolleman et al. 2019). Apart from NTHL1 Q90TER, at least seven other truncating variants have been identified in patients with NTHL1 associated tumor syndrome, such as NTHL1 A79fs (NTHL1 Ala79fs), NTHL1 Y130TER (NTHL1 Tyr130*), NTHL1 W182TER (NTHL1 Trp182*), NTHL1 c.709+1G&gt;A, NTHL1 I245fs (NTHL1 Ile245fs), NTHL1 W269TER (NTHL1 Trp269*), NTHL1 Q287TER (NTHL1 Gln287*) (Rivera et al. 2015, Broderick et al. 2017, Grolleman et al. 2019).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway604">
 <bp:pathwayOrder rdf:resource="#PathwayStep2460" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1809" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2412" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective MUTYH substrate binding</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">For a subset of MUTYH disease variants underlying MUTYH-associated polyposis (MAP), also known as familial adenomatous polyposis 2 (FAP2), it was shown that, in addition to impaired catalytic activity, they also exhibit reduced binding to their substrate, adenine mispaired with 8-oxoguanine (OGUA:Ade, also known as 8-oxoG:A). MUTYH alpha-3 isoform (MUTYH-3) mutants with demonstrated deficient binding to OGUA:Ade include missense variants MUTYH-3 Y165C, MUTYH-3 R227W, MUTYH-3 R231L, MUTYH-3 R231H, MUTYH-3 V232F, MUTYH-3 R260Q, MUTYH-3 P281L and MUTYH-3 G382D, nonsense variants MUTYH-3 Y90*, MUTYH-3 Q377*, MUTYH-3 E466*, and frameshift variant MUTYH-3 A368fs26* (commonly known as MUTYH 1103delC) (Chmiel et al. 2003, Parker et al. 2005, Ali et al. 2008, Molatore et al. 2010, D&apos;Agostino et al. 2010).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway603">
 <bp:pathwayOrder rdf:resource="#PathwayStep2459" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2461" />
 <bp:pathwayComponent rdf:resource="#Pathway604" />
 <bp:pathwayComponent rdf:resource="#Pathway605" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2411" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective Base Excision Repair Associated with MUTYH</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MUTYH gene is located on chromosome 1 and encodes a DNA glycosylase involved in base excision repair (BER). MUTYH (MYH) functions as an adenine DNA glycosylase and removes adenines and 2-hydroxyadenines on the newly synthesized DNA strand mispaired with guanines or 8-oxoguanines. 8-oxogunanines are produced by oxidation of guanines in DNA or by incorporation of 8-oxodGTP from the nucleotide pool into the newly synthesized DNA strand. Germline mutations in MUTYH cause the MUTYH-associated polyposis (MAP), a syndrome that resembles the familial adenomatous polyposis (FAP) syndrome, caused by mutations in the APC tumor suppressor gene. MAP is also known as the familial adenomatous polyposis 2 (FAP2) (OMIM:608456). MAP-affected individuals are predisposed to development of multiple colorectal adenomas and colorectal cancer. MAP is largely inherited in an autosomally recessive manner, with both MUTYH alleles affected. The predisposition of heterozygous MUTYH mutation carriers to MAP has not been completely ruled out (Fleischmann et al. 2004).  MUTYH is most frequently affected by missense mutations in MAP patients, with two major mutations, Y165C and G382D, reported in about 80% of MAP patients of European origin. In Japanese patients, the most frequently reported mutation was Q324H (Yanaru-Fujisawa et al. 2008). Residues Y165C and G382D in the abundant MUTYH isoform MUTYH alpha-3 (MUTYH-3), used in the majority of functional studies, correspond to Y176C and G393D, respectively, in the canonical UniProt isoform (MUTYH alpha-1) and to Y179C and G396, respectively, in the longest NCBI isoform, which is used as a reference isoform in the database InSiGHT (International Society for Gastrointestinal Hereditary Tumours Database). However, both the canonical UniProt and NCBI MUTYH isoforms are expressed at very low levels or not at all (Plotz et al. 2012). In addition to the isoform MUTYH alpha-3, the other two abundant MUTYH isoforms are MUTYH beta-3 and MUTYH gamma-3 (Plotz et al. 2012), which differ from MUTYH alpha-3 in the first exon used. Exons 1-alpha and 1-beta contain sequences that resemble a mitochondrial targeting signal (MTS). It was reported that MUTYH alpha-3 and MUTYH beta-3 predominantly localize to mitochondria, while MUTYH gamma-3 predominantly localizes to the nucleus (Takao et al. 1999). However, a nuclear localization signal is located at the C-terminus of all MUTYH isoforms and other studies suggested that all isoforms can localize to the nucleus and only a small fraction of MUTYH is targeted to the mitochondria (Ohtsubo et al. 2000, Ichinoe et al. 2004). A small number of functional studies of MUTYH mutants uses the MUTYH isoform gama-3 (Goto et al. 2010, Shinmura et al. 2012). Nuclear localization of MUTYH may be affected by a splicing site variant (Tao et al. 2004).  MAP, compared with APC-associated FAP, is characterized by a later age of onset and a smaller number and size of polyps. Germline MUTYH mutations are associated with an increased incidence of duodenal polyps, gastric cancer, melanoma, breast cancer, dental and dermoid cysts, and osteomas. MUTYH mutations are rarely reported in the sporadic colorectal cancer. Tumors that develop in MAP patients are characterized with an excess of G:C -&gt; T:A transversions in tumor suppressor genes, such as APC, and oncogenes, such as KRAS, which is a consequence of MUTYH functional impairment.  A single nucleotide polymorphism (SNP) at the splice donor site was reported to affect translation efficiency of MUTYH transcript, but its relevance for cancer predisposition has not been clarified (Yamaguchi et al. 2002). Catalytic activity of MUTYH and its mutants may be affected by posttranslational modifications (Parker et al. 2003, Kundu et al. 2010). Some MUTYH mutations reported in colorectal cancer do not affect MUTYH catalytic activity but disrupt the interaction of MUTYH with other proteins involved in DNA repair (Tominaga et al. 2004, Turco et al. 2013).  For review, please refer to Chow et al. 2004, Nielsen et al. 2011, Venesio et al. 2012, Mazzei et al. 2013.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway606">
 <bp:pathwayOrder rdf:resource="#PathwayStep2466" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2468" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2464" />
 <bp:pathwayComponent rdf:resource="#Pathway608" />
 <bp:pathwayComponent rdf:resource="#Pathway607" />
 <bp:pathwayComponent rdf:resource="#Pathway609" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2416" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective Base Excision Repair Associated with OGG1</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">OGG1 is the main DNA glycosylase responsible for removal of 8-oxoguanine (8oxoG), the most frequent type of oxidative DNA damage, from DNA and initiation of the base excision repair (Klungland et al. 1999, Minowa et al. 2000). A frequent OGG1 polymorphism increases the risk of breast and lung cancer in affected individuals, and inactivating mutations in OGG1 have been reported in various cancer types and in Alzheimer&apos;s disease. Ogg1 knockout mice are predisposed to cancer. For review, please refer to Boiteux et al. 2017. </bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway605">
 <bp:pathwayOrder rdf:resource="#PathwayStep2462" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1810" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2414" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective MUTYH substrate processing</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MUTYH disease variants underlying the MUTYH-associated polyposis (MAP), also known as familial adenomatous polyposis 2 (FAP2), show impaired catalytic activity with respect to cleaving adenine mispaired with 8-oxoguanine (OGUA:Ade, also known as 8-oxoG:A). For some of the mutants, defective substrate processing is further aggravated by reduced substrate binding. MUTYH alpha-3 isoform (MUTYH-3) mutants and MUTYH gamma-3 isoform (MUTYH-6) mutants with experimentally demonstrated deficiency in catalytic activity include missense mutants MUTYH-3 Y165C (MUTYH-6 Y151C), MUTYH-3 R171W, MUTYH-3 R227W, MUTYH-3 R231H, MUTYH-3 R231L, MUTYH-3 V232F,  MUTYH-3 R260Q, MUTYH-3 G272E, MUTYH-3 P281L, MUTYH-3 P391L (MUTYH-6 P377L), MUTYH-3 Q324H, MUTYH-3 Q324R,, MUTYH-3 A359V, MUTYH-3 G382D (MUTYH-6 G368D), MUTYH-3 A459D, MUTYH-6 R154H, MUTYH-6 I195V, MUTYH-6 M255V and MUTYH-3 L360P, in-frame indel mutants MUTYH-3 W138_M139insIW (also known as MUTYH 137insIW) and MUTYH-3 E466del (MUTYH-6 E452del), nonsense mutants MUTYH-3 Y90*, MUTYH-3 Q377*, and MUTYH-3 E466*, and frameshift mutant MUTYH-3 A368fs26* (commonly known as MUTYH 1103delC) (Jones et al. 2002, Chmiel et al. 2003, Wooden et al. 2004, Parker et al. 2005, Bai et al. 2005, Alhopuro et al. 2005, Bai et al. 2007, Ali et al. 2008, Yanaru-Fujisawa et al. 2008, Kundu et al. 2009, Forsbring et al. 2009, Molatore et al. 2010, D&apos;Agostino et al. 2010, Goto et al. 2010, Raetz et al. 2012, Shinmura et al. 2012).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway608">
 <bp:pathwayOrder rdf:resource="#PathwayStep2467" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1812" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2419" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective OGG1 Localization</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">OGG1 splicing isoform beta contains a mitochondrial targeting sequence at the N terminus and lacks the C terminal nuclear localization signal. OGG1beta localizes to mitochondria (Nishioka et al. 1999), where it might participate in the repair of mitochondrial DNA, although its role in mitochondrial base excision repair has not been confirmed. OGG1beta G12E mutant, reported in kidney cancer, is unable to translocate to the mitochondrion as the missense mutation disrupts the mitochondrial targeting sequence (Audebert et al. 2002).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway607">
 <bp:pathwayOrder rdf:resource="#PathwayStep2465" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1811" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2417" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective OGG1 Substrate Binding</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">OGG1 missense mutants reported in Alzheimer&apos;s disease, OGG1 A53T and OGG1 A288V, show decreased binding to 8 oxoguanine substrate (Mao et al. 2007).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway609">
 <bp:pathwayOrder rdf:resource="#PathwayStep2470" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2471" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2469" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1814" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1815" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1813" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2421" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective OGG1 Substrate Processing</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The majority of OGG1 mutants have been tested for their ability to excise 8-oxoguanine (8oxoG) from damaged DNA, while a small number of mutants have been tested for the ability to remove FapyG from DNA. The following OGG1 mutants show at least a partial loss of their ability to remove 8oxoG: OGG1 R46Q (Audebert, Chevillard et al. 2000; Audebert, Radicella et al. 2000); OGG1 R154H (Audebert, Radicella et al. 2000, Bruner et al. 2000); OGG1 R131Q (Chevillard et al. 1998, Bruner et al. 2000, Anderson and Dagget 2009); OGG1 R229Q (Hyun et al. 2000, Hyun et al. 2002, Hill and Evans 2007); OGG1 P266fs139* (Mao et al. 2007). OGG1 R46L and OGG1 R131G have not been functionally studied but have been reported in cancer and predicted to be pathogenic. They are annotated as candidate disease variants based on their similarity with OGG1 R46Q and OGG1 R131Q, respectively. OGG1 S326C, a frequent variant in European and Asian populations, is susceptible to oxidation, which diminishes catalytic activity under conditions of oxidative stress (Dherin et al. 1999, Yamane et al. 2004, Kershaw and Hodges 2012, Moritz et al. 2014). The following OGG1 mutants show at least a partial loss of their ability to remove FapyG: OGG1 R46Q (Audebert, Radicella et al. 2000); OGG1 R154H (Audebert, Radicella et al. 2000). OGG1 R46L has not been functionally studied but has been reported in cancer and predicted to be pathogenic. It is annotated as a candidate disease variant for FapyG excision, based on its similarity with OGG1 R46Q.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence2090">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1531">
 <bp:evidence rdf:resource="#Evidence1917" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Phosphorylation of BCR moiety of BCR-FGFR1</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence2091">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1532">
 <bp:evidence rdf:resource="#Evidence1918" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Phosphorylation of cytosolic FGFR1 fusion dimers</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence2092">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2093">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1530">
 <bp:evidence rdf:resource="#Evidence1916" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Dimerization of cytosolic FGFR1 fusion proteins</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence2094">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1535">
 <bp:evidence rdf:resource="#Evidence1921" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated FGFR1 mutants and fusions phosphorylate PLCG1</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence2095">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1536">
 <bp:evidence rdf:resource="#Evidence1922" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated FGFR1 mutants:p-FRS2 binds GRB2-SOS1</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence2096">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1533">
 <bp:evidence rdf:resource="#Evidence1919" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Tyrosine kinase inhibitors bind and inhibit cytosolic FGFR1 fusion dimer phosphorylation</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence2097">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1534">
 <bp:evidence rdf:resource="#Evidence1920" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">BCR-FGFR1 fusion:GRB2:p-GAB2:PIK3R1 binds PIK3CA </bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence2098">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1539">
 <bp:evidence rdf:resource="#Evidence1928" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective CSF2RA does not bind SFTPs</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence2099">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1537">
 <bp:evidence rdf:resource="#Evidence1923" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated FGFR1 mutants bind FRS2</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1538">
 <bp:evidence rdf:resource="#Evidence1924" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">p-4Y- PLCG1 dissociates from activated FGFR1 mutants and fusions</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway600">
 <bp:pathwayOrder rdf:resource="#PathwayStep2445" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2446" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1799" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1798" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2397" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective NTHL1 substrate processing</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NTHL1 D239Y is produced as a consequence of a single nucleotide polymorphism (SNP) rs3087468 in the NTHL1 gene. The frequency of this polymorphism varies in different populations. Substitution of aspartic acid residue at position 239 with tyrosine results in an NTHL1 protein that is still able to bind to damaged DNA but appears to have impaired glycosylase activity. Expression of NTHL1 D239Y in non-transformed human and mouse mammary epithelial cells increases genomic instability and leads to neoplastic transformation, acting as a dominant negative for wild-type NTHL1, through competition for substrate binding (Galick et al. 2013). It is uncertain if heterozygosity for NTHL1 D239Y polymorphism increases predisposition to cancer.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction198">
 <bp:evidence rdf:resource="#Evidence250" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">P protein oligomerizes</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction199">
 <bp:evidence rdf:resource="#Evidence251" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">M2-1 tetramer gets phosphorylated</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1550">
 <bp:evidence rdf:resource="#Evidence1954" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective TALDO1 does not transform Fru(6)P, E4P to SH7P, GA3P</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1542">
 <bp:evidence rdf:resource="#Evidence1934" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective pro-SFTPB does not translocate from ER membrane to multivesicle body</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1543">
 <bp:evidence rdf:resource="#Evidence1936" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective SLC34A2 does not cotransport HPO4(2-), 3Na+ from extracellular region to cytosol</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1540">
 <bp:evidence rdf:resource="#Evidence1930" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective SFTPA2 does not translocate from ER membrane to extracellular region</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1541">
 <bp:evidence rdf:resource="#Evidence1932" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective ABCA3 does not transport PC, PG from ER membrane to lamellar body</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1546">
 <bp:evidence rdf:resource="#Evidence1944" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective MUT does not isomerise L-MM-CoA to SUCC-CoA</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence2040">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1547">
 <bp:evidence rdf:resource="#Evidence1948" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective RPIA does not isomerize R5P to RU5P</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence2041">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1544">
 <bp:evidence rdf:resource="#Evidence1938" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective CSF2RB does not bind SFTPs</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence2042">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1545">
 <bp:evidence rdf:resource="#Evidence1940" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective pro-SFTPC does not translocate from ER membrane to multivesicle body</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence2043">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction196">
 <bp:evidence rdf:resource="#Evidence248" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Protein M2-1 tetramers bind protein P tetramer</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence2044">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction197">
 <bp:evidence rdf:resource="#Evidence249" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">P:PP1 dephosphorylates M2-1</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence2045">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction194">
 <bp:evidence rdf:resource="#Evidence246" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NS1:NS2 (1C:1B) localizes to mitochondria</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1548">
 <bp:evidence rdf:resource="#Evidence1950" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective TALDO1 does not transform SH7P, GA3P to Fru(6)P, E4P</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence2046">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction195">
 <bp:evidence rdf:resource="#Evidence247" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">p-S232-S237-P is further phosphorylated</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1549">
 <bp:evidence rdf:resource="#Evidence1952" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective RPIA does not isomerize RU5P to R5P</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence2047">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction192">
 <bp:evidence rdf:resource="#Evidence244" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">F0 gets N-glycosylated</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence2048">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction193">
 <bp:evidence rdf:resource="#Evidence245" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Nascent SH localizes to Golgi membrane</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence2049">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction190">
 <bp:evidence rdf:resource="#Evidence242" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">G is N-glycosylated</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction191">
 <bp:evidence rdf:resource="#Evidence243" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Nascent M2-1 binds Zn2+</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis8">
 <bp:controlled rdf:resource="#BiochemicalReaction15" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis9">
 <bp:controlled rdf:resource="#BiochemicalReaction16" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis6">
 <bp:controlled rdf:resource="#BiochemicalReaction9" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis7">
 <bp:controlled rdf:resource="#BiochemicalReaction11" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis4">
 <bp:controlled rdf:resource="#BiochemicalReaction7" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction189">
 <bp:evidence rdf:resource="#Evidence241" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">G is palmitoylated</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis5">
 <bp:controlled rdf:resource="#BiochemicalReaction8" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis2">
 <bp:controlled rdf:resource="#BiochemicalReaction2" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction187">
 <bp:evidence rdf:resource="#Evidence239" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Protein P tetramer binds protein L</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis3">
 <bp:controlled rdf:resource="#BiochemicalReaction3" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction188">
 <bp:evidence rdf:resource="#Evidence240" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">CK2 phosphorylates nascent P</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1560">
 <bp:evidence rdf:resource="#Evidence1969" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective IDUA does not hydrolyse the unsulfated alpha-L-iduronosidic link in DS</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1561">
 <bp:evidence rdf:resource="#Evidence1971" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective ARSB does not hydrolyse C4S/C6S chains</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1553">
 <bp:evidence rdf:resource="#Evidence1959" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective LCT does not hydrolyze Lac</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1554">
 <bp:evidence rdf:resource="#Evidence1960" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective SI does not hydrolyze Mal</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1551">
 <bp:evidence rdf:resource="#Evidence1956" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective ALDOB does not cleave Fru 1-P to GA and DHAP</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1552">
 <bp:evidence rdf:resource="#Evidence1958" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective SI does not hydrolyze maltotriose</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1557">
 <bp:evidence rdf:resource="#Evidence1964" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective KHK does not phosphorylate beta-D-fructose</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1558">
 <bp:evidence rdf:resource="#Evidence1967" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective IDUA does not hydrolyse Heparan sulfate chain(1)</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence2030">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1555">
 <bp:evidence rdf:resource="#Evidence1961" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective SI does not hydrolyze iMal</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence2031">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1556">
 <bp:evidence rdf:resource="#Evidence1962" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective SI does not hydrolyze Suc</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence2032">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction185">
 <bp:evidence rdf:resource="#Evidence237" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">G is O-glycosylated</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence2033">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis1">
 <bp:controlled rdf:resource="#BiochemicalReaction1" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction186">
 <bp:evidence rdf:resource="#Evidence238" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Mature G localizes to host cell plasma membrane</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence2034">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction183">
 <bp:evidence rdf:resource="#Evidence235" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Nascent sG localizes to ER lumen, gets glycosylated</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1559">
 <bp:evidence rdf:resource="#Evidence1968" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective IDUA does not hydrolyse Heparan sulfate chain(6)</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence2035">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction184">
 <bp:evidence rdf:resource="#Evidence236" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">F0 is cleaved, releasing F1, F2, F(110-136)</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence2036">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction181">
 <bp:evidence rdf:resource="#Evidence233" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">M dimer localizes to nucleus</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence2037">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction182">
 <bp:evidence rdf:resource="#Evidence234" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">N-/O-glycan-sG is secreted</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence2038">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2039">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction180">
 <bp:evidence rdf:resource="#Evidence232" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SH forms a pentamer</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1571">
 <bp:evidence rdf:resource="#Evidence1985" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective GUSB does not hydrolyse (HA)2</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1572">
 <bp:evidence rdf:resource="#Evidence1987" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective GLB1 does not hydrolyse a glycosaminoglycan</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1570">
 <bp:evidence rdf:resource="#Evidence1984" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective GUSB does not hydrolyse GlcA-&#946;1,3-GlcNAc</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1564">
 <bp:evidence rdf:resource="#Evidence1975" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective NAGLU does not hydrolyse Heparan sulfate chain(4)</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1565">
 <bp:evidence rdf:resource="#Evidence1977" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective HYAL1 does not hydrolyse Chondroitin chains</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1562">
 <bp:evidence rdf:resource="#Evidence1972" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective ARSB does not hydrolyse DS</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence2060">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1563">
 <bp:evidence rdf:resource="#Evidence1974" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective NAGLU does not hydrolyse heparan chain(2)</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence2061">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1568">
 <bp:evidence rdf:resource="#Evidence1981" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective IDS does not hydrolyse dermatan sulfate (Chebi:63517 chain)</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence2062">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1569">
 <bp:evidence rdf:resource="#Evidence1983" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective GUSB does not hydrolyse CS/HS precursor</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence2063">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1566">
 <bp:evidence rdf:resource="#Evidence1978" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective HYAL1 does not hydrolyse (HA)50</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence2064">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1567">
 <bp:evidence rdf:resource="#Evidence1980" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective IDS does not hydrolyse Heparan sulfate chain(5)</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence2065">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2066">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2067">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2068">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2069">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1582">
 <bp:evidence rdf:resource="#Evidence2005" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective GYS2 does not transfer glucose to growing glycogen chains</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1583">
 <bp:evidence rdf:resource="#Evidence2007" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective EPM2A does not dephosphorylate phosphoglycogen (type 2A disease)</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1580">
 <bp:evidence rdf:resource="#Evidence2000" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective DCXR does not reduce L-xylulose to xylitol</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1581">
 <bp:evidence rdf:resource="#Evidence2003" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective GYG1 is not autoglucosyolated</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1575">
 <bp:evidence rdf:resource="#Evidence1992" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective HGSNAT does not acetylate Heparan chain(1)</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1576">
 <bp:evidence rdf:resource="#Evidence1993" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective HGSNAT does not acetylate Heparan sulfate chain(3)</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1573">
 <bp:evidence rdf:resource="#Evidence1988" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective GLB1 does not hydrolyse linker chain(2)</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1574">
 <bp:evidence rdf:resource="#Evidence1990" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective GALNS does not hydrolyse sulfate from Gal6S in keratan sulfate</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence2050">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1579">
 <bp:evidence rdf:resource="#Evidence1998" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective GNS does not hydrolyse 6-sulfate from GlcNAc6S</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence2051">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2052">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1577">
 <bp:evidence rdf:resource="#Evidence1995" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective SGSH does not hydrolyse Heparan sulfate chain(2)</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence2053">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1578">
 <bp:evidence rdf:resource="#Evidence1996" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective SGSH does not hydrolyse Heparan sulfate chain(7)</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence2054">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2055">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2056">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2057">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2058">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2059">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence649">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence648">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1590">
 <bp:evidence rdf:resource="#Evidence2020" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective G6PC does not hydrolyze glucose 6-phosphate</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1593">
 <bp:evidence rdf:resource="#Evidence2028" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">H139Hfs13* PPM1K does not dephosphorylate BCKDH</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1594">
 <bp:evidence rdf:resource="#Evidence2030" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Loss-of-function DLD mutants don&apos;t dehydrogenate dihydrolipoyl DBT</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1591">
 <bp:evidence rdf:resource="#Evidence2023" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ACAT1 mutants don&apos;t synthesize propionyl-CoA or acetyl-CoA</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1592">
 <bp:evidence rdf:resource="#Evidence2026" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">DBT loss-of-function mutants don&apos;t synthesize BCAA-CoA</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1586">
 <bp:evidence rdf:resource="#Evidence2012" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective G6PC3 does not hydrolyze glucose 6-phosphate</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1587">
 <bp:evidence rdf:resource="#Evidence2014" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective GAA does not hydrolyze lysosomal glycogen</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence650">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1584">
 <bp:evidence rdf:resource="#Evidence2008" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective NHLRC1 does not ubiquitinate EPM2A (laforin) and PPP1R3C (PTG) (type 2B disease)</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1585">
 <bp:evidence rdf:resource="#Evidence2010" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective SLC37A4 does not exchange G6P and Pi across the ER membrane</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1588">
 <bp:evidence rdf:resource="#Evidence2016" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective GBE1 does not catalyze branch formation in growing glycogen chains (liver)</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1589">
 <bp:evidence rdf:resource="#Evidence2018" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective GYS1 does not transfer glucose to growing glycogen chains</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence656">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2000">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence655">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2001">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence658">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2002">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence657">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2003">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence652">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2004">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence651">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2005">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence654">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2006">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence653">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2007">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence659">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1597">
 <bp:evidence rdf:resource="#Evidence2036" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ECHS1 mutants don&apos;t synthesize beta-hydroxyisobutyryl-CoA</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1598">
 <bp:evidence rdf:resource="#Evidence2038" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">BCKDK loss-of-function mutations do not phosphorylate BCKDH</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence661">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1595">
 <bp:evidence rdf:resource="#Evidence2032" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">BCKDHA or BCKDHB loss-of-function mutants don&apos;t synthesize BCAA-CoA</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence660">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1596">
 <bp:evidence rdf:resource="#Evidence2034" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MCCC mutants don&apos;t synthesize beta-methylglutaconyl-CoA</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1599">
 <bp:evidence rdf:resource="#Evidence2040" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">HIBCH mutants don&apos;t synthesize beta-hydroxyisobutyrate</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence667">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence666">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence669">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence668">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence663">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence662">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence665">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence664">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2019">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence670">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence672">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence671">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2020">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2021">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence678">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2022">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence677">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2023">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2024">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence679">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2025">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence674">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2026">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence673">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2027">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence676">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2028">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence675">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2029">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2008">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2009">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence681">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence680">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence683">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence682">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2010">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence689">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2011">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence688">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2012">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2013">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2014">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence685">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2015">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence684">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2016">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence687">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2017">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence686">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2018">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep221">
 <bp:stepProcess rdf:resource="#BiochemicalReaction162" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep222">
 <bp:stepProcess rdf:resource="#Catalysis53" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction163" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep220">
 <bp:stepProcess rdf:resource="#Pathway50" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence692">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence691">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence694">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence693">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence690">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep214">
 <bp:stepProcess rdf:resource="#BiochemicalReaction156" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep215">
 <bp:stepProcess rdf:resource="#Catalysis49" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction157" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence699">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep212">
 <bp:stepProcess rdf:resource="#Pathway49" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep213">
 <bp:stepProcess rdf:resource="#BiochemicalReaction155" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep218">
 <bp:stepProcess rdf:resource="#Catalysis52" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction160" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence696">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep219">
 <bp:stepProcess rdf:resource="#BiochemicalReaction161" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence695">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep216">
 <bp:stepProcess rdf:resource="#BiochemicalReaction158" />
 <bp:stepProcess rdf:resource="#Catalysis50" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence698">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep217">
 <bp:stepProcess rdf:resource="#BiochemicalReaction159" />
 <bp:stepProcess rdf:resource="#Catalysis51" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence697">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep210">
 <bp:stepProcess rdf:resource="#Catalysis48" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction154" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep211">
 <bp:stepProcess rdf:resource="#Pathway48" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep209">
 <bp:stepProcess rdf:resource="#BiochemicalReaction153" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep203">
 <bp:stepProcess rdf:resource="#BiochemicalReaction125" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep204">
 <bp:stepProcess rdf:resource="#BiochemicalReaction148" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep201">
 <bp:stepProcess rdf:resource="#BiochemicalReaction146" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep202">
 <bp:stepProcess rdf:resource="#BiochemicalReaction147" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep207">
 <bp:stepProcess rdf:resource="#BiochemicalReaction151" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep208">
 <bp:stepProcess rdf:resource="#BiochemicalReaction152" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep205">
 <bp:stepProcess rdf:resource="#BiochemicalReaction149" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep206">
 <bp:stepProcess rdf:resource="#BiochemicalReaction150" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep200">
 <bp:stepProcess rdf:resource="#BiochemicalReaction145" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep140">
 <bp:stepProcess rdf:resource="#BiochemicalReaction101" />
 <bp:stepProcess rdf:resource="#Catalysis39" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep141">
 <bp:stepProcess rdf:resource="#BiochemicalReaction102" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep144">
 <bp:stepProcess rdf:resource="#BiochemicalReaction105" />
 <bp:stepProcess rdf:resource="#Catalysis41" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep145">
 <bp:stepProcess rdf:resource="#BiochemicalReaction106" />
 <bp:stepProcess rdf:resource="#Catalysis42" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep142">
 <bp:stepProcess rdf:resource="#BiochemicalReaction103" />
 <bp:stepProcess rdf:resource="#Catalysis40" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep143">
 <bp:stepProcess rdf:resource="#BiochemicalReaction104" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep137">
 <bp:stepProcess rdf:resource="#BiochemicalReaction98" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep138">
 <bp:stepProcess rdf:resource="#Catalysis38" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction99" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep135">
 <bp:stepProcess rdf:resource="#BiochemicalReaction97" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep136">
 <bp:stepProcess rdf:resource="#Pathway40" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep139">
 <bp:stepProcess rdf:resource="#BiochemicalReaction100" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep130">
 <bp:stepProcess rdf:resource="#Catalysis35" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction93" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep133">
 <bp:stepProcess rdf:resource="#Catalysis36" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction95" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep134">
 <bp:stepProcess rdf:resource="#Catalysis37" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction96" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep131">
 <bp:stepProcess rdf:resource="#BiochemicalReaction94" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep132">
 <bp:stepProcess rdf:resource="#Pathway39" />
</bp:PathwayStep>

<bp:BioSource rdf:ID="BioSource1">
 <bp:name rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Homo sapiens</bp:name>
</bp:BioSource>

<bp:PathwayStep rdf:ID="PathwayStep126">
 <bp:stepProcess rdf:resource="#BiochemicalReaction89" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep127">
 <bp:stepProcess rdf:resource="#BiochemicalReaction90" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep124">
 <bp:stepProcess rdf:resource="#BiochemicalReaction87" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep125">
 <bp:stepProcess rdf:resource="#BiochemicalReaction88" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep128">
 <bp:stepProcess rdf:resource="#Catalysis33" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction91" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep129">
 <bp:stepProcess rdf:resource="#Catalysis34" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction92" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction215">
 <bp:evidence rdf:resource="#Evidence267" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">M dimer is phosphorylated</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction216">
 <bp:evidence rdf:resource="#Evidence268" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">F subunits form trimers at plasma membrane rafts</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction213">
 <bp:evidence rdf:resource="#Evidence265" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">M forms a homodimer</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction214">
 <bp:evidence rdf:resource="#Evidence266" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SH pentamer is phosphorylated</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep122">
 <bp:stepProcess rdf:resource="#BiochemicalReaction85" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction211">
 <bp:evidence rdf:resource="#Evidence263" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">P binds to PPP1C complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep123">
 <bp:stepProcess rdf:resource="#Catalysis32" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction86" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction212">
 <bp:evidence rdf:resource="#Evidence264" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Nascent G signal peptide is cleaved at ER membrane</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep120">
 <bp:stepProcess rdf:resource="#BiochemicalReaction83" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep121">
 <bp:stepProcess rdf:resource="#Catalysis31" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction84" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction210">
 <bp:evidence rdf:resource="#Evidence262" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Nascent F signal peptide is cleaved at ER membrane</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction219">
 <bp:evidence rdf:resource="#Evidence271" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NS1 (1C) localizes to nucleus</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction217">
 <bp:evidence rdf:resource="#Evidence269" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">M2-1 localizes to nucleus</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction218">
 <bp:evidence rdf:resource="#Evidence270" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NS2 (1B) forms a homodimer</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep115">
 <bp:stepProcess rdf:resource="#BiochemicalReaction81" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep116">
 <bp:stepProcess rdf:resource="#Catalysis30" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction82" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep113">
 <bp:stepProcess rdf:resource="#BiochemicalReaction79" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep114">
 <bp:stepProcess rdf:resource="#BiochemicalReaction80" />
 <bp:stepProcess rdf:resource="#Catalysis29" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep119">
 <bp:stepProcess rdf:resource="#Pathway38" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep117">
 <bp:stepProcess rdf:resource="#Pathway36" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep118">
 <bp:stepProcess rdf:resource="#Pathway37" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction204">
 <bp:evidence rdf:resource="#Evidence256" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">F1 binds to F2 forming the F subunit</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction205">
 <bp:evidence rdf:resource="#Evidence257" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Nascent L binds Mg2+</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction202">
 <bp:evidence rdf:resource="#Evidence254" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Nascent N is phosphorylated</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction203">
 <bp:evidence rdf:resource="#Evidence255" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NS1 (1C) binds to NS2 (1B)</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep111">
 <bp:stepProcess rdf:resource="#BiochemicalReaction77" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction200">
 <bp:evidence rdf:resource="#Evidence252" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">F0 is palmitoylated</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep112">
 <bp:stepProcess rdf:resource="#BiochemicalReaction78" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction201">
 <bp:evidence rdf:resource="#Evidence253" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SH pentamer localizes to host cell plasma membrane</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep110">
 <bp:stepProcess rdf:resource="#BiochemicalReaction76" />
 <bp:stepProcess rdf:resource="#Catalysis28" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction208">
 <bp:evidence rdf:resource="#Evidence260" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Protein N forms decamers</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction209">
 <bp:evidence rdf:resource="#Evidence261" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Protein N forms hendecamers</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction206">
 <bp:evidence rdf:resource="#Evidence258" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">M dimer gets exported from nucleus</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction207">
 <bp:evidence rdf:resource="#Evidence259" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Protein M2-1 forms tetramers</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep104">
 <bp:stepProcess rdf:resource="#BiochemicalReaction70" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence601">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep105">
 <bp:stepProcess rdf:resource="#Catalysis27" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction71" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence600">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep102">
 <bp:stepProcess rdf:resource="#Catalysis26" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction68" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence603">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep103">
 <bp:stepProcess rdf:resource="#BiochemicalReaction69" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence602">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep108">
 <bp:stepProcess rdf:resource="#BiochemicalReaction74" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep109">
 <bp:stepProcess rdf:resource="#BiochemicalReaction75" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep106">
 <bp:stepProcess rdf:resource="#BiochemicalReaction72" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep107">
 <bp:stepProcess rdf:resource="#BiochemicalReaction73" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep184">
 <bp:stepProcess rdf:resource="#Pathway47" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence609">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep185">
 <bp:stepProcess rdf:resource="#BiochemicalReaction130" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence608">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep182">
 <bp:stepProcess rdf:resource="#Pathway46" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep183">
 <bp:stepProcess rdf:resource="#BiochemicalReaction127" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep188">
 <bp:stepProcess rdf:resource="#BiochemicalReaction133" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence605">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep189">
 <bp:stepProcess rdf:resource="#BiochemicalReaction134" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence604">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep186">
 <bp:stepProcess rdf:resource="#BiochemicalReaction131" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence607">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep187">
 <bp:stepProcess rdf:resource="#BiochemicalReaction132" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence606">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep180">
 <bp:stepProcess rdf:resource="#BiochemicalReaction128" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep181">
 <bp:stepProcess rdf:resource="#BiochemicalReaction129" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence612">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence611">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep179">
 <bp:stepProcess rdf:resource="#BiochemicalReaction127" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence614">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence613">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence610">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep173">
 <bp:stepProcess rdf:resource="#BiochemicalReaction122" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep174">
 <bp:stepProcess rdf:resource="#Pathway45" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence619">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep171">
 <bp:stepProcess rdf:resource="#BiochemicalReaction120" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep172">
 <bp:stepProcess rdf:resource="#BiochemicalReaction121" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep177">
 <bp:stepProcess rdf:resource="#BiochemicalReaction125" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence616">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep178">
 <bp:stepProcess rdf:resource="#BiochemicalReaction126" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence615">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep175">
 <bp:stepProcess rdf:resource="#BiochemicalReaction123" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence618">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep176">
 <bp:stepProcess rdf:resource="#BiochemicalReaction124" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence617">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep170">
 <bp:stepProcess rdf:resource="#BiochemicalReaction119" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence623">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence622">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep168">
 <bp:stepProcess rdf:resource="#Pathway43" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence625">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep169">
 <bp:stepProcess rdf:resource="#Pathway44" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence624">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence621">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence620">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep162">
 <bp:stepProcess rdf:resource="#BiochemicalReaction88" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep163">
 <bp:stepProcess rdf:resource="#BiochemicalReaction117" />
 <bp:stepProcess rdf:resource="#Catalysis45" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep160">
 <bp:stepProcess rdf:resource="#BiochemicalReaction115" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep161">
 <bp:stepProcess rdf:resource="#BiochemicalReaction116" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep166">
 <bp:stepProcess rdf:resource="#Catalysis30" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction82" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence627">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep167">
 <bp:stepProcess rdf:resource="#Pathway42" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence626">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep164">
 <bp:stepProcess rdf:resource="#Catalysis46" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction118" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence629">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep165">
 <bp:stepProcess rdf:resource="#BiochemicalReaction81" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence628">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep159">
 <bp:stepProcess rdf:resource="#Catalysis31" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction84" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence634">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence633">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep157">
 <bp:stepProcess rdf:resource="#BiochemicalReaction113" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence636">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep158">
 <bp:stepProcess rdf:resource="#BiochemicalReaction114" />
 <bp:stepProcess rdf:resource="#Catalysis44" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence635">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence630">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence632">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence631">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep151">
 <bp:stepProcess rdf:resource="#BiochemicalReaction110" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep152">
 <bp:stepProcess rdf:resource="#Catalysis43" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction111" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep150">
 <bp:stepProcess rdf:resource="#BiochemicalReaction109" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep155">
 <bp:stepProcess rdf:resource="#Catalysis33" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction91" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence638">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep156">
 <bp:stepProcess rdf:resource="#BiochemicalReaction112" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence637">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep153">
 <bp:stepProcess rdf:resource="#Catalysis27" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction71" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep154">
 <bp:stepProcess rdf:resource="#BiochemicalReaction90" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence639">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep148">
 <bp:stepProcess rdf:resource="#BiochemicalReaction108" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence645">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep149">
 <bp:stepProcess rdf:resource="#BiochemicalReaction65" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence644">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep146">
 <bp:stepProcess rdf:resource="#Pathway41" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence647">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep147">
 <bp:stepProcess rdf:resource="#BiochemicalReaction107" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence646">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence641">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence640">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence643">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence642">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction279">
 <bp:evidence rdf:resource="#Evidence360" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">B Nucleocapsid Assembly</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction277">
 <bp:evidence rdf:resource="#Evidence356" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Binding of M1 to vRNP</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction278">
 <bp:evidence rdf:resource="#Evidence357" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Newly synthesized vRNP for export</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction275">
 <bp:evidence rdf:resource="#Evidence353" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">vRNP Export through the nuclear pore</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction276">
 <bp:evidence rdf:resource="#Evidence355" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Binding of NEP/NS2 to vRNP:M1</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway691">
 <bp:pathwayOrder rdf:resource="#PathwayStep2628" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1885" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2575" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective SLC24A4 causes hypomineralized amelogenesis imperfecta (AI)</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The five members of the NCKX (SLC24) family are all able to exchange one Ca2+ and one K+ for four Na+. SLC24A4 encodes an exchanger protein NCKX4 which may play a role in calcium transport during amelogenesis (the process of formation of tooth enamel). SLC24A4 is upregulated in ameloblasts during the maturation stage of amelogenesis (Hu et al. 2012). Defects in SLC24A4 can cause hypomineralised amelogenesis imperfecta (AI), an autosomal recessive disorder in which tooth enamel formation fails. Screening of AI families identified mutations which severely diminish or abolish transport function of SLC24A4 (Parry et al. 2013, Wang et al. 2014).  Genetic variants in SLC24A4 define the skin/hair/eye pigmentation variation locus 6 (SHEP6; MIM:210750). In a genomewide association scan of thousands of Icelanders and Dutch, Sulem et al. found a strong association between the T allele of a SNP in the SLC24A4 gene and blond versus brown hair and blue versus green eyes (Sulem et al. 2007).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway690">
 <bp:pathwayOrder rdf:resource="#PathwayStep2626" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1884" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2573" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective SLC9A9 causes autism 16 (AUTS16)</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SLC9A9 encodes the sodium/hydrogen exchanger 9 NHE9 which is expressed ubiquitously and thought to play a housekeeping role in pH homeostasis in the late endosome membrane. A defect in SLC9A9 can contribute to susceptibility to autism 16 (AUTS16; MIM:613410). Autism, the prototypic pervasive developmental disorder (PDD), is a complex, multifactorial disorder characterised by reciprocal social interaction and communication impairment, restricted and stereotyped patterns of interests and activities, and the presence of developmental abnormalities by age 3 (Morrow et al. 2008, Kondapalli et al. 2014).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction273">
 <bp:evidence rdf:resource="#Evidence349" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Clathrin-Mediated Pit Formation And Endocytosis Of The Influenza Virion</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway693">
 <bp:pathwayOrder rdf:resource="#PathwayStep2632" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1887" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2579" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective SLC40A1 causes hemochromatosis 4 (HFE4) (macrophages)</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SLC40A1 (MTP1 aka ferroportin or IREG1) is highly expressed on macrophages where it mediates iron efflux from the breakdown of haem. SLC40A1 colocalises with ceruloplasmin (CP) which stablizes SLC40A1 and is necessary for the efflux reaction to occur. Six copper ions are required by ceruloplasmin as a cofactor. Defects in SLC40A1 can cause hemochromatosis 4 (HFE4; MIM:606069), a disorder of iron metabolism characterised by iron overload. Excess iron is deposited in a variety of organs leading to their failure, resulting in serious illnesses including cirrhosis, hepatomas, diabetes, cardiomyopathy, arthritis and hypogonadotropic hypogonadism. Severe effects of the disease don&apos;t usually appear until after decades of progressive iron overloading (De Domenico et al. 2005, 2006, 2011, Kaplan et al. 2011).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction274">
 <bp:evidence rdf:resource="#Evidence352" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Binding of vRNP:M1:NEP complex to CRM1 export receptor</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway692">
 <bp:pathwayOrder rdf:resource="#PathwayStep2630" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1886" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2577" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective SLC4A4 causes renal tubular acidosis, proximal, with ocular abnormalities and mental retardation (pRTA-OA)</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Members 4, 5, 7 and 9 of the SLC4A family couple the transport of bicarbonate (HCO3-) with sodium ions (Na+). SLC4A4 (aka NBCe1) is an electrogenic Na+/HCO3- cotransporter with a stoichiometry of 1:3. SLC4A4 is expressed in the kidney and pancreas, with lesser expression in many other tissues. Mutations in SLC4A4 can cause permanent isolated proximal renal tubular acidosis with ocular abnormalities and mental retardation (pRTA-OA), a rare autosomal recessive syndrome characterised by short stature, proximal renal tubular acidosis, mental retardation, bilateral glaucoma, cataracts and bandkeratopathy. pRTA results from the failure of the proximal tubular cells to reabsorb filtered HCO3-  from urine, leading to urinary HCO3- wasting and subsequent acidemia. HCO3- also needs to move out of cells in the eye, thus failure to do so can affect ocular pressure homeostasis (Horita et al. 2005, Kurtz    Zhu 2013, Kurtz    Zhu 2013b, Seki et al. 2013).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction271">
 <bp:evidence rdf:resource="#Evidence346" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Synthesis of PB1-F2</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway695">
 <bp:pathwayOrder rdf:resource="#PathwayStep2636" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1889" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2583" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective SLC4A1 causes hereditary spherocytosis type 4 (HSP4),  distal renal tubular acidosis (dRTA) and dRTA with hemolytic anemia (dRTA-HA)</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The proteins responsible for the exchange of Cl- with HCO3- are members of the SLC4 (1-3) and SLC26 (3, 4, 6, 7 and 9) transporter families. SLC4A1 (Band 3, AE1, anion exchanger 1) was the first bicarbonate transporter gene to be cloned and sequenced. It is ubiquitous throughout vertebrates and in humans, is  the major glycoprotein present on erythrocytes and the basolateral surfaces of kidney cells. Variations in erythroid SLC4A1 determine the Diego blood group system. Mutations in the erythrocyte form of SLC4A1 can cause hereditary spherocytosis type 4 (HSP4; MIM:612653), a disorder leading to haemolytic anaemia (HA). Some mutations in SLC4A1 can cause distal (type1) renal tubular acidosis (dRTA; MIM:179800) (an inability to acidify urine) and dRTA-HA (dRTA with hemolytic anemia) (MIM:611590)  (Tanner 2002, Romero et al. 2013). </bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction272">
 <bp:evidence rdf:resource="#Evidence347" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Binding of the influenza virion to the host cell</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway694">
 <bp:pathwayOrder rdf:resource="#PathwayStep2634" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1888" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2581" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective SLC11A2 causes hypochromic microcytic anemia, with iron overload 1 (AHMIO1)</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The primary site for absorption of dietary iron is the duodenum. Ferrous iron (Fe2+) is taken up from the gut lumen across the apical membranes of enterocytes and released into the portal vein circulation across basolateral membranes. The human gene SLC11A2 encodes the divalent cation transporter DCT1 (NRAMP2, Natural resistance-associated macrophage protein 2). DCT1 resides on the apical membrane of enterocytes and mediates the uptake of many metal ions, particularly ferrous iron, into these cells. Defects in SLC11A2 can cause hypochromic microcytic anemia, with iron overload 1 (AHMIO1; MIM:206100), a blood disorder characterised by high serum iron, large hepatic iron deposition, abnormal haemoglobin content in erythrocytes which are reduced in size and absence of sideroblasts and stainable bone marrow iron store (Shawki et al. 2012, Iolascon    De Falco 2009).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway697">
 <bp:pathwayOrder rdf:resource="#PathwayStep2640" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1891" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2587" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective SLCO2A1 causes primary, autosomal recessive hypertrophic osteoarthropathy 2 (PHOAR2)</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The human gene SLCO2A1 encodes prostaglandin transporter PGT. It is ubiquitously expressed and can transport the protaglandins PGD2, PGE1, PGE2 and PGF2A. This transport may be important for release of newly-formed prostaglandins (PGs) and/or their clearance of prostaglandins from the circulation. Defects in SLCO2A1 can cause hypertrophic osteoarthropathy, primary, autosomal recessive, 2 (PHOAR2; MIM:614441), a rare genodermatosis characterised by pachydermia, digital clubbing, periostosis and affecting more males than females (Castori et al. 2005, Seifert et al. 2012, Diggle et al. 2012, Madruga Dias et al. 2014).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction270">
 <bp:evidence rdf:resource="#Evidence345" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Viral Protein Synthesis</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway696">
 <bp:pathwayOrder rdf:resource="#PathwayStep2638" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1890" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2585" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective SLC9A6 causes  X-linked, syndromic mental retardation,, Christianson type (MRXSCH)</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SLC9A6 encodes the sodium/hydrogen exchanger 6 NHE6, a protein ubiquitously expressed but most abundant in mitochondria-rich tissues such as brain, skeletal muscle and heart. It is located on endosomal membranes and thought to play a housekeeping role in pH homeostasis in early endosomes. It mediates the electroneutral exchange of protons for Na+ and K+ across the early and recycling endosome membranes. Defects in SLC9A6 can cause mental retardation, X-linked, syndromic, Christianson type (MRXSCH; MIM:300243), a syndrome characterised by profound mental retardation, epilepsy, ataxia and microcephaly. MRXSCH shows phenotypic overlap with Angelman syndrome (Gilfillan et al. 2008, Schroer et al. 2010, Kondapalli et al. 2014).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway699">
 <bp:pathwayOrder rdf:resource="#PathwayStep2644" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1893" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2591" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective SLC6A5 causes hyperekplexia 3 (HKPX3)</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The amino acid glycine (Gly) plays an important role in neurotransmission. Its action is terminated by rapid re-uptake into the pre-synaptic terminal or surrounding glial cells. This re-uptake is mediated by the sodium- and chloride-dependent glycine transporters 1 and 2 (GLYT1 and GLYT2 respectively) (Broer    Gether 2012, Schweikhard    Ziegler 2012). GLYT2 is encoded by the human gene SLC6A5 and is predominantly expressed in the medulla. Defects in SLC6A5 cause startle disease (STHE or hyperekplexia (HKPX3; MIM:614618)), a neurologic disorder characterised by neonatal hypertonia, an exaggerated startle response to tactile or acoustic stimuli, and life-threatening neonatal apnea. Sometimes symptoms resolve in the first year of life (Bode    Lynch 2014, James et al. 2012).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway698">
 <bp:pathwayOrder rdf:resource="#PathwayStep2642" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1892" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2589" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Variant SLC6A14 may confer susceptibility towards obesity</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SLC6A14 mediates the uptake of multiple basic and nonpolar amino acids as well as beta-alanine across the plasma membrane. Uptake of one amino acid molecule is accompanied by uptake of two sodium ions and a chloride ion (Broer    Gether 2012, Schweikhard    Ziegler 2012). As assessed by Northern blotting, SLC6A14 is expressed at high levels in lung but only at low levels, if at all, in intestine or kidney. Variations in SLC6A14 may be associated with obesity (BMIQ11; MIM:300306) in some populations. SLC6A14 is an interesting candidate for obesity because it may potentially regulate tryptophan availability for serotonin synthesis and thus could affect appetite control (Suviolahti et al. 2003, Durand et al. 2004).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction268">
 <bp:evidence rdf:resource="#Evidence342" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Assembly of an Active Transcription Complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction269">
 <bp:evidence rdf:resource="#Evidence343" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Viral mRNA Export</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction266">
 <bp:evidence rdf:resource="#Evidence340" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Elongation, Polyadenylation and Termination</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction267">
 <bp:evidence rdf:resource="#Evidence341" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Priming and Initiation of Transcription</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction264">
 <bp:evidence rdf:resource="#Evidence338" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Export of Spliced Viral mRNA</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction265">
 <bp:evidence rdf:resource="#Evidence339" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Viral mRNA Splicing (M, NS segments)</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction262">
 <bp:evidence rdf:resource="#Evidence335" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">cRNA Extension</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction263">
 <bp:evidence rdf:resource="#Evidence336" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Initiation of cRNA Synthesis</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction260">
 <bp:evidence rdf:resource="#Evidence332" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Viral Polymerase Assembly</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction261">
 <bp:evidence rdf:resource="#Evidence333" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NP binds vRNA</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway679">
 <bp:pathwayOrder rdf:resource="#PathwayStep2604" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1837" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2553" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective SLC5A7 causes distal hereditary motor neuronopathy 7A (HMN7A)</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The human SLC5A7 gene encodes a sodium- and chloride-dependent, high affinity choline transporter (CHT) transports choline (Cho) from the extracellular space into neuronal cells. Cho uptake is the rate-limiting step in acetylcholine synthesis, a neurotransmitter released at the neuromuscular junction (NMJ). Defects in SLC5A7 can cause distal hereditary motor neuronopathy 7A (HMN7A; MIM:158580). Distal hereditary motor neuronopathies are a group of neuromuscular disorders caused by selective degeneration of motor neurons in the anterior horn of the spinal cord, without sensory deficit in the posterior horn. The clinical picture consists of a progressive distal muscle wasting and weakness in the legs without clinical sensory loss (Barwick et al. 2012).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway678">
 <bp:pathwayOrder rdf:resource="#PathwayStep2602" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1874" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2551" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective SLC34A2 causes pulmonary alveolar microlithiasis (PALM)</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SLC34A1 and 2 encode Na+/Pi cotransporters, which cotransport divalent phosphate (PO4(2-), Pi) with 3 Na+ ions. SLC34A2 is abundantly expressed in lung and to a lesser extent in tissues of epithelial origin including small intestine, pancreas, prostate, and kidney. Defects in SLC34A2 are a cause of pulmonary alveolar microlithiasis (PALM; MIM:265100), a rare disease characterised by the deposition of calcium phosphate microliths throughout the lungs. The disease follows a long-term progressive course, resulting in a slow deterioration of lung function (Corut et al. 2006, Forster et al. 2013).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction299">
 <bp:evidence rdf:resource="#Evidence381" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">HCMV Binds to the Host Cell via heparan sulfate proteoglycans (HSPG)</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction297">
 <bp:evidence rdf:resource="#Evidence378" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">C Nucleocapsid Assembly</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction298">
 <bp:evidence rdf:resource="#Evidence380" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">HCMV Nuclear Pore Docking</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction295">
 <bp:evidence rdf:resource="#Evidence376" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">HCMV C Nucleocapsid Translocation</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway671">
 <bp:pathwayOrder rdf:resource="#PathwayStep2588" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1867" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2537" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective HK1 causes hexokinase deficiency (HK deficiency)</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Cytosolic hexokinase 1 (HK1), together with isoforms HK2 and 3 and glucokinase (GCK), catalyse the irreversible reaction of alpha-D-glucose (Glc) and ATP to form alpha-D-glucose-6-phosphate (G6P) and ADP, the first step in glycolysis. HK1 is the predominant isoform of the different HKs in tissues that utilise glucose for their physiological function such as brain, lymphocytes, erythrocytes, platelets and fibroblasts. Defects in HK1 can cause hexokinase deficiency (HK deficiency; MIM:235700), a rare, autosomal recessive disease with nonspherocytic hemolytic anemia as the predominant clinical feature (Kanno 2000).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction296">
 <bp:evidence rdf:resource="#Evidence377" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Binding of pPR-AP to pAP to form the pPR-AP:pAP Complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway670">
 <bp:pathwayOrder rdf:resource="#PathwayStep2586" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1866" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2535" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective SLC1A3 causes episodic ataxia 6 (EA6)</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">There are two classes of glutamate transporters; the excitatory amino acid transporters (EAATs) which depend on an electrochemical gradient of Na+ ions and vesicular glutamate transporters (VGLUTs) which are proton-dependent. Together, these transporters uptake and release glutamate to mediate this neurotransmitter&apos;s excitatory signal and are part of the glutamate-gluatamine cycle.  The SLC1 gene family includes five high-affinity glutamate transporters encoded by SLC1, 2, 3, 6 and 7. These transporters can mediate transport of L-Glutamate (L-Glu), L-Aspartate (L-Asp) and D-Aspartate (D-Asp) with cotransport of 3 Na+ ions and H+ and antiport of a K+ ion. This mechanism allows glutamate into cells against a concentration gradient. This is a crucial factor in the protection of neurons against glutamate excitotoxicity (the excitation of nerve cells to their death) in the CNS (Zhou    Danbolt 2014).  SLC1A3 is highly expressed in the cerebellum but also found in the frontal cortex, hippocampus and basal ganglia. Defects in SLC1A3 have been shown to cause episodic ataxia type 6 (EA6; MIM:612656) where mutations in SLC1A3 can lead to decreased glutamate uptake, thus contributing to neuronal hyperexcitability to cause seizures, hemiplegia and episodic ataxia (Jen et al. 2005, de Vries et al. 2009).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction293">
 <bp:evidence rdf:resource="#Evidence374" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Late (L) Gene Expression</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway673">
 <bp:pathwayOrder rdf:resource="#PathwayStep2592" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1869" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2541" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective SLC2A10 causes arterial tortuosity syndrome (ATS)</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Four class III facilitative transporters can transport glucose; SLC2A6, 8, 10 and 12 (encoding GLUT6, 8, 10 and 12 respectively). SLC2A10 (located in the Type 2 diabetes-linked region of human chromosome 20q12-13.1) encodes GLUT10, a transporter with high affinity for glucose. GLUT10 is highly expressed in liver and pancreas but is present at lower levels in most tissues. Defects in SLC2A10 are the cause of arterial tortuosity syndrome (ATS), an autosomal recessive disorder of connective tissue characterised by tortuosity and elongation of major arteries, often resulting in death at a young age (Coucke et al. 2006, Callewaert et al. 2008).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction294">
 <bp:evidence rdf:resource="#Evidence375" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">pPR-AP:pAP cleaves the MCP:pPR-AP:pAP Complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway672">
 <bp:pathwayOrder rdf:resource="#PathwayStep2590" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1868" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2539" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective SLCO1B3 causes hyperbilirubinemia, Rotor type (HBLRR)</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">In the body, solute carrier organic anion transporter family member 1B3 (SLCO1B3) is expressed on the basolateral surfaces of hepatocytes and may play a role in the uptake of bilirubin (BIL), a breakdown product of heme that requires conjugation and excretion from the body. Defects in SLCO1B3 can cause hyperbilirubinemia, Rotor type (HBLRR; MIM:237450), an autosomal recessive form of primary conjugated hyperbilirubinemia. Mild jaundice, not associated with hemolysis, develops shortly after birth or in childhood (van de Steeg et al. 2012, Sticova    Jirsa 2013, Keppler 2014).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction291">
 <bp:evidence rdf:resource="#Evidence372" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">HCMV B Nucleocapsid Translocation</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway675">
 <bp:pathwayOrder rdf:resource="#PathwayStep2596" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1871" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2545" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective SLC16A1 causes symptomatic deficiency in lactate transport (SDLT)</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Four members of the SLC16A gene family encode classical monocarboxylate transporters MCT1-4. Widely expressed, they all function as proton-dependent transporters of monocarboxylic acids such as lactate and pyruvate and ketone bodies such as acetacetate and beta-hydroxybutyrate. These processes are crucial in the regulation of energy metabolism and acid-base homeostasis.  SLC16A1 encodes MCT1, a ubiquitiously expressed protein. Heterozygous defects in SLC16A1 were found in patients with symptomatic deficiency in lactate transport (SDLT aka erythrocyte lactate transporter defect; MIM:245340), resulting in an acidic intracellular environment and muscle degeneration with the release of myoglobin and creatine kinase (Merezhinskaya et al. 2000). This defect could compromise extreme performance in otherwise healthy individuals.  SLC16A1 is essential for lactate transport in muscle cells. It is also highly enriched in astrocytes and oligodendroglia, neuroglia that support, insulate and provide energy metabolites to axons. Oligodendroglia dysfunction can lead to axon degeneration in several diseases. The cause is unknown but disruption of SLC16A1 transporter produces axon damage and neuron loss in animal and cell culture models. In humans, this transporter is reduced in patients with amyotrophic lateral sclerosis (Lee et al. 2012).  In cancer cells, a common change is the upregulation of glycolysis. The anti-cancer drug candidate 3-bromopyruvate (3-BrPA) can inhibit glycolysis through its uptake into cancer cells via SLC16A1 so it is the main determinant of 3-BrPA sensitivity in these cells (Birsoy et al. 2013).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction292">
 <bp:evidence rdf:resource="#Evidence373" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Addition of Tegument to HCMV Nucleocapsid C</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway674">
 <bp:pathwayOrder rdf:resource="#PathwayStep2594" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1870" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2543" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective SLC22A12 causes renal hypouricemia 1 (RHUC1)</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Urate is a naturally occurring product of purine metabolism and is a scavenger of biological oxidants. Uric acid readily precipitates out of aqueous solutions causing gout and kidney stones. Due to this ability, changes in urate levels are implicated in numerous disease processes. The human gene SLC22A12 encodes urate transporter 1 (URAT1), predominantly expressed in the kidney and is involved in the regulation of blood urate levels. This transport can be trans-stimulated by organic anions such as L-lactate (LACT). Defects in SLC22A12 result in idiopathic renal hypouricaemia 1 (RHUC1; MIM:220150), a disorder characterised by impaired urate reabsorption at the apical membrane of proximal renal tubule cells and high urinary urate excretion (Wakida et al. 2005, Esparza Martin    Garcia Nieto 2011).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway677">
 <bp:pathwayOrder rdf:resource="#PathwayStep2600" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1873" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2549" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective SLC22A18 causes lung cancer (LNCR) and embryonal rhabdomyosarcoma 1 (RMSE1)</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The human gene SLC22A18 (aka TSSC5) encodes organic cation transporter-like protein 2 (ORCTL2). It is expressed at high levels in kidney, liver and colon and at lower levels in heart, brain and lung. ORCTL2 can transport organic cations such as chloroquine and quinidine with the antiport of protons.  The human chromosome region 11p15.5 is linked with Beckwith-Wiedemann syndrome (associated with susceptibility to Wilms&apos; tumor, rhabdomyosarcoma and hepatoblastoma). SLC22A18 is located in this region (Cooper et al. 1998, Lee et al. 1998). Mutations and/or reduced expression of SLC22A18 have been found in certain tumors such as lung cancer (LNCR; MIM:211980) (Lee et al. 1998) and embryonal rhabdomyosarcoma 1 (RMSE1; MIM:268210) (Schwienbacher et al. 1998). How SLC22A18 might be involved in growth regulation is poorly understood. There is speculation that it may be involved in resistance to chemotherapy drugs and/or in the export of genotoxic substances whose retention may increase the risk of tumor formation.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction290">
 <bp:evidence rdf:resource="#Evidence371" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">HCMV translocates from the endosome lumen to the extracellular region</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway676">
 <bp:pathwayOrder rdf:resource="#PathwayStep2598" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1872" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2547" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective SLC1A1 is implicated in schizophrenia 18 (SCZD18) and dicarboxylic aminoaciduria (DCBXA)</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">There are two classes of glutamate transporters; the excitatory amino acid transporters (EAATs) which depend on an electrochemical gradient of Na+ ions and vesicular glutamate transporters (VGLUTs) which are proton-dependent. Together, these transporters uptake and release glutamate to mediate this neurotransmitter&apos;s excitatory signal and are part of the glutamate-glutamine cycle.  The SLC1 gene family includes five high-affinity glutamate transporters encoded by SLC1, 2, 3, 6 and 7. These transporters can mediate transport of L-Glutamate (L-Glu), L-Aspartate (L-Asp) and D-Aspartate (D-Asp) with cotransport of 3 Na+ ions and H+ and antiport of a K+ ion. This mechanism allows glutamate into cells against a concentration gradient. This is a crucial factor in the protection of neurons against glutamate excitotoxicity (the excitation of nerve cells to their death) in the CNS (Zhou    Danbolt 2014).  SLC1A1 encodes an excitatory amino-acid carrier 1 (EAAC1, also called EAAT3) and is abundant particularly in brain but also in kidney, liver, muscle, ovary, testis and in retinoblastoma cell lines. In the kidney, SLC1A1 is present at apical membranes of proximal tubes where it serves as a major route of glutamate and aspartate reuptake from urine. Defects in SLC1A1 are the cause of dicarboxylic aminoaciduria (DCBXA; MIM:222730), an autosomal recessive  glutamate-aspartate transport defect in the kidney and intestine (Bailey et al. 2011). Mutations that can cause DCBXA are R445W and I395del (Bailey et al. 2011).  A defect in SLC1A1 is also implicated in schizophrenia 18 (SCZD18; MIM:615232). Schizophrenia (SCZD; MIM:181500) is a complex, multifactorial psychotic disorder characterised by disturbances in the form and content of thought, in mood, in sense of self and relationship to the external world and in behaviour. It ranks amongst the world&apos;s top 10 causes of long-term disability. At the neuropathological level, SCZD appears to be characterised by synaptic deficits, alterations in glutamate and dopamine neurotransmission and hypofrontality (a state of decreased cerebral blood flow (CBF) in the prefrontal cortex of the brain). Variations in the SLC1A1 gene can confer susceptibility to SCZD18 (Harris et al. 2013). In the remote Pacific island of Palau, the risk of SCZD is 2-3 times the worldwide rate. In a 5-generation Palauan family, an 84kb deletion was carried by psychosis patients and proposed to increase the disease risk more than 18-fold for family members (Myles-Worsley et al. 2013).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep195">
 <bp:stepProcess rdf:resource="#BiochemicalReaction140" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep196">
 <bp:stepProcess rdf:resource="#BiochemicalReaction141" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway689">
 <bp:pathwayOrder rdf:resource="#PathwayStep2624" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1883" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2571" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective SLC22A5 causes systemic primary carnitine deficiency (CDSP)</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The human SLC22A5,15 and 16 genes encode for sodium-dependent, high affinity carnitine cotransporters which maintain systemic and tissue concentrations of carnitine. Carnitine is essential for beta-oxidation of long-chain fatty acids to produce ATP. SLC22A5 encodes the organic cation/carnitine transporter 2 (OCTN2).  SLC22A5 is strongly expressed in the kidney, skeletal muscle, heart and placenta. Defects in SLC22A5 are the cause of systemic primary carnitine deficiency (CDSP; MIM:212140), an autosomal recessive disorder of fatty-acid oxidation caused by defective carnitine transport resulting in cardiac, skeletal, or metabolic symptoms. If diagnosed early, all clinical symptoms can be completely reversed with a carnitine supplement. However, if left untreated, patients will develop lethal heart failure (Shibbani et al. 2014, Tamai 2013).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep193">
 <bp:stepProcess rdf:resource="#BiochemicalReaction138" />
 <bp:stepProcess rdf:resource="#Catalysis47" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep194">
 <bp:stepProcess rdf:resource="#BiochemicalReaction139" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep199">
 <bp:stepProcess rdf:resource="#BiochemicalReaction144" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction288">
 <bp:evidence rdf:resource="#Evidence369" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">HCMV Formation of Final Envelopment Complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction289">
 <bp:evidence rdf:resource="#Evidence370" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Assembly of HCMV Procapsid</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep197">
 <bp:stepProcess rdf:resource="#BiochemicalReaction142" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction286">
 <bp:evidence rdf:resource="#Evidence367" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Translocation of SCP, Triplex (TRI) complex, CVC complex, and Accessory Proteins from the cytoplasm into the nucleous</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep198">
 <bp:stepProcess rdf:resource="#BiochemicalReaction143" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction287">
 <bp:evidence rdf:resource="#Evidence368" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Initiation of HCMV DNA Replication</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep191">
 <bp:stepProcess rdf:resource="#BiochemicalReaction136" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep192">
 <bp:stepProcess rdf:resource="#BiochemicalReaction137" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep190">
 <bp:stepProcess rdf:resource="#BiochemicalReaction135" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway680">
 <bp:pathwayOrder rdf:resource="#PathwayStep2606" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1856" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2554" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective SLC6A19 causes Hartnup disorder (HND)</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SLC6A19 encodes the sodium-dependent neutral amino acid transporter B(0)AT1 and mediates the uptake of neutral amino acids across the plasma membrane accompanied by uptake of a sodium ion. The protein is abundantly expressed in the small intestine and kidney (Broer    Gether 2012, Schweikhard    Ziegler 2012). Defects in SLC6A19 can cause Hartnup disorder (HND; MIM:234500), an autosomal recessive abnormality of renal and gastrointestinal neutral amino acid transport characterised by increased urinary and intestinal excretion of neutral amino acids. Symptoms include transient manifestations of rashes, cerebellar ataxia and psychotic behaviour (Broer 2009, Cheon et al. 2010). Some mutations in SLC6A19 are thought to contribute to the phenotypes iminoglycinuria (IG; MIM:242600) and hyperglycinuria (HG; MIM:138500) (Broer et al. 2008).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction284">
 <bp:evidence rdf:resource="#Evidence365" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">HCMV Final Envelopment</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway682">
 <bp:pathwayOrder rdf:resource="#PathwayStep2610" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1876" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2557" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective SLC26A4 causes Pendred syndrome (PDS)</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Solute carrier (SLC) genes that code chloride (Cl-)/bicarbonate (HCO3-) exchanger proteins are in the SLC4 and SLC26 families. SLC26A4 (pendrin) is thought to act as a chloride/anion exchanger but in the thyroid and inner ear, it also contributes to the conditioning of the endolymphatic fluid by mediating iodide (I-) transport. Defects in SLC26A4 can cause Pendred syndrome (PDS; MIM:274600), an autosomal recessive disorder characterised by congenital sensorineural hearing loss in association with thyroid goiter (Choi et al. 2011, Pesce    Kopp 2014).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction285">
 <bp:evidence rdf:resource="#Evidence366" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Binding of the major capsid protein (MCP) to the pPR-AP:pAP complex </bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway681">
 <bp:pathwayOrder rdf:resource="#PathwayStep2608" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1875" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2555" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective SLC2A9 causes hypouricemia renal 2 (RHUC2)</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The human SLC2A9 gene encodes the class II facilitative glucose transporter 9 (GLUT9). SLC2A9 is expressed mainly in kidney (proximal tubules of epithelial cells) and liver. SLC2A9 is a bona fide urate transporter (uric acid), but also the uptake of fructose (Fru) and glucose (Glc) at a low rate. Uric acid is the end product of purine metabolism in humans and great apes. Defects in SLC2A9 can cause renal hypouricemia 2 (RHUC2), a common inherited disorder characterised by impaired renal urate reabsorption and resultant low serum urate levels. Some patients present with severe complications, such as exercise-induced acute kidney injury (EIAKI) and nephrolithiasis (Esparza Martin    Garcia Nieto 2011, Sebesta 2012, Shen et al. 2014).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction282">
 <bp:evidence rdf:resource="#Evidence363" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">HCMV Genome Replication Completion</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway684">
 <bp:pathwayOrder rdf:resource="#PathwayStep2614" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1878" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2561" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective AVP does not bind AVPR2 and causes neurohypophyseal diabetes insipidus (NDI)</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Arginine vasopressin (AVP(20-28)) is a 9 amino-acid long signal peptide produced by cleavage of the precursor protein AVP in the hypothalamus. It mediates the reabsorption of water in the kidney and its synthesis and release are physiologically regulated by plasma osmolarity, blood pressure and/or blood volume. AVP(20-28) binds to vasopressin receptors AVPR1 and 2, located on the basolateral surface of the kidney collecting duct. This binding results in interaction of AVPRs with the G protein alpha-s. Following a cascade of downstream events, ultimately the water channel aquaporin 2 (AQP2) translocates from intracellular stores to the apical surface where it functions as the entry site for water reabsorption. When water balance is achieved, plasma levels of AVP(20-28) drop and AQP2 levels in the apical plasma membrane are decreased.  Mutations in AVP make it unavailable to its AVPRs in the kidney, resulting in dysregulation of water reabsorption. This can cause familial neurohypophyseal diabetes insipidus (FNDI), an autosomal dominant disorder characterised by persistent excessive thirst resulting in constant drinking (polydipsia) and passage of large volumes of urine (polyuria). In FNDI, the production and release of AVP from the posterior pituitary gland is impaired (Moeller et al. 2013). </bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction283">
 <bp:evidence rdf:resource="#Evidence364" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Assembly of the HCMV Genome DNA Replication Complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway683">
 <bp:pathwayOrder rdf:resource="#PathwayStep2612" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1877" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2559" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective SLC36A2 causes iminoglycinuria (IG) and hyperglycinuria (HG)</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SLC36A2 encodes proton-coupled amino acid transporter 2 (PAT2), a high-affinity cotransporter of glycine and proline coupled with the uptake of a proton in kidney and muscles (Schweikhard    Ziegler 2012). Defects in SLC36A2 can cause iminoglycinuria (IG; MIM:242600), an autosomal recessive abnormality of renal transport of glycine and the imino acids proline and hydroxyproline. Defects can also cause hyperglycinuria (HG; MIM:138500), a related disorder to IG which is characterised by excess glycine in the urine (Broer et al. 2008). Polymorphisms in the modifiers SLC6A18, 19 and 20, contribute to these phenotypes.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction280">
 <bp:evidence rdf:resource="#Evidence361" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Packaging of Viral Genome Into C Capsids</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway686">
 <bp:pathwayOrder rdf:resource="#PathwayStep2618" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1880" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2565" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective SLC2A1 causes GLUT1 deficiency syndrome 1 (GLUT1DS1)</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Members of the SLC2A family encode glucose transporter (GLUT) proteins that mediate the facilitated diffusion of glucose between the extracellular space and the cytosol. While the monomeric protein can form a channel and transport glucose, kinetic studies suggest that the functional form of the protein is a homotetramer. SLC2A1 (GLUT1) is expressed by many cell types, notably endothelial cells, red blood cells and cells of the brain. Its low Km for glucose (~1 mM) relative to normal blood glucose concentration (~5 mM) allows these cells to take up glucose independent of changes in blood glucose levels. Defects in SLC2A1 can cause neurological disorders with wide phenotypic variability. The most severe &apos;classic&apos; phenotype, GLUT1 deficiency syndrome 1 (GLUT1DS1; MIM:606777), comprises infantile-onset epileptic encephalopathy associated with delayed development, acquired microcephaly, motor incoordination and spasticity (Brockmann 2009, De Giorgis    Veggiotti 2013).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction281">
 <bp:evidence rdf:resource="#Evidence362" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Transport of MCP:pPR-AP:pAP Complex into the Nucleous</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway685">
 <bp:pathwayOrder rdf:resource="#PathwayStep2616" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1879" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2563" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective SLC34A1 causes hypophosphatemic nephrolithiasis/osteoporosis 1 (NPHLOP1)</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SLC34A1 and 2 encode Na+/Pi cotransporters, which cotransport divalent phosphate (PO4(2-), Pi) with 3 Na+ ions. SLC34A1 is an important Pi transporter mainly expressed in renal proximal tubules where it plays a major role in Pi homeostasis. Defects in SLC34A1 are the cause of hypophosphatemic nephrolithiasis/osteoporosis type 1 (NPHLOP1; MIM:612286), disease characterised by decreased renal phosphate absorption, hypophosphatemia, hyperphosphaturia, hypercalciuria, nephrolithiasis and implicated in the formation of renal calcium stones and/or bone demineralisation (Prie et al. 2002, Prie et al. 2004, Choi 2008, Boskey et al. 2013, Forster et al. 2013).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway688">
 <bp:pathwayOrder rdf:resource="#PathwayStep2622" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1882" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2569" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective RHAG causes regulator type Rh-null hemolytic anemia (RHN)</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Rhesus (Rh) blood group antigens consist of several membrane-associated polypeptides including RHAG, which is required for cell-surface expression of the complex. The Rh(null) phenotype arises from missing or severely deficient Rh antigens and sufferers present a clinical syndrome of varying severity characterised by abnormalities of red cell shape, cation transport and membrane phospholipid organisation. The human gene RHAG encodes a Rhesus blood group family type A glycoprotein (belonging to the SLC42 solute transporter family) which is expressed specifically in erythroid cells. A transport function for RHAG is suggested to mediate ammonium (NH4+) export from these cells and prevent toxic build-up of NH3/NH4+ (Westhoff et al. 2002, Ripoche et al. 2004). Defects in RHAG are the cause of regulator type Rh-null hemolytic anemia (RHN, Rh-deficiency syndrome). RHN is a form of chronic hemolytic anemia (Huang    Ye 2010).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway687">
 <bp:pathwayOrder rdf:resource="#PathwayStep2620" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1881" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2567" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective SLC5A2 causes renal glucosuria (GLYS1)</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The human gene SLC5A2 encodes a sodium-dependent glucose transporter (SGLT2), expressed in many tissues but primarily in the kidney, specifically S1 and S2 proximal tubule segments. It is a low affinity, high capacity transporter of glucose across the apical membrane, with co-transport of Na+ ions in a 1:1 ratio and is the main transporter of glucose in the kidney, responsible for approximately 98% of glucose reabsorption (reaminder by SGLT1). Defects in SLC5A2 are the cause of renal glucosuria (GLYS1; MIM:233100), an autosomal recessive renal tubular disorder characterised by glucosuria in the absence of both hyperglycemia and generalized proximal tubular dysfunction. Establishing definite genotype&#8211;phenotype correlations for GLYS1 is made difficult by variable expression of SLC5A2 and because other genes may have an impact on overall renal glucose resorption. Drugs that inhibit SLC5A2 are used to treat type 2 diabetes (T2D). The strategy to reduce hyperglycemia in T2D is to target renal glucose reabsorption by inhibiting SLC5A2 (Santer    Calado 2010, Calado et al. 2011).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction237">
 <bp:evidence rdf:resource="#Evidence294" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">RNP association</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway657">
 <bp:pathwayOrder rdf:resource="#PathwayStep2560" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1854" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2510" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective GCK causes maturity-onset diabetes of the young 2 (MODY2)</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Cytosolic glucokinase (GCK) (and three isoforms of hexokinase) catalyse the irreversible reaction of alpha-D-glucose (Glc) and ATP to form alpha-D-glucose-6-phosphate (G6P) and ADP, the first step in glycolysis. In the body, GCK is found only in hepatocytes and pancreatic beta cells. GCK and the hexokinase enzymes differ in that GCK has a higher Km than the hexokinases and is less readily inhibited by the reaction product. As a result, GCK should be inactive in the fasting state when glucose concentrations are low but in the fed state should have an activity proportional to glucose concentration. These features are thought to enable efficient glucose uptake and retention in the liver, and to function as a sensor of glucose concentration coupled to insulin release in pancreatic beta cells. Defects in GCK are can cause maturity-onset diabetes of the young 2 (MODY2; MIM:125851), a heritable early onset form of type II diabetes (Hussain 2010, Osbak et al. 2009).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction238">
 <bp:evidence rdf:resource="#Evidence295" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Association with M1 at cell membrane</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway656">
 <bp:pathwayOrder rdf:resource="#PathwayStep2558" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1853" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2508" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective SLC35A2 causes congenital disorder of glycosylation 2M (CDG2M)</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The human gene SLC35A2 encodes the UDP-galactose transporter. It is located on the Golgi membrane and mediates the antiport of UDP-Gal into the Golgi lumen in exchange for UMP. Nucleotide sugars such as UDP-Gal are used in protein glycosylation in the Golgi lumen. This transporter is also known to transport UDP-N-acetylgalactosamine (UDP-GalNAc) by the same antiport mechanism. Defects in SLC35A2 limit Golgi-localised pools of UDP-Gal, resulting in truncated beta-GlcNAc-terminated N-glycans and alpha-GalNAc-terminated O-glycans. Defects in SLC35A2 can cause congenital disorder of glycosylation 2M (CDG2M; MIM:300896), a disorder characterised by developmental delay, hypotonia, ocular defects and brain malformations (Ng et al. 2013). Congenital disorders of glycosylation (CDGs) are generally characterised by under-glycosylated serum glycoproteins and a wide spectrum of clinical features. Defects in SLC35A2 can also cause early infantile epileptic encephalopathy 22 (EIEE22; MIM:300896), a severe form of epilepsy characterised by by frequent tonic seizures or spasms beginning in infancy and accompanied by developmental problems (Kodera et al. 2013). </bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction235">
 <bp:evidence rdf:resource="#Evidence291" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Glycosylation and Folding of HA</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway659">
 <bp:pathwayOrder rdf:resource="#PathwayStep2564" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1856" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2514" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective SLC6A19 causes Hartnup disorder (HND)</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SLC6A19 encodes the sodium-dependent neutral amino acid transporter B(0)AT1 and mediates the uptake of neutral amino acids across the plasma membrane accompanied by uptake of a sodium ion. The protein is abundantly expressed in the small intestine and kidney (Broer    Gether 2012, Schweikhard    Ziegler 2012). Defects in SLC6A19 can cause Hartnup disorder (HND; MIM:234500), an autosomal recessive abnormality of renal and gastrointestinal neutral amino acid transport characterised by increased urinary and intestinal excretion of neutral amino acids. Symptoms include transient manifestations of rashes, cerebellar ataxia and psychotic behaviour (Broer 2009, Cheon et al. 2010). Some mutations in SLC6A19 are thought to contribute to the phenotypes iminoglycinuria (IG; MIM:242600) and hyperglycinuria (HG; MIM:138500) (Broer et al. 2008).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction236">
 <bp:evidence rdf:resource="#Evidence292" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Assembly of M2 tetramers</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway658">
 <bp:pathwayOrder rdf:resource="#PathwayStep2562" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1855" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2512" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective SLC35C1 causes congenital disorder of glycosylation 2C (CDG2C)</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The human gene SLC35C1 encodes a GDP-fucose transporter that resides on the Golgi membrane and mediates the transport of GDP-fucose into the Golgi lumen. Defects in SLC35C1 cause the congenital disorder of glycosylation type 2C (CDG2C aka leukocyte adhesion deficiency type II, LAD2), an autosomal recessive disorder characterised by moderate to severe psychomotor retardation, mild dysmorphism and impaired neutrophil motility (Lubke et al. 2001, Liu    Hirschberg 2013).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction233">
 <bp:evidence rdf:resource="#Evidence289" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Budding of vesicle with the HA trimer, NA tetramer and M2 tetramer from the endoplasmic reticulum into the cytosol</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction234">
 <bp:evidence rdf:resource="#Evidence290" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Fusion of vesicle containing the HA trimer, NA tetramer and M2 tetramer to the Golgi apparatus</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction231">
 <bp:evidence rdf:resource="#Evidence286" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Association of  NA into rafts</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction232">
 <bp:evidence rdf:resource="#Evidence287" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Trimerization of HA</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction239">
 <bp:evidence rdf:resource="#Evidence297" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Membrane fusion</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction230">
 <bp:evidence rdf:resource="#Evidence285" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Association of NP into rafts</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway651">
 <bp:pathwayOrder rdf:resource="#PathwayStep2548" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1849" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2499" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective SLC35A3 causes arthrogryposis, mental retardation, and seizures (AMRS)</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The human gene SLC35A3 encodes a UDP-GlcNAc transporter. It is ubiquitously expressed and resides on the Golgi membrane where it transports UDP- N-acetylglucosamine (UDP-GlcNAc) into the Golgi lumen in exchange for UMP. UDP-GlcNAc is a substrate required by Golgi-resident glycosyltransferases that generate branching of N-glycosylated proteins. Defects in SLC35A3 can cause arthrogryposis, mental retardation, and seizures (AMRS; MIM:615553) (Edvardson et al. 2013). Patient cells show a large reduction of tetraantennary N-glycans with an accumulation of abnormal lower-branched glycoproteins, although the serum N-glycome was normal.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway650">
 <bp:pathwayOrder rdf:resource="#PathwayStep2546" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1848" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2497" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective SLC6A3 causes Parkinsonism-dystonia infantile (PKDYS)</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The human gene SLC6A3 encodes the sodium-dependent dopamine transporter DAT which mediates the Na-dependent re-uptake of dopamine (DA) from the synaptic cleft back into cells, thereby terminating the action of DA (Broer    Gether 2012, Schweikhard    Ziegler 2012). Defects in SLC6A3 can cause Parkinsonism-dystonia infantile (PKDYS; MIM:613135), a neurodegenerative disorder characterised by infantile onset of parkinsonism and dystonia (Kurian et al. 2011).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway653">
 <bp:pathwayOrder rdf:resource="#PathwayStep2552" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1850" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2502" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective SLC12A3 causes Gitelman syndrome (GS)</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The SLC12A3 gene encodes for the Thiazide-sensitive sodium-chloride cotransporter (TSC). TSC mediates sodium and chloride removal from the distal convoluted tubule of the kidney. Defects in SLC12A3 are the cause of Gitelman syndrome (GS aka familial hypokalemic hypomagnesemia; MIM:263800). GS is an autosomal recessive disorder characterised by hypokalemic metabolic alkalosis, hypomagnesemia, and hypocalciuria. Patients can present with periods of muscular weakness and tetany, usually accompanied by abdominal pain, vomiting and fever. GS has overlapping features with Bartter syndrome (caused by defects in SLC12A1). This cotransporter is the major target for thiazide-type diuretics, used in the treatment of hypertension, extracellular fluid overload and renal stone disease (Nakhoul et al. 2012).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway652">
 <bp:pathwayOrder rdf:resource="#PathwayStep2550" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1848" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2501" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective SLC6A3 causes Parkinsonism-dystonia infantile (PKDYS)</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The human gene SLC6A3 encodes the sodium-dependent dopamine transporter DAT which mediates the Na-dependent re-uptake of dopamine (DA) from the synaptic cleft back into cells, thereby terminating the action of DA (Broer    Gether 2012, Schweikhard    Ziegler 2012). Defects in SLC6A3 can cause Parkinsonism-dystonia infantile (PKDYS; MIM:613135), a neurodegenerative disorder characterised by infantile onset of parkinsonism and dystonia (Kurian et al. 2011).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway655">
 <bp:pathwayOrder rdf:resource="#PathwayStep2556" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1852" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2506" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective SLC26A3 causes congenital secretory chloride diarrhea 1 (DIAR1)</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Solute carrier (SLC) genes that code chloride (Cl-)/bicarbonate (HCO3-) exchanger proteins are the SLC4 and SLC26 families. The chloride anion exchanger SLC26A3 (aka down-regulated in adenoma, DRA) mediates electrolyte and fluid absorption in the colon. It is also localised to the midpiece tail membrane of sperm where it plays a role in Cl-/HCO3- homeostasis during sperm epididymal maturation. Defects in SLC26A3 cause congenital chloride diarrhea 1 (DIAR1), a disease characterised by watery stools containing an excess of chloride resulting in dehydration, hypokalemia, and metabolic alkalosis (Alper    Sharma 2013, Wedenoja et al. 2011).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway654">
 <bp:pathwayOrder rdf:resource="#PathwayStep2554" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1851" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2504" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Variant SLC6A20 contributes towards hyperglycinuria (HG) and iminoglycinuria (IG)</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SLC6A20 encodes the sodium- and chloride-dependent transporter SIT1 and mediates the sodium-dependent uptake of imino acids such as L-proline, N-methyl-L-proline and pipecolate as well as N-methylated amino acids and glycine (Broer    Gether 2012, Schweikhard    Ziegler 2012). The human protein is expressed in the intestine and kidney. A common SNP in the SLC6A20 gene, a 596C-T transition that results in a thr199-to-met (T199M) substitution can contribute towards iminoglycinuria (IG; MIM:242600) or hyperglycinuria (HG; MIM:138500) (Broer et al. 2008). Overall, mutations in SLC36A2 together with polymorphisms in the modifiers SLC6A20, SLC6A18, and SLC6A19 constitute the genetic basis for these phenotypes.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction226">
 <bp:evidence rdf:resource="#Evidence281" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Hemagglutinin (HA) protein synthesis</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway668">
 <bp:pathwayOrder rdf:resource="#PathwayStep2582" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1864" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2531" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective SLC40A1 causes hemochromatosis 4 (HFE4) (duodenum)</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The primary site for absorption of dietary iron is the duodenum. Ferrous iron (Fe2+) is taken up from the gut lumen across the apical membranes of enterocytes and released into the portal vein circulation across basolateral membranes. The human gene SLC40A1 encodes the metal transporter protein MTP1 (aka ferroportin or IREG1). This protein resides on the basolateral membrane of enterocytes and mediates ferrous iron efflux into the portal vein. SLC40A1 colocalises with hephaestin (HEPH) which stablises it and is necessary for the efflux reaction to occur. Defects in SLC40A1 can cause hemochromatosis 4 (HFE4; MIM:606069), a disorder of iron metabolism characterised by iron overload. Excess iron is deposited in a variety of organs leading to their failure, resulting in serious illnesses including cirrhosis, hepatomas, diabetes, cardiomyopathy, arthritis and hypogonadotropic hypogonadism. Severe effects of the disease don&apos;t usually appear until after decades of progressive iron overloading  (De Domenico et al. 2005, 2006, 2011, Kaplan et al. 2011).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction227">
 <bp:evidence rdf:resource="#Evidence282" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Assembly of NA tetramers</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway667">
 <bp:pathwayOrder rdf:resource="#PathwayStep2580" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1863" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2529" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective CP causes aceruloplasminemia (ACERULOP)</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Ceruloplasmin (CP), synthesised in the liver and secreted into plasma, is a copper-binding (6-7 atoms per molecule) glycoprotein involved in iron trafficking in vertebrates. CP is essential for SLC40A1 (ferroportin) stability at the cell surface, the protein that mediates iron efflux from cells. CP also possesses ferroxidase activity, which oxidises ferrous iron (Fe2+) to ferric iron (Fe3+) following its transfer out of the cell. Fe3+ can then be loaded on to extracellular transferrin which transports it around the body to sites where it is required. Iron is vital for many metabolic processes such as electron transport and the transport and storage of oxygen.  Defects in CP (or indeed SLC40A1) can lead to the phenotype of iron overload as seen in the disorder aceruloplasminemia (ACERULOP; MIM:604290). It is a rare autosomal recessive disorder of iron metabolism characterised by iron accumulation mainly in the brain, but also in liver, pancreas and retina. Patients develop retinal degeneration, diabetes mellitus and neurological disturbance. ACERULOP belongs to a group of disorders known as NBIA (neurodegeneration with brain iron accumulation), distinguishing it from hereditary hemochromatosis (serum iron is high but the brain is usually not affected) and from disorders of copper metabolism such as Menkes and Wilson disease (Harris et al. 1995, Kono 2012, Musci et al. 2014).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction224">
 <bp:evidence rdf:resource="#Evidence279" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Palmitoylation of cysteine residues on HA in the cis-Golgi network</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction225">
 <bp:evidence rdf:resource="#Evidence280" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">M2 protein synthesis</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway669">
 <bp:pathwayOrder rdf:resource="#PathwayStep2584" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1865" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2533" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective SLC29A3 causes histiocytosis-lymphadenopathy plus syndrome (HLAS)</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The human gene SLC29A3 encodes the equilibrative nucleoside transporter 3 (ENT3). It is abundant in many tissues, especially the placenta and is localized intracellularly on the lysosomal membrane. SLC29A3 mediates the reversible transport of nucleosides as well as anticancer and antiviral agents such as cladribine, cordycepin, tubercidin and AZT. Defects in SLC29A3 can cause histiocytosis-lymphadenopathy plus syndrome (HLAS; MIM:602782), an autosomal recessive disorder characterised by combined features from 2 or more of four histiocytic disorders (Morgan et al. 2010, Colmenero et al. 2012, Young et al. 2013).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction222">
 <bp:evidence rdf:resource="#Evidence277" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Association of HA into rafts</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction223">
 <bp:evidence rdf:resource="#Evidence278" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Palmitoylation of cysteine residues on M2 in the cis-golgi network</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction220">
 <bp:evidence rdf:resource="#Evidence275" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Glycosylation of NA</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction221">
 <bp:evidence rdf:resource="#Evidence276" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Accumulation of M1 at the inner leaflet of the lipid bilayer</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction228">
 <bp:evidence rdf:resource="#Evidence283" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Neuraminidase (NA) synthesis</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction229">
 <bp:evidence rdf:resource="#Evidence284" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Transport of processed viral proteins to the cell membrane</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway660">
 <bp:pathwayOrder rdf:resource="#PathwayStep2566" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1857" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2516" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective SLC7A9 causes cystinuria (CSNU)</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SLC7A9 encodes the b(0,+)-type amino acid transporter 1 BAT1. As a heterodimer with SLC3A1 in the plasma membrane, SLC7A9 mediates the high-affinity, sodium-independent transport of cystine (CySS-, the oxidised form of L-cysteine) and dibasic amino acids in exchange for neutral amino acids and is thought to be responsible for the reabsorption of CySS-  and dibasic amino acids in the kidney tubule (Schweikhard    Ziegler 2012). Defects in SLC7A9 (or SLC3A1) can cause cystinuria (CSNU; MIM:220100), an autosomal disorder characterised by impaired renal reabsorption of cystine and dibasic amino acids. The low solubility of cystine causes the formation of calculi in the urinary tract resulting in obstructive uropathy, pyelonephritis, and, rarely, renal failure (Palacin et al. 2001, Mattoo    Goldfarb 2008, Fotiadis et al. 2013, Saravakos et al. 2014, Barbosa et al. 2012). Cystinuria is subcategorised as type A (mutations on SLC3A1) and type B (mutations on SLC7A9).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway662">
 <bp:pathwayOrder rdf:resource="#PathwayStep2570" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1840" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2520" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective SLC35A1 causes congenital disorder of glycosylation 2F (CDG2F)</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The human gene SLC35A1 encodes the CMP-sialic acid transporter which mediates the antiport of CMP-sialic acid (CMP-Neu5Ac) into the Golgi lumen in exchange for CMP (Ishida et al. 1996). Defects in SLC35A1 are the cause of congenital disorder of glycosylation type 2F (CDG2F; MIM:603585), characterised by under-glycosylated serum proteins. CDGs are a family of severe inherited diseases caused by a defect in protein N-glycosylation. These multisystem disorders present with a wide spectrum of phenotypes such as disorders of nervous system development, psychomotor retardation, dysmorphic features, hypotonia, coagulation disorders and immunodeficiency (Martinez-Duncker et al. 2005, Song 2013).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway661">
 <bp:pathwayOrder rdf:resource="#PathwayStep2568" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1858" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2518" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective SLC6A18 may confer susceptibility to iminoglycinuria and/or hyperglycinuria</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SLC6A18 encodes a neutral amino acid transporter B(0)AT3 which has preference for the amino acid glycine. It is abundantly expressed in the kidney, specifically the S2/3 segments of the kidney proximal tubule (Broer    Gether 2012, Schweikhard    Ziegler 2012). Iminoglycinuria (IG; MIM:242600) or hyperglycinuria (HG; MIM:138500) can arise from defects in SLC36A2, encoding a proton-coupled amino acid transporter 2 (PAT2), a high-affinity cotransporter of glycine and proline. Mutation in SLC6A18 may contribute to both IG and HG (Broer et al. 2008).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway664">
 <bp:pathwayOrder rdf:resource="#PathwayStep2574" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1860" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2523" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective SLC12A6 causes agenesis of the corpus callosum, with peripheral neuropathy (ACCPN)</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">K+/Cl- cotransport is implicated not only in regulatory volume decrease, but also in transepithelial salt absorption, renal K+ secretion, myocardial K+ loss during ischemia and regulation of neuronal Cl- concentration. Four genes (SLC12A4-7) encode the K+/Cl- cotransporters KCC1-4 respectively. Cotransport of K+ and Cl- is electroneutral with a 1:1 stoichiometry. These cotransporters function as homomultimers or heteromultimers with other K+/Cl- cotransporters. SLC12A6 encodes KCC3 which is highly expressed in heart, brain, spinal cord, kidney, muscle, pancreas and placenta. Defects in SLC12A6 are a cause of agenesis of the corpus callosum with peripheral neuropathy (ACCPN; MIM:218000), a autosomal recessive disease characterised by severe progressive sensorimotor neuropathy, mental retardation, dysmorphic features and variable degree of agenesis of the corpus callosum (Howard et al. 2002, Dupre et al. 2003, Salin-Cantegrel et al. 2011).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway663">
 <bp:pathwayOrder rdf:resource="#PathwayStep2572" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1859" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2521" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective SLC24A5 causes oculocutaneous albinism 6 (OCA6)</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Five members of the NCKX (SLC24) family are all able to exchange one Ca2+ and one K+ for four Na+. SLC24A5 (NCKX5, located on the trans-Golgi membrane) is the prediminant K+-dependent Na+/Ca2+ exchanger in melanocytes and is one of a handful of genes thought to play a role in determining human skin colour (Wilson et al. 2013). Defects in SLC24A5 can cause oculocutaneous albinism 6 (OCA6; MIM:113750), a disorder characterised by a reduction or complete loss of melanin in the skin, hair and eyes. Patients with this condition show accompanied eye symptoms (Kamaraj    Purohit 2014, Morice-Picard et al. 2014).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway666">
 <bp:pathwayOrder rdf:resource="#PathwayStep2578" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1862" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2527" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective SLC33A1 causes spastic paraplegia 42 (SPG42)</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The human gene SLC33A1 encodes acetyl-CoA transporter AT1. SLC33A1 transports cytosolic acetyl-CoA (Ac-CoA) to the Golgi apparatus lumen, where it serves as the substrate for acetyltransferases that O-acetylates sialyl residues of gangliosides and glycoproteins (Hirabayashi et al. 2013). Defects in SLC33A1 are the cause of spastic paraplegia autosomal dominant type 42 (SPG42; MIM:612539), a neurodegenerative disorder characterised by a variable speed of (but progressive) weakness and spasticity of the lower limbs (Lin et al. 2008, Hirabayashi et al. 2013). Defects in SLC33A1 can also cause congenital cataracts, hearing loss, and neurodegeneration (CCHLND; MIM:614482), an autosomal recessive disorder characterised by congenital cataracts, severe psychomotor retardation, and hearing loss, together with decreased serum ceruloplasmin and copper (Huppke et al. 2012). </bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway665">
 <bp:pathwayOrder rdf:resource="#PathwayStep2576" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1861" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2525" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective SLC17A5 causes Salla disease (SD) and ISSD</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SLC17A5 encodes a lysosomal sialic acid transporter, sialin (AST, membrane glycoprotein HP59) which exports sialic acid (N-acetylneuraminic acid, Neu5Ac) derived from the degradation of glycoconjugates from lysosomes. This export is dependent on the proton electrochemical gradient across the lysosomal membrane. SLC17A5 is present in the pathological tumor vasculature of the lung, breast, colon, and ovary, but not in the normal vasculature, suggesting that the protein may be critical to pathological angiogenesis. Sialin is not expressed in a variety of normal tissues, but is significantly expressed in human fetal lung. Defects in SLC17A5 cause Salla disease (SD) and infantile sialic acid storage disorder (ISSD aka N-acetylneuraminic acid storage disease, NSD). These diseases belong to the sialic acid storage diseases (SASDs)  and are autosomal recessive neurodegenerative disorders characterised by hypotonia, cerebellar ataxia and mental retardation with patients excreting large amounts of free Neu5Ac in urine. ISSD is a severe infantile form of SASD with a more severe clinical course than SD (Verheijen et al. 1999, Aula et al. 2000).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction259">
 <bp:evidence rdf:resource="#Evidence330" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">vRNA Extension</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway635">
 <bp:pathwayOrder rdf:resource="#PathwayStep2517" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2516" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1834" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1835" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2468" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Loss of MECP2 binding ability to 5mC-DNA</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Missense mutations in the methyl-CpG binding domain (MBD) of methyl-CpG-binding protein 2 (MECP2), spanning amino acids 90 to 162, negatively affect the binding ability of MECP2 to methylated DNA (Ghosh et al. 2008, Ho et al. 2008, Goffin et al. 2012, Mellen et al. 2012).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway634">
 <bp:pathwayOrder rdf:resource="#PathwayStep2514" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1833" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2466" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Loss of phosphorylation of MECP2 at T308</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Missense mutations of methyl-CpG-binding protein 2 (MECP2) in the vicinity of its threonine T308 phosphorylation site can negatively affect the ability of MECP2 to be phosphorylated at T308 in response to neuronal membrane depolarization (neuronal activity) (Ebert et al. 2013).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction257">
 <bp:evidence rdf:resource="#Evidence324" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Binding of NS1 to poly(A)-binding protein II (PABII)</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway637">
 <bp:pathwayOrder rdf:resource="#PathwayStep2663" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2521" />
 <bp:pathwayComponent rdf:resource="#Pathway638" />
 <bp:pathwayComponent rdf:resource="#Pathway709" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2473" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Disorders of transmembrane transporters</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Proteins with transporting functions can be roughly classified into 3 categories: ATP hydrolysis-coupled pumps, ion channels, and transporters. Pumps utilize the energy released by ATP hydrolysis to power the movement of substrates across the membrane against their electrochemical gradient. Channels in their open state can transfer substrates (ions or water) down their electrochemical gradient at an extremely high efficiency (up to 108 s-1). Transporters facilitate the movement of a specific substrate either against or with their concentration gradient at a lower speed (about 102 -104 s-1); as generally believed, conformational change of the transporter protein is involved in the transfer process. Diseases caused by defects in these transporter proteins are detailed in this section. Disorders associated with ABC transporters and SLC transporters are annotated here (Dean 2005).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction258">
 <bp:evidence rdf:resource="#Evidence329" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Initiation of vRNA Synthesis</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway636">
 <bp:pathwayOrder rdf:resource="#PathwayStep2519" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1836" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2471" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Loss of MECP2 binding ability to the NCoR/SMRT complex</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Missense mutations in the transcriptional repression domain of methyl-CpG-binding protein 2 (MECP2) can negatively affect binding of MECP2 to the nuclear receptor co-repressor (NCoR/SMRT) complex (Lyst et al. 2013, Ebert et al. 2013).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction255">
 <bp:evidence rdf:resource="#Evidence321" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NS1 binds PKR</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway639">
 <bp:pathwayOrder rdf:resource="#PathwayStep2523" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1837" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2475" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective SLC5A7 causes distal hereditary motor neuronopathy 7A (HMN7A)</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The human SLC5A7 gene encodes a sodium- and chloride-dependent, high affinity choline transporter (CHT) transports choline (Cho) from the extracellular space into neuronal cells. Cho uptake is the rate-limiting step in acetylcholine synthesis, a neurotransmitter released at the neuromuscular junction (NMJ). Defects in SLC5A7 can cause distal hereditary motor neuronopathy 7A (HMN7A; MIM:158580). Distal hereditary motor neuronopathies are a group of neuromuscular disorders caused by selective degeneration of motor neurons in the anterior horn of the spinal cord, without sensory deficit in the posterior horn. The clinical picture consists of a progressive distal muscle wasting and weakness in the legs without clinical sensory loss (Barwick et al. 2012).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction256">
 <bp:evidence rdf:resource="#Evidence323" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Binding of NS1 to cleavage and host polyadenylation specificity factor (CPSF)</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway638">
 <bp:pathwayOrder rdf:resource="#PathwayStep2528" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2605" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2649" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2607" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2524" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2601" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2645" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2569" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2526" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2603" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2647" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2641" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2565" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2522" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2643" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2567" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2561" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2563" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2609" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2617" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2619" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2579" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2536" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2613" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2657" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2538" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2615" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2659" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2575" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2532" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2653" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2577" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2534" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2611" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2655" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2571" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2573" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2530" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2651" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2581" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2627" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2629" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2623" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2547" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2625" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2549" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2542" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2543" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2587" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2621" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2545" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2589" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2583" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2540" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2661" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2585" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2591" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2639" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2557" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2635" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2559" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2637" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2553" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2597" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2631" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2555" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2599" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2633" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2593" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2551" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2595" />
 <bp:pathwayComponent rdf:resource="#Pathway657" />
 <bp:pathwayComponent rdf:resource="#Pathway656" />
 <bp:pathwayComponent rdf:resource="#Pathway659" />
 <bp:pathwayComponent rdf:resource="#Pathway658" />
 <bp:pathwayComponent rdf:resource="#Pathway691" />
 <bp:pathwayComponent rdf:resource="#Pathway690" />
 <bp:pathwayComponent rdf:resource="#Pathway693" />
 <bp:pathwayComponent rdf:resource="#Pathway494" />
 <bp:pathwayComponent rdf:resource="#Pathway692" />
 <bp:pathwayComponent rdf:resource="#Pathway651" />
 <bp:pathwayComponent rdf:resource="#Pathway695" />
 <bp:pathwayComponent rdf:resource="#Pathway650" />
 <bp:pathwayComponent rdf:resource="#Pathway694" />
 <bp:pathwayComponent rdf:resource="#Pathway653" />
 <bp:pathwayComponent rdf:resource="#Pathway697" />
 <bp:pathwayComponent rdf:resource="#Pathway652" />
 <bp:pathwayComponent rdf:resource="#Pathway696" />
 <bp:pathwayComponent rdf:resource="#Pathway655" />
 <bp:pathwayComponent rdf:resource="#Pathway699" />
 <bp:pathwayComponent rdf:resource="#Pathway654" />
 <bp:pathwayComponent rdf:resource="#Pathway698" />
 <bp:pathwayComponent rdf:resource="#Pathway668" />
 <bp:pathwayComponent rdf:resource="#Pathway701" />
 <bp:pathwayComponent rdf:resource="#Pathway667" />
 <bp:pathwayComponent rdf:resource="#Pathway700" />
 <bp:pathwayComponent rdf:resource="#Pathway703" />
 <bp:pathwayComponent rdf:resource="#Pathway669" />
 <bp:pathwayComponent rdf:resource="#Pathway702" />
 <bp:pathwayComponent rdf:resource="#Pathway705" />
 <bp:pathwayComponent rdf:resource="#Pathway704" />
 <bp:pathwayComponent rdf:resource="#Pathway707" />
 <bp:pathwayComponent rdf:resource="#Pathway706" />
 <bp:pathwayComponent rdf:resource="#Pathway708" />
 <bp:pathwayComponent rdf:resource="#Pathway660" />
 <bp:pathwayComponent rdf:resource="#Pathway662" />
 <bp:pathwayComponent rdf:resource="#Pathway661" />
 <bp:pathwayComponent rdf:resource="#Pathway664" />
 <bp:pathwayComponent rdf:resource="#Pathway663" />
 <bp:pathwayComponent rdf:resource="#Pathway666" />
 <bp:pathwayComponent rdf:resource="#Pathway665" />
 <bp:pathwayComponent rdf:resource="#Pathway679" />
 <bp:pathwayComponent rdf:resource="#Pathway678" />
 <bp:pathwayComponent rdf:resource="#Pathway639" />
 <bp:pathwayComponent rdf:resource="#Pathway671" />
 <bp:pathwayComponent rdf:resource="#Pathway670" />
 <bp:pathwayComponent rdf:resource="#Pathway673" />
 <bp:pathwayComponent rdf:resource="#Pathway672" />
 <bp:pathwayComponent rdf:resource="#Pathway675" />
 <bp:pathwayComponent rdf:resource="#Pathway674" />
 <bp:pathwayComponent rdf:resource="#Pathway677" />
 <bp:pathwayComponent rdf:resource="#Pathway676" />
 <bp:pathwayComponent rdf:resource="#Pathway646" />
 <bp:pathwayComponent rdf:resource="#Pathway645" />
 <bp:pathwayComponent rdf:resource="#Pathway689" />
 <bp:pathwayComponent rdf:resource="#Pathway648" />
 <bp:pathwayComponent rdf:resource="#Pathway647" />
 <bp:pathwayComponent rdf:resource="#Pathway649" />
 <bp:pathwayComponent rdf:resource="#Pathway680" />
 <bp:pathwayComponent rdf:resource="#Pathway682" />
 <bp:pathwayComponent rdf:resource="#Pathway681" />
 <bp:pathwayComponent rdf:resource="#Pathway640" />
 <bp:pathwayComponent rdf:resource="#Pathway684" />
 <bp:pathwayComponent rdf:resource="#Pathway683" />
 <bp:pathwayComponent rdf:resource="#Pathway642" />
 <bp:pathwayComponent rdf:resource="#Pathway686" />
 <bp:pathwayComponent rdf:resource="#Pathway641" />
 <bp:pathwayComponent rdf:resource="#Pathway685" />
 <bp:pathwayComponent rdf:resource="#Pathway644" />
 <bp:pathwayComponent rdf:resource="#Pathway688" />
 <bp:pathwayComponent rdf:resource="#Pathway643" />
 <bp:pathwayComponent rdf:resource="#Pathway687" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2474" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SLC transporter disorders</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The solute-carrier gene (SLC) superfamily encodes membrane-bound transporters comprising 55 gene families with at least 362 putatively functional protein-coding genes. The gene products include passive transporters, symporters and antiporters and are located in all cellular and organelle membranes. Curated here is a list of SLCs, where mutations within them can result in disease (Hediger et al. 2013).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction253">
 <bp:evidence rdf:resource="#Evidence318" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Translocation of Influenza A virus nonstructural protein 1 (NS1A) into the nucleus</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction254">
 <bp:evidence rdf:resource="#Evidence320" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Binding of NS1 to dsRNA</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction251">
 <bp:evidence rdf:resource="#Evidence315" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NA activation of TGF-beta</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction252">
 <bp:evidence rdf:resource="#Evidence317" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Release of NS1 homodimer</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction250">
 <bp:evidence rdf:resource="#Evidence314" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">PB1-F2 binds to the mitochondrial adenine nucleotide translocator 3 ANT3, inducing apoptosis</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway631">
 <bp:pathwayOrder rdf:resource="#PathwayStep2510" />
 <bp:pathwayComponent rdf:resource="#Pathway632" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2462" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Pervasive developmental disorders</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Pervasive developmental disorders (PDDs) largely overlap with the autism spectrum disorders (ASDs). PDDs manifest in childhood and mainly affect social interaction, including communication and behavior. PDDs can be caused by mutations in genes involved in brain development and function, environmental insults, or the combination of environmental factors and genetic susceptibility. The pervasive developmental disorder pathway that Reactome has annotated is the &quot;Loss of function of MECP2 in Rett syndrome&quot;. For review of this topic, please refer to Picket and London 2005, Currenti 2010, Elsabbagh et al. 2012, Ferreri 2014.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway630">
 <bp:pathwayOrder rdf:resource="#PathwayStep2509" />
 <bp:pathwayComponent rdf:resource="#Pathway631" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2461" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Disorders of Nervous System Development</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Neurodevelopmental disorders are chronic disorders that affect the function of the central nervous system (CNS) and impair motor skills, cognition, communication and/or behavior. While these disorders frequently stem from mutations in genes that directly control CNS development, they can also be a consequence of environmental insults such as hypoxic/ischemic injury, trauma, exposure to toxins, infections and nutritional deficiencies, or be indirectly caused by mutations in metabolic genes (reviewed by Ismail and Shapiro 2019). Disorders of nervous system development have been traditionally classified based on phenotypic traits (clinical presentation). Molecular genetics studies have revealed, however, that indistinguishable clinical presentations may result from pathogenic variants in different genes whose protein products function in connected biological pathways. On the other hand, distinct clinical presentations may be caused by pathogenic mutations in a single gene that functions in multiple biological pathways (Desikan and Bakrovich 2018). In the future, phenotype-based classification of neurodevelopmental disorders may be replaced by a more informative pathway-based nomenclature (Desikan and Bakrovich 2018). Biological pathways frequently impaired in neurodevelopmental disorders are signal transduction pathways such as the mTOR pathway in tuberous sclerosis complex (TSC) (Wong 2019) and the RAS/RAF/MAPK pathway in RASopathies (Kang and Lee 2019), neurotransmission pathways as in some autism spectrum disorders (ASD) (Burnashev and Szepetowski 2015, Hu et al. 2016), and pathways that regulate gene expression as in Mendelian disorders of epigenetic machinery (MDEM) (Fahrner and Bjornsson 2019).  So far,we have annotated the role of loss-of-function mutations in methyl-CpG-binding protein 2 (MECP2), an epigenetic regulator of transcription, in Rett syndrome, a pervasive developmental disorder that belongs to the MDEM category (Pickett and London 2005, Ferreri 2014).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway633">
 <bp:pathwayOrder rdf:resource="#PathwayStep2512" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1832" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2464" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Loss of MECP2 binding ability to 5hmC-DNA</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Missense mutations in the methyl-CpG binding domain (MBD) of MECP2, spanning amino acids 90 to 162, negatively affect the binding ability of MECP2 to hydroxymethylated DNA (Mellen et al. 2012).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway632">
 <bp:pathwayOrder rdf:resource="#PathwayStep2518" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2513" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2515" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2511" />
 <bp:pathwayComponent rdf:resource="#Pathway635" />
 <bp:pathwayComponent rdf:resource="#Pathway634" />
 <bp:pathwayComponent rdf:resource="#Pathway636" />
 <bp:pathwayComponent rdf:resource="#Pathway633" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2463" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Loss of function of MECP2 in Rett syndrome</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Loss of function mutations in methyl-CpG-binding protein 2 (MECP2), an epigenetic regulator of transcription, are the major cause of Rett syndrome, a neurodevelopmental disorder that affects 1 in 10,000-15,000 female births. The symptoms of Rett syndrome appear after 6-18 months of apparently normal postnatal development and include regression of acquired language and motor skills, stereotypic hand movements, intellectual disability, epileptic seizures and respiratory disturbances. Besides Rett syndrome, aberrant MECP2 expression is implicated as an underlying cause of other neuropsychiatric disorders (reviewed by Banerjee et al. 2012, Ebert and Greenberg 2013, Lyst and Bird 2015). Only functionally characterized MECP2 mutations are annotated. For a comprehensive list of MECP2 mutations reported in Rett syndrome, please refer to the RettBASE (http://mecp2.chw.edu.au), a database dedicated to curation of disease variants of MECP2, CDKL5 and FOXG1 in Rett syndrome (Krishnaraj et al. 2017).  The pathway &quot;Loss of MECP2 binding ability to the NCoR/SMRT complex&quot; describes MECP2 loss-of-function mutations reported in Rett syndrome that impair its ability to associate with the NCoR/SMRT complex.  The pathway &quot;Loss of phosphorylation of MECP2 at T308&quot; describe loss-of-function mutations in MECP2 reported in Rett syndrome that impair its ability to undergo phosphorylation at threonine residue 308 in response to neuronal activity.  The pathway &quot;Loss of MECP2 binding ability to 5hmC-DNA&quot; describes MECP2 loss-of-function mutations reported in Rett syndrome that impair the ability of MECP2 to bind to hydroxymethylated DNA.  The pathway &quot;Loss of MECP2 binding ability to 5mC-DNA&quot; describes MECP2 loss-of-function mutations reported in Rett syndrome that impair the ability of MECP2 to bind to methylated DNA.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction248">
 <bp:evidence rdf:resource="#Evidence311" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Conformation change in hemagglutinin freeing the fusion peptide of HA2</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway646">
 <bp:pathwayOrder rdf:resource="#PathwayStep2537" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1844" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2489" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective SLC20A2 causes idiopathic basal ganglia calcification 1 (IBGC1)</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The genes SLC20A1 and SLC20A2 encode for phosphate transporters 1 and 2 (PiT1 and PiT2 respectively). They both have a broad tissue distribution and may play a general housekeeping role in phosphate transport such as absorbing phosphate from interstitial fluid and in extracellular matrix and cartilage calcification as well as in vascular calcification.  They possess Na+-coupled phosphate (Pi) cotransporter function with a stoichiometry of 2:1 (Na+:Pi). Defects in SLC20A2 can cause idiopathic basal ganglia calcification 1 (IBGC1; MIM:213600), an autosomal dominant disorder characterised by vascular and pericapillary calcification by calcium phosphate in the basal ganglia and other brain regions. Affected individuals can either be asymptomatic or show a wide spectrum of neuropsychiatric symptoms including parkinsonism and dementia (Wang et al. 2012, Hsu et al. 2013, Ashtari et al. 2013, Forster et al. 2013).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction249">
 <bp:evidence rdf:resource="#Evidence312" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Concerted hemagglutinin pore formation</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway645">
 <bp:pathwayOrder rdf:resource="#PathwayStep2535" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1843" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2487" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective SLCO1B1 causes hyperbilirubinemia, Rotor type (HBLRR)</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The solute carrier organic anion transporter family member 1B1 (SLCO1B1) is expressed on the basolateral surfaces of hepatocytes and mediates the uptake of bilirubin (BIL), a breakdown product of heme degradation, to the liver where it is conjugated and excreted from the body. Defects in SLCO1B1 can cause hyperbilirubinemia, Rotor type (HBLRR; MIM:237450), an autosomal recessive form of primary conjugated hyperbilirubinemia. Mild jaundice, not associated with hemolysis, develops shortly after birth or in childhood (van de Steeg et al. 2012, Sticova    Jirsa 2013, Keppler 2014).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction246">
 <bp:evidence rdf:resource="#Evidence308" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Ribonucleoprotein release from M1 proteins</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway648">
 <bp:pathwayOrder rdf:resource="#PathwayStep2541" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1846" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2493" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective SLC6A2 causes orthostatic intolerance (OI)</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SLC6A2 encodes the sodium-dependent noradrenaline transporter NAT1 which terminates the action of the neurotransmitter noradrenaline by transporting it from the synapse back to its vesicles for storage and reuse (Broer    Gether 2012, Schweikhard    Ziegler 2012). SLC6A2 is expressed in the CNS and adrenal glands. Defects in SLC6A2 can cause orthostatic intolerance (OI; MIM:604715), a syndrome characterised by lightheadedness, fatigue and development of symptoms during upright standing, relieved by sitting back down again. Plasma norepinephrine concentration is abnormally high (Lambert    Lambert 2014).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction247">
 <bp:evidence rdf:resource="#Evidence310" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Fusion of the influenza virion HA2 protein transmembrane domain to the host cell endosome membrane</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway647">
 <bp:pathwayOrder rdf:resource="#PathwayStep2539" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1845" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2491" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective SLC27A4 causes ichthyosis prematurity syndrome (IPS)</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The SLC27 gene family code for fatty acid transport proteins (FATPs). Long chain fatty acids (LCFAs) are critical for many physiological and cellular processes as a primary energy source. Of the six FATPs characterised, three have been shown to mediate the influx of LCFAs into cells; FATP1, 4 and 6. SLC27A4 (FATP4) is the major intestinal LCFA transporter but is also expressed at lower levels in brain, kidney, liver and heart. SLC27A4 is also expressed in skin, where it has been shown to play a major role in epidermal development, being highly expressed in neonatal keratinocytes. Defects in SLC27A4 can cause ichthyosis prematurity syndrome (IPS; MIM:604194), a keratinisation disorder which is characterised by thickened epidermis and respiratory complications. Patients suffer from a lifelong non-scaly ichthyosis (Anderson    Stahl 2013).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction244">
 <bp:evidence rdf:resource="#Evidence304" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Docking and transport of the RNP:Karyopherin complex through the nuclear pore</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction245">
 <bp:evidence rdf:resource="#Evidence307" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Virion-associated M2 protein mediated ion infusion</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway649">
 <bp:pathwayOrder rdf:resource="#PathwayStep2544" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1847" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2495" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective SLC7A7 causes lysinuric protein intolerance (LPI)</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SLC7A7 encodes the y+L amino acid transporter 1 (y+LAT1). As a heterodimer with SLC3A2 in the plasma membrane, SLC7A7 mediates the exchange of arginine (L-Arg) for leucine (L-Leu) and a sodium ion (Na+). The physiological concentrations of arginine and leucine are expected to favor arginine export (Schweikhard    Ziegler 2012). Defects in SLC7A7 can cause Lysinuric protein intolerance (LPI; MIM:222700), a metabolic disorder characterised by decreased cationic amino acid (CAA) transport at the basolateral membrane of epithelial cells in the intestine and kidney, increased renal excretion of CAA and orotic aciduria. There is extreme variability clinically but typical symptoms include refusal to feed, vomiting and consequent failure to thrive. Hepatosplenomegaly, hematological anomalies and neurological involvement are recurrent clinical features (Sperandeo et al. 2008, Sebastio et al. 2011). </bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction242">
 <bp:evidence rdf:resource="#Evidence302" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Recognition of the Nuclear Localization Signal (NLS) by a Karyopherin Alpha Family Protein</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction243">
 <bp:evidence rdf:resource="#Evidence303" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Release of the RNP into the host cell nucleus</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction240">
 <bp:evidence rdf:resource="#Evidence299" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Neuraminidase enzymatic release from sialic acid</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction241">
 <bp:evidence rdf:resource="#Evidence301" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Recruitment of Karyopherin Beta to form a Trimeric Complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway640">
 <bp:pathwayOrder rdf:resource="#PathwayStep2525" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1838" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2477" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective SLC3A1 causes cystinuria (CSNU)</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Neutral and basic amino acid transport protein rBAT (SLC3A1) and b(0,+)-type amino acid transporter 1 (SLC7A9) are linked by a disulfide bridge to form system b(0,+)-like activity in the high affinity transport of neutral and dibasic amino acids and cystine. The SLC7A9:SLC3A1 heterodimer mediates the electrogenic exchange of extracellular amino acids such as L-arginine (L-Arg) and L-lysine (L-lys) and cystine (CySS-, the oxidised form of L-cysteine) for intracellular neutral amino acids such as L-leucine (L-Leu). These solute carriers are mainly expressed in the kidney and small intestine where they remove dibasic amino acids and cystine from the renal tubular and intestinal lumen respectively (Schweikhard    Ziegler 2012). Defects in SLC3A1 (or SLC7A9) can cause cystinuria (CSNU; MIM:220100), an autosomal recessive disorder characterised by impaired epithelial cell transport of cystine and dibasic amino acids in the proximal renal tubule and GI tract. The build-up and low solubility of cystine causes the formation of calculi in the urinary tract, resulting in obstructive uropathy, pyelonephritis and in severe cases, renal failure (Palacin et al. 2001, Mattoo    Goldfarb 2008, Fotiadis et al. 2013, Saravakos et al. 2014). Cystinuria is subcategorized as type A (mutations on SLC3A1) and type B (mutations on SLC7A9).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway642">
 <bp:pathwayOrder rdf:resource="#PathwayStep2529" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1840" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2481" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective SLC35A1 causes congenital disorder of glycosylation 2F (CDG2F)</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The human gene SLC35A1 encodes the CMP-sialic acid transporter which mediates the antiport of CMP-sialic acid (CMP-Neu5Ac) into the Golgi lumen in exchange for CMP (Ishida et al. 1996). Defects in SLC35A1 are the cause of congenital disorder of glycosylation type 2F (CDG2F; MIM:603585), characterised by under-glycosylated serum proteins. CDGs are a family of severe inherited diseases caused by a defect in protein N-glycosylation. These multisystem disorders present with a wide spectrum of phenotypes such as disorders of nervous system development, psychomotor retardation, dysmorphic features, hypotonia, coagulation disorders and immunodeficiency (Martinez-Duncker et al. 2005, Song 2013).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway641">
 <bp:pathwayOrder rdf:resource="#PathwayStep2527" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1839" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2479" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective SLC5A1 causes congenital glucose/galactose malabsorption (GGM)</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Sodium/glucose cotransporter 1 (SLC5A1 aka SGLT1) actively and reversibly transports glucose (Glc) into cells by Na+ cotransport with a Na+ to glucose coupling ratio of 2:1. SLC5A1 is mainly expressed in the microvilli of intestine and kidney and responsible for the absorption of sugars. Overexpressed SLC5A1 has been found in various cancers, possibly playing a role in preventing autophagic cell death by maintaining intracellular glucose levels. Defects in SLC5A1 can cause congenital glucose/galactose malabsorption (GGM; MIM:606824), an autosomal recessive disorder manifesting itself in newborns characterised by severe, life-threatening diarrhea which is usually fatal unless glucose and galactose are removed from the diet (Wright et al. 2002, Bergeron et al. 2008, Wright et al. 2007, Wright 2013).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway644">
 <bp:pathwayOrder rdf:resource="#PathwayStep2533" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1842" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2485" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective SLC12A1 causes Bartter syndrome 1 (BS1)</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The solute carrier family 12 member 1 (SLC12A1, NKCC2) is a kidney-specific, membrane-bound protein that cotransports two Cl- ions electroneutrally into cells with a Na+ ion and a K+ ion and plays a vital role in the regulation of ionic balance and cell volume. Defects in SLC12A1 can cause Bartter&#8217;s syndrome (BS1; MIM:601678), an autosomal-recessive disease salt-wasting disorder characterised by renal tubular hypokalaemia, metabolic alkalosis and hypercalciuria. Clinical features present in infancy and include muscle weakness, anorexia, polydipsia, polyuria, failure to thrive and mental and growth retardation (Favero et al. 2011, Gagnon    Delpire 2013).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway643">
 <bp:pathwayOrder rdf:resource="#PathwayStep2531" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1841" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2483" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective TPR may confer susceptibility towards thyroid papillary carcinoma (TPC)</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The nuclear pore complex (NPC) trafficks cargo across the nuclear membrane. Nucleoprotein TPR functions as a scaffolding element in the nuclear phase of the NPC essential for normal nucleocytoplasmic transport of proteins and mRNAs. The complex glucokinase (GCK1) and glucokinase regulatory protein (GKRP) can be translocated to the nucleus via the NPC. Defects in TPR may confer susceptibility towards thyroid papillary carcinona (TPC; MIM:18850), a common tumor of the thyroid that typically arises as an irregular, solid or cystic mass from otherwise normal thyroid tissue (Vriens et al. 2009, Bonora et al. 2010).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway503">
 <bp:pathwayOrder rdf:resource="#PathwayStep2222" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1675" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2177" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective DOLK causes DOLK-CDG</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Dolichol kinase (DOLK, TMEM15) normally mediates the phosphorylation of dolichol (DCHOL) to form dolichyl phosphate (DOLP) in the ER membrane (Fernandez et al. 2002). DOLP is an important substrate in the synthesis of N- and O-glycosylated proteins and GPI anchors. Defects in DOLK cause congenital disorder of glycosylation type 1m (DOLK-CDG, CDG1m, also known as dolichol kinase deficiency; MIM:610768), a severe mutisystem disorder characterised by under-glycosylated serum glycoproteins. This disorder has a very severe phenotype and death can occur in early life (Kranz et al. 2007).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway502">
 <bp:pathwayOrder rdf:resource="#PathwayStep2220" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1674" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2175" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective DPM1 causes DPM1-CDG</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Dolichyl-phosphate mannosyltransferase (DPM), a heterotrimeric protein embedded in the endoplasmic reticulum membrane, mediates the transfer of mannose (from cytosolic GDP-mannose) to dolichyl phosphate (DOLP) to form dolichyl-phosphate-mannose (DOLPman). The first subunit of the heterotrimer (DPM1) appears to be the actual catalyst, and the other two subunits (DPM2 and 3) appear to stabilise it (Maeda et al. 2000). Defects in DPM1 can cause congenital disorder of glycosylation 1e (DPM1-CDG, CDG-1e; MIM:608799), a multisystem disorder caused by a defect in glycoprotein biosynthesis and characterised by under-glycosylated serum glycoproteins (Kim et al. 2000, Imbach et al. 2000, Garcia-Silva et al. 2004).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway505">
 <bp:pathwayOrder rdf:resource="#PathwayStep2226" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1677" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2181" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective MPI causes MPI-CDG</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Mannose 6-phosphate isomerase (MPI) normally isomerises fructose 6-phosphate (Fru6P) to mannose 6-phosphate (Man6P) in the cytosol. Man6P is a precursor in the synthesis of GDP-mannose and dolichol-phosphate-mannose, required for mannosyl transfer reactions in the N-glycosylation of proteins. Defects in MPI cause congenital disorder of glycosylation 1b (MPI-CDG, previously known as CDG1b,; MIM:602579), a multisystem disorder characterised by under-glycosylated serum glycoproteins (Schollen et al. 2000). Unlike PMM2-CDG (CDG1a), there is no neurological involvement with MPI-CDG. Instead, patients present predominantly with diarrhoea, failure to thrive and protein-losing enteropathy (Pelletier et al. 1986). MPI-CDG is one of two CDGs that can be treated with oral mannose supplementation, but can be fatal if left untreated (Marquardt    Denecke 2003).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway504">
 <bp:pathwayOrder rdf:resource="#PathwayStep2224" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1676" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2179" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective SRD5A3 causes SRD5A3-CDG, KHRZ</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Polyprenol reductase (SRD5A3), resident on the endoplasmic reticulum membrane, normally mediates the reduction of the alpha-isoprene unit of polyprenol (pPNOL) to form dolichol (DCHOL) in a NADPH-dependent manner (Cantagrel et al. 2010). DCHOLs are substrates required for the synthesis of the lipid-linked oligosaccharide (LLO) precursor used for N-glycosylation. Defects in SRD5A3 cause congenital disorder of glycosylation 1q (SRD5A3-CDG, CDG1q; MIM:612379), a neurodevelopmental disorder characterised by under-glycosylated serum glycoproteins resulting in nervous system development, psychomotor retardation, hypotonia, coagulation disorders and immunodeficiency (Cantagrel et al. 2010, Kasapkara et al. 2012). Defects in SRD5A3 can also cause Kahrizi syndrome (KHRZ; MIM:612713), a neurodevelopmental disorder characterised by mental retardation, cataracts, holes in eye structures, pathological curvature of the spine, and coarse facial features (Kahrizi et al. 2011).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway507">
 <bp:pathwayOrder rdf:resource="#PathwayStep2230" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1679" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2185" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective GALT can cause GALCT</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Galactose-1-phosphate uridylyltransferase (GALT) is one of the enzymes involved in galactose metabolism in the Leloir pathway. GALT catalyses the transfer of uridine monophosphate (UMP) from UDP-glucose (UDP-Glc) to galactose-1-phosphate (Gal1P) to form UDP-galactose (UDP-Gal) and glucose 1-phosphate. Defects in GALT can cause Galactosemia (GALCT; MIM:230400), an autosomal recessive disorder of galactose metabolism presenting in neonatals that causes jaundice, cataracts and mental retardation (Bosch 2006).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway506">
 <bp:pathwayOrder rdf:resource="#PathwayStep2228" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1678" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2183" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective DHDDS causes RP59</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The ER membrane-associated enzyme dehydrodolichyl diphosphate synthase (DHDDS) (Endo et al. 2003) normally mediates the sequential head-to-tail cis addition of multiple isopentyl pyrophosphate (IPP) molecules to farnesyl pyrophosphate (E,E-FPP) to produce polyprenol pyrophosphate (pPPP) (Shridas et al. 2003). Dolichol in humans contain homologues ranging from 17-23 isoprene units, the most common homologues contain 19 or 20 isoprene units (Freeman et al. 1980). Dolichol is an important substrate in the N-glycosylation of proteins, including rhodopsin.  Defects in DHDDS cause retinitis pigmentosa 59 (RP59; MIM:613861), a pigment retinopathy, characterised by retinal pigment deposits (visible on fundus examination) and primary loss of rod photoreceptors followed by secondary loss of cone photoreceptors. Sufferers typically have night vision blindness and loss of mid to peripheral vision. As the condition progresses, they lose far peripheral vision and eventually central vision (Zuchner et al. 2011).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway509">
 <bp:pathwayOrder rdf:resource="#PathwayStep2235" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1682" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2190" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective GALK1 causes GALCT2</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Cytosolic galactokinase (GALK1) catalyses the first committed step in the Leloir pathway of galactose metabolism. GALK1 catalyses the phosphorylation of D-galactose (Gal) to form D-galactose 1-phosphate (Gal1P). Defects in GALK1 can cause type II galactosemia (GALCT2; MIM:230200), an autosomal recessive deficiency characterised by congenital cataracts during infancy and presenile cataracts in the adult population. Galactitol accumulation in the lens is the cause of these cataracts (Bosch et al. 2002).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway508">
 <bp:pathwayOrder rdf:resource="#PathwayStep2232" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2233" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1681" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1680" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2187" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective GNE causes sialuria, NK and IBM2</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Sialuria (MIM:269921) is caused by a metabolic defect where the UDP?N?acetylglucosamine 2?epimerase, N?acetylmannosamine kinase (GNE) gene lacks feedback inhibition resulting in constitutive overproduction of free sialic acid (Neu5Ac) (Montreuil et al. 1968, Fontaine et al. 1968). Sialuria is characterised by a large cytoplasmic accumulation and urinary excretion of Neu5Ac (Kamerling et al. 1979). Sialurias differ from sialidoses, in which there is storage and excretion of &apos;bound&apos; Neu5Ac. Defects in GNE also cause Nonaka myopathy (NK; MIM:605820), an early adult-onset disorder characterised by muscle weakness and wasting of distal muscles, especially the anterior tibial muscles (Nonaka et al. 1981, Asaka et al. 2001). Defects in GNE also cause inclusion body myopathy 2 (IBM2; MIM:600737), an autosomal recessive disorder with a similar phenotype to Nonaka myopathy (NK). IBM2 is an adult-onset, proximal and distal muscle weakness and wasting disorder. Muscle biospsy reveals from sufferers shows a rimmed vacuole myopathy and the degenerating muscle fibers contained abnormal amounts of beta-amyloid protein such as that found in neurodegenerative diorders. However, there is no neurological symptoms in these patients (Argov    Yarom 1984).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence2190">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2191">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2192">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2193">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2194">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2195">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2196">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2197">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2198">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2199">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway501">
 <bp:pathwayOrder rdf:resource="#PathwayStep2218" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1673" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2173" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective DPM2 causes DPM2-CDG</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Dolichyl-phosphate mannosyltransferase (DPM), a heterotrimeric protein embedded in the endoplasmic reticulum membrane, mediates the transfer of mannose (from cytosolic GDP-mannose) to dolichyl phosphate (DOLP) to form dolichyl-phosphate-mannose (DOLPman). The first subunit of the heterotrimer (DPM1) appears to be the actual catalyst, and the other two subunits (DPM2 and 3) appear to stabilise it (Maeda et al. 2000). Defects in DPM2 can cause congenital disorder of glycosylation 1u (DPM2-CDG, CDG1u; MIM:615042), a multisystem disorder caused by a defect in glycoprotein biosynthesis and characterised by under-glycosylated serum glycoproteins (Barone et al. 2012). CDG type 1 diseases result in a wide variety of clinical features, such as defects in the nervous system development, psychomotor retardation, dysmorphic features, hypotonia, coagulation disorders, and immunodeficiency.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway500">
 <bp:pathwayOrder rdf:resource="#PathwayStep2216" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1672" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2171" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective PMM2 causes PMM2-CDG</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Phosphomannomutase 2 (PMM2) normally catalyses the isomerisation of mannose 6-phosphate (Man6P) to mannose 1-phosphate (Man1P) in the cytosol of cells. Man1P is a precursor in the synthesis of GDP-mannose and dolichol-phosphate-mannose, required for critical mannosyl transfer reactions in the N-glycosylation of proteins. Mutations in the PMM2 gene are one of the causes of Jaeken syndrome, a congenital disorder of glycosylation type 1a (PMM2-CDG, previously CDG-1a) (Matthijs et al. 1997). PMM2-CDG was first described in Belgian identical twin sisters, characterized by psychomotor retardation and multiple serum glycoprotein abnormalities. Serum and CSF transferrin were found to be deficient in sialic acid (Jaeken et al. 1984). PMM2-CDG is the most common CDG disease subtype.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1400">
 <bp:evidence rdf:resource="#Evidence1736" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">RNF43 frameshift mutants show enhanced WNT siganling</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1403">
 <bp:evidence rdf:resource="#Evidence1743" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">PORCN-inhibitor LGK974 prevents WNT ligand palmitoyltation and secretion</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1404">
 <bp:evidence rdf:resource="#Evidence1746" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">APC truncation mutants have impaired AXIN binding</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1401">
 <bp:evidence rdf:resource="#Evidence1739" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Deletions of the AMER1 gene prevent expression of AMER1 protein</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1402">
 <bp:evidence rdf:resource="#Evidence1741" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Truncated AMER1 mutants destabilize the destruction complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1407">
 <bp:evidence rdf:resource="#Evidence1753" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">CTNNB1 S45 mutants aren&apos;t phosphorylated by CK1alpha</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1408">
 <bp:evidence rdf:resource="#Evidence1755" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">CTNNB1 S37 mutants aren&apos;t phosphorylated by GSK3beta</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1405">
 <bp:evidence rdf:resource="#Evidence1748" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">APC truncation mutants are not K63 polyubiquitinated</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1406">
 <bp:evidence rdf:resource="#Evidence1750" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">XAV939 binds tankyrase to stabilize axin and inhibit WNT signaling</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1409">
 <bp:evidence rdf:resource="#Evidence1757" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">CTNNB1 S33 mutants aren&apos;t phosphorylated by GSK3beta</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1410">
 <bp:evidence rdf:resource="#Evidence1759" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">CTNNB1 T41 mutants aren&apos;t phosphorylated by GSK3beta</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1411">
 <bp:evidence rdf:resource="#Evidence1761" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TFC7L2 mutants don&apos;t bind CTBP</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1414">
 <bp:evidence rdf:resource="#Evidence1768" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Constitutive phosphorylation of kinase domain KIT mutants</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1415">
 <bp:evidence rdf:resource="#Evidence1770" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Phosphorylation of juxtamembrane domain KIT mutants</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1412">
 <bp:evidence rdf:resource="#Evidence1763" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Misspliced GSK3beta mutants stabilize beta-catenin levels</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1413">
 <bp:evidence rdf:resource="#Evidence1765" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">misspliced mutants of LRP5 support enhanced beta-catenin-dependent signaling</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1418">
 <bp:evidence rdf:resource="#Evidence1774" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Ligand-independent dimerization of KIT extracellular domain mutants</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1419">
 <bp:evidence rdf:resource="#Evidence1776" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Phosphorylation of STATs downstream of KIT mutants</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1416">
 <bp:evidence rdf:resource="#Evidence1771" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Ligand-independent dimerization of KIT juxtamembrane domain mutants</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1417">
 <bp:evidence rdf:resource="#Evidence1773" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Phosphorylation of extracellular domain KIT mutants</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1421">
 <bp:evidence rdf:resource="#Evidence1778" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">JAK2 binds to p-KIT mutants</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1422">
 <bp:evidence rdf:resource="#Evidence1779" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">KIT mutants bind SFKs</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1420">
 <bp:evidence rdf:resource="#Evidence1777" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">KIT mutants bind GRB2-SOS</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence2160">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1425">
 <bp:evidence rdf:resource="#Evidence1782" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">p-KIT mutants:GRB2:SOS catalyzes nucleotide exchange on RAS</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence2161">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1426">
 <bp:evidence rdf:resource="#Evidence1783" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Recruitment of STATs by KIT mutants</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence2162">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1423">
 <bp:evidence rdf:resource="#Evidence1780" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Phosphorylated KIT mutants bind PI3K</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence2163">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1424">
 <bp:evidence rdf:resource="#Evidence1781" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Disassociation and translocation of STATs to the nucleus downstream of KIT mutants</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence2164">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1429">
 <bp:evidence rdf:resource="#Evidence1786" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Phosphorylation of JAK2 downstream of KIT mutants</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence2165">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2166">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1427">
 <bp:evidence rdf:resource="#Evidence1784" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Dimerization of STATs downstream of KIT mutants</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence2167">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1428">
 <bp:evidence rdf:resource="#Evidence1785" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">KIT mutants:PI3K catalyze synthesis of PIP3</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence2168">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2169">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1440">
 <bp:evidence rdf:resource="#Evidence1808" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">p-4Y-PLCG1 dissociates from activated FGFR4 mutants</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1432">
 <bp:evidence rdf:resource="#Evidence1793" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Regorafenib-resistant KIT mutants do not bind regorafenib</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1433">
 <bp:evidence rdf:resource="#Evidence1795" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Dasatinib-resistant KIT mutants do not bind dasatinib</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1430">
 <bp:evidence rdf:resource="#Evidence1789" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Imatinib-resistant KIT mutants do not bind imatinib</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1431">
 <bp:evidence rdf:resource="#Evidence1791" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Sunitinib-resistant KIT mutants do not bind sunitinib</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1436">
 <bp:evidence rdf:resource="#Evidence1801" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Sorafenib-resistant KIT mutants do not bind sorafenib</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence2150">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1437">
 <bp:evidence rdf:resource="#Evidence1803" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">KIT mutants bind type II TKIs</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence2151">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1434">
 <bp:evidence rdf:resource="#Evidence1797" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Masitinib-resistant KIT mutants do not bind masitinib</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence2152">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1435">
 <bp:evidence rdf:resource="#Evidence1799" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Nilotinib-resistant KIT mutants do not bind nilotinib</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence2153">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2154">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2155">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1438">
 <bp:evidence rdf:resource="#Evidence1804" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">KIT mutants bind type I TKIs</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence2156">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1439">
 <bp:evidence rdf:resource="#Evidence1805" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">KIT mutants bind ripretinib</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence2157">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2158">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2159">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1450">
 <bp:evidence rdf:resource="#Evidence1819" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FGFR4 kinase mutants are inhibited by PD170734</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1451">
 <bp:evidence rdf:resource="#Evidence1820" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated FGFR4 mutants:p-FRS2:GRB2:GAB1:PIK3R1 binds PIK3CA</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1443">
 <bp:evidence rdf:resource="#Evidence1811" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated FGFR4 mutants:p-FRS2 binds GRB2:GAB1:PIK3R1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1444">
 <bp:evidence rdf:resource="#Evidence1812" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated FGFR4 mutant-associated PI3K phosphorylates PIP2 to PIP3</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence2180">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1441">
 <bp:evidence rdf:resource="#Evidence1809" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated FGFR4 mutants phosphorylate PLCG1</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence2181">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1442">
 <bp:evidence rdf:resource="#Evidence1810" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated FGFR4 mutants bind PLCG1</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence2182">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1447">
 <bp:evidence rdf:resource="#Evidence1816" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Dimerization of FGFR4 mutants with enhanced kinase activity</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence2183">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1448">
 <bp:evidence rdf:resource="#Evidence1817" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Autocatalytic phosphorylation of FGFR4 Y367C mutant</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence2184">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1445">
 <bp:evidence rdf:resource="#Evidence1813" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated FGFR4 mutants:p-FRS2:GRB2:SOS1 activates RAS nucleotide exchange</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence2185">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1446">
 <bp:evidence rdf:resource="#Evidence1815" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Autocatalytic phosphorylation of FGFR4 mutants with enhanced kinase activity</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence2186">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2187">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2188">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1449">
 <bp:evidence rdf:resource="#Evidence1818" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Constitutive dimerization of FGFR4 Y367C mutant</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence2189">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1461">
 <bp:evidence rdf:resource="#Evidence1833" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FGFR2IIIa TM binds ligand and full length receptors to inhibit signaling</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1462">
 <bp:evidence rdf:resource="#Evidence1834" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Aberrant alternative splicing yields a secreted FGFR2 IIIa TM disease variant</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1460">
 <bp:evidence rdf:resource="#Evidence1830" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">p-4Y-PLCG1 dissociates from activated FGFR2 mutants</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1454">
 <bp:evidence rdf:resource="#Evidence1823" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated FGFR4 mutants bind FRS2</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1455">
 <bp:evidence rdf:resource="#Evidence1825" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated FGFR2 mutants:p-FRS2:GRB2:SOS1 activates RAS nucleotide exchange</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1452">
 <bp:evidence rdf:resource="#Evidence1821" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated FGFR4 mutants:p-FRS2 binds GRB2-SOS1</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence2170">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1453">
 <bp:evidence rdf:resource="#Evidence1822" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated FGFR4 mutants phosphorylate FRS2</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence2171">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1458">
 <bp:evidence rdf:resource="#Evidence1828" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated FGFR2 mutants bind FRS2</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence2172">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1459">
 <bp:evidence rdf:resource="#Evidence1829" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated FGFR2 mutants:p-FRS2:GRB2:GAB1:PIK3R1 binds PIK3CA</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence2173">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1456">
 <bp:evidence rdf:resource="#Evidence1826" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated FGFR2 mutants:p-FRS2 binds GRB2:GAB1:PIK3R1</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence2174">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1457">
 <bp:evidence rdf:resource="#Evidence1827" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated FGFR2 mutant-associated PI3K phosphorylates PIP2 to PIP3</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence2175">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2176">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2177">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2178">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2179">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway8">
 <bp:pathwayOrder rdf:resource="#PathwayStep14" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction7" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence14" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective gamma-carboxylation of F9</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Naturally occurring hemophilia B (HB)-associated point mutations in the FIX propeptide sequence reduce affinity to gamma-glutamyl carboxylase (GGCX) resulting in reduced &#947;-carboxylation and aberrant propeptide processing (Bentley AK et al. 1986; Rabiet MJ et al. 1987; Diuguid DL et al. 1986; Ware J et al. 1989; de la Salle C et al. 1993). Unprocessed FIX variants such as F9 N43Q/L or F9 N46S, circulate with the attached propeptide and show delayed FIX activation (Bentley AK et al. 1986; Diuguid DL et al. 1986; Ware J et al. 1989; de la Salle C et al. 1993).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence2118">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway7">
 <bp:pathwayOrder rdf:resource="#PathwayStep17" />
 <bp:pathwayOrder rdf:resource="#PathwayStep19" />
 <bp:pathwayOrder rdf:resource="#PathwayStep13" />
 <bp:pathwayOrder rdf:resource="#PathwayStep15" />
 <bp:pathwayComponent rdf:resource="#Pathway8" />
 <bp:pathwayComponent rdf:resource="#Pathway9" />
 <bp:pathwayComponent rdf:resource="#Pathway10" />
 <bp:pathwayComponent rdf:resource="#Pathway11" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence13" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective factor IX causes hemophilia B</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The F9 gene encodes coagulation factor IX (FIX), a vitamin K-dependent plasma protease that participates in the intrinsic blood coagulation pathway. FIX circulates as a zymogen, and is proteolytically activated to FIXa by activated FXIa or tissue factor-bound FVIIa. After being activated, FIXa forms a complex with Ca2+ ions, membrane phospholipids and coagulation factor VIIIa to activate coagulation factor X. Mutations within F9 gene that lead to quantitative and/or qualitative deficiencies in the circulating FIX protein are associated with hemophilia B (HB), a rare X-linked, recessively transmitted bleeding disorder (White GC et al. 2001; Rallapalli PM et al. 2013; Goodeve AC 2015). The disease severity in hemophilia is classified according to the plasma procoagulant levels of FIX activity. The severe form is defined as a factor level  1% of normal, the moderate form as a factor level of 1-5%, and the mild form with a factor level &gt;5 and  40%. Patients with severe hemophilia frequently develop hemorrhages into joints, muscles or soft tissues without any apparent cause. They can also suffer from life-threatening bleeding episodes such as intracranial hemorrhages. Persons with mild and moderate factor deficiency rarely experience spontaneous hemorrhages, and excessive bleeding mostly occurs only following trauma or in association with invasive procedures. A wide range of different genetic alterations are spread throughout the F9 gene, including single nucleotide substitutions, small and large deletions (Rallapalli PM et al. 2013). However functional consequences of most F9 mutations are poorly studied. The Reactome event describes altered functions of HB-associated FIX variants such as reduced FIX protein secretion due to defective expression and/or processing, failed proteolysis of factor X to Xa by defective FIX and failed formation of a membrane complex in the presence of Ca2+ ions, phospholipid, and cofactor VIIIa. The annotated HB-associated FIX variants are supported with data from functional studies (Usharani P et al. 1985; Spitzer SG et al. 1990; Ludwig M et a. 1992; Kurachi S et al. 1997; Branchini A et al. 2013).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence2119">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway9">
 <bp:pathwayOrder rdf:resource="#PathwayStep16" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction8" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence16" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective F9 activation</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Deficiency or dysfunction of FIX leads to hemophilia B (HB), an X-linked, recessive, bleeding disorder. On a molecular basis, HB is due to a heterogeneous spectrum of mutations spread throughout the F9 gene (Rallapalli PM et al. 2013). The Reactome event describes the defective proteolytic activation of FIX by factor XIa due to the presence of HB-associated point mutations R191C, R191H, R226Q and R226W in the cleavage sites of FIX (Liddell MB et al. 1989; Monroe DM et al. 1989; Suehiro K et al. 1989; Diuguid DL et al. 1989; Bertina RM et al.1990). In addition, naturally occurring point mutations in the FIX propeptide sequence such as N43Q, N43L or N46S are also annotated here. These FIX variants are secreted into the circulation with a mutant 18-amino acid propeptide still attached (Bentley AK et al. 1986; Galeffi P    Brownlee GG 1987). The unprocessed FIX variants were found to affect the function of the protein by destabilizing the calcium-induced conformation of FIX (Wojcik EG et al. 1997) and showed delayed activation by FXIa (Liddell MB et al. 1989; Ware J et al. 1989; de la Salle C et al. 1993; Wojcik EG et al. 1997; Bristol JA et al. 1993).   </bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence528">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence527">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence529">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1472">
 <bp:evidence rdf:resource="#Evidence1847" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Autocatalytic phosphorylation of FGFR2 ligand-independent  mutants</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1473">
 <bp:evidence rdf:resource="#Evidence1848" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Autocatalytic phosphorylation of FGFR2 point mutants with enhanced kinase activity</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1470">
 <bp:evidence rdf:resource="#Evidence1845" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FGFR2c mutants bind an expanded range of ligands</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1471">
 <bp:evidence rdf:resource="#Evidence1846" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Autocatalytic phosphorylation of FGFR2b mutants with enhanced ligand binding</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1465">
 <bp:evidence rdf:resource="#Evidence1838" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Dimerization of overexpressed FGFR2</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1466">
 <bp:evidence rdf:resource="#Evidence1839" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Tyrosine kinase inhibitors bind to overexpressed FGFR2 variants</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1463">
 <bp:evidence rdf:resource="#Evidence1836" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">GP369 inhibits activation of amplified FGFR2 signaling</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1464">
 <bp:evidence rdf:resource="#Evidence1837" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Autocatalytic phosphorylation of overexpressed FGFR2 variants</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1469">
 <bp:evidence rdf:resource="#Evidence1844" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Point mutants of FGFR2 bind and are inactivated by tyrosine kinase inhibitors</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1467">
 <bp:evidence rdf:resource="#Evidence1841" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FGFR2 fusions autophosphorylate</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1468">
 <bp:evidence rdf:resource="#Evidence1842" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FGFR2 fusions dimerize</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence2120">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence535">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2121">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence534">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2122">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway2">
 <bp:pathwayOrder rdf:resource="#PathwayStep2" />
 <bp:pathwayOrder rdf:resource="#PathwayStep37" />
 <bp:pathwayComponent rdf:resource="#Pathway20" />
 <bp:pathwayComponent rdf:resource="#Pathway3" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Diseases of hemostasis</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Hemostasis is a complex process that leads to the formation of a blood clot at the site of vessel injury. Three phases can be distinguished: primary hemostasis or formation of a platelet plug, secondary hemostasis, or coagulation and fibrinolysis (Kriz N et al. 2009). Defects in hemostasis cause an imbalance between the coagulation and fibrinolytic systems and may lead either to hypercoagulation, which can result in thrombosis, or to hypocoagulation and increased susceptibility to bleeding (also known as hemorrhagic diathesis) (van Herrewegen F et al. 2012a,b; Kumar R    Carcao M 2013). Abnormalities can result from disorders of the platelets (primary hemostasis defect), coagulation factors defects (secondary hemostasis defect), or a combination of both (van Herrewegen F et al. 2012a,b; Kumar R    Carcao M 2013). Coagulation disorders may be inherited or acquired. Further, abnormalities of the coagulation and fibrinolytic systems are coupled to the inflammatory response, which aggravates blood vessel permeability, inflammation, and cell damage in tissues (Sandra Margetic 2012; Kaplan AP    Joseph K  2016). This Reactome module describes abnormalities of the coagulation cascade (secondary hemostasis) due to defects of coagulation factor proteins such as factor VIII (FVIII), FIX or FXII. The module also describes an abnormal FXII- mediated activation of the pro-inflammatory kallikrein&#8208;kinin system (KKS) that leads to an excessive formation of bradykinin causing increased vascular permeability at the level of the post capillary venule and results in hereditary angioedema (HAE). </bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence537">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2123">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway1">
 <bp:pathwayOrder rdf:resource="#PathwayStep2507" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1260" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1969" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2717" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2394" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2701" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2520" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2378" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2351" />
 <bp:pathwayOrder rdf:resource="#PathwayStep48" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2441" />
 <bp:pathwayComponent rdf:resource="#Pathway217" />
 <bp:pathwayComponent rdf:resource="#Pathway734" />
 <bp:pathwayComponent rdf:resource="#Pathway637" />
 <bp:pathwayComponent rdf:resource="#Pathway724" />
 <bp:pathwayComponent rdf:resource="#Pathway26" />
 <bp:pathwayComponent rdf:resource="#Pathway629" />
 <bp:pathwayComponent rdf:resource="#Pathway2" />
 <bp:pathwayComponent rdf:resource="#Pathway387" />
 <bp:pathwayComponent rdf:resource="#Pathway563" />
 <bp:pathwayComponent rdf:resource="#Pathway576" />
 <bp:pathwayComponent rdf:resource="#Pathway587" />
 <bp:pathwayComponent rdf:resource="#Pathway597" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Disease</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Biological processes are captured in Reactome by identifying the molecules (DNA, RNA, protein, small molecules) involved in them and describing the details of their interactions. From this molecular viewpoint, human disease pathways have three mechanistic causes: the inclusion of microbially-expressed proteins, altered functions of human proteins, or changed expression levels of otherwise functionally normal human proteins. The first group encompasses the infectious diseases such as influenza, tuberculosis and HIV infection. The second group involves human proteins modified either by a mutation or by an abnormal post-translational event that produces an aberrant protein with a novel function. Examples include somatic mutations of EGFR and FGFR (epidermal and fibroblast growth factor receptor) genes, which encode constitutively active receptors that signal even in the absence of their ligands, or the somatic mutation of IDH1 (isocitrate dehydrogenase 1) that leads to an enzyme active on 2-oxoglutarate rather than isocitrate, or the abnormal protein aggregations of amyloidosis which lead to diseases such as Alzheimer&apos;s. Infectious diseases are represented in Reactome as microbial-human protein interactions and the consequent events. The existence of variant proteins and their association with disease-specific biological processes is represented by inclusion of the modified protein in a new or variant reaction, an extension to the &apos;normal&apos; pathway. Diseases which result from proteins performing their normal functions but at abnormal rates can also be captured, though less directly. Many mutant alleles encode proteins that retain their normal functions but have abnormal stabilities or catalytic efficiencies, leading to normal reactions that proceed to abnormal extents. The phenotypes of such diseases can be revealed when pathway annotations are combined with expression or rate data from other sources.  Depending on the biological pathway/process immediately affected by disease-causing gene variants, non-infectious diseases in Reactome are organized into diseases of signal transduction by growth factore receptors and second messengers, diseases of mitotic cell cycle, diseases of cellular response to stress, diseases of programmed cell death, diseases of DNA repair, disorders of transmembrane transporters, diseases of metabolism, diseases of immune system, diseases of neuronal system, disorders of developmental biology, disorders of extracellular matrix organization, and diseases of hemostatis.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence536">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2124">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway4">
 <bp:pathwayOrder rdf:resource="#PathwayStep4" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence4" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective factor IX causes thrombophilia</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">In healthy individuals factor IXa (FIXa), in a complex with factor VIIIa on the surfaces of activated platelets, catalyzes the formation of activated factor X with high efficiency. A substitution of leucine for arginine at residue 384 in FIX (FIX R384L, also know as FIX Padua) is a gain-of-function mutation that resulted in elevated FIX clotting activity in a patient with venous thrombosis (Simioni P et al. 2009).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence531">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2125">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway3">
 <bp:pathwayOrder rdf:resource="#PathwayStep3" />
 <bp:pathwayOrder rdf:resource="#PathwayStep5" />
 <bp:pathwayOrder rdf:resource="#PathwayStep21" />
 <bp:pathwayOrder rdf:resource="#PathwayStep8" />
 <bp:pathwayOrder rdf:resource="#PathwayStep12" />
 <bp:pathwayComponent rdf:resource="#Pathway7" />
 <bp:pathwayComponent rdf:resource="#Pathway12" />
 <bp:pathwayComponent rdf:resource="#Pathway4" />
 <bp:pathwayComponent rdf:resource="#Pathway6" />
 <bp:pathwayComponent rdf:resource="#Pathway5" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence3" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defects of contact activation system (CAS) and kallikrein/kinin system (KKS)</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The contact activation system (CAS) is a plasma protease cascade initiated by factor XII (FXII) that activates the pro-inflammatory kallikrein&#8208;kinin system (KKS) and the pro-coagulant intrinsic coagulation pathway (Renne T 2012; Renne T et al. 2012; Maas C et al. 2011; Schmaier AH 2016; Long AT et al. 2016). The CAS is initiated by the auto&#8208;activation of factor XII (FXII) on charged or neutral surfaces with conversion of plasma prekallikrein (PK) to plasma kallikrein (Samuel M et al. 1992; Ivanov I et al. 2017). These events are followed by reciprocal activation of FXII by kallikrein and amplification of each other&apos;s activation. Two branches of the CAS have been identified: (i) the inflammatory branch activates contact factors FXII and PK on the surface of endothelial cells resulting in release of the peptide bradykinin (BK) and (ii) the plasma coagulation branch activates FXII and FXI on the surface of platelets. The CAS is thought to be central to crosstalk between coagulation and inflammation and the underlying cause for various disorders affecting the cardiovascular system (Wu Y 2015; Long AT et al. 2016). Physiologically, a fine balance is normally maintained between blood flow and blood clotting, the dysfunction of which yields either hemorrhage or thrombosis. Defects in the intrinsic pathway coagulation factors (FVIII, FIX, and FXI) are associated with a significant bleeding tendency. The X-linked recessive disorders, hemophilia A (FVIII deficiency) and B (FIX deficiency), are associated with spontaneous and excessive hemorrhage, especially hemarthroses and muscle hematomas (Bowen DJ 2002; Goodeve AC 2015). A deficiency in FXI, which is encoded by a gene on chromosome 4, generally results in a less severe, but still significant, bleeding tendency (James P et al. 2014; Puy C et al. 2016). Although PK and FXIIa are recognized as upstream triggers for the intrinsic coagulation system, the clinical significance of these factors on thrombosis and hemorrhage is not fully understood. The CAS blockade results in prolonged coagulation times in the activated partial thromboplastin time (aPTT) assay. However, the absence of thrombotic and hemostatic abnormalities in individuals with genetic deficiencies of PK or FXII has suggested that the CAS plays a minimal role in physiological coagulation (M&#252;ller F et al. 2011). At the same time, excessive formation of bradykinin due to abnormal FXII-dependent KKS activation causes increased vascular permeability at the level of the post capillary venule and results in hereditary angioedema (HAE). HAE initiated by bradykinin is usually associated with SERPING1 (C1-INH) deficiency (Suffritti C et al. 2014). More rarely, HAE occurs in individuals with normal SERPING1 activity, and has been linked to mutations in other proteins, including FXII, plasminogen, and angiopoietin (Cichon S et al. 2006; Magerl M et al. 2017; Zuraw BL 2016; Ivanov I et al. 2019). This Reactome module describes abnormal FXII-dependent KKS activation that leads to an excessive formation of bradykinin causing increased vascular permeability at the level of the post capillary venule and results in hereditary angioedema (HAE). HAE caused by defective function of SERPING1 is also covered here. The module also includes disorders that can cause abnormal bleeding due to a shortage (deficiency) of coagulation factor proteins, which are involved in blood clotting. This module also describes elevation of FIX activity associated with thrombophilia. Genetic variants are named following Human Genome Variation Society (HGVS) nomenclature with sequence numbering starting from the first methionine of the protein as +1.(Goodeve AC et al.2011).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence530">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2126">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway6">
 <bp:pathwayOrder rdf:resource="#PathwayStep11" />
 <bp:pathwayOrder rdf:resource="#PathwayStep10" />
 <bp:pathwayOrder rdf:resource="#PathwayStep9" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction5" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction4" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction6" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence9" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective SERPING1 causes hereditary angioedema</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The reciprocal activation is initiated when zymogen factor XII (F12 or FXII) binds to a negatively charged surface, which induces FXII autoactivation. Activated FXII (FXIIa) converts prekallikrein (PK) to kallikrein, which proteolytically liberates bradykinin from high molecular weight kininogen (HK) (Renne T 2012; Renne T et al. 2012; Maas C et al. 2011). Kallikrein also activates FXII to produce more FXIIa (initially). FXIIa and kallikrein reciprocally activate their zymogens and thus generate a positive feedback loop. In the presence of sufficient amounts of active enzyme, FXIIa also generates active factor XI (FXIa) to potentiate the intrinsic coagulation pathway. All of these enzymatic steps are normally inhibited by C1-esterase inhibitor (C1-INH, encoded by the SERPING1 gene). Binding of the proinflammatory peptide hormone bradykinin to the bradykinin B2 receptor (B2R) activates various proinflammatory signaling pathways that increase vascular permeability and fluid efflux. An excessive formation of bradykinin due to uncontrolled activation of the coagulation factor XII (FXII)-dependent kallikrein-kinin system causes increased vascular permeability at the level of the postcapillary venule and results in hereditary angioedema (HAE) (Bossi F et al. 2009; Kaplan AP 2010; Suffritti C et al. 2014: Zuraw BL    Christiansen SC 2016). HAE is a rare life-threatening inherited edema disorder that is characterized by recurrent episodes of localized edema of the skin or of the mucosa of the gastrointestinal tract or upper airway. Angioedema initiated by bradykinin is usually associated with SERPING1 (C1-INH) deficiency. Thus, a major role of SERPING1 (C1-INH) is to prevent the development of excessive vascular permeability. More rarely, HAE occurs in individuals with normal SERPING1 activity, linked to mutations in other proteins, including FXII, plasminogen, and angiopoietin (Magerl M et al. 2017; Zuraw BL 2018; Ivanov I et al. 2019). Patients with HAE are heterozygous for deficiency of SERPING1.The disease, therefore, has an autosomal dominant inheritance and may result from lack of expression of SERPING1 from one allele (type 1 HAE) or from expression of a nonfunctional SERPING1 protein (type 2 HAE). This classification has however been challenged by observations of intermediary HAE types, that can arise, when small amounts of dysfunctional SERPING1 is present in the blood stream (Eldering E et al. 1995; Verpy E et al. 1995; Madsen DE et al. 2014).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence533">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2127">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway5">
 <bp:pathwayOrder rdf:resource="#PathwayStep6" />
 <bp:pathwayOrder rdf:resource="#PathwayStep7" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction3" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction2" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence6" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective factor XII causes hereditary angioedema</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Hereditary angioedema (HAE) is a rare life-threatening inherited edema disorder that is characterized by recurrent episodes of localized edema of the skin or of the mucosa of the gastrointestinal tract or upper airway. The edema formation in patients with HAE is primarily caused by a transient increased bradykinin release from high molecular weight kininogen (HK) due to uncontrolled activation of the coagulation factor XII (FXII)-dependent kallikrein kinin system (KKS) (Bossi F et al. 2009; Kaplan AP 2010; Suffritti C et al. 2014: Zuraw BL    Christiansen SC 2016). Angioedema initiated by bradykinin is usually associated with SERPING1 (C1-INH) deficiency. SERPING1 is the major regulator of the contact system. More rarely, HAE occurs in individuals with normal SERPING1 activity, and has been linked to mutations in other proteins, including FXII, plasminogen, and angiopoietin (Magerl M et al. 2017; Zuraw BL 2018; Ivanov I et al. 2019). Substitution of threonine 328 by either a lysine or an arginine residue (T328K or T328R) in the FXII proline-rich region has been identified in several families with HAE and normal SERPING1. FXII T328K or T328R variants change protein glycosylation and introduce a new site that is sensitive to enzymatic cleavage by fibrinolytic and coagulation proteases such as plasmin, thrombin, or FXIa (de Maat S et al. 2016; Ivanov I et al. 2019). The intrinsic capacity of the truncated form of FXII (329-615) (also known as &#948;FXII) to convert prekallikrein to kallikrein is greater than that of FXII leading to more kallikrein generated early during reciprocal activation (Ivanov I et al. 2019). Second, FXII (329-615) is a better kallikrein substrate than is FXII. The accelerated kallikrein/FXII activation with truncated FXII (329-615) appears to overwhelm the regulatory function of SERPING1 at normal plasma levels leading to uncontrolled bradykinin formation (de Maat S et al. 2016; Ivanov I et al. 2019). Binding of the proinflammatory peptide hormone bradykinin to the bradykinin B2 receptor (B2R) activates various proinflammatory signaling pathways that increase vascular permeability and fluid efflux. An excessive formation of bradykinin due to uncontrolled activation of FXII-dependent KKS causes increased vascular permeability at the level of the postcapillary venule and results in HAE (Zuraw BL    Christiansen SC 2016; de Maat S et al. 2016; Ivanov I et al. 2019). </bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence532">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2128">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2107">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2108">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2109">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence539">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence538">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1480">
 <bp:evidence rdf:resource="#Evidence1855" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated FGFR2 mutants:p-FRS2 binds GRB2-SOS1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1483">
 <bp:evidence rdf:resource="#Evidence1859" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated FGFR3 point, translocation and fusion mutants phosphorylate FRS2</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1484">
 <bp:evidence rdf:resource="#Evidence1860" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated FGFR3 point, translocation and fusion mutants:p-FRS2:GRB2:GAB1:PIK3R1 binds PIK3CA</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1481">
 <bp:evidence rdf:resource="#Evidence1856" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated FGFR2 mutants phosphorylate PLCG1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1482">
 <bp:evidence rdf:resource="#Evidence1857" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated FGFR2 mutants phosphorylate FRS2</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1476">
 <bp:evidence rdf:resource="#Evidence1851" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FP-1039 acts as a ligand-trap for FGFR2b-binding ligands in endometrial cancer</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1477">
 <bp:evidence rdf:resource="#Evidence1852" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Autocatalytic phosphorylation of FGFR2c mutants with enhanced ligand binding</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence540">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1474">
 <bp:evidence rdf:resource="#Evidence1849" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FGFR2b mutants bind an expanded range of ligands</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1475">
 <bp:evidence rdf:resource="#Evidence1850" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Dimerization of FGFR2 point mutants with enhanced kinase activity</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1478">
 <bp:evidence rdf:resource="#Evidence1853" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Dimerization of FGFR2 ligand-independent mutants</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1479">
 <bp:evidence rdf:resource="#Evidence1854" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated FGFR2 mutants bind PLCG1</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence546">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2110">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence545">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2111">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence548">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2112">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence547">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2113">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence542">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2114">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence541">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2115">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence544">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2116">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence543">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2117">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence549">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1490">
 <bp:evidence rdf:resource="#Evidence1868" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FGFR3c P250R mutant binds to ligand with enhanced affinity</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1491">
 <bp:evidence rdf:resource="#Evidence1869" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Autocatalytic phosphorylation of FGFR3 point mutants with enhanced kinase activity</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1494">
 <bp:evidence rdf:resource="#Evidence1874" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Autocatalytic phosphorylation of FGFR3 fusions</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1495">
 <bp:evidence rdf:resource="#Evidence1875" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FGFR3 fusions dimerize</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1492">
 <bp:evidence rdf:resource="#Evidence1871" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Dimerization of FGFR3 t(4;14) translocation mutants</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1493">
 <bp:evidence rdf:resource="#Evidence1872" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Autocatalytic phosphorylation of FGFR3 t(4;14) translocation mutants</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1487">
 <bp:evidence rdf:resource="#Evidence1865" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Dimerization of FGFR3 point mutants with enhanced kinase activity</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1488">
 <bp:evidence rdf:resource="#Evidence1866" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Constitutive dimerization of FGFR3 cysteine mutants</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence551">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1485">
 <bp:evidence rdf:resource="#Evidence1861" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FGFR3 mutants bind and are inactivated by tyrosine kinase inhibitors</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence550">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1486">
 <bp:evidence rdf:resource="#Evidence1864" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Autocatalytic phosphorylation of FGFR3 cysteine mutants</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence2140">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1489">
 <bp:evidence rdf:resource="#Evidence1867" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Autocatalytic phosphorylation of FGFR3c P250R mutant</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence2141">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2142">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence557">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2143">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence556">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2144">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence559">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2145">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence558">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2146">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence553">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2147">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence552">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2148">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence555">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2149">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence554">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2129">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence560">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1498">
 <bp:evidence rdf:resource="#Evidence1878" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated FGFR3 point, translocation and fusion mutants:p-FRS2 binds GRB2-SOS1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1499">
 <bp:evidence rdf:resource="#Evidence1879" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">p-4Y-PLCG1 dissociates from activated FGFR3 point and translocation mutants</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence562">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1496">
 <bp:evidence rdf:resource="#Evidence1876" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated FGFR3 point, translocation and fusion mutants:p-FRS2 binds GRB2:GAB1:PIK3R1</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence561">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1497">
 <bp:evidence rdf:resource="#Evidence1877" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated FGFR3 point, translocation and fusion mutants bind FRS2</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence2130">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2131">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence568">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2132">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence567">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2133">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2134">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence569">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2135">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence564">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2136">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence563">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2137">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence566">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2138">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence565">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2139">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep100">
 <bp:stepProcess rdf:resource="#BiochemicalReaction66" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep101">
 <bp:stepProcess rdf:resource="#BiochemicalReaction67" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence571">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence570">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence573">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence572">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence579">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence578">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence575">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence574">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence577">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence576">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence582">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence581">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence584">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence583">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence580">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence589">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence586">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence585">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence588">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence587">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence593">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence592">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence595">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence594">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence591">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence590">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2100">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2101">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2102">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence597">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2103">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence596">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2104">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence599">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2105">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence598">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2106">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction314">
 <bp:evidence rdf:resource="#Evidence402" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Transport of MHC I:Nef:AP-1:PACS-1 Complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction315">
 <bp:evidence rdf:resource="#Evidence403" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Degradation of MHC I Complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction312">
 <bp:evidence rdf:resource="#Evidence397" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Association of APOBEC3G:Vif with the Cul5-SCF complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction313">
 <bp:evidence rdf:resource="#Evidence398" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Association of Vif with APOBEC3G</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction310">
 <bp:evidence rdf:resource="#Evidence395" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Multi-ubiquitination of APOBEC3G</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction311">
 <bp:evidence rdf:resource="#Evidence396" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Proteosome-mediated degradation of APOBEC3G</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction318">
 <bp:evidence rdf:resource="#Evidence407" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Formation of Nef CD28 cytoplasmic tail complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction319">
 <bp:evidence rdf:resource="#Evidence408" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Internalization of Nef:CD28:Clathrin-Coated Pit Adapter Protein Complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction316">
 <bp:evidence rdf:resource="#Evidence404" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Formation of MHC I:Nef:AP-1:PACS-1 Complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction317">
 <bp:evidence rdf:resource="#Evidence405" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Formation of MHC I:Nef Complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction303">
 <bp:evidence rdf:resource="#Evidence385" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activation of Latent HCMV Genome</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction304">
 <bp:evidence rdf:resource="#Evidence386" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Viral UL47:UL48 Proteins Bind HCMV Tegumented Virion to Host Microtuble and Dynein complexs</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction301">
 <bp:evidence rdf:resource="#Evidence383" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Transcriptional Activation of the HCMV Genome</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction302">
 <bp:evidence rdf:resource="#Evidence384" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Endocytic Uptake of HCMV Virion</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction300">
 <bp:evidence rdf:resource="#Evidence382" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Delayed Early (DE) Gene Expression</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction309">
 <bp:evidence rdf:resource="#Evidence391" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">HCMV Binds Host Cell Receptor - Endocytic Pathway</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction307">
 <bp:evidence rdf:resource="#Evidence389" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Transport of HCMV DNA Into the Nucleus</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction308">
 <bp:evidence rdf:resource="#Evidence390" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Latent Transcriptinally Repressed HCMV Genome</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction305">
 <bp:evidence rdf:resource="#Evidence387" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Fusion of HCMV Envelope with Plasma Membrane</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction306">
 <bp:evidence rdf:resource="#Evidence388" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Immediate Early (IE) Gene Expression</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction336">
 <bp:evidence rdf:resource="#Evidence430" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Multimerization of Rev</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction337">
 <bp:evidence rdf:resource="#Evidence431" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Rev multimer-bound  HIV mRNA:CRM1 complex associates with Ran:GTP</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction334">
 <bp:evidence rdf:resource="#Evidence428" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Hydrolysis of Ran:GTP to Ran:GDP</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction335">
 <bp:evidence rdf:resource="#Evidence429" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Conversion of Ran-GDP to Ran-GTP</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction332">
 <bp:evidence rdf:resource="#Evidence424" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Nef Binds and activates the Src-family tyrosine kinase Lck</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction333">
 <bp:evidence rdf:resource="#Evidence425" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Nef Binds and activates the Src-family tyrosine kinase Hck</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction330">
 <bp:evidence rdf:resource="#Evidence422" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Nef mediated activation of the T-cell receptor</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction331">
 <bp:evidence rdf:resource="#Evidence423" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Nef binds a ternary complex comprising DOCK2 guanine nucleotide exchange factor for small Rho-family GTPase Rac, its cofactor ELMO1, and Rac, and activates Rac through this interaction</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction338">
 <bp:evidence rdf:resource="#Evidence432" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Rev multimer-bound HIV mRNA associates with Crm1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction339">
 <bp:evidence rdf:resource="#Evidence433" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Release of the HIV mRNA and Crm1 from Rev in the cytoplasm</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction325">
 <bp:evidence rdf:resource="#Evidence416" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Formation of a Nef:ARF1:CD4 complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction326">
 <bp:evidence rdf:resource="#Evidence417" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Nef mediated disruption of CD4:Lck Complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction323">
 <bp:evidence rdf:resource="#Evidence413" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Internalization of the CD8:Nef:AP-2 Complex:v-ATPase Complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction324">
 <bp:evidence rdf:resource="#Evidence415" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Internalization of the CD4:Nef:AP-2 Complex:v-ATPase Complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction321">
 <bp:evidence rdf:resource="#Evidence411" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Degradation of CD8</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction322">
 <bp:evidence rdf:resource="#Evidence412" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Formation of CD8:Nef:AP-2 Complex:v-ATPase Complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction320">
 <bp:evidence rdf:resource="#Evidence409" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Formation of Nef:Cd28:Clathrin-coated Pit Adapter Protein complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction329">
 <bp:evidence rdf:resource="#Evidence421" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Nef Binds and activates the Src-family tyrosine kinase Fyn</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction327">
 <bp:evidence rdf:resource="#Evidence418" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Degradation of CD4</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction328">
 <bp:evidence rdf:resource="#Evidence419" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Formation of CD4:Nef:AP-2 Complex:v-ATPase Complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence502">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence501">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence504">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence503">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence500">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence509">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence506">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence505">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence508">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence507">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway590">
 <bp:pathwayOrder rdf:resource="#PathwayStep2407" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2418" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2408" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2419" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2409" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2403" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2414" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2404" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2415" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2405" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2416" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2406" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2417" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2399" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2410" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2400" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2411" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2401" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2412" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2402" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2413" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2398" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1780" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1770" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1781" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1773" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1784" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1774" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1785" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1771" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1782" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1772" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1783" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1766" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1777" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1767" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1778" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1764" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1775" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1765" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1776" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1768" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1779" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1769" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2353" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer&apos;s disease models</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Post-mitotic neurons do not have an active cell cycle. However, deregulation of Cyclin Dependent Kinase-5 (CDK5) activity in these neurons can aberrantly activate various components of cell cycle leading to neuronal death (Chang et al. 2012). Random activation of cell cycle proteins has been shown to play a key role in the pathogenesis of several neurodegenerative disorders (Yang et al. 2003, Lopes et al. 2009). CDK5 is not activated by the canonical cyclins, but binds to its own specific partners, CDK5R1 and CDK5R2 (aka p35 and p39, respectively) (Tsai et al. 1994, Tang et al. 1995). Expression of p35 is nearly ubiquitous, whereas p39 is largely expressed in the central nervous system. A variety of neurotoxic insults such as beta-amyloid (A-beta), ischemia, excitotoxicity and oxidative stress disrupt the intracellular calcium homeostasis in neurons, thereby leading to the activation of calpain, which cleaves p35 into p25 and p10 (Lee et al. 2000). p25 has a six-fold longer half-life compared to p35 and lacks the membrane anchoring signal, which results in its constitutive activation and mislocalization of the CDK5:p25 complex to the cytoplasm and the nucleus. There, CDK5:p25 is able to access and phosphorylate a variety of atypical targets, triggering a cascade of neurotoxic pathways that culminate in neuronal death. One such neurotoxic pathway involves CDK5-mediated random activation of cell cycle proteins which culminate in neuronal death. Exposure of primary cortical neurons to oligomeric beta-amyloid (1-42) hyper-activates CDK5 due to p25 formation, which in turn phosphorylates CDC25A, CDC25B and CDC25C. CDK5 phosphorylates CDC25A at S40, S116 and S261; CDC25B at S50, T69, S160, S321 and S470; and CDC25C at T48, T67, S122, T130, S168 and S214. CDK5-mediated phosphorylation of CDC25A, CDC25B and CDC25C not only increases their phosphatase activities but also facilitates their release from 14-3-3 inhibitory binding. CDC25A, CDC25B and CDC25C in turn activate CDK1, CDK2 and CDK4 kinases causing neuronal death. Consistent with this mechanism, higher CDC25A, CDC25B and CDC25C activities were observed in human Alzheimer&apos;s disease (AD) clinical samples, as compared to age-matched controls. Inhibition of CDC25 isoforms confers neuroprotection to beta-amyloid toxicity, which underscores the contribution of this pathway to AD pathogenesis</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway592">
 <bp:pathwayOrder rdf:resource="#PathwayStep2423" />
 <bp:pathwayComponent rdf:resource="#Pathway593" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2378" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Loss of Function of TP53 in Cancer</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TP53 is the most frequently mutated tumor suppressor gene, with mutations present in more than 50% of human tumors and germline mutation in TP53 being underlying cause of the cancer-predisposing Li-Fraumeni syndrome (reviewed in Monti et al. 2020). The TP53 gene maps to chromosomal band 17p13 and encodes a transcription factor that contains four functional domains. A transactivation domain (TAD) involves amino acid residues 1-61 and is involved in interaction with components of the transcription machinery. A DNA binding domain (DBD) involves amino acid residues 94-290 and interacts with specific DNA target sequences called p53 response elements. A C-terminal domain (CTD) involves residues 357-393 and regulates DNA binding (reviewed in Monti et al. 2020). A tetramerization domain (TD) involves amino acids 325-355 and is needed for the formation of TP53 homotetramers. TP53 is considered the &#8220;guardian of the genome&#8221; (Lane 1992) as it is activated by DNA damage to initiate, depending on the amount of damage, cell cycle arrest, senescence or apoptosis (reviewed in Reinhardt and Schumacher 2012). In addition, TP53 regulates the expression of DNA repair genes, and is involved in the regulation of metabolism and autophagy (reviewed in Monti et al. 2020). Most cancer-derived TP53 mutations are missense mutations that affect the central DNA binding domain of TP53 (amino acid residues 94-312). Eight hotspot amino acid substitutions in this region (R175H, G245S, R248Q, R248W, R249S, R273H, R273S and R282W) are found in close to 30% of TP53-mutated cancers. Based on their functional impact, TP53 mutations can be classified as 1) loss-of-function (LOF), 2) partial LOF (which may involve temperature sensitivity); 3) wild type-like (WT-L) or super-transactivating (ST) mutants; 4) mutants with altered specificity (AS), which are active or partially active on some but inactive on other TP53 target genes; 5) dominant-negative (DN) mutants, able to tetramerize with and inhibit the activity of the wild type TP53 protein. Some of the TP53 mutants, especially in the category of ST and AS mutants, are gain-of-function (GOF) mutants, able to interact with novel target genes and/or novel components of the transcriptional machinery (reviewed in Monti et al. 2020, and Gencel-Augusto and Lozano 2020). Due to the complex function of WT-L, ST, AS and DN mutants of TP53, we have so far focused on annotating LOF mutants of TP53 which are unable to oligomerize due to mutations in the TD. Although accounting for a small percent of TP53 mutants, TD mutant are therefore considered to be completely defective in transcriptional activity, with no possibility of AS, DN and GOF effects (Ch&#232;ne and Bechter 1999, reviewed in Ch&#232;ne 2001, and Kamada et al. 2016). However, when overexpressed, some missense TD mutants of TP53 can form homotetramers and heterotetramers with the wild type TP53 which are partially functional and some extent of AS, DN and GOF effects may not be excluded for those mutants (Atz et al. 2000, reviewed in Ch&#232;ne 2001). In addition, the synthetic mutant p153(1-320) which consists of the first 320 amino acids and lacks the TD and CTD, while unable to tetramerize, can form stacked oligomers at the recombinant target gene promoter and induce transcription at a low level. Stacked oligomers are formed through interactions that involve amino acid residues outside the TD, which are facilitated by the presence of a target DNA sequence (Stenger et al. 1994).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway591">
 <bp:pathwayOrder rdf:resource="#PathwayStep2421" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1786" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2376" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective Intrinsic Pathway for Apoptosis Due to p14ARF Loss of Function</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Cancer-derived missense mutations in the CDKN2A gene that affect the C-terminal arginine-rich region of p14ARF (also known as CDKN2A transcription isoform 4, CDKN2A-4, p14 or ARF) impair p14ARF binding to the mitochondrial matrix protein C1QBP and interfere with p53-mediated apoptosis. Many mutations in the CDKN2A locus that affect C-terminal arginines of p14ARF are silent in p16INK4A (CDKN2A-1) (Itahana and Zhang 2008).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence513">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway594">
 <bp:pathwayOrder rdf:resource="#PathwayStep2426" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2427" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1788" />
 <bp:pathwayComponent rdf:resource="#Pathway595" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2381" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective RIPK1-mediated regulated necrosis</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Receptor Interacting Serine/Threonine Kinase 1 (RIPK1)-mediated regulated necrosis also called necroptosis is an important type of programmed cell death in addition to apoptosis. Necroptosis eventually leads to cell lysis and release of cytoplasmic content into the extracellular region. Necroptosis must be tightly controlled. Disregulated or defective necroptotic cell death is often associated with a tissue damage resulting in an intense inflammatory response. Defects of necroptosis may contribute to various pathological processes, including autoimmune disease, neurodegeneration, multiple cancers, and kidney injury.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence512">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway593">
 <bp:pathwayOrder rdf:resource="#PathwayStep2424" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1787" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2379" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Loss of function of TP53 in cancer due to loss of tetramerization ability</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The physiologically active form of TP53 is homotetramer, which represents a dimer of dimers (Lee et al. 1994, Clore et al. 1994, Jeffrey et al. 1995), with the dimer considered to represent a transient intermediate (Mateau et al. 1998, Mateau et al. 1999, Natan et al. 2009). The tetramerization domain (TD) of TP53 localizes to the C-terminal region and involves amino acid residues 325-355 and is connected to the DNA binding domain (DBD) via a short unstructured region (reviewed in Wang et al 1993). The destabilizing effects of some of the DBD mutations in TP53 can only be observed in the context of the TP53 tetramer, but not in monomeric TP53 (Lubin et al. 2010). A number of nonsense and frameshift truncations result in mutant TP53 proteins that lack the tetramerization domain. In addition, several missense mutations affect the tetramerization domain, some of which, like R342P and L344P, have been shown to impede tetramerization (Ch&#232;ne and Bechter 1999; Lubin et al. 2010). Oligomerization-defective TP53 TD mutants are considered to be complete loss-of-function mutants in terms of their transcriptional activity, without altered specificity, dominant-negative or gain-of-function effects (Ch&#232;ne and Bechter 1999, reviewed in Ch&#232;ne 2001). However, when overexpressed, some missense TD mutants of TP53 can form homotetramers and heterotetramers with the wild type TP53 which are partially functional and some extent of AS, DN and GOF effects may not be excluded for those mutants (Atz et al. 2000, reviewed in Ch&#232;ne 2001). In addition, the synthetic mutant p153(1-320) which consists of the first 320 amino acids and lacks the TD and the C-terminal domain (CTD), while unable to tetramerize, can form stacked oligomers at the recombinant target gene promoter and induce transcription at a low level. Stacked oligomers are formed through interactions that involve amino acid residues outside the TD, which are facilitated by the presence of a target DNA sequence (Stenger et al. 1994). Recombinant TP53 that consists of amino acid residues 83-323 also predominantly exists as a monomer (reviewed in Wang et al. 1994).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence515">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway596">
 <bp:pathwayOrder rdf:resource="#PathwayStep2438" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2439" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2440" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1795" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1796" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1797" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2390" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective pyroptosis</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Pyroptosis is a form of lytic inflammatory programmed cell death that is mediated by the pore&#8209;forming gasdermins (GSDMs) (Shi J et al. 2017) to stimulate immune responses through the release of pro&#8209;inflammatory interleukin (IL)&#8209;1&#946;, IL&#8209;18 (mainly in GSDMD-mediated pyroptosis) as well as danger signals such as adenosine triphosphate (ATP) or high mobility group protein B1 (HMGB1) (reviewed in Shi J et al. 2017; Man SM et al. 2017; Tang D et al. 2019; Lieberman J et al. 2019). Pyroptosis protects the host from microbial infection but can also lead to pathological inflammation if overactivated or dysregulated (reviewed in Orning P et al. 2019; Tang L et al. 2020). During infections, the excessive production of cytokines can lead to a cytokine storm, which is associated with acute respiratory distress syndrome (ARDS) and systemic inflammatory response syndrome (SIRS) (reviewed in Tisoncik JR et al. 2012; Karki R et al. 2020; Ragab D et al. 2020). Pyroptosis has a close but complicated relationship to tumorigenesis, affected by tissue type and genetic background. Pyroptosis can trigger potent antitumor immune responses or serve as an effector mechanism in antitumor immunity (Wang Q et al. 2020; Zhou  Z et al. 2020; Zhang Z et al. 2020), while in other cases, as a type of proinflammatory death, pyroptosis can contribute to the formation of a microenvironment suitable for tumor cell growth (reviewed in Xia X et al. 2019; Jiang M et al. 2020; Zhang Z et al. 2021). This Reactome module describes the defective GSDME function caused by cancer&#8209;related GSDME mutations (Zhang Z et al. 2020). It also shows epigenetic inactivation of GSDME due to hypermethylation of the GSDME promoter region (Akino K et al. 2007; Kim MS et al. 2008a,b; Croes L et al. 2017, 2018; Ibrahim J et al. 2019). Aberrant promoter methylation is considered to be a hallmark of cancer (Ehrlich M et al. 2002; Dong Y et al. 2014; Lam K et al. 2016; Croes L et al. 2018). Treatment with the DNA methyltransferase inhibitor decitabine (5&#8209;aza&#8209;2&apos;&#8209;deoxycytidine or DAC) may elevate GSDME expression in certain cancer cells (Akino K et al. 2007; Fujikane T et al. 2009; Wang Y et al. 2017).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence514">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway595">
 <bp:pathwayOrder rdf:resource="#PathwayStep2429" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2436" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2428" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2432" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2433" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2434" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2435" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2430" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2431" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1793" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1794" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1789" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction628" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1791" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction626" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1792" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction627" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1790" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2383" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Microbial modulation of RIPK1-mediated regulated necrosis</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activation of receptor-interacting serine/threonine protein (RIP) kinases RIPK1 and RIPK3  coordinate an immunogenic form of programmed cell death known as regulated necrosis or necroptosis (Upton JW et al. 2017). This form of necrosis leads to anti-viral inflammation in host through cell death-associated release of damage-associated molecular patterns (DAMPs) (Nailwal H    Ka-Ming Chan F 2019; Upton JW et al. 2017). Microbial pathogens are able to modulate host regulated necrosis through different triggers and pathways. The promotion and inhibition of host cell death vary and depend on the microbe types, virulence, and phenotypes (Upton JW et al. 2010, 2012, 2017; Jaclyn S Pearson JS et al. 2017; Petrie EJ et al. 2019; Fletcher-Etherington A et al. 2020; Nailwal H    Ka-Ming Chan F 2019; ).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway598">
 <bp:pathwayOrder rdf:resource="#PathwayStep2458" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2443" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2472" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2452" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2463" />
 <bp:pathwayComponent rdf:resource="#Pathway602" />
 <bp:pathwayComponent rdf:resource="#Pathway603" />
 <bp:pathwayComponent rdf:resource="#Pathway606" />
 <bp:pathwayComponent rdf:resource="#Pathway599" />
 <bp:pathwayComponent rdf:resource="#Pathway610" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2395" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Diseases of Base Excision Repair</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Germline mutations, single nucleotide polymorphisms (SNPs) and somatic mutations in several genes involved in base excision repair (BER), a DNA repair pathway where a damaged DNA base is excised and replaced with a correct base, are involved in the development of cancer and several other oxidative stress-related diseases. For review, please refer to Fu et al. 2012, Fletcher and Houlston 2010, Brenerman et al. 2014, Patrono et al. 2014, and D&apos;Errico et al. 2017.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway597">
 <bp:pathwayOrder rdf:resource="#PathwayStep2474" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2442" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2486" />
 <bp:pathwayComponent rdf:resource="#Pathway617" />
 <bp:pathwayComponent rdf:resource="#Pathway598" />
 <bp:pathwayComponent rdf:resource="#Pathway611" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2394" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Diseases of DNA repair</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Germline and somatic defects in genes that encode proteins that participate in DNA repair give rise to genetic instability that can lead to malignant transformation or trigger cellular senescence or apoptosis. Germline defects in DNA repair genes are an underlying cause of familial cancer syndromes and premature ageing syndromes. Somatic defects in DNA repair genes are frequently found in tumors. For review, please refer to Tiwari and Wilson 2019.  We have so far annotated diseases of mismatch repair, diseases of base excision repair and diseases of DNA double-strand break repair.  Defects in mammalian DNA mismatch repair (MMR) genes (MLH1, PMS2, MSH2, and MSH6) result in microsatellite instability (MSI) and reduced fidelity during replication and repair steps. Defective variants of MMR genes are associated with sporadic cancers with hypermutation phenotypes as well as hereditary cancer syndromes such as Lynch syndrome (hereditary non-polyposis colorectal cancer) and constitutional mismatch repair deficiency syndrome (CMMRD). MSI is an important predictor of sensitivity to cancer immunotherapy as the high mutational burden renders MSI tumors immunogenic and sensitive to programmed cell death-1 (PD-1) immune checkpoint inhibitors (Mandal et al. 2019). For review, please refer to Pena-Diaz and Rasmussen 2016, Sijmons and Hofstra 2016, Tabori et al. 2017, Baretti and Le 2018.  Germline mutations, single nucleotide polymorphisms (SNPs) and somatic mutations in several genes involved in base excision repair (BER), a DNA repair pathway where a damaged DNA base is excised and replaced with a correct base, are involved in the development of cancer and several oxidative stress-related diseases. For review, please refer to Fu et al. 2012, Fletcher and Houlston 2010, Brenerman et al. 2014, Patrono et al. 2014, and D&apos;Errico et al. 2017.  Germline mutations in genes involved in repair of DNA double-strand breaks (DSBs) are the underlying cause of several cancer predisposition syndromes, some of which also encompass developmental disorders associated with immune dysfunction, radiosensitivity and neurodegeneration. Somatic mutations in genes involved in DSB repair also occur in sporadic cancers. For review, please refer to McKinnon and Caldecott 2007, Keijzers et al. 2017, and Jachimowicz et al. 2019.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence511">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence510">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway599">
 <bp:pathwayOrder rdf:resource="#PathwayStep2447" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2444" />
 <bp:pathwayComponent rdf:resource="#Pathway601" />
 <bp:pathwayComponent rdf:resource="#Pathway600" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2396" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective Base Excision Repair Associated with NTHL1</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NTHL1 is a DNA N-glycosylase that catalyzes the first step in base excision repair (BER), the primary repair pathway for oxidative DNA damage. NTHL1 can recognize and remove oxidized cytosine, adenine and thymine, in the form of cytosine glycol (Cg), 4,6-diamino-5-formamidopyrimidine (FapyA), and thymine glycol (Tg), respectively. NTHL1 can also recognize and remove dihydrouracil (DHU), produced by cytosine deamination. Germline mutations that impair function of NTHL1 predispose affected patients to a cancer syndrome (NTHL1 syndrome) that involves adenomatous polyposis and colorectal cancer, similar to MUTYH-associated polyposis (MAP), but also causes development of tumors in other organs, such as breast, bladder, skin, uterus and brain. Only patients with mutations in both alleles of NTHL1 are affected, indicative of an autosomally recessive inheritance (Weren et al. 2015, Rivera et al. 2015, Broderick et al. 2017, Grolleman et al. 2019). Some common NTHL1 polymorphisms may results in reduced NTHL1 function, but predisposition of affected individuals to cancer has not been studied in full (Galick et al. 2013). Mice that are double knockout for Neil1 and Nthl1 genes accumulate DNA damage in the form of FapyA and FapyG and are more prone to development of lung adenocarcinoma than single Neil1 or Nthl1 gene knockouts (Chan et al. 2009). Biallelic loss-of-function mutations in NTHL1 result in a mutational signature characterized by C&gt;T transitions at non-CpG sites (Grolleman et al. 2019). For review, please refer to Weren et al. 2018. Besides loss-of-function mutations, NTHL1 is amplified and overexpressed in some cancers. NTHL1 overexpression leads to genomic instability in non-transformed human bronchial epithelial cells and may lead to malignant transformation (Limpose et al. 2018).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence517">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence516">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence519">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence518">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence524">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence523">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence526">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence525">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence520">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence522">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence521">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway579">
 <bp:pathwayOrder rdf:resource="#PathwayStep2382" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2384" />
 <bp:pathwayComponent rdf:resource="#Pathway581" />
 <bp:pathwayComponent rdf:resource="#Pathway580" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2337" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective Inhibition of DNA Recombination at Telomere</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ATRX (Alpha thalassemia mental retardation X-lined) and DAXX (Death domain-associated protein 6) chromatin remodeling factors form a complex that binds to subtelomeric regions and plays a role in inhibition of DNA recombination at telomere ends, probably by mediating loading of H3F3A histone at telomere ends and by repressing transcription of TERRA (Telomeric repeat containing RNA), a long noncoding telomeric repeats-containing RNA. Tumors positive for alternative lengthening of telomeres (ALT) markers often harbor loss-of-function mutations in ATRX, and more rarely in DAXX or missense mutations in H3F3A, implying that the impairment of function of one of these three proteins may contribute to initiation of the ALT process. Additionally, mutations in IDH, the tumor suppressor TP53 and SMARCAL1 are also observed in the context of ALT in certain types of human cancers, particularly sarcomas and tumors of the central nervous system (Jiao et al. 2012, Nicolle et al. 2019). For review, please refer to Gocha et al. 2013, Pickett and Reddel 2015, Amorim et al. 2016).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction398">
 <bp:evidence rdf:resource="#Evidence512" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Separation of elongating HIV-1 transcript from template</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction399">
 <bp:evidence rdf:resource="#Evidence513" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Addition of nucleotides leads to HIV-1 transcript elongation</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction396">
 <bp:evidence rdf:resource="#Evidence508" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Resumption of elongation of HIV-1 transcript after recovery from pausing</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction397">
 <bp:evidence rdf:resource="#Evidence509" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">2-4 nt.backtracking of Pol II complex on the HIV-1 template leading to elongation pausing</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway570">
 <bp:pathwayOrder rdf:resource="#PathwayStep2367" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1753" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2322" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective visual phototransduction due to STRA6 loss of function</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defects in STRA6 cause microphthalmia syndromic type 9 (MCOPS9, Matthew-Wood syndrome or Spear syndrome; MIM:601186) (Chassaing et al. 2009). Mutiple systems are affected by this fatal syndrome including occular and cardiac abnormalities. Microphthalmia (also called microphthalmos, nanophthalmia or nanophthalmos) is a developmental disorder of the eye that literally means small eye and in most cases results in blindness.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction394">
 <bp:evidence rdf:resource="#Evidence505" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TFIIS-mediated recovery of HIV-1 elongation from arrest</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway572">
 <bp:pathwayOrder rdf:resource="#PathwayStep2371" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1755" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2326" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective visual phototransduction due to OPN1MW loss of function</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Normal human colour vision is trichromatic, based on 3 types of cones that are maximally sensitive to light at approximately 420 nm (blue cones), 530 nm (green cones), and 560 nm (red cones). Neural circuits compare light absorbed by these 3 cone types to perceive those primary colours and combinations of them. Colour vision deficiencies result from genetic mutations that affect the expression of the full complement of cone photoreceptors and are classified by severity of deficiency (see reviews Deeb 2005, Simunovic 2010).  Deutan colourblindness (DCB, deuteranopia, partial colorblindness, green colourblindness; MIM:303800) is caused by mutations in the OPN1MW gene which encodes green cones. In European populations, red-green colourblindness is prevelant in 8% of males and 0.5% of females. This frequency is lower in non-European populations (Deeb 2005).  Defects in OPN1MW also cause X-linked cone dystrophy type 5 (COD5; MIM:303700), a retinal dystrophy characterized by progressive degeneration of cone photoreceptors but with preserved rod function. </bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction395">
 <bp:evidence rdf:resource="#Evidence506" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">7-14 nt. Backtracking of Pol II complex on the HIV-1 template leading to elongation arrest</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway571">
 <bp:pathwayOrder rdf:resource="#PathwayStep2369" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1754" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2324" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective visual phototransduction due to OPN1LW loss of function</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Blue cone monochromatism (BCM) is a rare X-linked congenital cone dysfunction characterized by the absence of functional long wavelength-sensitive (red) and medium wavelength-sensitive (green) cones in the retina. Colour discrimination is severely impaired from birth, and vision is derived from the preserved short wavelength-sensitive (blue) cones and rod photoreceptors. BCM typically presents with reduced visual acuity, pendular nystagmus, photophobia and patients often have myopia. BCM affects approximately 1 in 100,000 individuals and can be caused by loss-of-function mutations in the  OPN1LW  gene (see review Gardner et al. 2009).  Defects in OPN1LW also cause partial colorblindness, protan series (CBP, protanopia; MIM:303900) due to non-functional red cones (Ueyama et al. 2002).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction392">
 <bp:evidence rdf:resource="#Evidence502" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Unwinding of DNA for the nascent HIV-1 transcript: Second Transition</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway574">
 <bp:pathwayOrder rdf:resource="#PathwayStep2375" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1757" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2330" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective visual phototransduction due to ABCA4 loss of function</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ATP-binding cassette protein A4 (ABCA4, ABCR), expressed exclusively in retinal photoreceptors, is thought to be involved in the clearance of toxic by-products of the retinoid cycle. Defects in ABCA4 cause a diverse range of human diseases. One such disease is Stargardt&apos;s disease type 1 (STGD1, MIM:248200) (Allikmets et al. 1997), an autosomal recessive form of juvenile macular degeneration leading to progressive irreversible loss of central vision and delayed dark adaptation. STGD1 was first identified by Stargardt in 1909 (Stargardt, Arch. Klin. Exp. Ophthal. 71: 534-549, 1909), has an approximate prevalence of 1 in 10,000 (see reviews Paskowitz et al. 2006, Walia    Fishman 2009) and is usually diagnosed within the first two decades of life.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction393">
 <bp:evidence rdf:resource="#Evidence504" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Abortive termination of HIV-1 elongation after arrest</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway573">
 <bp:pathwayOrder rdf:resource="#PathwayStep2373" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1756" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2328" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective visual phototransduction due to RDH5 loss of function</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">11-cis-retinol dehydrogenase (RDH5) can reversibly catalyse the oxidation of all-trans-retinol (atROL, bound to RLBP1) to all-trans-retinal (atRAL) in retinal pigment epithelium (RPE) cells using NAD+ as cofactor. Defective RDH5 causes retinitis punctata albescens (RPA, also called fundus albipunctatus, FA; MIM:136880). RPA (an autosomal recessive disorder) is a form of stationary congenital night blindness characterised by a reduced regeneration rate of rod and cone photoreceptors and yellow-white lesions within the retina or the RPE. For review, please refer to Zeitz et al. 2015.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction390">
 <bp:evidence rdf:resource="#Evidence500" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Addition of nucleotides 5 through 9 on the growing HIV-1 transcript</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway576">
 <bp:pathwayOrder rdf:resource="#PathwayStep2379" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2386" />
 <bp:pathwayComponent rdf:resource="#Pathway582" />
 <bp:pathwayComponent rdf:resource="#Pathway577" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2334" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Diseases of mitotic cell cycle</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Diseases of mitotic cell cycle are caused by mutations in cell cycle regulators (Collins and Garrett 2005, Diaz-Moralli et al. 2013), such as retinoblastoma protein RB1 (Classon and Harlow 2002), as well as proteins involved in telomere maintenance, such as ATRX and DAXX (Sarek et al. 2015). These diseases mainly include different types of cancer, hereditary syndromes such as dyskeratosis congenita that may predispose affected patients to cancer, and neurodegenerative diseases (Webber et al. 2005).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction391">
 <bp:evidence rdf:resource="#Evidence501" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Abortive HIV-1 Initiation Before Second Transition</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway575">
 <bp:pathwayOrder rdf:resource="#PathwayStep2377" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1758" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2332" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Retinoid metabolism disease events</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Retinol binding protein (RBP4) delivers all-trans-retinol (atROL) from liver stores to peripheral tissues. Defects in RBP4 cause retinol-binding protein deficiency (RBP deficiency, MIM:180250), causing night vision problems and a typical &apos;xerophthalmic fundus&apos; with progressive atrophy of the retinal pigment epithelium (RPE) (Seeliger et al. 1999, Biesalski et al. 1999).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway578">
 <bp:pathwayOrder rdf:resource="#PathwayStep2381" />
 <bp:pathwayComponent rdf:resource="#Pathway579" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2336" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Alternative Lengthening of Telomeres (ALT)</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Alternative lengthening of telomeres (ALT) is a homologous recombination repair-directed telomere synthesis that takes place in 5-15% of tumors. ALT positive tumors often harbor loss-of-function mutations in ATRX (Alpha thalassemia mental retardation X-linked) or, more rarely, DAXX (Death domain-associated protein 6) chromatin remodeling factors, which may act to inhibit DNA recombination at telomere ends (reviewed by Gocha et al. 2013). The nuclear receptor complex NuRD-ZNF827 contributes to the recruitment of homologous recombination (HR) machinery to telomeres (Conomos et al. 2014). ALT is most prevalent in subsets of sarcomas, including osteosarcomas and some soft tissue sarcomas, brain cancers and neuroblastomas (Heaphy et al. 2011, Arora and Azzalin 2015). For review, please refer to Nabetani and Ishikawa 2011, Pickett and Reddel 2015, Verma and Greenberg 2016, Amorim et al. 2016, Sommer and Royle 2020, Zhang and Zou 2020.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway577">
 <bp:pathwayOrder rdf:resource="#PathwayStep2380" />
 <bp:pathwayComponent rdf:resource="#Pathway578" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2335" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Diseases of Telomere Maintenance</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Somatic mutations or rearrangements in genes involved in telomere maintenance enable immortalization of cancer cells either through upregulation of telomerase activity or through activation of alternative lengthening of telomeres (ALT) (Killela et al. 2013, reviewed by Gocha et al. 2013, Pickett and Reddel 2015, Amorim et al. 2016, Yuan et al. 2019). Germline mutations in telomere maintenance genes lead to telomere syndromes, such as dyskeratosis congenita (DC) and Hoyeraal-Hreidarsson (HH) syndrome, characterized by impaired ability to maintain telomere lengths during growth and development, leading to abnormally short telomere lengths and genomic instability that affects multiple organs and is associated with increased risk of certain cancers (reviewed by Sarek et al. 2015).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction389">
 <bp:evidence rdf:resource="#Evidence499" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Addition of the third nucleotide on the nascent HIV-1 transcript</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction387">
 <bp:evidence rdf:resource="#Evidence497" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Addition of nucleotides between position +11 and +30 on HIV-1 transcript</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction388">
 <bp:evidence rdf:resource="#Evidence498" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Unwinding of DNA for the nascent HIV-1 transcript</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction385">
 <bp:evidence rdf:resource="#Evidence495" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Abortive HIV-1 Initiation After Second Transition</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction386">
 <bp:evidence rdf:resource="#Evidence496" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Addition of the fourth nucleotide on the nascent HIV-1 transcript: Second Transition</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway581">
 <bp:pathwayOrder rdf:resource="#PathwayStep2385" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1760" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2340" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective Inhibition of DNA Recombination at Telomere Due to ATRX Mutations</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Many tumors that are positive for markers of alternative lengthening of telomeres (ALT) harbor loss-of-function mutations in the ATRX gene, encoding a chromatin remodeling protein ATRX. ATRX is thought to act together with DAXX and histone H3F3A to inhibit DNA recombination at telomere ends. For review, please refer to Heaphy et al. 2011, Gocha et al. 2014, Pickett and Reddel 2015, Amorim et al. 2016.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway580">
 <bp:pathwayOrder rdf:resource="#PathwayStep2383" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1759" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2338" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective Inhibition of DNA Recombination at Telomere Due to DAXX Mutations</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">A small portion of tumors that are positive for alternative lengthening of telomeres (ALT) markers and negative for mutations in the ATRX gene harbor loss-of-function mutations in the DAXX gene, which encodes the ATRX binding partner DAXX. For review, please refer to Gocha et al. 2013, and Pickett and Reddel 2015.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction383">
 <bp:evidence rdf:resource="#Evidence492" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">2-4 nt.backtracking of Pol II complex on the HIV-1 template leading to elongation pausing</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway583">
 <bp:pathwayOrder rdf:resource="#PathwayStep2390" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2388" />
 <bp:pathwayComponent rdf:resource="#Pathway585" />
 <bp:pathwayComponent rdf:resource="#Pathway584" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2343" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Aberrant regulation of mitotic G1/S transition in cancer due to RB1 defects</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">RB1 protein, also known as pRB or retinoblastoma protein, is a nuclear protein that plays a major role in the regulation of the G1/S transition during mitotic cell cycle in multicellular eukaryotes. RB1 performs this function by binding to activating E2Fs (E2F1, E2F2 and E2F3), and preventing transcriptional activation of E2F1/2/3 target genes, which include a number of genes involved in DNA synthesis. RB1 binds E2F1/2/3 through the so-called pocket region, which is formed by two parts, pocket domain A (amino acid residues 373-579) and pocket domain B (amino acid residues 640-771). Besides intact pocket domains, RB1 requires an intact nuclear localization signal (NLS) at its C-terminus (amino acid residues 860-876) to be fully functional (reviewed by Classon and Harlow 2002, Dick 2007). Functionally characterized RB1 mutations mostly affect pocket domains A and B and the NLS. RB1 mutations reported in cancer are, however, scattered over the entire RB1 coding sequence and the molecular consequences of the vast majority of these mutations have not been studied (reviewed by Dick 2007).  Many viral oncoproteins inactivate RB1 by competing with E2F1/2/3 for binding to the pocket region of RB1. RB1 protein is targeted by the large T antigen of the Simian virus 40 (SV40), the adenoviral E1A protein, and the E7 protein of oncogenic human papilloma viruses (HPVs) (reviewed by Classon and Harlow 2002).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction384">
 <bp:evidence rdf:resource="#Evidence494" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Addition of nucleotides 10 and 11 on the growing HIV-1 transcript: Third Transition</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway582">
 <bp:pathwayOrder rdf:resource="#PathwayStep2392" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2387" />
 <bp:pathwayComponent rdf:resource="#Pathway583" />
 <bp:pathwayComponent rdf:resource="#Pathway586" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2342" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Aberrant regulation of mitotic cell cycle due to RB1 defects</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">RB1 was the first tumor suppressor gene discovered. Bi-allelic loss of function of the RB1 gene, located at the chromosomal band 13q14, is the underlying cause of both familial and sporadic retinoblastoma, a pediatric eye cancer (reviewed by Lohmann and Gallie 2000, Knudson 2001, Corson and Gallie 2007). Besides retinoblastoma, carriers of germline RB1 mutations are predisposed to an array of other cancers, called second primary tumors, such as pinealoblastoma, osteosarcoma, leiomyosarcoma, rhabdomyosarcoma and melanoma (reviewed by Lohmann and Gallie 2000).  Inactivating somatic mutations in the RB1 gene are frequent in bladder cancer (Cancer Genome Atlas Research Network 2014), osteosarcoma (Ren and Gu 2017), ovarian cancer (Liu et al. 1994, Kuo et al. 2009, Cancer Genome Atlas Research Network 2011), small-cell lung carcinoma (reviewed by Gazdar et al. 2017), liver cancer (Ahn et al. 2014, Bayard et al. 2018) and esophageal cancer (Gao et al. 2014, Kishino et al. 2016, Salem et al. 2018).  The vast majority of RB1 mutations in cancer represent complete genomic deletions or nonsense and frameshift mutations that are predicted to result in null alleles. Missense mutations are rare and usually result in partially active RB1 mutants. Functionally characterized RB1 missense mutations and inframe deletions mostly affect pocket domains A and B and the nuclear localization signal (NLS). RB1 missense mutations reported in cancer are, however, scattered over the entire RB1 coding sequence and the molecular consequences of the vast majority of these mutations have not been studied (reviewed by Dick 2007).  The RB1 protein product, also known as pRB or retinoblastoma protein, is a nuclear protein that plays a major role in the regulation of the G1/S transition during mitotic cell cycle in multicellular eukaryotes. RB1 performs this function by binding to activating E2Fs (E2F1, E2F2 and E2F3), and preventing transcriptional activation of E2F1/2/3 target genes, which include a number of genes involved in DNA synthesis (reviewed by Classon and Harlow 2002, Dick 2007). RB1 also regulates mitotic exit by acting on SKP2, a component of the SCF E3 ubiquitin ligase complex. RB1 facilitates degradation of SKP2 by the anaphase promoting complex/cyclosome (APC/C), thus preventing SKP2-mediated degradation of the cyclin-dependent kinase inhibitor CDKN1B (p27Kip1). RB1-dependent accumulation of p27Kip1 plays an important role in mitotic exit and RB1-mediated tumor suppression (reviewed by Dyson 2016).  In addition to its role in regulation of the G1/S transition and mitotic exit, RB1 also performs other, non-canonical, functions, such as its role in the maintenance of genomic stability, which is linked to its role in chromosome condensation during mitotic prophase. The impact of RB1 mutations on these E2F-independent functions, which are still important for RB1-mediated tumor suppression, has been poorly studied (reviewed by Chau and Wang 2003, Burkhart and Sage 2008, Manning and Dyson 2012, Dyson 2016, Dick et al. 2018).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction381">
 <bp:evidence rdf:resource="#Evidence489" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">7-14 nt. Backtracking of Pol II complex on the HIV-1 template leading to elongation arrest</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway585">
 <bp:pathwayOrder rdf:resource="#PathwayStep2391" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1762" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2346" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective translocation of RB1 mutants to the nucleus</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">This pathway describes impaired nuclear localization of RB1 mutants that lack the nuclear localization signal (NLS) (Zacksenhaus et al. 1993, Bremner et al. 1997).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction382">
 <bp:evidence rdf:resource="#Evidence491" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Resumption of elongation of HIV-1 transcript after recovery from pausing</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway584">
 <bp:pathwayOrder rdf:resource="#PathwayStep2389" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1761" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2344" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective binding of RB1 mutants to E2F1,(E2F2, E2F3)</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">This pathway describes impaired binding of RB1 pocket domain mutants to activating E2Fs, E2F1, E2F2 and E2F3 (Templeton et al. 1991, Helin et al. 1993, Otterson et al. 1997, Ji et al. 2004).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway587">
 <bp:pathwayOrder rdf:resource="#PathwayStep2425" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2437" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2395" />
 <bp:pathwayComponent rdf:resource="#Pathway594" />
 <bp:pathwayComponent rdf:resource="#Pathway596" />
 <bp:pathwayComponent rdf:resource="#Pathway588" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2350" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Diseases of programmed cell death</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Programmed cell death is frequently impaired in cancer and is thought to significantly contribute to resistance to chemotherapy. Mutations and perturbations in expression of different proteins involved in programmed cell death, such as TP53 (p53), BH3-only family proteins, caspases and their regulators enable malignant cells to evade apoptosis (Ghavami et al. 2009, Chao et al. 2011, Wong 2011, Fernald and Kurokawa 2013, Ichim and Tait 2016). </bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction380">
 <bp:evidence rdf:resource="#Evidence488" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Abortive  termination of HIV-1 elongation after arrest (Tat-containing elongation complex)</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway586">
 <bp:pathwayOrder rdf:resource="#PathwayStep2393" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1763" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2348" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Aberrant regulation of mitotic exit in cancer due to RB1 defects</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">RB1 regulates mitotic exit by acting on SKP2, a component of the SCF E3 ubiquitin ligase complex. RB1 facilitates degradation of SKP2 by the anaphase promoting complex/cyclosome (APC/C), thus preventing SKP2-mediated degradation of the cyclin-dependent kinase inhibitor CDKN1B (p27Kip1). RB1-dependent accumulation of p27Kip1 plays an important role in mitotic exit and RB1-mediated tumor suppression (reviewed by Dyson 2016).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway589">
 <bp:pathwayOrder rdf:resource="#PathwayStep2397" />
 <bp:pathwayComponent rdf:resource="#Pathway590" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2352" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Neurodegenerative Diseases</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Neurodegenerative diseases manifest as the progressive dysfunction and loss of neurons, which is frequently accompanied by formation of misfolded protein deposits in the brain. Classification of neurodegenerative diseases is based on clinical symptoms, which depend on the anatomical region affected by neuronal dysfunction, the identity of misfolded proteins and cellular and subcellular pathology. In Alzheimer&#8217;s disease (AD), beta-amyloid protein (APP) deposits form in the extracellular space, where they can make plaques, while abnormally phosphorylated tau protein (MAPT) accumulates in neuronal cells. Beside AD, neuronal and/or glial inclusions of hyperphosphorylated tau are also found in Pick disease (PiD), neurofibrillary tangle-dementia (NFT), primary age-related tauopathy (PART), progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), argyrophilic grain disease (AGD) and globular glial tauopathies (GGT). In prion disease, such as Creutzfeldt-Jakob disease, deposits of PrP protein are formed mostly in the extracellular and presynaptic space. PrP deposits in neuronal cell bodies are mainly confined to endosomes and lysosomes, which is attributed to neuronal uptake of pathological proteins and intercellular prion spreading. In Parkinson disease (PD) and dementia with Lewy bodies (DLB), deposits of alpha-synuclein (SNCA) are formed in the cytoplasm of neuronal cell bodies and neurites. In multiple system atrophy (MSA), deposits of alpha-synuclein form in the cytoplasm of glial cells (Papp-Lantos bodies). Amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD) are characterized by ubiquitin-positive cytoplasmic inclusions of TAR DNA-binding protein 43 (TARDBP, commonly known as TDP-43), a protein that normally localizes to the nucleus. Pathological TDP-43 inclusions have been associated with the TDP-43 gene mutations, as well as mutations in several other genes, including C9orf72, GRN, VCP, SQSTM1, DCTN1 and OPTN. TDP-43 inclusions have also been reported in AD, DLB, hippocampal sclerosis (HS) and chronic traumatic encephalopathy. FUS protein-positive inclusion bodies are found in familial ALS, caused by mutations in the FUS gene, as well as in a small subgroup of FTLD-related diseases. FUS-positive inclusions may be accompanied by FET protein-positive inclusions. For a detailed review of molecular pathology of neurodegenerative diseases, please refer to Kovacs 2016. Within this broad domain, the process by which APP-triggered deregulation of CDK5 (cyclin-dependent kinase 5) triggers multiple neurodegenerative pathways associated with Alzheimer&apos;s disease has been annotated.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway588">
 <bp:pathwayOrder rdf:resource="#PathwayStep2422" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2396" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2420" />
 <bp:pathwayComponent rdf:resource="#Pathway592" />
 <bp:pathwayComponent rdf:resource="#Pathway591" />
 <bp:pathwayComponent rdf:resource="#Pathway589" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2351" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective Intrinsic Pathway for Apoptosis</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defects in the regulation of the intrinsic pathway for apoptosis are involved in diseases associated with increased cell loss, such as neurodegenerative diseases, as well as in diseases associated with impaired elimination of harmful cells, such as cancer and autoimmunity. For review, please refer to Reed 2001, Lavrik et al. 2009, and Tuzlak et al. 2016.  So far, Reactome has annotated apoptosis defects associated with the loss of function of the CDKN2A gene product p14ARF in cancer, loss of function of TP53 in cancer, and CDK5 dysregulation in neurodegenerative diseases. </bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway558">
 <bp:pathwayOrder rdf:resource="#PathwayStep2338" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2339" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1737" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1736" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2293" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective MMACHC causes MAHCC</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defects in MMACHC cause methylmalonic aciduria and homocystinuria type cblC (MMAHCC; MIM:277400). MMAHCC is the most common disorder of cobalamin metabolism and is characterized by decreased levels of the coenzymes adenosylcobalamin (AdoCbl) and methylcobalamin (MeCbl). Affected individuals may have developmental, haematologic, neurologic, metabolic, ophthalmologic, and dermatologic clinical findings (Lerner-Ellis et al. 2006).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway557">
 <bp:pathwayOrder rdf:resource="#PathwayStep2336" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1735" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2291" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective CBLIF causes IFD</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defects in cobalamin binding intrinsic factor CBLIF, aka gastric intrinsic factor GIF) cause hereditary intrinsic factor deficiency (IFD, aka congenital pernicious anemia; MIM:261000). IFD is an autosomal recessive disorder characterized by megaloblastic anemia (Tanner et al. 2005).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway559">
 <bp:pathwayOrder rdf:resource="#PathwayStep2341" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1738" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2296" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective MMAA causes MMA, cblA type</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defects in MMAA cause methylmalonic aciduria type cblA (cblA aka methylmalonic aciduria type A or vitamin B12-responsive methylmalonic aciduria of cblA complementation type; MIM:251100). Affected individuals accumulate methylmalonic acid in the blood and urine and are prone to potentially life threatening acidotic crises in infancy or early childhood (Dobson et al. 2002, Lerner-Ellis et al. 2004).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway550">
 <bp:pathwayOrder rdf:resource="#PathwayStep2322" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1728" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2277" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective TCN2 causes TCN2 deficiency</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective transcobalamin II (produced by the TCN2 gene) results in TCN2 deficiency (MIM:275350), an autosomal recessive disorder with early-onset in infancy characterized by failure to thrive, megaloblastic anemia, and pancytopenia. If left untreated, the disorder can result in mental retardation and neurologic abnormalities (Haberle et al. 2009).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway552">
 <bp:pathwayOrder rdf:resource="#PathwayStep2326" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1730" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2281" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective MTRR causes HMAE</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defects in MTRR cause methylcobalamin deficiency type E (cblE; methionine synthase reductase deficiency; MIM:236270) (Wilson et al. 1999). Patients with cblE exhibit megaloblastic anemia and hyperhomocysteinemia. SAM is used as a methyl donor in many biological reactions and demethylation of SAM produces S-adenosylhomocysteine, which is deadenosylated to form homocysteine. Homocysteine remethylation is carried out by MTR, which requires MTRR to maintain enzyme-bound cobalamin (Cbl) in its active form; but in cblE patients, MTR becomes inactivated and thus homocysteine accumulates.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway551">
 <bp:pathwayOrder rdf:resource="#PathwayStep2324" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1729" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2279" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective MMAB causes MMA, cblB type</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defects in MMAB cause methylmalonic aciduria type cblB (cblB aka methylmalonic aciduria type B or vitamin B12 responsive methylmalonicaciduria of cblB complementation type; MIM:251110). Affected individuals have methylmalonic aciduria and episodes of metabolic ketoacidosis, despite a functional methylmalonyl CoA mutase. In severe cases, newborns become severely acidotic and may die if acidosis is not treated promptly (Dobson et al. 2002).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway554">
 <bp:pathwayOrder rdf:resource="#PathwayStep2330" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1732" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2285" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective AMN causes MGA1</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defects in AMN cause recessive hereditary megaloblastic anemia 1 (RH-MGA1 aka MGA1 Norwegian type or Imerslund-Grasbeck syndrome, I-GS; MIM:261100). The Norwegian cases described by Imerslund were due to defects in AMN (Imerslund 1960). The resultant malabsorption of Cbl (vitamin B12) leads to impaired B12-dependent folate metabolism and ultimately impaired thymine synthesis and DNA replication.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway553">
 <bp:pathwayOrder rdf:resource="#PathwayStep2328" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1731" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2283" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective ABCD4 causes MAHCJ</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ATP-binding cassette sub-family D member 4 (ABCD4) is thought to mediate the lysosomal export of cobalamin (Cbl aka vitamin B12) into the cytosol, making it available for the production of Cbl cofactors. Cbl is an important cofactor for correct haematological and neurological functions. Defects in ABCD4 can cause methylmalonic aciduria and homocystinuria, cblJ type (MAHCJ; MIM:614857), a genetically heterogeneous metabolic disorder of Cbl metabolism characterised by decreased levels of the coenzymes adenosylcobalamin (AdoCbl) and methylcobalamin (MeCbl). Clinically, symptoms include feeding difficulties, poor growth, hypotonia, lethargy, anaemia and delayed development (Coelho et al. 2012).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway556">
 <bp:pathwayOrder rdf:resource="#PathwayStep2334" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1734" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2289" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective MMADHC causes MMAHCD</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defects in MMADHC cause methylmalonic aciduria and homocystinuria type cblD (MMAHCD; MIM:277410), a disorder of cobalamin metabolism characterized by decreased levels of the coenzymes adenosylcobalamin (AdoCbl) and methylcobalamin (MeCbl) (Coelho et al. 2008).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway555">
 <bp:pathwayOrder rdf:resource="#PathwayStep2332" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1733" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2287" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective CUBN causes MGA1</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defects in the CUBN gene cause recessive hereditary megaloblastic anemia 1 (RH-MGA1 aka MGA1 Finnish type or Imerslund-Grasbeck syndrome, I-GS; MIM:261100). The Finnish cases described by Grasbeck et al. were caused by defects in CUBN (Grasbeck et al. 1960). The resultant malabsorption of Cbl (cobalamin, vitamin B12) leads to impaired B12-dependent folate metabolism and ultimately impaired thymine synthesis and DNA replication.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway569">
 <bp:pathwayOrder rdf:resource="#PathwayStep2365" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1752" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2320" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective visual phototransduction due to OPN1SW loss of function</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Normal human colour vision is trichromatic, based on 3 types of cones that are maximally sensitive to light at approximately 420 nm (blue cones), 530 nm (green cones), and 560 nm (red cones). Neural circuits compare light absorbed by these 3 cone types to perceive those primary colours and combinations of them. Colour vision deficiencies result from genetic mutations that affect the expression of the full complement of cone photoreceptors and are classified by severity of deficiency (see reviews Deeb 2005, Simunovic 2010).  Tritan (blue-yellow, blue colourblindness, tritanopia; MIM:190900) deficiencies are rare (1 in 500) (Went    Pronk 1985) compared to those involving green- and red-cone deficiencies. The first report of tritan defects was in 1952 (Wright 1952). Tritan deficiencies are inherited as autosomal dominant traits (Kalmus 1955) and are a result of missense mutations in the blue-cone photopigment gene OPN1SW, leading to amino-acid substitutions in the protein sequence. Tritan defects are characterized by a selective deficiency of blue spectral sensitivity (Weitz et al. 1992).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway568">
 <bp:pathwayOrder rdf:resource="#PathwayStep2363" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1751" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2318" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective visual phototransduction due to LRAT loss of function</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Normally functioning lecithin retinol acyltransferase (LRAT) mediates the transfer of an acyl group onto all-trans-retinol (atROL), forming retinyl esters (REs), the storage form of retinoids. Defects in LRAT cause Leber congenital amaurosis type 14 (LCA14, MIM:613341), an autosomal recessive juvenile-onset retinal dystrophy affecting rod and cone photoreceptors. Leber congenital amaurosis (LCA) comprises a group of early-onset retinal dystrophies characterized by vision loss, nystagmus, and severe retinal dysfunction (Chung    Traboulsi 2009).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway561">
 <bp:pathwayOrder rdf:resource="#PathwayStep2344" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2345" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1740" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1739" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2299" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective BTD causes biotidinase deficiency</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">BTD deficiency is an autosomal recessive disorder in which the body is unable to recycle and reuse biotin (Btn). This results in a secondary Btn deficiency that leads to juvenile-onset multiple carboxylase deficiency (MIM:253260) (Wolf 2012, Wolf et al. 1983). Patients present with neurological and cutaneous symptoms, including seizures, hypotonia, skin rash, and alopecia, usually between the second and fifth months of life (Wolf 2010). Children with profound BTD deficiency are treated with pharmacological doses of biotin (5-20 mg daily). Neonatal screening for BTD deficiency is performed in most states of the United States and many other countries.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway560">
 <bp:pathwayOrder rdf:resource="#PathwayStep2346" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2343" />
 <bp:pathwayComponent rdf:resource="#Pathway561" />
 <bp:pathwayComponent rdf:resource="#Pathway562" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2298" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defects in biotin (Btn) metabolism</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Biotin (Btn, vitamin B7, vitamin H, coenzyme R) is an essential cofactor for five biotin-dependent carboxylase enzymes, involved in the synthesis of fatty acids, isoleucine, valine and in gluconeogenesis. Thus, Btn is necessary for cell growth, fatty acid synthesis and the metabolism of fats and amino acids. Inherited metabolic disorders characterized by deficient activities of all five biotin dependent carboxylases are termed multiple carboxylase deficiencies. Two congenital defects in biotin metabolism leading to multiple carboxylase deficiency are known, holocarboxylase synthetase deficiency (MIM 609018) and biotinidase deficiency (MIM 253260). In both scenarios symptoms include ketolactic acidosis, organic aciduria, hyperammonemia, skin rashes, hypotonia, seizures, developmental delay, alopecia, and coma. As humans are auxotrophic for Btn, the micronutrient must be obtained from external soures such as intestinal microflora and dietary forms. Accordingly, severe malnutrition can also give rise to biotin deficiency and multiple carboxylase deficiency. Biotin deficiency can also be induced by the excessive consumption of raw egg white that contains the biotin-binding protein avidin. Holocarboxylase synthetase deficiency arises when all five biotin-dependent enzymes are not biotinylated leading to their reduced activities. The defective genes causing these conditions are described here (Pendini et al. 2008, Suzuki et al. 2005). Biotinidase deficiency is caused by defects in the recycling of Btn. General symptoms include decreased appetite and growth, dermatitis and perosis. The defective genes causing these conditions are described here (Procter et al. 2013). </bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway563">
 <bp:pathwayOrder rdf:resource="#PathwayStep2352" />
 <bp:pathwayComponent rdf:resource="#Pathway564" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2307" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Diseases of the neuronal system</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Diseases of the neuronal system can affect sensory cells and transmission of signals between sensory cells and sensory neurons (Martemyanov and Sampath 2017), transmission of signals across electrical and chemical synapses in the nervous system (Picconi et al. 2012, Yin et al. 2012, Kida and Kato 2015), and transmission of signals between motor neurons and muscle cells (Sine 2012, Engel et al. 2015).  We have so far annotated diseases of visual phototransduction due to retinal degeneration caused by  defects in the genes involved in the retinoid cycle (Travis et al. 2007, Palczewski 2010, Fletcher et al. 2011, den Hollander et al. 2008). </bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway562">
 <bp:pathwayOrder rdf:resource="#PathwayStep2350" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2348" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2349" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2347" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1741" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1744" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1742" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1743" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2302" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective HLCS causes multiple carboxylase deficiency</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defects in HLCS causes holocarboxylase synthetase deficiency (HLCS deficiency aka early onset multiple carboxylase deficiency; MIM:253270). HLCS deficiency is an autosomal recessive disorder whereby deficient HLCS activity results in reduced activity of all five biotin-dependent carboxylases. Symptoms include metabolic acidosis, organic aciduria, lethargy, hypotonia, convulsions and dermatitis (Suzuki et al. 2005). Patients can present symptoms shortly after birth to up to early childhood and will be prescribed oral biotin supplements, typically 10-20 mg daily. Two classes of HLCS deficiency have been reported depending on whether patients respond to biotin therapy. Most patients respond favourably to treatment and show complete reversal of biochemical and clinical symptoms (Morrone et al. 2002, Dupuis et al. 1999). Here mutations in the HLCS active site cause a reduced affinity for biotin that can be overcome by pharmacological doses of the vitamin (Pendini et al. 2008). Patients who display incomplete responsiveness to biotin therapy have a poor long-term prognosis (Bailey et al. 2008).  Here mutations that reside outside of the enzyme&apos;s active site have no effect on biotin binding but do compromise the protein-protein interaction between the HLCS and its substrates, resulting in reduced biotinylation of all five carboxylases thus reducing their enzymatic activity (Mayende et al. 2012).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway565">
 <bp:pathwayOrder rdf:resource="#PathwayStep2370" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2372" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2366" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2356" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2368" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2362" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2374" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2364" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2354" />
 <bp:pathwayComponent rdf:resource="#Pathway569" />
 <bp:pathwayComponent rdf:resource="#Pathway568" />
 <bp:pathwayComponent rdf:resource="#Pathway570" />
 <bp:pathwayComponent rdf:resource="#Pathway572" />
 <bp:pathwayComponent rdf:resource="#Pathway571" />
 <bp:pathwayComponent rdf:resource="#Pathway574" />
 <bp:pathwayComponent rdf:resource="#Pathway573" />
 <bp:pathwayComponent rdf:resource="#Pathway567" />
 <bp:pathwayComponent rdf:resource="#Pathway566" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2309" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Retinoid cycle disease events</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The gene defects which cause diseases related to the retinoid cycle are described here (Travis et al. 2007, Palczewski 2010, Fletcher et al. 2011, den Hollander et al. 2008).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway564">
 <bp:pathwayOrder rdf:resource="#PathwayStep2353" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2376" />
 <bp:pathwayComponent rdf:resource="#Pathway565" />
 <bp:pathwayComponent rdf:resource="#Pathway575" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2308" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Diseases associated with visual transduction</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The process of vision involves two stages; the retinoid cycle which supplies and regenerates the visual chromophore required for vision and phototransduction which propagates the light signal. Defects in the genes involved in the retinoid cycle cause degenerative retinal diseases. These defective genes are described here (for reviews see Travis et al. 2007, Palczewski 2010, Fletcher et al. 2011, den Hollander et al. 2008).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway567">
 <bp:pathwayOrder rdf:resource="#PathwayStep2360" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2361" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2359" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2357" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2358" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1750" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1748" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1749" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1746" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1747" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2312" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Biosynthesis of A2E, implicated in retinal degradation</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Lipofuscin is a yellow-brown pigment grain composed mainly of lipids but also sugars and certain metals. Accumulation of lipofuscin is associated with degenerative diseases such as Alzheimer&apos;s disease, Parkinson&apos;s disease, chronic obstructive pulmonary disease and retinal macular degeneration.  A prominent component of lipofuscin in retinal pigment epithelial (RPE) cells is the bisretinoid A2E (di-retinoid-pyridinium-ethanolamine), the end-product of the condensation of 2 molecules of all-trans-retinal (atRAL) and phosphatidylethanolamine (PE) in photoreceptor outer disc membranes. Once formed, A2E is phagocytosed, together with outer segments (Kevany    Palczewski 2010), to RPE where it accumulates. There is no evidence as yet to indicate that A2E can be catabolised (Sparrow et al. 2012, Sparrow et al. 2010). A simplified biosynthetic pathway for A2E is described here.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway566">
 <bp:pathwayOrder rdf:resource="#PathwayStep2355" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1745" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2310" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective visual phototransduction due to RDH12 loss of function</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Retinol dehydrogenase RDH12 mediates the reversible, NADP(H)-dependent reduction of all-trans-retinal (atRAL) or 11-cis-retinal (11cRAL) to all-trans-retinol (atROL) or 11-cis-retinol (11cROL) respectively in photoreceptor cells.  Defects in RDH12 cause Leber congenital amaurosis type 13 (LCA13; MIM:612712). LCA defects are early-onset and severe retinal degenerations that are responsible for the most common cause of congenital blindness in infants and children (Janecke et al. 2004; Perrault et al. 2004).  Defects in RDH12 cause retinitis pigmentosa type 53 (RP53; MIM:612712), an autosomal recessive retinal dystrophy characterised by retinal pigment deposits and primary loss of rod photoreceptor cells followed by secondary loss of cone photoreceptor cells (Benayoun et al. 2009).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction358">
 <bp:evidence rdf:resource="#Evidence457" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Vpr binds nucleoporins</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway536">
 <bp:pathwayOrder rdf:resource="#PathwayStep2293" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2294" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1713" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1714" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2248" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective CYP27A1 causes CTX</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">CYP27A1, a mitochondrial matrix sterol hydroxylase, catalyses the 27-hydroxylation of side-chains of sterol intermediates (Cali et al. 1991). In the bile acid synthesis pathway, CYP27A1 catalyses the first step in the oxidation of the side chain of sterol intermediates such as cholestane-triols (Pikuleva et al. 1998). Defects in CYP27A1 can cause Cerebrotendinous xanthomatosis (CTX; MIM:213700), a rare sterol storage disorder. Decreased bile acid production results in the accumulation of sterol intermediates in many tissues, including brain. The disorder is characterised by progressive neurologic dysfunction, premature atherosclerosis and cataracts (Gallus et al. 2006).  </bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction359">
 <bp:evidence rdf:resource="#Evidence458" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Interaction of Vpr with importin alpha</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway535">
 <bp:pathwayOrder rdf:resource="#PathwayStep2291" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1712" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2246" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective AHCY causes HMAHCHD</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Adenosylhomocysteinase (AHCY) is a tetrameric, NAD+-bound, cytosolic protein that regulates all adenosylmethionine (AdoMet) dependent transmethylations by hydrolysing the feedback inhibitor adenosylhomocysteine (AdoHcy) to homocysteine (HCYS) and adenosine (Ade-Rib). Defects in AHCY cause Hypermethioninemia with S-adenosylhomocysteine hydrolase deficiency (HMAHCHD; MIM:613752), a metabolic disorder characterised by hypermethioninemia associated with failure to thrive, psychomotor retardation, facial dysmorphism with abnormal hair and teeth and myocardiopathy (Baric et al. 2004).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction356">
 <bp:evidence rdf:resource="#Evidence453" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Association of APOBEC3G with single-stranded region of forming HIV-1 minus strand</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway538">
 <bp:pathwayOrder rdf:resource="#PathwayStep2298" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1716" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2253" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective OPLAH causes OPLAHD</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The gamma-glutamyl cycle is a six-enzyme cycle that represents the primary pathway for glutathione synthesis and degradation. One step is the cleavage of 5-oxo-L-proline (OPRO) to form L-glutamate, coupled to the hydrolysis of ATP. This is catalysed by 5-oxoprolinase (OPLAH) is a homodimeric, cytosolic protein. Defects in OPLAH can cause 5-oxoprolinase deficiency (OPLAHD; MIM:260005), an extremely rare disorder of the gamma-glutamyl cycle about which debate continues as to whether it is a disorder or just a biochemical condition with no adverse clinical effects apart from 5-oxoprolinuria (Calpena et al. 2013, Almaghlouth et al. 2012, Aoyama    Nakaki 2013).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction357">
 <bp:evidence rdf:resource="#Evidence454" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Association of APOBEC3G with Gag</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway537">
 <bp:pathwayOrder rdf:resource="#PathwayStep2296" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1715" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2251" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective GCLC causes HAGGSD</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">In mammalian cells, many antioxidant defence systems exist which protect cells from subsequent exposure to oxidant stresses. One antioxidant is glutathione (GSH), a tripeptide present in virtually all cells that regulates the intracellular redox state and protects cells from oxidative injury. It is metabolised via the gamma-glutamyl cycle, which is catalysed by six enzymes. In man, hereditary deficiencies have been found in five of the six enzymes. Gamma-glutamylcysteine ligase (GCL) catalyses the first and rate-limiting step in GSH biosynthesis. GCL is a heterodimer of a catalytic heavy chain (GCLC) and a regulatory light chain (GCLM). Defects in the catalytic GCLC can cause hemolytic anemia due to gamma-glutamylcysteine synthetase deficiency (HAGGSD; MIM:230450), a disease characterised by hemolytic anemia, glutathione deficiency, myopathy, late-onset spinocerebellar degeneration, and peripheral neuropathy (Ristoff    Larsson 2007, Aoyama    Nakaki 2013).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction354">
 <bp:evidence rdf:resource="#Evidence450" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The Vpu:CD4:beta-TrCP complex recruits SKP1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction355">
 <bp:evidence rdf:resource="#Evidence452" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Deamination of C residues during synthesis of HIV-1 reverse transcript minus-strand</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway539">
 <bp:pathwayOrder rdf:resource="#PathwayStep2300" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1717" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2255" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective TPMT causes TPMT deficiency</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Methylation is a major biotransformation route of thiopurine drugs such as 6-mercaptopurine (6MP), used in the treatment of inflammatory diseases such as rheumatoid arthritis and childhood acute lymphoblastic leukemia. 6MP and its thioguanine nucleotide metabolites are principally inactivated by thiopurine methyltransferase (TPMT)-catalysed S-methylation.  Defects in TPMT can cause thiopurine S-methyltransferase deficiency (TPMT deficiency; MIM:610460). Patients with intermediate or no TPMT activity are at risk of toxicity such as myelosuppression after receiving standard doses of thiopurine drugs. Inter individual differences in response to these drugs are largely determined by genetic variation at the TPMT locus. TPMT exhibits an autosomal co dominant phenotype: About one in 300 people in Caucasian, African, African-American, and Asian populations are TPMT deficient. Approximately 6-10% of people in these populations inherit intermediate TPMT activity and are heterozygous at the TPMT locus. The rest are homozygous for the wild type allele and have high levels of TPMT activity. (Remy 1963, Weinshilboum et al. 1999, Couldhard    Hogarth 2005, Al Hadithy et al. 2005, Azimi et al. 2014).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction352">
 <bp:evidence rdf:resource="#Evidence448" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Association of Vpu with CD4</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction353">
 <bp:evidence rdf:resource="#Evidence449" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Ubiquitination of CD4 by Vpu:CD4:beta-TrCP:SKP1 complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction350">
 <bp:evidence rdf:resource="#Evidence446" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Degradation of ubiquitinated CD4</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction351">
 <bp:evidence rdf:resource="#Evidence447" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Vpu:CD4 associates with beta-TrCP</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway530">
 <bp:pathwayOrder rdf:resource="#PathwayStep2280" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1706" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2235" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective SLC35D1 causes SCHBCKD</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The UDP-glucuronic acid/UDP-N-acetylgalactosamine transporter (SLC35D1) is an ER membrane-spanning protein that transports nucleotide-sugars from the cytosol into the ER lumen. SLC35D1 transports UDP-GlcUA and UDP-GalNAc, which are substrates for the synthesis of chondroitin sulfate disaccharide repeats, suggesting a role in chondroitin sulfate biosynthesis. Mutations in SLC35D1 can cause Schneckenbecken dysplasia (SCHBCKD; MIM:269250), a rare, autosomal recessive, lethal short-limbed skeletal dysplasia affecting cartilage and skeletal development (Liu et al. 2010, Liu    Hirschberg 2013).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway532">
 <bp:pathwayOrder rdf:resource="#PathwayStep2284" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1708" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2239" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective CYP11B1 causes AH4</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Cytochrome P450 11B1, mitochondrial (CYP11B1) possesses steroid 11-beta-hydroxylase activity which can convert 11-deoxycortisol to cortisol. 11-beta-hydroxylase deficiency is one of the main causes of congenital adrenal hyperplasia (CAH) (5-8%), second only to 21-hydroxylase deficiency which accounts for more than 90% of CAH (Zhao et al. 2008). Defects in CYP11B1 can cause Adrenal hyperplasia 4 (AH4; MIM:202010), a form of congenital adrenal hyperplasia which is a common recessive disease due to failure to convert 11-deoxycortisol to cortisol. This impaired corticosteroid biosynthesis results in androgen excess, virilization and hypertension (White et al. 1991). </bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway531">
 <bp:pathwayOrder rdf:resource="#PathwayStep2282" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1707" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2237" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective GGT1 causes GLUTH</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">To be excreted in urine, glutathione conjugates undergo several hydrolysis steps to form mercapturic acids which are readily excreted. The first step is the hydrolysis of a gamma-glutamyl residue from the conjugate catalysed by gamma-glutamyltransferases (GGTs). These are membrane-bound, heterodimeric enzymes composed of light and heavy peptide chains. Extracellular glutathione (GSH) or its conjugates can be hydrolysed to give cysteinylglycine (CG, or CG conjugates) and free glutamate (L-Glu). Hydrolysis of GSH provides cells with a local cysteine supply and contributes to intracellular GSH levels (Heisterkamp et al. 2008). Defects in GGT1 can cause glutathionuria (GLUTH; MIM:231950), an autosomal recessive disorder characterised by increased GSH concentration in the plasma and urine. Mutations that cause GLUTH can occur in both chains of the GGT1 dimer (Heisterkamp et al. 2008, Aoyama    Nakaki 2013).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway534">
 <bp:pathwayOrder rdf:resource="#PathwayStep2289" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1711" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2244" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective FMO3 causes TMAU</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Trimethylamine (TMA) is present in the diet (in fish) but primarily formed in vivo from the breakdown of choline. It is N-oxidised by FMO3 in the liver, the major isoform active towards TMA. Trimethylaminuria (TMAU; MIM:602079, fish-odour syndrome) is a human genetic disorder characterised by an impaired ability to convert the malodourous TMA to its odourless N-oxide. Patients emit a foul odour, which resembles that of rotting fish and can be a psychologically disabling condition (Messenger et al. 2013).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway533">
 <bp:pathwayOrder rdf:resource="#PathwayStep2286" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2287" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1710" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1709" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2241" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective UGT1A4 causes hyperbilirubinemia</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">UDP-glucuronosyltransferases (UGTs) play a major role in the conjugation and therefore elimination of potentially toxic xenobiotics and endogenous compounds. The 1-4 isoform UGT1A4 is able to act upon lipophilic bilirubin, the end product of heme breakdown. Defects in UGT1A4 can cause hyperbilirubinemia syndromes ranging from mild forms such as Gilbert syndrome (GILBS; MIM:143500) to the more severe Crigler-Najjar syndromes 1 and 2 (CN1, CN2; MIM:218800 and MIM:606785) (Sticova    Jirsa 2013, Strassburg 2010, Udomuksorn et al. 2007, Costa 2006, Maruo et al. 2000).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction347">
 <bp:evidence rdf:resource="#Evidence442" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Association of multimerized Rev with beta-importin</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway547">
 <bp:pathwayOrder rdf:resource="#PathwayStep2337" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2316" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2327" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2318" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2329" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2333" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2323" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2335" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2325" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2340" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2331" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2321" />
 <bp:pathwayComponent rdf:resource="#Pathway558" />
 <bp:pathwayComponent rdf:resource="#Pathway557" />
 <bp:pathwayComponent rdf:resource="#Pathway549" />
 <bp:pathwayComponent rdf:resource="#Pathway548" />
 <bp:pathwayComponent rdf:resource="#Pathway559" />
 <bp:pathwayComponent rdf:resource="#Pathway550" />
 <bp:pathwayComponent rdf:resource="#Pathway552" />
 <bp:pathwayComponent rdf:resource="#Pathway551" />
 <bp:pathwayComponent rdf:resource="#Pathway554" />
 <bp:pathwayComponent rdf:resource="#Pathway553" />
 <bp:pathwayComponent rdf:resource="#Pathway556" />
 <bp:pathwayComponent rdf:resource="#Pathway555" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2271" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defects in cobalamin (B12) metabolism</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Cobalamin (Cbl, vitamin B12) is a nutrient essential for normal functioning of the brain and nervous system and for the formation of blood. Cbl-dependent methionine synthase (MTR) is required for conversion of 5-methyltetrahydrofolate (metTHF) to tetrahydrofolate (THF), in addition to its role in conversion of homocysteine to methionine. In Cbl deficiency, and in inborn errors of Cbl metabolism that affect function of methionine synthase, inability to regenerate THF from metTHF results in decreased function of folate-dependent reactions that are involved in 2 steps of purine biosynthesis and thymidylate synthesis. Cbl deficiency results in hyperhomocysteinemia (due to defects in the conversion of homocysteine to methionine which requires Cbl as a cofactor) and increased levels of methylmalonic acid (MMA). Methionine is used in myelin production, protein, neurotransmitter, fatty acid and phospholipid production and DNA methylation. Symptoms of Cbl deficiency are bone marrow promegaloblastosis (megaloblastic anemia) due to the inhibition of DNA synthesis (specifically purines and thymidine) and neurological symptoms. The defective genes involved in Cbl deficiencies are described below (Froese    Gravel 2010, Nielsen et al. 2012, Whitehead 2006, Watkins    Rosenblatt 2011, Fowler 1998).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction348">
 <bp:evidence rdf:resource="#Evidence443" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Rev:importin beta:B23 recruited to the nuclear pore</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway546">
 <bp:pathwayOrder rdf:resource="#PathwayStep2315" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2342" />
 <bp:pathwayComponent rdf:resource="#Pathway547" />
 <bp:pathwayComponent rdf:resource="#Pathway560" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2270" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defects in vitamin and cofactor metabolism</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Vitamins are essential nutrients, required in small amounts from the diet for the normal growth and development of a multicellular organism. Where there is vitamin deficiency, either by poor diet or a defect in metabolic conversion, diseases called Avitaminoses occur. Currently, cobalamin (Cbl, vitamin B12) metabolic defects are described below (Chapter 155 in The Metabolic and Molecular Bases of Inherited Disease, 8th ed, Scriver et al. 2001)</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction345">
 <bp:evidence rdf:resource="#Evidence440" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Association of Ran-GTP with importin-beta</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway549">
 <bp:pathwayOrder rdf:resource="#PathwayStep2319" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2320" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1726" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1727" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2274" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective MTR causes HMAG</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defects in MTR cause methylcobalamin deficiency type G (cblG; MIM:250940), an autosomal recessive inherited disease that causes mental retardation, macrocytic anemia, and homocystinuria (Leclerc et al. 1996, Gulati et al. 1996, Watkins et al. 2002).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction346">
 <bp:evidence rdf:resource="#Evidence441" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Rev associates with B23</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway548">
 <bp:pathwayOrder rdf:resource="#PathwayStep2317" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1725" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2272" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective CD320 causes MMATC</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defects in CD320 cause methylmalonic aciduria type TCblR (MMATC aka methylmalonic aciduria; MIM:613646) resulting in elevated methylmalonic acid (MMA) and homocysteine (HCYS) in newborns (Quadros et al. 2010).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction343">
 <bp:evidence rdf:resource="#Evidence437" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Rev molecules assemble onto the RRE RNA sequence through their ARM sequence</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction344">
 <bp:evidence rdf:resource="#Evidence439" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Translocation of Rev:importin-beta:B23 to the nucleus</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction341">
 <bp:evidence rdf:resource="#Evidence435" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Association of RanBP1 with Ran-GTP:CRM1:Rev:mRNA complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction342">
 <bp:evidence rdf:resource="#Evidence436" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Rev multimer-bound HIV mRNA:Crm1:Ran:GTP complex associates with the NPC</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction349">
 <bp:evidence rdf:resource="#Evidence444" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Disassembly of the Rev-importin beta-B23:Ran-GTP complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction340">
 <bp:evidence rdf:resource="#Evidence434" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Translocation of nuclear RNA transport complex to cytoplasm</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway541">
 <bp:pathwayOrder rdf:resource="#PathwayStep2304" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1719" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2259" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective CYP26C1 causes FFDD4</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Retinoic acid (RA) is a biologically active analogue of vitamin A (retinol). RA plays an important role in regulating cell growth and differentiation. CYP26C1 is involved in the metabolic breakdown of RA by 4-hydroxylation. While CYP26C1 can hydroxylate the trans form, it is unique in hydroxylating the 9-cis isomer of RA (9cRA) (Taimi et al. 2004). Defects in CYP26C1 can cause focal facial dermal dysplasia 4 (FFDD4; MIM:614974), a rare syndrome characterised by facial lesions.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway540">
 <bp:pathwayOrder rdf:resource="#PathwayStep2302" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1718" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2257" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective CYP4F22 causes ARCI5</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Cytochrome P450 4F22 (CYP4F22) is thought to 20-hydroxylate trioxilin A3 (TrXA3), an intermediary metabolite from the 12(R)-lipoxygenase pathway. This pathway is implicated in proliferative skin diseases. The major products of arachidonic acid in keratinocytes are 12- and 15-HETE which undergo biotransformation to products involved in skin hydration. CYP4F22 mutations can lead to autosomal recessive congenital ichthyosis 5 (ARCI5) (Lefevre et al. 2006, Lugassy et al. 2008).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway543">
 <bp:pathwayOrder rdf:resource="#PathwayStep2308" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1721" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2263" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective GSS causes GSS deficiency</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">In mammalian cells, many antioxidant defence systems exist which protect cells from subsequent exposure to oxidant stresses. One antioxidant is glutathione (GSH), a tripeptide present in virtually all cells that regulates the intracellular redox state and protects cells from oxidative injury. It is metabolised via the gamma-glutamyl cycle, which is catalysed by six enzymes. In man, hereditary deficiencies have been found in five of the six enzymes. Glutathione synthetase deficiency is the most frequently recognised disorder. Defects in GSS can cause glutathione synthetase deficiency (GSSD aka 5-oxoprolinase deficiency, MIM:266130), a severe autosomal recessive disorder characterised by an increased rate of haemolysis, 5-oxoprolinuria, CNS damage and recurrent bacterial infections. In this condition, decreased levels of cellular glutathione result in overstimulation of gamma-glutamylcysteine synthesis and its subsequent conversion to 5-oxoproline. Glutathione synthetase deficiency can be classed as mild, moderate or severe (Ristoff    Larsson 2007, Aoyama    Nakaki 2013).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway542">
 <bp:pathwayOrder rdf:resource="#PathwayStep2306" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1720" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2261" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective ACY1 causes encephalopathy</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Aminoacylase 1 (ACY1) is a cytosolic, homodimeric zinc-binding metalloenzyme with a wide range of tissue expression. It hydrolyses acylated L-amino acids (except L-aspartate) into L-amino acids and an acyl group. It can also hydrolyse N-acetylcysteine-S-conjugates. Defects in ACY1 can cause aminoacylase-1 deficiency (ACY1D; MIM:609924) resulting in encephalopathy, delay in psychomotor development, seizures and increased urinary excretion of several N-acetylated amino acids (Sass et al. 2006, Sass et al. 2007).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway545">
 <bp:pathwayOrder rdf:resource="#PathwayStep2312" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2313" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1723" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1724" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2267" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective UGT1A1 causes hyperbilirubinemia</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">UDP-glucuronosyltransferases (UGTs) play a major role in the conjugation and therefore elimination of potentially toxic xenobiotics and endogenous compounds. The 1-1 isoform UGT1A1 is able to act upon lipophilic bilirubin, the end product of heme breakdown. Defects in UGT1A1 can cause hyperbilirubinemia syndromes ranging from mild forms such as Gilbert syndrome (GILBS; MIM:143500) and transient familial neonatal hyperbilirubinemia (HBLRTFN; MIM:237900) to the more severe Crigler-Najjar syndromes 1 and 2 (CN1, CN2; MIM:218800 and MIM:606785) (Sticova    Jirsa 2013, Strassburg 2010, Udomuksorn et al. 2007, Costa 2006, Maruo et al. 2000).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway544">
 <bp:pathwayOrder rdf:resource="#PathwayStep2310" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1722" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2265" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective CYP1B1 causes Glaucoma</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Cytochrome P450 1B1 (CYP1B1) can oxidise a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics as well as activating a range of procarcinogens. A specific substrate is the female sex hormone estradiol-17beta (EST17b) which is 4-hydroxylated to 4-hydroxyestradiol-17beta 4OH-EST17b). Defects in CYP1B1 can cause glaucoma disorders such as Glaucoma 3, primary congenital, A (GLC3A; MIM:231300), Glaucoma, primary open angle (POAG; MIM:137760), Glaucoma 1, open angle, A (GLC1A; MIM:137750) and Peters anomaly (PAN; MIM:604229). These disorders cause a progressive optic neuropathy characterised by visual field defects that ultimately lead to irreversible blindness (Li et al. 2011, Sarfarazi et al. 2003, Vincent et al. 2001).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway514">
 <bp:pathwayOrder rdf:resource="#PathwayStep2281" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2261" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2283" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2309" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2249" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2305" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2307" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2245" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2267" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2301" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2269" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2303" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2263" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2285" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2265" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2288" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2292" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2251" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2273" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2295" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2290" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2311" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2257" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2279" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2259" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2253" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2275" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2297" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2255" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2277" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2299" />
 <bp:pathwayComponent rdf:resource="#Pathway536" />
 <bp:pathwayComponent rdf:resource="#Pathway535" />
 <bp:pathwayComponent rdf:resource="#Pathway516" />
 <bp:pathwayComponent rdf:resource="#Pathway538" />
 <bp:pathwayComponent rdf:resource="#Pathway515" />
 <bp:pathwayComponent rdf:resource="#Pathway537" />
 <bp:pathwayComponent rdf:resource="#Pathway518" />
 <bp:pathwayComponent rdf:resource="#Pathway517" />
 <bp:pathwayComponent rdf:resource="#Pathway539" />
 <bp:pathwayComponent rdf:resource="#Pathway519" />
 <bp:pathwayComponent rdf:resource="#Pathway530" />
 <bp:pathwayComponent rdf:resource="#Pathway532" />
 <bp:pathwayComponent rdf:resource="#Pathway531" />
 <bp:pathwayComponent rdf:resource="#Pathway534" />
 <bp:pathwayComponent rdf:resource="#Pathway533" />
 <bp:pathwayComponent rdf:resource="#Pathway525" />
 <bp:pathwayComponent rdf:resource="#Pathway524" />
 <bp:pathwayComponent rdf:resource="#Pathway527" />
 <bp:pathwayComponent rdf:resource="#Pathway526" />
 <bp:pathwayComponent rdf:resource="#Pathway529" />
 <bp:pathwayComponent rdf:resource="#Pathway528" />
 <bp:pathwayComponent rdf:resource="#Pathway541" />
 <bp:pathwayComponent rdf:resource="#Pathway540" />
 <bp:pathwayComponent rdf:resource="#Pathway521" />
 <bp:pathwayComponent rdf:resource="#Pathway543" />
 <bp:pathwayComponent rdf:resource="#Pathway520" />
 <bp:pathwayComponent rdf:resource="#Pathway542" />
 <bp:pathwayComponent rdf:resource="#Pathway523" />
 <bp:pathwayComponent rdf:resource="#Pathway545" />
 <bp:pathwayComponent rdf:resource="#Pathway522" />
 <bp:pathwayComponent rdf:resource="#Pathway544" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2200" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Metabolic disorders of biological oxidation enzymes</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The ability to process xenobiotica and many endogenous compounds is called biotransformation and is catalysed by enzymes mainly in the liver of higher organisms but also a number of other organs such as kidneys, gut and lungs. Metabolism occurs in two stages; phase 1 functionalisation and phase 2 conjugation. Defects in enzymes in these two phases can lead to disease (Nebert et al. 2013, Pikuleva    Waterman 2013, Zanger    Schwab 2013, Mudd 2013, Messenger et al. 2013, Aoyama    Nakaki 2013, Shih 2004, Millington 2013, Azimi et al. 2014, Sticova    Jirsa 2013).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway513">
 <bp:pathwayOrder rdf:resource="#PathwayStep2243" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1686" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2198" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective GFPT1 causes CMSTA1</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Glucosamine-fructose 6-phosphate aminotransferases 1 and 2 (GFPT1,2) are the first and rate-limiting enzymes in the hexosamine synthesis pathway, and thus formation of hexosamines like N-acetylglucosamine (GlcNAc). These enzymes probably play a role in limiting the availability of substrates for the N- and O-linked glycosylation of proteins. GFPT1 and 2 are required for normal functioning of neuromuscular synaptic transmission. Defects in GFPT1 lead to myasthenia, congenital, with tubular aggregates 1 (CMSTA1; MIM:610542), characterised by altered muscle fibre morphology and impaired neuromuscular junction development. Sufferers of CMSTA1 show a good response to acetylcholinesterase inhibitors (Senderek et al. 2011). The missense mutations observed do not always result in significant reduction in enzyme activity, but biopsies show reduced amounts of GFPT1 protein suggesting increased turnover or defective translation (Senderek et al. 2011).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction378">
 <bp:evidence rdf:resource="#Evidence485" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SPT5 subunit of Pol II binds the RNA triphosphatase (RTP)</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway516">
 <bp:pathwayOrder rdf:resource="#PathwayStep2250" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1690" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2205" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective CYP19A1 causes AEXS</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Aromatase (CYP19A1) catalyses the conversion of androstenedione (ANDST) to estrone (E1). Defects in CYP19A1 can cause aromatase excess syndrome (AEXS; MIM:139300) and aromatase deficiency (AROD; MIM:613546). Affected individuals cannot synthesise endogenous estrogens. In females the lack of estrogen leads to pseudohermaphroditism and progressive virilization at puberty, whereas in males pubertal development is normal (Bulun 2014).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction379">
 <bp:evidence rdf:resource="#Evidence487" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TFIIS-mediated recovery of elongation from arrest</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway515">
 <bp:pathwayOrder rdf:resource="#PathwayStep2246" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2247" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2248" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1689" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1687" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1688" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2201" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective CYP17A1 causes AH5</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Steroid 17-alpha-hydroxylase/17,20 lyase (CYP17A1) mediates both 17-alpha-hydroxylase and 17,20-lyase activity, allowing the adrenal glands and gonads to synthesise both 17-alpha-hydroxylated glucocorticoids and sex steroids respectively (Kagimoto et al. 1998). Defects in CYP17A1 can cause Adrenal hyperplasia 5 (AH5), a form of congenital adrenal hyperplasia (CAH), a common recessive disease due to defective synthesis of cortisol and sex steroids. Common symptoms include mild hypocortisolism, ambiguous genitalia in genetic males or failure of the ovaries to function at puberty in genetic females, metabolic alkalosis due to hypokalemia and low-renin hypertension. CYP17A1 can have defects in either or both of 17-alpha-hydroxylase and 17,20-lyase activities thus patients can show combined partial 17-alpha-hydroxylase/17,20-lyase deficiency or isolated 17,20-lyase deficiency traits (Yanase et al. 1992, Kater    Biglieri 1994, Fluck    Miller 2006, Miller 2012).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction376">
 <bp:evidence rdf:resource="#Evidence483" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Phosphorylation (Ser5) of RNA pol II CTD</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway518">
 <bp:pathwayOrder rdf:resource="#PathwayStep2254" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1692" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2209" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective CYP27B1 causes VDDR1B</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Vitamin D3 (cholecalciferol), synthesised in human skin by ultraviolet radiation action on 7-dehydrocholesterol, does not possess any biological activity. Vitamin D hormonal activity requires hydroxylation at the 25 and 1-alpha positions by cytochrome P450 enzymes CYP2R1 and CYP27B1 respectively. Vitamin D 25-hydroxylase (CYP2R1) catalyses the hydroxylation of vitamin D3 to calcidiol (CDL). Subsequent 1-alpha-hydroxylation of CDL produces calcitriol (CTL). CTL binds and activates the nuclear vitamin D receptor, with subsequent regulation of physiologic events such as calcium homeostasis, cellular differentiation and proliferation.  Defects in CYP2R1 can cause rickets, vitamin D-dependent 1B (VDDR1B; MIM:600081), a disorder caused by a selective deficiency of the active form of vitamin D (CTL) resulting in defective bone mineralization and clinical features of rickets (Pikuleva et al. 2013).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction377">
 <bp:evidence rdf:resource="#Evidence484" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Extrusion of 5&apos;-end of 30 nt long HIV-1 transcript through the pore in Pol II complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway517">
 <bp:pathwayOrder rdf:resource="#PathwayStep2252" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1691" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2207" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective MAT1A causes MATD</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">S-adenosylmethionine (AdoMet, SAM) is an important methyl donor in most transmethylation reactions. S-adenosylmethionine synthase isoform type-1 (MAT1A) catalyses the formation of AdoMet from methionine and ATP. Defects in MAT1A can cause methionine adenosyltransferase deficiency (MATD; MIM:250850), an inborn error of metabolism resulting in hypermethioninemia. In this condition, methionine accumulates because its conversion to AdoMet is impaired (Furujo et al. 2012, Mudd 2011).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction374">
 <bp:evidence rdf:resource="#Evidence481" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activation of GT</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction375">
 <bp:evidence rdf:resource="#Evidence482" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">RNA Polymerase II CTD (phosphorylated) binds to CE</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway519">
 <bp:pathwayOrder rdf:resource="#PathwayStep2256" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1693" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2211" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective CYP11A1 causes AICSR</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Cholesterol side-chain cleavage enzyme, mitochondrial (CYP11A1) normally catalyses the side-chain cleavage of cholesterol to form pregnenolone. Defects in CYP11A1 can cause Adrenal insufficiency, congenital, with 46,XY sex reversal (AICSR; MIM:613743). This is a rare disorder that can present as acute adrenal insufficiency in infancy with elevated ACTH and plasma renin activity and low or absent adrenal steroids. The severest phenotype is loss-of-function mutations associated with prematurity, complete under-androgenisation and severe, early-onset adrenal failure (Kim et al. 2008).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction372">
 <bp:evidence rdf:resource="#Evidence478" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Abortive HIV-1 initiation after formation of the first phosphodiester bond</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction373">
 <bp:evidence rdf:resource="#Evidence479" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">HIV Promoter Opening: First Transition</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction370">
 <bp:evidence rdf:resource="#Evidence476" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NTP binds active site of RNA Polymerase II in HIV-1 open pre-initiation complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction371">
 <bp:evidence rdf:resource="#Evidence477" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Nucleophillic attack by 3&apos;-hydroxyl oxygen of nascent HIV-1 transcript on the Alpha phosphate of NTP</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway510">
 <bp:pathwayOrder rdf:resource="#PathwayStep2237" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1683" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2192" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective GALE causes EDG</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Cytosolic UDP-galactose 4&apos;-epimerase (GALE) catalyses the reversible interconversion of UDP-D-galactose (UDP-Gal) and UDP-glucose (UDP-Glc), the third reacton in the Leloir pathway of galactose metabolism. GALE can also catalyse the epimerisation of UDP-N-acetylglucosamine to UDP-N-acetylgalactosamine. The active form of the enzyme is a homodimer with one molecule of bound NAD per monomer (GALE:NAD+ dimer). Defects in GALE can cause Epimerase-deficiency galactosemia (EDG; MIM:230350), or type III galactosemia (diseases of galactose metabolism) whose clinical features include early-onset cataracts, liver damage, deafness and mental retardation. Historically, it was considered that there were two forms of GALE deficidency; a benign (&quot;peripheral&quot;) form where there is no GALE activity in red blood cells and characterised by mild symptoms (Gitzelmann 1972) and a rarer &quot;generalised&quot; form with no detectable GALE activity in all tissues resulting in more severe symptoms (Holton et al. 1981). The disease is now considered to be a continuum (Openo et al. 2006).  </bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway512">
 <bp:pathwayOrder rdf:resource="#PathwayStep2241" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1685" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2196" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective PGM1 causes PGM1-CDG</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Phosphoglucomutases 1 and 2 (PGM1, 2) are involved in the cytosolic biosynthesis of nucleotide sugars needed for glycan biosynthesis, specifically, the isomerisation of glucose-6-phosphate (G6P) into glucose-1-phosphate (G1P). Defects in PGM1 can cause congenital disorder of glycosylation 1t (CDG1t, now known as PGM1-CDG; MIM:614921), a broad spectrum disorder characterised by under-glycosylated serum glycoproteins (Timal et al. 2012, Tegtmeyer et al. 2014). CDGs result in a wide variety of clinical features such as defects in nervous system development, psychomotor retardation, dysmorphic features, hypotonia, coagulation disorders, and immunodeficiency. </bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway511">
 <bp:pathwayOrder rdf:resource="#PathwayStep2239" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1684" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2194" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective DPM3 causes DPM3-CDG</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Dolichyl-phosphate mannosyltransferase (DPM), a heterotrimeric protein embedded in the endoplasmic reticulum membrane, mediates the transfer of mannose (from cytosolic GDP-mannose) to dolichyl phosphate (DOLP) to form dolichyl-phosphate-mannose (DOLPman). The first subunit of the heterotrimer (DPM1) appears to be the actual catalyst, and the other two subunits (DPM2 and 3) appear to stabilise it (Maeda et al. 2000). Defects in DPM3 can cause congenital disorder of glycosylation 1o (DPM3-CDG, CDG1o; MIM:612937), a multisystem disorder caused by a defect in glycoprotein biosynthesis and characterised by under-glycosylated serum glycoproteins. CDG type 1 diseases result in a wide variety of clinical features, such as defects in the nervous system development, psychomotor retardation, dysmorphic features, hypotonia, coagulation disorders, and immunodeficiency (Lefeber et al. 2009).  Four biosynthetic pathways depend on DOLPman; N-glycosylation, O-mannosylation, C-Mannosylation and GPI-anchor biosynthesis. A defect in DPM3 strongly reduces O-mannosylation of alpha-dystroglycan, explaining the clinical phenotype of muscular dystrophy and linking the congenital disorders of glycosylation with the dystroglycanopathies (Lefeber et al. 2009).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction369">
 <bp:evidence rdf:resource="#Evidence475" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Newly formed phosphodiester bond stabilized and PPi released</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway525">
 <bp:pathwayOrder rdf:resource="#PathwayStep2268" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1699" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2223" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective CYP27B1 causes VDDR1A</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Vitamin D3 (cholecalciferol), synthesised in human skin by ultraviolet radiation action on 7-dehydrocholesterol, does not possess any biological activity. Vitamin D hormonal activity requires hydroxylation at the 25 and 1-alpha positions by cytochrome P450 enzymes CYP2R1 and CYP27B1 respectively. Vitamin D 25-hydroxylase (CYP2R1) catalyses the hydroxylation of vitamin D3 to calcidiol (CDL). Subsequent 1-alpha-hydroxylation of CDL by CYP27B1 produces calcitriol (CTL). CTL binds and activates the nuclear vitamin D receptor, with subsequent regulation of physiologic events such as calcium homeostasis, cellular differentiation and proliferation.  Defects in CYP27B1 can cause rickets, vitamin D-dependent 1A (VDDR1A; MIM:264700), a disorder caused by deficiency of the active form of vitamin D (CTL) resulting in defective bone mineralization and clinical features of rickets. To date, 47 mutations have been identified, the majority of them (28) being missense mutations (Kim 2011, Cui et al. 2012).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway524">
 <bp:pathwayOrder rdf:resource="#PathwayStep2266" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1698" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2221" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective CYP26B1 causes RHFCA</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Retinoic acid (RA) is a biologically active analogue of vitamin A (retinol). RA plays an important role in regulating cell growth and differentiation.CYP26A1 and B1 are involved in the metabolic breakdown of RA by 4-hydroxylation. High expression levels of CYP26B1 in the cerebellum and pons of human brain suggests a protective role of specific tissues against retinoid damage (White et al. 2000). Defects in CYP26B1 can cause radiohumeral fusions with other skeletal and craniofacial anomalies (RHFCA; MIM:614416), a disease characterised by craniofacial malformations and multiple skeletal anomalies (Laue et al. 2011).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction367">
 <bp:evidence rdf:resource="#Evidence471" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Recruitment Of HIV Virion Budding Machinery</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway527">
 <bp:pathwayOrder rdf:resource="#PathwayStep2274" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1703" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2229" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective CYP2U1 causes SPG56</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Cytochrome P450 2U1 (CYP2U1) catalyses the hydroxylation of arachidonic acid, docosahexaenoic acid and other long chain fatty acids, generating bioactive eicosanoid derivatives which may play an important physiological role in fatty acid signaling processes. Defects in CYP2U1 can cause Spastic paraplegia 56, autosomal recessive (SPG56; MIM:615030), a neurodegenerative disorder characterised by a slow, gradual, progressive weakness and spasticity of the lower limbs (Tesson et al. 2012, Fink 2013).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction368">
 <bp:evidence rdf:resource="#Evidence473" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Fall Back to Closed Pre-initiation Complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway526">
 <bp:pathwayOrder rdf:resource="#PathwayStep2270" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2271" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2272" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1700" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1701" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1702" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2225" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective CYP11B2 causes CMO-1 deficiency</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Cytochrome P450 11B2, mitochondrial (CYP11B2 aka aldosterone hydroxylase) is an enzyme necessary for aldosterone biosynthesis via corticosterone (CORST) and 18-hydroxycorticosterone (18HCORST). Defects in CYP11B2 results in disorders of aldosterone synthesis. Corticosterone methyloxidase 1 and 2 deficiencies (CMO-1; MIM:203400 and CMO-2 deficiency; MIM:61060) are autosomal recessive disorders of aldosterone biosynthesis (Mitsuuchi et al. 1993, Bureik et al. 2002). In CMO-1 deficiency, aldosterone is undetectable in plasma, while its immediate precursor, 18HCORST, is low or normal. In CMO-2 deficiency, aldosterone can be low or normal, but at the expense of increased secretion of 18HCORST. Patients with CMO-2 deficiency have elevated plasma 18-hydroxycorticosterone/aldosterone ratios.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction365">
 <bp:evidence rdf:resource="#Evidence469" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">HIV Virion Budding</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway529">
 <bp:pathwayOrder rdf:resource="#PathwayStep2278" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1705" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2233" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective CYP21A2 causes AH3</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Steroid 21-hydroxylase (CYP21A2) specifically catalyses the 21-hydroxylation of steroids which is required for the adrenal synthesis of mineralocorticoids and glucocorticoids. Defects in CYP21A2 can cause adrenal hyperplasia 3 (AH3; MIM:201910), a form of congenital adrenal hyperplasia (CAH) where cortisol synthesis is defective. This results in increased ACTH levels, causing overproduction and accumulation of cortisol precursors, particularly 17-hydroxyprogesterone (17HPROG). The resultant excessive production of androgens causes virilization. 21-hydroxylase deficiency accounts for more than 90% of CAH cases and ranges from mild to complete loss of activity (White et al. 2000, White    Bachega 2012).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction366">
 <bp:evidence rdf:resource="#Evidence470" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Protease binds protease inhibitors</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway528">
 <bp:pathwayOrder rdf:resource="#PathwayStep2276" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1704" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2231" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective CYP24A1 causes HCAI</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Catabolic inactivation of the active, hormonal form of vitamin D3 (calcitriol, CALTOL, 1,25-dihydroxyvitamin D3) is initially carried out by 24-hydroxylation, mediated by 1,25-dihydroxyvitamin D3 24-hydroxylase (CYP24A1). The product formed is eventually transformed to calcitroic acid, the major water-soluble metabolite that can be excreted in bile. Defects in CYP24A1 can cause hypercalcemia infantile (HCAI; MIM:143880), a disorder characterised by abnormally high level of calcium in the blood, failure to thrive, vomiting, dehydration, and nephrocalcinosis (Schlingmann et al. 2011).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction363">
 <bp:evidence rdf:resource="#Evidence464" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Association of Tat with P-TEFb(Cyclin T1:Cdk9)</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction364">
 <bp:evidence rdf:resource="#Evidence468" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Maturation of HIV Virion</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction361">
 <bp:evidence rdf:resource="#Evidence461" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Translocation of Vpr to the mitochondria</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction362">
 <bp:evidence rdf:resource="#Evidence463" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Formation of the P-TEFb(Cyclin T1:Cdk9) complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction360">
 <bp:evidence rdf:resource="#Evidence460" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Association of Vpr with ANT1</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway521">
 <bp:pathwayOrder rdf:resource="#PathwayStep2260" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1695" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2215" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective TBXAS1 causes GHDD</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Thromboxane-A synthase (TBXAS1), an enzyme of the arachidonic acid cascade, produces thromboxane A2 (TXA2) from prostaglandin H2 (PGH2). Together with prostacyclin (PGI2), TXA2 plays a key role in the maintenance of haemostasis. It is also a constrictor of vascular and respiratory smooth muscle and implicated in the induction of osteoclast differentiation and activation. Defects in TBXAS1 can cause Ghosal hematodiaphyseal dysplasia (GHDD; MIM:231095), a rare autosomal recessive disorder characterised by increased bone density with predominant diaphyseal involvement and aregenerative anemia, a bone marrow failure where functional marrow cells are regenerated slowly or not at all (Genevieve et al. 2008).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway520">
 <bp:pathwayOrder rdf:resource="#PathwayStep2258" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1694" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2213" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective GGT1 in aflatoxin detoxification causes GLUTH</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">To be excreted in urine, glutathione conjugates undergo several hydrolysis steps to form mercapturic acids which are readily excreted. The first step is the hydrolysis of a gamma-glutamyl residue from the conjugate catalysed by gamma-glutamyltransferases (GGTs). These are membrane-bound, heterodimeric enzymes composed of light and heavy peptide chains. Extracellular glutathione (GSH) or its conjugates can be hydrolysed to give cysteinylglycine (CG, or CG conjugates) and free glutamate (L-Glu). Hydrolysis of GSH provides cells with a local cysteine supply and contributes to intracellular GSH levels (Heisterkamp et al. 2008). Defects in GGT1 can cause glutathionuria (GLUTH; MIM:231950), an autosomal recessive disorder characterised by increased GSH concentration in the plasma and urine. Mutations that cause GLUTH can occur in both chains of the GGT1 dimer (Heisterkamp et al. 2008, Aoyama    Nakaki 2013).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway523">
 <bp:pathwayOrder rdf:resource="#PathwayStep2264" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1697" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2219" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective MAOA causes BRUNS</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Amine oxidase (flavin-containing) A (MAOA) catalyses the oxidative deamination of biogenic and dietary amines, the regulation of which is critical for mental state homeostasis. MAOA, located on the mitochondrial outer membrane and requiring FAD as cofactor (Weyler 1989), preferentially oxidises biogenic amines such as 5-hydroxytryptamine (5HT), dopamine, noradrenaline and adrenaline. Defects in MAOA can cause Brunner syndrome (BRUNS; MIM:300615), a form of X-linked non-dysmorphic mild mental retardation. Male patients are affected by mild mental retardation and exhibit abnormal behaviour, including impulsive aggression (Brunner et al. 1993, Shih et al. 1999, Shih 2004).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway522">
 <bp:pathwayOrder rdf:resource="#PathwayStep2262" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1696" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2217" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective CYP7B1 causes SPG5A and CBAS3</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Bile acids are synthesised from cholesterol via two pathways - a classic neutral pathway involving cholesterol 7-alpha-hydroxylase (CYP7A1), and an acidic pathway involving 25-hydroxycholesterol 7-alpha-hydroxylase (CYP7B1). Defects in CYP7B1 can cause spastic paraplegia 5A (SPG5A), a neurodegenerative disorder characterised by a slow, gradual, progressive weakness and spasticity of the lower limbs (Tsaousidou et al. 2008).  Defects in CYP7B1 can also cause Congenital bile acid synthesis defect 3 (CBAS3; MIM:613812), a disorder resulting in severe cholestasis, cirrhosis and liver synthetic failure. Hepatic CYP7B1 activity is undetectable (Setchell et al. 1998).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence494">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence493">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence496">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence495">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence490">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence492">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence491">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence498">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence497">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence499">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis290">
 <bp:controlled rdf:resource="#BiochemicalReaction997" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis296">
 <bp:controlled rdf:resource="#BiochemicalReaction1010" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis295">
 <bp:controlled rdf:resource="#BiochemicalReaction1007" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis298">
 <bp:controlled rdf:resource="#BiochemicalReaction1014" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis297">
 <bp:controlled rdf:resource="#BiochemicalReaction1011" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis292">
 <bp:controlled rdf:resource="#BiochemicalReaction1000" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis291">
 <bp:controlled rdf:resource="#BiochemicalReaction999" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis294">
 <bp:controlled rdf:resource="#BiochemicalReaction1005" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis293">
 <bp:controlled rdf:resource="#BiochemicalReaction1002" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1300">
 <bp:evidence rdf:resource="#Evidence1607" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ERBB2 TMD/JMD mutants do not bind pertuzumab</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1301">
 <bp:evidence rdf:resource="#Evidence1609" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ERBB2 ECD mutants heterodimerize with EGFR</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence2280">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2281">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1304">
 <bp:evidence rdf:resource="#Evidence1612" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Phosphorylated heterodimers of ERBB2 ECD mutants and EGFR bind GRB2:GAB1</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence2282">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis299">
 <bp:controlled rdf:resource="#BiochemicalReaction1018" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1305">
 <bp:evidence rdf:resource="#Evidence1613" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ERBB2 ECD mutants bind TKIs</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence2283">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1302">
 <bp:evidence rdf:resource="#Evidence1610" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Heterodimers of ERBB2 ECD mutants and EGFR trans-autophosphorylate</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence2284">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1303">
 <bp:evidence rdf:resource="#Evidence1611" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Phosphorylated heterodimers of ERBB2 ECD mutants and EGFR bind SHC1</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence2285">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1308">
 <bp:evidence rdf:resource="#Evidence1616" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">RAS activation by SOS1 bound to phosphorylated heterodimers of ERBB2 ECD mutants and EGFR through GRB2</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence2286">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1309">
 <bp:evidence rdf:resource="#Evidence1617" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">GRB2:SOS1 binds to phosphorylated heterodimers of ERBB2 ECD mutants and EGFR</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence2287">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1306">
 <bp:evidence rdf:resource="#Evidence1614" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Phosphorylated heterodimers of ERBB2 ECD mutants and EGFR recruit GRB2:SOS1 through SHC1 </bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence2288">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1307">
 <bp:evidence rdf:resource="#Evidence1615" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Phosphorylated heterodimers of ERBB2 ECD mutants and EGFR, in complex with GRB2:GAB1, bind PI3K</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence2289">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1311">
 <bp:evidence rdf:resource="#Evidence1619" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Phosphorylated heterodimers of ERBB2 ECD mutants and EGFR phosphorylate PLCG1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1312">
 <bp:evidence rdf:resource="#Evidence1620" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">RAS guanyl nucleotide exchange mediated by the p-6Y- ERBB2 ECD mutants:EGF:p-6Y-EGFR:p-SHC1:GRB2:SOS1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1310">
 <bp:evidence rdf:resource="#Evidence1618" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Phosphorylated heterodimers of ERBB2 ECD mutants and EGFR bind PLCG1</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence2270">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1315">
 <bp:evidence rdf:resource="#Evidence1623" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">PI3K bound to phosphorylated heterodimers of ERBB2 ECD mutants and EGFR converts PIP2 to PIP3</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence2271">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1316">
 <bp:evidence rdf:resource="#Evidence1625" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">RAS activation by SOS1 bound to phosphorylated heterodimers of ERBB2 KD mutants and EGFR</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence2272">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1313">
 <bp:evidence rdf:resource="#Evidence1621" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ERBB2 ECD mutants bind trastuzumab</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence2273">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1314">
 <bp:evidence rdf:resource="#Evidence1622" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Phosphorylated heterodimers of ERBB2 ECD mutants and EGFR phosphorylate SHC1</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence2274">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1319">
 <bp:evidence rdf:resource="#Evidence1628" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ERBB2 KD mutants heterodimerize</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence2275">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2276">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1317">
 <bp:evidence rdf:resource="#Evidence1626" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ERBB2 KD mutants bind trastuzumab</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence2277">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1318">
 <bp:evidence rdf:resource="#Evidence1627" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Phosphorylated heterodimers of ERBB2 KD mutants phosphorylate SHC1</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence2278">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2279">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1330">
 <bp:evidence rdf:resource="#Evidence1639" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Phosphorylated heterodimers of ERBB2 KD mutants and EGFR phosphorylate PLCG1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1322">
 <bp:evidence rdf:resource="#Evidence1631" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Phosphorylated heterodimers of ERBB2 KD mutants bind SHC1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1323">
 <bp:evidence rdf:resource="#Evidence1632" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">PI3K bound to phosphorylated heterodimers of ERBB2 KD mutants and ERBB3 converts PIP2 to PIP3</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1320">
 <bp:evidence rdf:resource="#Evidence1629" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Phosphorylated heterodimers of ERBB2 KD mutants recruit GRB2:SOS1 through SHC1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1321">
 <bp:evidence rdf:resource="#Evidence1630" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Phosphorylated heterodimers of ERBB2 KD mutants and EGFR bind GRB2:GAB1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1326">
 <bp:evidence rdf:resource="#Evidence1635" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Phosphorylated heterodimers of ERBB2 KD mutants and ERBB3 bind PI3K</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1327">
 <bp:evidence rdf:resource="#Evidence1636" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Phosphorylated heterodimers of ERBB2 KD mutants and EGFR, in complex with GRB2:GAB1, bind PI3K</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1324">
 <bp:evidence rdf:resource="#Evidence1633" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">RAS activation by SOS1 bound to phosphorylated heterodimers of ERBB2 KD mutants</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1325">
 <bp:evidence rdf:resource="#Evidence1634" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ERBB2 KD mutants bind TKIs</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1328">
 <bp:evidence rdf:resource="#Evidence1637" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Phosphorylated heterodimers of ERBB2 KD mutants and EGFR bind PLCG1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1329">
 <bp:evidence rdf:resource="#Evidence1638" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Phosphorylated heterodimers of ERBB2 KD mutants and EGFR bind GRB2:SOS1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1340">
 <bp:evidence rdf:resource="#Evidence1650" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ERBB2 TMD/JMD mutants bind TKIs</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1341">
 <bp:evidence rdf:resource="#Evidence1651" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ERBB2 TMD/JMD mutants bind pertuzumab</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1333">
 <bp:evidence rdf:resource="#Evidence1643" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ERBB2 TMD/JMD heterodimers trans-autophosphorylate</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1334">
 <bp:evidence rdf:resource="#Evidence1644" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Phosphorylated heterodimers of ERBB2 TMD/JMD mutants and EGFR phosphorylate PLCG1</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence2290">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1331">
 <bp:evidence rdf:resource="#Evidence1640" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ERBB2 KD mutants trans-autophosphorylate</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence2291">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1332">
 <bp:evidence rdf:resource="#Evidence1641" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">PI3K bound to phosphorylated heterodimers of ERBB2 KD mutants and EGFR converts PIP2 to PIP3</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence2292">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1337">
 <bp:evidence rdf:resource="#Evidence1647" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">RAS activation by SOS1 bound to phosphorylated heterodimers of ERBB2 TMD/JMD mutants and EGFR</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence2293">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1338">
 <bp:evidence rdf:resource="#Evidence1648" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">RAS activation by SOS1 bound to phosphorylated heterodimers of ERBB2 TMD/JMD mutants</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence2294">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1335">
 <bp:evidence rdf:resource="#Evidence1645" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Phosphorylated heterodimers of ERBB2 TMD/JMD mutants phosphorylate SHC1</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence2295">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1336">
 <bp:evidence rdf:resource="#Evidence1646" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Phosphorylated heterodimers of ERBB2 TMD/JMD mutants and EGFR bind PLCG1</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence2296">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2297">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2298">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1339">
 <bp:evidence rdf:resource="#Evidence1649" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Phosphorylated ERBB2 TMD/JMD heterodimers bind SHC1</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence2299">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2239">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence407">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence406">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep420">
 <bp:stepProcess rdf:resource="#Pathway90" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence409">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence408">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1351">
 <bp:evidence rdf:resource="#Evidence1669" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">tamatinib-resistant FLT3 mutants don&apos;t bind tamatinib</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1352">
 <bp:evidence rdf:resource="#Evidence1671" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">sorafenib-resistant FLT3 mutants don&apos;t bind sorafenib</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1350">
 <bp:evidence rdf:resource="#Evidence1667" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">tandutinib-resistant FLT3 mutants don&apos;t bind tandutinib</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1344">
 <bp:evidence rdf:resource="#Evidence1654" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Phosphorylated heterodimers of ERBB2 TMD/JMD mutants and EGFR bind GRB2:SOS1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1345">
 <bp:evidence rdf:resource="#Evidence1655" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Phosphorylated heterodimers of ERBB2 TMD/JMD mutants recruit GRB2:SOS1 through SHC1</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep418">
 <bp:stepProcess rdf:resource="#BiochemicalReaction319" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1342">
 <bp:evidence rdf:resource="#Evidence1652" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ERBB2 TMD/JMD mutants bind trastuzumab</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep419">
 <bp:stepProcess rdf:resource="#BiochemicalReaction320" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1343">
 <bp:evidence rdf:resource="#Evidence1653" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ERBB2 TMD/JMD mutants hetrodimerize</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1348">
 <bp:evidence rdf:resource="#Evidence1663" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">sunitinib-resistant FLT3 mutants don&apos;t bind sunitinib</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1349">
 <bp:evidence rdf:resource="#Evidence1665" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">pexidartinib-resistant FLT3 mutants don&apos;t bind pexidartinib</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1346">
 <bp:evidence rdf:resource="#Evidence1659" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">KW2449-resistant FLT3 mutants don&apos;t bind KW2449</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence2240">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1347">
 <bp:evidence rdf:resource="#Evidence1661" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">midostaurin-resistant FLT3 mutants don&apos;t bind midostaurin</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence2241">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep412">
 <bp:stepProcess rdf:resource="#BiochemicalReaction314" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence414">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2242">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep413">
 <bp:stepProcess rdf:resource="#BiochemicalReaction315" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence413">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2243">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep410">
 <bp:stepProcess rdf:resource="#Pathway87" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence416">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2244">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep411">
 <bp:stepProcess rdf:resource="#Pathway88" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence415">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2245">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep416">
 <bp:stepProcess rdf:resource="#Pathway89" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence410">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2246">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep417">
 <bp:stepProcess rdf:resource="#BiochemicalReaction318" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence2247">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep414">
 <bp:stepProcess rdf:resource="#BiochemicalReaction316" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence412">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2248">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep415">
 <bp:stepProcess rdf:resource="#BiochemicalReaction317" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence411">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2249">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2228">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2229">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence418">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence417">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence419">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1362">
 <bp:evidence rdf:resource="#Evidence1689" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Ligand-independent dimerization of FLT3 fusion proteins</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1363">
 <bp:evidence rdf:resource="#Evidence1690" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">p-STAT5 dissociates from FLT3 fusion proteinsp-</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1360">
 <bp:evidence rdf:resource="#Evidence1687" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FLT3 fusions activate STAT5</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1361">
 <bp:evidence rdf:resource="#Evidence1688" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FLT3 fusions recruit PIK3CA through PIK3R1</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep409">
 <bp:stepProcess rdf:resource="#Pathway86" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1355">
 <bp:evidence rdf:resource="#Evidence1677" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">quizartinib-resistant FLT3 mutants don&apos;t bind quizartinib</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1356">
 <bp:evidence rdf:resource="#Evidence1679" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">semaxanib-resistant FLT3 mutants don&apos;t bind semaxanib&lt;br&gt;</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep407">
 <bp:stepProcess rdf:resource="#BiochemicalReaction312" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1353">
 <bp:evidence rdf:resource="#Evidence1673" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">lestaurtinib-resistant FLT3 mutants don&apos;t bind lestaurtinib</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep408">
 <bp:stepProcess rdf:resource="#BiochemicalReaction313" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1354">
 <bp:evidence rdf:resource="#Evidence1675" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">gilteritinib-resistant FLT3 mutants don&apos;t bind gilteritinib</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1359">
 <bp:evidence rdf:resource="#Evidence1685" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">crenolanib-resistant FLT3 mutants don&apos;t bind crenolanib</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1357">
 <bp:evidence rdf:resource="#Evidence1681" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">linafinib-resistant FLT3 mutants don&apos;t bind linifanib</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1358">
 <bp:evidence rdf:resource="#Evidence1683" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ponatinib-resistant FLT3 mutants don&apos;t bind ponatinib</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence2230">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep401">
 <bp:stepProcess rdf:resource="#BiochemicalReaction309" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence425">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2231">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep402">
 <bp:stepProcess rdf:resource="#Pathway83" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence424">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2232">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence427">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2233">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep400">
 <bp:stepProcess rdf:resource="#BiochemicalReaction308" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence426">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2234">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep405">
 <bp:stepProcess rdf:resource="#BiochemicalReaction310" />
 <bp:stepProcess rdf:resource="#Catalysis85" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence421">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2235">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep406">
 <bp:stepProcess rdf:resource="#BiochemicalReaction311" />
 <bp:stepProcess rdf:resource="#Catalysis86" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence420">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2236">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep403">
 <bp:stepProcess rdf:resource="#Pathway84" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence423">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2237">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep404">
 <bp:stepProcess rdf:resource="#Pathway85" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence422">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2238">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence429">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence428">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1370">
 <bp:evidence rdf:resource="#Evidence1697" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FLT3 fusions:GRB2 bind SOS1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1373">
 <bp:evidence rdf:resource="#Evidence1700" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FLT3 ITD- and STAT5-dependent CDKN1A gene expression</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1374">
 <bp:evidence rdf:resource="#Evidence1701" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Phosphorylated FLT3 fusions bind GRB2</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1371">
 <bp:evidence rdf:resource="#Evidence1698" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">p-STAT5 binds the NOX4 promoter</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1372">
 <bp:evidence rdf:resource="#Evidence1699" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">p-STAT5 binds the CDKN1A gene</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1366">
 <bp:evidence rdf:resource="#Evidence1693" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FLT3 ITD- and STAT5-dependent NOX4 gene expression</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1367">
 <bp:evidence rdf:resource="#Evidence1694" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FLT3 fusion dimers autophosphorylate</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence430">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1364">
 <bp:evidence rdf:resource="#Evidence1691" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FLT3 fusions recruit PIK3R1 through phosphorylated GAB2</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1365">
 <bp:evidence rdf:resource="#Evidence1692" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FLT3 fusions phosphorylate GAB2</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence2260">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2261">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1368">
 <bp:evidence rdf:resource="#Evidence1695" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">STAT5-dependent PIM1 gene expression downstream of FLT3 ITD and fusion mutants</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence2262">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1369">
 <bp:evidence rdf:resource="#Evidence1696" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FLT3 ITD- and NOX4-dependent H2O2 production</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence2263">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence436">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2264">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence435">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2265">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence438">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2266">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence437">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2267">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence432">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2268">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence431">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2269">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence434">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence433">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence439">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1380">
 <bp:evidence rdf:resource="#Evidence1709" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FLT mutants bind type I TKIs</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1381">
 <bp:evidence rdf:resource="#Evidence1711" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FLT3 mutants:GRB2:SOS1-mediated nucleotide exchange on RAS</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1384">
 <bp:evidence rdf:resource="#Evidence1714" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FLT3 mutants:GRB2:p-Y-GAB2 binds PTPN11</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1385">
 <bp:evidence rdf:resource="#Evidence1715" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Constitutive phosphorylation of FLT3 mutants</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1382">
 <bp:evidence rdf:resource="#Evidence1712" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FLT3 mutants recruit PIK3CA through PIK3R1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1383">
 <bp:evidence rdf:resource="#Evidence1713" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Ligand-independent dimerization of FLT3 mutants</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1377">
 <bp:evidence rdf:resource="#Evidence1704" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">p-STAT5 translocates to nucleus downstream of mutant FLT3</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1378">
 <bp:evidence rdf:resource="#Evidence1706" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">CBL mutants don&apos;t ubiquitinate FLT3</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence441">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1375">
 <bp:evidence rdf:resource="#Evidence1702" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SOS1-mediated nucleotide exchange of RAS downstream of FLT3 fusion mutants</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence440">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1376">
 <bp:evidence rdf:resource="#Evidence1703" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FLT3 fusions:GRB2 bind GAB2</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence2250">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1379">
 <bp:evidence rdf:resource="#Evidence1708" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FLT mutants bind type II TKIs</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence2251">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2252">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence447">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2253">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence446">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2254">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence449">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2255">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence448">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2256">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence443">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2257">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence442">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2258">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence445">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2259">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence444">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep460">
 <bp:stepProcess rdf:resource="#BiochemicalReaction353" />
 <bp:stepProcess rdf:resource="#Catalysis90" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep463">
 <bp:stepProcess rdf:resource="#BiochemicalReaction355" />
 <bp:stepProcess rdf:resource="#Catalysis91" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep464">
 <bp:stepProcess rdf:resource="#BiochemicalReaction356" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep461">
 <bp:stepProcess rdf:resource="#BiochemicalReaction354" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep462">
 <bp:stepProcess rdf:resource="#Pathway97" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1391">
 <bp:evidence rdf:resource="#Evidence1722" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">PTPN11:p-STAT5 translocates to nucleus downstream of mutant FLT3</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1392">
 <bp:evidence rdf:resource="#Evidence1723" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">PTPN11:p-STAT5 dissociates from mutant FLT3</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1390">
 <bp:evidence rdf:resource="#Evidence1721" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">PTPN11:p-STAT5 binds BCL2L1 promoter</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1395">
 <bp:evidence rdf:resource="#Evidence1726" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FLT3 mutant dimers bind GRB2</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1396">
 <bp:evidence rdf:resource="#Evidence1727" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FLT3 mutants recruit PIK3R1 through phosphorylated GAB2</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1393">
 <bp:evidence rdf:resource="#Evidence1724" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FLT3 ITD mutants phosphorylate STAT5</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1394">
 <bp:evidence rdf:resource="#Evidence1725" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FLT3 ITD mutants bind STAT5 through GAB2:PTPN11</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence450">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1388">
 <bp:evidence rdf:resource="#Evidence1719" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">p-STAT5 dissociates from mutant FLT3</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1389">
 <bp:evidence rdf:resource="#Evidence1720" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FLT3 ITD- and STAT5-dependent BCL2L1 gene expression</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence452">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1386">
 <bp:evidence rdf:resource="#Evidence1716" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FLT3 mutant dimers:GRB2 bind SOS1</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence451">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1387">
 <bp:evidence rdf:resource="#Evidence1717" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FLT3 mutants:GRB2 bind GAB2</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep456">
 <bp:stepProcess rdf:resource="#Pathway96" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence458">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep457">
 <bp:stepProcess rdf:resource="#Catalysis89" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction350" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence457">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep454">
 <bp:stepProcess rdf:resource="#BiochemicalReaction348" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence2200">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep455">
 <bp:stepProcess rdf:resource="#BiochemicalReaction349" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence459">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2201">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence454">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2202">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence453">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2203">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep458">
 <bp:stepProcess rdf:resource="#BiochemicalReaction351" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence456">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2204">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep459">
 <bp:stepProcess rdf:resource="#BiochemicalReaction352" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence455">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2205">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep452">
 <bp:stepProcess rdf:resource="#BiochemicalReaction346" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep453">
 <bp:stepProcess rdf:resource="#BiochemicalReaction347" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep450">
 <bp:stepProcess rdf:resource="#BiochemicalReaction335" />
 <bp:stepProcess rdf:resource="#Catalysis88" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep451">
 <bp:stepProcess rdf:resource="#BiochemicalReaction345" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence461">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1399">
 <bp:evidence rdf:resource="#Evidence1734" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Deletions in the AXIN1 gene prevent expression of AXIN1 protein</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence460">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence463">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1397">
 <bp:evidence rdf:resource="#Evidence1728" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FLT3 mutants phosphorylate GAB2</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence462">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1398">
 <bp:evidence rdf:resource="#Evidence1732" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">AXIN mutants destabilize the destruction complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep445">
 <bp:stepProcess rdf:resource="#BiochemicalReaction341" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence469">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep446">
 <bp:stepProcess rdf:resource="#BiochemicalReaction342" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence468">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep443">
 <bp:stepProcess rdf:resource="#BiochemicalReaction339" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep444">
 <bp:stepProcess rdf:resource="#BiochemicalReaction340" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep449">
 <bp:stepProcess rdf:resource="#BiochemicalReaction344" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence465">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence464">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep447">
 <bp:stepProcess rdf:resource="#BiochemicalReaction343" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence467">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep448">
 <bp:stepProcess rdf:resource="#Pathway95" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence466">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2217">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2218">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2219">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep441">
 <bp:stepProcess rdf:resource="#BiochemicalReaction337" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep442">
 <bp:stepProcess rdf:resource="#BiochemicalReaction338" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep440">
 <bp:stepProcess rdf:resource="#BiochemicalReaction336" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence472">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence471">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence474">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence473">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence470">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep434">
 <bp:stepProcess rdf:resource="#BiochemicalReaction332" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence2220">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep435">
 <bp:stepProcess rdf:resource="#BiochemicalReaction333" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence479">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2221">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep432">
 <bp:stepProcess rdf:resource="#BiochemicalReaction330" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence2222">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep433">
 <bp:stepProcess rdf:resource="#BiochemicalReaction331" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence2223">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep438">
 <bp:stepProcess rdf:resource="#BiochemicalReaction334" />
 <bp:stepProcess rdf:resource="#Catalysis87" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence476">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2224">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep439">
 <bp:stepProcess rdf:resource="#BiochemicalReaction335" />
 <bp:stepProcess rdf:resource="#Catalysis88" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence475">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2225">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep436">
 <bp:stepProcess rdf:resource="#Pathway93" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence478">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2226">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep437">
 <bp:stepProcess rdf:resource="#Pathway94" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence477">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2227">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2206">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2207">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2208">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2209">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep430">
 <bp:stepProcess rdf:resource="#Pathway92" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep431">
 <bp:stepProcess rdf:resource="#BiochemicalReaction329" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence483">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence482">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep429">
 <bp:stepProcess rdf:resource="#BiochemicalReaction328" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence485">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence484">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence481">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence480">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep423">
 <bp:stepProcess rdf:resource="#BiochemicalReaction323" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep424">
 <bp:stepProcess rdf:resource="#Pathway91" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence2210">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep421">
 <bp:stepProcess rdf:resource="#BiochemicalReaction321" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence2211">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep422">
 <bp:stepProcess rdf:resource="#BiochemicalReaction322" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence2212">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep427">
 <bp:stepProcess rdf:resource="#BiochemicalReaction326" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence487">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2213">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep428">
 <bp:stepProcess rdf:resource="#BiochemicalReaction327" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence486">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2214">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep425">
 <bp:stepProcess rdf:resource="#BiochemicalReaction324" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence489">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2215">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep426">
 <bp:stepProcess rdf:resource="#BiochemicalReaction325" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence488">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2216">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep382">
 <bp:stepProcess rdf:resource="#BiochemicalReaction291" />
 <bp:stepProcess rdf:resource="#Catalysis81" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep383">
 <bp:stepProcess rdf:resource="#BiochemicalReaction292" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep380">
 <bp:stepProcess rdf:resource="#BiochemicalReaction289" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep381">
 <bp:stepProcess rdf:resource="#BiochemicalReaction290" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep386">
 <bp:stepProcess rdf:resource="#BiochemicalReaction295" />
 <bp:stepProcess rdf:resource="#Catalysis83" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep387">
 <bp:stepProcess rdf:resource="#BiochemicalReaction296" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep384">
 <bp:stepProcess rdf:resource="#BiochemicalReaction293" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep385">
 <bp:stepProcess rdf:resource="#BiochemicalReaction294" />
 <bp:stepProcess rdf:resource="#Catalysis82" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep379">
 <bp:stepProcess rdf:resource="#BiochemicalReaction288" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep377">
 <bp:stepProcess rdf:resource="#BiochemicalReaction286" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep378">
 <bp:stepProcess rdf:resource="#BiochemicalReaction287" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep371">
 <bp:stepProcess rdf:resource="#BiochemicalReaction280" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep372">
 <bp:stepProcess rdf:resource="#BiochemicalReaction281" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep370">
 <bp:stepProcess rdf:resource="#BiochemicalReaction279" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep375">
 <bp:stepProcess rdf:resource="#BiochemicalReaction284" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep376">
 <bp:stepProcess rdf:resource="#BiochemicalReaction285" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep373">
 <bp:stepProcess rdf:resource="#BiochemicalReaction282" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep374">
 <bp:stepProcess rdf:resource="#BiochemicalReaction283" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep368">
 <bp:stepProcess rdf:resource="#Pathway80" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep369">
 <bp:stepProcess rdf:resource="#Pathway81" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep366">
 <bp:stepProcess rdf:resource="#BiochemicalReaction277" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep367">
 <bp:stepProcess rdf:resource="#BiochemicalReaction278" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep360">
 <bp:stepProcess rdf:resource="#Pathway77" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep361">
 <bp:stepProcess rdf:resource="#Pathway78" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep364">
 <bp:stepProcess rdf:resource="#Pathway79" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep365">
 <bp:stepProcess rdf:resource="#BiochemicalReaction276" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep362">
 <bp:stepProcess rdf:resource="#BiochemicalReaction274" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep363">
 <bp:stepProcess rdf:resource="#BiochemicalReaction275" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep357">
 <bp:stepProcess rdf:resource="#BiochemicalReaction272" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep358">
 <bp:stepProcess rdf:resource="#Pathway76" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep355">
 <bp:stepProcess rdf:resource="#Catalysis79" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction270" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep356">
 <bp:stepProcess rdf:resource="#BiochemicalReaction271" />
 <bp:stepProcess rdf:resource="#Catalysis80" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence2300">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2301">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2302">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep359">
 <bp:stepProcess rdf:resource="#BiochemicalReaction273" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence2303">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2304">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep350">
 <bp:stepProcess rdf:resource="#BiochemicalReaction266" />
 <bp:stepProcess rdf:resource="#Catalysis76" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep353">
 <bp:stepProcess rdf:resource="#BiochemicalReaction269" />
 <bp:stepProcess rdf:resource="#Catalysis78" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep354">
 <bp:stepProcess rdf:resource="#Pathway75" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep351">
 <bp:stepProcess rdf:resource="#BiochemicalReaction267" />
 <bp:stepProcess rdf:resource="#Catalysis77" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep352">
 <bp:stepProcess rdf:resource="#BiochemicalReaction268" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis205">
 <bp:controlled rdf:resource="#BiochemicalReaction727" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis204">
 <bp:controlled rdf:resource="#BiochemicalReaction726" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis207">
 <bp:controlled rdf:resource="#BiochemicalReaction733" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis206">
 <bp:controlled rdf:resource="#BiochemicalReaction732" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis201">
 <bp:controlled rdf:resource="#BiochemicalReaction725" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis200">
 <bp:controlled rdf:resource="#BiochemicalReaction724" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis203">
 <bp:controlled rdf:resource="#BiochemicalReaction726" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis202">
 <bp:controlled rdf:resource="#BiochemicalReaction726" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep346">
 <bp:stepProcess rdf:resource="#Catalysis74" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction263" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep347">
 <bp:stepProcess rdf:resource="#Pathway74" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep344">
 <bp:stepProcess rdf:resource="#Pathway73" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep345">
 <bp:stepProcess rdf:resource="#BiochemicalReaction262" />
 <bp:stepProcess rdf:resource="#Catalysis73" />
</bp:PathwayStep>

<bp:Catalysis rdf:ID="Catalysis209">
 <bp:controlled rdf:resource="#BiochemicalReaction737" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis208">
 <bp:controlled rdf:resource="#BiochemicalReaction735" />
</bp:Catalysis>

<bp:PathwayStep rdf:ID="PathwayStep348">
 <bp:stepProcess rdf:resource="#BiochemicalReaction264" />
 <bp:stepProcess rdf:resource="#Catalysis75" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep349">
 <bp:stepProcess rdf:resource="#BiochemicalReaction265" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway491">
 <bp:pathwayOrder rdf:resource="#PathwayStep2191" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1656" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2146" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective CHST14 causes EDS, musculocontractural type</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Carbohydrate sulfotransferase 14 (CHST14 also known as D4ST-1) mediates the transfer of sulfate to position 4 of further N-acetylgalactosamine (GalNAc) residues of dermatan sulfate (DS). Defects in CHST14 cause Ehlers-Danlos syndrome, musculocontractural type (MIM:601776). The Ehlers-Danlos syndromes (EDS) are a group of connective tissue disorders that share common features such as  skin hyperextensibility, articular hypermobility and tissue fragility (Beighton et al. 1998). The musculocontractural form of EDS (MIM:601776) include distinctive characteristics such as craniofacial dysmorphism, congenital contractures of fingers and thumbs, clubfeet, severe kyphoscoliosis and muscular hypotonia (Malfait et al. 2010).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway490">
 <bp:pathwayOrder rdf:resource="#PathwayStep2189" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1655" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2144" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective CHST3 causes SEDCJD</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Carbohydrate sulfotransferase 3 (CHST3) transfers sulfate (SO4(2-)) to position 6 of N-acetylgalactosamine (GalNAc) residues of chondroitin-containg proteins resulting in chondroitin sulfate (CS), the predominant glycosaminoglycan present in cartilage. Defects in CHST3 result in spondyloepiphyseal dysplasia with congenital joint dislocations (SEDCJD; MIM:143095), a bone dysplasia clinically characterized by severe progressive kyphoscoliosis (abnormal curvature of the spine), arthritic changes with joint dislocations and short stature in adulthood (Unger et al. 2010).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway493">
 <bp:pathwayOrder rdf:resource="#PathwayStep2195" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2196" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2197" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1658" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1659" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1660" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2150" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective HEXB causes GM2G2</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Beta-hexosaminidase (HEX) cleaves the terminal N-acetyl galactosamine (GalNAc) from glycosaminoglycans (GAGs) and any other molecules containing a terminal GalNAc. There are two forms of HEX; HEXA and B. The A form is a trimer of the subunits alpha, beta A and beta B. The B form is a tetramer of 2 beta A and 2 beta B subunits (O&apos;Dowd et al. 1988). Defects in the two subunits cause lysosomal storage diseases marked by the accumulation of GM2 gangliosides in neuronal cells.  Defects in the beta subunits are the cause of GM2-gangliosidosis type 2 (GM2G2; MIM:268800), also known as Sandhoff disease (Sandhoff et al. 1968, Banerjee et al. 1991). Sandhoff disease is an autosomal recessive lysosomal storage disease clinically indistinguishable from GM2-gangliosidosis type 1, presenting early blindness with cherry-red spots on the macula, progressive motor and mental deterioration and macrocephaly. Death usually occurs by the age of 3 years.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway492">
 <bp:pathwayOrder rdf:resource="#PathwayStep2193" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1657" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2148" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective B3GALT6 causes EDSP2 and SEMDJL1</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The biosynthesis of dermatan sulfate/chondroitin sulfate and heparin/heparan sulfate glycosaminoglycans (GAGs) starts with the formation of a tetrasaccharide linker sequence attached to the core protein. Beta-1,3-galactosyltransferase 6 (B3GALT6) is one of the critical enzymes involved in the formation of this linker sequence. Defects in B3GALT6 causes Ehlers-Danlos syndrome progeroid type 2 (EDSP2; MIM:615349), a severe disorder resulting in a broad spectrum of skeletal, connective tissue and wound healing problems. Defects in B3GALT6 can also cause spondyloepimetaphyseal dysplasia with joint laxity type 1 (SEMDJL1; MIM:271640), characterised by spinal deformaty and lax joints, especially of the hands and respiratory compromise resulting in early death (Nakajima et al. 2013, Malfait et al. 2013).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway495">
 <bp:pathwayOrder rdf:resource="#PathwayStep2201" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2202" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2203" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2204" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1663" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1664" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1662" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1665" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2156" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective EXT1 causes exostoses 1, TRPS2 and CHDS</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Heparan sulfate (HS) is involved in regulating various body functions functions during development, homeostasis and pathology including blood clotting, angiogenesis and metastasis of cancer cells. Exostosin 1 and 2 (EXT1 and 2) glycosyltransferases are required to form HS. They are able to transfer N-acetylglucosamine (GlcNAc) and glucuronate (GlcA) to HS during its synthesis. The functional form of these enzymes appears to be a complex of the two located on the Golgi membrane. Defects in either EXT1 or EXT2 can cause hereditary multiple exostoses 1 (Petersen 1989) and 2 (McGaughran et al. 1995) respectively (MIM:133700 and MIM:133701), autosomal dominant disorders characterized by multiple projections of bone capped by cartilage resulting in deformed legs, forearms and hands. Trichorhinophalangeal syndrome, type II (TRPS2 aka Langer-Giedion syndrome, LGS) is a disorder that combines the clinical features of trichorhinophalangeal syndrome type I (TRPS1, MIM:190350) and multiple exostoses type I, caused by mutations in the TRPS1 and EXT1 genes, respectively (Langer et al. 1984, Ludecke et al. 1995). Defects in EXT1 may also be responsible for chondrosarcoma (CHDS; MIM:215300) (Schajowicz    Bessone 1967, Hecht et al. 1995).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway494">
 <bp:pathwayOrder rdf:resource="#PathwayStep2199" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1661" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2154" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective SLC26A2 causes chondrodysplasias</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The SLC26A1 and 2 genes encode sulfate transporter proteins that facilitate sulfate uptake into cells, critical in cartilage for sulfation of proteoglycans and extracellular matrix organization. Defects in SLC26A2 result in impaired SO4(2-) transport leading to insufficient sulfation of cartilage proteoglycans. Defective SLC26A2 is implicated in the pathogenesis of a spectrum of autosomal recessive human chondrodysplasias. Severity of symptoms range from mild (diastrophic dysplasia; MIM:222600), intermediate (atelosteogenesis type II; MIM256050) to severe (achondrogenesis type 1B; MIM:600972) (Superti-Furga et al. 1996, Dwyer et al. 2010, Dawson    Markovich 2005).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway497">
 <bp:pathwayOrder rdf:resource="#PathwayStep2209" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1668" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2164" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective ST3GAL3 causes MCT12 and EIEE15</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">CMP-N-acetylneuraminate-beta-1,4-galactoside alpha-2,3-sialyltransferase (ST3GAL3) mediates the transfer of sialic acid from CMP-sialic acid to galactose-containing glycoproteins and forms the sialyl Lewis a epitope on proteins which are required for attaining and/or maintaining higher cognitive functions. Some defects in ST3GAL3 result in mental retardation, autosomal recessive 12 (MRT12; MIM:611090), a disorder characterised by below average general intellectual function and impaired adaptive behaviour (Najmabadi et al. 2007,  Hu et al. 2011). Another defect of ST3GAL3 can cause early infantile epileptic encephalopathy-15 (EIEE15: MIM:615006), resulting in severe mental retardation (Edvardson et al. 2012).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway496">
 <bp:pathwayOrder rdf:resource="#PathwayStep2206" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2207" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1667" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1666" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2161" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective PAPSS2 causes SEMD-PA</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defects in PAPSS2 cause spondyloepimetaphyseal dysplasia Pakistani type (SEMD-PA; MIM:612847), a bone disease characterized by epiphyseal dysplasia with mild metaphyseal abnormalities. Clinical features include short stature from birth, short and bowed lower limbs, mild brachydactyly, kyphoscoliosis, abnormal gait and enlarged knee joints. Some patients may manifest premature pubarche and hyperandrogenism (Ahmed et al. 1998, Noordam et al. 2009, Miyake et al. 2012).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway499">
 <bp:pathwayOrder rdf:resource="#PathwayStep2240" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2227" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2238" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2217" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2229" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2219" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2223" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2234" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2225" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2236" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2215" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2231" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2242" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2221" />
 <bp:pathwayComponent rdf:resource="#Pathway503" />
 <bp:pathwayComponent rdf:resource="#Pathway502" />
 <bp:pathwayComponent rdf:resource="#Pathway513" />
 <bp:pathwayComponent rdf:resource="#Pathway505" />
 <bp:pathwayComponent rdf:resource="#Pathway504" />
 <bp:pathwayComponent rdf:resource="#Pathway507" />
 <bp:pathwayComponent rdf:resource="#Pathway506" />
 <bp:pathwayComponent rdf:resource="#Pathway509" />
 <bp:pathwayComponent rdf:resource="#Pathway508" />
 <bp:pathwayComponent rdf:resource="#Pathway510" />
 <bp:pathwayComponent rdf:resource="#Pathway501" />
 <bp:pathwayComponent rdf:resource="#Pathway512" />
 <bp:pathwayComponent rdf:resource="#Pathway500" />
 <bp:pathwayComponent rdf:resource="#Pathway511" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2170" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Diseases associated with glycosylation precursor biosynthesis</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Glycosylation diseases associated with the enzymes that mediate the biosynthesis of glycosylation precursors are curated in this section (Jaeken    Matthijs 2007, Freeze et al. 2015).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway498">
 <bp:pathwayOrder rdf:resource="#PathwayStep2212" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2213" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2211" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1669" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1670" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1671" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2166" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective B4GALT1 causes B4GALT1-CDG (CDG-2d)</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Congenital disorders of glycosylation (CDG, previously called carbohydrate-deficient glycoprotein syndromes, CDGSs), are a group of hereditary multisystem disorders. They are characterized biochemically by hypoglycosylation of glycoproteins, diagnosed by isoelectric focusing (IEF) of serum transferrin. There are two types of CDG, types I and II. Type I CDG has defects in the assembly of lipid-linked oligosaccharides or their transfer onto nascent glycoproteins, whereas type II CDG comprises defects of trimming, elongation, and processing of protein-bound glycans. Clinical symptoms are dominated by severe psychomotor and mental retardation, as well as blood coagulation abnormalities (Jaeken 2013). B4GALT1-CDG (CDG type IId) is a multisystem disease, characterized by dysmorphic features, hydrocephalus, hypotonia and blood clotting abnormalities (Hansske et al. 2002).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway471">
 <bp:pathwayOrder rdf:resource="#PathwayStep2147" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1632" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2102" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective ALG1 causes CDG-1k</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Chitobiosyldiphosphodolichol beta-mannosyltransferase (ALG1) normally tranfers a mannose moiety to the lipid-linked oligosaccharide (LLO aka N-glycan precursor) which is required for subsequent N-glycosylation of proteins. Defects in ALG1 can cause congenital disorder of glycosylation 1k (ALG1-CDG, previously known as CDG1k; MIM:608540), a multisystem disorder characterised by under-glycosylated serum glycoproteins. CDG type 1 diseases result in a wide variety of clinical features, such as defects in the nervous system development, psychomotor retardation, dysmorphic features, hypotonia, coagulation disorders, and immunodeficiency. Compared to other CDGs, ALG1-CDG has a very severe phenotype, which can result in an early death (Schwarz et al. 2004, Kranz et al. 2004, Dupre et al. 2010).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway470">
 <bp:pathwayOrder rdf:resource="#PathwayStep2145" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1631" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2100" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective ALG12 causes CDG-1g</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Dol-P-Man:Man(7)GlcNAc(2)-PP-Dol alpha-1,6-mannosyltransferase (ALG12) (Chantret et al. 2002) normally tranfers the 8th mannose moiety to the lipid-linked oligosaccharide (LLO aka N-glycan precursor) which is required for subsequent N-glycosylation of proteins. Defects in ALG12 are associated with congenital disorder of glycosylation 1g (ALG12-CDG, CDG1g; MIM:607143), a multisystem disorder caused by a defect in glycoprotein biosynthesis and characterised by under-glycosylated serum glycoproteins (Chantret et al. 2002, Grubenmann et al. 2002). CDG type 1 diseases result in a wide variety of clinical features, such as defects in the nervous system development, psychomotor retardation, dysmorphic features, hypotonia, coagulation disorders, and immunodeficiency.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway473">
 <bp:pathwayOrder rdf:resource="#PathwayStep2161" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2151" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2163" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2157" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2159" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2153" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2165" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2155" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2167" />
 <bp:pathwayComponent rdf:resource="#Pathway480" />
 <bp:pathwayComponent rdf:resource="#Pathway482" />
 <bp:pathwayComponent rdf:resource="#Pathway481" />
 <bp:pathwayComponent rdf:resource="#Pathway475" />
 <bp:pathwayComponent rdf:resource="#Pathway474" />
 <bp:pathwayComponent rdf:resource="#Pathway477" />
 <bp:pathwayComponent rdf:resource="#Pathway476" />
 <bp:pathwayComponent rdf:resource="#Pathway479" />
 <bp:pathwayComponent rdf:resource="#Pathway478" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2106" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Diseases associated with O-glycosylation of proteins</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Glycosylation is the most abundant modification of proteins, variations of which occur in all living cells. Glycosylation can be further categorized into N-linked (where the oligosaccharide is conjugated to Asparagine residues) and O-linked glycosylation (where the oligosaccharide is conjugated to Serine, Threonine and possibly Tyrosine residues). Within the family of O-linked glycosylation, the oligosaccharides attached can be further categorized according to their reducing end residue: GalNAc (often described as mucin-type, due to the abundance of this type of glycosylation on mucins), Mannose and Fucose. This section reviews currently known congenital disorders of glycosylation associated with defects of protein O-glycosylation (Cylwik et al. 2013, Freeze et al. 2014).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway472">
 <bp:pathwayOrder rdf:resource="#PathwayStep2149" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1633" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2104" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective ALG2 causes CDG-1i</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Alpha 1,3/1,6 mannosyltransferase ALG2 (ALG2) is a bifunctional mannosyltransferase normally tranfers a mannose moiety to the lipid linked oligosaccharide (LLO aka N glycan precursor) which is required for subsequent N glycosylation of proteins. Defects in ALG2 can cause congenital disorder of glycosylation 1i (ALG2-CDG, previously known as CDG1i; MIM:607906), a multisystem disorder characterised by under glycosylated serum glycoproteins. CDG type 1 diseases result in a wide phenotypic spectrum, from poor neurological development, psychomotor retardation and dysmorphic features to hypotonia, coagulation abnormalities and immunodeficiency (Thiel et al. 2003). Defect in ALG2 can also cause congenital myasthenic syndrome (ALG2-CMS), which is due to a defect in neuromuscular signal transmission (Cossins et al. 2013). The most commonly affected muscles include proximal limb muscles. Mutations causing ALG2-CMS include p.V68G and p.72_75delinsSPR (Cossins et al. 2013). </bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep399">
 <bp:stepProcess rdf:resource="#BiochemicalReaction307" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway475">
 <bp:pathwayOrder rdf:resource="#PathwayStep2154" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1635" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2109" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective C1GALT1C1 causes TNPS</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Glycoprotein-N-acetylgalactosamine 3-beta-galactosyltransferase 1 (C1GALT1; MIM:610555) mediates the transfer of Galactose (Gal) from UDP-galactose to single O-linked GalNAc residues (Tn antigens) to form Core 1 structures on glycoproteins. C1GALT1 is active when in complex with the molecular chaperone C1GALT1C1 (aka COSMC; MIM:300611) which assists the folding and/or stability of C1GALT1. Defects in C1GALT1C1 causes somatic Tn polyagglutination syndrome (TNPS; MIM:300622), characterised by the polyagglutination of erythrocytes by naturally occurring anti-Tn antibodies following exposure of the Tn antigen on their surface. Defects in C1GALT1C1 render C1GALT1 inactive and results in the accumulation of the incompletely glycosylated Tn antigen. The Tn antigen is tumour-associated, found in a majority of human carcinomas, and is not normally expressed in peripheral tissues or blood cells (Crew et al. 2008, Ju et al. 2014). C1GALT1 and C1GALT1C1 belong to the CAZy family GT31 (www.cazy.org).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway474">
 <bp:pathwayOrder rdf:resource="#PathwayStep2152" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1634" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2107" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective B3GALTL causes PpS</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Human beta-1,3-glucosyltransferase like protein (B3GALTL, HGNC Approved Gene Symbol: B3GLCT; MIM:610308; CAZy family GT31), localised on the ER membrane, glucosylates O-fucosylated proteins. The resultant glc-beta-1,3-fuc disaccharide modification on thrombospondin type 1 repeat (TSR1) domain-containing proteins is thought to assist in the secretion of many of these proteins from the ER lumen, and mediate an ER quality-control mechanism of folded TSRs (Vasudevan et al. 2015). Defects in B3GALTL can cause Peters plus syndrome (PpS; MIM:261540), an autosomal recessive disorder characterised by anterior eye chamber defects, short stature, delay in growth and mental developmental and cleft lip and/or palate (Heinonen    Maki 2009).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway477">
 <bp:pathwayOrder rdf:resource="#PathwayStep2158" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1637" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2113" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective GALNT12 causes CRCS1</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The family of UDP GalNAc:polypeptide N acetylgalactosaminyltransferases (GalNAc transferases, GALNTs) carry out the addition of N acetylgalactosamine on serine, threonine or possibly tyrosine residues on a wide variety of proteins, and most commonly associated with mucins (Wandall et al. 1997). This reaction takes place in the Golgi apparatus (Rottger et al. 1998). There are 20 known members of the GALNT family, 15 of which have been characterised and 5 candidate members which are thought to belong to this family based on sequence similarity (Bennett et al. 2012). The GALNT-family is classified as belonging to CAZy family GT27. Defects in one of the GALNT family, GALNT12 (Guo et al. 2002) (MIM: 610290) can result in decreased glycosylation of mucins, mainly expressed in the digestive organs such as the stomach, small intestine and colon, and may play a role in colorectal cancer 1 (CRCS1; MIM:608812). CRCS1 is a complex disease characterised by malignant lesions arising from the inner walls of the colon and rectum (Guda et al. 2009, Clarke et al. 2012).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway476">
 <bp:pathwayOrder rdf:resource="#PathwayStep2156" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1636" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2111" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective POMT1 causes MDDGA1, MDDGB1 and MDDGC1</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Co-expression of both protein O-mannosyl-transferases 1 and 2 (POMT1 and POMT2; CAZy family GT39) is necessary for enzyme activity, that is mediating the transfer of mannosyl residues to the hydroxyl group of serine or threonine residues of proteins such as alpha-dystroglycan (DAG1; MIM:128239). DAG1 is a cell surface protein that plays an important role in the assembly of the extracellular matrix in muscle, brain, and peripheral nerves by linking the basal lamina to cytoskeletal proteins. Defects in POMT1 (MIM:607423) results in defective glycosylation of DAG1 and can cause severe congenital muscular dystrophy-dystroglycanopathies ranging from a severe type A, MDDGA1 (brain and eye abnormalities; MIM:236670), through a less severe type B, MDDGB1 (congenital form with mental retardation; MIM:613155) to a milder type C, MDDGC1 (limb girdle form; MIM:609308) (Bertini et al. 2011, Wells 2013).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway479">
 <bp:pathwayOrder rdf:resource="#PathwayStep2162" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1639" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2117" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective GALNT3 causes HFTC</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The family of UDP GalNAc:polypeptide N acetylgalactosaminyltransferases (GalNAc transferases, GALNTs) carry out the addition of N acetylgalactosamine (GalNAc) on serine, threonine or possibly tyrosine residues on a wide variety of proteins, most commonly associated with mucins.  This is the initial reaction in the biosynthesis of GalNAc-type O linked oligosaccharides (Wandall et al. 1997). This reaction takes place in the Golgi apparatus (Rottger et al. 1998). There are 20 known members of the GALNT family, 15 of which have been characterised and 5 candidate members which are thought to belong to this family based on sequence similarity (Bennett et al. 2012). The GALNT-family is classified as belonging to CAZy family GT27. Defects in one of the GALNT family genes, GALNT3 (MIM:601756), can cause familial hyperphosphatemic tumoral calcinosis (HFTC; MIM:211900). HFTC is a rare autosomal recessive severe metabolic disorder characterised by the progressive deposition of calcium phosphate crystals in the skin, soft tissues and sometimes bone (Chefetz et al. 2005). The biochemical observation is hyperphosphatemia, caused by increased renal absorption of phosphate (Chefetz et al. 2005, Ichikawa et al. 2005). Some patients manifest recurrent, transient, painful swellings of the long bones with radiological evidence of periosteal reaction and cortical hyperostosis (Frishberg et al. 2005).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway478">
 <bp:pathwayOrder rdf:resource="#PathwayStep2160" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1638" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2115" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective LARGE causes MDDGA6 and MDDGB6</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Glycosyltransferase-like protein LARGE (MIM:603590) is a bifunctional glycosyltransferase with both xylosyltransferase and beta-1,3-glucuronyltransferase activities involved in the biosynthesis of a phosphorylated O-mannosyl trisaccharide, a structure present in alpha-dystroglycan (DAG1; MIM:128239) which plays a key role in skeletal muscle function and regeneration. LARGE contains two substrate-specific GT-domains and belongs to the CAZy glycosyltransferase families GT8 and GT49. Defects in LARGE result in hypoglycosylation of DAG1 and cause several congenital muscular dystrophies (CMDs). Muscular dystrophy-dystroglycanopathy congenital with brain and eye anomalies A6 (MDDGA6; MIM:613154) is associated with brain anomalies, eye malformations, profound mental retardation, and death usually in the first years of life (Clement et al. 2008, Mercuri et al. 2009). Muscular dystrophy-dystroglycanopathy congenital with mental retardation B6 (MDDGB6; MIM:608840) is associated with profound mental retardation, white matter changes and structural brain abnormalities (Longman et al. 2003).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep393">
 <bp:stepProcess rdf:resource="#BiochemicalReaction301" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep394">
 <bp:stepProcess rdf:resource="#BiochemicalReaction302" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep391">
 <bp:stepProcess rdf:resource="#BiochemicalReaction299" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep392">
 <bp:stepProcess rdf:resource="#BiochemicalReaction300" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep397">
 <bp:stepProcess rdf:resource="#BiochemicalReaction305" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep398">
 <bp:stepProcess rdf:resource="#BiochemicalReaction306" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep395">
 <bp:stepProcess rdf:resource="#BiochemicalReaction303" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep396">
 <bp:stepProcess rdf:resource="#BiochemicalReaction304" />
 <bp:stepProcess rdf:resource="#Catalysis84" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep390">
 <bp:stepProcess rdf:resource="#BiochemicalReaction298" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway480">
 <bp:pathwayOrder rdf:resource="#PathwayStep2164" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1640" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2119" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective LFNG causes SCDO3</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The Fringe family (CAZy family GT31) of glycosyltransferases in mammals includes LFNG (lunatic fringe; MIM:602576), MFNG (manic fringe; MIM:602577) and RFNG (radical fringe; MIM:602578). Fringe enzymes function in the Golgi apparatus where they initiate the elongation of O-linked fucose on fucosylated peptides by the addition of a beta 1,3 N-acetylglucosaminyl group (GlcNAc) (Moloney et al. 2000). Fringe enzymes elongate conserved O fucosyl residues conjugated to EGF repeats of NOTCH, modulating NOTCH activity (Cohen et al. 1997, Johnston et al. 1997) by decreasing the affinity of NOTCH extracellular domain for JAG ligands (Bruckner et al. 2000).  The spondylocostal dysostoses (SCDs) are a group of disorders that arise during embryonic development by a disruption of somitogenesis. The Notch signalling pathway is essential for somitogenesis, the precursors of vertebra and associated musculature. Defects in one of the Fringe enzymes, beta-1,3-N-acetylglucosaminyltransferase lunatic fringe (LFNG), can cause spondylocostal dysostosis, autosomal recessive 3 (SCDO3, MIM:609813), a condition of variable severity associated with vertebral and rib segmentation defects (Sparrow et al. 2006).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway482">
 <bp:pathwayOrder rdf:resource="#PathwayStep2168" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1642" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2123" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective POMT2 causes MDDGA2, MDDGB2 and MDDGC2</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Co-expression of both protein O-mannosyl-transferases 1 and 2 (POMT1 and POMT2; CAZy family GT39) is necessary for enzyme activity, that is mediating the transfer of mannosyl residues to the hydroxyl group of serine or threonine residues of proteins such as alpha-dystroglycan (DAG1; MIM:128239). DAG1 is a cell surface protein that plays an important role in the assembly of the extracellular matrix in muscle, brain, and peripheral nerves by linking the basal lamina to cytoskeletal proteins. Defects in POMT2 (MIM:607439) results in defective glycosylation of DAG1 and can cause severe congenital muscular dystrophy dystroglycanopathies ranging from a severe type A, MDDGA2 (brain and eye abnormalities; MIM:613150), through a less severe type B, MDDGB2 (congenital form with mental retardation; MIM:613156) to a milder type C, MDDGC2 (limb girdle form; MIM:603158) (Bertini et al. 2011, Wells 2013).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway481">
 <bp:pathwayOrder rdf:resource="#PathwayStep2166" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1641" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2121" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective POMGNT1 causes MDDGA3, MDDGB3 and MDDGC3</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Protein O-linked-mannose beta-1,2-N-acetylglucosaminyltransferase 1 (POMGNT1; CAZy family GT61; MIM:606822) mediates the transfer of N-acetylglucosaminyl (GlcNAc) residues to mannosylated proteins such as mannose-O-serine-dystroglycan (man-O-Ser-DAG1). DAG1 is a cell surface protein that plays an important role in the assembly of the extracellular matrix in muscle, brain, and peripheral nerves by linking the basal lamina to cytoskeletal proteins. Defects in POMGNT1 (MIM:606822) result in disrupted glycosylation of DAG1 and can cause severe congenital muscular dystrophy-dystroglycanopathies ranging from a severe type A3 (MDDGA3; MIM:253280), through a less severe type B3 (MDDGB3; MIM:613151) to a milder type C3 (MDDGC3; MIM:613157) (Bertini et al. 2011, Wells 2013).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence403">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway484">
 <bp:pathwayOrder rdf:resource="#PathwayStep2171" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2172" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1643" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1644" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2126" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective CHSY1 causes TPBS</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Chondroitin sulfate synthases (CHSY) are involved in the synthesis of chondroitin sulfate, adding alternatingly glucuronate (GlcA) and N-acetylgalactosamine (GalNAc) to the growing chondroitin polymer (Mizumoto et al. 2013). Defects in CHSY1 cause temtamy preaxial brachydactyly syndrome (TPBS; MIM:605282), a syndrome characterized by multiple congenital anomalies, mental retardation, sensorineural deafness, growth retardation and bilateral symmetric digital anomalies mainly in the form of preaxial brachydactyly (literally, shortness of fingers and toes) and hyperphalangism (Temtamy et al. 1998, Race et al. 2010, Tian et al. 2010).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence402">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway483">
 <bp:pathwayOrder rdf:resource="#PathwayStep2182" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2194" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2173" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2184" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2190" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2170" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2192" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2205" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2208" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2186" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2198" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2177" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2188" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2210" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2200" />
 <bp:pathwayComponent rdf:resource="#Pathway491" />
 <bp:pathwayComponent rdf:resource="#Pathway490" />
 <bp:pathwayComponent rdf:resource="#Pathway493" />
 <bp:pathwayComponent rdf:resource="#Pathway492" />
 <bp:pathwayComponent rdf:resource="#Pathway484" />
 <bp:pathwayComponent rdf:resource="#Pathway495" />
 <bp:pathwayComponent rdf:resource="#Pathway494" />
 <bp:pathwayComponent rdf:resource="#Pathway486" />
 <bp:pathwayComponent rdf:resource="#Pathway497" />
 <bp:pathwayComponent rdf:resource="#Pathway485" />
 <bp:pathwayComponent rdf:resource="#Pathway496" />
 <bp:pathwayComponent rdf:resource="#Pathway488" />
 <bp:pathwayComponent rdf:resource="#Pathway487" />
 <bp:pathwayComponent rdf:resource="#Pathway498" />
 <bp:pathwayComponent rdf:resource="#Pathway489" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2125" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Diseases associated with glycosaminoglycan metabolism</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">A number of genetic disorders are caused by mutations in the genes encoding glycosyltransferases and sulfotransferases, enzymes responsible for the synthesis of  glycosaminoglycans (GAGs) as well as hexosaminidase degradation of GAGs (Mizumoto et al. 2013).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep388">
 <bp:stepProcess rdf:resource="#BiochemicalReaction297" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence405">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway486">
 <bp:pathwayOrder rdf:resource="#PathwayStep2180" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2181" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2179" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2178" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1650" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1651" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1649" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1648" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2133" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective EXT2 causes exostoses 2</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Heparan sulfate (HS) is involved in regulating various body functions during development, homeostasis and pathology including blood clotting, angiogenesis and metastasis of cancer cells. Exostosin 1 and 2 (EXT1 and 2) glycosyltransferases are required to form HS. They are able to transfer N-acetylglucosamine (GlcNAc) and glucuronate (GlcA) to HS during its synthesis. The functional form of these enzymes appears to be a complex of the two located on the Golgi membrane. Defects in either EXT1 or EXT2 can cause hereditary multiple exostoses 1 (Petersen 1989) and 2 (McGaughran et al. 1995) respectively (MIM:133700 and MIM:133701), autosomal dominant disorders characterised by multiple projections of bone capped by cartilage resulting in deformed legs, forearms and hands.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep389">
 <bp:stepProcess rdf:resource="#Pathway82" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence404">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway485">
 <bp:pathwayOrder rdf:resource="#PathwayStep2174" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2175" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2176" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1645" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1646" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1647" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2129" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective HEXA causes GM2G1</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Beta-hexosaminidase (HEX) cleaves the terminal N-acetyl galactosamine (GalNAc) from glycosaminoglycans (GAGs) and any other molecules containing a terminal GalNAc. There are two forms of HEX; HEXA and B. The A form is a trimer of the subunits alpha, beta A and beta B. The B form is a tetramer of 2 beta A and 2 beta B subunits (O&apos;Dowd et al. 1988). Defects in the two subunits cause lysosomal storage diseases marked by the accumulation of GM2 gangliosides in neuronal cells. Defects in the alpha subunits are the cause of GM2-gangliosidosis type 1 (GM2G1) (MIM:272800), also known as Tay-Sachs disease (Okada    O&apos;Brien 1969, Nakano et al. 1988). Classical Tay-Sachs disease is characterised by infant-onset neurodegeneration followed by paralysis, dementia and blindness, Death occurs by the age of 2 or 3 (Okada et al. 1971). The two other forms of Tay-Sachs disease, juvenile- and adult-onset, are less commom and severe than the infant-onset form (Suzuki et al. 1970, Johnson et al. 1982).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway488">
 <bp:pathwayOrder rdf:resource="#PathwayStep2185" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1653" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2140" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective B3GAT3 causes JDSSDHD</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferases1, 2 and 3 (B3GAT1-3) are involved in forming the linker tetrasaccharide present in heparan sulfate and chondroitin sulfate. Defects in B3GAT3 cause multiple joint dislocations, short stature, craniofacial dysmorphism, and congenital heart defects (JDSSDHD; MIM:245600). This is an autosomal recessive disease characterized by dysmorphic facies, elbow, hip and knee dislocations, clubfeet, short stature and cardiovascular defects (Steel    Kohl 1972, Bonaventure et al. 1992, Baasanjav et al. 2011). JDSSDHD has phenotypic similarities to Larsen syndrome (Larsen et al. 1950).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway487">
 <bp:pathwayOrder rdf:resource="#PathwayStep2183" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1652" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2138" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective B4GALT7 causes EDS, progeroid type</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Ehlers&#8211;Danlos syndrome (EDS) is a group of inherited connective tissue disorders, caused by a defect in the synthesis of collagen types I or III. Abnormal collagen renders connective tissues more elastic. The severity of the mutation can vary from mild to life-threatening. There is no cure and treatment is supportive, including close monitoring of the digestive, excretory and particularly the cardiovascular systems. Defective B4GALT7, a galactosyltransferase important in proteoglycan synthesis, causes the progeroid variant of EDS (MIM:130070). Features include an aged appearance, developmental delay, short stature, generalized osteopenia, defective wound healing, hypermobile joints, hypotonic muscles, and loose but elastic skin (Okajima et al. 1999).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence401">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence400">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway489">
 <bp:pathwayOrder rdf:resource="#PathwayStep2187" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1654" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2142" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective CHST6 causes MCDC1</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Carbohydrate sulfotransferase 6 (CHST6) catalyzes the transfer of sulfate to position 6 of non-reducing ends of N-acetylglucosamine (GlcNAc) residues on keratan sulfate (KS). KS plays a central role in maintaining corneal transparency. Defective CHST6 (Nakazawa et al. 1984) results in unsulfated keratan deposited within the intracellular space and the extracellular corneal stroma leading to macular dystrophy, corneal type I (MCDC1; MIM:217800). MCDC1 is an early-onset, ocular disease characterized by bilateral, progressive corneal opacification, and reduced corneal sensitivity (Jones    Zimmerman 1961). MCD can be subdivided into 2 types on the basis of immunohistochemical studies and serum analysis for keratan sulfate; MCD type I, in which there is a virtual absence of sulfated KS-specific antibody response in the serum and cornea and MCD type II, in which the normal KS-specific antibody response is present in cornea and serum (Yang et al. 1988).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway459">
 <bp:pathwayOrder rdf:resource="#PathwayStep2119" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2120" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2121" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2122" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1616" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1617" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1618" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1619" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2074" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective MAN1B1 causes MRT15</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Endoplasmic reticulum mannosyl-oligosaccharide 1,2-alpha-mannosidase (MAN1B1) normally trims single mannose residues from misfolded glycoproteins, targeting them for degradation and thus providing a quality control process for N-glycoyslated proteins. Defects in MAN1B1 can cause mental retardation, autosomal recessive 15 (MRT15; MIM:614202), a disorder resulting in nonsyndromic moderate to severe mental retardation. It is characterised by significantly below average intellectual functioning associated with impaired adaptative behaviour during the developmental period (Rafiq et al. 2010, Rafiq et al. 2011).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway458">
 <bp:pathwayOrder rdf:resource="#PathwayStep2117" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1615" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2072" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective ALG14 causes ALG14-CMS</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">UDP-N-acetylglucosamine transferase subunit ALG14 homolog (ALG14) forms a complex with ALG13 protein and is required for the addition of the second N-acetylglucosamine (GlcNAc) to the lipid linked oligosaccharide (LLO) intermediate (GlcNAcDOLDP) (Gao et al. 2005). Defects in ALG14 can cause congenital myasthenic syndrome (ALG14-CMS), which is due to a defect in neuromuscular signal transmission (Cossins et al. 2013). The most commonly affected muscles include proximal limb muscles. Mutations causing ALG14-CMS include p.P65L and p.R104* (Cossins et al. 2013).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Catalysis rdf:ID="Catalysis252">
 <bp:controlled rdf:resource="#BiochemicalReaction926" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis251">
 <bp:controlled rdf:resource="#BiochemicalReaction925" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis254">
 <bp:controlled rdf:resource="#BiochemicalReaction929" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis253">
 <bp:controlled rdf:resource="#BiochemicalReaction928" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis250">
 <bp:controlled rdf:resource="#BiochemicalReaction924" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis259">
 <bp:controlled rdf:resource="#BiochemicalReaction940" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis256">
 <bp:controlled rdf:resource="#BiochemicalReaction932" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis255">
 <bp:controlled rdf:resource="#BiochemicalReaction930" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis258">
 <bp:controlled rdf:resource="#BiochemicalReaction939" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis257">
 <bp:controlled rdf:resource="#BiochemicalReaction938" />
</bp:Catalysis>

<bp:Pathway rdf:ID="Pathway451">
 <bp:pathwayOrder rdf:resource="#PathwayStep2102" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1607" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2057" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Phenylketonuria</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Phenylalanine hydroxylase (PAH) normally catalyzes the conversion of phenylalanine to tyrosine. In the absence of functional PAH, phenylalanine accumulates to high levels in the blood and is converted to phenylpyruvate and phenyllactate (Clemens et al. 1990; Langenbeck et al. 1992; Mitchell et al. 2011). The extent of these conversions is modulated by genetic factors distinct from PAH, as siblings with the identical PAH defect can produce different amounts of them (Treacy et al. 1996). Both L-amino acid oxidase (Boulland et al. 2004) and Kynurenine--oxoglutarate transaminase 3 (Han et al. 2004) can catalyze the conversion of phenylalanine to phenylpyruvate and lactate dehydrogenase can catalyze the conversion of the latter molecule to phenyllactate (Meister 1950), in reactions not annotated here.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway450">
 <bp:pathwayOrder rdf:resource="#PathwayStep2100" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1606" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2055" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective APRT disrupts adenine salvage</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Normally in humans, adenine formed in processes such as polyamine biosynthesis can be salvaged by conversion to AMP, catalyzed by APRT (adenine phosphoribosyltransferase). In the absence of APRT activity, however, accumulated adenine is instead converted to 2,8-dioxo-adenine. Accumulation of insoluble crystals of 2,8-dioxo-adenine in the kidneys causes the kidney damage that is a major symptom of APRT deficiency in humans (Van Acker et al. 1977; Boll&#233;e et al. 2012).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway453">
 <bp:pathwayOrder rdf:resource="#PathwayStep2106" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1609" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2061" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Abnormal conversion of 2-oxoglutarate to 2-hydroxyglutarate</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Somatic mutations affecting arginine residue 132 of IDH1 (isocitrate dehydrogenase 1, a cytosolic enzyme that normally catalyzes the NADP+-dependent conversion of isocitrate to 2-oxoglutarate), are very commonly found in human glioblastomas (Parsons et al. 2008). These mutant proteins efficiently catalyze the NADPH-dependent reduction of 2-oxoglutarate to form 2-hydroxyglutarate. Cells expressing the mutant protein accumulate elevated levels of 2-hydroxyglutarate, probably in the cytosol as IDH1 is a cytosolic enzyme. The fate of the 2-hydroxyglutarate is unclear, but the high frequency with which the mutation is found in surveys of primary tumors is consistent with the possibility that it is advantageous to the tumor cells (Dang et al 2009).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway452">
 <bp:pathwayOrder rdf:resource="#PathwayStep2104" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1608" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2059" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective ACTH causes obesity and POMCD</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The precursor peptide pro-opiomelanocortin (POMC) gives rise to many peptide hormones through cleavage. The cleavage products corticotropin (ACTH) and beta-lipotropin give rise to smaller peptides that have distinct biologic activities: alpha-melanotropin and corticotropin-like intermediate lobe peptide (CLIP) are formed from ACTH; gamma-LPH and beta-endorphin are formed from beta-LPH. ACTH (POMC(138-176) stimulates the adrenal glands to release cortisol, a glucocorticoid released in response to stress whose primary functions are to stimulate gluconeogenesis, suppress the immune system and aid metabolism of fats, proteins and carbohydrates.  Defects in ACTH can cause obesity (MIM:601665) resulting in excessive accumulation of body fat (Challis et al. 2002, Millington 2013). Defects in ACTH can also cause pro-opiomelanocortinin deficiency (POMCD; MIM:609734) where affected individuals present early-onset obesity, adrenal insufficiency and red hair (Krude et al. 1998, Krude et al. 2003).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway455">
 <bp:pathwayOrder rdf:resource="#PathwayStep2140" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2130" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2128" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2118" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2109" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2146" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2114" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2125" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2136" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2148" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2116" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2138" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2142" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2132" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2144" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2123" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2134" />
 <bp:pathwayComponent rdf:resource="#Pathway459" />
 <bp:pathwayComponent rdf:resource="#Pathway458" />
 <bp:pathwayComponent rdf:resource="#Pathway469" />
 <bp:pathwayComponent rdf:resource="#Pathway460" />
 <bp:pathwayComponent rdf:resource="#Pathway471" />
 <bp:pathwayComponent rdf:resource="#Pathway470" />
 <bp:pathwayComponent rdf:resource="#Pathway462" />
 <bp:pathwayComponent rdf:resource="#Pathway461" />
 <bp:pathwayComponent rdf:resource="#Pathway472" />
 <bp:pathwayComponent rdf:resource="#Pathway464" />
 <bp:pathwayComponent rdf:resource="#Pathway463" />
 <bp:pathwayComponent rdf:resource="#Pathway466" />
 <bp:pathwayComponent rdf:resource="#Pathway465" />
 <bp:pathwayComponent rdf:resource="#Pathway457" />
 <bp:pathwayComponent rdf:resource="#Pathway468" />
 <bp:pathwayComponent rdf:resource="#Pathway456" />
 <bp:pathwayComponent rdf:resource="#Pathway467" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2064" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Diseases associated with N-glycosylation of proteins</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Congenital disorders of glycosylation (CDGs) are a group of autosomal recessive disorders caused by enzymatic defects in the synthesis and processing of asparagine (N)-linked glycans or oligosaccharides on glycoproteins. These glycoconjugates play critical roles in processes such as metabolism, cell recognition and adhesion, cell migration, protease resistance, host defense, and antigenicity. CDGs are divided into 2 main groups: type I CDGs comprise defects in the assembly of the dolichol lipid-linked oligosaccharide (LLO) chain and its transfer to the nascent protein, whereas type II CDGs comprise defects in the trimming and processing of protein-bound glycans (Marquardt    Denecke 2003, Grunewald et al. 2002, Hennet 2012, Cylwik et al. 2013).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway454">
 <bp:pathwayOrder rdf:resource="#PathwayStep2150" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2108" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2169" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2214" />
 <bp:pathwayComponent rdf:resource="#Pathway473" />
 <bp:pathwayComponent rdf:resource="#Pathway483" />
 <bp:pathwayComponent rdf:resource="#Pathway455" />
 <bp:pathwayComponent rdf:resource="#Pathway499" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2063" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Diseases of glycosylation</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Diseases of glycosylation, usually referred to as congenital disorders of glycosylation (CDG), are rare inherited disorders ascribing defects of nucleotide-sugar biosynthesis and transport, glycosyl transfer events and vesicular transport. Most CDGs cause neurological impairment ranging from severe psychomotor retardation to mild intellectual disability. Defects in N-glycosylation are the main cause of CDGs (Marquardt    Denecke 2003, Grunewald et al. 2002, Hennet 2012, Goreta et al. 2012) and can be identified by a characteristic abnormal isoelectric focusing profile of plasma transferrin (Jaeken et al. 1984, Stibler    Jaeken 1990). Disorders of O-glycosylation, glycosaminoglycan and glycolipid metabolism have recently been discovered and, together with N-glycosylation, represent the major pathways affected by glycan biosynthetic disorders (Freeze 2006, Jaeken 2011). In addition, glycosylation diseases associated with the enzymes that mediate the biosynthesis of glycosylation precursors are described in this section. As the number of these disorders has increased, nomenclature has been simplified so that now, the name of the mutant gene is followed by the abbreviation CDG (Jaeken et al. 2009). Effective therapies for most types of CDGs are so far not available (Thiel    Korner 2013).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway457">
 <bp:pathwayOrder rdf:resource="#PathwayStep2115" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1614" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2070" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective ALG11 causes CDG-1p</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">GDP-Man:Man(3)GlcNAc(2)-PP-Dol alpha-1,2-mannosyltransferase (ALG11) transfers the fourth and fifth mannoses (Man) to the N-glycan precursor in an alpha-1,2 orientation. These additions are the last two on the cytosolic side of the ER membrane before the N-glycan is flipped to the luminal side of the membrane. Recently discovered defects in ALG11 have been linked to congential disorder of glycosylation, type 1p (ALG11-CDG, CGD1p) (Rind et al. 2010, Thiel et al. 2012). The disease is a multi-system disorder characterised by under-glycosylated serum glycoproteins. Early-onset developmental retardation, dysmorphic features, hypotonia, coagulation disorders and immunodeficiency are reported features of this disorder (Rind et al. 2010, Thiel et al. 2012).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway456">
 <bp:pathwayOrder rdf:resource="#PathwayStep2113" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2110" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2111" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2112" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1612" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1613" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1610" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1611" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2065" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective MPDU1 causes CDG-1f</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Mannose-P-dolichol utilisation defect 1 protein (MPDU1) is required for the efficient utilisation of the mannose donor dolichyl-phospho-mannose (DOLPman) in the synthesis of both lipid-linked oligosaccharides (LLOs) and glycosylphosphatidylinositols. Defects in MPDU1 can cause congenital disorder of glycosylation 1f (MPDU1-CDG, CDG-1f; MIM:609180), a multisystem disorder caused by a defect in glycoprotein biosynthesis and characterised by under-glycosylated serum glycoproteins. CDG type 1 diseases result in a wide phenotypic spectrum, such as poor neurological development, psychomotor retardation, dysmorphic features, hypotonia, coagulation abnormalities and immunodeficiency. In this condition, DOLPman is no longer utilised in transferase reactions extending LLOs, even as substrate levels and transferase enzyme activities appear normal (Anand et al. 2001, Schenk et al. 2001).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway469">
 <bp:pathwayOrder rdf:resource="#PathwayStep2143" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1630" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2098" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective NEU1 causes sialidosis</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Sialidases have important roles in the degradation of glycoconjugates by removing terminal sialic acid residues. Defects in sialidase 1 (NEU1) cause sialidosis, a lysosomal storage disease characterised by the progressive lysosomal storage of sialidated glycopeptides and oligosaccharides and the accumulation and excretion of N-acetylneuraminic acid (Neu5Ac) covalently-linked (&apos;bound&apos;) glycoconjugates (Lowden    O&apos;Brien 1979). The sialidoses are distinct from the sialurias in which there is storage and excretion of &apos;free&apos; Neu5Ac. Sialidosis manifests into types I and II forms. Type I is the milder form, also known as the &apos;normosomatic&apos; type or the cherry red spot-myoclonus syndrome. Sialidosis type II is the more severe form with an earlier onset, and is also known as the &apos;dysmorphic&apos; type.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Catalysis rdf:ID="Catalysis263">
 <bp:controlled rdf:resource="#BiochemicalReaction947" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis262">
 <bp:controlled rdf:resource="#BiochemicalReaction944" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis265">
 <bp:controlled rdf:resource="#BiochemicalReaction950" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis264">
 <bp:controlled rdf:resource="#BiochemicalReaction948" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis261">
 <bp:controlled rdf:resource="#BiochemicalReaction943" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis260">
 <bp:controlled rdf:resource="#BiochemicalReaction941" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis267">
 <bp:controlled rdf:resource="#BiochemicalReaction955" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis266">
 <bp:controlled rdf:resource="#BiochemicalReaction952" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis269">
 <bp:controlled rdf:resource="#BiochemicalReaction959" />
</bp:Catalysis>

<bp:Pathway rdf:ID="Pathway460">
 <bp:pathwayOrder rdf:resource="#PathwayStep2124" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1620" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2079" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective ALG3 causes CDG-1d</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Dol-P-Man:Man(5)GlcNAc(2)-PP-Dol alpha-1,3-mannosyltransferase (ALG3) adds the sixth mannose (although the first to be derived from dolichyl-phosphate-mannose, DOLPman) to the lipid-linked oligosaccharide (LLO) intermediate GlcNAc(2) Man(5) (PPDol)1 (Korner et al. 1999). Defects in ALG3 are associated with congenital disorder of glycosylation 1d (ALG3-CDG, CDG1d; MIM:601110), a multisystem disorder caused by a defect in glycoprotein biosynthesis and characterised by under-glycosylated serum glycoproteins. CDG type 1 diseases result in a wide variety of clinical features, such as defects in the nervous system development, psychomotor retardation, dysmorphic features, hypotonia, coagulation disorders, and immunodeficiency (Sun et al. 2005).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Catalysis rdf:ID="Catalysis268">
 <bp:controlled rdf:resource="#BiochemicalReaction958" />
</bp:Catalysis>

<bp:Pathway rdf:ID="Pathway462">
 <bp:pathwayOrder rdf:resource="#PathwayStep2129" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1623" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2084" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective RFT1 causes CDG-1n</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The N-glycan precursor is flipped across the ER membrane, moving it from the cytosolic side to the ER lumenal side. The exact mechanism of this translocation is not well understood but protein RFT1 homolog (RFT1) is known to be involved  (Helenius et al. 2002). Defects in RFT1 are associated with congenital disorder of glycosylation 1n (RFT1-CDG, CDG-1n). The disease is a multi-system disorder characterised by under-glycosylated serum glycoproteins. Early-onset developmental retardation, dysmorphic features, hypotonia, coagulation disorders and immunodeficiency are reported features of this disorder (Haeuptle et al. 2008).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway461">
 <bp:pathwayOrder rdf:resource="#PathwayStep2126" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2127" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1621" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1622" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2081" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective ALG9 causes CDG-1l</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Alpha-1,2-mannosyltransferase ALG9 (ALG9) normally catalyses the transfer of mannose to the lipid-linked oligosaccharide (LLO) precursor. It adds the 7th and 9th mannose moieties to LLO. Defects in ALG9 are associated with congenital disorder of glycosylation 1l (ALG9-CDG, CDG1l; MIM:608776), a multisystem disorder caused by a defect in glycoprotein biosynthesis and characterised by under-glycosylated serum glycoproteins. CDG type 1 diseases result in a wide variety of clinical features, such as defects in the nervous system development, psychomotor retardation, dysmorphic features, hypotonia, coagulation disorders, and immunodeficiency (Frank et al. 2004, Weinstein et al. 2005). The LLO profile showed accumulation of (GlcNAc)2 (Man)6 (PP-Dol)1 and (GlcNAc)2 (Man)8 (PP-Dol)1 fragments, suggesting a defect in ALG9 and correlating with the normal function of ALG9 in adding the 7th and 9th mannose moieties (Frank et al. 2004).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway464">
 <bp:pathwayOrder rdf:resource="#PathwayStep2133" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1625" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2088" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective MOGS causes CDG-2b</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">After the lipid-linked oligosaccharide (LLO) precursor is attached to the protein, the outer alpha-1,2-linked glucose is removed by by mannosyl-oligosaccharide glucosidase (MOGS). This is a mandatory step for protein folding control and glycan extension. Defects in MOGS are associated with congenital disorder of glycosylation type IIb (CDGIIb), a multisystem disorder caused by a defect in glycoprotein biosynthesis and characterised by under-glycosylated serum glycoproteins (De Praeter et al. 2000, Voelker et al. 2002). Type II CDGs refer to defects in the trimming and processing of protein-bound glycans.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway463">
 <bp:pathwayOrder rdf:resource="#PathwayStep2131" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1624" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2086" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective ALG8 causes CDG-1h</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The probable dolichyl pyrophosphate Glc1Man9GlcNAc2 alpha-1,3-glucosyltransferase (ALG8) (Stanchi et al. 2001, Chantret et al. 2003) normally adds the second glucose moiety to the lipid-linked oligosaccharide precursor (LLO aka N-glycan precursor) which is required for subsequent N-glycosylation of proteins. Defects in ALG8 can cause congenital disorder of glycosylation 1h (ALG8-CDG, CDG-1h; MIM:608104), a multisystem disorder characterised by under-glycosylated serum glycoproteins (Chantret et al. 2003, Schollen et al. 2004). ALG8 deficiency is accompanied by an accumulation of the N-glycan precursor (Glc)1 (GlcNAc)2 (Man)9 (PP-Dol)1. CDG type 1 diseases result in a wide variety of clinical features, such as defects in the nervous system development, psychomotor retardation, dysmorphic features, hypotonia, coagulation disorders, and immunodeficiency.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway466">
 <bp:pathwayOrder rdf:resource="#PathwayStep2137" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1627" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2092" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective ALG6 causes CDG-1c</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Dolichyl pyrophosphate Man9GlcNAc2 alpha-1,3-glucosyltransferase (ALG6) normally adds the first glucose moiety to the lipid-linked oligosaccharide precursor (LLO aka N-glycan precursor) which is required for subsequent N-glycosylation of proteins (Imbach et al. 1999). Defects in ALG6 can cause congenital disorder of glycosylation 1c (ALG6-CDG, CDG-1c; MIM:603147), a multisystem disorder characterised by under-glycosylated serum glycoproteins (Imbach et al. 1999, Imbach et al. 2000, Westphal et al. 2000, Sun et al. 2005). ALG6 deficiency is accompanied by an accumulation of the N-glycan precursor (GlcNAc)2 (Man)9 (PP-Dol)1 and is the second most common CDG disease subtype after PMM2-CDG (CDG-1a) (Imbach et al. 1999). CDG type 1 diseases result in a wide variety of clinical features, such as defects in the nervous system development, psychomotor retardation, dysmorphic features, hypotonia, coagulation disorders, and immunodeficiency.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway465">
 <bp:pathwayOrder rdf:resource="#PathwayStep2135" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1626" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2090" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective MGAT2 causes CDG-2a</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Alpha-1,6-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferase (MGAT2) normally catalyses the transfer of a GlcNAc moiety onto the alpha-1,6 mannose of an alpha-1,4 branch of oligomannose N-glycans to form complex N-glycans (Tan et al. 1995). Defects in MGAT2 are associated with congenital disorder of glycosylation type IIa (MGAT2-CDG, CDG-2a; MIM:212066), a multisystem disorder caused by a defect in glycoprotein biosynthesis and characterised by under-glycosylated serum glycoproteins (Tan et al. 1996,  Cormier-Daire et al. 2000,  Alkuraya 2010, Alazami et al. 2012). Type II CDGs refer to defects in the trimming and processing of protein-bound glycans.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway468">
 <bp:pathwayOrder rdf:resource="#PathwayStep2141" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1629" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2096" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective B4GALT1 causes CDG-2d</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Congenital disorders of glycosylation (CDG, previously called carbohydrate-deficient glycoprotein syndromes, CDGSs), are a group of hereditary multisystem disorders. They are characterized biochemically by hypoglycosylation of glycoproteins, diagnosed by isoelectric focusing (IEF) of serum transferrin. There are two types of CDG, types I and II. Type I CDG has defects in the assembly of lipid-linked oligosaccharides or their transfer onto nascent glycoproteins, whereas type II CDG comprises defects of trimming, elongation, and processing of protein-bound glycans. Clinical symptoms are dominated by severe psychomotor and mental retardation, as well as blood coagulation abnormalities (Jaeken 2013). B4GALT1-CDG (CDG type IId) is a multisystem disease, characterized by dysmorphic features, hydrocephalus, hypotonia and blood clotting abnormalities (Hansske et al. 2002).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway467">
 <bp:pathwayOrder rdf:resource="#PathwayStep2139" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1628" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2094" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective DPAGT1 causes CDG-1j, CMSTA2</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">UDP-N-acetylglucosamine--dolichyl-phosphate N-acetylglucosaminephosphotransferase (DPAGT1) catalyses the initial committed step in the biosynthesis of dolichyl pyrophosphate-oligosaccharides. Defects in DPAGT1 cause congenital disorder of glycosylation 1j (DPAGT1-CDG, previously known as CDG-1j; MIM:608093), a multisystem disorder characterised by under-glycosylated serum glycoproteins (Wu et al. 2003, Timal et al. 2012). Congenital disorders of glycosylation result in a wide variety of clinical features, such as defects in the nervous system development, psychomotor retardation, dysmorphic features, hypotonia, coagulation disorders, and immunodeficiency. Defects in DPAGT1 can also cause myasthenic syndrome, congenital, with tubular aggregates, 2 (CMSTA2; MIM:614750), characterised by muscle weakness of mainly the proximal limb muscles, with tubular aggregates present on muscle biopsy. Sufferers find walking difficult and fall frequently. Younger sufferers show hypotonia and poor head control. A disorder of neuromuscular transmission is detected on electromyography (Belaya et al. 2012, Finlayson et al. 2013).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway437">
 <bp:pathwayOrder rdf:resource="#PathwayStep2076" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1595" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2031" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Loss-of-function mutations in BCKDHA or BCKDHB cause MSUD</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Mutations in either of the protein subunits of the E1 decarboxylase subcomplex of BCKDH are associated with Maple Syrup Urine Disease 1 (MSUD1). Mutations of residues in BCKDHA that participate in subunit associations or that form part of the hydrophobic core destabilize the overall assembly of BCKDH and are associated with classic Maple Syrup Urine Disease 1A (Aevarsson et al, 2000; reviewed in Straus et al, 2020; Biswas et al, 2019). Mutations of BCKDHA with less drastic effects on structural  stability of the overall BCKDH complex are generally associated with intermediate or intermittent forms of MSUD, and are not annotated in this pathway (reviewed in Strauss et al, 2020)  Mutations in BCKDHB appear to be causative in 35% of MSUD cases(reviewed in Strauss et al, 2020). Classic Maple Syrup Disease 1B is associated with severe loss-of-function mutations in BCKDHB that destabilize the protein interaction interfaces and compromise structural integrity of the complex (reviewed in Straus et al, 2020; Biswas et al, 2019).  Less detrimental mutations in BCKDHB are not annotated in this pathway and are generally associated with intermediate or intermittent forms of MSUD (reviewed in Strauss et al, 2020).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway436">
 <bp:pathwayOrder rdf:resource="#PathwayStep2074" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1594" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2029" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Loss-of-function mutations in DLD cause MSUD3/DLDD</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Mutations in the dihydrolipoyl dehydrogenase (DLD) gene are associated with dihydrolipoyl dehydrogenase deficiency (DLDD), an autosomal recessive disorder characterized by lactic acidosis and neurological deterioration (reviewed in Quinonez et al, 2021). DLDD is sometimes referred to as Maple Syrup Urine Disease 3 due to its effects on BCKDH function, but the phenotype is distinct due to the involvement of DLD in multiple protein complexes (reviewed in Strauss et al, 2020). DLD encodes the shared E3 component of the multiprotein mitochondrial enzymes BCKDH (branched-chain amino acid dehydrogenase), KGDH (alpha-ketoglutarate deydrogenase) and PDH (pyruvate dehydrogenase). In consequence mutations in DLD have pleiotropic effects and manifest with a range of clinical outcomes, including increased urinary excretion of alpha-keto acids and accumulation of pyruvate and plasma branched-chain amino acids in plasma (reviewed in Quinonez and Thoene, 2021). Mutations in DLD often occur as compound heterozygotes complicating the assignment of pathogenic effect. Moreover, the severity of phenotypic effects displayed in vivo does not correlate linearly with the extent of residual DLD enzymatic activity in vitro (Shany et al, 1999; Cameron et al, 2006; Quinonez et al, 2013; reviewed in Quinonez and Thoene, 2021).  </bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway439">
 <bp:pathwayOrder rdf:resource="#PathwayStep2080" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1597" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2035" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Mitochondrial short-chain enoyl-CoA hydratase deficiency 1</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ECHS1 (short-chain enoyl-CoA hydratase, also known as SCEH) is a mitochondrial enzyme that plays roles in fatty acid oxidation and valine metabolism (Yamada et al, 2015). In the branched-chain amino acid catabolism pathway, ECHS1 has specificity for the valine derivative methylacrylyl-CoA, but can also act on the leucine derivative 3-methylcrotonyl-CoA. ECHS1 binds to the isoleucine derivative tiglyl-CoA, but does not appreciably catalyze its hydration (Yamada et al, 2015; Ferdinandusse et al, 2015). Homozygous mutations in ECHS1 are associated with a severe Leigh-like disorder, characterized by cardiac aberrations, encephalopathy and epilepsy and severe developmental and neurological delays, likely arising at least in large measure from the accumulation of toxic levels of methylacrylyl-CoA (Peters et al, 2014; Haack et al, 2015; Yamada et al, 2015; Ferinandusse et al, 2015; Sakai et al, 2015; Tetreault et al, 2015; Kohda et al, 2016; Fitzsimmons et al, 2018).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway438">
 <bp:pathwayOrder rdf:resource="#PathwayStep2078" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1596" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2033" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">3-Methylcrotonyl-CoA carboxylase deficiency</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">3-methylcrotonyl-CoA carboxylase catalyzes the reversible conversion of 3-methylcrotonyl-CoA to 3-methylglutaconyl-CoA, the fourth step in the catabolism of leucine (Chu et al, 2007; Son et al, 2020). MCCC is composed of two subunits encoded by MCCC1 and MCCC2. MCCC1 protein is covalently attached to a biotin moiety that is essential for the ATP dependent carboxylation activity, while MCCC2 contributes carboxyltransferase activity (Holzinger et al, 2001; Lau et al, 1979; Gallardo et al, 2001; Baumgartner et al, 2001). Mutations in either subunit of the enzyme, MCCC1 and MCCC2, are associated with 3-methylcrotonyl-CoA carboxylase deficiency (MCCD), also known as 3-methylcrotonylglycinuria, an autosomal recessive inborn error of metabolism characterized by accumulation and excretion of 3-hydroxyvaleric acid and 3-methylcrotonylglycine (Bannwart et al, 1992; Lehnert et al, 1996; Baumgartner et al, 2005). MCCD is the most prevalent organic aciduria with frequencies ~ 1:50,000 but has variable clinical phenotypes. 1-2% of affected individuals are at risk of a severe adverse effect that manifests during the neonatal period with severe neurological impairment while ~10% of affected individuals develop only minor symptoms (Baumgartner et al, 2001; Gallardo et al, 2001; Gruenert et al, 2012). Mutations in MCCC1 and MCCC2 have been identified that affect the stability or activity of the alpha or beta subunit, occasionally by compromising the essential biotinylation of the protein (Gallardo et al, 2001; Grunert et al, 2012; Fonseca et al, 2016; Dantas et al, 2005 ; Steen et al, 1999; Morscher et al, 2012 ; Baumgartner et al, 2001; 2004; Uematsu et al, 2007; Holzinger et al, 2001).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Catalysis rdf:ID="Catalysis274">
 <bp:controlled rdf:resource="#BiochemicalReaction967" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis273">
 <bp:controlled rdf:resource="#BiochemicalReaction965" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis276">
 <bp:controlled rdf:resource="#BiochemicalReaction971" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis275">
 <bp:controlled rdf:resource="#BiochemicalReaction969" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis270">
 <bp:controlled rdf:resource="#BiochemicalReaction961" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis272">
 <bp:controlled rdf:resource="#BiochemicalReaction963" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis271">
 <bp:controlled rdf:resource="#BiochemicalReaction962" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis278">
 <bp:controlled rdf:resource="#BiochemicalReaction975" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis277">
 <bp:controlled rdf:resource="#BiochemicalReaction973" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis279">
 <bp:controlled rdf:resource="#BiochemicalReaction976" />
</bp:Catalysis>

<bp:Pathway rdf:ID="Pathway431">
 <bp:pathwayOrder rdf:resource="#PathwayStep2083" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2085" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2081" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2087" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2066" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2077" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2068" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2079" />
 <bp:pathwayComponent rdf:resource="#Pathway439" />
 <bp:pathwayComponent rdf:resource="#Pathway438" />
 <bp:pathwayComponent rdf:resource="#Pathway440" />
 <bp:pathwayComponent rdf:resource="#Pathway442" />
 <bp:pathwayComponent rdf:resource="#Pathway441" />
 <bp:pathwayComponent rdf:resource="#Pathway433" />
 <bp:pathwayComponent rdf:resource="#Pathway432" />
 <bp:pathwayComponent rdf:resource="#Pathway443" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2021" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Diseases of branched-chain amino acid catabolism</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Mutations in the genes that encode enzymes responsible for the catabolism of the branched-chain amino acids leucine, isoleucine and valine give rise to a number of inborn errors of metabolism (IEMs). Although IEMs are individually rare, collectively they are relatively common with an estimated overall prevalence of ~1:800 live births (Mak et al, 2013). The frequency of particular IEMs is also highly variable across different populations, a result in part of founder effects in closed populations. For instance, although the overall frequency of Maple Syrup Urine disease is 1:185,000 live births (Strauss et al, 2020), the frequency rises to 1:380 in some Old Order Mennonite communities (Fisher et al, 1991). Accumulation of toxic intermediary metabolites causes a range of clinical phenotypes in patients with IEMs including metabolic acidosis, vomiting, seizures, psychomotor and developmental delays and death (reviewed in Schrier Vergano et al, 2022; Holo&#269;ek, 2018; Neinast et al, 2019).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway430">
 <bp:pathwayOrder rdf:resource="#PathwayStep2064" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1590" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2019" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Glycogen storage disease type Ia (G6PC)</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Glucose-6-phosphatase (G6PC) associated with the inner face of the endoplasmic reticulum membrane normally catalyzes the hydrolysis of glucose-6-phosphate to glucose and orthophosphate. Defects in glucose-6-phosphatase are the cause of glycogen storage disease type Ia (Lei et al. 1993, 1995, Chou and Mansfield 2008).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway433">
 <bp:pathwayOrder rdf:resource="#PathwayStep2073" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2075" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2071" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2069" />
 <bp:pathwayComponent rdf:resource="#Pathway437" />
 <bp:pathwayComponent rdf:resource="#Pathway436" />
 <bp:pathwayComponent rdf:resource="#Pathway435" />
 <bp:pathwayComponent rdf:resource="#Pathway434" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2024" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Maple Syrup Urine Disease</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The branched-chain alpha ketoacid dehydrogenase complex (BCKDH) catalyzes the oxidative decarboxylation of branched-chain keto acids in the mitochondrial matrix as the second step in the degradation of branched-chain amino acids (BCAAs) leucine, valine and isoleucine, providing acetyl CoA and succinyl CoA intermediates for the Krebs Cycle (reviewed in Strauss et al, 2020; Zhang et al, 2023).  BCKDH is a multi-enzyme complex consisting of three sub-complexes, the E2 transacylase, the E1 decarboxylase and the E3 dehydrogenase. The core of BCKDH is the E2 transacylase domain, made up of 24 copies of Dihydrolipoamide Branched-chain Transacylase (DBT) arranged in octahedral symmetry. Surrounding the E2 core are 12 copies of the E1 decarboxylase tetramer (each of which consists of a dimer of BCKDHA and a dimer of BCKDHB) and six copies of the E3 dehydrogenase (each consisting of a dimer of Dihydrolipoyl Dehydrogenase (DLD)). The E3 subcomplex is not specific to BCKDH but is also a component of the pyruvate dehydrogenase complex (PDC) and the alpha-ketoglutarate dehydrogenase complex (alpha-KGDC) (Chang et al, 2002; Brautigam et al, 2005; Aevarsson et al, 2000; reviewed in Biswas et al, 2019; Strauss et al, 2020).  In addition to the E1, E2 and E3 components, the BCKDH complex also depends on other cofactors- lipoamide for the function of the E2 transacylase, thiamine diphosphate and potassium for the function of the E1 decarboxylase and FAD and NAD+ for the function of the E3 dehydrogenase (Chang et al, 2002; Brautigam et al, 2005; Aevarsson et al, 2000; reviewed in Biswas et al, 2019; Strauss et al, 2020).  The activity of BCKDH is regulated by the association of BCKD kinase (BCKDK) and protein phosphatase 1K (PPM1K) with the macromolecular complex (Reed et al, 1985). Phosphorylation of BCKDHB S342 by BCKDK inhibits the catalytic activity of BCKDH, while PPM1K-mediated dephosphorylation activates it (Li et al, 2004; Wynn et al, 2004; Wynn et al, 2012). BCKDK is itself negatively regulated by thiamine (Chuang et al, 2006).  Structures for each of the subcomplexes of human BCKDH have been solved, and the complex has a total molecular mass on the order of 4 million Da (Chang et al, 2002; Brautigam et al, 2005; Aevarsson et al, 2000).  Loss-of-function mutations in the BCKDHA, BCKDHB and DBT genes disrupt the stability and the activity of the BCKDH complex, causing an accumulation of branched-chain keto-acids that causes the characteristic odor associated with Maple Syrup Urine disease (MSUD), an inborn error of metabolism with a prevalence of 1:185,000 live births (reviewed in Strauss et al, 2020; Biswas et al, 2019). MSUD is an autosomal recessive disorder and in its classic neonatal form is characterized by a maple syrup odor to the urine, poor feeding, mental and physical retardation, lethargy, seizures, coma and death. Classic MSUD, like the intermediate, intermittent and thiamine-responsive forms described below, may arise as a result of mutations in any of BCKDHA, BCKDHB or DBT. Classic MSUD is characterized by the lowest (~0-3%) residual enzymatic activity of all the forms, and presents clinically during the neonatal period. An intermediate form (residual activity ~3-30%) manifests clinically many months after birth with signs of mental retardation and developmental delay. Patients with the intermittent form of MSUD have normal levels of BCAA and BCKA and normal development and physiology while healthy, but are triggered into manifesting symptoms of MSUD when stressed by, for instance, infection. The existence of a thiamine-responsive form of MSUD, in which symptoms are alleviated by dietary thiamine, is somewhat controversial, but may reflect the inhibitory effect of thiamine on BCKDK, relieving inhibition of BCKDH activity (Chaung et al, 2006; reviewed in Strauss et al, 2020, Biswas et al, 2019). Mandatory newborn screening programs include testing for MSUD, allowing for early intervention that is especially critical in cases of classic MSUD (Strauss et al, 2020)  Mutations in DLD, the E3 subunit shared with PDH and alpha-KGDH, affect the enzymatic activity of all three complexes and are responsible for a more severe disorder called dihydrolipoamide dehydrogenase deficiency (DLDD). DLLD generally results in death in infancy due to lactic acidosis (Taylor et al, 1978; reviewed in Ambrus, 2019).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway432">
 <bp:pathwayOrder rdf:resource="#PathwayStep2067" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1591" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2022" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Beta-ketothiolase deficiency</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ACAT1 is a mitochondrial enzyme that plays a role in metabolism of ketone bodies and isoleucine catabolism (Fukao et al, 1991; Haapalainen et al, 2007; reviewed in Fukao et al, 2019). As part of isoleucine catabolism in the mitochondria, ACAT1 catalyzes the thiolytic degradation of alpha-methylacetoacetyl-CoA to propionyl-CoA and acetyl-CoA (Fukao et al, 1991; Happalainen et al, 2007). Mutations in ACAT1 that affect protein stability and enzymatic activity are associated with beta-ketothiolase deficiency, also known as alpha-methylacetoacetic aciduria, an inborn error of metabolism that is identified by the presence of isoleucine intermediate metabolites in bodily fluids (Daum et al, 1973; Schutgens et al, 1982; Fukao et al, 1991; Fukao et al, 1992; Wakazono et al, 1995; Fukao et al, 1998; Sakurai et al, 2007; reviewed in Korman, 2006; Fukao et al, 2019). Neonatal onset is rare and most affected individuals present between 6 and 18 months with metabolic acidosis, lethargy, vomiting and sometimes coma (reviewed in Korman, 2006). As with other disorders of branched-chain metabolism, there is not a direct correlation between genotype and severity of phenotypic presentation (reviewed in Korman, 2006).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway435">
 <bp:pathwayOrder rdf:resource="#PathwayStep2072" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1593" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2027" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">H139Hfs13* PPM1K causes a mild variant of  MSUD</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">PPM1K is a mitochondrial protein phosphatase that removes the inhibitory phosphorylation from the E1 beta subunit of branched-chain ketoacid dehydrogenase (BCKDH) to restore BCKDH activity (Lu et al, 2007; Lu et al, 2009 a, b; Wynn et al, 2012; Zhou et al, 2012).  BCKDH is responsible for the oxidative decarboxylation of branched-chain amino acid (BCAA) derivatives of leucine, valine and isoleucine, providing acetyl CoA and succinyl CoA intermediates for the Krebs Cycle (reviewed in Strauss et al, 2020; Zhang et al, 2023). Loss-of-function mutations in subunits of BCKDH cause accumulation of toxic BCAAs in the urine, neurological defects and are the cause of Maple Syrup Urine disease (MSUD). More recently, a frameshift mutation in PPM1K was identified as the probable cause of a mild variant of MSUD (Oyarzabal et al, 2012). This frameshift introduces a stop codon at residue 151, destabilizing the protein, and transfection of PPM1K-deficient fibroblast lines with WT PPM1K restores BCKDH activity (Oyarzabal et al, 2012). </bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway434">
 <bp:pathwayOrder rdf:resource="#PathwayStep2070" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1592" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2025" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Loss-of-function mutations in DBT cause MSUD2</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Loss-of-function mutations in DBT disrupt the integrity of the E2 subunit of BCKDH, resulting in MSUD2 (reviewed in Strauss et al, 2020; Biswas et al, 2019).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway448">
 <bp:pathwayOrder rdf:resource="#PathwayStep2096" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1604" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2051" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective HPRT1 disrupts guanine and hypoxanthine salvage</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Normally in humans, guanine and hypoxanthine can be salvaged by conversion to GMP and IMP, catalyzed by HPRT1 (hypoxanthine guanine phosphoribosyltransferase). In the absence of HPRT1 activity, however, accumulated guanine and hypoxanthine are catabolized by XDH (xanthine dehydrogenase / oxidase) to urate (Fu    Jinnah 2012).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway447">
 <bp:pathwayOrder rdf:resource="#PathwayStep2095" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2097" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2099" />
 <bp:pathwayComponent rdf:resource="#Pathway448" />
 <bp:pathwayComponent rdf:resource="#Pathway449" />
 <bp:pathwayComponent rdf:resource="#Pathway450" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2050" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Nucleotide salvage defects</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defects in APRT and HGPRT lead to synthesis of 2,8-dioxo-adenine and overproduction of uric acid, respectively, associated with kidney damage and other symptoms (Boll&#233;e et al. 2012; Fu    Jinnah 2012). Defects in ADA lead to accumulation of (deoxy)adenosine and consequent severe combined immunodeficiency (Akeson et al. 1988).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway449">
 <bp:pathwayOrder rdf:resource="#PathwayStep2098" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1605" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2053" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective ADA disrupts (deoxy)adenosine deamination</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Normally in humans, adenosine and deoxyadenosine can be deaminated to inosine and deoxyinosine, catalyzed by ADA (adenosine deaminase). In the absence of ADA activity, however, accumulated nucleosides disrupt lymphoid cell function, leading to severe combined immunodeficiency (Hirschhorn et al. 1989, 1990).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Catalysis rdf:ID="Catalysis285">
 <bp:controlled rdf:resource="#BiochemicalReaction991" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis284">
 <bp:controlled rdf:resource="#BiochemicalReaction988" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis287">
 <bp:controlled rdf:resource="#BiochemicalReaction993" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis286">
 <bp:controlled rdf:resource="#BiochemicalReaction992" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis281">
 <bp:controlled rdf:resource="#BiochemicalReaction982" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis280">
 <bp:controlled rdf:resource="#BiochemicalReaction980" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis283">
 <bp:controlled rdf:resource="#BiochemicalReaction985" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis282">
 <bp:controlled rdf:resource="#BiochemicalReaction983" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis289">
 <bp:controlled rdf:resource="#BiochemicalReaction996" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis288">
 <bp:controlled rdf:resource="#BiochemicalReaction994" />
</bp:Catalysis>

<bp:Pathway rdf:ID="Pathway440">
 <bp:pathwayOrder rdf:resource="#PathwayStep2082" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1598" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2037" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Branched-chain ketoacid dehydrogenase kinase deficiency</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Branched-chain ketoacid dehydrogenase kinase deficiency (BCKDKD) is a neurological disorder that arises due to mutations in branched-chain ketoacid dehydrogenase kinase (BCKDK) (Joshi et al 2006; Novarino et al, 2012; Garcia-Cazorla et al, 2014; Tangeraas et al, 2023). BCKDK is a negative regulator of the branched-chain ketoacid dehydrogenase complex (BCKDH), the enzyme responsible for oxidative decarboxylation of branched-chain amino acid derivatives. BCKDK-dependent phosphorylation of serine residues in the E1 alpha subunit of the enzyme BCKDHA inactivates the BCKDH (Popov et al, 1992; Li et al, 2004; Wynn et al, 2004). Inactivating mutations of BCKDK are associated with impaired intellectual development, microencephaly and autism (Joshi et al 2006; Novarino et al, 2012; Garcia-Cazorla et al, 2014; Tangeraas et al, 2023). Consistent with the role of BCKDK in inhibiting BCKDH activity, inactivating mutations in BCKDK result in higher levels of BCKDH activity and reduced BCAAs in plasma, tissues and urine in mouse models, patients and cell lines (Joshi et al, 2006; Novarino et al, 2012). Symptoms of BCKDK deficiency are alleviated in mouse models by dietary supplementation with a BCAA-enriched diet (Joshi et al, 2006; Novarino et al, 2012).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway442">
 <bp:pathwayOrder rdf:resource="#PathwayStep2086" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1600" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2041" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">3-methylglutaconic aciduria</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Mutations in AUH are associated with 3-methylglutaconic aciduria, a rare autosomal recessive disorder. AUH catalyzes the fifth step in the catabolism of leucine, the conversion of 3-methylglutaconyl-CoA to 3-hydroxy-methylglutaryl-CoA (Iljst et al, 2002; Ly et al, 2003; Mack et al, 2006). Mutations that affect AUH stability or function result in accumulation of metabolic intermediates such as 3-methylglutaconic acid, 3-methylglutaric acid and 3-hydroxyisovaleric acid that are excreted in urine (Duran et al, 1982; Ly et al, 2002; Mack et al, 2006; Nardecchia et al, 2022). The clinical presentation of 3-methylglutaconic aciduria is variable ranging from no-to-mild symptoms to severe encephalopathy, metabolic acidosis and coma (Nardecchia et al, 2022). </bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway441">
 <bp:pathwayOrder rdf:resource="#PathwayStep2084" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1599" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2039" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">3-hydroxyisobutyryl-CoA hydrolase deficiency</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">3-hydroxyisobutyryl-CoA hydrolase deficiency is an autosomal recessive inborn error of metabolism caused by mutations in HIBCH, a mitochondrial enzyme that catalyzes the fifth step of the valine catabolic pathway (Hawes et al, 1996; Brown et al, 1982; Loupatty et al, 2007). Like mutations in ECHS1, the enzyme that catalyzes the third step of valine metabolism, HIBCH mutations result in accumulation of toxic metabolic intermediates and manifest clinically with severe psychomotor and developmental delays, neurodegeneration and brain lesions, characteristic of a Leigh-like syndrome (Brown et al, 1982; Loupatty et al, 2007; Ferdinandusse et al, 2013; Peters et al, 2015; Reuter et al, 2014; D&apos;Gama et al, 2020; reviewed in Rahman et al, 2023).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway444">
 <bp:pathwayOrder rdf:resource="#PathwayStep2094" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2090" />
 <bp:pathwayComponent rdf:resource="#Pathway447" />
 <bp:pathwayComponent rdf:resource="#Pathway445" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2045" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Diseases of nucleotide metabolism</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Metabolic reactions disrupted by deficiencies of ADA, APRT, HPRT1, and PNP are annotated here.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway443">
 <bp:pathwayOrder rdf:resource="#PathwayStep2088" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1601" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2043" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Isovaleric acidemia</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Isovaleric acidemia is an inborn error of metabolism that arises due to mutations in isovaleryl-CoA dehydrogenase (IVD), a mitochondrial enzyme that catalyzes the third step in the catabolic pathway for leucine, the conversion of isovaleryl-CoA and FAD to  beta-methylcrotonyl-CoA and FADH2 (Tanaka et al, 1966; Finocchiaro et al. 1978; Rhead and Tanaka 1980). Isovaleric acidemia has variable clinical presentation and lacks a clear correspondence between genotypic alterations and phenotypic outcome (Vockley and Ensenauer, 2006). Symptoms include vomiting, seizures, low energy, and a characteristic sweaty foot odor due to presence of isovaleric acid, 3-hydroxyisovaleric acid, isovarleryl-glycine and isovaleryl-carnitine in blood and urine (Vockley et al, 1991; Mohsen et al, 1998; Zaki et al, 2017; Dercksen et al, 2012; D&apos;Annibale et al, 2021).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway446">
 <bp:pathwayOrder rdf:resource="#PathwayStep2092" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2093" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1602" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1603" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2047" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective PNP disrupts phosphorolysis of (deoxy)guanosine and (deoxy)inosine</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Normally in humans, PNP (purine nucleotide phosphorylase) catalyzes the conversion of (deoxy)guanosine and (deoxy)inosine to guanine and hypoxanthine, respectively. In the absence of PNP activity, however, these purine nucleosides accumulate, disrupting lymphoid cell function and leading to severe immunodeficiency (Aust et al. 1992; Williams et al. 1987).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway445">
 <bp:pathwayOrder rdf:resource="#PathwayStep2091" />
 <bp:pathwayComponent rdf:resource="#Pathway446" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2046" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Nucleotide catabolism defects</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Purine nucleotide phosphorylase defects (Aust et al. 1992, Williams et al. 1987) are annotated here.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway415">
 <bp:pathwayOrder rdf:resource="#PathwayStep2031" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2032" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1573" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1572" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1986" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MPS IV - Morquio syndrome B</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defects in beta-galactosidase (GLB1; MIM:611458) can result in GM1 gangliosidosis (GM1; MIM:230500) (Nishimoto et al. 1991) (not described here), with several phenotypes indicating mental deterioration, as well as in mucopolysaccharidosis IVB, a characteristic mucopolysaccharidosis with no neurological symptoms (Callahan 1999).  Mucopolysaccharidosis IVB (MPS IVB, Morquio&apos;s syndrome B; MIM:253010) is a rare, autosomal recessive mucopolysaccharide storage disease characterized by intracellular accumulation of keratan sulfate (KS), skeletal dysplasia and corneal clouding. There is no central nervous system involvement, intelligence is normal and there is increased KS excretion in urine (Suzuki et al. &quot;Beta-galactosidase deficiency (beta-galactosidosis): GM1 gangliosidosis and Morquio B disease&quot;, p3775-3809 in Stryer et al. 2001). MPSIVB is caused by a defect in betagalactosidase (GLB1), which normally cleaves terminal galactosyl residues from glycosaminoglycans, gangliosides and glycoproteins. The GLB1 gene spans 62.5 kb and contains 16 exons (Oshima et al.1988, Santamaria et al. 2007) and maps to chromosome 3p21.33 (Takano    Yamanouchi 1993).  </bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway414">
 <bp:pathwayOrder rdf:resource="#PathwayStep2029" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2027" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2028" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1569" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1571" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1570" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1982" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MPS VII - Sly syndrome</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Mucopolysaccharidosis type VII (MPS VII, Sly syndrome, beta-glucuronidase deficiency; MIM:253220) is an autosomal recessive lysosomal storage disease characterized by a deficiency of the enzyme beta-glucuronidase (GUSB; MIM:611499) which would normally cleave glucuronide residues from dematan sulphate, keratan sulphate and chondroitin sulphate, resulting in build up of these GAGs in cells and tissues (Sly et al. 1973). The gene encoding GUSB is 21 kb long, contains 12 exons and gives rise to two different types of cDNAs, through an alternate splicing mechanism (Miller et al. 1990). It maps to 7q11.21-q11.22 (Speleman et al. 1996). The phenotype is highly variable, ranging from severe causing death, non-immune hydrops fetalis (Vervoort et al. 1996) to mild forms with survival into adulthood (Storch et al. 2003). Most patients with the intermediate phenotype show hepatomegaly, skeletal anomalies, coarse facies, and variable degrees of mental impairment (Shipley et al. 1993, Tomatsu et al. 2009).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway417">
 <bp:pathwayOrder rdf:resource="#PathwayStep2036" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2037" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1575" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1576" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1991" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MPS IIIC - Sanfilippo syndrome C</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Mucopolysaccharidosis III (Sanfilippo syndrome) was described in 1963 by a pediatrician named Sylvester Sanfilippo (J. Pediat. 63: 837838, 1963, no reference). Mucopolysaccharidosis type IIIC (MPS IIIC, Sanfilippo syndrome C; MIM:252930) is an autosomal recessive genetic disorder due to the loss of heparan alpha-glucosaminide N-acetyltransferase (HGSNAT; MIM:610453) that normally acetylates the non-reducing terminal alpha-glucosamine residue of  heparan sulfate. The molecular defects underlying MPS IIIC remained unknown for almost three decades due to the low tissue content and instability of HGSNAT. But, during the last decade, the gene was cloned in parallel by two different groups and shown to contain 18 exons and span approximately 62Kb (Fan et al. 2006, Hrebicek et al. 2006). Loss of HGSNAT results in build up of this glycosaminglycan (GAG) in cells and tissues and is characterized by severe central nervous system degeneration but only with mild somatic disease and death occurs typically during the second or third decade of life (Kresse et al. 1978, Klein et al. 1978, Feldhammer et al. 2009, de Ruijter et al. 2011).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway416">
 <bp:pathwayOrder rdf:resource="#PathwayStep2034" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1574" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1989" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MPS IV - Morquio syndrome A</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Mucopolysaccharidosis IV A (MPS IVA, MPS4A, Morquio&apos;s syndrome, Morquio&apos;s; MIM:253000) is a rare, autosomal recessive mucopolysaccharide storage disease, first described simultaneously in 1929 by L Morquio (Morquio L, Sur une forme de distrophie familiale, Bull Soc Pediat, Paris, 27, 1929, 145-152) and JF Brailsford (Brailsford, JF, Chondro-osteo-dystrophy: roentgenographic and clinical features of child with dislocation of vertebrae,  Am j Surg, 7, 1929, 404-410). MPSIVA is caused by a deficiency in N-acetylgalactosamine 6-sulfatase (GALNS; MIM:612222) which normally hydrolyses 6-sulfate groups of N-acetylgalactosamine 6-sulfate units of chondroitin sulfate (CS) and of galactose 6-sulfate units of keratan sulfate (KS) (Matalon et al. 1974). The result is accumulation of KS/DS in cells and overexcretion in urine. Severe osteochondrodysplasia is a commonly seen phenotype for this disease. The severity of the disease is variable but severe cases limits lifespan to their 20&apos;s or 30&apos;s (Prat et al. 2008, Tomatsu et al. 2011). The gene coding for human GALNS was mapped to chromosome 16q24.3 (Masuno et al. 1993) and its structure described at the same time by two independent groups as comprising 14 exons and spanning approximately 40-50 kb (Nakashima et al.1994, Morris et al.1994). </bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway419">
 <bp:pathwayOrder rdf:resource="#PathwayStep2042" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1579" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1997" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MPS IIID - Sanfilippo syndrome D</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Mucopolysaccharidosis III (Sanfilippo syndrome) was described in 1963 by a pediatrician named Sylvester Sanfilippo (J. Pediat. 63: 837-838, 1963, no reference). Mucopolysaccharidosis type IIID (MPS IIID, Sanfilippo syndrome D, MIM:252940) is an autosomal recessive genetic disorder due to the loss of N-acetyl-D-glucosamine 6-sulfatase (GNS; MIM:607664), that hydrolyses the 6-sulfate groups of the N-acetyl-D-glucosamine 6-sulfate units of the glycosaminoglycans (GAGs) heparan sulfate and keratan sulfate. GNS is localized to chromosome 12q14 and has 14 exons spanning 46 kb (Robertson et al. 1988, Mok et al. 2003). Loss of enzyme activity leads to lysosomal accumulation and urinary excretion of  heparan sulfate and N-acetylglucosamine 6-sulfate residues (Mok et al. 2003). Keratan sulphate does not accumulate in MPS IIID, as beta-linked N-acetyl-D-glucosamine 6-sulphate can be cleaved by beta-hexosaminidase A (Kresse et al. 1980). This disorder is characterized by progressive mental deterioration but only moderate physical abnormalities and death duing the second or third decade of life, presenting a phenotype similar to MPSIIIA (Jones et al. 1997, de Ruijter et al. 2011).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway418">
 <bp:pathwayOrder rdf:resource="#PathwayStep2040" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2039" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1577" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1578" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1994" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MPS IIIA - Sanfilippo syndrome A</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Mucopolysaccharidosis III (MPS III, Sanfilippo syndrome) was described in 1963 by a pediatrician named Sylvester Sanfilippo (J. Pediat. 63: 837-838, 1963, no reference). Mucopolysaccharidosis IIIA (MPS IIIA, Sanfilippo syndrome A, MIM:252900) is a rare, autosomal recessive lysosomal storage disease characterised by severe CNS degeneration in early childhood leading to death between 10 and 20 years of age. A deficiency of the enzyme N-sulphoglucosamine sulphohydrolase (SGSH, MIM:605270), which normally hydrolyses the sulfate group from the terminal N-sulphoglucosamine residue of heparan sulfate (HS), leads to the build-up of HS in cells and tissues and its presence in urine (van de Kamp et al. 1981, Yogalingam    Hopwood 2001, de Ruijter et al. 2011). The gene encoding N-sulfoglucosamine sulfohydrolase, SGSH, was cloned in 1995 (Scott et al.1995) and, later, shown to contain 8 exons spanning approximately 11 kb (Karageorgos et al. 1996).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Catalysis rdf:ID="Catalysis210">
 <bp:controlled rdf:resource="#BiochemicalReaction739" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis216">
 <bp:controlled rdf:resource="#BiochemicalReaction791" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis215">
 <bp:controlled rdf:resource="#BiochemicalReaction786" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis218">
 <bp:controlled rdf:resource="#BiochemicalReaction796" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis217">
 <bp:controlled rdf:resource="#BiochemicalReaction795" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis212">
 <bp:controlled rdf:resource="#BiochemicalReaction746" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis211">
 <bp:controlled rdf:resource="#BiochemicalReaction741" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis214">
 <bp:controlled rdf:resource="#BiochemicalReaction758" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis213">
 <bp:controlled rdf:resource="#BiochemicalReaction748" />
</bp:Catalysis>

<bp:Pathway rdf:ID="Pathway411">
 <bp:pathwayOrder rdf:resource="#PathwayStep2018" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2019" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1564" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1563" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1973" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MPS IIIB - Sanfilippo syndrome B</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Mucopolysaccharidosis III (Sanfilippo syndrome) was described in 1963 by a pediatrician named Sylvester Sanfilippo (J. Pediat. 63: 837838, 1963, no reference). MPS IIIB (Mucopolysaccharidosis type IIIB, MPS IIIB, Sanfilippo syndrome type B; MIM:252920) is an autosomal recessive genetic disorder due to loss of function of alpha-N-acetylglucosaminidase (NAGLU; MIM:609701), involved in the hydrolysis of terminal non-reducing N-acetylglucosamine residues in heparan sulfate (HS) The gene encoding NAGLU was cloned in 1996 by Zhao and colleagues. It contains 6 exons and spans 8.3 kb on chromosome 17q21 (Zhao et al. 1996). MPSIIIB is characterized by severe CNS retardation but only mild somatic disease and death usually occurs in the second or third decade of life (Zhao et al. 1996, Yogalingam    Hopwood 2001, de Ruijter et al. 2011). MPS IIIB shows extensive molecular heterogeneity (Schmidtchen et al. 1998).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Catalysis rdf:ID="Catalysis219">
 <bp:controlled rdf:resource="#BiochemicalReaction798" />
</bp:Catalysis>

<bp:Pathway rdf:ID="Pathway410">
 <bp:pathwayOrder rdf:resource="#PathwayStep2015" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2016" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1562" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1561" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1970" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MPS VI - Maroteaux-Lamy syndrome</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Mucopolysaccharidosis type VI (MPS VI, Maroteaux-Lamy syndrome, polydystrophic dwarfism; MIM:253200) is an autosomal recessive lysosomal storage disorder caused by a deficiency in arylsulfatase B (ARSB, N-acetyl-galactosamine 4-sulfatase; MIM:611542). It is named after two French physicians, Pierre Maroteaux and Maurice Emil Joseph Lamy. Maroteaux first described this disorder as a novel dysostosis associated with increased urinary excretion of chondroitin sulfate (CS; Maroteaux et al. 1963). The gene encoding ARSB is mapped to chromosome 5q11-q13 (Fidzianska et al. 1984) and contains 8 exons spanning about 206 kb (Karangeorgos et al. 2007). Defective ARSB results in build up of dermatan sulfate (DS) and chondroitin sulfate (CS) in soft tissues causing compression and blockages in blood vessels, nerves, trachea, corneal clouding and disrupting normal bone development. Symptoms are similar to MPS I but with normal intelligence generally (Rapini et al. 2007, Valayannopoulos et al. 2010).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway413">
 <bp:pathwayOrder rdf:resource="#PathwayStep2025" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2024" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1568" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1567" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1979" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MPS II - Hunter syndrome</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Mucopolysaccharidosis II (MPS II, Hunter syndrome, MIM:309900) is an X-linked, recessive genetic disorder which therefore primarily affects males. MPS II was first described in 1917, by Major Charles Hunter (Hunter 1917) and is caused by a deficiency (or absence) of iduronate-2-sulfatase (IDS, MIM:300823), which would normally hydrolyse the 2-sulfate groups of the L-iduronate 2-sulfate units of dermatan sulfate, heparan sulfate and heparin. Without IDS, these GAGs accumulate in the body and are excessively excreted in urine. Although the disease was known since the early 1970s, being the first MPS to be defined clinically in humans, it wasn&apos;t until the 1990s that IDS was cloned. It is now known to be localized to Xq28 (Wilson et al. 1991) and contain 9 exons (Flomen et al. 1993) spanning approximately 24 kb (Wilson et al. 1993). Build up can occur in the liver and spleen as well as in the walls and valves of the heart (reduced hepatic and cardiac function, liver/spleen hepatosplenomegaly), airways (leading to obstructive airway disease), all major joints and bones (joint stiffness and skeletal deformities) and in brain (severe mental retardation). The rate of progression and degree of severity of the disorder can be different for each person with MPS II. Severe forms of the disorder can result in death in childhood whereas those with a &quot;milder&quot; form can expect to live to their 20&apos;s or 30&apos;s.   Some patients even survive into their fifth and sixth decades of life (Wraith et al. 2008, Beck 2011).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway412">
 <bp:pathwayOrder rdf:resource="#PathwayStep2021" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2022" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1565" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1566" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1976" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MPS IX - Natowicz syndrome</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Mucopolysaccharidosis type IX (MPS IX, Natowicz syndrome, Hyaluronidase deficiency, MIM:601492) is a rare lysosomal storage disease characterized by high hyaluronan (HA) concentration in the serum resulting from deficiency in hyaluronidase 1 (HYAL1, MIM:607071) which normally hydrolyses 1-4 linkages between N-acetylglucosamine (GlcNAc) and D-glucuronate (GlcA) residues. Symptoms of MPS IX are periodically painful soft tissue masses around the joints, acquired short stature and erosion of the hip joint, although joint movement and intelligence are normal (Natowicz et al. 1996, Triggs-Raine et al. 1999). </bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway426">
 <bp:pathwayOrder rdf:resource="#PathwayStep2056" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1586" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2011" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Severe congenital neutropenia type 4 (G6PC3)</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Glucose-6-phosphatase 3 (G6PC3) associated with the endoplasmic reticulum membrane normally catalyzes the hydrolysis of glucose-6-phosphate to glucose and orthophosphate. In the body, this enzyme is ubiquitously expressed; mutations that inactivate it are associated with severe congenital neutropenia (but not with fasting hypoglycemia or lactic acidemia) (Boztug et al. 2009, 2012).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway425">
 <bp:pathwayOrder rdf:resource="#PathwayStep2054" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1585" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2009" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Glycogen storage disease type Ib (SLC37A4)</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The SLC37A4 transport protein in the endoplasmic reticulum membrane normally mediates the exchange of cytosolic glucose-6-phosphate and orthophosphate from the endoplasmic reticulum lumen. Defects in this transporter are associated with glycogen storage disease type Ib (Gerin et al. 1997; Chen et al. 2008; Veiga-da-Cunha et al. 1998).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway428">
 <bp:pathwayOrder rdf:resource="#PathwayStep2060" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1588" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2015" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Glycogen storage disease type IV (GBE1)</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Normally, cytosolic glycogen branching enzyme (GBE1) associated with glycogen granules transfers terminal alpha(1,4) glucose blocks to form alpha(1,6) branches on growing glycogen molecules of both liver and muscle types. In the absence of GBE1 activity, abnormal amylopectin-like glycogen with longer alpha(1,4) chains and fewer branch points forms in all tissues where glycogen is normally found. Presentation of the disease is clinically heterogeneous: missense and nonsense mutations associated with little or no enzyme activity can lead to progressive liver disease or neuromuscuolar disease (Bao et al. 1996; Bruno et al. 2004).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway427">
 <bp:pathwayOrder rdf:resource="#PathwayStep2058" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1587" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2013" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Glycogen storage disease type II (GAA)</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Glycogen storage disease type II (GSD II - Pompe&apos;s disease) is caused by mutations that reduce or eliminate the activity of lysosomal alpha-glucosidase (GAA) (Hers 1963). The presentation of GSD II varies with the severity of the mutation: patients with little or no GAA activity are affected shortly after birth and multiple tissues are severely affected. Patients with higher levels of GAA activity present later in life, often with symptoms restricted tocardiac and  skeletal muscle (Leslie    Tinkle). At a cellular level, symptoms of the disease are due to accumulation of structurally normal glycogen in lysosomes. Glycogen, thought to enter lysosomes via autophagy, is fully degraded by GAA (Brown et al. 1970), but accumulates if the enzyme is absent or reduced in activity. The two mutant alleles annotated here are associated with near-complete loss of enzyme activity and early onset of disease (Hermans et al. 1991; Zhong et al. 1991). Many other mutant alleles have been described and their residual activities correlated with disease presentation (e.g., Kroos et al. 2012).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway429">
 <bp:pathwayOrder rdf:resource="#PathwayStep2062" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1589" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2017" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Glycogen storage disease type 0 (muscle GYS1)</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Glycogen synthase 1 (GYS1 &quot;muscle&quot;) is widely expressed in the body. It normally catalyzes the addition of glucose residues to a growing glycogen molecule. In its absence, glycogen synthesis fails. This deficiency is most prominently associated with exercise intolerance and cardiomyopathy (Kolberg et al. 2007; Cameron et al. 2009).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Catalysis rdf:ID="Catalysis221">
 <bp:controlled rdf:resource="#BiochemicalReaction806" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis220">
 <bp:controlled rdf:resource="#BiochemicalReaction801" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis227">
 <bp:controlled rdf:resource="#BiochemicalReaction827" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis226">
 <bp:controlled rdf:resource="#BiochemicalReaction820" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis229">
 <bp:controlled rdf:resource="#BiochemicalReaction879" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis228">
 <bp:controlled rdf:resource="#BiochemicalReaction878" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis223">
 <bp:controlled rdf:resource="#BiochemicalReaction814" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis222">
 <bp:controlled rdf:resource="#BiochemicalReaction808" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis225">
 <bp:controlled rdf:resource="#BiochemicalReaction819" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis224">
 <bp:controlled rdf:resource="#BiochemicalReaction816" />
</bp:Catalysis>

<bp:Pathway rdf:ID="Pathway420">
 <bp:pathwayOrder rdf:resource="#PathwayStep2044" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1580" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1999" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Essential pentosuria</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Essential pentosuria, the excretion in the urine of high levels of L-xylulose, is a benign autosomal recessive trait found in Ashkenazi Jewish and Lebanese populations. It is due to mutations that inactivate DXCR (L-xylulose reductase) and thus prevent the conversion of L-xylulose to xylitol in the glucuronate pathway (Pierce et al. 2011; Wang    van Eys 1970).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway422">
 <bp:pathwayOrder rdf:resource="#PathwayStep2047" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1581" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2002" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Glycogen storage disease type XV (GYG1)</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Glycogen synthesis is normally initiated by the autoglycosylation of glycogenin (GYG) to form oligo (1,4)-alpha-D-glucosyl GYG. A missense mutation of GYG1 yields a protein that cannot undergo glucosylation, leading to failure of glycogen synthesis, associated with muscle weakness and other abnormalities (Moslemi et al. 2010).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway421">
 <bp:pathwayOrder rdf:resource="#PathwayStep2050" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2061" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2063" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2053" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2048" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2059" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2055" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2046" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2057" />
 <bp:pathwayComponent rdf:resource="#Pathway426" />
 <bp:pathwayComponent rdf:resource="#Pathway425" />
 <bp:pathwayComponent rdf:resource="#Pathway428" />
 <bp:pathwayComponent rdf:resource="#Pathway427" />
 <bp:pathwayComponent rdf:resource="#Pathway429" />
 <bp:pathwayComponent rdf:resource="#Pathway430" />
 <bp:pathwayComponent rdf:resource="#Pathway422" />
 <bp:pathwayComponent rdf:resource="#Pathway424" />
 <bp:pathwayComponent rdf:resource="#Pathway423" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2001" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Glycogen storage diseases</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The regulated turnover of glycogen plays a central, tissue-specific role in the maintenance of blood glucose levels and in the provision of glucose to tissues such as muscle and brain in response to stress. Defects in the enzymes involved in glycogen turnover are associated with abnormal responses to fasting and exercise that can differ widely in their presentation and severity. Additional symptoms can be the result of accumulation of abnormal products of glycogen metabolism (Hauk et al. 1959; Hers 1964; Shin 2006). Annotations are provided here for diseases due to deficiencies of GYS1 and GYS1 (glycogen synthase 1 and 2; glycogen storage disease type 0 (GSD type 0), of G6PC (glucose-6-phosphatase, GSD type Ia) and the SLC37A4 transporter (GSD type Ib), of GAA (lysosomal acid alpha-glucosidase, GSD type II), of GBE1 (glycogen branching enzyme, GSD type IV), and of GYG1 (glycogenin 1, GSD XV). Two additional diseases, myoclonic epilepsy of Lafora (Roach et al. 2012) and severe congenital neutropenia type 4 (Boztug et al. 2009), are included as they are due to defects in enzymes of glycogen metabolism.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway424">
 <bp:pathwayOrder rdf:resource="#PathwayStep2051" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2052" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1584" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1583" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2006" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Myoclonic epilepsy of Lafora</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Lafora disease is a progressive neurodegenerative disorder with onset typically late in childhood, characterized by seizures and progressive neurological deterioration and death within ten years of onset. Recessive mutations in EPM2A (laforin) and NHLRC1 (malin) have been identified as causes of the disease. The disease is classified here as one of glycogen storage as EPM2A (laforin) and NHLRC1 (malin) regulate normal glycogen turnover and defects in either protein are associated with the formation of Lafora bodies, accumulations of abnormal, insoluble glycogen molecules in tissues including  brain, muscle, liver, and heart (Ramachandran et al. 2009; Roach et al. 2012). Consistent with a central role for glycogen accumulation in the disease, reduced (Turnbull et al. 2011) or absent (Pederson et al. 2013) glycogen synthase activity prevents Lafora Disease in mouse models. Type 2A disease. EPM2A (laforin) associated with cytosolic glycogen granules, normally catalyzes the removal of the phosphate groups added rarely but consistently to growing glycogen molecules (Tagliabracci et al. 2011). Defects in this catalytic activity lead to the formation of phosphorylated glycogen molecules that are insoluble and that show abnormal branching patterns (Minassian et al. 1998, Serratosa et al. 1999, Tagliabracci et al. 2011). Type 2B disease. NHLRC1 (malin) normally mediates polyubiquitination of EPM2A (laforin) and PPP1R3C (PTG). The two polyubiquitinated proteins are targeted for proteasome-mediated degradation, leaving a glycogen-glycogenin particle associated with glycogen synthase. In the absence of NHLRC1 activity, EPM2A and PPP1R3C proteins appear to persist,  associated with the formation of abnormal, stable glycogen granules (Lafora bodies) (Chan et al. 2003; Gentry et al. 2005). In NHLRC1 knockout mice PPP1R3C levels are unchanged rather than increased, suggesting that NHLRC1 does not target PPP1R3C for degradation.  However, EPM2A protein levels are increased in this knockout consistent with NHLRC1&apos;s proposed role (DePaoli-Roach et al. 2010).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway423">
 <bp:pathwayOrder rdf:resource="#PathwayStep2049" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1582" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence2004" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Glycogen storage disease type 0 (liver GYS2)</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Glycogen synthase 2 (GYS2 &quot;liver&quot;) normally catalyzes the addition of glucose residues to a growing glycogen molecule. In its absence, glycogen synthesis fails. Expression of GYS2 is confined to the liver and its deficiency is most prominently associated with fasting hypoglycemia (Gitzelmann et al. 1996; Orho et al. 1998).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Catalysis rdf:ID="Catalysis230">
 <bp:controlled rdf:resource="#BiochemicalReaction881" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis232">
 <bp:controlled rdf:resource="#BiochemicalReaction890" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis231">
 <bp:controlled rdf:resource="#BiochemicalReaction886" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis238">
 <bp:controlled rdf:resource="#BiochemicalReaction911" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis237">
 <bp:controlled rdf:resource="#BiochemicalReaction904" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis239">
 <bp:controlled rdf:resource="#BiochemicalReaction912" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis234">
 <bp:controlled rdf:resource="#BiochemicalReaction900" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis233">
 <bp:controlled rdf:resource="#BiochemicalReaction896" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis236">
 <bp:controlled rdf:resource="#BiochemicalReaction903" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis235">
 <bp:controlled rdf:resource="#BiochemicalReaction902" />
</bp:Catalysis>

<bp:Pathway rdf:ID="Pathway404">
 <bp:pathwayOrder rdf:resource="#PathwayStep1998" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1550" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1953" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TALDO1 deficiency: failed conversion of  Fru(6)P, E4P to SH7P, GA3P</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Mutations in transaldolase 1 (TALDO1), an enzyme of the pentose phosphate pathway that normally mediates the reversible interconversion of D-fructose 6-phosphate and D-erythrose 4-phosphate to form sedoheptulose 7-phosphate and D-glyceraldehyde 3-phosphate, have been associated with congenital liver disease (Wamelink et al. 2008).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway403">
 <bp:pathwayOrder rdf:resource="#PathwayStep1996" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1549" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1951" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">RPIA deficiency: failed conversion of RU5P to R5P</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">A mutation in ribose-5-phosphate isomerase (RPIA), an enzyme of the pentose phosphate pathway that normally mediates the reversible interconversion of   D-ribulose 5-phosphate and ribose 5-phosphate, has been associated with a slowly progressive leukoencephalopathy (Wamelink et al. 2008).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway406">
 <bp:pathwayOrder rdf:resource="#PathwayStep2003" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2004" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2005" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2006" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2002" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1553" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1554" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1552" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1555" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1556" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1957" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Intestinal saccharidase deficiencies</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defects in in two enzymes required for intestinal digestion of dietary carbohydrate, lactase (LCT, a domain of lactase-phlorizin hydrolase protein) and sucrase-isomaltase (SI), are annotated here. The first affects nursing infants; the second affects individuals after weaning. The disaccharide lactose is a major constituent of human breast milk. To be taken up from the gut in the nursing infant, this sugar must first be hydrolyzed by LCT present on the external face of enterocytes in microvilli of the small intestine. Mutations that disrupt LCT activity are associated with acute illness in newborn children as lactose fermentation by gut bacteria leads to severe diarrhea. The condition is effectively treated by feeding affected infants a lactose-free formula. This congenital disease is distinct from the down-regulation of LCT expression after weaning in many human populations that is associated with a milder form of lactose intolerance in adults (Jarvela et al. 2009). The starch in a post-weaning diet is digested by amylases to di- and oligosaccharides that must be further digested to monosaccharides in order to be taken up from the lumen of the small intestine into endothelial cells of the intestinal brush border. If they are not digested, a process in which enterocyte-associated SI plays a central role, they remain in the gut lumen and are fermented by gut bacteria, leading to osmotic and fermentative diarrhea (Naim et al. 2012; Van Beers et al. 1995).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway405">
 <bp:pathwayOrder rdf:resource="#PathwayStep2000" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1551" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1955" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Hereditary fructose intolerance</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Deficiencies in aldolase B arising from mutations in the aldolase B gene (ALDOB) prevent the cleavage of fructose 1-phosphate to glyceraldehyde (GA) and dihydroxyacetone phosphate (DHAP), leading to hereditary fructose intolerance (HFI). This autosomal recessive disorder is potentially fatal, but can be managed by exclusion of fructose from the diet (Cox et al. 1988; Tolan 1995).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway408">
 <bp:pathwayOrder rdf:resource="#PathwayStep2030" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2041" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2020" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2014" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2026" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2038" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2017" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2010" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2033" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2023" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2035" />
 <bp:pathwayComponent rdf:resource="#Pathway415" />
 <bp:pathwayComponent rdf:resource="#Pathway414" />
 <bp:pathwayComponent rdf:resource="#Pathway417" />
 <bp:pathwayComponent rdf:resource="#Pathway416" />
 <bp:pathwayComponent rdf:resource="#Pathway419" />
 <bp:pathwayComponent rdf:resource="#Pathway418" />
 <bp:pathwayComponent rdf:resource="#Pathway409" />
 <bp:pathwayComponent rdf:resource="#Pathway411" />
 <bp:pathwayComponent rdf:resource="#Pathway410" />
 <bp:pathwayComponent rdf:resource="#Pathway413" />
 <bp:pathwayComponent rdf:resource="#Pathway412" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1965" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Mucopolysaccharidoses</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The mucopolysaccharidoses (MPS) are a group of rare, inherited lysosomal storage disorders caused by deficiencies of enzymes catalyzing the stepwise degradation of glycosaminoglycans (GAGs, originally called mucopolysaccharides) (Neufeld    Muenzer in Scriver et al. 2001). Catabolism of the GAGs dermatan sulfate, heparan sulfate, heparin, keratan sulfate, chondroitin sulfate or hyaluronan may be blocked at one or more steps, resulting in lysosomal accumulation of GAG fragments of varying size. Over time these collect in the cells, blood and connective tissues ultimately resulting in progressive irreversible cellular damage which affects appearance, physical abilities, organ and system function, vision, and usually mental development (Lehman et al. 2011, Ashworth et al. 2006). Life expectancy is also reduced. There are 11 known enzyme deficiencies that give rise to 7 distinct MPS. These disorders are biochemically characterized by elevated levels of partially or undegraded GAGs in lysosomes, blood, urine and cerebro-spinal fluid (Muenzer 2011, Coutinho et al. 2012). The MPS are part of the lysosomal storage disease family, a group of about 50 genetic disorders caused by deficient lysosomal proteins (Ballabio    Gieselmann 2009).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway407">
 <bp:pathwayOrder rdf:resource="#PathwayStep2008" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1557" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1963" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Essential fructosuria</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Deficiencies in KHK (ketohexokinase) are associated with essential fructosuria (Bonthron et al. 1994).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway409">
 <bp:pathwayOrder rdf:resource="#PathwayStep2011" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2012" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2013" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1558" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1559" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1560" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1966" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MPS I - Hurler syndrome</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Mucopolysaccharidosis type I (MPS I, Hurler syndrome, Hurler&apos;s disease, gargoylism, Scheie, Hirler-Scheie syndrome;  MIM:607014, 607015 and 607016) is an autosomal recessive genetic disorder where there is a deficiency of alpha-L iduronidase (IDUA, MIM:252800), a glycosidase that removes non-reducing terminal alpha-L-iduronide residues during the lysosomal degradation of the glycosaminoglycans heparan sulphate and dermatan sulphate (McKusick 1959). In 1992, Scott and colleagues were able to clone and purify the gene that encodes this enzyme, IDUA, demonstrating that it spans approximately 19 kb and contains 14 exons (Scott et al. 1992). Hurler syndrome is named after a German paediatrician Gertrud Hurler (1919, no reference available). The result is build up of heparan sulfate and dermatan sulfate in the body and increased urinary excretion of these GAGs. Symptoms and signs include hepatosplenomegaly, dwarfism, unique facial features, corneal clouding, retinopathy, progressive mental retardation appears during childhood and early death can occur due to organ damage (Campos    Monaga 2012). MPS I is divided into three subtypes, ranging from severe to mild phenotypes; Mucopolysaccharidosis type IH (MPSIH, Hurler syndrome, MIM:607014), mucopolysaccharidosis type IH/S (MPSIH/S, HurlerScheie syndrome, MIM: 607015) and mucopolysaccharidosis type IS (MPSIS, Scheie syndrome, MIM: 607016) respectively (McKusick 1972).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Catalysis rdf:ID="Catalysis241">
 <bp:controlled rdf:resource="#BiochemicalReaction914" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis240">
 <bp:controlled rdf:resource="#BiochemicalReaction913" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis243">
 <bp:controlled rdf:resource="#BiochemicalReaction916" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis242">
 <bp:controlled rdf:resource="#BiochemicalReaction915" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis249">
 <bp:controlled rdf:resource="#BiochemicalReaction923" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis248">
 <bp:controlled rdf:resource="#BiochemicalReaction922" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis245">
 <bp:controlled rdf:resource="#BiochemicalReaction919" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis244">
 <bp:controlled rdf:resource="#BiochemicalReaction917" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis247">
 <bp:controlled rdf:resource="#BiochemicalReaction921" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis246">
 <bp:controlled rdf:resource="#BiochemicalReaction920" />
</bp:Catalysis>

<bp:Pathway rdf:ID="Pathway400">
 <bp:pathwayOrder rdf:resource="#PathwayStep1997" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1993" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1995" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1991" />
 <bp:pathwayComponent rdf:resource="#Pathway404" />
 <bp:pathwayComponent rdf:resource="#Pathway403" />
 <bp:pathwayComponent rdf:resource="#Pathway402" />
 <bp:pathwayComponent rdf:resource="#Pathway401" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1946" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Pentose phosphate pathway disease</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Mutant forms of two enzymes of the pentose phosphate pathway have been associated with disease in humans. A mutation in ribose-5-phosphate isomerase (RPIA), which normally mediates the reversible interconversion of D-ribulose-5-phosphate and ribose-5-phosphate, has been associated with a slowly progressive leukoencephalopathy, and mutations in transaldolase 1 (TALDO1), which normally mediates the reversible interconversion of D-fructose 6-phosphate and D-erythrose-4-phosphate to form sedoheptulose-7-phosphate and D-glyceraldehyde-3-phosphate, have been associated with congenital liver disease (Wamelink et al. 2008).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway402">
 <bp:pathwayOrder rdf:resource="#PathwayStep1994" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1548" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1949" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TALDO1 deficiency: failed conversion of SH7P, GA3P to Fru(6)P, E4P</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Mutations in transaldolase 1 (TALDO1), an enzyme of the pentose phosphate pathway that normally mediates the reversible interconversion of sedoheptulose 7-phosphate and D-glyceraldehyde 3-phosphate to form D-fructose 6-phosphate and D-erythrose 4-phosphate, have been associated with congenital liver disease (Wamelink et al. 2008).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway401">
 <bp:pathwayOrder rdf:resource="#PathwayStep1992" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1547" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1947" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">RPIA deficiency: failed conversion of R5P to RU5P</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">A mutation in ribose-5-phosphate isomerase (RPIA), an enzyme of the pentose phosphate pathway that normally mediates the reversible interconversion of  ribose 5-phosphate and D-ribulose 5-phosphate, has been associated with a slowly progressive leukoencephalopathy (Wamelink et al. 2008).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence373">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence372">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence375">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence374">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence371">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence370">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence377">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence376">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence379">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence378">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence384">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence383">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence386">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence385">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence380">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence382">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence381">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence388">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence387">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence389">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence395">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence394">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence397">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence396">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence391">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence390">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence393">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence392">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence399">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence398">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis175">
 <bp:controlled rdf:resource="#BiochemicalReaction655" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis174">
 <bp:controlled rdf:resource="#BiochemicalReaction654" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis177">
 <bp:controlled rdf:resource="#BiochemicalReaction657" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis176">
 <bp:controlled rdf:resource="#BiochemicalReaction656" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis171">
 <bp:controlled rdf:resource="#BiochemicalReaction649" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis170">
 <bp:controlled rdf:resource="#BiochemicalReaction648" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis173">
 <bp:controlled rdf:resource="#BiochemicalReaction652" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis172">
 <bp:controlled rdf:resource="#BiochemicalReaction650" />
</bp:Catalysis>

<bp:Evidence rdf:ID="Evidence1070">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1071">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis179">
 <bp:controlled rdf:resource="#BiochemicalReaction661" />
</bp:Catalysis>

<bp:Evidence rdf:ID="Evidence1072">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis178">
 <bp:controlled rdf:resource="#BiochemicalReaction659" />
</bp:Catalysis>

<bp:Evidence rdf:ID="Evidence1073">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1074">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1075">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1076">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1077">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1078">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1079">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis180">
 <bp:controlled rdf:resource="#BiochemicalReaction662" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis186">
 <bp:controlled rdf:resource="#BiochemicalReaction693" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis185">
 <bp:controlled rdf:resource="#BiochemicalReaction685" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis188">
 <bp:controlled rdf:resource="#BiochemicalReaction694" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis187">
 <bp:controlled rdf:resource="#BiochemicalReaction693" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis182">
 <bp:controlled rdf:resource="#BiochemicalReaction667" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis181">
 <bp:controlled rdf:resource="#BiochemicalReaction663" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis184">
 <bp:controlled rdf:resource="#BiochemicalReaction674" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis183">
 <bp:controlled rdf:resource="#BiochemicalReaction668" />
</bp:Catalysis>

<bp:Evidence rdf:ID="Evidence2390">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1060">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2391">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1061">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2392">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis189">
 <bp:controlled rdf:resource="#BiochemicalReaction695" />
</bp:Catalysis>

<bp:Evidence rdf:ID="Evidence1062">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2393">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1063">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2394">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1064">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2395">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1065">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2396">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1066">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2397">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1067">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2398">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1068">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2399">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1069">
</bp:Evidence>

<bp:Catalysis rdf:ID="Catalysis191">
 <bp:controlled rdf:resource="#BiochemicalReaction708" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis190">
 <bp:controlled rdf:resource="#BiochemicalReaction698" />
</bp:Catalysis>

<bp:Pathway rdf:ID="Pathway96">
 <bp:pathwayOrder rdf:resource="#PathwayStep460" />
 <bp:pathwayOrder rdf:resource="#PathwayStep461" />
 <bp:pathwayOrder rdf:resource="#PathwayStep457" />
 <bp:pathwayOrder rdf:resource="#PathwayStep458" />
 <bp:pathwayOrder rdf:resource="#PathwayStep459" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction354" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction352" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction353" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction350" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction351" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence445" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Vpu mediated degradation of CD4</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The HIV-1 Vpu protein promotes the degradation of the CD4 receptor by  recruiting an SCF like ubiquitination complex that promotes CD4 degradation.  Vpu links beta-TrCP to CD4 at the ER membrane through interactions with beta-TrCP and  the cytoplasmic tail of CD4. The SKP1 component of the SCF complex is then recruited to the Vpu:beta-TrCP:CD4 promoting ubiquitination and subsequent proteasome-mediated degradation of CD4 (reviewed in Li et al., 2005). Vpu has also been shown to also increases progeny virus secretion from infected cells. Although the precise role of Vpu in this process is not yet known, it  may affect  ion conductive membrane pore formation and/or interference with TASK-1, an acid-sensitive K+ channel  that inhibits virion release in some cells (see references in Li et al., 2005).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Catalysis rdf:ID="Catalysis197">
 <bp:controlled rdf:resource="#BiochemicalReaction723" />
</bp:Catalysis>

<bp:Pathway rdf:ID="Pathway97">
 <bp:pathwayOrder rdf:resource="#PathwayStep463" />
 <bp:pathwayOrder rdf:resource="#PathwayStep464" />
 <bp:pathwayOrder rdf:resource="#PathwayStep465" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction356" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction357" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction355" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence451" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">APOBEC3G mediated resistance to HIV-1 infection</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Representatives of the apolipoprotein B mRNA editing enzyme catalytic polypeptide 3 (APOBEC3) family provide innate resistance to exogeneous and endogenous retroviruses (see Cullen 2006 for a recent review).  Humans and other primates encode a cluster of seven different cytidine deaminases with APOBEC3G, APOBEC3F and APOBEC3B having some anti HIV-1 activity. Our understanding is most complete for APOBEC3G which has been described first and the reactions described herein will focus on this representative enzyme.  APOBEC3G is a cytoplasmic protein which strongly restricts replication of Vif deficient HIV-1 (Sheehy 2002). It is expressed in cell populations that are susceptible to HIV infection (e.g., T-lymphocytes and macrophages).  In the producer cell, APOBEC3G is incorporated into budding HIV-1 particles through an interaction with HIV-1 gag nucleocapsid (NC) protein in a RNA-dependent fashion.   Within the newly infected cell (= target cell), virus-associated APOBEC3G regulates the infectivity of HIV-1 by deaminating cytidine to uracil in the minus-strand viral DNA intermediate during reverse transcription. Deamination results in the induction of G-to-A hypermutations in the plus-strand viral DNA which subsequently can either be integrated as a non-functional provirus or degraded before integration.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Catalysis rdf:ID="Catalysis196">
 <bp:controlled rdf:resource="#BiochemicalReaction722" />
</bp:Catalysis>

<bp:Pathway rdf:ID="Pathway98">
 <bp:pathwayOrder rdf:resource="#PathwayStep470" />
 <bp:pathwayOrder rdf:resource="#PathwayStep467" />
 <bp:pathwayComponent rdf:resource="#Pathway99" />
 <bp:pathwayComponent rdf:resource="#Pathway100" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence455" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Interactions of Vpr with host cellular proteins</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Vpr has been implicated in multiple processes during HIV-1 replication, including nuclear import of the pre-integration complex (PIC)(Heinzinger et al., 1994), apoptosis (Stewart et al., 1997) and induction of cell cycle G2/M arrest (He et al., 1995; Re et al., 1995; Zhao et al., 1996).   Interactions between Vpr and host nucleoporins (importin) appear to facilitate the nuclear import of the PIC (Popov et al., 1998; Vodicka et al., 1998) while interactions between Vpr the adenine nucleotide transporter (ANT) protein at the inner mitochondrial membrane may contribute to release of apoptosis factors by promoting permeabilization of the mitochondrial outer membrane (Jacotot et al., 2000).    Vpr induces cell cycle G2/M arrest by promoting hyperphosphorylation of Cdk1/Cdc2 (Re et al., 1995; Zhao et al., 1996). However, it is unclear which protein(s) Vpr interacts with to cause this effect. For recent reviews, see, (Li et al., 2005; Zhao, Bukrinsky, and Elder, 2005). Progression of cells from G2 phase of the cell cycle to mitosis is a tightly regulated cellular process that requires activation of the Cdk1/Cdc2 kinase, which determines onset of mitosis in all eukaryotic cells. The activity of Cdk1/Cdc2 is regulated in part by the phosphorylation status of tyrosine 15 (Tyr15) on Cdk1/Cdc2, which is phosphorylated by Wee1 kinase during late G2 and is rapidly dephosphorylated by the Cdc25 tyrosine phosphatase to trigger entry into mitosis. These Cdk1/Cdc2 regulators are the downstream targets of two well-characterized G2/M checkpoint pathways which prevent cells from entering mitosis when cellular DNA is damaged or when DNA replication is inhibited. It is clear that Vpr induces cell cycle G2/M arrest by promoting Tyr15 phosphorylation of Cdk1/Cdc2 both in human and fission yeast cells (Elder et al., 2000;  Re et al., 1995; Zhao et al., 1996), which modulates host cell cycle machinery to benefit viral survival or replication. Although some aspects of Vpr-induced G2/M arrest resembles induction of host cellular checkpoints, increasing evidence suggests that Vpr induces cell cycle G2 arrest through a mechanism that is to some extent different from the classic G2/M checkpoints. One the unique features distinguishing Vpr-induced G2 arrest from the classic checkpoints is the role of phosphatase 2A (PP2A) in Vpr-induced G2 arrest (Elder, Benko, and Zhao, 2002; Elder et al., 2001; Masuda et al., 2000).  Interestingly, PP2A is targeted by a number of other viral proteins including SV40 small T antigen, polyomavirus T antigen, HTLV Tax and adenovirus E4orf4. Thus an in-depth understanding of the molecular mechanisms underlying Vpr-induced G2 arrest will provide additional insights into the basic biology of cell cycle G2/M regulation and into the biological significance of this effect during host-pathogen interactions.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Catalysis rdf:ID="Catalysis199">
 <bp:controlled rdf:resource="#BiochemicalReaction723" />
</bp:Catalysis>

<bp:Pathway rdf:ID="Pathway99">
 <bp:pathwayOrder rdf:resource="#PathwayStep468" />
 <bp:pathwayOrder rdf:resource="#PathwayStep469" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction358" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction359" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence456" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Vpr-mediated nuclear import of PICs</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Vpr appears to function in anchoring  the PIC to the nuclear envelope. This anchoring likely involves interactions between Vpr and host nucleoporins.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Catalysis rdf:ID="Catalysis198">
 <bp:controlled rdf:resource="#BiochemicalReaction723" />
</bp:Catalysis>

<bp:Pathway rdf:ID="Pathway92">
 <bp:pathwayOrder rdf:resource="#PathwayStep431" />
 <bp:pathwayOrder rdf:resource="#PathwayStep434" />
 <bp:pathwayOrder rdf:resource="#PathwayStep435" />
 <bp:pathwayOrder rdf:resource="#PathwayStep432" />
 <bp:pathwayOrder rdf:resource="#PathwayStep433" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction332" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction333" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction330" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction331" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction329" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence420" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Nef and signal transduction</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Nef interferes with cellular signal transduction pathways in a number of ways. Nef is associated with lipid rafts through its amino-terminal myristoylation and a proline-rich SH3-binding domain. These cholesterol-rich membrane microdomains appear to concentrate potent signaling mediators. Nef was found to complex with and activate serine/threonine protein kinase PAK-2, which may contribute to activation of infected cells. In vitro, HIV-infected T cells produce enhanced levels of interleukin-2 during activation. When expressed in macrophages, Nef intersects the CD40L signaling pathway inducing secretion of chemokines and other factors that attract resting T cells and promote their infection by HIV.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Catalysis rdf:ID="Catalysis193">
 <bp:controlled rdf:resource="#BiochemicalReaction719" />
</bp:Catalysis>

<bp:Pathway rdf:ID="Pathway93">
 <bp:pathwayOrder rdf:resource="#PathwayStep437" />
 <bp:pathwayOrder rdf:resource="#PathwayStep448" />
 <bp:pathwayComponent rdf:resource="#Pathway94" />
 <bp:pathwayComponent rdf:resource="#Pathway95" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence426" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Interactions of Rev with host cellular proteins</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">In order to facilitate the transport of incompletely spliced HIV-1 transcripts, Rev shuttles between the cytoplasm and nucleus using host cell transport mechanisms (reviewed in Li et al. 2005).  Nuclear import appears to be achieved by the association of Rev with importin-beta and B23 and docking at the nuclear pore through interactions between importin-beta and nucleoporins. The dissociation of Rev with the import machinery and the subsequent export of Rev-associated HIV-1 mRNA complex requires Ran-GTP. Ran GTP associates with importin-beta, displacing its cargo. Crm1 associates with the Rev:RNA complex and Ran:GTP and is believed to interact with nucleoporins facilitating docking of the RRE-Rev-CRM1-RanGTP complex to the nuclear pore and the translocation of the complex across the nuclear pore complex. In the cytoplasm, RanBP1 associates with Ran-GTP causing the Crm1-Rev-Ran-GTP complex to disassemble. The Ran GAP protein promotes the hydrolysis of  RanGTP to Ran GDP. The activities of Ran GAP in the cytoplasm and  Ran-GEF, which converts RAN-GDP to Ran-GTP in the nucleus, produce a gradient of Ran-GTP/GDP  required for this shuttling of Rev and other cellular transport proteins.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Catalysis rdf:ID="Catalysis192">
 <bp:controlled rdf:resource="#BiochemicalReaction712" />
</bp:Catalysis>

<bp:Pathway rdf:ID="Pathway94">
 <bp:pathwayOrder rdf:resource="#PathwayStep441" />
 <bp:pathwayOrder rdf:resource="#PathwayStep442" />
 <bp:pathwayOrder rdf:resource="#PathwayStep440" />
 <bp:pathwayOrder rdf:resource="#PathwayStep445" />
 <bp:pathwayOrder rdf:resource="#PathwayStep446" />
 <bp:pathwayOrder rdf:resource="#PathwayStep443" />
 <bp:pathwayOrder rdf:resource="#PathwayStep444" />
 <bp:pathwayOrder rdf:resource="#PathwayStep438" />
 <bp:pathwayOrder rdf:resource="#PathwayStep439" />
 <bp:pathwayOrder rdf:resource="#PathwayStep447" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction336" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction337" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction334" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction335" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction343" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction341" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction342" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction340" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction338" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction339" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence427" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Rev-mediated nuclear export of HIV RNA</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The  HIV-1 genome contains 9 genes encoded by a single transcript. In order for the virus to replicate, unspliced, singly-spliced and fully spliced viral mRNA must be exported from the nucleus. The HIV-1 mRNA splice sites are inefficient resulting it the accumulation of a pool of incompletely spliced RNAs (Staffa and Cochrane, 1994).  In the early stages of the viral life cycle, or in the absence of the viral Rev protein, completely spliced viral mRNA which encode the regulatory proteins Tat, Nef and Rev are exported from the nucleus while the incompletely spliced structural protein encoding transcripts are held within the nucleus by cellular proteins that normally function in preventing the nuclear export of cellular pre-mRNA.  Export of both unspliced and partially spliced mRNA is mediated by the viral protein Rev which is recruited, along with cellular cofactors, to the Rev Response Element (RRE) within the HIV-1 mRNA sequence (Malim et al., 1990; Fischer et al., 1994). The cellular hRIP protein is essential for correct Rev-mediated export of viral RNAs to the cytoplasm (Sanchez-Velar et al., 2004; Yu et al., 2005).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Catalysis rdf:ID="Catalysis195">
 <bp:controlled rdf:resource="#BiochemicalReaction721" />
</bp:Catalysis>

<bp:Pathway rdf:ID="Pathway95">
 <bp:pathwayOrder rdf:resource="#PathwayStep452" />
 <bp:pathwayOrder rdf:resource="#PathwayStep453" />
 <bp:pathwayOrder rdf:resource="#PathwayStep450" />
 <bp:pathwayOrder rdf:resource="#PathwayStep451" />
 <bp:pathwayOrder rdf:resource="#PathwayStep454" />
 <bp:pathwayOrder rdf:resource="#PathwayStep455" />
 <bp:pathwayOrder rdf:resource="#PathwayStep449" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction347" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction348" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction345" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction335" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction346" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction344" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction349" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence438" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Nuclear import of Rev protein</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Nuclear import of Rev involves the cellular proteins including importin-beta and  B23 and is mediated by an arginine-rich nuclear localization signal (NLS) within the RNA binding domain of the Rev protein. The NLS of Rev associates with importin- beta as well as  B23  which has been shown to function in the nuclear import of ribosomal proteins. The Rev-importin beta-B23 complex associates with the nuclear pore through interactions between  importin beta and nucleoporin. Upon entry into the nucleus, Ran-GTP associates with  importin beta resulting in in the disassembly of the  importin beta-Rev-B23 complex and the release of Rev cargo.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Catalysis rdf:ID="Catalysis194">
 <bp:controlled rdf:resource="#BiochemicalReaction719" />
</bp:Catalysis>

<bp:Evidence rdf:ID="Evidence1090">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1201">
 <bp:evidence rdf:resource="#Evidence1465" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SMAD4 MH2 Domain Mutants do not bind phosphorylated SMAD2 and SMAD3</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence1091">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1202">
 <bp:evidence rdf:resource="#Evidence1468" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">An anchoring protein ZFYVE9 (SARA) does not recruit SMAD2/3 to TGFB1:TGFBR2:p-TGFBR1 KD Mutants</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence1092">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1093">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1200">
 <bp:evidence rdf:resource="#Evidence1462" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated TGFBR1 cannot phosphorylate SMAD2 and SMAD3 Phosphorylation Motif Mutants</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence1094">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1205">
 <bp:evidence rdf:resource="#Evidence1475" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Dimeric TGFB1 does not bind TGFBR2 MSI frameshift mutants</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence1095">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1206">
 <bp:evidence rdf:resource="#Evidence1478" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">HHAT G287V doesn&apos;t palmitoylate Hh-Np</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence1096">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1203">
 <bp:evidence rdf:resource="#Evidence1470" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TGFBR2 does not recruit TGFBR1 LBD Mutants</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence1097">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1204">
 <bp:evidence rdf:resource="#Evidence1473" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">TGFBR2 KD mutants do not phosphorylate TGFBR1</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence1098">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1209">
 <bp:evidence rdf:resource="#Evidence1482" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Hh processing variants are recruited to SEL1:SYVN at the ER membrane</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence1099">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1207">
 <bp:evidence rdf:resource="#Evidence1480" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Hh processing variants are translocated to the cytosol in a VCP-dependent manner</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1208">
 <bp:evidence rdf:resource="#Evidence1481" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">HPE SHH variants don&apos;t undergo autoproteolytic cleavage</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1220">
 <bp:evidence rdf:resource="#Evidence1497" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Phosphorylation of RAF1 mutants</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1212">
 <bp:evidence rdf:resource="#Evidence1485" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">processing defective Hh variants are degraded by the proteasome</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence1080">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1213">
 <bp:evidence rdf:resource="#Evidence1488" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MAPKs are phosphorylated downstream of BRAF and RAF fusion dimers</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence1081">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1210">
 <bp:evidence rdf:resource="#Evidence1483" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Hh processing variants are ubiquitinated</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence1082">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1211">
 <bp:evidence rdf:resource="#Evidence1484" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Hh processing variants bind lectins</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence1083">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1216">
 <bp:evidence rdf:resource="#Evidence1491" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Dissociation of BRAF/RAF fusion complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence1084">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1217">
 <bp:evidence rdf:resource="#Evidence1492" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">BRAF and RAF fusion mutant dimers are phosphorylated</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence1085">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1214">
 <bp:evidence rdf:resource="#Evidence1489" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">p-BRAF and RAF fusion dimers bind MAP2Ks and MAPKs</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence1086">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1215">
 <bp:evidence rdf:resource="#Evidence1490" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">p-BRAF and RAF fusion dimers phosphorylate MAP2Ks</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence1087">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1088">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1089">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1218">
 <bp:evidence rdf:resource="#Evidence1494" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Loss-of-function NF1 variants don&apos;t stimulate RAS GTPase activity</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1219">
 <bp:evidence rdf:resource="#Evidence1496" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">CR2 RAF1 mutants don&apos;t bind YWHAB</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence1029">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway78">
 <bp:pathwayOrder rdf:resource="#PathwayStep362" />
 <bp:pathwayOrder rdf:resource="#PathwayStep363" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction275" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction274" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence351" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NEP/NS2 Interacts with the Cellular Export Machinery</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The viral RNP complex is exported from the nucleus via the host cell CRM1 export pathway (Fukuda, 1997; Neumann, 2000; reviewed in Buolo, 2006). The vRNP complex does not interact directly with CRM1 to form an export complex. Rather, an additional viral protein, nuclear export protein (NEP/NS2), acts as an adaptor, binding the viral matrix M1 protein and CRM1, thus linking the viral RNP with CRM1 (Martin, 1991; O&apos;Neill, 1998; Neumann, 2000; Akarsu, 2003).  The CRM1/exportin-1 complex recruits additional host cell proteins, and traverses the nuclear pore into the cytosol.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway79">
 <bp:pathwayOrder rdf:resource="#PathwayStep365" />
 <bp:pathwayOrder rdf:resource="#PathwayStep366" />
 <bp:pathwayOrder rdf:resource="#PathwayStep367" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction277" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction278" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction276" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence354" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Viral RNP Complexes in the Host Cell Nucleus</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Viral RNP is assembled in the host cell nucleus through the interaction of full-length negative strand viral RNA (vRNA) and the viral nucleocapsid (NP) and matrix (M1) proteins. Studies of interactions of the purified components in vitro and of tissue culture model systems expressing various combinations of the components have established roles for both NP and M1 proteins in the assembly of a complex that has the physical properties of vRNP purified from virions and that can be exported from the host cell nucleus (Whittaker, 1996; Huang, 2001; Baudin, 2001).  Viral RNP complexes have been found in the nucleoplasm, and also in the nuclear periphery, associated with the nuclear matrix or chromatin, particularly for vRNA-containing complexes and M1 protein (Elton, 2005; Garcia-Robles, 2005; Takizawa et al., 2006).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway74">
 <bp:pathwayOrder rdf:resource="#PathwayStep350" />
 <bp:pathwayOrder rdf:resource="#PathwayStep353" />
 <bp:pathwayOrder rdf:resource="#PathwayStep351" />
 <bp:pathwayOrder rdf:resource="#PathwayStep352" />
 <bp:pathwayOrder rdf:resource="#PathwayStep348" />
 <bp:pathwayOrder rdf:resource="#PathwayStep349" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction268" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction269" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction266" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction267" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction264" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction265" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence337" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Viral Messenger RNA Synthesis</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Like the mRNAs of the host cell, influenza virus mRNAs are capped and polyadenylated (reviewed in Neumann, 2004). The methylated caps, however, are scavenged from host cell mRNAs and serve as primers for viral RNA synthesis, a process termed &apos;cap-snatching&apos; (Krug, 1981; Hagen, 1994). The PB2 polymerase protein binds the cap, activating endonucleolytic cleavage of the host mRNA by PB1.  The 3&apos; poly-A tracts on viral messages are generated by polymerase stuttering on poly-U tracts near the 5&apos; end of the template vRNA (Robertson, 1981; Zheng, 1999). The second process allows polyadenylation of viral mRNAs when the host cell polyadenylation process has been inhibited (Engelhardt, 2006; Amorim, 2006).  Notably, early transcripts (including NP and NS1) accumulate in the cytoplasm before late transcripts (M1, HA, and NS2), and in varying abundances, suggesting additional control mechanisms regulating viral gene expression (Shapiro, 1987; Hatada, 1989; Amorim, 2006).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway75">
 <bp:pathwayOrder rdf:resource="#PathwayStep355" />
 <bp:pathwayOrder rdf:resource="#PathwayStep356" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction271" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction270" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence344" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Viral mRNA Translation</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Spliced and unspliced viral mRNA in the cytoplasm are translated by host cell ribosomal translation machinery (reviewed in Kash, 2006).  At least ten viral proteins are synthesized:  HA, NA, PB1, PB2, PA, NP, NS1, NEP/NS2, M1, and M2.  Viral mRNA translation is believed to be enhanced by conserved 5&apos;UTR sequences that interact with the ribosomal machinery and at least one cellular RNA-binding protein, G-rich sequence factor 1 (GRSF-1), has been found to specifically interact with the viral 5&apos; UTRs.  (Park, 1995; Park, 1999).  The viral NS1 protein and the cellular protein P58(IPK) enhance viral translation indirectly by preventing the activation of the translational inhibitor PKR (Salvatore, 2002;  Goodman, 2006).  The viral NS1 protein has also been proposed to specifically enhance translation through interaction with host poly(A)-binding protein 1 (PABP1) (Burgui, 2003).  Simultaneously, host cell protein synthesis is downregulated in influenza virus infection through still uncharacterized mechanisms (Katze, 1986; Garfinkel, 1992; Kash, 2006).  In most human influenza A strains (such as PR8), the PB1 mRNA segment is capable of producing a second protein, PB1-F2, from a short +1 open reading frame initiating downstream of the PB1 ORF initiation codon (Chen, 2001).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway76">
 <bp:pathwayOrder rdf:resource="#PathwayStep359" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction273" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence348" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Entry of Influenza Virion into Host Cell via Endocytosis</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Virus particles bound to the cell surface can be internalized by four mechanisms. Most internalization appears to be mediated by clathrin-coated pits, but internalization via caveolae, macropinocytosis, and by non-clathrin, non-caveolae pathways has also been described for influenza viruses.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway77">
 <bp:pathwayOrder rdf:resource="#PathwayStep361" />
 <bp:pathwayOrder rdf:resource="#PathwayStep364" />
 <bp:pathwayComponent rdf:resource="#Pathway78" />
 <bp:pathwayComponent rdf:resource="#Pathway79" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence350" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Export of Viral Ribonucleoproteins from Nucleus</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Influenza genomic RNA (vRNA), synthesized in the nucleus of the infected host cell, is packaged into ribonucleoprotein (RNP) complexes containing viral polymerase proteins and NP (nucleocapsid).  NP trimers bind the sugar phosphate backbone of the vRNA. As influenza viral RNP complexes are too large for passive diffusion out of the nucleus, utilization of the cellular nuclear export machinery is achieved by viral adaptor proteins.  Matrix protein (M1) is critical for export of the complex from the nucleus, mediating the interaction of the RNP complex with the viral NEP/NS2 protein, which in turn interacts with host cell CRM1/exportin-1 nuclear export protein (Martin, 1991; O&apos;Neill, 1998; Neumann et al., 2000; Elton, 2001; Cros, 2003; Ye, 2006; reviewed in Boulo, 2006).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway70">
 <bp:pathwayOrder rdf:resource="#PathwayStep354" />
 <bp:pathwayOrder rdf:resource="#PathwayStep341" />
 <bp:pathwayOrder rdf:resource="#PathwayStep347" />
 <bp:pathwayOrder rdf:resource="#PathwayStep344" />
 <bp:pathwayOrder rdf:resource="#PathwayStep338" />
 <bp:pathwayComponent rdf:resource="#Pathway74" />
 <bp:pathwayComponent rdf:resource="#Pathway75" />
 <bp:pathwayComponent rdf:resource="#Pathway71" />
 <bp:pathwayComponent rdf:resource="#Pathway72" />
 <bp:pathwayComponent rdf:resource="#Pathway73" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence327" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Influenza Viral RNA Transcription and Replication</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">In the host cell nucleus, the viral negative-strand RNA (vRNA) serves as a template for the synthesis both of capped, polyadenylated viral messenger RNA and of full-length positive-strand RNA or complementary RNA (cRNA). The cRNA is associated with the same viral proteins as the vRNA. It serves as a template for the synthesis of new vRNA molecules, which in turn serve as a template for mRNA particularly early in infection, and cRNA. Viral RNA polymerase subunits (PB1, PB2, and PA) and nucleoprotein (NP) enter the host cell nucleus and catalyze all three of these reactions. During initial infection, these proteins enter the nucleus as part of the viral RNP complex.  After the first round of viral mRNA synthesis (primary transcription) and translation, newly synthesized viral polymerase proteins and NP localize to the nucleus to catalyze further mRNA transcription and vRNA/cRNA replication.  Late in the infection process, the synthesis of vRNA and nuclear export of newly synthesized vRNP (vRNA complexed with NP and viral polymerase) is increased relative to transcription (Krug, 1981; Braam, 1983; Kawakami, 1983; Huang, 1990; Cros, 2003; Fodor, 2004; Deng, 2005; Amorim, 2006; reviewed in Neumann, 2004; Engelhardt, 2006;  Buolo, 2006).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1230">
 <bp:evidence rdf:resource="#Evidence1508" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">RAS:GTP:p-RAF complexes paradoxically bind MAP2Ks and MAPKs</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway71">
 <bp:pathwayOrder rdf:resource="#PathwayStep340" />
 <bp:pathwayOrder rdf:resource="#PathwayStep339" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction259" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction258" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence328" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">vRNA Synthesis</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The synthesis of full-length negative strand viral RNA from a cRNA template is believed to follow the same principles as the synthesis of cRNA from a vRNA template.  The cRNA, complexed with viral nucleocapsid (NP) protein, is used as template by the trimeric viral polymerase (Pritlove, 1995; Vreede, 2004; Crow, 2004), and newly synthesized vRNA molecules are immediately packaged with NP molecules to form ribonucleoprotein complexes (Vreede, 2004).  There is some evidence that the production of vRNA-containing vRNP occurs in the nuclear matrix as well as the nucleoplasm (Takizawa, 2006).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1231">
 <bp:evidence rdf:resource="#Evidence1509" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">RAF is paradoxically phosphorylated downstream of kinase-inactive RAF</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway72">
 <bp:pathwayOrder rdf:resource="#PathwayStep342" />
 <bp:pathwayOrder rdf:resource="#PathwayStep343" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction260" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction261" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence331" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">vRNP Assembly</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">For each of eight gene segments, a viral ribonucleoprotein (vRNP), containing a viral negative-sense RNA (vRNA) segment complexed with nucleoprotein (NP) and the trimeric influenza polymerase (PB1, PB2, and PA), is assembled in the nucleus (Braam, 1983; Jones, 1986; Cros, 2003; reviewed in Buolo, 2006).  The vRNP functions in three modes (reviewed in Mikulasova, 2000; Neumann, 2004):  (1) transcription, which synthesizes viral messenger RNA from the vRNA template using as primers 5&apos; ends of cellular mRNAs containing the cap;  (2) replication, which produces positive-sense complementary RNA (cRNA) and subsequently vRNA, both complexed with NP and the trimeric polymerase;  or (3), the vRNP is exported from the nucleus into the cytoplasm and is incorporated into assembling virions at the plasma membrane.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway73">
 <bp:pathwayOrder rdf:resource="#PathwayStep346" />
 <bp:pathwayOrder rdf:resource="#PathwayStep345" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction262" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction263" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence334" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">cRNA Synthesis</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Synthesis of full length complementary viral RNA (cRNA) requires that vRNA transcription initiates without the help of a host cell methyl RNA cap as a primer (Crow, 2004; Vreede, 2004; Deng, 2006), and that it proceeds to the 5&apos; end of the vRNA template without stuttering on the sub-terminal poly-U sequence.  Free viral NP protein appears to play a central role in enabling both of these features of cRNA synthesis, although the molecular details of its role remain unclear (Shapiro, 1988; Medcalf, 1999; Mullin, 2004).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1223">
 <bp:evidence rdf:resource="#Evidence1500" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">RAF1 mutant complexes phosphorylate MAP2K dimer</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1224">
 <bp:evidence rdf:resource="#Evidence1501" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Dissociation of RAS:RAF1 mutant complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1221">
 <bp:evidence rdf:resource="#Evidence1498" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">RAF1 mutants show enhanced heterodimerization with BRAF</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway80">
 <bp:pathwayOrder rdf:resource="#PathwayStep369" />
 <bp:pathwayOrder rdf:resource="#PathwayStep389" />
 <bp:pathwayComponent rdf:resource="#Pathway81" />
 <bp:pathwayComponent rdf:resource="#Pathway82" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence358" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">HCMV Infection</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Herpesviruses have a unique four-layered structure: a core containing the large, double-stranded DNA genome is enclosed by an icosapentahedral capsid which is composed of capsomers. The capsid is surrounded by an amorphous protein coat called the tegument. It is encased in a glycoprotein-bearing lipid bilayer envelope.  Herpesviruses are divided into three groups: alpha-herpesviruses, beta-herpesviruses, and gamma-herpesviruses. The beta herpesviruses have a restricted host range. Their reproductive life cycle is long (days), with infection progressing slowly in cell culture systems. These viruses cause their host cells to enlarge, as exemplified by a human cytomegalovirus (HCMV) infection. These viruses can establish latent infection in secretory glands, cells of the reticuloendothelial system, and the kidneys.  Human Cytomegalovirus, or HCMV, is a common virus that infects people of all ages. In the United States, nearly one in three children are already infected with HCMV by age 5 years. Over half of adults by age 40 have been infected with HCMV. Once HCMV is in a person&#8217;s body, it stays there for life and can reactivate.  Cytomegalovirus causes three clinical syndromes:  (1) Congenital cytomegalovirus infection (when symptomatic) causes hepatosplenomegaly, retinitis, rash, and central nervous system involvement.  (2) In about 10 per cent of older children and adults, primary cytomegalovirus infection causes a mononucleosis syndrome with fever, malaise, atypical lymphocytosis, and pharyngitis.  (3) Immunocompromised hosts (transplant recipients and human immunodeficiency virus [HIV]-infected individuals) may develop life-threatening disseminated disease involving the lungs, gastrointestinal tract, liver, retina, and central nervous system.  Experimentally HCMV can be propagated in multiple cell lines. When propagated in human fibroblasts, HCMV clinical isolates acquire mutations in a manner that suggests a process of adaptation. Two strains of HCMV AD169 (grown from cultures of adenoid tissue taken from a 7-year-old girl) and Towne (developed as an attenuated vaccine by passaging 125 times in vitro) were initially used as the primary clinical strains. As only 26 % of HCMV canonical genes (45/171) are essential for viral replication in vitro it became important that a model strain be developed.  The Merlin BAC was derived for this use. Produced using a bacterial artificial chromosome (BAC) cloning system (to avoid adaptation/degradation of the genome with each passage) the Merlin strain contains a complete HCMV genome that is thought to accurately to represent the original clinical agent from which it was derived. It is also a reproducible source of clonal virus (via transfection) and is capable of reconstituting phenotypically wild-type virus.  The lifecycle represented here uses the Merlin strain where possible.Infectious Human Cytomegalovirus (HCMV) particles enter the cell through interaction with cellular receptors. Once in the cytoplasm capsid and tegument proteins are delivered to the cytosol. The capsid travels to the nucleus, where the genome is delivered and circularized. Tegument proteins regulate host cell responses and initiate the expression of viral I immediate early genes. This is followed by delayed early genes, which initiate viral genome replication, then late genes. Late gene expression initiates capsid assembly in the nucleus, followed by nuclear egress to the cytosol. Capsids associate with tegument proteins in the cytosol and are trafficked to the viral assembly complex that contains components from the endoplasmic reticulum, Golgi apparatus, and endosomal machinery. The capsids acquire additional tegument proteins and a viral envelope by budding into intracellular vesicles. These vesicles fuse with the plasma membrane to release enveloped infectious particles along with non-infectious dense bodies.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1222">
 <bp:evidence rdf:resource="#Evidence1499" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MAP2Ks phosphorylate MAPKs downstream of RAF1 mutants</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1227">
 <bp:evidence rdf:resource="#Evidence1505" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Inactive BRAF mutants:mutant RAS:GTP bind RAF1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1228">
 <bp:evidence rdf:resource="#Evidence1506" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Dissociation of paradoxically activated RAS:BRAF complexes</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence2360">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1030">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1225">
 <bp:evidence rdf:resource="#Evidence1502" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MAP2Ks and MAPKs bind to the activated mutant RAF1 complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence2361">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1031">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1226">
 <bp:evidence rdf:resource="#Evidence1504" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated MAP2Ks phosphorylate MAPKs downstream of inactive BRAF mutants</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence2362">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1032">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2363">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1033">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2364">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1034">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1229">
 <bp:evidence rdf:resource="#Evidence1507" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">RAS:GTP:inactive p-RAF complexes phosphorylate MAP2Ks</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence2365">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1035">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2366">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1036">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2367">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1037">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2368">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1038">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2369">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1039">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1018">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2349">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1019">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway89">
 <bp:pathwayOrder rdf:resource="#PathwayStep418" />
 <bp:pathwayOrder rdf:resource="#PathwayStep419" />
 <bp:pathwayOrder rdf:resource="#PathwayStep417" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction320" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction318" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction319" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence406" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Nef mediated downregulation of CD28 cell surface expression</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Down-regulation of CD28 receptors involves a dileucine-based motif in the second disordered loop of Nef, which connects Nef to adaptor protein (AP) complex, which is a part of cellular endocytosis machinery. Nef induces accelerated endocytosis of CD28 via clathrin-coated pits followed by lysosomal degradation.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway85">
 <bp:pathwayOrder rdf:resource="#PathwayStep407" />
 <bp:pathwayOrder rdf:resource="#PathwayStep408" />
 <bp:pathwayOrder rdf:resource="#PathwayStep405" />
 <bp:pathwayOrder rdf:resource="#PathwayStep406" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction312" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction313" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction310" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction311" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence394" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Vif-mediated degradation of APOBEC3G</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The HIV-1 accessory protein Vif (Viral infectivity factor) is required for the efficient infection of primary cell populations (e.g., lymphocytes and macrophages) and &apos;non-permissive&apos; cell lines. Vif neutralises the host DNA editing enzyme, APOBEC3G, in the producer cell. Indeed, in the absence of a functional Vif, APOBEC3G is selectively incorporated into the budding virions and in the next cycle of infection leads to the deamination of deoxycytidines (dC) within the minus-strand cDNA during reverse transcription (Sheehy et al 2003; Li et al., 2005 ; Stopak et al. 2003). Deamination changes cytidine to uracil and thus results in G to A transitions and stop codons in the provirus. The aberrant cDNAs produced in the infected cell can either be integrated in form of non-functional proviruses or degraded.  Vif  counteracts the antiviral activity of APOBEC3G by associating directly with it and promoting its polyubiquitination and degradation by the 26S proteasome.  Vif binds APOBEC3G and recruits it into an E3 ubiquitin-enzyme complex composed by the cytoplasmic proteins Cullin5, Rbx, ElonginC and ElonginB (Yu et al., 2003) . Thus, in the presence of Vif, APOBEC3G incorporation into the virion is minimal. </bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway86">
 <bp:pathwayOrder rdf:resource="#PathwayStep430" />
 <bp:pathwayOrder rdf:resource="#PathwayStep410" />
 <bp:pathwayComponent rdf:resource="#Pathway87" />
 <bp:pathwayComponent rdf:resource="#Pathway92" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence399" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The role of Nef in HIV-1 replication and disease pathogenesis</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The HIV-1 Nef protein is a 27-kDa myristoylated protein that is abundantly produced during the early phase of viral replication cycle. It is highly conserved in all primate lentiviruses, suggesting that its function is essential for survival of these pathogens. The protein name &quot;Nef&quot; was derived from early reports of its negative effect on viral replication, thus &apos;negative factor&apos; or Nef. Subsequently it has been demonstrated that Nef plays an important role in several steps of HIV replication. In addition, it appears to be a critical pathogenic factor, as Nef-deficient SIV and HIV are significantly less pathogenic than the wild-type viruses, whereas Nef-transgenic mice show many features characteristic to HIV disease.  The role of Nef in HIV-1 replication and disease pathogenesis is determined by at least four independent activities of this protein. Nef affects the cell surface expression of several cellular proteins, interferes with cellular signal transduction pathways, enhances virion infectivity and viral replication, and regulates cholesterol trafficking in HIV-infected cells.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway87">
 <bp:pathwayOrder rdf:resource="#PathwayStep420" />
 <bp:pathwayOrder rdf:resource="#PathwayStep424" />
 <bp:pathwayOrder rdf:resource="#PathwayStep411" />
 <bp:pathwayOrder rdf:resource="#PathwayStep416" />
 <bp:pathwayComponent rdf:resource="#Pathway90" />
 <bp:pathwayComponent rdf:resource="#Pathway91" />
 <bp:pathwayComponent rdf:resource="#Pathway89" />
 <bp:pathwayComponent rdf:resource="#Pathway88" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence400" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Nef-mediates down modulation of cell surface receptors by recruiting them to clathrin adapters</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The maximal virulence of HIV-1 requires Nef, a virally encoded peripheral membrane protein. Nef binds to the adaptor protein (AP) complexes of coated vesicles, inducing an expansion of the endosomal compartment and altering the surface expression of cellular proteins including CD4 and class I major histocompatibility complex.  Nef affects the cell surface expression of several cellular proteins. It down-regulates CD4, CD8, CD28, and major histocompatibility complex class I and class II proteins, but upregulates the invariant chain of MHC II (CD74). To modulate cell surface receptor expression, Nef utilizes several strategies, linked to distinct regions within the Nef protein. Since all these receptors are essential for proper functions of the immune system, modulation of their surface expression by Nef has profound effects on anti-HIV immune responses. Down-regulation of MHC I protects HIV-infected cells from host CTL response, whereas down-modulation of CD28 and CD4 probably limits the adhesion of a Nef-expressing T cell to the antigen-presenting cell, thus promoting the movement of HIV-infected cells into circulation and the spread of the virus.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway88">
 <bp:pathwayOrder rdf:resource="#PathwayStep412" />
 <bp:pathwayOrder rdf:resource="#PathwayStep413" />
 <bp:pathwayOrder rdf:resource="#PathwayStep414" />
 <bp:pathwayOrder rdf:resource="#PathwayStep415" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction314" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction315" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction316" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction317" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence401" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Nef mediated downregulation of MHC class I complex cell surface expression</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Down-regulation of MHC class I involves Nef-mediated connection in the endosomes between MHC-I&apos;s cytoplasmic tail and the phosphofurin acidic cluster sorting protein-1 (PACS-1)-dependent protein-sorting pathway. Down-regulation of MHC I protects HIV-infected cells from host CTL response.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway81">
 <bp:pathwayOrder rdf:resource="#PathwayStep371" />
 <bp:pathwayOrder rdf:resource="#PathwayStep382" />
 <bp:pathwayOrder rdf:resource="#PathwayStep372" />
 <bp:pathwayOrder rdf:resource="#PathwayStep383" />
 <bp:pathwayOrder rdf:resource="#PathwayStep380" />
 <bp:pathwayOrder rdf:resource="#PathwayStep370" />
 <bp:pathwayOrder rdf:resource="#PathwayStep381" />
 <bp:pathwayOrder rdf:resource="#PathwayStep375" />
 <bp:pathwayOrder rdf:resource="#PathwayStep386" />
 <bp:pathwayOrder rdf:resource="#PathwayStep376" />
 <bp:pathwayOrder rdf:resource="#PathwayStep387" />
 <bp:pathwayOrder rdf:resource="#PathwayStep373" />
 <bp:pathwayOrder rdf:resource="#PathwayStep384" />
 <bp:pathwayOrder rdf:resource="#PathwayStep374" />
 <bp:pathwayOrder rdf:resource="#PathwayStep385" />
 <bp:pathwayOrder rdf:resource="#PathwayStep379" />
 <bp:pathwayOrder rdf:resource="#PathwayStep377" />
 <bp:pathwayOrder rdf:resource="#PathwayStep388" />
 <bp:pathwayOrder rdf:resource="#PathwayStep378" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction279" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction288" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction289" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction286" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction297" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction287" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction284" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction295" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction285" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction296" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction282" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction293" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction283" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction294" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction280" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction291" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction281" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction292" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction290" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence359" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">HCMV Late Events</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Once Human Cytomegalovirus (HCMV) Immediate Early (IE) and Delayed Early (DE) gene products begin to appear the processes driving DNA replication, Late (L) gene expression, and virion assembly begin.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1241">
 <bp:evidence rdf:resource="#Evidence1524" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Moderate kinase activity BRAF mutants:RAS:GTP homo/heterodimerize</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway82">
 <bp:pathwayOrder rdf:resource="#PathwayStep393" />
 <bp:pathwayOrder rdf:resource="#PathwayStep394" />
 <bp:pathwayOrder rdf:resource="#PathwayStep391" />
 <bp:pathwayOrder rdf:resource="#PathwayStep392" />
 <bp:pathwayOrder rdf:resource="#PathwayStep397" />
 <bp:pathwayOrder rdf:resource="#PathwayStep398" />
 <bp:pathwayOrder rdf:resource="#PathwayStep395" />
 <bp:pathwayOrder rdf:resource="#PathwayStep396" />
 <bp:pathwayOrder rdf:resource="#PathwayStep401" />
 <bp:pathwayOrder rdf:resource="#PathwayStep399" />
 <bp:pathwayOrder rdf:resource="#PathwayStep400" />
 <bp:pathwayOrder rdf:resource="#PathwayStep390" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction303" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction304" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction301" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction302" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction299" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction300" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction298" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction309" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction307" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction308" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction305" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction306" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence379" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">HCMV Early Events</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Once in the cytoplasm the capsid and tegument proteins are free to interact with host proteins. The capsid travels to the nucleus, where the genome is delivered and circularized. Tegument proteins regulate host cell responses and initiate the expression of viral I immediate early genes. This is followed by the expression of delayed early genes.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1242">
 <bp:evidence rdf:resource="#Evidence1525" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated MAP2Ks phosphorylate MAPKs downstream of moderate kinase activity BRAF mutants</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway83">
 <bp:pathwayOrder rdf:resource="#PathwayStep476" />
 <bp:pathwayOrder rdf:resource="#PathwayStep403" />
 <bp:pathwayComponent rdf:resource="#Pathway102" />
 <bp:pathwayComponent rdf:resource="#Pathway84" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence392" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">HIV Infection</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The global pandemic of Human Immunodeficiency Virus (HIV) infection has resulted in tens of millions of people   infected by the virus  and millions more affected. UNAIDS estimates around 40 million HIV/AIDS patients worldwide with 75% of them   living in sub-Saharan Africa.  The primary method of HIV infection is by sexual exposure while nonsexual HIV transmission also can occur through transfusion with contaminated blood products, injection drug use, occupational exposure,accidental needlesticks or mother-to-child transmission.  HIV damages the immune system, leaving the infected person vulnerable to a variety of  &quot;opportunistic&quot; infections arising from   host immune impairment (Hare, 2004). HIV-1 and the less common HIV-2 belong to the family of retroviruses. HIV-1 contains a single-stranded RNA genome that is 9 kilobases in length and contains 9 genes that encode 15 different proteins. These proteins are classified as: structural proteins (Gag, Pol, and Env), regulatory proteins (Tat and Rev), and accessory proteins (Vpu, Vpr, Vif, and Nef) (Frankel and Young,1998).  HIV infection  cycle can be divided into two phases: 1. An  Early phase  consisting of early events occuring after HIV infection of  a susceptible target cell  and a  2.  Late phase  comprising the later events in the HIV-infected cell resulting in the assembly of new infectious virions. The section titled  HIV lifecycle  consists of annotations of events in these two phases. The virus has developed various molecular strategies to suppress the antiviral immune responses (innate, cellular and humoral) of the host.   HIV-1 viral auxiliary proteins (Tat, Rev, Nef, Vif, Vpr and Vpu) play important roles in these host-pathogen interactions (Li et al.,2005). The section titled  Host interactions of HIV factors  highlights these complex post-infection processes.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway84">
 <bp:pathwayOrder rdf:resource="#PathwayStep409" />
 <bp:pathwayOrder rdf:resource="#PathwayStep462" />
 <bp:pathwayOrder rdf:resource="#PathwayStep473" />
 <bp:pathwayOrder rdf:resource="#PathwayStep456" />
 <bp:pathwayOrder rdf:resource="#PathwayStep466" />
 <bp:pathwayOrder rdf:resource="#PathwayStep436" />
 <bp:pathwayOrder rdf:resource="#PathwayStep404" />
 <bp:pathwayComponent rdf:resource="#Pathway85" />
 <bp:pathwayComponent rdf:resource="#Pathway96" />
 <bp:pathwayComponent rdf:resource="#Pathway86" />
 <bp:pathwayComponent rdf:resource="#Pathway97" />
 <bp:pathwayComponent rdf:resource="#Pathway98" />
 <bp:pathwayComponent rdf:resource="#Pathway101" />
 <bp:pathwayComponent rdf:resource="#Pathway93" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence393" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Host Interactions of HIV factors</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Like all viruses, HIV-1 must co-opt the host cell macromolecular transport and processing machinery. HIV-1 Vpr and Rev proteins play key roles in this co-optation. Efficient HIV-1 replication likewise requires evasion of APOBEC3G-mediated mutagenesis of reverse transcripts, a process mediated by the viral Vif protein.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1240">
 <bp:evidence rdf:resource="#Evidence1523" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Dissociation of moderate activity BRAF complexes</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1234">
 <bp:evidence rdf:resource="#Evidence1515" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SHOC2 M173I disrupts the SHOC2:MRAS:PP1 complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1235">
 <bp:evidence rdf:resource="#Evidence1517" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MAP2K mutants constitutively phosphorylate MAPKs</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway90">
 <bp:pathwayOrder rdf:resource="#PathwayStep423" />
 <bp:pathwayOrder rdf:resource="#PathwayStep421" />
 <bp:pathwayOrder rdf:resource="#PathwayStep422" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction323" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction321" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction322" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence410" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Nef Mediated CD8 Down-regulation</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Human immunodeficiency virus (HIV) Nef is a membrane-associated protein decreasing surface expression of CD4, CD28, and major histocompatibility complex class I on infected cells. Nef also strongly down-modulates surface expression of the beta-chain of the CD8alphabeta receptor by accelerated endocytosis, while CD8 alpha-chain expression is less affected. Mutational analysis of the cytoplasmic tail of the CD8 beta-chain indicates that an FMK amino acid motif is critical for the Nef-induced endocytosis. Although independent of CD4, endocytosis of the CD8 beta-chain is abrogated by the same mutations in Nef that affect CD4 down-regulation, suggesting common molecular interactions. The ability to down-regulate the human CD8 beta-chain was conserved in HIV-1, HIV-2, and simian immunodeficiency virus SIVmac239 Nef and required an intact AP-2 complex.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1232">
 <bp:evidence rdf:resource="#Evidence1510" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Inactive BRAF mutants bind mutant RAS:GTP</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway91">
 <bp:pathwayOrder rdf:resource="#PathwayStep429" />
 <bp:pathwayOrder rdf:resource="#PathwayStep427" />
 <bp:pathwayOrder rdf:resource="#PathwayStep428" />
 <bp:pathwayOrder rdf:resource="#PathwayStep425" />
 <bp:pathwayOrder rdf:resource="#PathwayStep426" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction325" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction326" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction324" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction327" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction328" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence414" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Nef Mediated CD4 Down-regulation</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The presence of Nef accelerates endocytosis and lysosomal degradation of the transmembrane glycoprotein CD4. CD4 has its own internalization motif, though this motif is normally concealed by CD4 interaction with Lck, a tyrosine kinase. Nef is known to disrupt this interaction and then facilitate a cascade of protein interactions that ultimately result in the degradation of internalized CD4 protein. The final set of protein interactions that direct Nef to the beta-subunit of the COPI coatomers are at this time unclear.  A benefit for the virus from CD4 down-modulation is abolition of interaction between the receptor and the Env protein of the budding virus, which likely increases HIV release from infected cell as well as infectivity of viral particles.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1233">
 <bp:evidence rdf:resource="#Evidence1513" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Mutant MRAS:SHOC2:PPP1CC complexes dephosphorylate inactive RAFs</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1238">
 <bp:evidence rdf:resource="#Evidence1521" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Moderate kinase activity BRAF mutants bind RAS:GTP</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1239">
 <bp:evidence rdf:resource="#Evidence1522" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">RAS:GTP:moderate kinase activity p-RAF complexes bind MAP2Ks and MAPKs</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1236">
 <bp:evidence rdf:resource="#Evidence1519" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">RAS:GTP:moderate kinase activity p-RAF complexes phosphorylate MAP2Ks</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence2350">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1020">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1237">
 <bp:evidence rdf:resource="#Evidence1520" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">RAF is phosphorylated downstream of moderate kinase activity BRAF mutants</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence2351">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence304">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1021">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2352">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence303">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1022">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2353">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence306">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1023">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2354">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence305">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1024">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2355">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence300">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1025">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2356">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1026">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2357">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence302">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1027">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2358">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence301">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1028">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2359">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway56">
 <bp:pathwayOrder rdf:resource="#PathwayStep298" />
 <bp:pathwayOrder rdf:resource="#PathwayStep299" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction233" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction234" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence288" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Transport of HA trimer, NA tetramer and M2 tetramer from the endoplasmic reticulum to the Golgi Apparatus</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Processed viral proteins are transported from the endoplasmic reticulum to the Golgi apparatus.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence308">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway57">
 <bp:pathwayOrder rdf:resource="#PathwayStep303" />
 <bp:pathwayOrder rdf:resource="#PathwayStep304" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction237" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction238" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence293" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Packaging of Eight RNA Segments</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">For a budding influenza virus to be fully infectious is it essential that it contains a full complement of the eight vRNA segments. Two different models have been proposed for packaging of the vRNPs into newly assembling virus particles; the random incorporation model and the selective incorporation model. The random incorporation model as its name suggests proposes that there is no selection at all on which vRNPs are packaged. It is assumed that each vRNP has equal probability of being packaged, and that if enough vRNPS are packaged a particular percentage of budding virions will receive at least one copy of each genome segment. This model is supported by evidence that infectious virions may possess more than eight vRNPs assuring the presence of a full complement of eight vRNPs in a significant percentage of virus particles. Mathematical analysis of packaging suggested that twelve RNA segments would need to be packaged in order to obtain approximately 10% of virus particles that are fully infectious (Enami, 1991), a number that is compatible with experimental data (Donald, 1954). Due to the low amount of RNA per virion (estimated at 1-2% w/w), enumeration of the precise number of RNAs packaged in a virion is difficult. The selective incorporation model, suggests that each vRNA segment contains a unique &quot;packaging signal&quot; allowing it to act independently, with each vRNA segment being packaged selectively. There is increasing evidence to support the theory of a packaging signal within the coding regions at both the 5&apos; and 3&apos; end of the genomic RNA, with signals being reported for all segments except segment 7 (Ozawa 2007, Muramoto 2006, Fujii 2005, Fujii 2003, Watanabe 2003, Liang 2005). The exact method by which individual vRNP segments are packaged is not known but it has been hypothesized to occur via specific RNA-RNA or protein-RNA interactions. This model is also supported by thin section electron microscopy images of influenza particles that show eight distinct &quot;dots&quot;, presumably vRNPs within virus particles (Noda 2006).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence307">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway58">
 <bp:pathwayOrder rdf:resource="#PathwayStep306" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction239" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence296" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Budding</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The process by which influenza virus particles bud from an infected cell is not very well understood.  Accumulation of M1 at the inner leaflet of the plasma membrane is thought to be the trigger for the initiation of bud formation.  This bud formation continues until the inner core of the virus is completely enveloped.  Completion of the budding process requires the membrane at the base of the bud to fuse.  Although M1 is thought to be the driving force for bud formation, other viral and cellular proteins have been demonstrated to affect size and shape of the virus particle.  Generally, influenza virus particles are either spherical or filamentous and this characteristic morphology is genetically linked to the M segment (Bourmakina, 2003; Roberts, 1998).  Host factors such as polarization and the actin cytoskeleton play a critical role in determining the shape of filamentous particles (Roberts, 1998; Simpson-Holley, 2002).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway59">
 <bp:pathwayOrder rdf:resource="#PathwayStep308" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction240" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence298" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Release</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Once the viral envelope has separated from the cell membrane Influenza virus particles are actively released to complete the budding process. HA (hemagglutinin) anchors the virus to the cell by binding to sialic acid-containing receptors on the cell surface.   The enzymatic activity of the neuraminidase (NA) protein removes the sialic acid and releases the virus from the host cell. NA activity is also required to remove sialic acid from the carbohydrates present on the viral glycoproteins to prevent the viral particles from aggregating.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence309">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway52">
 <bp:pathwayOrder rdf:resource="#PathwayStep261" />
 <bp:pathwayOrder rdf:resource="#PathwayStep262" />
 <bp:pathwayOrder rdf:resource="#PathwayStep260" />
 <bp:pathwayOrder rdf:resource="#PathwayStep243" />
 <bp:pathwayOrder rdf:resource="#PathwayStep265" />
 <bp:pathwayOrder rdf:resource="#PathwayStep244" />
 <bp:pathwayOrder rdf:resource="#PathwayStep266" />
 <bp:pathwayOrder rdf:resource="#PathwayStep241" />
 <bp:pathwayOrder rdf:resource="#PathwayStep263" />
 <bp:pathwayOrder rdf:resource="#PathwayStep242" />
 <bp:pathwayOrder rdf:resource="#PathwayStep264" />
 <bp:pathwayOrder rdf:resource="#PathwayStep280" />
 <bp:pathwayOrder rdf:resource="#PathwayStep258" />
 <bp:pathwayOrder rdf:resource="#PathwayStep259" />
 <bp:pathwayOrder rdf:resource="#PathwayStep256" />
 <bp:pathwayOrder rdf:resource="#PathwayStep278" />
 <bp:pathwayOrder rdf:resource="#PathwayStep257" />
 <bp:pathwayOrder rdf:resource="#PathwayStep279" />
 <bp:pathwayOrder rdf:resource="#PathwayStep250" />
 <bp:pathwayOrder rdf:resource="#PathwayStep272" />
 <bp:pathwayOrder rdf:resource="#PathwayStep251" />
 <bp:pathwayOrder rdf:resource="#PathwayStep273" />
 <bp:pathwayOrder rdf:resource="#PathwayStep270" />
 <bp:pathwayOrder rdf:resource="#PathwayStep271" />
 <bp:pathwayOrder rdf:resource="#PathwayStep254" />
 <bp:pathwayOrder rdf:resource="#PathwayStep276" />
 <bp:pathwayOrder rdf:resource="#PathwayStep255" />
 <bp:pathwayOrder rdf:resource="#PathwayStep277" />
 <bp:pathwayOrder rdf:resource="#PathwayStep252" />
 <bp:pathwayOrder rdf:resource="#PathwayStep274" />
 <bp:pathwayOrder rdf:resource="#PathwayStep253" />
 <bp:pathwayOrder rdf:resource="#PathwayStep275" />
 <bp:pathwayOrder rdf:resource="#PathwayStep247" />
 <bp:pathwayOrder rdf:resource="#PathwayStep269" />
 <bp:pathwayOrder rdf:resource="#PathwayStep248" />
 <bp:pathwayOrder rdf:resource="#PathwayStep245" />
 <bp:pathwayOrder rdf:resource="#PathwayStep267" />
 <bp:pathwayOrder rdf:resource="#PathwayStep246" />
 <bp:pathwayOrder rdf:resource="#PathwayStep268" />
 <bp:pathwayOrder rdf:resource="#PathwayStep249" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction215" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction216" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction213" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction214" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction211" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction212" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction198" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction199" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction210" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction219" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction217" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction218" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction196" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction197" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction194" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction195" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction192" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction193" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction190" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction191" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction204" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction205" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction202" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction203" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction189" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction200" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction201" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction187" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction188" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction208" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction209" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction206" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction207" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction185" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction186" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction183" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction184" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction181" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction182" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction180" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence231" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Maturation of hRSV A proteins</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Human respiratory syncytial virus contains 10 genes which are translated into 11 proteins, of which 2 have translation isoforms due to use of alternative translation initiation codons. These proteins function in viral replication and host interaction. Fusion protein F, glycoprotein G, and both variants of small hydrophobic protein, SH and SHt, get glycosylated and F, G, and SH later migrate to the plasma membrane where virion assembly takes place. Matrix protein M first translocates to the nucleus and back to cytosol before serving as a scaffold at the assembly site. M2-1 is also found in the nucleus. Phosphorylations, partially transient, appear to be necessary for oligomerization and function of the SH, N, P, M, and M2-1 proteins (Gan    Torres, 2011; McLellan et al, 2013; Muniyandi et al, 2018; Anderson et al, 2021).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway53">
 <bp:pathwayOrder rdf:resource="#PathwayStep360" />
 <bp:pathwayOrder rdf:resource="#PathwayStep282" />
 <bp:pathwayOrder rdf:resource="#PathwayStep309" />
 <bp:pathwayOrder rdf:resource="#PathwayStep357" />
 <bp:pathwayOrder rdf:resource="#PathwayStep314" />
 <bp:pathwayOrder rdf:resource="#PathwayStep325" />
 <bp:pathwayOrder rdf:resource="#PathwayStep358" />
 <bp:pathwayOrder rdf:resource="#PathwayStep322" />
 <bp:pathwayOrder rdf:resource="#PathwayStep337" />
 <bp:pathwayComponent rdf:resource="#Pathway64" />
 <bp:pathwayComponent rdf:resource="#Pathway54" />
 <bp:pathwayComponent rdf:resource="#Pathway65" />
 <bp:pathwayComponent rdf:resource="#Pathway76" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction272" />
 <bp:pathwayComponent rdf:resource="#Pathway77" />
 <bp:pathwayComponent rdf:resource="#Pathway70" />
 <bp:pathwayComponent rdf:resource="#Pathway60" />
 <bp:pathwayComponent rdf:resource="#Pathway61" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence272" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Influenza Infection</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">For centuries influenza epidemics have plagued man; with influenza probably being the disease described by Hippocrates in 412 BC. Today it remains a major cause of morbidity and mortality worldwide with large segments of the human population affected every year. Many animal species can be infected by influenza viruses, often with catastrophic consequences. An influenza pandemic is a continuing global level threat. The 1918 influenza pandemic is a modern example of how devastating such an event could be with an estimated 50 million deaths worldwide.  Influenza viruses belong to the family of Orthomyxoviridae; viruses with segmented RNA genomes that are negative sense and single-stranded (Baltimore 1971). Influenza virus strains are named according to their type (A, B, or C), the species from which the virus was isolated (omitted if human), location of isolate, the number of the isolate, the year of isolation, and in the case of influenza A viruses, the hemagglutinin (H) and neuraminidase (N) subtype. For example, the virus of H5N1 subtype isolated from chickens in Hong Kong in 1997 is: influenza A/chicken/Hong Kong/220/97(H5N1) virus. Currently 16 different hemagglutinin (H1 to H16) subtypes and 9 different neuraminidase (N1 to N9) subtypes are known for influenza A viruses. Most human disease is due to influenza viruses of the A type. The events of influenza infection have been annotated in Reactome primarily use protein and genome references to the Influenza A virus A/Puerto Rico/8/1934 H1N1 strain. The influenza virus particle initially associates with a human host cell by binding to sialic acid receptors on the host cell surface. Sialic acids are found on many vertebrate cells and numerous viruses make use of this ubiquitous receptor. The bound virus is endocytosed by one of four distinct mechanisms. Once endocytosed the low endosomal pH sets in motion a number of steps that lead to viral membrane fusion mediated by the viral hemagglutinin (HA) protein, and the eventual release of the uncoated viral ribonucleoprotein complex into the cytosol of the host cell. The ribonucleoprotein complex is transported through the nuclear pore into the nucleus. Once in the nucleus, the incoming negative-sense viral RNA (vRNA) is transcribed into messenger RNA (mRNA) by a primer-dependent mechanism. Replication occurs via a two step process. A full-length complementary RNA (cRNA), a positive-sense copy of the vRNA, is first made and this in turn is used as a template to produce more vRNA. The viral proteins are expressed and processed and eventually assemble with vRNAs at what will become the budding sites on the host cell membrane. The viral protein and ribonucleoprotein complexes are assembled into complete viral particles and bud from the host cell, enveloped in the host cell&apos;s membrane.  Infection of a human host cell with influenza virus triggers an array of defensive host processes. This coevolution has driven the development of host processes that interfere with viral replication, notably the production of type I interferon. At the some time the virus counters these responses with the viral NS1 protein playing a central role in the viral response to the host cells defense.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway54">
 <bp:pathwayOrder rdf:resource="#PathwayStep283" />
 <bp:pathwayOrder rdf:resource="#PathwayStep302" />
 <bp:pathwayOrder rdf:resource="#PathwayStep307" />
 <bp:pathwayOrder rdf:resource="#PathwayStep305" />
 <bp:pathwayComponent rdf:resource="#Pathway57" />
 <bp:pathwayComponent rdf:resource="#Pathway58" />
 <bp:pathwayComponent rdf:resource="#Pathway59" />
 <bp:pathwayComponent rdf:resource="#Pathway55" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence273" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Virus Assembly and Release</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Influenza viruses assemble and bud from the apical plasma membrane of polarized cells e.g. lung epithelial cells of the infected host. This asymmetrical process (i.e. apical [Influenza virus] or basolateral [Marburg virus]) is thought to have an important role in viral pathogenesis and tissue tropism. In most cases the individual viral envelope proteins are seen to accumulate at the same polar surface from which virus budding occurs, suggesting that they determine the maturation site</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway55">
 <bp:pathwayOrder rdf:resource="#PathwayStep294" />
 <bp:pathwayOrder rdf:resource="#PathwayStep284" />
 <bp:pathwayOrder rdf:resource="#PathwayStep295" />
 <bp:pathwayOrder rdf:resource="#PathwayStep292" />
 <bp:pathwayOrder rdf:resource="#PathwayStep293" />
 <bp:pathwayOrder rdf:resource="#PathwayStep287" />
 <bp:pathwayOrder rdf:resource="#PathwayStep288" />
 <bp:pathwayOrder rdf:resource="#PathwayStep285" />
 <bp:pathwayOrder rdf:resource="#PathwayStep296" />
 <bp:pathwayOrder rdf:resource="#PathwayStep286" />
 <bp:pathwayOrder rdf:resource="#PathwayStep297" />
 <bp:pathwayOrder rdf:resource="#PathwayStep290" />
 <bp:pathwayOrder rdf:resource="#PathwayStep291" />
 <bp:pathwayOrder rdf:resource="#PathwayStep289" />
 <bp:pathwayOrder rdf:resource="#PathwayStep300" />
 <bp:pathwayOrder rdf:resource="#PathwayStep301" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction226" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction227" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction224" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction235" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction225" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction236" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction222" />
 <bp:pathwayComponent rdf:resource="#Pathway56" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction223" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction220" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction231" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction221" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction232" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction228" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction229" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction230" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence274" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Assembly of Viral Components at the Budding Site</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Following synthesis on membrane-bound ribosomes, the three viral integral membrane proteins, HA (hemagglutinin), NA (neuraminidase) and M2 (ion channel) enter the host endoplasmic reticulum (ER) where all three are folded and HA and NA are glycosylated. Subsequently HA is assembled into a trimer. HA, NA and M2 are transported to the Golgi apparatus where cysteine residues on HA and M2 are palmitoylated. Furin cleaves HA into HA1 and HA2 subunits and all three proteins are directed to the virus assembly site on the apical plasma membrane via apical sorting signals. The signals for HA and NA reside on the transmembrane domains (TMD) while the sorting signal for M2 is not yet characterized. The TMDs of HA and NA also contain the signals for lipid raft association. Lipid rafts are non-ionic detergent-resistant lipid microdomains within the plasma membrane that are rich in sphingolipids and cholesterol. Examination of purified virus particles indicates that influenza virus buds preferentially from these microdomains.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1252">
 <bp:evidence rdf:resource="#Evidence1539" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">RAF is phosphorylated downstream of oncogenic RAS </bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1253">
 <bp:evidence rdf:resource="#Evidence1540" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">RAS mutants bind inactive RAF</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway50">
 <bp:pathwayOrder rdf:resource="#PathwayStep221" />
 <bp:pathwayOrder rdf:resource="#PathwayStep222" />
 <bp:pathwayOrder rdf:resource="#PathwayStep225" />
 <bp:pathwayOrder rdf:resource="#PathwayStep223" />
 <bp:pathwayOrder rdf:resource="#PathwayStep224" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction165" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction166" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction163" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction164" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction162" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence211" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Respiratory syncytial virus genome replication</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Replication of the negative sense genomic RNA of the human respiratory syncytial virus (RSV) occurs through the positive sense intermediate, also known as antigenomic RNA. RNA synthesis is performed by the RNA-dependent RNA polymerase (RdRP) complex composed at a minimum of the L protein, which is the catalytic subunit of RdRP, and P protein. Protein M2-1 that acts as a processivity factor is described as a consitutive RdRP subunit by some and as an accessory RdRP subunit by other studies (reviewed in Fearns and Deval 2016). Replication of both genomic and antigenomic RNA depends on encapsidation by protein N, which has regions that interact with both protein P and protein L. Encapsidation protects genomic and antigenomic RNA from degradation as these RNAs do not possess the 5&apos; cap and the poly(A) tail. Replication occurs after primary transcription. Accumulation of the protein M2-2 is responsible for the shift of RNA synthesis from transcription to replication through a mechanism that has not been fully elucidated (For review, refer to Collins and Melero 2011, Battles and McLellan 2019).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1250">
 <bp:evidence rdf:resource="#Evidence1537" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Homo- or heterodimerization of RAF downstream of mutant RAS</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway51">
 <bp:pathwayOrder rdf:resource="#PathwayStep232" />
 <bp:pathwayOrder rdf:resource="#PathwayStep233" />
 <bp:pathwayOrder rdf:resource="#PathwayStep230" />
 <bp:pathwayOrder rdf:resource="#PathwayStep231" />
 <bp:pathwayOrder rdf:resource="#PathwayStep236" />
 <bp:pathwayOrder rdf:resource="#PathwayStep237" />
 <bp:pathwayOrder rdf:resource="#PathwayStep234" />
 <bp:pathwayOrder rdf:resource="#PathwayStep235" />
 <bp:pathwayOrder rdf:resource="#PathwayStep229" />
 <bp:pathwayOrder rdf:resource="#PathwayStep227" />
 <bp:pathwayOrder rdf:resource="#PathwayStep238" />
 <bp:pathwayOrder rdf:resource="#PathwayStep228" />
 <bp:pathwayOrder rdf:resource="#PathwayStep239" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction169" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction167" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction178" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction168" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction179" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction176" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction177" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction174" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction175" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction172" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction173" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction170" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction171" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence217" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Translation of respiratory syncytial virus mRNAs</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The 10 subgenomic mRNAs of human respiratory syncytial virus A (hRSV A) are translated into 11 proteins. Except for the M2 mRNA, each mRNA encodes one distinct protein. The two overlapping open reading frames (ORFs) of the M2 mRNA encode proteins M2-1 and M2-2.  The M2-1 product of the M2 gene is a transcription processivity factor, while the M2-2 product of the M2 gene is a nonstructural protein that regulates the switch between transcription and genome replication. The N mRNA encodes the nucleoprotein, which forms decameric and hendecameric rings around which viral genomic RNA is packaged. The L and P mRNAs encode the large polymerase subunit and the phosphoprotein polymerase cofactor subunit, respectively, of the RNA-dependent RNA polymerase complex (RdRP). The SH, G, and F mRNAs encode three proteins that are embedded in the viral envelope: small hydrophobic protein, attachment protein, and fusion protein, respectively. The secreted isoform of G protein (sG), involved in mediation of immune evasion, and the truncated form of SH (SHt), are translated from G mRNA and SH mRNA, respectively, through the usage of an alternative start codon. The NS1 and NS2 genes encode nonstructural proteins that function together to inhibit apoptosis and interferon response in infected cells. For review, please refer to Battles and McLellan 2019.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1251">
 <bp:evidence rdf:resource="#Evidence1538" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated MAP2Ks phosphorylate MAPKs downstream of oncogenic RAS</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1245">
 <bp:evidence rdf:resource="#Evidence1529" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">High kinase activity BRAF complexes phosphorylate MAP2Ks</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1246">
 <bp:evidence rdf:resource="#Evidence1530" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated MAP2Ks phosphorylate MAPKs downstream of high kinase activity BRAF mutants</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1243">
 <bp:evidence rdf:resource="#Evidence1527" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Dimerization of BRAF V600E splice variants contributes to BRAF inhibitor resistance</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1244">
 <bp:evidence rdf:resource="#Evidence1528" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">High kinase activity BRAF mutants bind MAP2Ks and MAPKs</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence2380">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1050">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1249">
 <bp:evidence rdf:resource="#Evidence1534" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Constitutively active MAPK1 mutants are not dephosphorylated by DUSPs</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence2381">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1051">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2382">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1052">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1247">
 <bp:evidence rdf:resource="#Evidence1531" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Dissociation of high activity BRAF complexes</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence2383">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1053">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1248">
 <bp:evidence rdf:resource="#Evidence1532" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Inhibitors bind and inhibit highly active BRAF mutants</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence2384">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence315">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1054">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2385">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence314">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1055">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2386">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence317">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1056">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2387">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence316">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1057">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2388">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence311">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1058">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2389">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence310">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1059">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence313">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence312">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence319">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway67">
 <bp:pathwayOrder rdf:resource="#PathwayStep332" />
 <bp:pathwayOrder rdf:resource="#PathwayStep333" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction257" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction256" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence322" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Inhibition of Host mRNA Processing and RNA Silencing</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The Influenza Virus NS1 protein inhibits the cleavage and polyadenylation specificity factor CPSF and the PABII components of the host cell 3&apos; end processing machinery, preventing efficient 3&apos; end processing of host pre-mRNAs. NS1 also inhibits the splicing of pre-mRNAs, resulting in their retention within the host cell nucleus.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence318">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway68">
 <bp:pathwayOrder rdf:resource="#PathwayStep335" />
 <bp:pathwayComponent rdf:resource="#Pathway69" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence325" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Inhibition of Interferon Synthesis</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Interferon Synthesis is inhibited.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway69">
 <bp:pathwayOrder rdf:resource="#PathwayStep336" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction254" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence326" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Inhibition of IFN-beta</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Since the presence of intracellular dsRNA serves as the signal for virus infection and triggers host interferon (IFN) synthesis the simplest model for viral NS1 protein function is that it sequesters dsRNA and thus prevents the downstream signaling required to activate IRF-3, NF-kB and AP-1. These findings are strongly supported by mutational analyses of NS1 that indicate that the IFN antagonist properties of NS1 depend on its ability to bind dsRNA. However, a compensatory mutation (S42G), which was acquired during the passaging of the mutant RNA-binding virus, results in partial restoration of wild-type phenotype but does not restore RNA binding. This indicates that the ability of NS1 to inhibit IFN synthesis is not solely dependent on dsRNA binding and that additional mechanisms may be involved.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway63">
 <bp:pathwayOrder rdf:resource="#PathwayStep319" />
 <bp:pathwayOrder rdf:resource="#PathwayStep320" />
 <bp:pathwayOrder rdf:resource="#PathwayStep321" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction248" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction249" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction247" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence309" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Fusion of the Influenza Virion to the Host Cell Endosome</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">After the virus binds to the target cell surface and is endocytosed, the low pH of the endosome causes the viral HA (hemagglutinin) to undergo a structural change which frees the fusion peptide of its HA2 subunit  allowing it to interact with the endosome membrane. The transmembrane domain of the HA2 (inserted into the viral membrane) and the fusion peptide (inserted into the endosomal membrane) are in juxtaposition in the acidic pH structure of HA. The concerted structural change of several hemagglutinin molecules then opens a pore through which the viral RNP will be able to pass into the host cell cytosol.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway64">
 <bp:pathwayOrder rdf:resource="#PathwayStep324" />
 <bp:pathwayOrder rdf:resource="#PathwayStep323" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction251" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction250" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence313" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Influenza Virus Induced Apoptosis</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Influenza A virus induces apoptosis in a variety of ways including activation of host TGF-beta by expression of viral NA, M1 and M2 proteins, and by the binding of viral PB1-F2 to host mitochondrial adenine nucleotide translocator 3 (ANT3).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1260">
 <bp:evidence rdf:resource="#Evidence1552" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">PI3K gain of function mutants phosphorylate PIP2 to PIP3</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway65">
 <bp:pathwayOrder rdf:resource="#PathwayStep331" />
 <bp:pathwayOrder rdf:resource="#PathwayStep334" />
 <bp:pathwayOrder rdf:resource="#PathwayStep328" />
 <bp:pathwayOrder rdf:resource="#PathwayStep326" />
 <bp:pathwayOrder rdf:resource="#PathwayStep327" />
 <bp:pathwayComponent rdf:resource="#Pathway67" />
 <bp:pathwayComponent rdf:resource="#Pathway68" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction253" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction252" />
 <bp:pathwayComponent rdf:resource="#Pathway66" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence316" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NS1 Mediated Effects on Host Pathways</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Viral NS1 protein is a nuclear, dimeric protein that is highly expressed in infected cells and has dsRNA-binding activity. The RNA-binding domain lies within the N-terminal portion of the protein. The NS1 RNA-binding domain forms a symmetric homodimer with a six-helical fold. Mutational analysis has demonstrated that dimer formation is crucial for RNA-binding. The basic residues are believed to make contact with the phosphate backbone of the RNA which is consistent with an observed lack of sequence specificity. Neither NS1 nor its bound RNA undergo any significant structural changes upon binding. The NS1 dimer spans the minor groove of canonical A-form dsRNA. The non-RNA binding portion of NS1 has been termed the effector domain and includes binding sites for host cell poly (A)-binding protein II (PABII) and the 30kDa subunit of cleavage and polyadenylation specificity factor (CPSF).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway66">
 <bp:pathwayOrder rdf:resource="#PathwayStep330" />
 <bp:pathwayOrder rdf:resource="#PathwayStep329" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction255" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction254" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence319" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Inhibition of PKR</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The key role played by PKR in the innate response to virus infection is emphasized by the large number of viruses that encode PKR inhibitors.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1263">
 <bp:evidence rdf:resource="#Evidence1556" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">PIP2-bound p-S473-AKT1 mutant binds PIP2-bound PDPK1</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway60">
 <bp:pathwayOrder rdf:resource="#PathwayStep310" />
 <bp:pathwayOrder rdf:resource="#PathwayStep313" />
 <bp:pathwayOrder rdf:resource="#PathwayStep311" />
 <bp:pathwayOrder rdf:resource="#PathwayStep312" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction244" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction242" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction243" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction241" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence300" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Transport of Ribonucleoproteins into the Host Nucleus</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">An unusual characteristic of the influenza virus life cycle is its dependence on the nucleus. Trafficking of the viral genome into and out of the nucleus is a tightly regulated process with all viral RNA synthesis occurring in the nucleus. The eight influenza virus genome segments never exist as naked RNA but are associated with four viral proteins to form viral ribonucleoprotein complexes (vRNPs). The major viral protein in the RNP complex is the nucleocapsid protein (NP), which coats the RNA. The remaining proteins PB1, PB2 and PA bind to the partially complementary ends of the viral RNA, creating the distinctive panhandle structure. These RNPs (10-20nm wide) are too large to passively diffuse into the nucleus and therefore, once released from an incoming particle must rely on the active import mechanism of the host cell nuclear pore complex. All proteins in the RNP complex can independently localize to the nucleus due to the presence of nuclear localization signals (NLSs) which mediate their interaction with the nuclear import machinery, including the RanGTPase (Fodor, 2004; Deng et al., 2006). However the signals on NP have been shown to be both sufficient and necessary for the import of viral RNA.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1264">
 <bp:evidence rdf:resource="#Evidence1557" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">PDPK1 phosphorylates AKT1 E17K mutant</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway61">
 <bp:pathwayOrder rdf:resource="#PathwayStep318" />
 <bp:pathwayOrder rdf:resource="#PathwayStep315" />
 <bp:pathwayComponent rdf:resource="#Pathway63" />
 <bp:pathwayComponent rdf:resource="#Pathway62" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence305" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Fusion and Uncoating of the Influenza Virion</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Uncoating of viral particles takes place in the host cell endosome. Acidification of the endosome promotes fusion of the viral and endosomal membranes, causing a structural change in the viral hemagglutinin (HA) and freeing the fusion peptide of its HA2 subunit to interact with the endosome membrane. The concerted structural change of several HA molecules opens up a pore through which the viral RNP passes into the cytosol of the cell. The precise timing and the location of uncoating (early vs. late endosomes) depends on the pH-mediated transition of the specific HA molecule involved. The virus-associated M2 ion channel protein allows the influx of H+ ions into the virion, which disrupts protein-protein interactions, resulting in the release of RNP free of the viral M1 matrix protein. Thus the HA mediated fusion of the viral membrane with the endosomal membrane and the M2-mediated release of the RNP results in the release of the RNP complex into the cytosol. Amantadine and rimantadine have been shown to block the ion channel activity of the M2 protein and thus interfere with uncoating.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1261">
 <bp:evidence rdf:resource="#Evidence1554" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">AKT1 E17K mutant is phosphorylated by TORC2 complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway62">
 <bp:pathwayOrder rdf:resource="#PathwayStep317" />
 <bp:pathwayOrder rdf:resource="#PathwayStep316" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction246" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction245" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence306" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Uncoating of the Influenza Virion</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The precise timing and location of uncoating (early vs. late endosomes) depends on the pH-mediated transition of the specific viral hemagglutinin (HA) molecule involved. The uncoating of influenza viruses in endosomes is blocked by changes in pH caused by weak bases (e.g. ammonium chloride and chloroquine) or ionophores (e.g. monensin). Effective uncoating is also dependent on the presence of the viral M2 ion channel protein. Early on it was recognized that amantadine and rimantadine inhibit replication immediately following virus infection. Later it was found that the virus-associated M2 protein allows the influx of H+ ions into the virion, which disrupts protein-protein interactions, resulting in the release of viral RNP free of the viral matrix (M1) protein. Amantadine and rimantadine have been shown to block the ion channel activity of the M2 protein and thus uncoating. The HA mediated fusion of the viral membrane with the endosomal membrane and the M2-mediated release of the RNP results in the appearance of free RNP complexes in the cytosol. This completes the uncoating process. The time frame for the uncoating process has been examined by inhibiting virus penetration with ammonium chloride. Typically, virus particles show a penetration half time of about 25 minutes after viral adsorption. Ten minutes later (half time of 34 minutes after adsorption) RNP complexes are found in the nucleus. Uptake of RNP molecules through nuclear pores is an active process, involving the nucleo-cytoplasmic trafficking machinery of the host cell.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1262">
 <bp:evidence rdf:resource="#Evidence1555" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">AKT1 E17K mutant phosphorylates BAD</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1256">
 <bp:evidence rdf:resource="#Evidence1543" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Dissociation of oncogenic RAS:RAF complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1257">
 <bp:evidence rdf:resource="#Evidence1546" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">RAS GTPase mutants don&apos;t hydrolyze GTP</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence320">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1254">
 <bp:evidence rdf:resource="#Evidence1541" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Mutant RAS:p-RAF complexes bind MAP2Ks and MAPKs</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1255">
 <bp:evidence rdf:resource="#Evidence1542" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Mutant RAS:p-RAF complexes phosphorylate MAP2Ks</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence2370">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1040">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2371">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1041">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1258">
 <bp:evidence rdf:resource="#Evidence1548" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">RAS GAP mutants aren&apos;t stimulated by GAPs</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence2372">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1042">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1259">
 <bp:evidence rdf:resource="#Evidence1551" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">PI3K inhibitors block PI3K catalytic activity</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence2373">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence326">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1043">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2374">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence325">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1044">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2375">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence328">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1045">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2376">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence327">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1046">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2377">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence322">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1047">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2378">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence321">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1048">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2379">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence324">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1049">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence323">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway38">
 <bp:pathwayOrder rdf:resource="#PathwayStep130" />
 <bp:pathwayOrder rdf:resource="#PathwayStep122" />
 <bp:pathwayOrder rdf:resource="#PathwayStep123" />
 <bp:pathwayOrder rdf:resource="#PathwayStep120" />
 <bp:pathwayOrder rdf:resource="#PathwayStep131" />
 <bp:pathwayOrder rdf:resource="#PathwayStep121" />
 <bp:pathwayOrder rdf:resource="#PathwayStep126" />
 <bp:pathwayOrder rdf:resource="#PathwayStep127" />
 <bp:pathwayOrder rdf:resource="#PathwayStep124" />
 <bp:pathwayOrder rdf:resource="#PathwayStep125" />
 <bp:pathwayOrder rdf:resource="#PathwayStep128" />
 <bp:pathwayOrder rdf:resource="#PathwayStep129" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction90" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction88" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction89" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction84" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction85" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction86" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction87" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction91" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction92" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction93" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction83" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction94" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence120" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ADORA2B mediated anti-inflammatory cytokines production</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The natural ligand for adenosine receptor A2B (ADORA2B) is extracellular adenosine (Ad-Rib), formed from the reduction of ATP by ENTDPases. ATP enters the extracellular space in response to parasite infection, tissue injury, apoptosis amongst other stress factors and has chemotactic and excitatory effects (Cekic et al.2016).  The reduction of ATP to Ade Rib is thought to be a regulatory mechanism by which the synthesis of anti inflammatory cytokines is induced. In addition, killing mechanisms are switched off (Figueiredo et al. 2016). Accordingly, increased expression of ADORA2B in monocytes correlates with higher Leishmania donovani parasites loads alongside increment of IL10 production (Vijayamahantesh et al. 2016). Exacerbation of lesion development in L. amazonensis infected mice also correlated with high amounts of Ade Rib (Figueiredo et al. 2016).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence2316">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway39">
 <bp:pathwayOrder rdf:resource="#PathwayStep133" />
 <bp:pathwayOrder rdf:resource="#PathwayStep134" />
 <bp:pathwayOrder rdf:resource="#PathwayStep135" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction95" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction96" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction97" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence133" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">LTC4-CYSLTR mediated IL4 production</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The Leukotriene C4 (LTC4) is a metabolite of arachidonic acid that can be produced intracellularly or extracellularly. LTC4 binds an unidentified, intracellular cysLTR. Signalling downstream LTC4 cysLTR binding has been associated with the production of IL4, independent of the GPCR associated heterotrimeric protein Gq (Bandeira Melo et al. 2002).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence2317">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2318">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2319">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway34">
 <bp:pathwayOrder rdf:resource="#PathwayStep89" />
 <bp:pathwayComponent rdf:resource="#Pathway35" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence89" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Leishmania phagocytosis</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The internalization mechanism of leishmania parasites depends on not only the dynamic nature of the parasite&apos;s surface, but whether it is a non infective (procyclic) or infective (metacyclic) promastigote or infective amastigote, and also its virulent nature (Ueno et al.  2012    Lee et al. 2018). Host receptors reported to facilitate Leishmania internalization include the third complement receptor (CR3), first complement receptor (CR1), mannose receptor (MR), Fc gamma receptors (FCGRs) and fibronectin receptors (FNRs) (Ueno et al  2012). The route of entry to the macrophage can affect the fate of the Leishmania parasite (Ueno et al.  2012).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep342">
 <bp:stepProcess rdf:resource="#BiochemicalReaction260" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway35">
 <bp:pathwayOrder rdf:resource="#PathwayStep91" />
 <bp:pathwayOrder rdf:resource="#PathwayStep90" />
 <bp:pathwayOrder rdf:resource="#PathwayStep93" />
 <bp:pathwayOrder rdf:resource="#PathwayStep100" />
 <bp:pathwayOrder rdf:resource="#PathwayStep92" />
 <bp:pathwayOrder rdf:resource="#PathwayStep101" />
 <bp:pathwayOrder rdf:resource="#PathwayStep95" />
 <bp:pathwayOrder rdf:resource="#PathwayStep94" />
 <bp:pathwayOrder rdf:resource="#PathwayStep97" />
 <bp:pathwayOrder rdf:resource="#PathwayStep115" />
 <bp:pathwayOrder rdf:resource="#PathwayStep96" />
 <bp:pathwayOrder rdf:resource="#PathwayStep116" />
 <bp:pathwayOrder rdf:resource="#PathwayStep99" />
 <bp:pathwayOrder rdf:resource="#PathwayStep113" />
 <bp:pathwayOrder rdf:resource="#PathwayStep98" />
 <bp:pathwayOrder rdf:resource="#PathwayStep114" />
 <bp:pathwayOrder rdf:resource="#PathwayStep111" />
 <bp:pathwayOrder rdf:resource="#PathwayStep112" />
 <bp:pathwayOrder rdf:resource="#PathwayStep110" />
 <bp:pathwayOrder rdf:resource="#PathwayStep104" />
 <bp:pathwayOrder rdf:resource="#PathwayStep105" />
 <bp:pathwayOrder rdf:resource="#PathwayStep102" />
 <bp:pathwayOrder rdf:resource="#PathwayStep103" />
 <bp:pathwayOrder rdf:resource="#PathwayStep108" />
 <bp:pathwayOrder rdf:resource="#PathwayStep109" />
 <bp:pathwayOrder rdf:resource="#PathwayStep106" />
 <bp:pathwayOrder rdf:resource="#PathwayStep107" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction66" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction67" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction68" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction69" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction73" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction74" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction75" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction76" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction70" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction71" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction72" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction59" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction77" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction56" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction78" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction57" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction79" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction58" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction62" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction63" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction64" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction65" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction80" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction81" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction60" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction82" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction61" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence90" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FCGR3A-mediated phagocytosis</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The Fc gamma receptors (FCGRs) have been reported to facilitate Leishmania internalization, especially when in its amastigote form (Ueno et al. 2012). Following cell-to-cell propagation within an established infection or reinfection of a previously infected host, the IgG produced by the host covers the surface of Leishmania amastigote parasites, making them more susceptible to phagocytosis through FCGRs (Polando et al. 2013).  Classically, phagocytosis via FCGRs has been associated with the subsequent activation of Rac GTPases and Cdc42 which in turn activate the phagocyte&apos;s NADPH oxidase, contributing to the activation of killing mechanisms (Ueno et al. 2012).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence329">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep343">
 <bp:stepProcess rdf:resource="#BiochemicalReaction261" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway36">
 <bp:pathwayOrder rdf:resource="#PathwayStep118" />
 <bp:pathwayComponent rdf:resource="#Pathway37" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence118" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Leishmania parasite growth and survival</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Leishmania parasites infecting macrophages are considered a good model to study successful evolutionary mechanisms of evasion of the macrophage mediated immune response (Olivier et al. 2005). To evade killing by the host, Leishmania parasites manipulate the host&apos;s cellular signaling mechanisms, to prevent the production of microbicidal molecules and stimulating the activation of protective signaling pathways or to interfere with effective antigen presentation (Liu et al. 2012a). In most natural infections or after the resolution of the disease, a few Leishmania parasites remain in the host, perhaps as a product of a balance between forces favouring parasite persistence and those favouring destruction (Mandell et al.  2017).  </bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep340">
 <bp:stepProcess rdf:resource="#BiochemicalReaction259" />
 <bp:stepProcess rdf:resource="#Catalysis72" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway37">
 <bp:pathwayOrder rdf:resource="#PathwayStep132" />
 <bp:pathwayOrder rdf:resource="#PathwayStep146" />
 <bp:pathwayOrder rdf:resource="#PathwayStep136" />
 <bp:pathwayOrder rdf:resource="#PathwayStep119" />
 <bp:pathwayComponent rdf:resource="#Pathway38" />
 <bp:pathwayComponent rdf:resource="#Pathway39" />
 <bp:pathwayComponent rdf:resource="#Pathway41" />
 <bp:pathwayComponent rdf:resource="#Pathway40" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence119" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Anti-inflammatory response favouring Leishmania parasite infection</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Macrophages specializing in tissue repair or associated with a Th2-type immune response are more permissive to infection with leishmania, since their defense mechanisms are not very efficient in eliminating the parasite and can contribute to its persistence (Lee et al. 2018).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep341">
 <bp:stepProcess rdf:resource="#Pathway72" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway30">
 <bp:pathwayOrder rdf:resource="#PathwayStep60" />
 <bp:pathwayOrder rdf:resource="#PathwayStep71" />
 <bp:pathwayOrder rdf:resource="#PathwayStep70" />
 <bp:pathwayOrder rdf:resource="#PathwayStep62" />
 <bp:pathwayOrder rdf:resource="#PathwayStep73" />
 <bp:pathwayOrder rdf:resource="#PathwayStep61" />
 <bp:pathwayOrder rdf:resource="#PathwayStep72" />
 <bp:pathwayOrder rdf:resource="#PathwayStep53" />
 <bp:pathwayOrder rdf:resource="#PathwayStep64" />
 <bp:pathwayOrder rdf:resource="#PathwayStep75" />
 <bp:pathwayOrder rdf:resource="#PathwayStep63" />
 <bp:pathwayOrder rdf:resource="#PathwayStep74" />
 <bp:pathwayOrder rdf:resource="#PathwayStep55" />
 <bp:pathwayOrder rdf:resource="#PathwayStep66" />
 <bp:pathwayOrder rdf:resource="#PathwayStep54" />
 <bp:pathwayOrder rdf:resource="#PathwayStep65" />
 <bp:pathwayOrder rdf:resource="#PathwayStep57" />
 <bp:pathwayOrder rdf:resource="#PathwayStep68" />
 <bp:pathwayOrder rdf:resource="#PathwayStep56" />
 <bp:pathwayOrder rdf:resource="#PathwayStep67" />
 <bp:pathwayOrder rdf:resource="#PathwayStep59" />
 <bp:pathwayOrder rdf:resource="#PathwayStep58" />
 <bp:pathwayOrder rdf:resource="#PathwayStep69" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction26" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction37" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction27" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction38" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction28" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction39" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction29" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction33" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction44" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction34" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction45" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction24" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction35" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction46" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction25" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction36" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction40" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction30" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction41" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction31" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction42" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction32" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction43" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence53" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Purinergic signaling in leishmaniasis infection</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The purinoreceptors are divided into inotropic (P2XR) and metabotropic (P2YR) subtypes whose ligands are the nucleotides ATP and UDP respectively (Cekic et al. 2016). The binding of these nucleotides to their receptors on macrophages have been associated with the activation of the inflammasome leading to the subsequent activation of interleukin 1 beta (IL1&#946;) and TNF-&#945; (Cekic et al. 2016    Figueiredo et al. 2016). The liberation of ATP comes from tissues facing stressful stimuli such as a tissue injury or microorganism infection, amongst others. As a regulatory mechanism, certain enzymes can reduce ATP to Adenosine and a nucleoside can stimulate signalling pathways leading to the synthesis of anti-inflammatory cytokines (Cekic et al. 2016).    The activation of the receptor P2RX7 was shown to lead to the activation of killing mechanisms or cell death programs, ending up in the elimination of microbes such as Leishmania amazonensis, Mycobacterium tuberculosis, Chlamydia psittaci, and Toxoplasma gondii (Coutinho-Silva et al. 2012    Idzko, 2014).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1270">
 <bp:evidence rdf:resource="#Evidence1563" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">AKT inhibitors block AKT membrane recruitment</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway31">
 <bp:pathwayOrder rdf:resource="#PathwayStep77" />
 <bp:pathwayComponent rdf:resource="#Pathway32" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence77" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Killing mechanisms</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The long-lasting Leishmania infection is established within macrophages in which the most effective killing response is the production of reactive oxygen species (ROS) and reactive nitrogen species (RNS). (Rossi and Fasel 2018). Additionally, autophagy has been described as an innate immune mechanism for eliminating intracellular pathogens, although its role in restricting Leishmania replication is unclear (Veras et al. 2019)</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1271">
 <bp:evidence rdf:resource="#Evidence1564" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">AKT1 E17K mutant phosphorylates NR4A1 (NUR77)</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway32">
 <bp:pathwayOrder rdf:resource="#PathwayStep80" />
 <bp:pathwayOrder rdf:resource="#PathwayStep82" />
 <bp:pathwayOrder rdf:resource="#PathwayStep81" />
 <bp:pathwayOrder rdf:resource="#PathwayStep84" />
 <bp:pathwayOrder rdf:resource="#PathwayStep83" />
 <bp:pathwayOrder rdf:resource="#PathwayStep86" />
 <bp:pathwayOrder rdf:resource="#PathwayStep85" />
 <bp:pathwayOrder rdf:resource="#PathwayStep79" />
 <bp:pathwayOrder rdf:resource="#PathwayStep78" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction48" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction49" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction55" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction47" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction51" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction52" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction53" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction54" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction50" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence78" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">WNT5:FZD7-mediated leishmania damping</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Wnt-5a (WNT5) is known for being a highly specific regulated gene in response to microbial infection (Blumenthal et al. 2006, Pereira et al. 2008    Ljungberg et al. 2019) including leishmaniasis (Chakraborty et al. 2017), where it seems to be involve in mechanisms that dampen the parasite load within main host macrophages (Chakraborty et al. 2017). In addition, WNT5 is a highly responsive gene in human macrophages present in chronic diseases such as rheumatoid arthritis (Sen et al. 2000), cancer (Pukrop et al. 2006), atherosclerosis (Christman et al. 2008) and obesity (Ouchi et al. 2010    Ljungberg et al. 2019).  Frizzled-7 (FZD7) acts as a receptor of WNT5 which, upon binding, is implicated in the initiation of the non-canonical WNT pathway that ends up in the re-accommodation of the cytoskeleton to allow a process called planar cell polarity (PCP) (Ljungberg et al. 2019). The activation of the WNT5:FZD7 non-canonical signalling cascade that drives PCP is being studied for its involvement in inflammatory responses (Shao et al. 2016). Treatment of RAW264.7 macrophages with recombinant Wnt5a induced NADPH oxidase-mediated ROS production, which has been suggested to contribute to the macrophage control of L. donovani. Consequently, detailed understanding of how WNT signaling network defines host responses to infection could be important to identify potential targets (Ljungberg et al. 2019).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway33">
 <bp:pathwayOrder rdf:resource="#PathwayStep88" />
 <bp:pathwayComponent rdf:resource="#Pathway34" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence88" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Parasite infection</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Leishmania parasites are dimorphic protozoa, being extracellular and flagellated (promastigotes) in the vector insect, and intracellular and aflagellated (amastigotes) in the host. While the vector fly feeds on the blood of the host, it transmits the promastigotes which are subsequently phagocytosed. The transition to the non motile form occurs within the phagosomal pathway; this process requires the delay of the maturation of the phagosome in such a way that the pH conditions are not harmful to the promastigote. Once it is in the amastigote form, maturation of the parasitophorous vacuole continues (Mart&#237;nez L&#243;pez et al. 2018).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1274">
 <bp:evidence rdf:resource="#Evidence1567" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">AKT1 E17K mutant phosphorylates CREB1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1275">
 <bp:evidence rdf:resource="#Evidence1568" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">AKT1 E17K mutant translocates to the nucleus</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1272">
 <bp:evidence rdf:resource="#Evidence1565" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">AKT1 E17K mutant binds PIP2</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1273">
 <bp:evidence rdf:resource="#Evidence1566" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">AKT1 E17K mutant phosphorylates caspase-9</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1267">
 <bp:evidence rdf:resource="#Evidence1560" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">AKT1 E17K mutant phosphorylates MDM2</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1268">
 <bp:evidence rdf:resource="#Evidence1561" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">AKT1 E17K mutant phosphorylates TSC2, inhibiting it</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence331">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1265">
 <bp:evidence rdf:resource="#Evidence1558" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">AKT1 E17K mutant phosphorylates p21Cip1 and p27Kip1</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence330">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1266">
 <bp:evidence rdf:resource="#Evidence1559" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">AKT1 E17K mutant phosphorylates CHUK (IKKalpha)</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1269">
 <bp:evidence rdf:resource="#Evidence1562" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">AKT1 E17K mutant phosphorylates AKT1S1 (PRAS40)</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep335">
 <bp:stepProcess rdf:resource="#Pathway69" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence337">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep336">
 <bp:stepProcess rdf:resource="#BiochemicalReaction254" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence336">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2320">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep333">
 <bp:stepProcess rdf:resource="#BiochemicalReaction257" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence339">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2321">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep334">
 <bp:stepProcess rdf:resource="#Pathway68" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence338">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2322">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep339">
 <bp:stepProcess rdf:resource="#BiochemicalReaction258" />
 <bp:stepProcess rdf:resource="#Catalysis71" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence333">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2323">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence332">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2324">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep337">
 <bp:stepProcess rdf:resource="#Pathway70" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence335">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2325">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep338">
 <bp:stepProcess rdf:resource="#Pathway71" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence334">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2326">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway49">
 <bp:pathwayOrder rdf:resource="#PathwayStep214" />
 <bp:pathwayOrder rdf:resource="#PathwayStep215" />
 <bp:pathwayOrder rdf:resource="#PathwayStep213" />
 <bp:pathwayOrder rdf:resource="#PathwayStep218" />
 <bp:pathwayOrder rdf:resource="#PathwayStep219" />
 <bp:pathwayOrder rdf:resource="#PathwayStep216" />
 <bp:pathwayOrder rdf:resource="#PathwayStep217" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction158" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction159" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction156" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction157" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction155" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction161" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction160" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence203" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Respiratory syncytial virus genome transcription</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The negative sense, single-stranded RNA (-ssRNA) genome of the respiratory syncytial virus (RSV) is transcribed into 10 positive sense messenger RNAs that encode 11 viral proteins. The 10 viral mRNAs, going from the 3&apos; end, are: 1C (NS1) mRNA,1B (NS2) mRNA, N mRNA, P mRNA, M mRNA, SH mRNA, G mRNA, F mRNA, M2 mRNA, and L mRNA. Except for the M2 mRNA, each mRNA contains a single open reading frame (ORF). The two overlapping open reading frames (ORFs) of the M2 mRNA are translated into two distinct proteins, M2-1 and M2-2.  The N mRNA encodes the nucleoprotein, while the L and P mRNAs encode the large polymerase subunit and the phosphoprotein polymerase cofactor subunit, respectively, of the RNA-dependent RNA polymerase complex (RdRP). The M2-1 mRNA encodes a transcription processivity factor, while the M2-2 mRNA encodes a nonstructural protein that regulates the switch between transcription and genome replication. The SH, G and F mRNAs encode three proteins that are embedded in the viral envelope: small hydrophobic protein, attachment protein and fusion protein, respectively. The secreted isoform of G protein (sG), involved in mediation of immune evasion, and the truncated form of SH (SHt), are translated from G mRNA and SH mRNA, respectively, through the usage of an alternative start codon. The NS1 and NS2 mRNAs encode nonstructural proteins that function together to inhibit apoptosis and interferon response in infected cells. All RSV mRNAs undergo 5&apos; capping and 3&apos; polyadenylation, performed by the viral RdRP. For review, please refer to Battles and McLellan 2019.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence2305">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2306">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2307">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2308">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway45">
 <bp:pathwayOrder rdf:resource="#PathwayStep177" />
 <bp:pathwayOrder rdf:resource="#PathwayStep178" />
 <bp:pathwayOrder rdf:resource="#PathwayStep175" />
 <bp:pathwayOrder rdf:resource="#PathwayStep176" />
 <bp:pathwayOrder rdf:resource="#PathwayStep179" />
 <bp:pathwayOrder rdf:resource="#PathwayStep180" />
 <bp:pathwayOrder rdf:resource="#PathwayStep181" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction127" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction128" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction125" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction126" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction123" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction124" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction129" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence167" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Respiratory syncytial virus (RSV) attachment and entry</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The entry of human respiratory syncytial virus (RSV) into host cells involves attachment of the virion to the host cell surface, through interaction of viral envelope proteins with host cell attachment factors, and fusion of the viral membrane with the host cell membrane. The G glycoprotein is the attachment protein that interacts with surface molecules of the host cells, enabling the RSV virions to bind to their target cells. While the F glycoprotein may facilitate attachment, its primary function is to promote fusion of the viral and host cell membranes. The SH protein is dispensable for entry. For review, please refer to Battles and McLellan 2019.  Using human primary airway epithelial cell cultures, it was established that RSV efficiently infects the airway epithelium from the luminal surface and specifically targets ciliated airway epithelial cells. In the absence of immune response, RSV causes no obvious cytopathology (Zhang et al. 2002).  In addition to ciliated respiratory epithelial cells, RSV may infect granulocytes and cause a delay in constitutive apoptosis of neutrophils and eosinophils (Lindemans et al. 2006). RSV can also infect neonatal-specific regulatory B cells, which may contribute to high viral load and disease severity in infants (Zhivaki et al. 2017).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep331">
 <bp:stepProcess rdf:resource="#Pathway67" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence2309">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway46">
 <bp:pathwayOrder rdf:resource="#PathwayStep184" />
 <bp:pathwayOrder rdf:resource="#PathwayStep183" />
 <bp:pathwayOrder rdf:resource="#PathwayStep199" />
 <bp:pathwayOrder rdf:resource="#PathwayStep210" />
 <bp:pathwayOrder rdf:resource="#PathwayStep200" />
 <bp:pathwayOrder rdf:resource="#PathwayStep197" />
 <bp:pathwayOrder rdf:resource="#PathwayStep198" />
 <bp:pathwayOrder rdf:resource="#PathwayStep209" />
 <bp:pathwayOrder rdf:resource="#PathwayStep203" />
 <bp:pathwayOrder rdf:resource="#PathwayStep204" />
 <bp:pathwayOrder rdf:resource="#PathwayStep201" />
 <bp:pathwayOrder rdf:resource="#PathwayStep202" />
 <bp:pathwayOrder rdf:resource="#PathwayStep207" />
 <bp:pathwayOrder rdf:resource="#PathwayStep208" />
 <bp:pathwayOrder rdf:resource="#PathwayStep205" />
 <bp:pathwayOrder rdf:resource="#PathwayStep206" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction127" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction149" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction147" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction125" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction148" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction145" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction146" />
 <bp:pathwayComponent rdf:resource="#Pathway47" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction143" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction154" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction144" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction152" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction142" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction153" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction150" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction151" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence175" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">RSV-host interactions</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Airway epithelial cells are the primary target for human respiratory syncytial virus (hRSV) and other inhaled pathogens (Zhang et al., 2002). In response to RSV infection, airway epithelial cells initiate both inflammatory responses and antiviral immune responses to effectively eliminate the virus (reviewed by Espinoza, Bueno et al., 2014; Lay et al., 2016; Hu et al., 2020; Ouyang et al., 2022). Pattern recognition receptors (PRRs), including Toll-like receptors (TLRs) and retinoic acid-inducible gene-I-like receptors (RLRs), detect viral components such as RSV genomic RNA and trigger the production of pro-inflammatory cytokines, chemokines, and type I interferons (Liu et al. 2007; reviewed by Espinoza et al., 2014; Hu et al., 2020; Ouyang et al., 2022). Additionally, airway epithelial cells recruit other innate immune cells including polymorphonuclear leukocytes (PMNs), macrophages, and natural killer cells to establish an antiviral environment and facilitate the resolution of inflammation within the lungs (Miura 2019). The impact of RSV infection on the host cell transcriptome and proteome is reviewed by Hu et al., 2020. The adaptive immune response controls RSV infection by secreting antibodies (Jones et al., 2018; Fong et al., 2023) or by cytotoxic T lymphocytes (CTLs) that recognize and eliminate RSV-infected cells (Lukens et al., 2010; De et al., 2023). RSV evolved strategies to evade or subvert these host responses, allowing an infection to be established and persist within the host (reviewed by Espinoza, Bohmwald et al., 2014; Lay et al., 2016; Hu et al., 2020; Brasier 2020; Stephens    Varga 2020; Ouyang et al., 2022; van Royen et al., 2022). For example, the NS1 and NS2 proteins target the signaling molecules involved in the innate immune response suppressing PRR-induced IFN production and IFN-mediated signaling pathways (reviewed by Sedeyn et al., 2019; Thornhill    Verhoeven, 2020). Viral SH has been implicated in inhibiting apoptotic pathway, a type of non-inflammatory cell death that limits viral propagation (Li et al., 2015). At the same time, Triantafilou et al. (2013) have reported that viral SH promotes an inflammatory necrotic cell death to release the cell content. Further, the binding of RSV G protein to leukocytes involves the host CX3C chemokine receptor 1 (CX3CR1) and results in blocking signaling and trafficking of CX3CR1-expressing Th1 immune cells to the lungs, facilitating RSV infection (Harcourt et al., 2006). The hRSV NS2 protein induces cell shedding into large airways causing an acute airway obstruction in an animal model of RSV infection through an unknown mechanism (Liesman et al., 2014).  Several host factors contribute to the pathogenesis of RSV infection and its long-term effects, including age, prematurity, underlying respiratory conditions such as chronic lung disease including cystic fibrosis, deficiencies in specific immune components or dysregulated immune responses (reviewed by Carvajal et al., 2019). In some cases, an exaggerated immune response to RSV infection can affect the host&apos;s ability to control viral infection leading to immunopathology. For example, elevated production of Th2-type cytokines (IL-4, IL-5 and IL-13) in response to RSV infection leads to airway hyperreactivity and increased risk of developing asthma after hRSV infection (Vu et al., 2019; Dong et al., 2023; reviewed by Norlander    Peebles 2020; Manti    Piedimonte 2022). The outcome of RSV infection depends on a complex interplay between the immune responses induced by the host and the strategies developed by RSV to subvert these responses. This Reactome module describes molecular mechanisms by which specific RSV components modulate innate and adaptive immune responses, programmed cell death, and host gene expression.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep332">
 <bp:stepProcess rdf:resource="#BiochemicalReaction256" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway47">
 <bp:pathwayOrder rdf:resource="#PathwayStep195" />
 <bp:pathwayOrder rdf:resource="#PathwayStep185" />
 <bp:pathwayOrder rdf:resource="#PathwayStep196" />
 <bp:pathwayOrder rdf:resource="#PathwayStep193" />
 <bp:pathwayOrder rdf:resource="#PathwayStep194" />
 <bp:pathwayOrder rdf:resource="#PathwayStep188" />
 <bp:pathwayOrder rdf:resource="#PathwayStep189" />
 <bp:pathwayOrder rdf:resource="#PathwayStep186" />
 <bp:pathwayOrder rdf:resource="#PathwayStep187" />
 <bp:pathwayOrder rdf:resource="#PathwayStep191" />
 <bp:pathwayOrder rdf:resource="#PathwayStep192" />
 <bp:pathwayOrder rdf:resource="#PathwayStep190" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction138" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction139" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction136" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction137" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction134" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction135" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction132" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction133" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction130" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction141" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction131" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction140" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence176" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Evasion by RSV of host interferon responses</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Infection with human respiratory syncytial virus (hRSV) is typically associated with low to undetectable levels of type I interferons (IFNs). Several hRSV proteins interact with host innate immune system factors that support the type I interferon response. Nonstructural proteins NS1 and NS2 localize to mitochondria and nucleus where they bind MAVS, DDX58, TRIM25, IRF3, and CREBBP, affecting DDX58/IFIH1-mediated interferon induction (reviewed by Thornhill    Verhoeven, 2020). Additionally, hRSV nucleoprotein interacts with MDA5 downregulating the interferon response and with PKR (EIF2AK2) blocking the innate immune system signal for shutting down protein translation. Further interactions of the M, SH, and G proteins are reviewed by van Royen et al, 2022.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway48">
 <bp:pathwayOrder rdf:resource="#PathwayStep240" />
 <bp:pathwayOrder rdf:resource="#PathwayStep220" />
 <bp:pathwayOrder rdf:resource="#PathwayStep226" />
 <bp:pathwayOrder rdf:resource="#PathwayStep212" />
 <bp:pathwayComponent rdf:resource="#Pathway49" />
 <bp:pathwayComponent rdf:resource="#Pathway52" />
 <bp:pathwayComponent rdf:resource="#Pathway50" />
 <bp:pathwayComponent rdf:resource="#Pathway51" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence202" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Respiratory syncytial virus (RSV) genome replication, transcription and translation</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">After the human respiratory syncytial virus A (hRSV A) enters host cells, an initial round of transcription and translation of virally-encoded mRNAs ensues, which is followed by genome replication.  The negative sense, single-stranded RNA (-ssRNA) genome of the human respiratory syncytial virus (RSV) A is 15.2 kb long and contains 10 genes that encode 11 proteins. The 10 genes, going from the 3&apos; end to the 5&apos; end of the -ssRNA are: 1C (NS1), 1B (NS2), N, P, M, SH, G, F, M2, and L. Except for the M2 gene, each gene encodes one protein. The two overlapping open reading frames (ORFs) of the M2 gene encode proteins M2-1 and M2-2.  The N gene encodes the nucleoprotein, which forms decameric and hendecameric (11-fold) rings around which viral genomic RNA is packaged. The L and P genes encode the large polymerase subunit and the phosphoprotein polymerase cofactor subunit, respectively, of the RNA-dependent RNA polymerase complex (RdRP) (reviewed in Battles and McLellan 2019). The L protein contains three conserved enzymatic domains: the RNA-dependent RNA polymerase (RdRp) domain, the polyribonucleotidyl transferase (PRNTase or capping) domain, and the methyltransferase (MTase) domain (reviewed in Sutto-Ortiz et al. 2023). The M2-1 product of the M2 gene is a transcription processivity factor, while the M2-2 product of the M2 gene is a nonstructural protein that regulates the switch between transcription and genome replication. The SH, G, and F genes encode three proteins that are embedded in the viral envelope: small hydrophobic protein, attachment protein, and fusion protein, respectively. The secreted isoform of G protein (sG) mediates immune evasion. The NS1 and NS2 genes encode nonstructural proteins that function together to inhibit apoptosis and interferon response in infected cells. For review, please refer to Battles and McLellan 2019.  The genomic -ssRNA and the antigenome RNA are encapsidated as they are synthesized, and the association of the nascent RNA with the N protein is likely what causes the replicating polymerase to be processive, with the processivity being further augmented by the M2-1 processivity factor (reviewed in Fearns and Deval 2016). The C-terminal arm of the N protein, known to interact with the P protein subunit of RdRP complex, extends above the plane of N decamers. The interaction between N and P proteins may allow the RdRP complex to distort the helical conformation of the nucleocapsid during RNA synthesis. A long beta-hairpin in the N-terminal region of the N protein may be the site of contact with the catalytic L subunit of the RdRP complex. The proposed model for RNA synthesis in RSV is that the RdRP complex induces a hinge movement of the N-terminal region with respect to the C-terminal region of the N protein that allows the polymerase to thread through the template RNA without the need to disassemble the nucleocapsid (Tawar et al. 2009). The hinge movement would enable 11 bases available for readout at a time (Tawar et al. 2009), consistent with the accumulation of abortive transcripts 9-11 nucleotides in length in P protein phosphorylation mutants that impair transcript elongation (Dupuy et al. 1999).  The M2-2 protein regulates the shift from positive to negative sense RNA synthesis. While the mechanism has not been fully elucidated, M2-2 was shown to directly bind to the L protein and to inhibit positive sense RNA synthesis (reviewed in Noton and Fearns 2015).  For review, please refer to Collins et al. 2013. </bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep330">
 <bp:stepProcess rdf:resource="#BiochemicalReaction255" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway41">
 <bp:pathwayOrder rdf:resource="#PathwayStep151" />
 <bp:pathwayOrder rdf:resource="#PathwayStep162" />
 <bp:pathwayOrder rdf:resource="#PathwayStep152" />
 <bp:pathwayOrder rdf:resource="#PathwayStep163" />
 <bp:pathwayOrder rdf:resource="#PathwayStep160" />
 <bp:pathwayOrder rdf:resource="#PathwayStep150" />
 <bp:pathwayOrder rdf:resource="#PathwayStep161" />
 <bp:pathwayOrder rdf:resource="#PathwayStep155" />
 <bp:pathwayOrder rdf:resource="#PathwayStep166" />
 <bp:pathwayOrder rdf:resource="#PathwayStep156" />
 <bp:pathwayOrder rdf:resource="#PathwayStep153" />
 <bp:pathwayOrder rdf:resource="#PathwayStep164" />
 <bp:pathwayOrder rdf:resource="#PathwayStep154" />
 <bp:pathwayOrder rdf:resource="#PathwayStep165" />
 <bp:pathwayOrder rdf:resource="#PathwayStep148" />
 <bp:pathwayOrder rdf:resource="#PathwayStep159" />
 <bp:pathwayOrder rdf:resource="#PathwayStep149" />
 <bp:pathwayOrder rdf:resource="#PathwayStep157" />
 <bp:pathwayOrder rdf:resource="#PathwayStep147" />
 <bp:pathwayOrder rdf:resource="#PathwayStep158" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction116" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction117" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction114" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction115" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction112" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction88" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction113" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction110" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction111" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction109" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction107" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction118" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction108" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction90" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction84" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction65" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction91" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction81" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction71" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction82" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence147" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FCGR3A-mediated IL10 synthesis</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Interleukin 10 (IL-10) is an important immunoregulatory cytokine produced by many cell populations; in macrophages it is induced after the stimulation of TLRs, Fc&#947; receptors or by the TLR-Fc&#947;R crosstalk (Vogelpoel et al. 2014    Saninet al. 2015). Classically, its function is considered to be the limitation and termination of inflammatory responses and the regulation of differentiation of several immune cells (Asadullah et al. 2003). There is increasing evidence of the role of IL-10 in parasite infection outcomes either as a protective or a pathological mediator (Asadullah et al. 2003). In the context of the parasitic disease cutaneous leishmaniasis, Leishmania amastigotes opsonized by IgG induce IL-10 response through Fc&#947;Rs, which in turn supresses the killing mechanisms in phagocytic cells. (Chu et al. 2010).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1281">
 <bp:evidence rdf:resource="#Evidence1576" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">CLIP1-LTK fusion binds PI3K to activate AKT</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway42">
 <bp:pathwayOrder rdf:resource="#PathwayStep281" />
 <bp:pathwayOrder rdf:resource="#PathwayStep368" />
 <bp:pathwayOrder rdf:resource="#PathwayStep402" />
 <bp:pathwayOrder rdf:resource="#PathwayStep168" />
 <bp:pathwayOrder rdf:resource="#PathwayStep615" />
 <bp:pathwayComponent rdf:resource="#Pathway80" />
 <bp:pathwayComponent rdf:resource="#Pathway53" />
 <bp:pathwayComponent rdf:resource="#Pathway43" />
 <bp:pathwayComponent rdf:resource="#Pathway133" />
 <bp:pathwayComponent rdf:resource="#Pathway83" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence160" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Viral Infection Pathways</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Viral infection pathways aim to capture molecular mechanisms of human viral diseases related to viral adhesion and penetration of human host cells, viral genome replication and synthesis of viral proteins, interaction of viral proteins with the proteins of the human host, and evasion of the host&apos;s immune defense.  Viral infection pathways currently include the life cycles of SARS-CoV viruses, influenza virus, HIV (human immunodeficiency virus), and human cytomegalovirus (HCMV).  Newly discovered coronaviruses SARS-CoV-1 and SARS-CoV-2 cause severe acute respiratory syndrome (SARS). These viruses belong to the family Coronaviridae, characterized by the presence of lipid envelope and genome in the form of single-stranded, linear, nonsegmented, positive-sense RNA.  Influenza viruses, the causative agents of flu, belong to the family Orthomyxoviridae, characterized by the presence of lipid envelope and genome in the form of single-stranded, segmented, negative-sense RNA.  Human immunodeficiency viruses (HIV), the causative agents of acquired immunodeficiency syndrome (AIDS), belong to the genus Lentivirus, family Retroviridae, characterized by the presence of lipid envelope and genome in the form of single-stranded, nonsegmented, linear, diploid, positive-sense RNA that produces a DNA intermediate during viral replication. Namely, retroviral RNA-directed DNA polymerase (reverse transcriptase) transcribes genomic RNA into viral DNA that integrates into host cell&apos;s DNA as a provirus.  Human cytomegalovirus (HCMV), one of the causative agents of infectious mononucleosis and pneumonia, belongs to the the family of herpesviruses (Herpesviridae), characterized by their large size, presence of lipid envelope, and genome in the form of linear double-stranded DNA that encodes more than a hundred different proteins. </bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1282">
 <bp:evidence rdf:resource="#Evidence1577" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">CLIP1-LTK fusion autophosphorylates</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway43">
 <bp:pathwayOrder rdf:resource="#PathwayStep174" />
 <bp:pathwayOrder rdf:resource="#PathwayStep182" />
 <bp:pathwayOrder rdf:resource="#PathwayStep211" />
 <bp:pathwayOrder rdf:resource="#PathwayStep169" />
 <bp:pathwayComponent rdf:resource="#Pathway45" />
 <bp:pathwayComponent rdf:resource="#Pathway46" />
 <bp:pathwayComponent rdf:resource="#Pathway48" />
 <bp:pathwayComponent rdf:resource="#Pathway44" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence161" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Respiratory Syncytial Virus Infection Pathway</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Infection with human respiratory syncytial virus (hRSV) is transmitted through close contact, fomites, and aerosolized droplets. RSV first infects the epithelial lining of the upper respiratory tract and nasopharynx where the virus begins to replicate, and from there it may spread to the lower respiratory tract - bronchioles and alveoli - especially in infants. Immune response to RSV infection increases mucus production which, in combination with inflammation, leads to the narrowing of airways and bronchiolitis. Experimental vaccination with a formalin-inactivated RSV has been associated with vaccine-enhanced disease, which has hindered vaccine development and led to advancement of costly and modestly effective therapies based on monoclonal antibodies (mAb) and small molecules, which act to block RSV entry and have been reserved for high-risk patients (reviewed in Battles and McLellan 2019, and Pandya et al. 2019). Recently, a prophylactic mAb Nirsevimab was approved for use in all infants (reviewed in Keam 2023). Some of the preF vaccines, which elicit immune response against the pre-fusion conformation of the F protein (pre-F), are in the late stages of clinical trial or undergoing approval for being used in elderly patients and pregnant women (reviewed in Jenkins et al. 2023).  RSV is classified into two distinct subtypes, RSV A and RSV B, predominantly based on antigenic and sequence-based variations in the viral envelope protein G, involved in virus attachment to the host cells. Multiple RSV genotypes are often in co-circulation with a dominance shift between RSV A and RSV B subtypes occurring every 1-2 years. The majority of RSV molecular studies use a limited number of historical isolates, the so-called laboratory strains, of which hRSV A substrain A2 is the most commonly used. If not indicated otherwise, the events described in this pathway refer to findings from hRSV A2-based studies.  For review, please refer to Battles and McLellan 2019, and Pandya et al. 2019.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway44">
 <bp:pathwayOrder rdf:resource="#PathwayStep173" />
 <bp:pathwayOrder rdf:resource="#PathwayStep171" />
 <bp:pathwayOrder rdf:resource="#PathwayStep172" />
 <bp:pathwayOrder rdf:resource="#PathwayStep170" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction121" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction122" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction120" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction119" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence162" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Assembly and release of respiratory syncytial virus (RSV) virions</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">A mature virion of the respiratory syncytial virus (RSV) consists of the ribonucleoprotein complex (RNP) surrounded by the protein matrix and a lipid bilayer envelope. The RNP is composed of the genomic negative sense single-stranded (-ssRNA) that is tightly associated with the N protein (nucleoprotein) and the RNA-dependent RNA polymerase complex (RdRP). The RdRP consists of the L protein subunit (large polymerase subunit), the P protein subunit (phosphoprotein polymerase cofactor), and the M2-1 protein, which acts as a transcription processivity factor. The matrix consists of the M (matrix) protein. The M2-1 protein serves as the bridge between the RNP and the M protein. The matrix supports the viral envelope. The viral envelope contains three embedded viral proteins: fusion protein (F), attachment protein (G), and a small hydrophobic protein (SH). The M protein associates with the cytoplasmic domain of the F protein. The SH protein forms a pentameric ion channel in the viral envelope and is thought to delay apoptosis of infected cells. The assembly and budding of RSV virions primarily occurs at the apical surface of ciliated airway epithelial cells where viral filaments containing RNPs form. The budding of RSV virions requires interactions between viral proteins, host cytoskeletal proteins, and membrane. For review, please refer to Shaikh and Crowe 2013, and Battles and McLellan 2019.  Based on the findings that P, M, and F proteins are sufficient for formation of viral&#8209;like particles (VLPs), P protein, particularly its highly phosphorylated serine/threonine&#8209;rich region between amino acids 39 and 57 that likely interacts with M and/or F proteins, may play an important role in the assembly (Meshram and Oomens 2019). </bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1280">
 <bp:evidence rdf:resource="#Evidence1575" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">CLIP1-LTK promotes MAPK1 and MAPK3 phosphorylation</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1285">
 <bp:evidence rdf:resource="#Evidence1582" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ERBB2 binds TKIs</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1286">
 <bp:evidence rdf:resource="#Evidence1583" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ERBB2 binds trastuzumab</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1283">
 <bp:evidence rdf:resource="#Evidence1578" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">CLIP1(1-1083)-LTK(488-864) fusion dimerizes</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway40">
 <bp:pathwayOrder rdf:resource="#PathwayStep140" />
 <bp:pathwayOrder rdf:resource="#PathwayStep141" />
 <bp:pathwayOrder rdf:resource="#PathwayStep144" />
 <bp:pathwayOrder rdf:resource="#PathwayStep145" />
 <bp:pathwayOrder rdf:resource="#PathwayStep142" />
 <bp:pathwayOrder rdf:resource="#PathwayStep143" />
 <bp:pathwayOrder rdf:resource="#PathwayStep137" />
 <bp:pathwayOrder rdf:resource="#PathwayStep138" />
 <bp:pathwayOrder rdf:resource="#PathwayStep139" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction105" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction106" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction103" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction104" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction99" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction101" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction102" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction100" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction98" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence137" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">CD163 mediating an anti-inflammatory response</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">High expression of the membrane protein CD163 in macrophages is a characteristic of tissues responding to inflammation elicited either by an intracellular pathogen infection (such as Mycobacterium leprae or Leishmania spp.) or due to an acute or chronic inflammatory disorder. The soluble form of this molecule, sCD163, is considered to be a potential inflammation biomarker and a therapeutic target; sCD163 is formed from the increased shedding of CD163 mediated by the tumor necrosis factor-&#945; (TNF-&#945;) cleaving enzyme, ADAM17 (Etzerodt    Moestrup 2013, Silva et al. 2017). The biological function of sCD163 is not yet clear, although several possible functions have been proposed: opsonization of Staphylococcus aureus, inhibition of T-cell proliferation and inhibition of tumor necrosis factor-like weak inducer of apoptosis (TWEAK) (Tran et al. 2005).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1284">
 <bp:evidence rdf:resource="#Evidence1581" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ERBB2 homodimerization</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence340">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1278">
 <bp:evidence rdf:resource="#Evidence1571" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">AKT1 E17K mutant phosphorylates forkhead box transcription factors</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1279">
 <bp:evidence rdf:resource="#Evidence1573" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">PTEN cancer mutants do not dephosphorylate PIP3</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence342">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1276">
 <bp:evidence rdf:resource="#Evidence1569" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">AKT1 E17K mutant phosphorylates GSK3</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence341">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1277">
 <bp:evidence rdf:resource="#Evidence1570" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">AKT1 E17K mutant phosphorylates RSK</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep324">
 <bp:stepProcess rdf:resource="#Catalysis69" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction251" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence348">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep325">
 <bp:stepProcess rdf:resource="#Pathway65" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence347">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep322">
 <bp:stepProcess rdf:resource="#Pathway64" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence2310">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep323">
 <bp:stepProcess rdf:resource="#BiochemicalReaction250" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence349">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2311">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep328">
 <bp:stepProcess rdf:resource="#Pathway66" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence344">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2312">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep329">
 <bp:stepProcess rdf:resource="#BiochemicalReaction254" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence343">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2313">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep326">
 <bp:stepProcess rdf:resource="#BiochemicalReaction252" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence346">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2314">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep327">
 <bp:stepProcess rdf:resource="#BiochemicalReaction253" />
 <bp:stepProcess rdf:resource="#Catalysis70" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence345">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2315">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway16">
 <bp:pathwayOrder rdf:resource="#PathwayStep29" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction14" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence29" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective F8 binding to the cell membrane</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The Reactome event describes the defective interaction between the thrombin-activated FVIIIa protein and phospholipid membrane surfaces caused by hemophilia A-associated FVIII variants, such as A2220P, A2220del and Q2330P.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence1007">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2338">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway17">
 <bp:pathwayOrder rdf:resource="#PathwayStep31" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction15" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence31" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective F8 cleavage by thrombin</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">In normal human plasma, thrombin cleaves factor VIII (FVIII) after arginine residues 391 (A1-A2 domain junction) and 759 (A2-B domain junction) to yield heavy chain fragments and at R1708 (a3-A3 junction) to yield the light chain fragment (Eaton D et al. 1986; Hill-Eubanks DC et al. 1989). Mutations affecting arginine residues located at the thrombin cleavage sites of factor VIII protein result in mild/moderate hemophilia A (HA) (Pattinson JK et al. 1990; Arai M et al. 1990; Schwaab R et al. 1991). The Reactome event describes failed thrombin-mediated activation of HA-associated FVIII variants (R391C, R391H, S392L, R1708C and R1708H) due to defects at or close to thrombin cleavage sites.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence1008">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2339">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway18">
 <bp:pathwayOrder rdf:resource="#PathwayStep33" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction16" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence33" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective F8 sulfation at Y1699</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Hemophilia A (HA) is a bleeding disorder caused by lack of or a defective factor VIII (FVIII) protein and results from defects in the F8 gene (Peyvandi F et al. 2016). In healthy individuals, FVIII is synthesized as a large glycoprotein of 2351 amino acids with a discrete domain structure: A1-A2-B-A3-C1-C2 (Wood WI et al. 1984; Vehar GA et al. 1984; Toole JJ et al. 1984). Upon synthesis, FVIII is translocated into the lumen of the endoplasmic reticulum (ER), where it undergoes extensive processing including cleavage of a signal peptide and N-linked glycosylation at asparagine residues (Kaufman RJ et al. 1988, 1997; Kaufman RJ 1998). In the ER lumen of mammalian cells FVIII interacts with the protein chaperones calnexin (CNX), calreticulin (CRT), and immunoglobulin-binding protein (BiP or GRP78) that facilitate proper folding of proteins prior to trafficking to the Golgi compartment (Marquette KA et al. 1995; Swaroop M et al. 1997; Pipe SW et al. 1998; Kaufman RJ et al. 1997; Kaufman RJ 1998). Trafficking from the ER to the Golgi compartment is facilitated by LMAN1 and multiple combined factor deficiency 2 (MCFD2) cargo receptor complex (Zhang B et al. 2005; Zheng, C et al. 2010, 2013). Within the Golgi apparatus, FVIII is subject to further processing, including modification of the N-linked oligosaccharides to complex-type structures, O-linked glycosylation, and sulfation of specific Tyr-residues (Kaufman RJ 1998). Upon secretion from the cell, FVIII is cleaved at two sites in the B-domain to form a heterodimer consisting of the heavy chain containing the A1-A2-B domains in a metal ion-dependent complex with the light chain consisting of the A3-C1-C2 domains (Kaufman RJ et al. 1997; Kaufman RJ 1998). The Reactome event describes defects within the secretory pathway due to mutations in the F8 gene that can impair FVIII synthesis, folding, intracellular processing and transport which result in a lack or reduced levels of the plasma FVIII protein. The module includes also an event of defective post-translational tyrosine sulfonation of FVIII in the Golgi apparatus that is required for the optimal interaction between the secreted FVIII and the von Willebrand factor (VWF).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence1009">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway19">
 <bp:pathwayOrder rdf:resource="#PathwayStep35" />
 <bp:pathwayOrder rdf:resource="#PathwayStep36" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction17" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction18" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence35" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective F8 accelerates dissociation of the A2 domain</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Retention of A2 polypeptide is required for normal stability of activated factor VIII (FVIIIa) and dissociation of A2 correlates with FVIIIa inactivation and consequent loss of FXase activity. Hemophilia A (HA)-associated mutations (R550H, A303E, S308L, N713I, R717W and R717L) within the predicted A1-A2 and A2-A3 interface are thought to disrupt potential intersubunit hydrogen bonds and have the molecular phenotype of increased rate of inactivation of FVIIIa due to increased rate of A2 subunit dissociation (Pipe SW et al. 1999; Hakeos WH et al. 2002)</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway12">
 <bp:pathwayOrder rdf:resource="#PathwayStep28" />
 <bp:pathwayOrder rdf:resource="#PathwayStep30" />
 <bp:pathwayOrder rdf:resource="#PathwayStep22" />
 <bp:pathwayOrder rdf:resource="#PathwayStep32" />
 <bp:pathwayOrder rdf:resource="#PathwayStep24" />
 <bp:pathwayOrder rdf:resource="#PathwayStep34" />
 <bp:pathwayOrder rdf:resource="#PathwayStep26" />
 <bp:pathwayComponent rdf:resource="#Pathway16" />
 <bp:pathwayComponent rdf:resource="#Pathway17" />
 <bp:pathwayComponent rdf:resource="#Pathway18" />
 <bp:pathwayComponent rdf:resource="#Pathway19" />
 <bp:pathwayComponent rdf:resource="#Pathway13" />
 <bp:pathwayComponent rdf:resource="#Pathway14" />
 <bp:pathwayComponent rdf:resource="#Pathway15" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence22" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective factor VIII causes hemophilia A</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Hemophilia A is an X&#8208;chromosome&#8208;linked recessive bleeding disorder defined by a qualitative and/or quantitative factor VIII (FVIII, F8) deficiency (Salen P    Babiker HM 2019). Patients affected by the mild form of the disease (FVIII activity 0.05&#8211;0.4 IU/mL) suffer from bleedings occurring after trauma or surgery. In severe hemophilia A patients (FVIII activity 0.01 IU/mL) bleedings occur spontaneously, whereas moderate hemophilia A patients (FVIII activity 0.01&#8211;0.05 IU/mL present with an intermediate bleeding phenotype (White GC 2nd et al. 2001). In healthy individuals, FVIII is synthesized as an &#8764; 300-kDa glycoprotein by hepatocytes, liver sinusoidal endothelial cells, and certain types of endothelial cells (Wion KL et al. 1995; Jacquemin M et al. 2006; Shahani T et al. 2009; Turner NA    Moake JL 2015). The FVIII protein contains a domain sequence A1-A2-B-ap-A3-C1-C2 and circulates as an A1-A2-B:ap-A3-C1-C2 heterodimer bound noncovalently to the von Willebrand factor (vWF) protein. vWF protects FVIII from rapid clearance (Lenting PJ et al. 2007). During the activation of FVIII by thrombin to FVIIIa, the B domain and an activation peptide (ap) are released, and cleavage between the A1 and A2 domains produces an A1:A2:A3-C1-C2 heterotrimer (Lollar P    Parker ET 1991; Nogami K et al. 2005; Newell JL    Fay PJ 2007; 2009). Once activated, FVIIIa dissociates from vWF and binds to the membrane of activated platelets to assemble with activated factor IX (FIXa) (Gilbert GE    Arena AA 1996; Ahmad SS et al. 2003; Panteleev MA et al. 2004; Ngo JC et al. 2008). At physiologic concentrations, the A2 subunit spontaneously dissociates, leading to loss of FVIIIa cofactor activity (Lollar P    Parker CG 1990). Hemophilia A results from a broad spectrum of mutations that occur along the entire length of the F8 gene causing diverse molecular phenotypes that result in similar disease states (Peyvandi F et al. 2016). Together with missense mutations being the most common type of mutations in hemophilia A, a relatively frequent cause is ascribable to nonsense and splice site mutations, deletions/insertions and promoter mutations (Hakeos WH et al. 2002; Wei W et al. 2017; Jacquemin M et al. 2000; Amano K et al. 1998; Gilbert GE et al. 2012; Pahl S et al. 2014; Peyvandi F et al. 2016). In addition, the inversion of intron 1 or 22 in the F8 gene is responsible for approximately half of severely affected hemophilia A patients (Antonarakis SE et al. 1995). Although specific FVIII missense mutations correlate with defects including decreased secretion or stability and specific functional impairment of FVIII, the mechanisms of the majority of missense mutations are poorly understood (Hakeos WH et al. 2002; Wei W et al. 2017, 2018; Jacquemin M et al. 2000; Amano K et al. 1998; Gilbert GE et al. 2012; Pahl S et al. 2014). The Reactome module describes several molecular mechanisms underlying hemophilia A which include:(1) low-level secretion of defective FVIII molecule as a result of impaired FVIII folding and intracellular processing, (2) reduced ability of FVIII variants to bind to von Willebrand factor (VWF) that leads to instability of FVIII variants in the plasma, (3) abnormal interaction of defective FVIII with FIXa. Defects in FVIII activity may also result in potentially slowing down FVIII activation by thrombin or altering stability of activated FVIIIa.  </bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep320">
 <bp:stepProcess rdf:resource="#BiochemicalReaction248" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway13">
 <bp:pathwayOrder rdf:resource="#PathwayStep23" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction11" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence23" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective cofactor function of FVIIIa variant</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Factor VIII (FVIII) in its activated form, FVIIIa, acts as a cofactor to the serine protease FIXa, in the conversion of the zymogen FX to the active enzyme (FXa). Missense mutations within the S577-Q584 region of FVIII have been associated with mild/moderate hemophilia A (HA) (Amano K et al. 1998; Celie PH et al. 1999; Jenkins PV et al. 2002). A functional assay demonstrated that the mutations S577F, V578A, D579A, and Q584R interfere with FVIIIa:FIXa-mediated stimulation of FX activation thus the effect of the mutations is to reduce the cofactor potential of FVIII in FXa generation. The Reactome event describes failed generation of FXa as the functional consequence of the FIXa interaction with HA-associated FVIIIa variants due to reduced ability of defective FVIII to act as a cofactor for FIXa within the intrinsic tenase complex.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep321">
 <bp:stepProcess rdf:resource="#BiochemicalReaction249" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway14">
 <bp:pathwayOrder rdf:resource="#PathwayStep25" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction12" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence25" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective F8 secretion</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Hemophilia A (HA) is a bleeding disorder caused by lack of or a defective factor VIII (FVIII) protein and results from defects in the F8 gene (Peyvandi F et al. 2016). In healthy individuals, FVIII is synthesized as a large glycoprotein of 2351 amino acids with a discrete domain structure: A1-A2-B-A3-C1-C2 (Wood WI et al. 1984; Vehar GA et al. 1984; Toole JJ et al. 1984). Upon synthesis, FVIII is translocated into the lumen of the endoplasmic reticulum (ER), where it undergoes extensive processing including cleavage of a signal peptide and N-linked glycosylation at asparagine residues (Kaufman RJ et al. 1988, 1997; Kaufman RJ 1998). In the ER lumen of mammalian cells FVIII interacts with the protein chaperones calnexin (CNX), calreticulin (CRT), and immunoglobulin-binding protein (BiP or GRP78) that facilitate proper folding of proteins prior to trafficking to the Golgi compartment (Marquette KA et al. 1995; Swaroop M et al. 1997; Pipe SW et al. 1998; Kaufman RJ et al. 1997; Kaufman RJ 1998). Trafficking from the ER to the Golgi compartment is facilitated by LMAN1 and multiple combined factor deficiency 2 (MCFD2) cargo receptor complex (Zhang B et al. 2005; Zheng, C et al. 2010, 2013). Within the Golgi apparatus, FVIII is subject to further processing, including modification of the N-linked oligosaccharides to complex-type structures, O-linked glycosylation, and sulfation of specific Tyr-residues (Kaufman RJ 1998). Upon secretion from the cell, FVIII is cleaved at two sites in the B-domain to form a heterodimer consisting of the heavy chain containing the A1-A2-B domains in a metal ion-dependent complex with the light chain consisting of the A3-C1-C2 domains (Kaufman RJ et al. 1997; Kaufman RJ 1998). The Reactome event describes defects within the secretory pathway due to mutations in the F8 gene that can impair FVIII synthesis, folding, intracellular processing and transport which result in a lack or reduced levels of the plasma FVIII protein. The module includes also an event of defective post-translational tyrosine sulfonation of FVIII in the Golgi apparatus that is required for the optimal interaction between the secreted FVIII and the von Willebrand factor (VWF).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway15">
 <bp:pathwayOrder rdf:resource="#PathwayStep27" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction13" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence27" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective F8 binding to von Willebrand factor</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Upon secretion from the cell, FVIII circulates in a tight complex with the multimeric glycoprotein von Willebrand Factor (vWF), which is essential for maintaining stable levels of FVIII in the circulation (reviewed by Pipe SW et al. 2016). Genetic mutations in the F8 gene can compromise FVIII binding to vWF thus decreasing FVIII values in the plasma causing hemophilia A (HA), an X-linked recessive bleeding disorder.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1292">
 <bp:evidence rdf:resource="#Evidence1591" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ERBB2 T862A does not bind sapitinib</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1293">
 <bp:evidence rdf:resource="#Evidence1593" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ERBB2 T733I does not bind tesevatinib</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway10">
 <bp:pathwayOrder rdf:resource="#PathwayStep18" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction9" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence18" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective F9 variant does not activate FX</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Factor IX (FIX) deficiency is associated with mild to severe bleeding in hemophilia B (HB) patients (Rallapalli PM et al. 2013). HB is caused by a wide range of mutations that can include point mutations (nonsense and missense), insertions, deletions and other complex rearrangements of the F9 gene (Rallapalli PM et al. 2013). The Reactome event describes failed generation of FXa as the functional consequence of the defective serine protease activity of hemophilia B (HB)-associated FIX variants such as G363R    G363E (Lu Q et al. 2015), G357E (Miyata T et al. 1991), A436V (Usharani P et al. 1985), I443T (Hamaguchi N et al. 1991), G409V (Bajaj SP et al. 1990), D410H and S411G (Ludwig M et al. 1992).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1290">
 <bp:evidence rdf:resource="#Evidence1587" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">RAS guanyl-nucleotide exchange mediated by SOS1 in complex with GRB2 and ERBB2 homodimer:p-SHC1</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway11">
 <bp:pathwayOrder rdf:resource="#PathwayStep20" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction10" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence20" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective F9 secretion</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">A deficiency or dysfunction of factor IX (FIX) caused by mutations in the F9 gene is associated with a blood clotting disorder hemophilia B (HB). The FIX protein level may be decreased in the circulation by F9 mutations affecting FIX protein synthesis, stability, or secretion (Kurachi S et al. 1997; Enjolras N et al. 2004; Branchini A et al. 2013, 2017; Tajnik M et al. 2016; Odaira K et al. 2019). The Reactome event describes intracellular accumulation and/or decreased secretion of FIX due to different HB-related genetic alterations spread throughout the F9 gene.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1291">
 <bp:evidence rdf:resource="#Evidence1588" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Recruitment of GRB2:SOS1 to p-SHC1 in complex with phosphorylated ERBB2 homodimer</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1296">
 <bp:evidence rdf:resource="#Evidence1599" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ERBB2 T798M does not bind afatinib</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1297">
 <bp:evidence rdf:resource="#Evidence1601" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Resistant ERBB2 KD mutants do not bind trastuzumab</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1294">
 <bp:evidence rdf:resource="#Evidence1595" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Resistant ERBB2 KD mutants do not bind neratinib</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1295">
 <bp:evidence rdf:resource="#Evidence1597" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ERBB2 KD mutants do not bind osimertinib</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence351">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1289">
 <bp:evidence rdf:resource="#Evidence1586" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SHC1 binds phosphorylated ERBB2 homodimer</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence350">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep319">
 <bp:stepProcess rdf:resource="#BiochemicalReaction247" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence353">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1287">
 <bp:evidence rdf:resource="#Evidence1584" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ERBB2 homodimer phosphorylates SHC1</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence352">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1288">
 <bp:evidence rdf:resource="#Evidence1585" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Trans-autophosphorylation of ERBB2 homodimer</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence2340">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep313">
 <bp:stepProcess rdf:resource="#BiochemicalReaction244" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence359">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1010">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2341">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep314">
 <bp:stepProcess rdf:resource="#Pathway61" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence358">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1011">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2342">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep311">
 <bp:stepProcess rdf:resource="#BiochemicalReaction242" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence1012">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2343">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep312">
 <bp:stepProcess rdf:resource="#BiochemicalReaction243" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence1013">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2344">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep317">
 <bp:stepProcess rdf:resource="#BiochemicalReaction246" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence355">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1014">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2345">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep318">
 <bp:stepProcess rdf:resource="#Pathway63" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence354">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1015">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2346">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep315">
 <bp:stepProcess rdf:resource="#Pathway62" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence357">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1016">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2347">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep316">
 <bp:stepProcess rdf:resource="#Catalysis68" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction245" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence356">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1017">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2348">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway27">
 <bp:pathwayOrder rdf:resource="#PathwayStep50" />
 <bp:pathwayComponent rdf:resource="#Pathway28" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence50" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Parasitic Infection Pathways</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Parasitic infection pathways aim to capture molecular mechanisms of human parasitic diseases related to parasite adhesion to and invasion of human host cells and tissues, toxigenicity (interaction of parasite-produced toxins with the human host), and evasion of the host&apos;s immune defense.  Parasitic infection pathways currently include Leishmania infection-related pathways.  The parasites of the genus Leishmania are blood flagellates transmitted to humans by sandflies. Leishmania causes infections of the skin and mucous membranes that can spread to internal organs (viscera), such as liver, spleen and bone marrow. Visceral leishmaniasis is often fatal.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence2327">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway28">
 <bp:pathwayOrder rdf:resource="#PathwayStep51" />
 <bp:pathwayOrder rdf:resource="#PathwayStep76" />
 <bp:pathwayOrder rdf:resource="#PathwayStep87" />
 <bp:pathwayOrder rdf:resource="#PathwayStep117" />
 <bp:pathwayComponent rdf:resource="#Pathway29" />
 <bp:pathwayComponent rdf:resource="#Pathway36" />
 <bp:pathwayComponent rdf:resource="#Pathway31" />
 <bp:pathwayComponent rdf:resource="#Pathway33" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence51" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Leishmania infection</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Intracellular parasites of the genus Leishmania constitute the etiologic agent of a disease complex called Leishmaniasis. Leishmania parasites alternate between two distinct developmental stages: the insect-adapted, flagellated, extracellular &#8220;promastigote&#8221; and the mammal-adapted, non flagellated, intracellular &#8220;amastigote&#8221; form, where the later resides within phagolysosomal vesicles of the phagocytic cell (Liu et al. 2012a). Paradoxically, the macrophage, which is the main host cell where the parasite replicates and grows, is at the same time the main cell responsible for its elimination.  The uptake of Leishmania promastigotes by host cells is a receptor mediated process that initiates phagocytosis (Ueno et al. 2012). Some parasites differentiate and survive within the macrophage phagolysosomes; others are killed by the acidic and higher temperature environment (Rossi et al. 2018). In the end, it is the balance between the host and parasitic factors that control the activation/deactivation of macrophages that determines the fate of the parasites as well as the infection outcome (Liu et al. 2012b).  The pathways curated here summarize the major steps of parasite internalization by the macrophage, the defence mechanisms that are turned on and the mechanisms of evasion of the parasite to counteract them.  </bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence2328">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway29">
 <bp:pathwayOrder rdf:resource="#PathwayStep52" />
 <bp:pathwayComponent rdf:resource="#Pathway30" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence52" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Cell recruitment (pro-inflammatory response)</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Migration of immune cells is orchestrated by a fine balance of cytokine and chemokine responses. During Leishmania macrophage interaction, either pro inflammatory or anti-inflammatory cytokines are produced, having an impact in the establishment of infection and further clinical outcome (Navas et al. 2014). Toll like receptors, GPCRs such as the purinergic receptors P2YRs, complement receptor 3A and interleukin receptor 15 amongst others, have been associated with the production of pro inflammatory cytokines (Lai and Gallo 2012    Cekic et al. 2016). A strong pro inflammatory response in the acute phase of the infection helps to control the parasite load when the recruited cells enhance microbiocidal mechanisms. However, alterations in the chemokine network may contribute to uncontrolled immune responses that can modulate parasite survival and promote or mitigate the associated immunopathology, thereby influencing the outcome of infection (Navas et al. 2014).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence2329">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway23">
 <bp:pathwayOrder rdf:resource="#PathwayStep43" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction21" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence43" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective VWF cleavage by ADAMTS13 variant</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Under normal physiological conditions, a disintegrin and metalloproteinase with thrombospondin type 1 repeats 13 (ADAMTS13) downregulates VWF procoagulant activity by cleaving the peptide bond between Tyr1605 and Met1606 within the A2 domain of VWF in a shear-dependent manner. Deficiencies in ADAMTS13 activity results in defective cleavage of ultra large VWF multimer in the plasma and are associated with excessive thrombi formation in the microvasculature in patients with thrombotic thrombocytopenic purpura (TTP) (Zheng XL 2015; Sukumar S et al. 2021). TTP is caused either by inherited mutations in the ADAMTS13 gene or by acquired inhibitory autoantibodies directed against the ADAMTS13 protein. This Reactome event describes defective cleavage of VWF by TTP-causing loss-of-function ADAMTS13 variants, A250V, P475S, Q449*, which showed normal or slightly reduced secretion (Kokame K et al., 2002; Uchida T et al., 2004; Markham-Lee Z et al., 2022).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway24">
 <bp:pathwayOrder rdf:resource="#PathwayStep45" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction22" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence45" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Enhanced binding of GP1BA variant to VWF multimer:collagen </bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The Reactome event describes gain-of-function variants of glycoprotein Ib &#945; (GPIb&#945;, encoded by GP1BA) that cause macrothrombocytopenia and mucocutaneous bleeding in patients with platelet-type von Willebrand disease (PT-VWD) due to enhanced affinity for von Willebrand factor (VWF).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep310">
 <bp:stepProcess rdf:resource="#BiochemicalReaction241" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway25">
 <bp:pathwayOrder rdf:resource="#PathwayStep47" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction23" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence47" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective VWF binding to collagen type I </bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Upon vascular injury, circulating von Willebrand factor (VWF) binds to exposed vascular collagen. This Reactome event shows defective binding of VWF to collagen type I caused by loss-of-function mutations in the A3 domain of VWF found in patients with von Willebrand disease (VWD) type 2M, which is characterized by defects in platelet adhesion and/or collagen binding with normal or subnormal VWF multimer distribution.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway26">
 <bp:pathwayOrder rdf:resource="#PathwayStep49" />
 <bp:pathwayOrder rdf:resource="#PathwayStep167" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1070" />
 <bp:pathwayComponent rdf:resource="#Pathway27" />
 <bp:pathwayComponent rdf:resource="#Pathway181" />
 <bp:pathwayComponent rdf:resource="#Pathway42" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence49" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Infectious disease</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Infectious diseases are ones due to the presence of pathogenic microbial agents in human host cells. Processes annotated in this category include bacterial, viral and parasitic infection pathways.  Bacterial infection pathways currently include some metabolic processes mediated by intracellular Mycobacterium tuberculosis, the actions of clostridial, anthrax, and diphtheria toxins, and the entry of Listeria monocytogenes into human cells.  Viral infection pathways currently include the life cycles of SARS-CoV viruses, influenza virus, HIV (human immunodeficiency virus), and human cytomegalovirus (HCMV).  Parasitic infection pathways currently include Leishmania infection-related pathways.  Fungal infection pathways and prion diseases have not been annotated.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway20">
 <bp:pathwayOrder rdf:resource="#PathwayStep38" />
 <bp:pathwayOrder rdf:resource="#PathwayStep40" />
 <bp:pathwayOrder rdf:resource="#PathwayStep42" />
 <bp:pathwayOrder rdf:resource="#PathwayStep44" />
 <bp:pathwayOrder rdf:resource="#PathwayStep46" />
 <bp:pathwayComponent rdf:resource="#Pathway23" />
 <bp:pathwayComponent rdf:resource="#Pathway24" />
 <bp:pathwayComponent rdf:resource="#Pathway25" />
 <bp:pathwayComponent rdf:resource="#Pathway21" />
 <bp:pathwayComponent rdf:resource="#Pathway22" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence38" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defects of platelet adhesion to exposed collagen</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">This Reactome module describes dysfunctions in platelet adhesion caused by mutations in different genes, including VWF, ADAMTS13 and GP1BA. </bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway21">
 <bp:pathwayOrder rdf:resource="#PathwayStep39" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction19" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence39" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective binding of VWF variant to GPIb:IX:V</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">This Reactome event describes von Willebrand disease (VWD)-associated missense mutations in the A1 domain of VWF, namely VWF S1358N, S1387I, S1394F and Q1402P, that compromise the clot formation due to reduced binding to GPIb (Larsen DM et al., 2013).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway22">
 <bp:pathwayOrder rdf:resource="#PathwayStep41" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction20" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence41" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Enhanced cleavage of VWF variant by ADAMTS13</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Under normal physiological conditions, a disintegrin and metalloproteinase with thrombospondin type 1 repeats 13 (ADAMTS13) downregulates von Willebrand factor (VWF) procoagulant activity by cleaving the peptide bond between Tyr1605 and Met1606 of VWF in a shear-dependent manner. This Reactome event describes von Willebrand disease (VWD)-associated missense mutations VWF Y1584C (Bowen DJ et al., 2005; Keeney S et al., 2007; Pruss CM et al., 2012), I1568N, G1579R, G1631D, and C1099P (Jacobi PM et al., 2012), which showed enhanced susceptibility to ADAMTS13-mediated proteolysis. </bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence362">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence361">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep308">
 <bp:stepProcess rdf:resource="#Catalysis67" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction240" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence364">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1298">
 <bp:evidence rdf:resource="#Evidence1603" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Resistant ERBB2 KD mutants do not bind AEE788</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep309">
 <bp:stepProcess rdf:resource="#Pathway60" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence363">
</bp:Evidence>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1299">
 <bp:evidence rdf:resource="#Evidence1605" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Resistant ERBB2 KD mutants do not bind lapatinib</bp:displayName>
</bp:BiochemicalReaction>

<bp:Evidence rdf:ID="Evidence360">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep302">
 <bp:stepProcess rdf:resource="#Pathway57" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence2330">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep303">
 <bp:stepProcess rdf:resource="#BiochemicalReaction237" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence369">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1000">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2331">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep300">
 <bp:stepProcess rdf:resource="#BiochemicalReaction235" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence1001">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2332">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep301">
 <bp:stepProcess rdf:resource="#BiochemicalReaction236" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence1002">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2333">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep306">
 <bp:stepProcess rdf:resource="#BiochemicalReaction239" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence366">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1003">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2334">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep307">
 <bp:stepProcess rdf:resource="#Pathway59" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence365">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1004">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2335">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep304">
 <bp:stepProcess rdf:resource="#BiochemicalReaction238" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence368">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1005">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2336">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep305">
 <bp:stepProcess rdf:resource="#Pathway58" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence367">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence1006">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2337">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep261">
 <bp:stepProcess rdf:resource="#BiochemicalReaction200" />
 <bp:stepProcess rdf:resource="#Catalysis62" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep262">
 <bp:stepProcess rdf:resource="#BiochemicalReaction201" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep260">
 <bp:stepProcess rdf:resource="#BiochemicalReaction199" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep265">
 <bp:stepProcess rdf:resource="#BiochemicalReaction204" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep266">
 <bp:stepProcess rdf:resource="#BiochemicalReaction205" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1190">
 <bp:evidence rdf:resource="#Evidence1447" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Autophosphorylation of cytosolic PDGFRA and PDGFRB fusion proteins</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep263">
 <bp:stepProcess rdf:resource="#BiochemicalReaction202" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep264">
 <bp:stepProcess rdf:resource="#BiochemicalReaction203" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1193">
 <bp:evidence rdf:resource="#Evidence1451" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Autophosphorylation of PDGFR mutant dimers</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1194">
 <bp:evidence rdf:resource="#Evidence1452" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Ligand-independent dimerization of PDGFR mutants</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1191">
 <bp:evidence rdf:resource="#Evidence1448" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Ligand-independent dimerization of cytosolic PDGFRA and PDGFRB fusion proteins</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1192">
 <bp:evidence rdf:resource="#Evidence1450" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">PI3-kinase binds to mutant PDGFR receptor</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1197">
 <bp:evidence rdf:resource="#Evidence1455" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">STAT binds to the mutant PDGFRA receptor</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1198">
 <bp:evidence rdf:resource="#Evidence1456" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">PI3K catalyses the phosphorylation of PIP2 to PIP3 downstream of mutant PDGFR</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1195">
 <bp:evidence rdf:resource="#Evidence1453" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SOS-mediated nucleotide exchange of RAS downstream of mutant PDGFR receptors</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1196">
 <bp:evidence rdf:resource="#Evidence1454" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">GRB2:SOS1 complex binds to mutant PDGFR receptor</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1188">
 <bp:evidence rdf:resource="#Evidence1444" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">PI3-kinase binds to PDGFRA extracellular domain dimers</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1189">
 <bp:evidence rdf:resource="#Evidence1445" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SOS-mediated nucleotide exchange on RAS downstream of PDGFRA extracellular domain dimers</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep258">
 <bp:stepProcess rdf:resource="#BiochemicalReaction197" />
 <bp:stepProcess rdf:resource="#Catalysis61" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep259">
 <bp:stepProcess rdf:resource="#BiochemicalReaction198" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep256">
 <bp:stepProcess rdf:resource="#BiochemicalReaction195" />
 <bp:stepProcess rdf:resource="#Catalysis60" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep257">
 <bp:stepProcess rdf:resource="#BiochemicalReaction196" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence2400">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2401">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2402">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2403">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep250">
 <bp:stepProcess rdf:resource="#Catalysis59" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction189" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep251">
 <bp:stepProcess rdf:resource="#BiochemicalReaction190" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep254">
 <bp:stepProcess rdf:resource="#BiochemicalReaction193" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep255">
 <bp:stepProcess rdf:resource="#BiochemicalReaction194" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep252">
 <bp:stepProcess rdf:resource="#BiochemicalReaction191" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep253">
 <bp:stepProcess rdf:resource="#BiochemicalReaction192" />
</bp:PathwayStep>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction1199">
 <bp:evidence rdf:resource="#Evidence1460" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Phosphorylated SMAD2/3 MH2 Domain Mutants do not bind SMAD4</bp:displayName>
</bp:BiochemicalReaction>

<bp:PathwayStep rdf:ID="PathwayStep247">
 <bp:stepProcess rdf:resource="#BiochemicalReaction186" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep248">
 <bp:stepProcess rdf:resource="#BiochemicalReaction187" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep245">
 <bp:stepProcess rdf:resource="#Catalysis57" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction184" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep246">
 <bp:stepProcess rdf:resource="#BiochemicalReaction185" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep249">
 <bp:stepProcess rdf:resource="#Catalysis58" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction188" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence2415">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep240">
 <bp:stepProcess rdf:resource="#Pathway52" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence2416">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2417">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2418">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep243">
 <bp:stepProcess rdf:resource="#BiochemicalReaction182" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence2419">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep244">
 <bp:stepProcess rdf:resource="#Catalysis56" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction183" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep241">
 <bp:stepProcess rdf:resource="#BiochemicalReaction180" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep242">
 <bp:stepProcess rdf:resource="#BiochemicalReaction181" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway390">
 <bp:pathwayOrder rdf:resource="#PathwayStep1974" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1540" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1929" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective SFTPA2 causes IPF</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">One function of the pulmonary collectins, surfactant proteins A1, A2, A3 and D (SFTPAs, D), is that they influence surfactant homeostasis, contributing to the physical structures of lipids in the alveoli and to the regulation of surfactant function and metabolism. They are directly secreted from alveolar type II cells into the airway to function as part of the surfactant. The mechanism of secretion is unknown. Mutations in SFTPA2 disrupt protein structure and the defective protein is retained in the ER membrane causing idiopathic pulmonary fibrosis (IPF; MIM:178500). IPF is one of a family of idiopathic pneumonias sharing clinical features of shortness of breath, formation of scar tissue and varying degrees of inflammation and/or fibrosis on lung biopsy. IPF is typically progressive, leading to death from respiratory failure within 2-5 years of diagnosis in the majority of instances (Meltzer    Noble 2008, Noble    Barkauskas 2012).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway392">
 <bp:pathwayOrder rdf:resource="#PathwayStep1978" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1542" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1933" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective pro-SFTPB causes SMDP1 and RDS</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Pulmonary surfactant-associated protein B (SFTPB), amongst other roles, is a component of surfactant, a surface-active film that helps reduce surface tension in alveoli. Defects in the SFTPB gene result in loss-of-function SFTPB proteins and accumulation of partially-processed , inactive pro-SFTPC in alveoli. Defects in SFTPB can cause pulmonary surfactant metabolism dysfunction 1 (SMDP1; MIM:265120), a rare lung disorder due to impaired surfactant homeostasis characterised by alveoli filling with floccular material. Excessive lipoprotein accumulation in the alveoli results in a form of respiratory distress syndrome in premature infants (RDS; MIM:267450) (Vorbroker et al. 1995, Li et al. 2004, Wert et al. 2009, Whitsett et al. 2015).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway391">
 <bp:pathwayOrder rdf:resource="#PathwayStep1976" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1541" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1931" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective ABCA3 causes SMDP3</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ATP-binding cassette sub-family A member 3 (ABCA3) plays an important role in the formation of pulmonary surfactant, probably by transporting phospholipids such as phosphatidylcholine (PC) and phosphatidylglycerol (PG) from the ER membrane to lamellar bodies (LBs). PC and PG are the major phospholipid constituents of pulmonary surfactant. LBs are the surfactant storage organelles of type II epithelial cells from where phospholipids can be secreted together with surfactant proteins (SFTPs) into the alveolar airspace. Defects in ABCA3 can cause pulmonary surfactant metabolism dysfunction type 3 (SMDP3; MIM:610921), resulting in respiratory distress in newborns and interstitial lung disease (ILD) in children (Whitsett et al. 2015).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway394">
 <bp:pathwayOrder rdf:resource="#PathwayStep1982" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1544" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1937" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective CSF2RB causes SMDP5</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Surfactant catabolism by alveolar macrophages plays a small but critical part in surfactant recycling and metabolism. Upon ligand binding, granulocyte-macrophage colony-stimulating factor receptor (GM-CSFR), a heterodimer of alpha (CSF2RA) and beta (CSF2RB) subunits, initiates a signalling process that not only induces proliferation, differentiation and functional activation of hematopoietic cells but can also determine surfactant uptake into alveolar macrophages and its degradation via clathrin-coated vesicles. Defects in human CSF2RB can cause pulmonary surfactant metabolism dysfunction 5 (SMDP5; MIM:614370, aka pulmonary alveolar proteinosis 5, PAP5), a rare lung disorder due to impaired surfactant homeostasis characterised by alveoli filling with floccular material causing respiratory failure (Greenhill    Kotton 2009, Whitsett et al. 2015).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway393">
 <bp:pathwayOrder rdf:resource="#PathwayStep1980" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1543" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1935" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective SLC34A2 causes PALM</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The human gene SLC34A2 encodes NaPi-2b which is abundantly expressed in lung and to a lesser degree in epithelia of other tissues including small intestine, pancreas, prostate, and kidney. In the lung, SLC34A2 is expressed only in alveolar type II cells, which are responsible for surfactant production, so it is proposed that it uptakes liberated phosphate from the alveolar fluid for surfactant production. SLC34A2 cotransports divalent phosphate (HPO4(2-)) with three Na+ ions (electrogenic transport) from the extracellular region into alveolar type II cells. Defects in SLC34A2 can cause pulmonary alveolar microlithiasis (PALM; MIM:265100), a rare disease characterised by the deposition of calcium phosphate microliths (tiny, roundish corpuscles) throughout the lung. Most patients remain asymptomatic for years or decades, the disease following a long-term, progressive course resulting in slow deterioration of lung functions. PALM can result in a potentially lethal disease (Yin et al. 2013, Ferreira Francisco et al. 2013, Whitsett et al. 2015).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep236">
 <bp:stepProcess rdf:resource="#BiochemicalReaction176" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway396">
 <bp:pathwayOrder rdf:resource="#PathwayStep1986" />
 <bp:pathwayComponent rdf:resource="#Pathway397" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1941" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Diseases of mitochondrial beta oxidation</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Of the array of known defects of mitochondrial lipid metabolism, one is annotated in Reactome, methylmalonic acidurioa due to deficiencies of the MMUT (Methylmalonyl-CoA mutase, mitochondrial) enzyme (Worgan et al. 2006)</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep237">
 <bp:stepProcess rdf:resource="#BiochemicalReaction177" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway395">
 <bp:pathwayOrder rdf:resource="#PathwayStep1984" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1545" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1939" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective pro-SFTPC causes SMDP2 and RDS</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Pulmonary surfactant-associated protein C (SFTPC), amongst other roles, is a component of surfactant, a surface-active film that helps reduce surface tension in alveoli. Defects in the SFTPC gene result in protein misfolding, misrouting and/or misprocessing resulting in accumulation of partially-processed, inactive pro-SFTPC in alveoli causing cell toxicity. Defects in SFTPC can cause pulmonary surfactant metabolism dysfunction 2 (SMDP2; MIM:610913), a rare lung disorder due to impaired surfactant homeostasis characterised by alveoli filling with floccular material. Cellular responses to the misfolded pro-SFTPC products include ER stress, the activation of reactive oxygen species and autophagy. Excessive lipoprotein accumulation in the alveoli results in a form of respiratory distress syndrome in premature infants (RDS; MIM:267450) (Thomas et al. 2002, Mulugeta et al. 2005, Thurm et al. 2013, Whitsett et al. 2015).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep234">
 <bp:stepProcess rdf:resource="#BiochemicalReaction174" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway398">
 <bp:pathwayOrder rdf:resource="#PathwayStep1988" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1546" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1943" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective MUT causes MMAM</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defects in MUT cause methylmalonic aciduria, mut type (MMAM; MIM:251000), an often fatal disorder of organic acid metabolism (Worgan et al. 2006).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence2420">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep235">
 <bp:stepProcess rdf:resource="#BiochemicalReaction175" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway397">
 <bp:pathwayOrder rdf:resource="#PathwayStep1987" />
 <bp:pathwayComponent rdf:resource="#Pathway398" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1942" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Diseases of propionyl-CoA catabolism</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Propionyl-CoA catabolism is the aspect of mitochondrial beta-oxidation affected by the one disease of this process annotated in Reactome.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence2421">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2422">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway399">
 <bp:pathwayOrder rdf:resource="#PathwayStep2007" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2009" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1999" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2043" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1990" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2001" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2045" />
 <bp:pathwayComponent rdf:resource="#Pathway406" />
 <bp:pathwayComponent rdf:resource="#Pathway405" />
 <bp:pathwayComponent rdf:resource="#Pathway408" />
 <bp:pathwayComponent rdf:resource="#Pathway407" />
 <bp:pathwayComponent rdf:resource="#Pathway420" />
 <bp:pathwayComponent rdf:resource="#Pathway400" />
 <bp:pathwayComponent rdf:resource="#Pathway421" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1945" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Diseases of carbohydrate metabolism</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The processes by which dietary carbohydrate is digested to monosaccharides and these are taken up from the gut lumen into cells where they are oxidized to yield energy or consumed in biosynthetic processes are a central part of human metabolism and defects in them can lead to serious disease. Defects annotated here affect saccharide digestion in the gut lumen, fructose metabolism, and the pentose phosphate pathway. In addition, the defect in glucuronate catabolism that leads to essential pentosuria, a benign phenotype that is one of Garrod&apos;s original four inborn errors of metabolism, is annotated.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Evidence rdf:ID="Evidence2423">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep238">
 <bp:stepProcess rdf:resource="#BiochemicalReaction178" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence2424">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep239">
 <bp:stepProcess rdf:resource="#BiochemicalReaction179" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence2425">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2404">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2405">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2406">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2407">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep232">
 <bp:stepProcess rdf:resource="#BiochemicalReaction172" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence2408">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep233">
 <bp:stepProcess rdf:resource="#BiochemicalReaction173" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence2409">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep230">
 <bp:stepProcess rdf:resource="#BiochemicalReaction170" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep231">
 <bp:stepProcess rdf:resource="#BiochemicalReaction171" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep225">
 <bp:stepProcess rdf:resource="#Catalysis55" />
 <bp:stepProcess rdf:resource="#BiochemicalReaction166" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep226">
 <bp:stepProcess rdf:resource="#Pathway51" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep223">
 <bp:stepProcess rdf:resource="#BiochemicalReaction164" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep224">
 <bp:stepProcess rdf:resource="#BiochemicalReaction165" />
 <bp:stepProcess rdf:resource="#Catalysis54" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence2410">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep229">
 <bp:stepProcess rdf:resource="#BiochemicalReaction169" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence2411">
</bp:Evidence>

<bp:Evidence rdf:ID="Evidence2412">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep227">
 <bp:stepProcess rdf:resource="#BiochemicalReaction167" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence2413">
</bp:Evidence>

<bp:PathwayStep rdf:ID="PathwayStep228">
 <bp:stepProcess rdf:resource="#BiochemicalReaction168" />
</bp:PathwayStep>

<bp:Evidence rdf:ID="Evidence2414">
</bp:Evidence>

<bp:Pathway rdf:ID="Pathway370">
 <bp:pathwayOrder rdf:resource="#PathwayStep1901" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1869" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1875" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1898" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1899" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1900" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1871" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1872" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1873" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1874" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1870" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1455" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1458" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1459" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1456" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1457" />
 <bp:pathwayComponent rdf:resource="#Pathway371" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1479" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1480" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1481" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1460" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1482" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1824" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Signaling by FGFR2 in disease</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The FGFR2 gene has been shown to be subject to activating mutations and gene amplification leading to a variety of proliferative and developmental disorders depending on whether these events occur in the germline or arise somatically.  Activating FGFR2 mutations in the germline give rise to a range of craniosynostotic conditions including Pfeiffer, Apert, Jackson-Weiss, Crouzon and Beare-Stevensen Cutis Gyrata syndromes.  These autosomal dominant skeletal disorders are characterized by premature fusion of several sutures in the skull, and in some cases also involve syndactyly (abnormal bone fusions in the hands and feet) (reviewed in Webster and Donoghue, 1997; Burke, 1998; Cunningham, 2007).   Activating FGFR2 mutations arising somatically have been linked to the development of gastric and endometrial cancers (reviewed in Greulich and Pollock, 2011; Wesche, 2011).  Many of these mutations are similar or identical to those that contribute to the autosomal disorders described above.  Notably, loss-of-function mutations in FGFR2 have also been recently described in melanoma (Gartside, 2009).  FGFR2 may also contribute to tumorigenesis through overexpression, as FGFR2 has been identified as a target of gene amplification in gastric and breast cancers (Kunii, 2008; Takeda, 2007).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway372">
 <bp:pathwayOrder rdf:resource="#PathwayStep1877" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1878" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1461" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1462" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1832" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Signaling by FGFR2 IIIa TM</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">A soluble truncated form of FGFR2 is aberrantly expressed in an Apert Syndrome mouse model and inhibits FGFR signaling in vitro and in vivo.  This variant, termed FGFR IIIa TM, arises from an misspliced transcript that fuses exon 7 to exon 10 and that escapes nonsense-mediated decay.  FGFR2 IIIa TM may inhibit signaling by sequestering FGF ligand and/or by forming nonfunctional heterodimers with full-length receptors at the cell surface (Wheldon et al, 2011).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway371">
 <bp:pathwayOrder rdf:resource="#PathwayStep1879" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1876" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1887" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1884" />
 <bp:pathwayComponent rdf:resource="#Pathway372" />
 <bp:pathwayComponent rdf:resource="#Pathway374" />
 <bp:pathwayComponent rdf:resource="#Pathway373" />
 <bp:pathwayComponent rdf:resource="#Pathway375" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1831" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FGFR2 mutant receptor activation</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Autosomal dominant mutations in FGFR2 are associated with the development of a range of skeletal disorders including Beare-Stevensen cutis gyrata syndrome, Pfeiffer syndrome, Jackson-Weiss syndrome, Crouzon syndrome and Apert Syndrome (reveiwed in Burke, 1998; Webster and Donoghue 1997; Cunningham, 2007).  Activating point mutations have also been identified in FGFR2 in ~15% of endometrial cancers, as well as to a lesser extent in ovarian and gastric cancers (Dutt, 2008; Pollock, 2007; Byron, 2010; Jang, 2001).  Activating mutations in FGFR2 are thought to contribute to receptor activation through diverse mechanisms, including constitutive ligand-independent dimerization (Robertson, 1998), expanded range and affinity for ligand (Ibrahimi, 2004b; Yu, 2000) and enhanced kinase activity (Byron, 2008; Chen, 2007).  FGFR2 amplifications have been identified in 10% of gastric cancers, where they are associated with poor prognosis diffuse cancers (Hattori, 1996; Ueda, 1999; Shin, 2000; Kunii, 2008) , and in ~1% of breast cancers (Turner, 2010; Tannheimer, 2000).   FGFR2 amplification often occur in conjunction with deletions of C-terminal exons, resulting in expression of a internalization- and degradation-resistant form of the receptor (Takeda, 2007; Cha, 2008, 2009). Signaling through overexpressed FGFR2 shows evidence of being ligand-independent and sensitive to FGFR inhibitors  (Lorenzi, 1997; Takeda, 2007; Cha, 2009). More recently, FGFR2 fusion proteins have been identified in a number of cancers; these are thought to form constitutive ligand-independent dimers based on the dimerization domains of the 3&apos; fusion partners and contribute to cellular proliferation and tumorigenesis in a kinase-inhibitor sensitive manner (Wu, 2013; Arai, 2013; Seo, 2012; reviewed in Parker, 2014). </bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway374">
 <bp:pathwayOrder rdf:resource="#PathwayStep1886" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1885" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1467" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1468" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1840" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Signaling by FGFR2 fusions</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FGFR2 fusions have been identified in cancers such as lung, breast, thyroid and cholangiocarcinoma (Wu et al, 2013; Seo et al, 2012; Arai et al, 2013).  Of all the FGF receptors, FGFR2 shows the broadest range of 3&apos; fusion partners, including BICC1, AHCYL1, CIT, CCDC6, CASP7, AFF3, OFD1 and CCAR2.  Many of these fusion partners contain dimerization domains, suggesting that the resulting fusions may demonstrate constitutive ligand-independent activation (Wu et al, 2013; Arai et al, 2013; Seo et al, 2012; reviewed in Parker et al, 2014).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway373">
 <bp:pathwayOrder rdf:resource="#PathwayStep1882" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1883" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1880" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1881" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1465" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1466" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1463" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1464" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1835" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Signaling by FGFR2 amplification mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FGFR2 amplifications have been identified in 10% of gastric cancers, where they are associated with poor prognosis diffuse cancers (Hattori, 1996; Ueda, 1999; Shin, 2000; Kunii, 2008) , and in ~1% of breast cancers (Turner, 2010; Tannheimer, 2000).   FGFR2 amplification often occur in conjunction with deletions of C-terminal exons, resulting in expression of a internalization- and degradation-resistant form of the receptor (Takeda, 1999; Cha, 2008, 2009). Amplification affects signaling without altering the intrinsic kinase activity of the receptor. Signaling through overexpressed FGFR2 also shows evidence of being ligand-independent and sensitive to FGFR inhibitors  (Lorenzi, 1997; Takeda, 1999; Cha, 2009).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway376">
 <bp:pathwayOrder rdf:resource="#PathwayStep1923" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1924" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1903" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1925" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1904" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1926" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1920" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1921" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1922" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1905" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1927" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1906" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1498" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1499" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1485" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1496" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1497" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1502" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1503" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1500" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1501" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1483" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1484" />
 <bp:pathwayComponent rdf:resource="#Pathway377" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1858" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Signaling by FGFR3 in disease</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The FGFR3 gene has been shown to be subject to activating mutations and gene amplification leading to a variety of proliferative and developmental disorders depending on whether these events occur in the germline or arise somatically.    Activating mutations in FGFR3 are associated with the development of a range of skeletal dysplasias that result in dwarfism (reviewed in Webster and Donoghue, 1997; Burke et al, 1998; Harada et al, 2009).  The most common form of human dwarfism is achondroplasia (ACH), which is caused by mutations G380R and G375C in the transmembrane domain of FGFR3 that are thought to promote ligand-independent dimerization (Rousseau et al, 1994; Shiang et al, 1994; Bellus et al, 1995a)  Hypochondroplasia (HCH) is a milder form dwarfism that is the result of mutations in the tyrosine kinase domain of FGFR3 (Bellus et al, 1995b).  Two neonatal lethal conditions, thanatophoric dysplasia type I and II (TDI and TDII) are also the result of mutations in FGFR3; TDI arises from a range of mutations that either result in the formation of unpaired cysteine residues in the extracellular region that promote aberrant ligand-independent dimerization or by mutations that introduce stop codons (Rousseau et al, 1995; Rousseau et al, 1996, D&apos;Avis et al,1998).  A single mutation, K650E in the second tyrosine kinase domain of FGFR3 is responsible for all identified cases of TDII (Tavormina et al, 1995a, b).  Other missense mutations at the same K650 residue give rise to Severe Achondroplasia with Developmental Disorders and Acanthosis Nigricans (SADDAN) syndrome (Tavormina et al, 1999; Bellus et al, 1999).   The severity of the phenotype arising from many of the activating FGFR3 mutations has recently been shown to correlate with the extent to which the mutations activate the receptor (Naski et al, 1996; Bellus et al, 2000)   In addition to mutations that cause dwarfism syndromes, a Pro250Arg mutation in the conserved dipeptide between the IgII and IgIII domains has been identified in an atypical craniosynostosis condition (Bellus et al, 1996; Reardon et al, 1997).  This mutation, which is paralogous to mutations seen in FGFR1 and 2 in Pfeiffer and Apert Syndrome, respectively, results in an increase in ligand-binding affinity for the receptor (Ibrahimi et al, 2004b).   Of all the FGF receptors, FGFR3 has perhaps the best established link to the development in cancer.  50% of bladder cancers have somatic mutations in the coding sequence of FGFR3; of these, more than half occur in the extracellular region at a single position (S249C) (Cappellen et al, 1999; Naski et al, 1996; di Martino et al, 2009, Sibley et al, 2001).  Activating mutations are also seen in the juxta- and trans-membrane domains, as well as in the kinase domain (reviewed in Weshe et al, 2011).  As is the case for the other receptors, many of the activating mutations that are seen in FGFR3-related cancers mimic the germline FGFR3 mutations that give rise to autosomal skeletal disorders and include both ligand-dependent and independent mechanisms (reviewed in Webster and Donoghue, 1997; Burke et al, 1998). In addition to activating mutations, the FGFR3 gene is subject to a translocation event in 15% of multiple myelomas (Avet-Loiseau et al, 1998; Chesi et al, 1997).  This chromosomal rearrangement puts the FGFR3 gene under the control of the highly active IGH promoter and promotes overexpression and constitutive activation of FGFR3.  In a small proportion of multiple myelomas, the translocation event is accompanied by activating mutations in the FGFR3 coding sequence (Chesi et al, 1997).  More recently, a number of fusion proteins of FGFR3 have been identified in various cancers (Singh et al, 2012; Williams et al, 2013; Parker et al, 2013; Wu et al, 2013; Wang et al, 2014; Yuan et al, 2014; reviewed in Parker et al, 2014). The most common fusion protein is TACC3, a coiled coil protein involved in mitotic spindle assembly.  FGFR3 fusion proteins are constitutively active and appear to contribute to proliferation and tumorigenesis through activation of the ERK and AKT signaling pathways (reviewed in Parker et al, 2014).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway375">
 <bp:pathwayOrder rdf:resource="#PathwayStep1897" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1888" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1889" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1893" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1894" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1895" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1896" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1890" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1891" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1892" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1476" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1477" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1474" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1475" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1469" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1478" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1472" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1473" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1470" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1471" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1843" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activated point mutants of FGFR2</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Autosomal dominant mutations in FGFR2 are associated with the development of a range of skeletal disorders including Beare-Stevensen cutis gyrata syndrome, Pfeiffer syndrome, Jackson-Weiss syndrome, Crouzon syndrome and Apert Syndrome (reveiwed in Burke, 1998; Webster and Donoghue 1997; Cunningham, 2007).  Mutations that give rise to Crouzon, Jackson-Weiss and Pfeiffer syndromes tend to cluster in the third Ig-like domain of the receptor, either in exon IIIa (shared by the IIIb and the IIIc isoforms) or in the FGFR2c-specific exon IIIc.  These mutations frequently involve creation or removal of a cysteine residue, leading to the formation of an unpaired cysteine residue that is thought to promote intramolecular dimerization and thus constitutive, ligand-independent activation (reviewed in Burke, 1998; Webster and Donoghue, 1997; Cunningham, 2007).  Mutations in FGFR2 that give rise to Apert Syndrome cluster to the highly conserved Pro-Ser dipeptide in the IgII-Ig III linker; mutations in the paralogous residues of FGFR1 and 3 give rise to Pfeiffer and Muenke syndromes, respectively (Muenke, 1994; Wilkie, 1995; Bellus, 1996). Development of Beare-Stevensen cutis gyrata is associated with mutations in the transmembrane-proximal region of the receptor (Przylepa, 1996), and similar mutations in FGFR3 are linked to the development of thanatophoric dysplasia I (Tavormina, 1995a).  These mutations all affect FGFR2 signaling without altering the intrinsic kinase activity of the receptor.   Activating point mutations have also been identified in FGFR2 in ~15% of endometrial cancers, as well as to a lesser extent in ovarian and gastric cancers (Dutt, 2008; Pollock, 2007; Byron, 2010; Jang, 2001).  These mutations are found largely in the extracellular region and in the kinase domain of the receptor, and parallel activating mutations seen in autosomal dominant disorders described above.   Activating mutations in FGFR2 are thought to contribute to receptor activation through diverse mechanisms, including constitutive ligand-independent dimerization (Robertson, 1998), expanded range and affinity for ligand (Ibrahimi, 2004b; Yu, 2000) and enhanced kinase activity (Byron, 2008; Chen, 2007).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway378">
 <bp:pathwayOrder rdf:resource="#PathwayStep1912" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1913" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1910" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1911" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1909" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1908" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1487" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1488" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1486" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1489" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1490" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1491" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1863" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Signaling by activated point mutants of FGFR3</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activating point mutations in FGFR3 are found in the extracellular ligand-binding domain, the transmembrane region and the tyrosine kinase domain and are believed to result in ligand-independent activation of the receptor (Webster and Donoghue, 1996; Wenbster, 1997).  These mutations, although initially characterized in the context of autosomal skeletal disorders, are now being identified in a range of cancers including bladder, cervical, breast, prostate, head and neck, and multiple myeloma (reviewed in Wesche, 2011). </bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway377">
 <bp:pathwayOrder rdf:resource="#PathwayStep1914" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1917" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1907" />
 <bp:pathwayComponent rdf:resource="#Pathway380" />
 <bp:pathwayComponent rdf:resource="#Pathway378" />
 <bp:pathwayComponent rdf:resource="#Pathway379" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1862" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FGFR3 mutant receptor activation</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The FGFR3 gene has been shown to be subject to activating mutations and gene amplification leading to a variety of proliferative and developmental disorders depending on whether these events occur in the germline or arise somatically.  As is the case for the other receptors, many of the activating mutations that are seen in FGFR3-related cancers mimic the germline FGFR3 mutations that give rise to autosomal skeletal disorders and include both ligand-dependent and independent mechanisms (reviewed in Webster and Donoghue, 1997; Burke et al, 1998; Wesche et al, 2011). In addition to activating mutations, the FGFR3 gene is subject to a translocation event in 15% of multiple myelomas (Avet-Loiseau et al, 1998; Chesi et al, 1997). This chromosomal rearrangement puts the FGFR3 gene under the control of the highly active IGH promoter and promotes overexpression and constitutive activation of FGFR3 (Otsuki et al, 1999).  In a small proportion of multiple myelomas, the translocation event is accompanied by activating mutations in the FGFR3 coding sequence (Chesi et al, 1997; Onwuazor et al, 2003; Ronchetti et al, 2001). Finally, FGFR3 is subject to fusion events in a number of cancers, including lung, bladder and glioblastoma (Singh et al, 2012; Parker et al, 2013; Williams et al, 2013; Wu et al, 2013; Capelletti et al, 2014; Yuan et al, 2014; Wang et al, 2014; Carneiro et al, 2015; reviewed in Parker et al, 2014). These fusions are constitutively active based on dimerization domains provided by the fusion partners and support transformation and proliferation through downstream signaling pathways such as ERK and AKT (Singh et al, 2012; Williams et al, 2013; Parker et al, 2013; reviewed in Parker et al, 2014).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway379">
 <bp:pathwayOrder rdf:resource="#PathwayStep1915" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1916" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1492" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1493" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1870" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">t(4;14) translocations of FGFR3</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Translocations which put the FGFR3 gene under the control of the strong IGH promoter have been identified in 15% of multiple myelomas (Avet-Loiseau, 1998; Chesi, 1997; Chesi, 2001).  This translocation, which occurs 70kb upstream of the FGFR3 gene, also involves the nearby multiple myeloma SET-domain containing (MMSET) gene (Lauring, 2008), and although the contribution of each of these genes to the development of cancer has not been fully elucidated, several studies have shown that t(4:14) myeloma cell lines are sensitive to FGFR3 inhibitors (Trudel, 2006; Qing, 2009).  In ~5% of cases, the translocation is accompanied by activating mutations of FGFR3 (Onwuazor, 2003; Ronchetti, 2001).  The t(4;14) translocation results in overexpression of FGFR3 and subsequent ligand independent or anomalous ligand-dependent signaling (Otsuki, 1999).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep294">
 <bp:stepProcess rdf:resource="#BiochemicalReaction230" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep295">
 <bp:stepProcess rdf:resource="#BiochemicalReaction231" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep292">
 <bp:stepProcess rdf:resource="#BiochemicalReaction228" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep293">
 <bp:stepProcess rdf:resource="#BiochemicalReaction229" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep298">
 <bp:stepProcess rdf:resource="#BiochemicalReaction233" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep299">
 <bp:stepProcess rdf:resource="#BiochemicalReaction234" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep296">
 <bp:stepProcess rdf:resource="#BiochemicalReaction232" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep297">
 <bp:stepProcess rdf:resource="#Pathway56" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep290">
 <bp:stepProcess rdf:resource="#BiochemicalReaction226" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep291">
 <bp:stepProcess rdf:resource="#BiochemicalReaction227" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway381">
 <bp:pathwayOrder rdf:resource="#PathwayStep1934" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1967" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1935" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1968" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1930" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1931" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1932" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1965" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1933" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1966" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1929" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1535" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1536" />
 <bp:pathwayComponent rdf:resource="#Pathway382" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1506" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1507" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1504" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1537" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1505" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1538" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1508" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1509" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1884" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Signaling by FGFR1 in disease</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The FGFR1 gene has been shown to be subject to activating mutations, chromosomal rearrangements and gene amplification leading to a variety of proliferative and developmental disorders depending on whether these events occur in the germline or arise somatically (reviewed in Webster and Donoghue, 1997; Burke, 1998; Cunningham, 2007; Wesche, 2011; Greulich and Pollock, 2011).     Activating mutation P252R in FGFR1 is associated with the development of Pfeiffer syndrome, characterized by craniosynostosis (premature fusion of several sutures in the skull) and broadened thumbs and toes (Muenke, 1994; reviewed in Cunningham, 2007).  This residue falls in a highly conserved Pro-Ser dipeptide between the second and third Ig domains of the extracellular region of the receptor. The mutation is thought to increase the number of hydrogen bonds formed with the ligand and to thereby increase ligand-binding affinity (Ibrahimi, 2004a). Unlike other FGF receptors, few activating point mutations in the FGFR1 coding sequence have been identified in cancer.  Point mutations in the Ig II-III linker analagous to the P252R Pfeiffer syndrome mutation have been identified in lung cancer and melanoma (Ruhe, 2007; Davies, 2005), and two kinase-domain mutations in FGFR1 have been identified in glioblastoma (Rand, 2005, Network TCGA, 2008).  In contrast,  FGFR1 is a target of chromosomal rearrangements in a number of cancers.  FGFR1 has been shown to be recurrently translocated in the 8p11 myeloproliferative syndrome (EMS), a pre-leukemic condition also known as stem cell leukemia/lymphoma (SCLL) that rapidly progresses to leukemia.  This translocation fuses the kinase domain of FGFR1 with the dimerization domain of one of 10 identified fusion partners, resulting in the constitutive dimerization and activation of the kinase (reviewed in Jackson, 2010).    Amplification of the FGFR1 gene has been implicated as a oncogenic factor in a range of cancers, including breast, ovarian, bladder, lung, oral squamous carcinomas, and rhabdomyosarcoma (reviewed in Turner and Grose, 2010; Wesche, 2011; Greulich and Pollock, 2011), although there are other candidate genes in the amplified region and the definitive role of FGFR1 has not been fully established. More recently, FGFR1 fusion proteins have been identified in a number of cancers; these are thought to undergo constitutive ligand-independent dimerization and activation based on dimerization motifs found in the fusion partners (reviewed in Parker, 2014).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway380">
 <bp:pathwayOrder rdf:resource="#PathwayStep1918" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1919" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1494" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1495" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1873" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Signaling by FGFR3 fusions in cancer</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">In recent years, recurrent fusions of FGFR3 have been identified in a number of cancers, including glioblastoma and cancers of the lung and bladder, among others (Singh et al, 2012; Parker et al, 2013; Williams et al, 2013; Wu et al, 2013; Capelletti et al, 2014; Yuan et al, 2014; Wang et al, 2014; Carneiro et al, 2015; reviewed in Parker et al, 2014). The most common fusion partner of FGFR3 is TACC3 (transforming acidic coiled coil protein 3), a protein involved in mitotic spindle assembly and chromosome segregation (Lin et al, 2010; Burgess et al, 2015).  FGFR3 fusions are constitutively active and may form oligomers in a ligand-independent manner based on dimerization domains provided by the fusion partner (Singh et al, 2012; Williams et al, 2013; Parker et al, 2013; reviewed in Parker et al, 2014). Transformation and proliferation appear to be promoted through activation of the ERK and AKT signaling pathways. In contrast, PLC gamma signaling is not stimulated downstream of FGFR3 fusions, as the PLC gamma docking site is not present in the fusion.  FGFR3 fusions are sensitive to protein kinase inhibitors, suggesting their potential as therapeutic targets (Singh et al, 2012; Williams et al, 2013; Wu et al, 2013; reviewed in Parker et al, 2014).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway383">
 <bp:pathwayOrder rdf:resource="#PathwayStep1937" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1938" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1510" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1511" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1892" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Signaling by plasma membrane FGFR1 fusions</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">In addition to the cytosolic FGFR1 fusions identified in 8 myeloproliferative syndrome, plasma membrane localized FGFR1 fusions have been identified in glioblastoma, breast cancer and non small cell lung cancers (Singh et al, 2012; Wu et al, 2013; Wang et al, 2014).  A FGFR1:TACC1 fusion identified in glioblastoma promotes anchorage independent growth when expressed in Rat1A cells, while an ERLIN2:FGFR1 fusion in breast cancer shows constitutive autophosphorylation when expressed in HEK 293 cells (Singh et al, 2012; Wu et al, 2013).  All FGFR1 fusions tested also shown increased sensitivity to growth inhibition upon treatment with kinase inhibitors (Singh et al, 2012; Wu et al, 2013; Wang et al, 2014; reviewed in Parker et al, 2014).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway382">
 <bp:pathwayOrder rdf:resource="#PathwayStep1936" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1944" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1950" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1939" />
 <bp:pathwayComponent rdf:resource="#Pathway383" />
 <bp:pathwayComponent rdf:resource="#Pathway385" />
 <bp:pathwayComponent rdf:resource="#Pathway384" />
 <bp:pathwayComponent rdf:resource="#Pathway386" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1891" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FGFR1 mutant receptor activation</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The FGFR1 gene has been shown to be subject to activating mutations, chromosomal rearrangements and gene amplification leading to a variety of proliferative and developmental disorders depending on whether these events occur in the germline or arise somatically (reviewed in Webster and Donoghue, 1997; Burke, 1998; Cunningham, 2007; Wesche, 2011; Greulich and Pollock, 2011). Many of the resulting mutant FGFR1 proteins can dimerize and promote signaling in a ligand-independent fashion, although signal transduction may still be amplified in the presence of ligand (reviewed in Turner and Gross, 2010; Greulich and Pollock, 2011; Wesche et al, 2011).  </bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway385">
 <bp:pathwayOrder rdf:resource="#PathwayStep1945" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1946" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1947" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1948" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1949" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1520" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1517" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1518" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1516" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1519" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1900" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Signaling by FGFR1 amplification mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Amplification or activation of FGFR1 has been reported in  lung cancer (Weiss, 2001; Marek, 2009; Dutt, 2011), breast cancer (Reis-Filho, 2006; Turner, 2010), oral squamous carcinoma (Freier, 2007), esophageal squamous cell carcinomas (Ishizuka, 2002), ovarian cancer (Gorringe, 2007), bladder cancer (Simon, 2001), prostate cancer (Edwards, 2003; Acevedo, 2007) and rhabodomyosarcoma (Missiaglia, 2009).  Unlike the case for FGFR2 amplifications, FGFR1 amplifications are not associated with additional point mutations and affect signaling without altering the intrinsic kinase activity of the receptor.  Overexpressed FGFR1 appears to signal at a basal level in a ligand-independent fashion, but is also able to be stimulated by exogenous ligand.  Downstream activation may be the result of aberrant paracrine or autocrine stimulation (reviewed in Turner and Gross, 2010; Greulich and Pollock, 2011).  FGFR1 amplification has not been conclusively demonstrated to be the causative oncogenic agent in all of the cancer types mentioned above, and other genes in the 8p11 region may also be candidates in some cases (Bass, 2009; Bernard-Pierrot, 2008; Ray, 2004).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway384">
 <bp:pathwayOrder rdf:resource="#PathwayStep1941" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1942" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1943" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1940" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1513" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1514" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1512" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1515" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1895" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Signaling by activated point mutants of FGFR1</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Unlike FGFR2 and FGFR3, FGFR1 appears not to be a frequent target of activating point mutations (reviewed in Wesche, 2011; Turner and Grose, 2010).  Germline point mutations at residue P252 have been identified in Pfeiffer syndrome (reviewed in Webster and Donoghue, 1997; Burke, 1998; Cunningham, 2007) while mutation of the same residue arising somatically has been identified in melanoma and lung cancer (Ruhe, 2007; Davies, 2005).  Two kinase domain mutations have been characterized in glioblastoma (Rand, 2005; Network TCGA, 2008), both at positions that are also mutated in an autosomal disorder in one of the FGFR family members (Muenke, 1994; Bellus, 1995a; Bellus, 2000; Tavormina, 1995a; Tavormina, 1999).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep289">
 <bp:stepProcess rdf:resource="#BiochemicalReaction225" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway387">
 <bp:pathwayOrder rdf:resource="#PathwayStep1989" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1985" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2107" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1970" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2103" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2105" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2314" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2065" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2089" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2101" />
 <bp:pathwayOrder rdf:resource="#PathwayStep2244" />
 <bp:pathwayComponent rdf:resource="#Pathway514" />
 <bp:pathwayComponent rdf:resource="#Pathway546" />
 <bp:pathwayComponent rdf:resource="#Pathway396" />
 <bp:pathwayComponent rdf:resource="#Pathway451" />
 <bp:pathwayComponent rdf:resource="#Pathway431" />
 <bp:pathwayComponent rdf:resource="#Pathway453" />
 <bp:pathwayComponent rdf:resource="#Pathway452" />
 <bp:pathwayComponent rdf:resource="#Pathway444" />
 <bp:pathwayComponent rdf:resource="#Pathway388" />
 <bp:pathwayComponent rdf:resource="#Pathway399" />
 <bp:pathwayComponent rdf:resource="#Pathway454" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1925" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Diseases of metabolism</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Metabolic processes in human cells generate energy through the oxidation of molecules consumed in the diet and mediate the synthesis of diverse essential molecules not taken in the diet as well as the inactivation and elimination of toxic ones generated endogenously or present in the extracellular environment. Mutations that disrupt these processes by inactivating a required enzyme or regulatory protein, or more rarely by changing its specificity can lead to severe diseases. Metabolic diseases annotated here involve aspects of carbohydrate, glycosylation, amino acid (phenylketonuria), surfactant and vitamin metabolism, and biological oxidations. One somatic mutation that affects cytosolic isocitrate metabolism, often found in glioblastomas and some lymphoid neoplasms, is also annotated. Also described are mutated forms of adrenocorticotropic hormone (ACTH) that can lead to obesity, resulting in excessive accumulation of body fat. </bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway386">
 <bp:pathwayOrder rdf:resource="#PathwayStep1956" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1957" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1958" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1959" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1952" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1963" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1953" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1964" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1954" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1955" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1960" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1961" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1951" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1962" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1531" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1521" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1532" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1530" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1524" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1525" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1522" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1533" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1523" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1534" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1528" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1529" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1526" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1527" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1906" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Signaling by cytosolic FGFR1 fusion mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">8p11 myeloproliferative syndrome (EMS) is an aggressive disorder that is associated with a translocation event at the FGFR1 gene on chromosome 8p11.  Typical symptoms upon diagnosis include eosinophilia and associated T-cell lymphoblastic lymphoma; the disease rapidly advances to acute leukemia, usually of myeloid lineage.  At present the only effective treatment is allogenic stem cell transplantation (reviewed in Jackson, 2010).    At the molecular level, EMS appears to be caused by translocation events on chromosome 8 that create gene fusions between the intracellular domain of FGFR1 and an N-terminal partner gene that encodes a dimerization domain.  The resulting fusion protein dimerizes in a ligand-independent fashion based the N-terminal domain provided by the partner protein and stimulates constititutive downstream FGFR1 signaling without altering the intrisic kinase activity of the receptor.  To date, 11 partner genes have been identified: ZMYM2, FGFR1OP, FGFR1OP2, HERVK, TRIM24, CUX1, BCR, CEP110, LRRFIP1, MYO18A and CPSF6, although not all have been functionally characterized (reviewed in Jackson, 2010, Turner and Grose, 2010; Wesche, 2011).   Where examined, cell lines carrying FGFR1 fusion genes have been shown to be transforming  and to support IL3-independent proliferation through anti-apoptotic, prosurvival pathways(Lelievre, 2008; Ollendorff, 1999; Chase, 2007; Guasch, 2001; Wasag 2011; Roumiantsev, 2004; Demiroglu, 2001; Smedley, 1999).  Signaling appears to occur predominantly through PLCgamma, PI3K and STAT signaling, with a more minor contribution from MAPK activation.  Because the fusion proteins lack the FRS2-binding site, the mechanism of MAPK activation is unclear.  Recruitment of  GRB2:SOS1 through recruitment of SHC is one possibility (Guasch, 2001).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway389">
 <bp:pathwayOrder rdf:resource="#PathwayStep1972" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1539" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1927" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Defective CSF2RA causes SMDP4</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Surfactant catabolism by alveolar macrophages plays a small but critical part in surfactant recycling and metabolism. Upon ligand binding, granulocyte-macrophage colony-stimulating factor receptor (GM-CSFR), a heterodimer of alpha (CSF2RA) and beta (CSF2RB) subunits, initiates a signalling process that not only induces proliferation, differentiation and functional activation of hematopoietic cells but can also determine surfactant uptake into alveolar macrophages and its degradation via clathrin-coated vesicles. Defects in human CSF2RA can cause pulmonary surfactant metabolism dysfunction 4 (SMDP4; MIM:300770, aka congenital pulmonary alveolar proteinosis, (PAP)), a rare lung disorder due to impaired surfactant homeostasis characterised by alveoli filling with floccular material. Cellular responses to the misfolded pro-SFTPC products include ER stress, the activation of reactive oxygen species and autophagy. Excessive lipoprotein accumulation in the alveoli results in a form of respiratory distress syndrome in premature infants (RDS; MIM:267450) (Whitsett et al. 2015).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway388">
 <bp:pathwayOrder rdf:resource="#PathwayStep1979" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1975" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1977" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1981" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1971" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1983" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1973" />
 <bp:pathwayComponent rdf:resource="#Pathway390" />
 <bp:pathwayComponent rdf:resource="#Pathway392" />
 <bp:pathwayComponent rdf:resource="#Pathway391" />
 <bp:pathwayComponent rdf:resource="#Pathway394" />
 <bp:pathwayComponent rdf:resource="#Pathway393" />
 <bp:pathwayComponent rdf:resource="#Pathway395" />
 <bp:pathwayComponent rdf:resource="#Pathway389" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1926" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Diseases associated with surfactant metabolism</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The reactions annotated here describe genetic defects in genes regulating surfactant homeostasis which are associated with severe acute and chronic lung diseases in newborns and older infants (Whitsett et al. 2015).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep283">
 <bp:stepProcess rdf:resource="#Pathway55" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep284">
 <bp:stepProcess rdf:resource="#BiochemicalReaction220" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway359">
 <bp:pathwayOrder rdf:resource="#PathwayStep1833" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1430" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1788" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Imatinib-resistant KIT mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Imatinib is approved for treatment of cancers carrying primary mutations in the KIT receptor. Imatinib binds and inhibits the inactive state of the receptor, including the conformation promoted by exon 11 mutations that relieve the auto-inhibition of the WT protein. Resistance to imatinib arises due to the polyclonal expansion of subpopulations bearing secondary KIT mutations in the ATP binding pocket or the activation loop of the protein (Serrano et al, 2019; reviewed in Roskoski, 2018; Klug et al, 2018; Corless et al, 2011).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep281">
 <bp:stepProcess rdf:resource="#Pathway53" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep282">
 <bp:stepProcess rdf:resource="#Pathway54" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep287">
 <bp:stepProcess rdf:resource="#BiochemicalReaction223" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep288">
 <bp:stepProcess rdf:resource="#BiochemicalReaction224" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep285">
 <bp:stepProcess rdf:resource="#BiochemicalReaction221" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep286">
 <bp:stepProcess rdf:resource="#BiochemicalReaction222" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep280">
 <bp:stepProcess rdf:resource="#BiochemicalReaction219" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway350">
 <bp:pathwayOrder rdf:resource="#PathwayStep1805" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1411" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1760" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Signaling by TCF7L2 mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">~50% of colorectal cancers with microsatellite instability show frameshift mutations in TCF7L2 that result in the loss of the CTBP-binding region (Duval et al, 1999; Cuillliere-Dartigues et al, 2006).  These cancer cells show decreased colocalization of CTBP and TCF7L2 and have increased expression of a TCF-dependent reporter gene (Cuilliere-Dartigues et al, 2006).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway352">
 <bp:pathwayOrder rdf:resource="#PathwayStep1809" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1413" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1764" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Signaling by LRP5 mutants </bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">LRP5 is subject to an in-frame missplicing event in breast and parathyroid cancers that renders the protein insensitive to inhibition by the WNT antagonist DKK1.  Expression of the mutant protein results in elevated levels of active, unphosphorylated beta-catenin and enhanced TCF-dependent WNT-signaling, promoting cellular proliferation (Bjorklund et al 2007a, b; Bjorklund et al, 2009).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway351">
 <bp:pathwayOrder rdf:resource="#PathwayStep1807" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1412" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1762" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Signaling by GSK3beta mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">GSK3beta is subject to in-frame missplicing in CML stem cells resulting in the production of mutant protein that lacks the AXIN and FRAT binding domains.  Cells containing this mutant GSK3beta show elevated levels of nuclear beta-catenin and enhanced TCF-dependent reporter activity (Jamieson et al, 2008; Abrahamsson et al, 2009).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep278">
 <bp:stepProcess rdf:resource="#BiochemicalReaction217" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway354">
 <bp:pathwayOrder rdf:resource="#PathwayStep1812" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1414" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1767" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Signaling by kinase domain mutants of KIT</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activating mutations in the kinase domain of KIT are found in a small number of cases of AML and melanoma, as well as in myeloproliferative syndromes, mastocytosis and germ cell tumors (Longley et al, 1996; 1999; Nagata et al, 1995; Beghini et al, 2000; Ning et al, 2001; Tian et al, 1999; Kemmer et al, 2004; reviewed in Roskoski, 2018; Meng and Carvajal, 2019). Mutations in the kinase domain and activation loop of KIT (encoded by exons 13, 14 and 17) also arise in gastrointestinal stromal tumors (GIST) as primary mutations ( 1%) and as secondary resistance mutations in response to treatment with imatinib (Chen et al, 2004; Serrano et al, 2019; Gajiwala et al, 2008; McLean et al, 2008; reviewed in Antonescu, 2006; Roskoski, 2018; Wu et al, 2019; Corless et al, 2011). Activating kinase mutants of KIT are constitutively active in the absence of ligand and can be tyrosine phosphorylated in the absence of dimerization (Furitsu et al, 1993; Hirota et al, 1998; Tsujimura et al, 1994).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep279">
 <bp:stepProcess rdf:resource="#BiochemicalReaction218" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway353">
 <bp:pathwayOrder rdf:resource="#PathwayStep1813" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1846" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1816" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1831" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1811" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1819" />
 <bp:pathwayComponent rdf:resource="#Pathway354" />
 <bp:pathwayComponent rdf:resource="#Pathway356" />
 <bp:pathwayComponent rdf:resource="#Pathway355" />
 <bp:pathwayComponent rdf:resource="#Pathway366" />
 <bp:pathwayComponent rdf:resource="#Pathway358" />
 <bp:pathwayComponent rdf:resource="#Pathway357" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1766" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Signaling by KIT in disease</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">KIT signaling is important in several processes including stem cell maintenance, erythropoiesis, mast cell development, lymphopoiesis, melanogenesis and maintenance of interstitial cell of Cajal (Hirota et al, 1998; Chi et al, 2010). Gain-of-function mutations in KIT have been identified at low frequency in a number of diseases, including AML, melanoma and mast and germ cell tumors, and at higher frequency in gastrointesinal stromal tumors (reviewed in Lennartsson and Roonstrand, 2012; Abbaspour Babaei et al, 2016; Roskoski, 2018).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway356">
 <bp:pathwayOrder rdf:resource="#PathwayStep1817" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1818" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1418" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1417" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1772" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Signaling by extracellular domain mutants of KIT</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Many of the described KIT mutations are located in the fifth Ig-like domain, encoded by exon 8 and 9. The fifth Ig-like domain of KIT plays a critical role in stabilizing the receptor dimers formed upon SCF binding, allowing these mutations to support constitutive activation of the receptor (Yuzawa et al, 2007; reviewed in Lennartsson and Ronnstrand, 2012)</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway355">
 <bp:pathwayOrder rdf:resource="#PathwayStep1814" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1815" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1415" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1416" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1769" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Signaling by juxtamembrane domain KIT mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Mutations in the juxtamembrane region of KIT, encoded by exon 11, are especially prevalent as initiating events in gastrointestinal stromal tumors (GIST), but are also found at lower frequency in other cancers such as AML and melanoma (reviewed in Antonescu, 2006; Roskoski, 2018). Mutations in this region of KIT are believed to disrupt an auto-inhibitory function, leading to constitutive enzyme activation (Ma et al, 1999; Chan et al, 2003; Mol et al, 2004; reviewed in Roskoski, 2018). Unlike kinase domain mutants, juxtamembrane domain KIT mutants still undergo dimerization, although in a ligand-independent manner (Hirota et al, 1998; Furitsu et al, 1993; reviewed in Lennartsson and Roonstrand, 2012).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway358">
 <bp:pathwayOrder rdf:resource="#PathwayStep1836" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1838" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1842" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1832" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1844" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1834" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1840" />
 <bp:pathwayComponent rdf:resource="#Pathway359" />
 <bp:pathwayComponent rdf:resource="#Pathway361" />
 <bp:pathwayComponent rdf:resource="#Pathway360" />
 <bp:pathwayComponent rdf:resource="#Pathway363" />
 <bp:pathwayComponent rdf:resource="#Pathway362" />
 <bp:pathwayComponent rdf:resource="#Pathway365" />
 <bp:pathwayComponent rdf:resource="#Pathway364" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1787" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Drug resistance of KIT mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activating mutations in the juxtamembrane domain of KIT are common in some cancers, including gastrointestinal stromal tumors, melanoma and acute myeloid leukemia (reviewed in Roskoski, 2018). These mutations are sensitive to inhibition with imatinib, which in 2001 was the first tyrosine kinase inhibitor approved for treatment of cancer (Demetri et al, 2002; Corless et al, 2011; reviewed in Zitvogel, 2016). Although highly successful in prolonging survival, imatinib-resistance develops in most patients due to appearance of secondary mutations, often in the ATP-binding pocket or in the activation loop of the kinase domain (Gajiwala et al, 2008; Serrano et al, 2019; reviewed in Roskoski, 2018; Napolitano and Vincenzi, 2019)</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway357">
 <bp:pathwayOrder rdf:resource="#PathwayStep1824" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1825" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1826" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1827" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1820" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1821" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1822" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1823" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1830" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1828" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1829" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1421" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1422" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1420" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1425" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1426" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1423" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1424" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1429" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1419" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1427" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1428" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1775" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Activation of the PI3K/mTOR, RAS/MAPK and STAT signaling pathways has been observed downstream of activated extracellular, juxtamembrane and kinase domain mutants of KIT, although downstream signaling has not been studied in great detail in all cases. Activation of these pathways contributes to cellular proliferation, avoidance of apoptosis, and actin cytoskeletal organization (Dunesing et al, 2004; Bauer et al, 2007; Chi et al, 2010; Bosbach et al, 2017; reviewed in Lennartsson and Roonstrand, 2012; Corless et al, 2011).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep272">
 <bp:stepProcess rdf:resource="#BiochemicalReaction211" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep273">
 <bp:stepProcess rdf:resource="#BiochemicalReaction212" />
 <bp:stepProcess rdf:resource="#Catalysis64" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep270">
 <bp:stepProcess rdf:resource="#BiochemicalReaction209" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep271">
 <bp:stepProcess rdf:resource="#BiochemicalReaction210" />
 <bp:stepProcess rdf:resource="#Catalysis63" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep276">
 <bp:stepProcess rdf:resource="#BiochemicalReaction215" />
 <bp:stepProcess rdf:resource="#Catalysis66" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep277">
 <bp:stepProcess rdf:resource="#BiochemicalReaction216" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep274">
 <bp:stepProcess rdf:resource="#BiochemicalReaction213" />
</bp:PathwayStep>

<bp:PathwayStep rdf:ID="PathwayStep275">
 <bp:stepProcess rdf:resource="#BiochemicalReaction214" />
 <bp:stepProcess rdf:resource="#Catalysis65" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway361">
 <bp:pathwayOrder rdf:resource="#PathwayStep1837" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1432" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1792" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Regorafenib-resistant KIT mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Regorafenib is a type II tyrosine kinase inhibitor that is approved for treatment of advanced gastrointestinal stromal tumors with KIT mutations. Regorafenib is effective in imatinib-resistant tumors carrying secondary mutations in exon 14 (gatekeeper mutation), and most KIT secondary mutations encoded by exons 17 and 18 (the activation loop) (Demetri et al, 2013; Serrano et al, 2017, Serrano et al, 2019; reviewed in Roskoski, 2018; Klug et al, 2018; ).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway360">
 <bp:pathwayOrder rdf:resource="#PathwayStep1835" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1431" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1790" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Sunitinib-resistant KIT mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Sunitinib is a class II tyrosine kinase inhibitor that is often used as a second line treatment in KIT-mutated cancers that develop resistance to imatinib (Heinrich et al, 2008; Serrano et al, 2017; reviewed in Roskoski, 2018; Corless et al, 2011).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep269">
 <bp:stepProcess rdf:resource="#BiochemicalReaction208" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway363">
 <bp:pathwayOrder rdf:resource="#PathwayStep1841" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1434" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1796" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Masitinib-resistant KIT mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Mastinib is a class II tyrosine kinase inhibitor that targets mutant and wild-type FGFR3, PDGFR and c-KIT (Dubreuil, 2009). Masitinib, like imatinib, is effective in inhibiting the activity of juxtamembrane mutant forms of KIT, but is ineffective against many of the mutations in the activation loop and ATP-binding cleft of the receptor (Dubreuil, 2009; Serrano et al, 2019; reviewed in Demetri, 2011).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway362">
 <bp:pathwayOrder rdf:resource="#PathwayStep1839" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1433" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1794" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Dasatinib-resistant KIT mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Dasatinib is a type II tyrosine kinase inhibitor that is active against KIT receptors with mutations in the juxtamembrane and activation loop domains, but shows only partial activity against KIT receptors with mutations at residue V654 (Schittenhelm et al, 2006; Serrano et al, 2019).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep267">
 <bp:stepProcess rdf:resource="#BiochemicalReaction206" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway365">
 <bp:pathwayOrder rdf:resource="#PathwayStep1845" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1436" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1800" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Sorafenib-resistant KIT mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Sorafenib is a type II tyrosine kinase inhibitor that is approved for use in hepatocellular and renal cell carcinoma. It is active against KIT receptors with mutations in the ATP-binding cleft and the activation loop, with the exception of substitutions at D816, which are resistant (Guida et al, 2007; Heinrich et al, 2012; Serrano et al, 2019; Weisberg et al, 2019; reviewed in Roskoski, 2018; Klug et al, 2012).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:PathwayStep rdf:ID="PathwayStep268">
 <bp:stepProcess rdf:resource="#BiochemicalReaction207" />
</bp:PathwayStep>

<bp:Pathway rdf:ID="Pathway364">
 <bp:pathwayOrder rdf:resource="#PathwayStep1843" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1435" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1798" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Nilotinib-resistant KIT mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Nilotinib is a type II tyrosine kinase inhibitor currently in clinical trials for treatment of KIT-mutant cancers, and shows variable effectiveness against mutations in exon 11, 13, 17 and 18. Nilotinib is ineffective against the gatekeeper mutation T670I (Kissova et al, 2016; Guo et al, 2007; Roberts et al, 2007; Serrano et al, 2019).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway367">
 <bp:pathwayOrder rdf:resource="#PathwayStep1868" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1902" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1851" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1928" />
 <bp:pathwayComponent rdf:resource="#Pathway370" />
 <bp:pathwayComponent rdf:resource="#Pathway381" />
 <bp:pathwayComponent rdf:resource="#Pathway376" />
 <bp:pathwayComponent rdf:resource="#Pathway368" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1806" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Signaling by FGFR in disease</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">A number of skeletal and developmental diseases have been shown to arise as a result of mutations in the FGFR1, 2 and 3 genes.  These include dwarfism syndromes (achondroplasia, hypochondroplasia and the neonatal lethal disorders thanatophoric dysplasia I and II), as well as craniosynostosis disorders such as Pfeiffer, Apert, Crouzon, Jackson-Weiss and Muenke syndromes (reviewed in Webster and Donoghue 1997; Burke, 1998, Cunningham, 2007; Harada, 2009).  These mutations fall into four general regions of the receptor: a) the immunoglobulin (Ig)-like domain II-III linker region,  b) the alternatively spliced second half of the Ig III domain, c) the transmembrane domain and d) the tyrosine kinase domain (reviewed in Webster and Donoghue, 1997).  With the exception of mutations in class b), which affect only the relevant splice variant, these mutations may be present in either the &apos;b&apos; or &apos;c&apos; isoforms. These activating mutations affect FGFR function by altering or expanding the ligand-binding range of the receptors (see for instance Ibrahimi, 2004a), by promoting ligand-independent dimerization (for instance, Galvin,1996; Neilson and Friesel, 1996; d&apos;Avis,1998) or by increasing the activity of the kinase domain (for instance, Webster, 1996; Naski, 1996; Tavormina, 1999; Bellus, 2000).  Thus, a number of the point mutations found in FGFR receptors alter their activity without altering their intrinsic kinase activity.  Many of the mutations that promote constitutive dimerization do so by creating or removing cysteine residues; the presence of an unpaired cysteine in the receptor is believed to promote dimerization through the formation of intramolecular disulphide bonds (Galvin, 1996; Robertson, 1998). Paralogous mutations at equivalent positions have been identified in more than one FGF receptor, sometimes giving rise to different diseases.  For instance, mutation of the highly conserved FGFR2 Ser252-Pro253 dipeptide in the region between the second and third Ig domain is responsible for virtually all cases of Apert Syndrome (Wilkie, 1995), while paralogous mutations in FGFR1 (S252R) and FGFR3 (P250R) are associated with Pfeiffer and Crouzon syndromes, respectively (Bellus, 1996).  FGFR4 is unique in that mutations of this gene are not known to be associated with any developmental disorders.  Recently, many of the same activating mutations in the FGFR genes that have been characterized in skeletal and developmental disorders have begun to be identified in a range of cancers (reviewed in  Turner and Gross, 2010; Greulich and Pollock, 2011; Wesche, 2011).  The best established link between a somatic mutation of an FGFR and the development of cancer is in the case of FGFR3, where 50% of bladder cancers have mutations in the FGFR3 coding sequence.  Of these mutations, which largely match the activating mutations seen in thanatophoric dysplasias, over half occur at a single residue (S249C) (Cappellen, 1999; van Rhijn, 2002).  Activating mutations have also been identified in the coding sequences of FGFR1, 2 and 4 (for review, see Wesche, 2011)  In addition to activating point mutations, the FGFR1, 2 and 3 genes are subject to misregulation in cancer through gene amplification and translocation events, which are thought to lead to overexpression and ligand-independent dimerization (Weiss, 2010; Turner, 2010; Kunii, 2008; Takeda, 2007; Chesi, 1997; Avet-Loiseau, 1998; Ronchetti, 2001).  It is important to note, however, that in each of these cases, the amplification or translocation involve large genomic regions encompassing additional genes, and the definitive roles of the FGFR genes in promoting oncogenesis has not been totally established. In the case of FGFR1, translocation events also give rise to FGFR1 fusion proteins that contain the intracellular kinase domain of the receptor fused to a dimerization domain from the partner gene.  These fusions, which are expressed in a pre-leukemic myeloproliferative syndrome, dimerize constitutively based on the dimerization domain provided by the fusion partner and are constitutively active (reviewed in Jackson, 2010).  </bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway366">
 <bp:pathwayOrder rdf:resource="#PathwayStep1847" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1848" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1849" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1437" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1438" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1439" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1802" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">KIT mutants bind TKIs</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Aberrant signaling by activated forms of KIT can be inhibited by tyrosine kinase inhibitors. Primary mutations in KIT are frequently found in exon 11, encoding the juxtamembrane domain responsible for autoinhibition of the kinase. These mutations are generally sensitive to tyrosine kinase inhibitors such as imatinib. Accumulation of secondary mutations in the ATP-binding pocket and the activation loop of the kinase domain contributes to resistance to first line tyrosine kinase inhibitors. KIT receptors with in these regions are sensitive to a panel of additional tyrosine kinase inhibitors such as sunitinib and regorafenib (Serrano et al, 2019; reviewed in Roskoski, 2018; Klug et al, 2018; Serrano et al, 2017).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway369">
 <bp:pathwayOrder rdf:resource="#PathwayStep1859" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1860" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1861" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1862" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1863" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1447" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1448" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1446" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1449" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1450" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1814" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FGFR4 mutant receptor activation</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FGFR4 is perhaps the least well studied of the FGF receptors, and unlike the case for the other FGFR genes, mutations in FGFR4 are not known to be associated with any developmental disorders.  Recently, however, somatically arising mutations in the FGFR4 coding sequence have begun to be identified in some cancers.  (Taylor, 2009; Ruhe, 2007; Roidl, 2010).  The resulting mutant versions of FGFR4 promote aberrant signaling through ligand-independent dimerization and enhanced autophosphorylation, among other mechanisms (Roidl, 2009; Taylor, 2009).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway368">
 <bp:pathwayOrder rdf:resource="#PathwayStep1857" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1858" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1853" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1864" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1854" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1865" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1855" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1866" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1856" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1867" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1852" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1443" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1454" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1444" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1441" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1452" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1442" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1453" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1445" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1440" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1451" />
 <bp:pathwayComponent rdf:resource="#Pathway369" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1807" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Signaling by FGFR4 in disease</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FGFR4 is perhaps the least well studied of the FGF receptors, and unlike the case for the other FGFR genes, mutations in FGFR4 are not known to be associated with any developmental disorders.  Recently, however, somatically arising mutations in the FGFR4 coding sequence have begun to be identified in some cancers.  8% of rhabdomyosarcomas have activating mutations in the kinase domain of FGFR4.  Two of these mutations - N535K (paralogous to the FGFR2 N550K allele found in endometrial cancers) and V550E - have been shown to support the oncogenic transformation of NIH 3T3 cells (Taylor, 2009).  An FGFR4 Y367C mutation has also been identified in breast cancers (Ruhe, 2007; Roidl, 2010); mutations of paralogous residues in FGFR2 and FGFR3 are associated with both skeletal dysplasias and the development of diverse cancers (Pollock, 2007; Ruhe, 2007; Rousseau, 1996; Chesi, 1997, 2001).   Finally, a SNP at position 388 of FGFR4 is associated with aggressive disease development.  Expression of the G388R allele in breast, colorectal and prostate cancers is correlated with rapid progression times and increased rates of recurrence and metastasis (Bange, 2002; Spinola, 2005; Wang, 2004).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway338">
 <bp:pathwayOrder rdf:resource="#PathwayStep1783" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1401" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1738" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Deletions in the AMER1 gene destabilize the destruction complex</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Genomic deletions of the entire AMER1/WTX gene occur in about 12% of Wilms tumors, a pediatric kidney cancer.  Nonsense and missense mutations have also been identified (Ruteshouser et al, 2008; Wegert et al, 2009).  AMER1 is a known component of the destruction complex and interacts directly with beta-catenin through the C-terminal half (Major et al, 2007).  siRNA depletion of AMER1 in mammalian cells stabilizes cellular beta-catenin levels and increases the expression of a beta-catenin-dependent reporter gene, suggesting that AMER1 is a tumor suppressor gene (Major et al, 2007; reviewed in Huff, 2011).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway337">
 <bp:pathwayOrder rdf:resource="#PathwayStep1784" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1782" />
 <bp:pathwayComponent rdf:resource="#Pathway338" />
 <bp:pathwayComponent rdf:resource="#Pathway339" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1737" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Signaling by AMER1 mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">AMER1/WTX is a component of the destruction complex that interacts directly with beta-catenin through its C-terminal half.  Depletion of AMER1 through siRNA stabilizes cellular beta-catenin levels and increases transcriptional activity in a reporter assay consistent with a role for AMER1 in the degradation of beta-catenin (Major et al, 2007).  Deletions of the entire AMER1 gene have been reported in Wilms tumor, as have nonsense and missense mutations that truncate the protein before the beta-catenin interaction domain.  These mutations are predicted to stabilize beta-catenin and increase WNT signaling (reviewed in Saito-Diaz et al, 2013; Huff, 2011).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction158">
 <bp:evidence rdf:resource="#Evidence207" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">L protein acts as a cap N7 methyltransferase to modify RSV mRNAs</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction159">
 <bp:evidence rdf:resource="#Evidence208" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">L protein acts as a cap 2&apos;-O-methyltransferase to modify RSV mRNAs</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway339">
 <bp:pathwayOrder rdf:resource="#PathwayStep1785" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1402" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1740" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Truncations of AMER1 destabilize the destruction complex</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">AMER1/WTX is a known component of the destruction complex and interacts directly with beta-catenin through the C-terminal half (Major et al, 2007).  siRNA depletion of AMER1 in mammalian cells stabilizes cellular beta-catenin levels and increases the expression of a beta-catenin-dependent reporter gene, suggesting that AMER1 is a tumor suppressor gene (Major et al, 2007; reviewed in Huff, 2011).  Consistent with this, nonsense and missense mutations that truncate AMER1 and result in loss of the beta-catenin binding region have been identified in Wilms tumor, a pediatric kidney cancer (Ruteshouser et al, 2008; Wegert et al, 2009).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction156">
 <bp:evidence rdf:resource="#Evidence205" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">RdRP binds hRSV nucleocapsid</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction157">
 <bp:evidence rdf:resource="#Evidence206" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Transcription of respiratory syncytial virus subgenomic positive sense mRNAs</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction154">
 <bp:evidence rdf:resource="#Evidence201" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SH pentamer transports K+</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction155">
 <bp:evidence rdf:resource="#Evidence204" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Asvasiran binds N mRNA</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis131">
 <bp:controlled rdf:resource="#BiochemicalReaction491" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis130">
 <bp:controlled rdf:resource="#BiochemicalReaction488" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis133">
 <bp:controlled rdf:resource="#BiochemicalReaction493" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis132">
 <bp:controlled rdf:resource="#BiochemicalReaction492" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis139">
 <bp:controlled rdf:resource="#BiochemicalReaction506" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis138">
 <bp:controlled rdf:resource="#BiochemicalReaction505" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis135">
 <bp:controlled rdf:resource="#BiochemicalReaction498" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis134">
 <bp:controlled rdf:resource="#BiochemicalReaction495" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis137">
 <bp:controlled rdf:resource="#BiochemicalReaction504" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis136">
 <bp:controlled rdf:resource="#BiochemicalReaction503" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction152">
 <bp:evidence rdf:resource="#Evidence199" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ISGylation of BECN1</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway330">
 <bp:pathwayOrder rdf:resource="#PathwayStep1748" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1749" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1754" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1755" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1750" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1772" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1751" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1752" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1753" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1770" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1771" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1386" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1397" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1387" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1381" />
 <bp:pathwayComponent rdf:resource="#Pathway331" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1384" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1395" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1385" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1396" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1382" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1383" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1710" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Signaling by FLT3 ITD and TKD mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FLT3 is subject to internal tandem duplications (ITDs) of lengths varying from 3 to 1236 base pairs (Nakao et al, 1996; Kiyoi et al 1997, Meshinchi et al, 2008; reviewed in Kazi and Roonstrand, 2019). These ITDs are generally found in the juxtamembrane domain, or more rarely, the first tyrosine kinase domain (TKD) and disrupt the autoinhibitory loop of the receptor, constitutively activating it (Kiyoi et al, 2002; Griffith et al, 2004; reviewed in Lagunas-Rangel and Chavez-Valencia, 2017; Kazi and Roonstrand, 2019). FLT3 ITDs are found in ~25% of acute myeloid leukemias (AMLs) and represent the most frequent mutation of this cancer (reviewed in Kazi and Roonstrand, 2019, Klug et al, 2018) At lower frequency, FLT3 is subject to activating point mutations (~7% of AML cases). These mutations tend to cluster in the TKD, with mutation of the activation loop residue D835 and the gatekeeper F691 residue the most common sites (Griffin et al, 2001; Jiang et al, 2004; reviewed in Kazi and Roonstrand, 2019).  FLT3 ITD and TKD mutants support cellular transformation through activation of downstream signaling pathways such as the MAP kinase, PI3K/AKT and STAT5 cascades. There is some debate about the extent to which the pathways activated by the ITD and TKD mutants are distinct, with some evidence that STAT5 signaling, in particular, is more characteristic of FLT3 ITD activation (Hayakawa et al, 2000; Choudhary et al, 2005; Grundler et al, 2005; Choudhary et al, 2007; Yoshimoto et al, 2009; Leischner et al, 2012; Janke et al, 2014; Marhall et al, 2018; reviewed in Chan, 2011; Kazi and Roonstrand, 2019).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction153">
 <bp:evidence rdf:resource="#Evidence200" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">OAS2 binds viral dsRNA</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction150">
 <bp:evidence rdf:resource="#Evidence197" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">RSV G binds CD209,CLEC4M</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway332">
 <bp:pathwayOrder rdf:resource="#PathwayStep1804" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1788" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1779" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1795" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1774" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1786" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1806" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1781" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1808" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1793" />
 <bp:pathwayComponent rdf:resource="#Pathway337" />
 <bp:pathwayComponent rdf:resource="#Pathway350" />
 <bp:pathwayComponent rdf:resource="#Pathway341" />
 <bp:pathwayComponent rdf:resource="#Pathway352" />
 <bp:pathwayComponent rdf:resource="#Pathway340" />
 <bp:pathwayComponent rdf:resource="#Pathway351" />
 <bp:pathwayComponent rdf:resource="#Pathway345" />
 <bp:pathwayComponent rdf:resource="#Pathway333" />
 <bp:pathwayComponent rdf:resource="#Pathway344" />
 <bp:pathwayComponent rdf:resource="#Pathway336" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1729" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Signaling by WNT in cancer</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">The WNT signaling pathway has been linked with cancer ever since the identification of the first WNT as a gene activated by integration of mouse mammary tumor virus proviral DNA in virally-induced breast tumors (Nusse et al, 1984).  The most well known example of aberrant WNT signaling in cancer is in colorectal cancer, where an activating mutation in a WNT pathway component is seen in 90% of sporadic cases.  Inappropriate WNT pathway activation has also been implicated in most other solid human cancers but is not always associated with mutations in WNT pathway components (reviewed in Polakis, 2012). Both tumor suppressors and oncogenes have been identified in the so-called canonical WNT pathway, which regulates WNT-dependent transcription by promoting the degradation of beta-catenin in the absence of ligand (reviewed in Polakis, 2012).  Loss-of-function mutations in the destruction complex components APC, Axin and AMER1 and gain-of-function mutations in beta-catenin itself cause constitutive signaling and are found in cancers of the intestine, kidney, liver and stomach, among others (Polakis, 1995; Segiditsas and Tomlinson, 2006; Peifer and Polakis, 2000; Laurent-Puig et al, 2001; Liu et al, 2000; Satoh et al, 2000; Major et al, 2007; Ruteshouser et al, 2008). WNTs and WNT pathway components are also frequently over- or under-expressed in various cancers, and these changes are correlated with epigenetic regulation of promoter activity.  In some contexts, both the canonical and non-canonical WNT signaling, which governs processes such as cell polarity and morphogenesis, may also contribute to tumor formation by promoting cell migration, invasiveness and metastasis.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction151">
 <bp:evidence rdf:resource="#Evidence198" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">RSV dsRNA binds DDX58</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway331">
 <bp:pathwayOrder rdf:resource="#PathwayStep1758" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1769" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1759" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1765" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1766" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1756" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1767" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1757" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1768" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1761" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1762" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1763" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1764" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1760" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1391" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1392" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1390" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1373" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1371" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1393" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1372" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1394" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1388" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1366" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1377" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1389" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1368" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1369" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1718" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">STAT5 activation downstream of FLT3 ITD mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">STAT5 signaling appears to be preferentially activated downstream of FLT3 ITD mutants relative to the wild-type or FLT3 TKD mutants, although this is subject to some debate (Choudhary et al, 2005; Reindl et al, 2006; Bagrintseva et al, 2005; Grundler et al, 2003; Choudhary et al, 2007; Marhall et al, 2018; reviewed in Choudhary et al, 2005). STAT5 activation contributes to oncogenesis by promoting the transcription of a number of factors involved in regulating cell cycle progression, proliferation and apoptosis, among others (Kim et al, 2005; Nabinger et al, 2013; Takahashi et al, 2004; Godfrey et al, 2012; Hayakawa et al, 2000; reviewed in Murphy and Rani, 2015).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway334">
 <bp:pathwayOrder rdf:resource="#PathwayStep1776" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1398" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1731" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">AXIN missense mutants destabilize the destruction complex</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Alterations in AXIN1 have been detected in a number of different cancers including liver and colorectal cancer and medullablastoma, among others (reviewed in Salahshor and Woodgett, 2005).  Missense and nonsense mutations that disrupt or remove protein-protein interaction domains are common, and AXIN variants in cancers tend to disrupt the formation of a functional destruction complex (Satoh et al, 2000; Taniguchi et al, 2002;  Webster et al, 2000; Shimizu et al, 2002).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway333">
 <bp:pathwayOrder rdf:resource="#PathwayStep1777" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1775" />
 <bp:pathwayComponent rdf:resource="#Pathway334" />
 <bp:pathwayComponent rdf:resource="#Pathway335" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1730" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Signaling by AXIN mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">AXIN1 and AXIN2 are critical scaffolding proteins of the beta-catenin destruction complex and make protein-protein interactions with several of the other complex components including APC, GSK3, CK1 and beta-catenin itself through specific domains (reviewed in Saito-Diaz et al, 2013). Because of its role in promoting the degradation of beta-catenin and thereby restricting WNT signaling, AXIN1 is regarded as a tumor suppressor; consistent with this, biallelic mutations in AXIN1 that abrogate its expression or result in the production of truncated proteins have been identified in some human cancers, notably in hepatocellular and  colorectal carcinomas and medullobalstoma (Satoh et al, 2000; Taniguchi et al, 2002; Shimizu et al, 2002; Dahmen et al, 2001; reviewed in Salahshor and Woodgett, 2005).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway336">
 <bp:pathwayOrder rdf:resource="#PathwayStep1780" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1400" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1735" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Signaling by RNF43 mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">RNF43 and related protein ZNRF3 are E3 ubiquitin ligases that negatively regulate WNT signaling by downregulating FZD receptors at the cell surface (Mukai et al, 2010; Hao et al, 2012).  Frameshift loss-of-function mutations in RNF43 that enhance WNT signaling have been identified in pancreatic and colorectal cancers; the proliferation of these cells is dependent on the presence of secreted WNT, as their growth is abrogated by treatment of cells with the Porcupine inhibitor LGK974 (Koo et al, 2012; Jiang et al, 2013).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway335">
 <bp:pathwayOrder rdf:resource="#PathwayStep1778" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1399" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1733" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Deletions in the AXIN1 gene destabilize the destruction complex</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Deletions in the AXIN1 gene have been identified in 2 hepatocellular carcinoma cell lines.  These deletions, which remove the N-terminal exons of the gene,  compromise AXIN1 expression and result in elevated expression of a TCF-dependent reporter (Satoh et al, 2000, reviewed in Salahshor and Woodgett, 2005).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction149">
 <bp:evidence rdf:resource="#Evidence196" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">RSV sG binds TLR2:TLR6</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway349">
 <bp:pathwayOrder rdf:resource="#PathwayStep1803" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1410" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1758" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">CTNNB1 T41 mutants aren&apos;t phosphorylated</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">T41 mutations of beta-catenin interfere with GSK3 phosphorylation and result in stabilization and nuclear accumulation of the protein (Moreno-Bueno et al, 2002; Taniguchi et al, 2002; reviewed in Polakis, 2012).  T41 mutations have been identified in cancers of the liver and brain, as well as in the pituitary, endometrium, large intestine and skin, among others (reviewed in Polakis, 2000; Saito-Diaz et al, 2013).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway348">
 <bp:pathwayOrder rdf:resource="#PathwayStep1801" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1409" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1756" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">CTNNB1 S33 mutants aren&apos;t phosphorylated</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">S33 mutations of beta-catenin interfere with GSK3 phosphorylation and result in stabilization and nuclear localization of the protein and enhanced WNT signaling (Groen et al, 2008; Nhieu et al, 1999; Clements et al, 2002; reviewed in Polakis, 2000).  S33 mutations have been identified in cancers of the central nervous system, liver, endometrium and stomach, among others (reviewed in Polakis, 2000).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction147">
 <bp:evidence rdf:resource="#Evidence194" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">RSV ssRNA binds C-ter TLR7 dimer</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction148">
 <bp:evidence rdf:resource="#Evidence195" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">sG binds to HSPGs</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction145">
 <bp:evidence rdf:resource="#Evidence192" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NS1 (1C) binds to Mediator complex</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction146">
 <bp:evidence rdf:resource="#Evidence193" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NS1 (1C) binds H2BC15</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction143">
 <bp:evidence rdf:resource="#Evidence190" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">RSV dsRNA binds TLR3</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction144">
 <bp:evidence rdf:resource="#Evidence191" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NS2 (1B) binds to MAP1B</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis142">
 <bp:controlled rdf:resource="#BiochemicalReaction528" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis141">
 <bp:controlled rdf:resource="#BiochemicalReaction523" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis144">
 <bp:controlled rdf:resource="#BiochemicalReaction536" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis143">
 <bp:controlled rdf:resource="#BiochemicalReaction533" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis140">
 <bp:controlled rdf:resource="#BiochemicalReaction521" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis149">
 <bp:controlled rdf:resource="#BiochemicalReaction573" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis146">
 <bp:controlled rdf:resource="#BiochemicalReaction543" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis145">
 <bp:controlled rdf:resource="#BiochemicalReaction537" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis148">
 <bp:controlled rdf:resource="#BiochemicalReaction568" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis147">
 <bp:controlled rdf:resource="#BiochemicalReaction567" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction141">
 <bp:evidence rdf:resource="#Evidence188" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NS1 (1C) binds to CREBBP</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway341">
 <bp:pathwayOrder rdf:resource="#PathwayStep1789" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1791" />
 <bp:pathwayComponent rdf:resource="#Pathway343" />
 <bp:pathwayComponent rdf:resource="#Pathway342" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1744" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Signaling by APC mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">APC is a large and central component of the destruction complex, which limits signaling in the absence of WNT ligand by promoting the ubiquitin-mediated degradation of beta-catenin.  APC interacts with numerous components of the destruction complex, including AXINs (AXIN1 and AXIN2), GSK3s (GSK3alpha and GSK3beta), CK1, PP2A and beta-catenin, and these interactions are critical for the phosphorylation and degradation of beta-catenin (reviewed in Saito-Diaz et al, 2013).  APC is itself the target of phosphorylation and K63 ubiquitination in the absence of WNT signaling and these modifications are required for its interactions with other components of the destruction complex (Tran and Polakis, 2012; Ha et al, 2004; reviewed in Stamos and Weis, 2013).  More than 85% of sporadic and hereditary colorectal tumors carry loss-of-function mutations in APC.  Most of the mutations are frameshifts and result in truncated proteins that lack the SAMP motifs and the 15 and 20 aa repeats that are implicated in binding AXIN and regulating beta-catenin binding and degradation (Miyoshi et al, 1992; Nagase and Nakamura, 1993; reviewed in Segditas and Tomlinson, 2006).  Cancers expressing truncated APC have high levels of cytoplasmic beta-catenin and deregulated expression of WNT target genes (Korinek et al, 1997).  Approximately 15% of the colorectal tumors with wild-type APC harbor phosphodegron mutations of beta-catenin; interestingly, mutations in APC and beta-catenin are mutually exclusive events.  Similar to APC-mutant tumors, beta-catenin is stabilized in these tumors and constitutive WNT target activation is detected  (Morin et al, 1997; reviewed in Polakis, 2000).  </bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction142">
 <bp:evidence rdf:resource="#Evidence189" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SH binds to BCAP31</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway340">
 <bp:pathwayOrder rdf:resource="#PathwayStep1787" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1403" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1742" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">LGK974 inhibits PORCN</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Aberrant WNT signaling is associated with the development of numerous cancers, and strategies for targeting this pathway are under intense investigation (reviewed in Polakis, 2012; Polakis, 2000; Yao et al, 2011).  Secretion of WNT ligand depends on its PORCN-dependent palmitoleoylation in the ER, making PORCN a attractive therapeutic target in cases where WNT is aberrantly over-expressed (reviewed in MacDonald et al, 2009).  LGK974 is a PORCN-inhibitor that was identified in a screen for compounds that abrogate the secretion of WNT ligands, and is in Phase I clinical trials for the treatment of WNT-dependent cancers (Liu et al, 2013)</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway343">
 <bp:pathwayOrder rdf:resource="#PathwayStep1792" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1405" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1747" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">APC truncation mutants are not K63 polyubiquitinated</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">APC has been shown to be reversibly modified with K63-linked polyubiquitin chains.  This modification is required for the assembly of the destruction complex and subsequent degradation of beta-catenin in the absence of WNT ligand.  K63-polyubiquitination of APC is lacking in a number of colorectal cancer cell lines expressing truncated forms of APC, and these lines have aberrantly high beta-catenin levels and WNT pathway activation (Tran and Polakis, 2012).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction140">
 <bp:evidence rdf:resource="#Evidence187" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">RSV NS1 (1C) binds TRIM25</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway342">
 <bp:pathwayOrder rdf:resource="#PathwayStep1790" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1404" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1745" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">APC truncation mutants have impaired AXIN binding</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Mutations in the APC tumor suppressor gene are common in  colorectal and other cancers and cluster in the central mutation cluster region (MCR) of the gene (Miyoshi et al, 1992; Nagase and Nakamura, 1993; Dihlmann et al, 1999; reviewed in Bienz and Clevers, 2000).  These mutations generally result in truncated proteins that destabilize the destruction complex and result in elevated WNT pathway activation (reviewed in Polakis, 2000).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway345">
 <bp:pathwayOrder rdf:resource="#PathwayStep1802" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1798" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1800" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1796" />
 <bp:pathwayComponent rdf:resource="#Pathway349" />
 <bp:pathwayComponent rdf:resource="#Pathway348" />
 <bp:pathwayComponent rdf:resource="#Pathway347" />
 <bp:pathwayComponent rdf:resource="#Pathway346" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1751" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Signaling by CTNNB1 phospho-site mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Mutations in exon 3 of the beta-catenin gene have been identified in a number of human cancers (Morin et al, 1997; Rubinfeld et al, 1997; reviewed in Polakis, 2000; Polakis, 2007).  These mutations generally affect serine and threonine residues (S33, S37, T41, S45) that are the sites of phosphorylation by CK1 and GSK3; phosphorylation of these residues is required for the ubiquitin-mediated degradation of beta-catenin.  Hence mutation of these phospho-acceptor sites stabilizes beta-catenin, allowing it to accumulate, translocate to the nucleus and activate WNT signaling through association with LEF1/TCF DNA binding partners (Hart et al, 1999; Peifer and Polakis, 2000; Laurent-Puig et al, 2001; reviewed in Saito-Diaz et al, 2013).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway344">
 <bp:pathwayOrder rdf:resource="#PathwayStep1794" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1406" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1749" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">XAV939 stabilizes AXIN</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">XAV939 binds to the catalytic sites of tankyrase 1 and 2 and inhibits the ADP-ribosylation of AXIN1 and 2. Treatment of cells with XAV939 significantly increases the protein, but not the mRNA levels of AXIN1 and 2 and supports a strong increase in the level of GSK3beta-AXIN complexes.  These cells also show increased phosphorylation of beta-catenin, decreased beta-catenin protein levels and a corresponding decrease in beta-catenin dependent transcription.  Treatment of DLD-1 cells with XAV939 has also been shown to inhibit proliferation (Huang et al, 2009).  XAV939 has not been tested in a clinical setting.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway347">
 <bp:pathwayOrder rdf:resource="#PathwayStep1799" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1408" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1754" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">CTNNB1 S37 mutants aren&apos;t phosphorylated</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">S37 mutations of beta-catenin interfere with GSK3 phosphorylation and stabilize the protein, resulting in enhanced WNT pathway signaling (Nhieu et al, 1999; Clements et al, 2002; reviewed in Polakis, 2000).  S37 mutations have been identified in cancers of the brain, liver, ovary and large intestine, among others (reviewed in Polakis, 2000).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway346">
 <bp:pathwayOrder rdf:resource="#PathwayStep1797" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1407" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1752" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">CTNNB1 S45 mutants aren&apos;t phosphorylated</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">S45 mutants of beta-catenin have been identified in colorectal and hepatocellular carcinomas, soft tissue cancer and Wilms Tumors, among others (reviewed in Polakis, 2000). These mutations abolish the CK1alpha phosphorylation site of beta-catenin which acts as a critical priming site for GSK3 phosphorylation of T41( and subsequently S37 and S33) thus  preventing its ubiquitin-mediated degradation (Morin et al, 1997; Amit et al, 2002).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway316">
 <bp:pathwayOrder rdf:resource="#PathwayStep1702" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1349" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1664" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">pexidartinib-resistant FLT3 mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Pexidartinib is a type II tyrosine kinase inhibitor that is active against FLT3, including the quizartinib-resistant gatekeeper mutation F691L. Activating mutations at TKD aspartic acid residue 835 are resistant to pexidartinib-mediated inhibition, however (Smith et al, 2015a, b). </bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway315">
 <bp:pathwayOrder rdf:resource="#PathwayStep1700" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1348" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1662" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">sunitinib-resistant FLT3 mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Sunitinib is a first generation type II tyrosine kinase inhibitor with broad specifity for receptor tyrosine kinases, including FLT3. This pathway describes FLT3 mutants that show resistance to sunitinib-mediated inhibition (reviewed in Kazi and Roonstrand, 2019).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway318">
 <bp:pathwayOrder rdf:resource="#PathwayStep1706" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1351" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1668" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">tamatinib-resistant FLT3 mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Tamatinib is a type I tyrosine kinase inhibitor with activity against FLT3. This pathway describes FLT3 mutants that are resistant to inhibition by tamatinib (Nguyen et al, 2017).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway317">
 <bp:pathwayOrder rdf:resource="#PathwayStep1704" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1350" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1666" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">tandutinib-resistant FLT3 mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Tandutinib, also known as MLN519, is a type II tyrosine kinase inhibitor with activity against FLT3 (Clark et al, 2004; reviewed in Staudt et al, 2018; Daver et al, 2019). This pathway describes FLT3 mutants that are resistant to tandutinib-mediated inhibition.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction178">
 <bp:evidence rdf:resource="#Evidence229" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NS1 (1C) mRNA is translated into protein NS1 (1C)</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction179">
 <bp:evidence rdf:resource="#Evidence230" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">M mRNA is translated into protein M</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway319">
 <bp:pathwayOrder rdf:resource="#PathwayStep1708" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1352" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1670" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">sorafenib-resistant FLT3 mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Sorafenib is a first generation type II tyrosine kinase inhibitor with broad specificity for receptor tyrosine kinases including FLT3. This pathway describes FLT3 mutants that are resistant to sorafenib-mediated inhibition (Nguyen et al 2017; Linblad et al, 2017;reviewed in Kazi and Roonstrand, 2019).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction176">
 <bp:evidence rdf:resource="#Evidence227" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">P mRNA is translated into protein P</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction177">
 <bp:evidence rdf:resource="#Evidence228" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">N mRNA is translated into protein N</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis153">
 <bp:controlled rdf:resource="#BiochemicalReaction578" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis152">
 <bp:controlled rdf:resource="#BiochemicalReaction577" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis155">
 <bp:controlled rdf:resource="#BiochemicalReaction595" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis154">
 <bp:controlled rdf:resource="#BiochemicalReaction594" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis151">
 <bp:controlled rdf:resource="#BiochemicalReaction576" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis150">
 <bp:controlled rdf:resource="#BiochemicalReaction575" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis157">
 <bp:controlled rdf:resource="#BiochemicalReaction604" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis156">
 <bp:controlled rdf:resource="#BiochemicalReaction599" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis159">
 <bp:controlled rdf:resource="#BiochemicalReaction614" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis158">
 <bp:controlled rdf:resource="#BiochemicalReaction610" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction174">
 <bp:evidence rdf:resource="#Evidence225" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">M2 mRNA is translated into protein M2-1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction175">
 <bp:evidence rdf:resource="#Evidence226" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SH mRNA is translated into protein SHt</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction172">
 <bp:evidence rdf:resource="#Evidence223" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">G mRNA is translated into nascent secreted G protein</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway310">
 <bp:pathwayOrder rdf:resource="#PathwayStep1690" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1688" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1689" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1684" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1685" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1686" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1687" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1680" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1691" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1681" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1692" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1682" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1683" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1340" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1341" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1333" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1344" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1334" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1345" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1342" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1343" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1337" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1338" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1335" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1336" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1339" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1642" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Signaling by ERBB2 TMD/JMD mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Recurrent missense mutations in regions encoding the transmembrane domain (TMD) and the juxtamembrane domain (JMD) are frequently reported in cancer. The ERBB2 TMD mutants include ERBB2 V659E, ERBB2 V659K, ERBB2 G660D, ERBB2 G660R, ERBB2 S653C, ERBB2 R677L and ERBB2 R678Q. The ERBB2 JMD mutants include ERBB2 E693K and ERBB2 Q709L. ERBB2 TMD mutants  ERBB2 V659E, ERBB2 G660D and S653C (de Martino et al. 2014) are known to be activating. ERBB2 TMD/JMD mutants ERBB2 R678Q, ERBB2 E693K, and ERBB2 Q709L mutations may be activating when co-expressed with a wild type ERBB2 receptor (Pahuja et al. 2018). TMD and JMD mutations can activate ERBB2 signaling by improving the active dimer interface or by stabilizing the active conformation. TMD/JMD mutants that are activating in the presence of wild type ERBB2, such as ERBB2 R678Q, may form homodimers with the wild type ERBB2 (Pahuja et al. 2018).  Based on trans-autophosphorylation of ERBB2 and its dimerization partners EGFR and ERBB3, the following ERBB2 TMD/JMD mutants are assumed to form heterodimers with EGFR and ERBB3: ERBB2 S653C (de Martino et al. 2014) ERBB2 R678Q (Bose et al. 2013, Pahuja et al. 2018).  Phosphorylation of tyrosine residues in the C-tail of ERBB2 was shown for the following ERBB2 TMD/JMD mutants: ERBB2 V659E (Pahuja et al. 2018); ERBB2 V659K (Pahuja et al. 2018); ERBB2 G660D (Pahuja et al. 2018); ERBB2 G660R (Pahuja et al. 2018); ERBB2 S653C (de Martino et al. 2014 - phosphorylation at Y1248 demonstrated); ERBB2 R677L (Pahuja et al. 2018); ERBB2 R678Q (Bose et al. 2013; de Martino et al. 2014 - phosphorylation at Y1248 demonstrated; Pahuja et al. 2018); ERBB2 Q709L (Pahuja et al. 2018)  Phosphorylation of tyrosine residues in the C-tail of EGFR was demonstrated for ERBB2 S653C (de Martino et al. 2014 - phosphorylation at Y1068) and ERBB2 R678Q (Bose et al. 2013; de Martino et al. 2014 - phosphorylation at Y1068).  Phosphorylation of tyrosine residues in the C-tail of ERBB3 was demonstrated for ERBB2 S653C (de Martino et al. 2014 - phosphorylation at Y1197) and ERBB2 R678Q (Bose et al. 2013; de Martino et al. 2014 - phosphorylation at Y1197).  Activation of downstream RAS signaling was shown for ERBB2 S653C (de Martino et al. 2014) and ERBB2 R678Q (Bose et al. 2013, de Martino et al. 2014) through activating tyrosine phosphorylation on ERKs (MAPK1 and MAPK3) and SHC1.  Activation of downstream PLCG1 signaling was demonstrated for ERBB2 R678Q, through activating tyrosine phosphorylation on PLCG1 (Bose et al. 2013).  Activation of PI3K/AKT signaling by ERBB2 TMD/JMD mutants has not been tested.  Signaling by ERBB2 V659K, ERBB2 G660D, ERBB2 G660R, ERBB2 R677L, ERBB2 E693K and ERBB2 Q709L has not been sufficiently studied and they are annotated as candidates.  The following ERBB2 TMD/JMD mutants are sensitive to  the therapeutic antibody trastuzumab (herceptin): ERBB2 V659E (Pahuja et al. 2018); ERBB2 G660D (Pahuja et al. 2018); ERBB2 G660R (Pahuja et al. 2018); ERBB2 R678Q (Bose et al. 2013, Pahuja et al. 2018); ERBB2 Q709L (Pahuja et al. 2018);  With respect to pertuzumab, a therapeutic antibody that block ligand-driven heterodimerization of ERBB2, ERBB2 R678Q is sensitive to pertuzumab, while ERBB2 V659E, ERBB2 G660D, ERBB2 G660R and probably ERBB2 Q709L are resistant (Pahuja et al. 2018).  The following ERBB2 TMD/JMD mutants are sensitive to lapatinib: ERBB2 S653C (de Martino et al. 2014); ERBB2 R678Q (Bose et al. 2013);  The following ERBB2 TMD/JMD mutants are sensitive to neratinib: ERBB2 V659E (Pahuja et al. 2018); ERBB2 G660D (Pahuja et al. 2018); ERBB2 G660R (Pahuja et al. 2018); ERBB2 R678Q (Bose et al. 2013, Pahuja et al. 2018); ERBB2 Q709L (Pahuja et al. 2018);  The following ERBB2 TMD/JMD mutants are sensitive to afatinib: ERBB2 G660D (Pahuja et al. 2018); ERBB2 G660R (Pahuja et al. 2018); ERBB2 S653C (de Martino et al. 2014); ERBB2 R678Q (Pahuja et al. 2018); ERBB2 Q709L (Pahuja et al. 2018).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction173">
 <bp:evidence rdf:resource="#Evidence224" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">SH mRNA is translated into protein SH</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction170">
 <bp:evidence rdf:resource="#Evidence221" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">L mRNA is translated into protein L</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway312">
 <bp:pathwayOrder rdf:resource="#PathwayStep1707" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1719" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1709" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1703" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1715" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1705" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1717" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1699" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1721" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1711" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1701" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1713" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1695" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1697" />
 <bp:pathwayComponent rdf:resource="#Pathway316" />
 <bp:pathwayComponent rdf:resource="#Pathway315" />
 <bp:pathwayComponent rdf:resource="#Pathway326" />
 <bp:pathwayComponent rdf:resource="#Pathway318" />
 <bp:pathwayComponent rdf:resource="#Pathway317" />
 <bp:pathwayComponent rdf:resource="#Pathway319" />
 <bp:pathwayComponent rdf:resource="#Pathway321" />
 <bp:pathwayComponent rdf:resource="#Pathway320" />
 <bp:pathwayComponent rdf:resource="#Pathway323" />
 <bp:pathwayComponent rdf:resource="#Pathway322" />
 <bp:pathwayComponent rdf:resource="#Pathway314" />
 <bp:pathwayComponent rdf:resource="#Pathway325" />
 <bp:pathwayComponent rdf:resource="#Pathway313" />
 <bp:pathwayComponent rdf:resource="#Pathway324" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1657" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Drug resistance of FLT3 mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FLT3 is mutated in ~30% of acute myeloid leukemias (AML), with internal tandem duplications (ITDs) representing the majority of these mutations and activating point mutants occurring at lower frequency. FLT3 mutations also occur at lower rates in other cancers (reviewed in Kazi and Roonstrand, 2018; Daver et al, 2019; Larroas-Garcia and Baer, 2017). Mutation of FLT3 has been identified as a driver in progression of AML and in consequence is a promising therapeutic target. A number of first and second generation inhibitors have been demonstrated to have activity against FLT3, but accumulation of secondary mutations leads to the development of resistance. These secondary mutations further shift the equilibrium of the receptor toward the activated state, making even the second-generation type II TKIs less effective. In consequence, considerable effort is devoted to discovery of type II and, in particular, type I TKIs that are active against highly activated FLT3 alleles (reviewed in Daver et al, 2019; Staudt et al, 2018; Lim et al, 2017; Klug et al, 2018).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction171">
 <bp:evidence rdf:resource="#Evidence222" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">G mRNA is translated into membrane-bound G protein</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway311">
 <bp:pathwayOrder rdf:resource="#PathwayStep1747" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1744" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1723" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1742" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1694" />
 <bp:pathwayComponent rdf:resource="#Pathway327" />
 <bp:pathwayComponent rdf:resource="#Pathway329" />
 <bp:pathwayComponent rdf:resource="#Pathway328" />
 <bp:pathwayComponent rdf:resource="#Pathway330" />
 <bp:pathwayComponent rdf:resource="#Pathway312" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1656" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FLT3 signaling in disease</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FLT3 is a type III receptor tyrosine kinase (RTK). The extracellular domain consists of 5 immunoglobulin (Ig) domains that contribute to dimerization and ligand binding. The intracellular region has a juxtamembrane domain that plays a role in autoinhibiting the receptor in the absence of ligand, and a bi-lobed kinase region with an activation loop and the catalytic cleft (reviewed in Klug et al, 2018). Signaling through FLT3 occurs after ligand-induced dimerization and transautophosphorylation, and promotes signaling through the MAP kinase, PI3K and STAT5 pathways, among others. FLT3 signaling promotes cellular proliferation and differentiation and contributes to haematopoeisis. FLT3 is mutated in up to 30% of acute myeloid leukemias. ~25% of the FLT3 mutations in AML cases occur as internal tandem duplications (ITDs) either in the juxtamembrane domain region encoded by exon 14 or the tyrosine kinase domain (TKD), while ~7-10% of AML cases contain FLT3 missense mutations in the TKD (reviewed in Klug et al, 2018; Daver et al, 2019). These mutations all support ligand-independent activation of the receptor and result in constitutive activation and signaling (Zheng et al, 2004; reviewed in Klug et al, 2018; Kazi and Roonstrand, 2019). In rare cases, the FLT3 locus is also subject to translocations that generate constitutively active fusion proteins (reviewed in Kazi and Roonstrand, 2019). Oncogenic FLT3 activity can be targeted with tyrosine kinase inhibitors, although resistance often arises due to secondary mutations or activation of bypass pathways (reviewed in Staudt et al, 2018; Daver et al, 2019).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway314">
 <bp:pathwayOrder rdf:resource="#PathwayStep1698" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1347" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1660" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">midostaurin-resistant FLT3 mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Midostaurin, also known as PKC412, is a type I tyrosine kinase inhibitor with activity against FLT3 (reviewed in Kazi and Roonstrand, 2019; Luskin and DeAngelo, 2017). This pathway describes FTL3 mutants that are resistant to inhibition by midostaurin.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway313">
 <bp:pathwayOrder rdf:resource="#PathwayStep1696" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1346" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1658" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">KW2449-resistant FLT3 mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">KW-2449 is a second generation, type I aurora kinase and FLT3 tyrosine kinase inhibitor, Despite effectiveness against a number of FLT3 mutant alleles, it has been withdrawn from development due to poor pharmacodynamics (reviewed in Larrosa-Garcia and Baer, 2017; Kazi and Roonstrand, 2019). This pathway describes FLT3 mutants that are resistant to inhibition by KW-2449.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway327">
 <bp:pathwayOrder rdf:resource="#PathwayStep1729" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1725" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1736" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1726" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1737" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1727" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1738" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1728" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1739" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1732" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1733" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1734" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1724" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1735" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1740" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1730" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1741" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1731" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1370" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1362" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1373" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1363" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1374" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1360" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1371" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1361" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1372" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1366" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1377" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1367" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1364" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1375" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1365" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1376" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1368" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1369" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1686" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Signaling by FLT3 fusion proteins</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">In addition to internal tandem duplications and activating point mutations, FLT3 is also subject at low frequency to translocations that generate fusion proteins. These fusion proteins occur in some chronic myeloid leukemias as well as myeloid neoplasms with eosinophilia, and generate constitutively active proteins by virtue of fusing a N-terminal partner encoding a dimerization domain with the intracellular region of FLT3 (reviewed in Reiter and Gotlib, 2017; Kazi and Roonstrand, 2019). To date, 6 fusion partner genes of FLT3 have been identified: ETV6, TRIP11, MYO18A, SPTBN1, GOLGB1 and ZMYM2 (Balwin et al, 2007; Vu et al, 2006; Walz et al, 2011; Falchi et al, 2014; Chung et al, 2017; Troadec et al, 2017; Grand et al, 2007; Jawhar et al, 2017; Zhang et al, 2018).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway326">
 <bp:pathwayOrder rdf:resource="#PathwayStep1722" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1359" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1684" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">crenolanib-resistant FLT3 mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Crenolanib is a second-generation type I tyrosine kinase inhibitor with activity against FLT3 (reviewed in Daver et al, 2019; Staudt et al, 2018; Larrosa-Garcia and Bauer, 2017). This pathway describes FLT3 mutants that are resistant to crenolanib-mediated inhibition.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction169">
 <bp:evidence rdf:resource="#Evidence220" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NS2 (1B) mRNA is translated into protein NS2</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway329">
 <bp:pathwayOrder rdf:resource="#PathwayStep1745" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1746" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1379" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1380" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1707" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FLT3 mutants bind TKIs</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Aberrant signaling by activated forms of FLT3 can be inhibited by tyrosine kinase inhibitors (TKIs). FLT3 receptors are class III receptor tyrosine kinase receptors, also known as dual-switch. Dual-switch receptors are activated through a series of phosphorylation and conformational changes that move the receptor from the inactive form to the fully activated form. Type II TKIs bind to the inactive form of the receptor at a site adjacent to the ATP-binding cleft, while type I TKIs bind to the active form (reviewed in Klug et al, 2018; Daver et al, 2019).  FLT3 internal tandem duplications (ITDs) are found in ~25-30% of acute myeloid leukemias, and are present at lower frequencies in other cancers (reviewed in Kazi and Roostrand, 2019; Patnaik et al, 2018). These ITDs generally occur in a tyrosine-rich region of exon 14, encoding the juxtamembrane domain region of the protein; at a lower frequency, ITDs are found in the first tyrosine kinase domain (TKD1). In addition to ITDs, a number of point mutations in the juxtamembrane domain have also been identified. Juxtamembrane domain mutations affect an autoinhibitory loop, shifting the equilibrium of the receptor towards the activated state; despite this, however, juxtamembrane domain mutants remain predominantly in the inactive state and as such are susceptible to inhibition by type II TKIs (reviewed in Patnaik et al, 2018; Kazi and Roonstrand et al, 2019).   Activation loop mutations more strongly favor the active conformation of the receptor and are susceptible to inhibition by both type II and type I TKIs. The most prevalent FLT3 mutation, D835Y, promotes the active conformation strongly enough to be resistant to type II TKIs (Patnaik et al, 2017; Klug et al, 2018; Daver et al, 2019).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway328">
 <bp:pathwayOrder rdf:resource="#PathwayStep1743" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1378" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1705" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FLT3 signaling by CBL mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Missense and splicing mutants have been identified in the E3 ubiquitin ligase CBL in a number of cancers including acute and chronic myeloid leukemias, among others. These cancers show elevated signaling through FLT3 as a result of impaired CBL-mediated downregulation of the receptor (Sargin et al, 2007; Reindl et al, 2009; Caligiuri et al, 2007; Abbas et al, 2008).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction167">
 <bp:evidence rdf:resource="#Evidence218" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">M2 mRNA is translated into protein M2-2</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction168">
 <bp:evidence rdf:resource="#Evidence219" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">F mRNA is translated into nascent protein F</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction165">
 <bp:evidence rdf:resource="#Evidence215" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Synthesis of antigenomic RNA of human respiratory syncytial virus</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction166">
 <bp:evidence rdf:resource="#Evidence216" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Abortive replication of hRSV A</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis164">
 <bp:controlled rdf:resource="#BiochemicalReaction636" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis163">
 <bp:controlled rdf:resource="#BiochemicalReaction635" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis166">
 <bp:controlled rdf:resource="#BiochemicalReaction639" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis165">
 <bp:controlled rdf:resource="#BiochemicalReaction638" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis160">
 <bp:controlled rdf:resource="#BiochemicalReaction619" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis162">
 <bp:controlled rdf:resource="#BiochemicalReaction632" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis161">
 <bp:controlled rdf:resource="#BiochemicalReaction631" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis168">
 <bp:controlled rdf:resource="#BiochemicalReaction643" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis167">
 <bp:controlled rdf:resource="#BiochemicalReaction642" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis169">
 <bp:controlled rdf:resource="#BiochemicalReaction646" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction163">
 <bp:evidence rdf:resource="#Evidence213" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Synthesis of negative sense genomic RNA of respiratory syncytial virus</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction164">
 <bp:evidence rdf:resource="#Evidence214" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Packaging of antigenomic RNA of human respiratory syncytial virus</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction161">
 <bp:evidence rdf:resource="#Evidence210" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Lumicitabine binds RdRP on nucleocapsid</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway321">
 <bp:pathwayOrder rdf:resource="#PathwayStep1712" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1354" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1674" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">gilteritinib-resistant FLT3 mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Gilteritinib is a second-generation type I tyrosine kinase inhibitor with activity against FLT3 (reviewed in Daver et al, 2019; Hassanein et l, 2016; Lim et al, 2017; Luxkin et al, 2017). This pathway describes FLT3 mutants that are resistant to inhibition by gilteritinib.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction162">
 <bp:evidence rdf:resource="#Evidence212" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Formation of hRSV A dsRNA intermediate form</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway320">
 <bp:pathwayOrder rdf:resource="#PathwayStep1710" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1353" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1672" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">lestaurtinib-resistant FLT3 mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Lestaurtinib is a first-generation, type I tyrosine kinase inhibitor with activity against a range of receptor tyrosine kinases including FLT3 (reviewed in Larrosa-Garcia and Baer, 2017; Staudt et al, 2018; Daver et al, 2019). This pathway describes FLT3 mutants that are resistant to lestaurtinib-mediated inhibition.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway323">
 <bp:pathwayOrder rdf:resource="#PathwayStep1716" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1356" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1678" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">semaxanib-resistant FLT3 mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Semaxanib, also known as SU5614, is an investigational type I tyrosine kinase inhibitor with activity against a wide range of receptor tyrosine kinases. It is not currently approved for clinical use. This pathway describes FLT3 mutants that show resistance to semaxanib-mediated inhibition (Yee et al, 2002; Spiekermann et al, 2003).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction160">
 <bp:evidence rdf:resource="#Evidence209" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Polyadenylation of respiratory syncytial virus subgenomic positive-sense mRNAs</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway322">
 <bp:pathwayOrder rdf:resource="#PathwayStep1714" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1355" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1676" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">quizartinib-resistant FLT3 mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Quizartinib is a type II tyrosine kinase inhibitor that is in phase III clinical trials for treatment of acute myeloid leukemias with FLT3 internal tandem duplications (ITDs). This pathway describes FLT3 mutants that display resistance to quizartinib (reviewed in Kazi and Roonstrand, 2019; Daver et al, 2019).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway325">
 <bp:pathwayOrder rdf:resource="#PathwayStep1720" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1358" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1682" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ponatinib-resistant FLT3 mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Ponatinib is a first generation tyrosine kinase inhibitor with activity against a broad range of receptor tyrosine kinases, including FLT3 (reviewed Pemmeraju et al, 2014; Kazi and Roonstrand, 2019). This pathway describes FLT3 mutants that are resistant to inhibition by ponatinib.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway324">
 <bp:pathwayOrder rdf:resource="#PathwayStep1718" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1357" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1680" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">linifanib-resistant FLT3 mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Linifanib is a type I tyrosine kinase inhibitor with activity against a broad range of receptor tyrosine kinases including FLT3. This pathway describes FLT3 mutants that are resistant to inhibition by linifanib (Hernandez-Davies et al, 2011; Nguyen et al, 2017).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction116">
 <bp:evidence rdf:resource="#Evidence157" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">IL10 gene produces IL10 protein</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction117">
 <bp:evidence rdf:resource="#Evidence158" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Phosphorylation and activation of PLCG due to FCGR3A effect</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction114">
 <bp:evidence rdf:resource="#Evidence155" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">IP3R:I(1,4,5)P3 tetramer transports Ca2+ from ER lumen to cytosol</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction115">
 <bp:evidence rdf:resource="#Evidence156" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">IgG binds the surface of the amastigote form of Leishmania</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction112">
 <bp:evidence rdf:resource="#Evidence153" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">IP3 binds to the IP3 receptor, opening the endoplasmic reticulum Ca2+ channel</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction113">
 <bp:evidence rdf:resource="#Evidence154" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Calcium binds calmodulin</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction110">
 <bp:evidence rdf:resource="#Evidence151" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Release of PLCG from FCGR3A</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction111">
 <bp:evidence rdf:resource="#Evidence152" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Adenylate cyclase produces cAMP</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction118">
 <bp:evidence rdf:resource="#Evidence159" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">PLC-gamma1 hydrolyses PIP2</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction119">
 <bp:evidence rdf:resource="#Evidence163" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Formation of hRSV A matrix lattice</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction105">
 <bp:evidence rdf:resource="#Evidence145" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">iRHOM2 transports ADAM17:Zn2+ from Golgi to the plasma membrane</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway305">
 <bp:pathwayOrder rdf:resource="#PathwayStep1640" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1298" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1602" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Resistance of ERBB2 KD mutants to AEE788</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">This pathway describes resistance of ERBB2 KD mutants to tyrosine kinase inhibitor AEE788 (Kancha et al. 2011).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction106">
 <bp:evidence rdf:resource="#Evidence146" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">FURIN cleaves ADAM17</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway304">
 <bp:pathwayOrder rdf:resource="#PathwayStep1638" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1297" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1600" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Resistance of ERBB2 KD mutants to trastuzumab</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">This pathway describes resistance of ERBB2 KD mutants to therapeutic antibody trastuzumab (herceptin) (Bose et al. 2013, Rexer et al. 2013, Hanker et al. 2017, Nagano et al. 2018).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction103">
 <bp:evidence rdf:resource="#Evidence143" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">PLK2, MAPK14 phosphorylate ADAM17</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway307">
 <bp:pathwayOrder rdf:resource="#PathwayStep1644" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1300" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1606" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Drug resistance in ERBB2 TMD/JMD mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">With respect to pertuzumab, a therapeutic antibody that block ligand-driven heterodimerization of ERBB2, ERBB2 R678Q is sensitive to pertuzumab, while ERBB2 V659E, ERBB2 G660D, ERBB2 G660R and probably ERBB2 Q709L are resistant (Pahuja et al. 2018).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction104">
 <bp:evidence rdf:resource="#Evidence144" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">sCD163 binds MYH9 in T-cells</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway306">
 <bp:pathwayOrder rdf:resource="#PathwayStep1642" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1299" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1604" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Resistance of ERBB2 KD mutants to lapatinib</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">This pathway describes resistance of ERBB2 KD mutants to tyrosine kinase inhibitor lapatinib (Trowe et al. 2008, Kancha et al. 2011, Bose et al. 2013, Rexer et al. 2013, Yang et al. 2015, Hanker et al. 2017, Cocco et al. 2018, Nagano et al. 2018).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction101">
 <bp:evidence rdf:resource="#Evidence141" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">p-S,T-ADAM17(215-827):Zn2+ cleaves CD163</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway309">
 <bp:pathwayOrder rdf:resource="#PathwayStep1666" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1677" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1667" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1678" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1668" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1669" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1662" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1673" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1663" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1674" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1664" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1675" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1665" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1676" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1670" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1671" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1672" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1330" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1322" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1323" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1320" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1331" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1321" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1332" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1326" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1316" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1327" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1324" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1325" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1319" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1317" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1328" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1318" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1329" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1624" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Signaling by ERBB2 KD Mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Mutations in the kinase domain (KD) of ERBB2 result in constitutive activation of ERBB2 signaling, facilitate heterodimerization of ERBB2 with other EGFR family members and increase the signaling intensity, leading to cellular transformation (Kancha et al. 2011). Only a subset of potential heterodimerization partners has been tested for most ERBB2 KD mutant proteins, so our annotations here are correspondingly limited. ERBB2 L755S and ERBB2 V777L cancer variants were shown to heterodimerize with ERBB3 (HER3) at a higher rate than wild type ERBB2 (Croessmann et al. 2019). Increased activity of ERBB2 L755S, ERBB2 L755P, ERBB2 V777L, ERBB2 D769H, ERBB2 D769Y, ERBB2 V842I, ERBB2 R896C and ERBB2 G778_P780dup in the presence of either EGFR (Kancha et al. 2011, Bose et al. 2013) or ERBB3 (Kancha et al. 2011, Bose et al. 2013, Collier et al. 2013) as a heterodimerization partner was also observed. The interplay of ERBB2 G778_P780dup, ERBB2 I767M and ERBB2 R896C with ERBB3 has not been tested. ERBB2 L869R mutant shows increased activity in the presence of ERBB3, which is further augmented in the presence of dimerization-facilitating ERBB3 E928G mutants (Hanker et al. 2017). The interplay of ERBB2 L869R with EGFR has not been tested. Heterodimerization of ERBB2 KD mutants with ERBB4 has not been tested and ERBB4 is a candidate heterodimerization partner for these KD variants. ERBB2 H878Y mutant has ten times higher kinase activity than the wild type ERBB2 (Hu, Wan et al. 2015; Hu, Hu et al. 2015), but its heterodimerization properties have not been studied and it is therefore annotated as a candidate.  Ligand requirements have not been studied in the context of heterodimerization of ERBB2 KD mutants, but it is assumed that ligands are required.  The signaling properties of ERBB2 L755M (Gonzalez-Alonso et al. 2015), ERBB2 L755W (COSMIC database: Forbes et al. 2017), ERBB2 V777E (Dietz et al. 2017), ERBB2 V777M (Lee et al. 2006, Ross et al. 2016, Zehir et al. 2017), ERBB2 D769N (Tschui et al. 2015), ERBB2 V842E (Siroy et al. 2015), ERBB2 R896H (Cancer Genome Atlas Research Network 2011), ERBB2 L869Q (Lee et al. 2006) and ERBB2 H878R (Trowe et al. 2008, Zehir et al. 2017) have not been experimentally tested, but they are predicted to be pathogenic (COSMIC database: Forbes et al. 2017) and they are annotated as candidates. ERBB2 T733I (Trowe et al. 2008), ERBB2 T798I (Trowe et al. 2008, Hanker et al. 2017) and ERBB2 T798M (Hanker et al. 2017) usually occur as secondary ERBB2 mutations and are responsible for treatment failure. On their own, ERBB2 T733I and ERBB2 T798I appear to be weakly transforming compared with the other ERBB2 KD mutants. As their signaling properties have been poorly studied, ERBB2 T733I, ERBB2 T798I and ERBB2 T798M are annotated as candidates. The binding of ERBB2 KD mutants to ERBIN and the HSP90:CDC37 chaperone:co-chaperone complex has not been tested but is assumed to occur similarly to the wild type ERBB2. Signaling by ERBB2 KD mutants has been organized into subpathways based on the current knowledge of biology of these mutants (heterodimerization, downstream signaling, drug interaction) and on the sequence similarity of their mutations.</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction102">
 <bp:evidence rdf:resource="#Evidence142" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ADAM17 binds Zn2+</bp:displayName>
</bp:BiochemicalReaction>

<bp:Pathway rdf:ID="Pathway308">
 <bp:pathwayOrder rdf:resource="#PathwayStep1648" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1659" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1649" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1655" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1656" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1646" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1657" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1647" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1658" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1651" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1652" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1653" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1654" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1660" />
 <bp:pathwayOrder rdf:resource="#PathwayStep1650" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1311" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1301" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1312" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1310" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1304" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1315" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1305" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1302" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1313" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1303" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1314" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1308" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1309" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1306" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1307" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1608" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Signaling by ERBB2 ECD mutants</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">ERBB2 extracellular domain (ECD) mutants harbor missense mutations that lead to substitutions of amino acid residues in the heterodimerization arm contact surface, involved in formation of ERBB2 heterodimers. The functionally studied ERBB2 ECD mutants, ERBB2 G309A (Bose et al. 2013), ERBB2 G309E (Greulich et al. 2012) and ERBB2 S310F (Greulich et al. 2012) seem to preferntially heterodimerize with EGFR. Heterodimerization of ERBB2 G309E involves formation of disulfide bonds (Greulich et al. 2012). ERBB2 S310F shows stronger activation of downstream signaling than ERBB2 G309A and ERBB2 G309E, and is hyperphosphorylated on tyrosine residues in the C-tail (Greulich et al. 2012), while the C-tail phosphorylation of ERBB2 G309A (Bose et al. 2013) and ERBB2 G309E (Greulich et al. 2012) is comparable to the wild type ERBB2.  RAS signaling and PLCgamma1 signaling are activated dowsntream of all three ERBB2 ECD mutants, ERBB2 G309A (Bose et al. 2013), ERBB2 G309E (Greulich et al. 2012) and ERBB2 S310F (Greulich et al. 2012), as evidenced by activating phosphorylation on ERKs (MAPK1 and MAPK3) and PLCG1, respectively. ERBB2 G309E and ERBB2 S310F also activate PI3K/AKT signaling, demonstrated by activating phosphorylation of AKT1 (Greulich et al. 2012). Activation of PI3K/AKT signaling downstream of ERBB2 G309A has not been tested. Signaling downstream of ERBB2 S310Y has been poorly characterized and it is annotated as a candidate. Many regulators of cell migration show increased phosphorylation in cells expressing ERBB2 G309E and ERBB2 S310F (Greulich et al. 2012). Comapred with the wild type ERBB2, ERBB2 G309E, ERBB2 S310F and ERBB2 S310Y are more sensitive to the ERBB2-directed therapeutic antibody trastuzumab (herceptin) and to tyrosine kinase inhibitors lapatinib, neratinib and afatinib (Greulich et al. 2012). ERBB2 G309A was also responsive to trastuzumab, lapatinib and neratinib (Bose et al. 2013).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction100">
 <bp:evidence rdf:resource="#Evidence140" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">sCD163 translocates from extracellular region to cytosol</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis100">
 <bp:controlled rdf:resource="#BiochemicalReaction390" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction109">
 <bp:evidence rdf:resource="#Evidence150" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Recruitment of PLCgamma to membrane due to FCGR3A effect</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction107">
 <bp:evidence rdf:resource="#Evidence148" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">CREB1 binds IL-10 promoter</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction108">
 <bp:evidence rdf:resource="#Evidence149" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Opsonized leishmania amastigote binds FCGR3</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis106">
 <bp:controlled rdf:resource="#BiochemicalReaction412" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis105">
 <bp:controlled rdf:resource="#BiochemicalReaction411" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis108">
 <bp:controlled rdf:resource="#BiochemicalReaction417" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis107">
 <bp:controlled rdf:resource="#BiochemicalReaction416" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis102">
 <bp:controlled rdf:resource="#BiochemicalReaction402" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis101">
 <bp:controlled rdf:resource="#BiochemicalReaction392" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis104">
 <bp:controlled rdf:resource="#BiochemicalReaction404" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis103">
 <bp:controlled rdf:resource="#BiochemicalReaction403" />
</bp:Catalysis>

<bp:Pathway rdf:ID="Pathway301">
 <bp:pathwayOrder rdf:resource="#PathwayStep1632" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1294" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1594" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Resistance of ERBB2 KD mutants to neratinib</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">This pathway describes resistance of ERBB2 KD mutants to tyrosine kinase inhibitor neratinib (Hanker et al. 2017).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Catalysis rdf:ID="Catalysis109">
 <bp:controlled rdf:resource="#BiochemicalReaction418" />
</bp:Catalysis>

<bp:Pathway rdf:ID="Pathway300">
 <bp:pathwayOrder rdf:resource="#PathwayStep1630" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1293" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1592" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Resistance of ERBB2 KD mutants to tesevatinib</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">This pathway describes resistance of ERBB2 KD mutants to tyrosine kinase inhibitor tesevatinib (Trowe et al. 2018).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway303">
 <bp:pathwayOrder rdf:resource="#PathwayStep1636" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1296" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1598" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Resistance of ERBB2 KD mutants to afatinib</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">This pathway describes resistance of ERBB2 KD mutants to tyrosine kinase inhibitor afatinib (Rexer et al. 2013, Hanker et al. 2017).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:Pathway rdf:ID="Pathway302">
 <bp:pathwayOrder rdf:resource="#PathwayStep1634" />
 <bp:pathwayComponent rdf:resource="#BiochemicalReaction1295" />
 <bp:organism rdf:resource="#BioSource1" />
 <bp:evidence rdf:resource="#Evidence1596" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Resistance of ERBB2 KD mutants to osimertinib</bp:displayName>
 <bp:comment rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">This pathway describes resistance of ERBB2 KD mutants to tyrosine kinase inhibitor osimertinib (Hanker et al. 2017).</bp:comment>
 <bp:dataSource rdf:resource="#Provenance1" />
</bp:Pathway>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction138">
 <bp:evidence rdf:resource="#Evidence185" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Ubiquitination of STAT2</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction139">
 <bp:evidence rdf:resource="#Evidence186" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Association of NS1 (1C) with Cul5 and SCF</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction136">
 <bp:evidence rdf:resource="#Evidence183" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">N interacts with IFIH1</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction137">
 <bp:evidence rdf:resource="#Evidence184" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NS1 (1C) binds to MAVS</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction134">
 <bp:evidence rdf:resource="#Evidence181" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NS2 (1B) binds DDX58</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction135">
 <bp:evidence rdf:resource="#Evidence182" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">NS1 (1C) binds to IRF3</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction132">
 <bp:evidence rdf:resource="#Evidence179" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">MAVS and DDX58 interact</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction133">
 <bp:evidence rdf:resource="#Evidence180" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Recruitment of STAT2 to p-IFNAR1</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis111">
 <bp:controlled rdf:resource="#BiochemicalReaction430" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis110">
 <bp:controlled rdf:resource="#BiochemicalReaction423" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis117">
 <bp:controlled rdf:resource="#BiochemicalReaction437" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis116">
 <bp:controlled rdf:resource="#BiochemicalReaction436" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis119">
 <bp:controlled rdf:resource="#BiochemicalReaction441" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis118">
 <bp:controlled rdf:resource="#BiochemicalReaction438" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis113">
 <bp:controlled rdf:resource="#BiochemicalReaction432" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis112">
 <bp:controlled rdf:resource="#BiochemicalReaction431" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis115">
 <bp:controlled rdf:resource="#BiochemicalReaction435" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis114">
 <bp:controlled rdf:resource="#BiochemicalReaction433" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction130">
 <bp:evidence rdf:resource="#Evidence177" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">CREBBP, EP300 binds p-T,4S-IRF3:p-T,4S-IRF3</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction131">
 <bp:evidence rdf:resource="#Evidence178" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">RSV N binds PKR</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction127">
 <bp:evidence rdf:resource="#Evidence172" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">G protein binds CX3CR1 on host cell surface</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction128">
 <bp:evidence rdf:resource="#Evidence173" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">hRSV A enters host cell through membrane fusion</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction125">
 <bp:evidence rdf:resource="#Evidence170" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">RSV F binds TLR4:LY96:CD14</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction126">
 <bp:evidence rdf:resource="#Evidence171" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">F protein binds NCL on host cell surface</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction123">
 <bp:evidence rdf:resource="#Evidence168" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">hRSV A enters host cell through macropinocytosis</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction124">
 <bp:evidence rdf:resource="#Evidence169" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Release of hRSV A nucleocapsid from macropinosome</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction121">
 <bp:evidence rdf:resource="#Evidence165" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">N protein coats hRSV genomic (-)ssRNA</bp:displayName>
</bp:BiochemicalReaction>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction122">
 <bp:evidence rdf:resource="#Evidence166" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Budding of hRSV A virions from infected cell</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis120">
 <bp:controlled rdf:resource="#BiochemicalReaction442" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis122">
 <bp:controlled rdf:resource="#BiochemicalReaction454" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis121">
 <bp:controlled rdf:resource="#BiochemicalReaction449" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction129">
 <bp:evidence rdf:resource="#Evidence174" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">F inhibitors bind F on RSV virion</bp:displayName>
</bp:BiochemicalReaction>

<bp:Catalysis rdf:ID="Catalysis128">
 <bp:controlled rdf:resource="#BiochemicalReaction484" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis127">
 <bp:controlled rdf:resource="#BiochemicalReaction483" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis129">
 <bp:controlled rdf:resource="#BiochemicalReaction487" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis124">
 <bp:controlled rdf:resource="#BiochemicalReaction476" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis123">
 <bp:controlled rdf:resource="#BiochemicalReaction472" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis126">
 <bp:controlled rdf:resource="#BiochemicalReaction482" />
</bp:Catalysis>

<bp:Catalysis rdf:ID="Catalysis125">
 <bp:controlled rdf:resource="#BiochemicalReaction481" />
</bp:Catalysis>

<bp:BiochemicalReaction rdf:ID="BiochemicalReaction120">
 <bp:evidence rdf:resource="#Evidence164" />
 <bp:displayName rdf:datatype = "http://www.w3.org/2001/XMLSchema#string">Packaging of RdRP complex with replicated hRSV A nucleocapsid</bp:displayName>
</bp:BiochemicalReaction>
</rdf:RDF>